<SEC-DOCUMENT>0000885590-23-000018.txt : 20230504
<SEC-HEADER>0000885590-23-000018.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504164121
ACCESSION NUMBER:		0000885590-23-000018
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		23889530

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>bhc-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:15d8a82e-3541-4c94-ac5d-dc1f963a0c8b,g:acd10879-3b31-4117-a8f7-2a1c419d7f06,d:403fd8161ca64d5ab28658fcd748a8e4--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:bhc="http://www.bauschhealth.com/20230331" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M18zLTEtMS0xLTIwNzcxNQ_92172b60-cc0b-46b2-87fa-2faff4f49b62">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M180LTEtMS0xLTIwNzcxNQ_fbabfbf9-20f4-44e5-b73e-4cc5ef9bed34">12/31</ix:nonNumeric><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M181LTEtMS0xLTIwNzcxNQ_8ab8451a-e7b5-4c74-a720-e2f6370980e3">2023</ix:nonNumeric><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M182LTEtMS0xLTIwNzcxNQ_ce6bb5da-be62-4b09-9d03-1796bfcc3133">Q1</ix:nonNumeric><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M183LTEtMS0xLTIwNzcxNQ_d0149991-f27c-49b8-ba8c-e0d883ce89cc">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i67fe16b7aeb642b693472e36f685e38b_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83MC9mcmFnOmMxNDRmMGIwNzlhODQ5ZTM5MzQwOTYzNjY4YmZkMGNmL3RhYmxlOjE2NDY4OTZiMDI3OTRmNzM4YmUzOTU2NDk1MTc3MjE2L3RhYmxlcmFuZ2U6MTY0Njg5NmIwMjc5NGY3MzhiZTM5NTY0OTUxNzcyMTZfMC0xLTEtMS0yMDc3MTU_481f7f80-a732-4464-bd62-9f7e0df3c93c">0.5</ix:nonFraction><ix:nonNumeric contextRef="id4cb8742033349bdafbfd0dbe5122c94_D20220905-20220905" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzEyOA_7d8122c2-092a-4cd8-b6dd-b57d32d9fc25">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDI0NA_b622811e-eab0-4467-ba1f-ded7a871e35c">P4Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i698b41841b3b43b49795ffc3a7917a63_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfNDIw_370e4722-2759-4f40-b1be-e73a2795ad7c">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ife9b18a3d3a749e8b7ea0da438e8d116_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfNDIz_6cee4566-84b1-4035-87e6-0a6b42318788">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ib4f57ee4d6844129b313a85678998a48_D20220905-20220905" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfNDI2_f8529b49-4a61-43c1-a018-5ab2e8578242">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3b21867a93d5434bb4b2455d1f6434d2_D20230306-20230306" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfMjE5OTAyMzI1NzcxOQ_2d5e4765-b16f-4474-96d2-d83dd1200faa">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i1a35d63101ac4254a8698cf3aee3959f_D20230306-20230306" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfMjE5OTAyMzI1NzcyNw_9f31fdc8-b92e-44df-835b-8fc29c65c94c">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i6160a9c0226049118b1c6eadb8592be1_D20230306-20230306" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfMjE5OTAyMzI1NzczNQ_458cdcc6-0d3f-48a1-b892-a1035d73fd47">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62f07f63ca2d4846a0d70246d162c824_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0498740aa6eb46ce88de603fe0598d20_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i57d70860978f416995c6e78078eb91fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia19ded4922bb433e8435b8239b8ff307_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c6e6704998497797963a331448aaea_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie687efc76f874ebeb1aae627bb6e171e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d37d3e40784682946238eaa429b35e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i32b7e06a9d3a4aeb99dd497ebfb356f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452d83aa9dde4d01b6869dd5703fdaf8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc3e9fd64df947f9a8f763d6cc90b963_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e558abb1f7e4945be1efbb15c0857e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12545de9cf64750aa8d3591b5e00bc7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94c5658cc65a4a05b4ff0e04db19ee97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a8b96ed7f940c5845ec8d2f802a9d4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3dd81794064434383ac1286a5053baf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808b863dada9457f923ca993a3bea323_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic162d17ac63741d18133d43351ec92b7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40ddc921f07a4aeeacf02c27134db643_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66672939efa64ce0a7f6175881cc8e7b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8ba4914a69d4cb8b1fc752df5873883_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2f6084f5a4426387b1bdba497c5c63_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbac5f0d9d24f8a8f825099f3394fec_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946e14205ef041e8972492d11be8775d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i371252488c904680b474dfac8b94f900_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f7f8f2ef85a49f4afe5effddaa485c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf9314740a5046e6b7fbcde6a1225413_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c02450191db423fbdddbea92953f1fa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fcf82d8c82b4464bcd33142e1f338cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8902b132c274ce980a60fe03aa09c6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82e229d35290440d93fbde9447d92bd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce9f18c7cd9441ba37c871b38e9c09e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcbd578c19014c70a67ef1fb87173055_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1b2462e77bf46ba99a8e0c38ea11630_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3484672c1b4b38a05983fa5254b458_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04b8551dc9c4d889a6e5fd80cbc09f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f710c703f87477bb1995e048a1ad4c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i080749f8173b49ce89929a1cd63c2560_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib63d0633dd2449069f3d40c923633c0b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77426eee8f534f118cfa729bb49d9f39_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21c3f3c6b4a24d8cb42af4f8458f66e6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i479ac929919e4b9391ed384f3e44de72_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63bf7af9472e4ef792681b0e8c4f7da0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:context id="i4c8c5d995a3747e29d7c4e9cef2e105f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0c7a0e030f4effa3695934ea837e9f_I20220601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a49d1ee9a464f5db7a10d853a1a1349_D20230331-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e45b6ebd3b048e894cd2c2e5aedafa4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie10c054fa2de4824aef49eafab2b651e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i135bc17430224f338814ab96077762d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief70a603ee11466f94467c535a3e3125_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823782cb59e242d194dab1df20d01ab8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd82fd1b04c4ca5a90663181d0b9281_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe64f13b6ba4162ae7430acb9dbf957_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c4dfdc7ef14cc9bc3a3ac6abfe8664_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e80003bff24d46bd9d4b8a36e49cd0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3840f2154ebb4758a2ccbd787ed21972_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e0087ac09e4486ea85863d74934cc18_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if83655d1435547e9a88be7c0a6a44473_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c661f0c33684c05ba82c765639b2da8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcaaa7bc80ae4f49a0ec057d07433721_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dfb70e0fd024446818c699b54888111_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i391ac9a452be4bdcb904867d4fb45391_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1fb66cbda4b4013887d1e87c53164eb_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i318586ad088847fe9e02f2dbe2f1d9be_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8290334f6ddb49b48369b500e2a37633_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57521c3e1fc6438c83e45eed46549020_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80ef4ad0b68c4cc98d683b6b92852ec3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic21e95c278304743bdfd808b5bcf88c0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f4502c99efb4e1192389a486b24fec4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd2d65e95c5455ba33597d7af92fae1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6de88d59e31147e89b39381c09c53f91_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieda7c01115f14fb48e402b3e7a8d7854_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd272b84eca74392a824eff8a9e1189e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2463be0b4714169986c616ff3005117_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c1aa2507e474247b21581cd979cbf95_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8b23fc6b3d427ebf6b56614132eabc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie930191b929c4961b8ea3b30d8630a7d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d287acf3b954277b424a867b92331d4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c5df1eca1d6410e9c23987eab19795d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fea59117d2a4ea787d736618e348ab1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i399b542872cf4b8a95bc8a36570e3ecd_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5563f26ef24b288a82a1f6a3909255_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:AcuFocusIncAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib72c99bc651a43d89f88a30576ef0099_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:AcuFocusIncAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda71fa1050f4cd99d1b0487cabdc232_I20230117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:AcuFocusIncAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i274f7bd9f55d4414ae43d99e682cd28a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7994dfc403646e5bff69630f9cc9aa6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47206664dbc844039797dc32726a84f4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie718797acbb14934a88039b0b7639ab6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06ac642717c94b2bb1846110be0fc60d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7219dc1016d84387a28c86b12d9cf065_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ecdb94ccdc9431b9447675875213cc0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifffa5ab43fca470998ef4bc73c508195_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05beb5b79d2d4d1786504e1574156b9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a57514fe2b45cc95ad51616dde5842_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8571f31f2d94cbcaa0a6cf746cebae6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08edcda8013b411a8ae514fb186572f3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7702b9b65346fdbe57769e179c3810_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0daaca70154c40aeaacadd2265003e58_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9716709350419c83c375cd1e7f06dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2d1c1b6390420dbae526e06c3bf460_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0830e0c16af34c70b916f4b40dd82c53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7e1e14aa134850b3ef64a8fc34014e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia244db96c1c640908fc33b4da08106d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f2aa66d564423a8584754ff4101e8c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba72009cea324aec8b99aef7cc724d7a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibee7e52beb8e43fda8b440f37c8ebe57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedc061681ca144219826ecd1f58d340a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1769e6ad7e4ee4ba7d31d32deaa20b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11e5b05711c41bc94278235adbc4f4c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28a74559e034fe78617f85992188d35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095b974a4eda46539b55e501e35cecd5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ecae6a4337c43a6a5d0f8fb9b2a8820_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72f352e9aecb43c082504ada58284827_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibebb6d14814347889239321501ae010a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7d14de197c840548e735b7c5dccffd4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5134dadb2714e1785041a8064f00e00_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf6e5891da834960a8eb4d5a50ad53f2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba2db723f4a453284cf02585362f5f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibccb47312bd346279aaf43b1d2624d18_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95be04917e9242a4b3ab893073a4e5ac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d884c3b238b4a9484042a7ec80e4c08_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e0459eac81b48d391a6ba5f7a204bc9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9fc2637fe14e8da7c94ff2d6063b4f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1660d479841841a083afc611c4742172_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab4bebd84ef941c29f23b2b4ac6c05a9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6e400c24a6461b88808840db8e4b5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22eb775dada74a4cbae4ccbc53d12e07_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i056164fc33e8477cbf8aadaeb9855ca2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6357772b0f77447aac759696baca2658_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfd26c8ad7914e708774f00d667fddae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82576bfa08994cd9af972d7222b8c478_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="if9f1fb1cd13846c38b5c4a4cafd8a808_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20a127e123344f5a9df3c653c0441ff_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d7b079169584b7b827bc3ad599a02a0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147a77a2853541b8ac642c9ce50dfb79_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7363eb7130846d498238f0c9266f211_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f59cd43aff447ff9034642bf45fa138_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e658e3f4fe444859560086bf4a59a49_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28204be5e8ef457b9c492f5b766ac878_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id06b415e61b344bdb2ccda942b08f59b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48125eb5f60a4e3fa677f9dba896c944_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5705188337dd4a7f9f61104a2f18967b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2610664ed984b688dd611a19b847b62_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84330219b21546d7b29a854334867cd0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0d15fc2eafe4f60beb93612549521a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b48c13c21214c678ad36cf685b3b072_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dd0103274754e1fb33a46edcf042268_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3da26cfaf00043bdbba7864b5a155ec6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa692efa530140f8a1a881ba8a8249c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818c74f66a48498dba0c587f79830579_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:TradeNamesNoLongerUsedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbe4581fb4234dbdafb70170994354db_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf755e2bc874449e82907e0d22cf8c11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e744695a9e45b9b9ad55074d322f8a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fafe0032cba4aa1a32eca01ef3aca20_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a66af6adc904896a8ff0e7c2c1bd921_D20220930-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-30</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b6bf825c7324cacac00e1ebf2a1c71e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179f309e60d44d41af3ca366ec893b8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i778f77cb42414cb5ac34f18b66605477_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa6d2cd08c24125aa6dc092aad37002_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9d39794e57948c0b3f7a07a43885d87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb32f84fce124fcdbdda1eb3094fee46_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id52bba3d92b045cd9377b763545b3f6b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53fcd851b0d54c2dbe32c186e8d2ecb0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c329081547a4cdf98e1aa393d8972f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2455a2fae6ad431e922a0ba988eb6a34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f2a2fe52aa458190c6047336e73de4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i659a2f673c4a4411ab26d25784b4be92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if298046fc580453c82cae116d877a880_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a6d2460268490a812b6a04661c6a65_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic769315b03e548d48d1dd48f1f5ce5a2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc08a22ed7434483b9c22e1d5222d8b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8bc248d85e49df8afec2958aab8781_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294049ce13fc4119883d1b65b4fb4e3f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c81e913fa06452b960a94c4319affd4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dd72c321919418dbd266cd1519b7af3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f49db76bb9048269a4225f0617c7e08_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6075831fea84e2eb08c47c4f0c4d29b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40329b767834642890bfb55575f5122_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e632bea1f6478b9fa7efc4a42012da_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9aa533c5f43d49389b83002df6cdf881_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="iab9c3331e15a44048291c40dafad29a2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b85418b2df045ccaf777f6a153cd251_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff9524a8dec942a8bde2eb81616907d3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ae7f8afd93140b892be236df15ed51f_D20220506-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-06</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad75129d06c348f0be0dddaa52c9ed51_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f99abdbe264be492c1ab50a81c5fa7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370ee4cf54624da09da5e76a026c3802_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41f572ad45a949229f9b0322d3dfb46d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c9e3a1139454651b2a0528c0e2b983c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84e42d2305b3476a936b8caf47cb8b60_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45fcaa6d1e16450c95f03e1749bb60ac_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if400b9a66b464bc39f29a0744063105e_D20221001-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4230998f842f4bbc82a0ea680d4b577b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d9d9cd168d4fe98734f508386e2be0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfc0cbc0a72349eeb0612d5fd6410c80_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i063a380689344325b47343a660c9c908_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2263e23bd8e642778b2df9b8853237be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81245af4c6a84955ba0724a4c0e69852_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb5c0b0ff6ea4e92a88b245ac951ddde_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52924d69272c4ce08a9238494afb5ce1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73805f2008b0493784b73a6e474d0511_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14e66b94be8048c395bd7d7ffcc1ac3e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f96c4977bdf4527aca21c11e00b2edf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304f673759f44464b17361dc1fe3b487_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibacd0f91a9214e0fbe96138d126d5254_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d7b5fbd1e7f4531a59766d450386804_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d37517b7d6b4cbc982519aae076487f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e85debb9de747678b7cdb6f20a35b55_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53b662a6d4d41fead56abf94df3152b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d56d7f093844549b20bc3e68c8d823_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bfca85fb4024a6b94e76897fbe51927_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fce4dedbd8421eb73bafb553597896_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i016ac45dbd954b42a38d2dbcdf824196_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dd2ee808a54032b36dcaee1eacb64f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a5b69b0416d497d8056a590118b802a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i552ec672b451433a9e90f1b3839c487f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05ac9da4a9e044b0b3404afa13818036_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if57b9dc8ffac4b9b9b063a8ef1df4a6a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4de0d68bab3b4961969accc3d866508c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69eca3a5c1014c4fb4646db720b2ce73_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d865df747b04091979d8849df30eb08_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f5d88c4fc174c4ba4624f3bda26b88f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95707314425842cd82eb737ebe900f57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d21d625b784308ba11c8058938ddbe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i798ef0f209fb49009a6ca1d36a285f67_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a65dde3c3aa45549c7496b96199b6f8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0cd3f81eb14fbb885bef7666346a89_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied3ed0b49365444fad700d85b63bf260_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50270179827249f7adf2f7e4718cc6cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff54ecadaabf473d8116b32464b6b6a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7af656ef0f457484bd906468e5c84f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1ae1e47647b4e16abae2c02f07359b3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98cbac4569eb4a4897d65431dc5af7a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513ab91ef61a48c09cebf7bccfcc7994_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d700d6fa904cbabe449baab21de04e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i573bed6abe6342a9a2cca0beda4b3a3d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf7970cd462c4d338f9b250f47fc2cc7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2b7f1301cd4d6580b57be2d9bceba4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d23cbe1712d416fb576aaa815a0484b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2be8ab73b940ed95457d1d1dafe5af_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d45443ba5c4563bf3b25ec62964df1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5debb458ebf44991aaa7a159d30b758f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c38375327d4fa899cba5594e9d68b1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d52fbe0aac4ea784789ee582df1295_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i903eec80383246d8b63564df58e178c8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248fddc88f4a495caa1b4df3c4650cee_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i837a88fd5e964623b1aadc43f080279c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a389a27060343e5b22dc6da4936a17a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbfe4cdc452d465ebd08f232cee67b17_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38bd752f2804e82b66372aac33a299b_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d1ec0044004c3e9a1bd3cdc1fdd988_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a4f5fc4d13488fa1eb6879e85815a5_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74a383df89994d61aacc54ce4b2086ff_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6aef544f55e4d479ca0c5fdb0d3ac29_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69b14ba8ead54d019ac598383a31b62d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae292b83994f4eaa9429e631a6fdf509_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa16e6b0d894c1dada5fbfacfcbe3c9_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc18552483b945af9947da7d748f3797_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i941c4bbefa5240ef85c8e4f4ab0ca948_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c6dcc61b60403380d1c1c8b2e65827_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10b0cd89c2794a4a8c71d587e55cec38_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c472af859db4ef39a87c178260df1d4_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e11f388f2ee40dcbd589e6df1e9378c_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6752a30275734197a62fc5a9b8672ce1_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7bb320564f4aceb4edc483cb34a747_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577454bd748e4d5a8c05a2a6ddfbd23a_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3948c6f5951248dfa12e05ac7dbbe705_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e21098d0ad2484097856f68e1b275a2_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0cbf9921846406db6bd00b95257c769_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9fcf0826bd4e36b2683c1eebfca266_D20230331-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fcb41cb5a94e678206e69414bc0b5d_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2d58899a97e4cab97bd1a214b38f6cb_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84889b9489a14e36877c0478bea79508_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c18712f4b5d49ac81d008a300ff10e9_D20221129-20221129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1261229BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib21fed5341d54d0e89405e700d2488cd_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70d7dc79e80f485e9b0e3247e4c85728_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3edcc26eaf534e8eb544ca874238a97e_I20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd01cd11a7445c4a00b066d23512c4f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8621c3667fbf460daa121b9c4ae610ed_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie155f835e73f43c0a0a7a12dcfe3ddb7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i510257e58ffa4decb28c62ab425bbac7_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0248ec1e93ba4d7ea8d09b465512a94f_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1922ecd18a2e46a48b9820d0ee052834_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e35bf60d1c341548e91652443b6c303_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id29818a3e24849c9872d1d9f53ab8b00_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67b7c28c9224ebf8f9b868d72b01bf9_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6520558979e64b11a055e7cb64fefcb3_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b28056246f43a38618df0e494a97e4_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f67059f3db74cc48b901c7b97bad681_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22c0fcb53a541a5b34a13bce7623b83_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10bb7c9cf0764db899519673b3e54aa0_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a2772683b4144eb8f2ccc0181cce01e_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f2841ca1e44cdc95d5d3f351c569c0_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f18a15a09b463389c535fe19ade465_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0cba2f234984f27bed6d219b8e46492_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4accda99c8474fb514ff5e90f2c9c5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id65c9d3aa0e147cbbacd4d3353c0d376_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031f71ba66044feeb7830f5561dbd4bb_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i547ceb5147ad4e2db654418ebe7f7568_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52c91df8447249489b14e04f36239c8d_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie985a1f2ae2940ddaae3a79acd52e7d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0760722bf5d4183839a587492c1db15_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860c8720321c489a82c36ce3d3e91c8a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id094eccb229a4fd2b63155f5f349149b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i089a9da68a994aa6a72f9953208ab0d3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i970ab9f80f5f40959c2ab1571822b0d8_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fe16b7aeb642b693472e36f685e38b_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85b588e044c940eca8328840cfc28748_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c45857d12dd4d23981e438c843ec5cc_D20220621-20220621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-21</xbrli:startDate><xbrli:endDate>2022-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a72442b14b74396a03e29bc48cf80d5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4cb8742033349bdafbfd0dbe5122c94_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05b5bf3a3e34503a29b0b66b71f201e_I20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb50a893b673454784c495a665d8a5a8_D20230424-20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-24</xbrli:startDate><xbrli:endDate>2023-04-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3863db1d928d4e059096c4ab578fc383_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8868f6921a25423eaf40a6f726a3c0f9_D20220505-20220505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-05</xbrli:startDate><xbrli:endDate>2022-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceRestrictedShareUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7df102d4344988ae96ebc9a50e6c5f_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24036d8d6074ecdacda84c97de2156f_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57dc496593aa4b0eb2e9577518a5942f_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8032e2d6aa4162adae2cb4b0bb8097_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2c3fa275d2440c596a3bed71d4c3b85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2ed2192fcc941a696c261e49cf75b05_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i406d990fd1d347fe9b57aac1683865e7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68adcae65fa245a48869470ea3438264_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666b40934018485093be0f36415a1be9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac84c79811c44f82877f5606d96b198a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb261569c3d84cc38298b5c87946b5a9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic545e6c12b6344cf81caeedddfb12a1d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e00e72db8d42a6b5461ecf16e5d5a6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad26ab4e7aaa42cead89d21e59618776_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19de0acd56e49d687b026d53ef417fa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4df47c6c0de44dfa8ac7d75e4c88624a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6511364c8e784a6ea61cc24f22c25e3f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibda9a2e4a2b849239f2f10392436563f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76926d6eb76743fb893fda0b5ee0cd1a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfbb4a76db045fd9ebe9fb23d5d7ecf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c3d0bb2bf64e46be06eed20ec48919_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698b41841b3b43b49795ffc3a7917a63_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9b18a3d3a749e8b7ea0da438e8d116_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4f57ee4d6844129b313a85678998a48_D20220905-20220905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-05</xbrli:startDate><xbrli:endDate>2022-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b21867a93d5434bb4b2455d1f6434d2_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a35d63101ac4254a8698cf3aee3959f_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6160a9c0226049118b1c6eadb8592be1_D20230306-20230306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-06</xbrli:startDate><xbrli:endDate>2023-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ffe0c3f62ab46708e444bc96954e538_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78900a84c814e17a0700f44d77a770a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08ba76927daa47f698849aaa8387e768_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf8da1fe72640db95834f27357c5bde_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d3136d31994fbdb7cb150bafef9389_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19848514ed9a48b79bf2c5a2c418cae9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7f6f3cf8d14cc58d92cb9b35e61a89_D20221108-20221108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2018AndTaxYear2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-08</xbrli:startDate><xbrli:endDate>2022-11-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i5eb53786821248ca8b1f2d53e1c01d20_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb496022dc8e4cf08fe49993684b187c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaebb38b5c93f4c928fa764fbd3fde9ce_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81b6547380c64dd2a50784794125d70e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519005c4e8bf4fa49fe850dc4fd0f0ff_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabca2dedff2549f2a26e0f9e0fc903e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if51c4186ebf842d9bc523ee7341ac28b_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="ifc7b2df681304b2890b3963d6767bdca_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="i4673169a9f5042a890348f2de0d3b0de_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i458f2edb3ff040f987cabd221cc1abb6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="ia0de8367b153476aa320c433be6e8642_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i39bb1640622d4df192d462ee18b711d5_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i9f50f038b4734b508b66b728e2f90a2b_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number_business"><xbrli:measure>bhc:number_business</xbrli:measure></xbrli:unit><xbrli:context id="ic47ec016d3f14e9687e6fd9195affb3e_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="i1f2bdc093e6f469e94ae4f92c6ae44c9_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="i1bbfea8bf36146258594bca2c1b2d4fa_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i770a218322c748019334a4cf693ddec3_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fef41f4b68f4a788694d3e96118dc2d_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i005975800f4b45b88a890051cc8ed460_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09d4ece01b0b4cbe82efb645a38a84ad_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945b95d4642547dc948d93764b9fa34e_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57a59221634247afa741a3029a821408_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176472c9a91947a58428394faa66f2cc_D20200326-20200326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-26</xbrli:startDate><xbrli:endDate>2020-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b70ae48ac824b238ebdfb47f23616a7_D20220721-20220721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-21</xbrli:startDate><xbrli:endDate>2022-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9c399e8c9cd4e7ca1b0299006f338c2_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d679a98f75427f88c6ebe76a942e45_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:AurobindoPharmaLimitedLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6350305849648ffb0d2318c6a4aff11_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="defendant"><xbrli:measure>bhc:defendant</xbrli:measure></xbrli:unit><xbrli:unit id="proceeding"><xbrli:measure>bhc:proceeding</xbrli:measure></xbrli:unit><xbrli:context id="i4d5d5d30a78743fcbe52b8144e75f596_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f2f806ddb64cfc8ebb70476e207aae_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b0c4fb144a4119b0353b9e796c5864_D20230504-20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26816d2d301f4b2e814b747046bafd99_D20210910-20210910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1a1acd7be5d4003ac3ff92ab403c379_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e4a619c05e48ffb995b93d387f88e3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>bhc:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i993f123539934cffbde85472ef746930_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b05eff1ebcf4f5b980a23bd07d03ae4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2eb449f9874ce181c5a5a55b53420a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i879843cb6d494828a7a39d54b19d72ca_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a43da3b1f6244ca9940203efc29fea7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68a72c1f5224ee9b35a0e482c1dadbb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2b286567c0d4c80b0020c5f649deaeb_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9efca43066164f5f8a7d4d69da63efec_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CaliforniaProposition65RelatedMatterLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e4af957468b4b74a17f3a7d3f6e1b6d_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80385ad9ebe4c0bb7c80610f3bae724_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide8c6d648ece4cb38926e0893d4d16cb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa7faccfc9e4b2ca204f3c85a970f69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023a58638ddd46eca36de268fb813f97_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be070c32a5a4c1ba81697834d0ed884_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4f39f4056646cc9b55c92a148ec539_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedcb8713c7af444fb8b6d03e82848ff6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46df43952df846588596009246e5d41d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24da3a29fc44884abed656c976f1185_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5067f998a0774347a1ba8dddd05e828d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84476c66acf64d629d1829a442bdd45f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844e35405a554f25b15ab800349871ec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c0d405070e646faa7642b41b7cf60bc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291a59d0cc7a41f998a11690ab1a3fc2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if231378ef6374003b9b4b0a7109a7cd7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95a4bade0b5f449babad9d26acb96982_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac1d18d3c5e49c2bfc56953bf92f5c6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f2d378c39e4f668000688f3e489870_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7dd91b590f846dd9b290718829cfd6a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b225b3f8b0746bfb199706e955676a9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id89d66db36c64eceab4715ffe59e84a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8743518cdefc482a9aa2ddf769e627d3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc1d8878ec541b1826e3e74d410810e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c847d919d274b11b0a404d202cae423_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39116494adc049f9a0fbb011b1049e08_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5866e33824490488ff419bebdbb6ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8662c383a6524d2ea7cd1a7de3a66edd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia643f63ceee34dc993fdef9436ce2e49_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a5eb1f6967e48d08f792876eb21bd30_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i239109b0a39046aa954f3569a8c23d66_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8d23297ea6d4d9baf0ea77a0ff9cf17_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42629885d170479c82e079fcc16ce6af_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30903274eb934e56a09474d3bcc6a0e1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i295b427c6e5842fcb723434d6f3a5a70_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324909a15d044fbfa04c98f71ac58540_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e5c70cdd5da42c8a415fdc4ee3a7406_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05fec92c81a743af8199d506c268b2b6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a76d1cc780742139bbe99625081f16e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeb0507fddbe4ccab01b0ef5a88ce5d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92ca67bd6ac74e69949d588a28fb81f3_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0507fe44b91427c8643ec0c7610c2bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c93ea65ff5e4ed7b39b1bf2ffc5657f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6774d58be5dd408890835ff4f0d2deeb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3de643ea5a37490db8249b80a35d9852_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d81a5cdc4704a17830a70621a701a43_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0092c04e97d44cc7b8e987d7db42f7fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3b4496691294c8ab8af9894359f523e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id67a9b004e36401d8688fc07e50d19a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d7bed392714c149189fa93868f8a48_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82cb62cbef5f4deca4f2e8e3e580d3f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9a2611542a49d9bc16e7aa4527978d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56013d342ab744dca87c96542224d7e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88fa31de50ca45b6a6a7b566720bcf21_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae6f318f371c4cbb8d697ce6f04abbb9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26e30d1cbd3240e3bfa7140161b77af8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b3e2d64225341b0baf9cc892bc9fd23_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4924f823451e44f3b29db4603696acb0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78fdb3892eb45d4b6b4521c1d544510_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf234d805c8b4bf18c742891e6f5b611_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13033d3d942041598d62836da3fc1150_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a6ba62744a40428a6ebad3dd21ae27_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6956da0da306428e9c7adf2d607c14ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954aadc6d7e24b478f75085b14eb996d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice48058f29044c469949c88a452cb9bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15d3638d8904493b1d72ff76791bcb8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ae1eb1ecc54f668ec2295f497fe096_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e328edc701b4e18a474924165dee258_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015bfad0089f4e8fb03abd4e78cccd35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if576ecdebb9d4e7ea72213c7c3d64c5f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8814d42191f44bb4856713e244453471_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba18df505885492da7aa2619531de2b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92b667bc7804456b38e70fa08da5099_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb0e6403a294c32ae63824bc6e1c102_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8101afe6ef64e7d899f1670a46f8de9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice4470b739f04d39a1886b3405bfed9f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284ff13718b143468083c69139f95230_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d85c2876042450a967e14abaddd63cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdbe909a002041d9bac599bf26407059_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic36a4000ae884c6883a2abeb82097b07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="ib4db0b41aa7f45ffbc8ed78d848702cd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idccd693104244d1e850fcf6797ba4971_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34eb56c13bb140ba8a8a420a15ef17ba_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2544c5919fe1473d9274d0f8c6f34aba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd68bfa811af4e1f80cef02be120e2ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54f840f01d0d48f58279fe4612f1e496_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab38f7e31c74f2c8d237669db709e1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5a6fa5e6dc44421b695211384e133e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e193566415d44f1b34e042c627e3a6a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5c293c01084dc9ada28fd87e45e84f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56aa6955c9e4050b0a86980dfe8ef9c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c155e8345e4852a74a094f971e33b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe94207c53504992b03639c875317423_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b71032da9c24495bd516ea636fbb96a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f0b8edeace144f9838fb73ef992a4bf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia525c6b1240948b7ac3d8f4ff68a197a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i228b85d7ce4e492abb7d118eda50756f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4208ff78234d48a6b95a64d673fb7301_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490f355f2ecc4859b9a79fb726c9eab2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4991ff736cbb4e52a8b67af6a4dd540d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia62501d6a5964b1fb2ce175fd8d9ab7a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdf32169d53448eaa447c6c6a95ff0ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd0ec5f9323645c896a31a7b9d2c0ffc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7febcf7dfef54f08a344f4e803874e80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269a979c418a4bc98d8b0cfceca3b1df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3eef7c95b3471bad3220dc8f4e560d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470bfc29961247a9b005e84b7140ad3c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c45e66c585145df8939a8f99dceb756_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020c8cc6877448239e19574641b420c0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb78d4f9fa147ca952eee7a47399459_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53c0c9f9a29c4194a26ee2fc5d2a2278_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7e267a0214438590a982060fcfc8e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdbf70eb870c4f4c96edf59101416ef8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940b858ec7d04ba6b3901bcdc58f422f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia377fd0a03cc4bc29b88b780401b204b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia318e977ae6f4e10a9742bbf5ef4c757_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcw_f3183705-211b-4155-9172-99004cecc9af">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:0.1%"></td><td style="width:2.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NDcyNmQ3ZGU2MDA2NGRmNzk3MDdhZGEwNDE3MzhmMDAvdGFibGVyYW5nZTo0NzI2ZDdkZTYwMDY0ZGY3OTcwN2FkYTA0MTczOGYwMF8wLTAtMS0xLTIwNzcxNQ_c1edfdf8-a82a-4037-8c2c-1b14b2a7ccd2">&#9746;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-align:right;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Quarterly Period Ended</span></div></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NDcyNmQ3ZGU2MDA2NGRmNzk3MDdhZGEwNDE3MzhmMDAvdGFibGVyYW5nZTo0NzI2ZDdkZTYwMDY0ZGY3OTcwN2FkYTA0MTczOGYwMF8xLTItMS0xLTIwNzcxNQ_2b1ef8c2-fc93-40cf-8deb-730159f419f7">March 31, 2023</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NDcyNmQ3ZGU2MDA2NGRmNzk3MDdhZGEwNDE3MzhmMDAvdGFibGVyYW5nZTo0NzI2ZDdkZTYwMDY0ZGY3OTcwN2FkYTA0MTczOGYwMF8zLTAtMS0xLTIwNzcxNQ_a9b7858f-62f8-4144-8bf4-b11f2184a43c">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">           &#160;</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcx_20e15b6b-a25b-4d98-8991-9f8df0f0167b">001-14956</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY0_5443fab5-8f89-48f3-ae01-87347f2f49d3">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"></td><td style="width:22.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NzFhYThjZmUzNzcwNDJjN2IxN2MzOTJkMDA2MzIwYzEvdGFibGVyYW5nZTo3MWFhOGNmZTM3NzA0MmM3YjE3YzM5MmQwMDYzMjBjMV8wLTAtMS0xLTIwNzcxNQ_143502e1-b426-4881-ad40-a6e7f0b5bc11">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NzFhYThjZmUzNzcwNDJjN2IxN2MzOTJkMDA2MzIwYzEvdGFibGVyYW5nZTo3MWFhOGNmZTM3NzA0MmM3YjE3YzM5MmQwMDYzMjBjMV8wLTQtMS0xLTIwNzcxNQ_9ba3978d-a290-4049-875b-c78cf531a753">Canada</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NzFhYThjZmUzNzcwNDJjN2IxN2MzOTJkMDA2MzIwYzEvdGFibGVyYW5nZTo3MWFhOGNmZTM3NzA0MmM3YjE3YzM5MmQwMDYzMjBjMV8wLTctMS0xLTIwNzcxNQ_b422c8f1-687a-43ee-bb5e-3acab1d265a8">98-0448205</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY1_bcab6baa-5360-436d-91ff-11ae7e7f8f32">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcy_380aedcb-b656-4f13-bdd0-67a0b8bb8021">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcz_2dcfac19-9927-413e-b427-23582f96f056">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY2_b7061d40-78fd-498e-8ff1-6670374cb7f2">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY3_33696802-c744-4b6f-8c6a-8fb59978a5f6">H7L 4A8</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTYx_a9e12b4e-6add-42e8-8d7f-1bc2a2715428">514</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY4_14c1e438-50fb-4ee6-adfd-37fe50df0014">744-6792</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.522%"><tr><td style="width:1.0%"></td><td style="width:29.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NTAyN2M3NTgzYzBiNGM3Mzk1YWEyYjgwYzY4ZWJkY2EvdGFibGVyYW5nZTo1MDI3Yzc1ODNjMGI0YzczOTVhYTJiODBjNjhlYmRjYV8xLTAtMS0xLTIwNzcxNQ_dba9e61d-0a8a-4b19-aced-7328496e474e">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NTAyN2M3NTgzYzBiNGM3Mzk1YWEyYjgwYzY4ZWJkY2EvdGFibGVyYW5nZTo1MDI3Yzc1ODNjMGI0YzczOTVhYTJiODBjNjhlYmRjYV8xLTEtMS0xLTIwNzcxNQ_75bb66a6-0acc-49e1-b50e-9bde5e9d1963">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NTAyN2M3NTgzYzBiNGM3Mzk1YWEyYjgwYzY4ZWJkY2EvdGFibGVyYW5nZTo1MDI3Yzc1ODNjMGI0YzczOTVhYTJiODBjNjhlYmRjYV8xLTItMS0xLTIwNzcxNQ_474f8295-ffb8-45ca-89ee-bd204796f584">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or&#160;15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTYy_0a8e9761-e81f-41dc-b2da-6055b8935328">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or&#160;for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY5_409265de-ede2-4e87-a671-2e43dfa8db48">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6OGQ4OWJmNzJlODgyNDFjNTgwNGI0ZWQ3MzVlZWQ0MDkvdGFibGVyYW5nZTo4ZDg5YmY3MmU4ODI0MWM1ODA0YjRlZDczNWVlZDQwOV8wLTAtMS0xLTIwNzcxNQ_405b2ea9-f161-438a-a545-18c69fcfec78">Large accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6OGQ4OWJmNzJlODgyNDFjNTgwNGI0ZWQ3MzVlZWQ0MDkvdGFibGVyYW5nZTo4ZDg5YmY3MmU4ODI0MWM1ODA0YjRlZDczNWVlZDQwOV8wLTctMS0xLTIwNzcxNQ_8ef72948-0003-4289-a876-98b4127a9006">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6OGQ4OWJmNzJlODgyNDFjNTgwNGI0ZWQ3MzVlZWQ0MDkvdGFibGVyYW5nZTo4ZDg5YmY3MmU4ODI0MWM1ODA0YjRlZDczNWVlZDQwOV8wLTktMS0xLTIwNzcxNQ_eb97f40b-f316-4873-89d6-8a307ff2fac5">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as&#160;defined in Rule&#160;12b-2 of the Exchange Act). Yes &#9744; No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTYz_79236daa-754c-4008-a00d-ac38894f8fbb">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable&#160;date.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares, no par value&#160;&#8212; <ix:nonFraction unitRef="shares" contextRef="i62f07f63ca2d4846a0d70246d162c824_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTI5_03d2080e-7877-40a7-aee2-02cb59f20b0c">363,723,880</ix:nonFraction> shares outstanding as of April 28, 2023.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED MARCH&#160;31, 2023 </span></div><div style="margin-bottom:16pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part&#160;I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_19">Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_22">Condensed Consolidated Balance Sheets as of March 31, 2023 and December&#160;31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_25">Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_28">Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_28">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_31">Condensed Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_31">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_34">Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_34">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_37">Notes to the Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_37">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_106">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_106">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_217">Quantitative and&#160;Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:27pt;text-align:right;text-indent:-27pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_217">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_220">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_220">75</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part&#160;II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_229">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_229">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_232">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_232">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_235">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:40.5pt;text-align:right;text-indent:-40.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_235">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_238">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_238">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_241">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_241">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_244">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_244">76</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_247">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_247">76</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#i403fd8161ca64d5ab28658fcd748a8e4_250">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-align:right;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i403fd8161ca64d5ab28658fcd748a8e4_250">78</a></span></div></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED MARCH&#160;31, 2023 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Introductory Note</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Quarterly Report on Form&#160;10-Q for the quarterly period ended March&#160;31, 2023 (this &#8220;Form&#160;10-Q&#8221;) to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies&#160;Inc. and its subsidiaries, taken together. In this Form&#160;10-Q, references to&#160;&#8220;$&#8221; are to United&#160;States (&#8220;U.S.&#8221;) dollars, references to &#8220;&#8364;&#8221; are to Euros and references to &#8220;CAD&#8221; are to Canadian dollars. Unless otherwise indicated, the statistical and financial data contained in this Form&#160;10-Q are presented as of March&#160;31, 2023.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_13"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning of applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;), as described in more detail under the heading &#8220;Forward-Looking Statements&#8221; in Item 2 of Part I of this Form 10-Q. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found (i) in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February 23, 2023, under Item&#160;1A. &#8220;Risk Factors&#8221;; and (ii) in the Company&#8217;s other filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;). When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider such factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the list of important factors, as described in more detail under the heading &#8220;Forward-Looking Statements&#8221; in Item 2 of Part I of this Form 10-Q, that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_16"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_19"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Financial Statements</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_22"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:70.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.886%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="padding-left:36pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMy0xLTEtMS0yMDc3MTU_beca91c5-59c3-4c0f-a8a8-a026f942cd58">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMy0zLTEtMS0yMDc3MTU_d14f20f8-4268-4178-bb46-28e1a0311729">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNC0xLTEtMS0yMDc3MTU_dc3695b3-ed61-47ef-8f8d-41cb9b84dfe8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNC0zLTEtMS0yMDc3MTU_27db9cbc-be6f-47b0-bdb5-d4f77c85ab74">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNS0xLTEtMS0yMDc3MTU_1e25689b-ca1d-467b-bb47-7bd618ae37f2">1,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNS0zLTEtMS0yMDc3MTU_333de74a-0724-477c-a1db-1245db1b2154">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNi0xLTEtMS0yMDc3MTU_bf623966-931f-4d5c-88c0-350f7dc5c062">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNi0zLTEtMS0yMDc3MTU_c1937e2e-89de-4a63-ad05-8db8cc5a5520">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNy0xLTEtMS0yMDc3MTU_b9b22924-8df4-4b22-8475-e507c44fcaf4">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNy0zLTEtMS0yMDc3MTU_3cd9ecd8-2f00-4506-9d02-1ef725267ee0">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOC0xLTEtMS0yMDc3MTU_7a4b4eec-5cb1-4c62-a15c-e64e666fb45c">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOC0zLTEtMS0yMDc3MTU_79cd9b85-036c-4849-adb8-7af8044ddd16">4,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOS0xLTEtMS0yMDc3MTU_cd60600a-1390-4597-a314-cc502f6aab2f">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOS0zLTEtMS0yMDc3MTU_dae5416e-d82f-4d99-b77c-88f63d1dcfdd">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTAtMS0xLTEtMjA3NzE1_3db0ab40-e0b2-4056-a464-e2998acd2cc6">5,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTAtMy0xLTEtMjA3NzE1_8f90065b-034c-4341-b4f6-a16462d1f3cc">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTEtMS0xLTEtMjA3NzE1_bf8687b3-c592-48a9-b4e0-ebc8b431a8ba">11,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTEtMy0xLTEtMjA3NzE1_0e07a5d9-ba33-4cf6-9b4b-36b630c796f7">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTItMS0xLTEtMjA3NzE1_1fab6476-f133-413d-83f2-d85853b71ab0">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTItMy0xLTEtMjA3NzE1_933de959-e4eb-4fc9-b768-f8c99edfc8b7">2,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTMtMS0xLTEtMjA3NzE1_7656639e-d9ac-4aba-9846-61a6f3bea259">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTMtMy0xLTEtMjA3NzE1_64d16a5b-edaf-4f78-8fea-d7ee67fc387e">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTQtMS0xLTEtMjA3NzE1_65ecc4f9-492d-4739-b3d7-45d5ffafcaab">25,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTQtMy0xLTEtMjA3NzE1_c48797e1-ff09-4ede-bda2-5b8a242fc044">25,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTctMS0xLTEtMjA3NzE1_e7ef111c-5010-45b4-928e-304614161791">561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTctMy0xLTEtMjA3NzE1_f57c67a6-c465-4b40-a10e-e2ebd7abd2b0">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTgtMS0xLTEtMjA3NzE1_58cb1417-f6ff-41f9-bc22-d99efcb2f835">2,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTgtMy0xLTEtMjA3NzE1_0853e00b-65af-494d-b130-f337e2666717">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTktMS0xLTEtMjA3NzE1_99e2f1b4-fdce-4caa-89bf-61292bd8d474">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTktMy0xLTEtMjA3NzE1_1132080c-5e0e-496b-a9a7-34f313aa2470">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjAtMS0xLTEtMjA3NzE1_84efd69c-2ce6-4b09-9e09-882946b94cfe">3,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjAtMy0xLTEtMjA3NzE1_a602e829-bbe7-4ed2-94be-b17b2186704e">3,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjEtMS0xLTEtMjA3NzE1_127cc900-ca21-4966-93fb-eb0093e18e82">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjEtMy0xLTEtMjA3NzE1_d0422475-2b4f-4b6d-be13-8f756efe6c45">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjItMS0xLTEtMjA3NzE1_b599f7f9-ea28-46e6-855e-d3b20a53ca4a">20,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjItMy0xLTEtMjA3NzE1_5dcd2ac4-7d9b-4b85-b112-372d748af206">20,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjMtMS0xLTEtMjA3NzE1_a9256b9f-f557-4690-8b89-518092585d24">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjMtMy0xLTEtMjA3NzE1_47b8895d-672b-452a-9283-700519e97d9d">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjQtMS0xLTEtMjA3NzE1_369dd59e-4df9-4bb8-b0e0-8bf98aa49c13">746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjQtMy0xLTEtMjA3NzE1_c0a366ea-f770-40d8-a21c-be9a567c81b7">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjUtMS0xLTEtMjA3NzE1_d0fa272f-a7bd-44b0-8711-6e37680163d0">25,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjUtMy0xLTEtMjA3NzE1_5cde4a46-3130-4a40-b367-14971210d147">25,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjYtMS0xLTEtMjA3NzE1_e71ea39c-ea2c-47c9-b94c-cf9b490e1f40"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjYtMy0xLTEtMjA3NzE1_af184c3a-aac4-4cd0-ae70-b7bc285c5db8"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjI_4e212c75-eba1-4638-b580-df32362d1966"><ix:nonFraction unitRef="shares" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjI_fb1a13fc-1510-4abc-a436-9d04e19de223">363,607,062</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjk_0913db0b-0361-4bad-8da9-0b5f6042ab89"><ix:nonFraction unitRef="shares" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjk_9d91e4de-10ec-4c1e-90bf-8033b719fb0a">361,898,846</ix:nonFraction></ix:nonFraction> issued and outstanding at March 31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMS0xLTEtMjA3NzE1_97c98ff5-b8a6-48e5-a497-181f08cfbd64">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMy0xLTEtMjA3NzE1_9303dcc4-c2c5-4ab8-86d1-f5f5e95baf3f">10,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjktMS0xLTEtMjA3NzE1_404f81ee-533a-4a27-993a-9cc1af01906d">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjktMy0xLTEtMjA3NzE1_6cf4d775-94d0-47aa-861e-097973855b67">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzAtMS0xLTEtMjA3NzE1_15a80177-ff7e-4827-84a6-b7f757e03b09">9,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzAtMy0xLTEtMjA3NzE1_dc76dd48-8e3b-4977-bd56-f2809440a000">9,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzEtMS0xLTEtMjA3NzE1_1c46548f-c320-43d7-81be-bbda99c7f583">1,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzEtMy0xLTEtMjA3NzE1_9b71792a-ddbd-4955-aa20-5ac76465329c">2,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzItMS0xLTEtMjA3NzE1_80afacfe-0109-41ce-81c7-e45d84c5a879">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzItMy0xLTEtMjA3NzE1_023d87ec-2520-4a3a-af66-6e1b7a48e555">692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzMtMS0xLTEtMjA3NzE1_3b13e93e-521c-4204-8c28-96ca5927d1b6">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzMtMy0xLTEtMjA3NzE1_8ff14440-46b3-4d48-975a-fabe4c4a0cc2">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzQtMS0xLTEtMjA3NzE1_e1dc2f90-e2b8-494d-a112-0d7cc278ca3b">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzQtMy0xLTEtMjA3NzE1_07a1bcf6-9bd5-44a7-8799-ac0aae790c64">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzUtMS0xLTEtMjA3NzE1_d9dc83c4-83fc-497b-8312-13ce158d4e46">25,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzUtMy0xLTEtMjA3NzE1_2b93a175-cb75-4cab-94ac-91fcdff376a1">25,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_25"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.476%"><tr><td style="width:1.0%"></td><td style="width:78.340%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19ded4922bb433e8435b8239b8ff307_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMy01LTEtMS0yMDc3MTU_25dd1f39-db1d-42c9-b70f-9c464f408409">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c6e6704998497797963a331448aaea_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMy03LTEtMS0yMDc3MTU_ebb0833f-ff07-4d02-b6a6-86f9a7dd034a">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie687efc76f874ebeb1aae627bb6e171e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNC01LTEtMS0yMDc3MTU_af0e0311-6047-4efe-9b52-092efb050921">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d37d3e40784682946238eaa429b35e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNC03LTEtMS0yMDc3MTU_5c0d1076-7ac8-43e1-8f22-c58f350cb620">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNS01LTEtMS0yMDc3MTU_b4ab0497-dc14-4d7f-9977-1519cdd29539">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNS03LTEtMS0yMDc3MTU_a62e8a30-d5c6-433a-97c3-8712221c871a">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(excluding amortization and impairments of intangible assets)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia19ded4922bb433e8435b8239b8ff307_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNy01LTEtMS0yMDc3MTU_82e7f5a1-e1be-48a5-97db-c90d50fd4605">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c6e6704998497797963a331448aaea_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNy03LTEtMS0yMDc3MTU_510f8942-17f9-44a9-9f0e-460893ff1d18">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie687efc76f874ebeb1aae627bb6e171e_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOC01LTEtMS0yMDc3MTU_e1ac5962-3fc7-496b-b881-5876a7f85f27">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d37d3e40784682946238eaa429b35e_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOC03LTEtMS0yMDc3MTU_26432013-ba5a-4bde-8f5d-607b5af0a264">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOS01LTEtMS0yMDc3MTU_df5e7fab-2726-4367-a5c9-4c54eecfee0f">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOS03LTEtMS0yMDc3MTU_2b416a5f-8bf0-4f44-87d2-0f6e6f938e09">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTAtNS0xLTEtMjA3NzE1_b2fe57c5-7a92-47ec-9eec-e5be6e2686e7">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTAtNy0xLTEtMjA3NzE1_5c444ae7-c0b5-465a-8383-97b0e5379ff6">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTEtNS0xLTEtMjA3NzE1_ba2a4374-2749-42fe-8c6e-d86ee29b3453">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTEtNy0xLTEtMjA3NzE1_88ac4d20-ce8e-4afc-a702-cb5a03ab8f23">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTMtNS0xLTEtMjA3NzE1_24f79745-d93c-429e-837d-9274e034293b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTMtNy0xLTEtMjA3NzE1_ccd74831-f370-4e56-b81b-baceb3b5473e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTQtNS0xLTEtMjA3NzE1_77275bce-2251-4ecf-a4bb-fc9a78cf345c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTQtNy0xLTEtMjA3NzE1_97aa7ae4-3046-4e13-984f-b6c1046561cf">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTUtNS0xLTEtMjA3NzE1_f13c9e66-eb58-453e-8e31-dbbfe82f24f6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTUtNy0xLTEtMjA3NzE1_e7cdd115-96c9-4449-a6c9-5c40e40cf02a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTctNS0xLTEtMjA3NzE1_61ada127-8f87-47c0-9e13-67eb65567d5d">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTctNy0xLTEtMjA3NzE1_1f448cc7-fa8b-46a0-b75c-7ccc7c8d5188">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTgtNS0xLTEtMjA3NzE1_77b64367-1991-4dff-9002-2d035e3fb850">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTgtNy0xLTEtMjA3NzE1_5ae87207-485c-4414-93e1-f15ff540ef1e">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTktNS0xLTEtMjA3NzE1_d4912071-2aad-454b-a506-295ca2426830">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTktNy0xLTEtMjA3NzE1_5168c7c2-f852-4e43-baf8-10d399aea7cd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjAtNS0xLTEtMjA3NzE1_d2ad3622-7664-43ad-acf9-ee12be2173d1">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjAtNy0xLTEtMjA3NzE1_98c710c9-7699-42a2-a108-cc3f3b287034">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjItNS0xLTEtMjA3NzE1_7fe6ee55-146a-448a-8295-2c158adadd5b">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjItNy0xLTEtMjA3NzE1_fc9b46f6-6baa-41a6-8e6d-badd0089453b">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjMtNS0xLTEtMjA3NzE1_142bfcd8-b728-47ad-85ff-1dd1962e7f5d">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjMtNy0xLTEtMjA3NzE1_5cb23cee-0f99-44b5-b75c-9f12e8a767e3">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjQtNS0xLTEtMjA3NzE1_5d582135-bced-4993-96c1-8ade01a915af">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjQtNy0xLTEtMjA3NzE1_dc181c69-be22-4194-a2bf-8b0a6df1f1ad">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjUtNS0xLTEtMjA3NzE1_159f250f-c82b-473f-9eb3-208f06f6dbc5">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjUtNy0xLTEtMjA3NzE1_ee4be0c6-afca-4614-8737-771f88936c2b">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjYtNS0xLTEtMjA3NzE1_34d52762-c5a9-4966-8129-34e299872ad4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjYtNy0xLTEtMjA3NzE1_528863cf-fd73-4d1b-806f-15e9afc42a45">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjctNS0xLTEtMjA3NzE1_6f4998e0-e721-4359-baa1-4c47909656e9">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjctNy0xLTEtMjA3NzE1_2a2e0568-2300-4bbb-a801-71fd8bed73b4">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNS0xLTEtMjA3NzE1_5d2a9f8d-2120-4754-be0f-d5cce55aac30"><ix:nonFraction unitRef="usdPerShare" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNS0xLTEtMjA3NzE1_759a968e-fbfe-45db-96aa-3f9fac613b69">0.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNy0xLTEtMjA3NzE1_950d4ee7-017b-47c3-bc7d-013f8fd32d09"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNy0xLTEtMjA3NzE1_f8c5825f-96a7-4d96-a310-852ed5263f8b">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNS0xLTEtMjE5MDAx_7111d1bc-58a2-49d8-a934-5e5b684291a9"><ix:nonFraction unitRef="shares" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNS0xLTEtMjE5MDAx_7a77166b-daf2-4880-8f02-3ce576155160">363.3</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNy0xLTEtMjE5MDAx_3b37c142-7b89-4edd-b849-bfa6c7adf67f"><ix:nonFraction unitRef="shares" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNy0xLTEtMjE5MDAx_f9a9a8d6-52ed-4b00-a907-67ae700cf7c1">360.8</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.964%"><tr><td style="width:1.0%"></td><td style="width:73.495%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.035%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfMi01LTEtMS0yMDc3MTU_5f52adb8-5365-4a65-855a-40060dd3ff65">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfMi03LTEtMS0yMDc3MTU_0a160bbd-e547-4c2e-b197-cc228e439421">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNC01LTEtMS0yMDc3MTU_0396b36c-91fa-4471-879e-07187f55db0c">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNC03LTEtMS0yMDc3MTU_957cbf25-ba1f-4a60-b332-f879943ce3b4">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments, net of income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNS01LTEtMS0yMDc3MTU_a1c32124-f249-40df-9346-90d45c34fd7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNS03LTEtMS0yMDc3MTU_6f80ebaf-3b8f-46a7-9c1b-94f07d0007cd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNi01LTEtMS0yMDc3MTU_5d37f972-7520-40ac-8c65-04f536bfce20">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNi03LTEtMS0yMDc3MTU_e195b18d-954c-4a58-88b0-0a8c9e5592c6">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNy01LTEtMS0yMDc3MTU_f96a668b-8f80-4a07-8b0c-948b4829a184">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNy03LTEtMS0yMDc3MTU_024e2ad1-a30d-49ce-b65d-e0cb06bcc02c">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss (income) attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOC01LTEtMS0yMDc3MTU_ccd9c894-c49d-4b37-8995-256a185d1322">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOC03LTEtMS0yMDc3MTU_9e4e69a4-eefa-4fe8-a74d-0df4ded75ebe">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOS01LTEtMS0yMDc3MTU_f76f7258-e15a-4c00-9544-cbe136e4c772">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOS03LTEtMS0yMDc3MTU_9e631101-e156-439b-8278-7b504798b96c">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders&#8217;<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity<br/>(Deficit)</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i32b7e06a9d3a4aeb99dd497ebfb356f9_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMi0xLTEtMjA3NzE1_bc91f6c3-ea42-4217-9988-82e045851ef9">361.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32b7e06a9d3a4aeb99dd497ebfb356f9_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtNC0xLTEtMjA3NzE1_40c7b5cd-b854-40f5-8925-727a7d41a037">10,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452d83aa9dde4d01b6869dd5703fdaf8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtNi0xLTEtMjA3NzE1_68da8887-6ee2-4025-bfe1-453cbcf26b5d">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc3e9fd64df947f9a8f763d6cc90b963_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtOC0xLTEtMjA3NzE1_d963a480-45fe-411a-8b0a-1e958ca85fcf">9,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e558abb1f7e4945be1efbb15c0857e4_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTAtMS0xLTIwNzcxNQ_70c0e09c-2616-4543-b62c-f84e32ce1a59">2,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12545de9cf64750aa8d3591b5e00bc7_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTItMS0xLTIwNzcxNQ_536ba151-3443-4a5d-8715-ab7fdf61afb1">692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94c5658cc65a4a05b4ff0e04db19ee97_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTQtMS0xLTIwNzcxNQ_386bb514-c013-4698-98b9-a6c2a5157a20">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTYtMS0xLTIwNzcxNQ_9ef2c31d-a477-4f37-a9c1-dc471b3b5b3b">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6a8b96ed7f940c5845ec8d2f802a9d4_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtMi0xLTEtMjA3NzE1_53d8b811-a39a-4c64-96a3-912edc96dcc2">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6a8b96ed7f940c5845ec8d2f802a9d4_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtNC0xLTEtMjA3NzE1_61fedd09-5ac2-44be-967b-cc91a60d6d0f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtNi0xLTEtMjA3NzE1_cce4e5d5-b145-48eb-8209-2816e30b054a">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtMTYtMS0xLTIwNzcxNQ_7aa9ddf4-ed2a-43f9-8525-724daf2897f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzEtNi0xLTEtMjA3NzE1_82007c21-ece0-48c5-bcaa-b5a08660c5ed">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzEtMTItMS0xLTIwNzcxNQ_cdc4e4c2-64c0-4e1a-af6e-4c3394636fde">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzEtMTYtMS0xLTIwNzcxNQ_4eaed946-8950-4744-9219-31c54b7554ae">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzItNi0xLTEtMjA3NzE1_6e1691b8-241e-4741-9bde-774b05bcdd40">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzItMTItMS0xLTIwNzcxNQ_12cccb86-6886-4f38-9481-3b19eed81a34">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzItMTYtMS0xLTIwNzcxNQ_bcf79616-bc95-44e9-bd2a-6502940c107a">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">B+L vested shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtNi0xLTEtMjM4NjYz_48275131-4e0c-477e-beaf-7a2a45cc5f31">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTItMS0xLTIzODU3MA_417245b9-2b15-4a43-8d7a-311c523e71ea">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i808b863dada9457f923ca993a3bea323_D20230101-20230331" decimals="-6" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzMtMTQtMS0xLTIwNzcxNQ_6c4fddc0-2fd7-45c7-bb91-e5caceffe5b7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzMtMTYtMS0xLTIwNzcxNQ_2775f5fc-fd37-457c-b81e-c89de3138409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic162d17ac63741d18133d43351ec92b7_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtOC0xLTEtMjA3NzE1_160f501c-e07b-4f32-a3f8-7b8ae9d79efa">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTItMS0xLTIwNzcxNQ_ba74735b-3a16-454d-bb30-3c677759e6ff">201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i808b863dada9457f923ca993a3bea323_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTQtMS0xLTIwNzcxNQ_f575b77c-f88e-455d-bbf1-964f3e7b5e3f">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTYtMS0xLTIwNzcxNQ_8cafb275-6d7e-4f25-8b88-67c0bf46dda2">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40ddc921f07a4aeeacf02c27134db643_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTAtMS0xLTIwNzcxNQ_3c8d6aa2-d1c4-42df-956b-ca81cbfdde3e">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTItMS0xLTIwNzcxNQ_d5091e73-7909-475b-a572-8e5581117151">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i808b863dada9457f923ca993a3bea323_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTQtMS0xLTIwNzcxNQ_94656f3e-b4c9-45c7-a767-a8ef65c0e64b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTYtMS0xLTIwNzcxNQ_a98ca305-90be-424f-9744-ce4cc2e94b5a">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, March 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66672939efa64ce0a7f6175881cc8e7b_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMi0xLTEtMjA3NzE1_03fe481e-03ec-4dbb-8502-69aaabbfd29d">363.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66672939efa64ce0a7f6175881cc8e7b_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtNC0xLTEtMjA3NzE1_a8095ba5-ca65-4c5e-acb3-1a5973ebb6f2">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8ba4914a69d4cb8b1fc752df5873883_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtNi0xLTEtMjA3NzE1_1519dfd0-defe-4c2b-8316-ef78ca8e5a05">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a2f6084f5a4426387b1bdba497c5c63_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtOC0xLTEtMjA3NzE1_80dc273d-ec5b-4569-8201-59d97c2f2a6a">9,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbac5f0d9d24f8a8f825099f3394fec_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTAtMS0xLTIwNzcxNQ_e9c3af61-7a93-4dbb-99a4-ca5b5e113732">1,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i946e14205ef041e8972492d11be8775d_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTItMS0xLTIwNzcxNQ_7a047af2-50c0-4b8c-9388-ef01fbdb3314">800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371252488c904680b474dfac8b94f900_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTQtMS0xLTIwNzcxNQ_9d60cf8c-70b3-4cce-8f68-531bde0fc797">945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTYtMS0xLTIwNzcxNQ_baf04ecb-358b-43a1-a211-bf31387e909f">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMi0xLTEtMjA3NzE1_34d13ea6-3ff1-4feb-ac4c-49d1b7b811ee">359.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktNC0xLTEtMjA3NzE1_1f06e0e9-22c1-41c7-a2bf-29be486d20d4">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f7f8f2ef85a49f4afe5effddaa485c8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktNi0xLTEtMjA3NzE1_0f2d0cd6-27a3-4a77-ba71-a6570dc41e77">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf9314740a5046e6b7fbcde6a1225413_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktOC0xLTEtMjA3NzE1_dff4fcc5-411a-4c8f-8e1d-9505abfba130">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c02450191db423fbdddbea92953f1fa_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTAtMS0xLTIwNzcxNQ_ba9f52d6-a94e-44bc-9e0f-0d6bccd3cf40">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fcf82d8c82b4464bcd33142e1f338cd_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTItMS0xLTIwNzcxNQ_383df489-ec39-49d1-875c-9d7a91763bbc">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8902b132c274ce980a60fe03aa09c6f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTQtMS0xLTIwNzcxNQ_02f4d73c-f5c2-47b7-b854-24e2ebcc67c9">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTYtMS0xLTIwNzcxNQ_e7000266-1764-49e9-8d77-cedac5f0f727">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ce9f18c7cd9441ba37c871b38e9c09e_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItMi0xLTEtMjI5MTk1_e60faca5-9d56-42b2-aede-a04da78fcb77">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce9f18c7cd9441ba37c871b38e9c09e_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItNC0xLTEtMjI5MTk1_13559d21-c4e6-4fa4-b246-1b2c71d853c3">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDEtNi0xLTEtMjA3NzE1_66e514a0-007e-43aa-9075-f5b7f9643f7c">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDEtMTItMS0xLTIwNzcxNQ_82a0c8be-7da6-4d0f-af60-646e0cd84fac">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDEtMTYtMS0xLTIwNzcxNQ_a4814ab4-60fa-462b-b23e-f1e675614fd1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItNi0xLTEtMjA3NzE1_a6585db0-dcd8-4c0a-b670-aabc0ce61a96">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItMTItMS0xLTIwNzcxNQ_2aba291a-7e1d-436a-899f-8cb45a345bab">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItMTYtMS0xLTIwNzcxNQ_83bef0b8-c9f6-4a49-90cb-a0b2357b8b80">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDQtNi0xLTEtMjI5MTk3_24072507-5087-47b0-be9b-c48f380a50f2">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDMtMTItMS0xLTIwNzcxNQ_ad93fb47-8bc9-49f5-9366-c1c3117044e1">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDMtMTYtMS0xLTIwNzcxNQ_8a67f625-fae1-4988-b47d-531d99c06211">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcbd578c19014c70a67ef1fb87173055_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtOC0xLTEtMjA3NzE1_f52470c1-03ca-4de2-97e0-decbe48fe91c">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtMTItMS0xLTIwNzcxNQ_d4ba786a-201f-4f44-a7e4-c59a8134d14c">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1b2462e77bf46ba99a8e0c38ea11630_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtMTQtMS0xLTIwNzcxNQ_e883a873-7265-42b6-ad6f-5ef814d0dc1a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtMTYtMS0xLTIwNzcxNQ_118e1186-4190-48fd-b7d1-d317b6d3440b">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e3484672c1b4b38a05983fa5254b458_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDYtMTAtMS0xLTIwNzcxNQ_78f2b4d5-8250-46ff-8a31-8f28899a473f">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDYtMTItMS0xLTIwNzcxNQ_c8ce6918-bb36-46ed-949b-021761d108f2">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDYtMTYtMS0xLTIwNzcxNQ_ac1b6aa5-2ae9-49f4-915f-03a85fe39d37">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Balances, March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id04b8551dc9c4d889a6e5fd80cbc09f4_I20220331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMi0xLTEtMjA3NzE1_fa0d453f-3496-4198-9c37-812e454134f1">361.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id04b8551dc9c4d889a6e5fd80cbc09f4_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctNC0xLTEtMjA3NzE1_1725d90c-4168-4af4-853d-06848d03a39f">10,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f710c703f87477bb1995e048a1ad4c3_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctNi0xLTEtMjA3NzE1_3e727bb0-3d53-4d95-8e79-af54c23e97f7">415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i080749f8173b49ce89929a1cd63c2560_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctOC0xLTEtMjA3NzE1_ae9a58d6-fcea-4b47-b192-0033c2283db3">9,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63d0633dd2449069f3d40c923633c0b_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTAtMS0xLTIwNzcxNQ_033a85be-eb4e-4e91-a4c5-a0467ff79398">1,974</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77426eee8f534f118cfa729bb49d9f39_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTItMS0xLTIwNzcxNQ_e3d03f72-5099-49f5-9216-89ddfb39f162">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21c3f3c6b4a24d8cb42af4f8458f66e6_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTQtMS0xLTIwNzcxNQ_350a71a8-7711-450d-bd44-d07ec8b4cfac">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTYtMS0xLTIwNzcxNQ_b13261fc-489d-4b0a-ad7d-c59f1caecb3e">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:81.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMy0xLTEtMS0yMDc3MTU_5f52adb8-5365-4a65-855a-40060dd3ff65">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMy0zLTEtMS0yMDc3MTU_0a160bbd-e547-4c2e-b197-cc228e439421">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNS0xLTEtMS0yMDc3MTU_509aa640-06d8-40b7-8f82-0ecec9fb956c">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNS0zLTEtMS0yMDc3MTU_b1e7d1c3-e4e8-471d-b0a4-34cf7e532662">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and write-off of debt premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNi0xLTEtMS0yMDc3MTU_64bd3f72-c372-4b57-bd2f-3bd9225b50c2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNi0zLTEtMS0yMDc3MTU_e8d59155-05e0-45ae-873e-c443bcf579d5">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNy0xLTEtMS0yMDc3MTU_24f79745-d93c-429e-837d-9274e034293b">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNy0zLTEtMS0yMDc3MTU_ccd74831-f370-4e56-b81b-baceb3b5473e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfOS0xLTEtMS0yMDc3MTU_83d960df-a11f-432b-adb1-c66c520179b2">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfOS0zLTEtMS0yMDc3MTU_0f51727c-3851-4e3d-b1c9-dabe20709119">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allowances for losses on trade receivable and inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTAtMS0xLTEtMjA3NzE1_4dd97471-3c4a-4e82-a4c6-490a51a0b71f">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTAtMy0xLTEtMjA3NzE1_fdcfe25c-ffd5-4977-b40e-fecf1f53f33b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTEtMS0xLTEtMjA3NzE1_5807f1a6-19e1-461f-84a2-4d8ad6b21e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTEtMy0xLTEtMjA3NzE1_e208e1d6-df3a-46ca-ac47-bd15170fe555">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to accrued legal settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTMtMS0xLTEtMjA3NzE1_0083bc32-0037-4e2f-8bb7-d2f2143615b2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTMtMy0xLTEtMjA3NzE1_35018995-9b58-42c9-876c-e9e19f6d97ef">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTQtMS0xLTEtMjA3NzE1_d7e43bd6-5ff8-4a30-b8e2-3627fa96642c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTQtMy0xLTEtMjA3NzE1_7a076f79-62b2-4425-8357-b8157a0693bf">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTUtMS0xLTEtMjA3NzE1_317c335c-9e53-4b85-9885-8dc5ed1fa6e6">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTUtMy0xLTEtMjA3NzE1_a0912cc7-068d-4f2e-b7a6-e119fd43acf0">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange gain (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTYtMS0xLTEtMjA3NzE1_929997c0-2cbe-4878-9347-bc738801514f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTYtMy0xLTEtMjA3NzE1_1615f6ff-26cd-4ca7-b3ee-3e0a7c04abeb">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTctMS0xLTEtMjA3NzE1_29b7b72b-9fa7-4bd2-9c22-ef755d3b72c9">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:DerivativeGainExcludedComponent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTctMy0xLTEtMjA3NzE1_ae26769d-cf44-4331-8ccd-b3c65a32c3a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjEtMS0xLTEtMjA3NzE1_f7f836d2-8668-4c4e-b4b3-8c17db18f7d4">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjEtMy0xLTEtMjA3NzE1_5085211b-fa06-4458-86ed-597341bf6bc6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjMtMS0xLTEtMjA3NzE1_fbd2319a-ab8e-40c6-bbe3-e01126ef9e86">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjMtMy0xLTEtMjA3NzE1_701ae1ce-068f-4068-932e-6033aa02e4ae">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjQtMS0xLTEtMjA3NzE1_5a2dd4dd-ce8e-4b38-bd6d-97e24b76626e">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjQtMy0xLTEtMjA3NzE1_471c1117-4b18-4a32-8cac-a5406a470872">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjUtMS0xLTEtMjA3NzE1_d2a42607-cadb-41ac-93a0-ec8880352f68">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjUtMy0xLTEtMjA3NzE1_d7018efb-a89b-4d72-9cc9-e27fe4d5e7e5">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjYtMS0xLTEtMjA3NzE1_d2d8dc7b-3b61-4e82-b294-e11d21107af8">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjYtMy0xLTEtMjA3NzE1_955eb239-0076-4035-a184-a90355bd314e">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjctMS0xLTEtMjA3NzE1_5d57f54d-c677-44be-b7dc-c9d7e1461fec">154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjctMy0xLTEtMjA3NzE1_a716947c-63ca-4ccf-bbc1-2009d2dd3291">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:PaymentsToAcquireBusinessesAndForOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMS0xLTEtMjMzNjg5_5bb855e1-ce3f-4710-9640-a1defc50d969">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:PaymentsToAcquireBusinessesAndForOtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMy0xLTEtMjMzNjg5_ce72e119-1575-4058-bf24-fae2cdcf7070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMS0xLTEtMjA3NzE1_3320ea58-1e13-454a-bea2-4f0a4426aca0">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMy0xLTEtMjA3NzE1_5776ae58-d042-4e7d-b446-18a813dea40c">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for intangible and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzAtMS0xLTEtMjA3NzE1_7ca7890e-94f4-401a-8184-3836600da458">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzAtMy0xLTEtMjA3NzE1_2e7f1a3b-5961-4a80-947f-be08076b8dfa">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzEtMS0xLTEtMjA3NzE1_a553cd8d-65dd-4168-afa1-244163c974bb">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzEtMy0xLTEtMjA3NzE1_e63f79a5-7088-491b-af6f-76cb02c44f26">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzItMS0xLTEtMjA3NzE1_09bcd488-8866-48b9-9b7b-29c61831a520">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzItMy0xLTEtMjA3NzE1_9aa1b753-6811-41f6-81da-b4b67a0ea6cd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest settlements from cross-currency swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzQtMS0xLTEtMjA3NzE1_b51b990a-782f-438b-badc-6e1c651297cc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzQtMy0xLTEtMjA3NzE1_5098cd54-15b7-4e02-a4d2-01f92787f985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzUtMS0xLTEtMjA3NzE1_2b3769c1-c446-49f6-9c72-cde4b4b7b569">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzUtMy0xLTEtMjA3NzE1_fb215f4b-f692-4a3e-925e-931cd02e3e00">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzctMS0xLTEtMjA3NzE1_035ee789-0978-4281-9fe0-3035dec9c36d">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzctMy0xLTEtMjA3NzE1_82809ccc-8298-4ef5-857d-6922396a404f">986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzgtMS0xLTEtMjA3NzE1_2bfb59b8-c8b5-4c76-840e-a895ea33d711">279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzgtMy0xLTEtMjA3NzE1_6000f6db-927a-4957-ae01-2a723fe44628">485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of employee withholding taxes related to share-based awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDItMS0xLTEtMjA3NzE1_f8941f08-b81c-4e9a-9880-3a0de0667a03">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDItMy0xLTEtMjA3NzE1_7b30bf31-477a-42e8-9ecf-a267f1cd4fe5">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDMtMS0xLTEtMjA3NzE1_283e168d-b4b1-4e31-8be4-0212d07dda57">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDMtMy0xLTEtMjA3NzE1_d646769c-bb26-42e4-a97b-08cd7a36be13">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDQtMS0xLTEtMjA3NzE1_bb21364f-2f59-4558-86eb-698f077c700e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDQtMy0xLTEtMjA3NzE1_179dd780-7d9b-4105-85d9-428938564ce6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDUtMS0xLTEtMjA3NzE1_e14cd510-7203-40c7-a69d-cab3d6f0ec0b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDUtMy0xLTEtMjA3NzE1_b5dfd338-7411-46a9-8d9e-1300f442b771">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDYtMS0xLTEtMjA3NzE1_4151a393-d08c-4276-b19e-ea8ea53d6a33">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDYtMy0xLTEtMjA3NzE1_9692991b-6e6f-4d11-9c51-a04cf9d7e4df">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and other</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDctMS0xLTEtMjA3NzE1_60005081-77bb-429e-b33b-671923740351">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDctMy0xLTEtMjA3NzE1_17cc5422-bbec-4dd1-b239-643f661ad666">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDgtMS0xLTEtMjA3NzE1_539f61a8-3070-4955-b381-af455055ad5a">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDgtMy0xLTEtMjA3NzE1_c0bed0d0-a165-4285-88b0-86edb5ecb3ae">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDktMS0xLTEtMjA3NzE1_4e2c98cb-5cb5-4f39-84b0-78921b161b95">591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDktMy0xLTEtMjA3NzE1_dbd67146-19f4-4f01-bdd7-b7aa4e971d9c">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTAtMS0xLTEtMjA3NzE1_37fea78e-20a9-4879-9fd1-9730f0c4e972">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTAtMy0xLTEtMjA3NzE1_1818dd53-4193-46a2-b88a-15539dbae3c8">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTEtMS0xLTEtMjA3NzE1_148e9aa7-edb3-4887-87b6-237b8175d0d1">518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTEtMy0xLTEtMjA3NzE1_d6b3ed97-b53b-4d63-8837-2fc40c27eabb">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTItMS0xLTEtMjA3NzE1_42b8d7f7-010d-41fe-ab86-4fa6ff126d9c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTItMy0xLTEtMjA3NzE1_d2dd3eca-7809-42c4-9adb-7f7c5a026a3e">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTQtMS0xLTEtMjA3NzE1_59f48ab2-a39e-463a-a890-be6dbc6b533e">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTQtMy0xLTEtMjA3NzE1_18aa7aae-7eaa-466b-a15d-c55a9ef4546f">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_40"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80MC9mcmFnOjM1YjhhYTM1NjJiZTQ2Mjc5NTQyMTI1YWU2OTE5ZGRiL3RleHRyZWdpb246MzViOGFhMzU2MmJlNDYyNzk1NDIxMjVhZTY5MTlkZGJfNzkz_a749bf45-6fd4-4f61-ae30-7b343b1168b9" continuedAt="id96b48a8af684179a0e06b7107cb47ad" escape="true">DESCRIPTION OF BUSINESS </ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id96b48a8af684179a0e06b7107cb47ad">Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and aesthetic medical devices, and, through its approximately <ix:nonFraction unitRef="number" contextRef="i63bf7af9472e4ef792681b0e8c4f7da0_I20230331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80MC9mcmFnOjM1YjhhYTM1NjJiZTQ2Mjc5NTQyMTI1YWU2OTE5ZGRiL3RleHRyZWdpb246MzViOGFhMzU2MmJlNDYyNzk1NDIxMjVhZTY5MTlkZGJfNDUz_1901135b-febd-4776-9627-c8b55697717a">89</ix:nonFraction>% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80MC9mcmFnOjM1YjhhYTM1NjJiZTQ2Mjc5NTQyMTI1YWU2OTE5ZGRiL3RleHRyZWdpb246MzViOGFhMzU2MmJlNDYyNzk1NDIxMjVhZTY5MTlkZGJfNzc2_ab803e7e-1d1a-45b8-a949-efcb70bfab87">100</ix:nonFraction> countries.</ix:continuation></span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_43"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAyMA_0b4a4803-76b8-4f06-a784-c29a3d5623de" continuedAt="i13be0ba8f86f445b80311cc2b1249d4c" escape="true">SIGNIFICANT ACCOUNTING POLICIES </ix:nonNumeric></span></div><ix:continuation id="i13be0ba8f86f445b80311cc2b1249d4c" continuedAt="i0759c08854274119bb7fcfc6043cc33e"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAyNw_dc29b2a4-50a8-404e-8964-609fc2e3ccec" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;) on February&#160;23, 2023. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2022. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its plan to separate its eye health business, consisting of its Bausch + Lomb global Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221; or &#8220;B+L&#8221;) from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On May 5, 2022, the registration statement related to the initial public offering of Bausch +Lomb (the &#8220;B+L IPO&#8221;) was declared effective, and B+L&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, B+L was an indirect wholly-owned subsidiary of Bausch Health. On May 10, 2022, a wholly owned subsidiary of Bausch Health sold <ix:nonFraction unitRef="shares" contextRef="i4c8c5d995a3747e29d7c4e9cef2e105f_D20220510-20220510" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMTA5OTUxMTY1MTE2Mg_d815f40d-3cba-4dc2-9d62-5699397a83ce">35,000,000</ix:nonFraction> common shares of B+L pursuant to the B+L IPO. Upon the closing of the B+L IPO and after giving effect to the subsequent partial exercise of the over-allotment option by the underwriters, Bausch Health indirectly holds <ix:nonFraction unitRef="shares" contextRef="i7e0c7a0e030f4effa3695934ea837e9f_I20220601" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMjE5OTAyMzI3OTEyNg_db3a5419-adcf-4174-80d2-70a8bb2c0720">310,449,643</ix:nonFraction> common shares of Bausch + Lomb, which represents approximately <ix:nonFraction unitRef="number" contextRef="i7a49d1ee9a464f5db7a10d853a1a1349_D20230331-20230331" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMjE5OTAyMzI3OTEzOQ_0ce20ba3-52bb-4c50-8571-17691e331f8a">89</ix:nonFraction>% of B+L&#8217;s outstanding common shares as of March&#160;31, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all relevant factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company comprised of the Salix, International, Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical), and Solta Medical aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other than the effects of the B+L IPO described above, these unaudited Condensed Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAyNQ_2be4d0a6-a3eb-449c-8302-4d34b3381b23" continuedAt="i86c5757fdbc64fc49c05d9dde2b07b3d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, and </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i0759c08854274119bb7fcfc6043cc33e"><ix:continuation id="i86c5757fdbc64fc49c05d9dde2b07b3d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div></ix:continuation><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAzOQ_e45f8a57-f6fd-4fc8-b4ea-5225e5551b79" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMjE5OTAyMzI3OTczNQ_fa3df2e8-a361-43d4-9638-9e92797c9825" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div></ix:nonNumeric></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_46"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ3Ng_84fda20c-b87d-4cad-92ce-867759e37631" continuedAt="ic1a0244f35b24ae294f21daf85ea2e99" escape="true"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ4Mg_87b36d74-c612-4e48-9530-5e66921e2c52" continuedAt="i5a5038b2e117455fa8de80dd7410261c" escape="true">REVENUE RECOGNITION </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ic1a0244f35b24ae294f21daf85ea2e99" continuedAt="ic1d3dfeb0e6e4ca7b9432b2044ce5f0a"><ix:continuation id="i5a5038b2e117455fa8de80dd7410261c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue which is derived primarily from contract manufacturing for third parties and which is not material. See Note 18, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="ic1d3dfeb0e6e4ca7b9432b2044ce5f0a"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ2Mg_bb1d91d7-d5f8-4cbc-9290-de0ab26c709b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the three months ended March 31, 2023 and 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e45b6ebd3b048e894cd2c2e5aedafa4_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi0yLTEtMS0yMDc3MTU_8b9ae241-ff24-475f-8ec7-71c3c6018294">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10c054fa2de4824aef49eafab2b651e_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi00LTEtMS0yMDc3MTU_6e4489a4-a5a9-46c8-97ad-87073c387eb7">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i135bc17430224f338814ab96077762d3_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi02LTEtMS0yMDc3MTU_3740b147-54bf-43cf-8e35-c6d12a87eede">1,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief70a603ee11466f94467c535a3e3125_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi04LTEtMS0yMDc3MTU_37935eb9-c156-4346-9f58-3f8cf0e7fa56">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823782cb59e242d194dab1df20d01ab8_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi0xMC0xLTEtMjA3NzE1_4657bba1-5ca7-4882-aca7-afac9be71136">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi0xMi0xLTEtMjA3NzE1_d592a289-5f47-4903-a689-e8373e1cf2d7">1,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd82fd1b04c4ca5a90663181d0b9281_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy0yLTEtMS0yMDc3MTU_1cae38f6-e1cd-4726-9c58-2a7177d989f5">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe64f13b6ba4162ae7430acb9dbf957_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy00LTEtMS0yMDc3MTU_5c4be8f9-932b-4886-a628-397a8b08188e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c4dfdc7ef14cc9bc3a3ac6abfe8664_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy02LTEtMS0yMDc3MTU_78a5bf2b-f7b1-4f29-9353-5b40e92cfecf">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e80003bff24d46bd9d4b8a36e49cd0_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy04LTEtMS0yMDc3MTU_f5069b90-e9fe-4ff0-a407-4730c6e5b50c">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3840f2154ebb4758a2ccbd787ed21972_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy0xMC0xLTEtMjA3NzE1_2c7d4293-f6df-4146-a890-934b55bf4551">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy0xMi0xLTEtMjA3NzE1_43e60e6b-f92f-485f-a03d-0b245a1712c3">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bd82fd1b04c4ca5a90663181d0b9281_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC0yLTEtMS0yMDc3MTU_61ef3cae-9fa3-4810-b3d8-69d3124f0b8b">148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fe64f13b6ba4162ae7430acb9dbf957_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC00LTEtMS0yMDc3MTU_fe287927-c823-4472-b720-13fab5c86529">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20c4dfdc7ef14cc9bc3a3ac6abfe8664_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC02LTEtMS0yMDc3MTU_2bcc3939-d3e5-4f07-8eee-e1b46b08538d">729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42e80003bff24d46bd9d4b8a36e49cd0_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC04LTEtMS0yMDc3MTU_64b21892-386d-4ddd-b72d-cd91dc0d315b">487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3840f2154ebb4758a2ccbd787ed21972_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC0xMC0xLTEtMjA3NzE1_08ac6f3e-1100-4d07-84e5-3062d2edc21a">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC0xMi0xLTEtMjA3NzE1_b572ac5e-89e0-454e-8891-5991f058946e">1,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e0087ac09e4486ea85863d74934cc18_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS0yLTEtMS0yMDc3MTU_6ff190d9-debf-4e49-97c9-08b8f174c14e">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83655d1435547e9a88be7c0a6a44473_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS00LTEtMS0yMDc3MTU_b705ca58-593c-4fd8-8b07-2ba8579e14a2">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c661f0c33684c05ba82c765639b2da8_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS02LTEtMS0yMDc3MTU_532702fc-d3a6-4732-af28-dc37554d6379">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcaaa7bc80ae4f49a0ec057d07433721_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS04LTEtMS0yMDc3MTU_289491c0-2a1b-48be-b60c-07191035d171">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dfb70e0fd024446818c699b54888111_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS0xMC0xLTEtMjA3NzE1_ef7f065c-5467-463c-a284-e79378d41a3c">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS0xMi0xLTEtMjA3NzE1_e146d160-84b7-4328-be8c-244a35b8eab8">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i391ac9a452be4bdcb904867d4fb45391_I20230331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNDg2Mw_40e6b6c0-9f59-4e66-a5a9-0baf06e81a16">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if1fb66cbda4b4013887d1e87c53164eb_I20230101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNDg3MA_2b1320b1-1de3-45ab-8487-90078ff02e53">40</ix:nonFraction>&#160;million as of March 31, 2023 and January 1, 2023, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were <ix:nonFraction unitRef="usd" contextRef="i318586ad088847fe9e02f2dbe2f1d9be_D20230101-20230331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNTAxOQ_6daa8e65-65bb-4600-9651-b0b8c681246b">no</ix:nonFraction> price appreciation credits during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8290334f6ddb49b48369b500e2a37633_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi0yLTEtMS0yMDc3MTU_e1df7b59-3c95-43ca-8c91-959e4468a03b">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57521c3e1fc6438c83e45eed46549020_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi00LTEtMS0yMDc3MTU_30465f18-9984-43b0-b0ec-9301aa1007b6">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80ef4ad0b68c4cc98d683b6b92852ec3_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi02LTEtMS0yMDc3MTU_cc067f8b-318a-46f5-8231-db4faca132f2">944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic21e95c278304743bdfd808b5bcf88c0_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi04LTEtMS0yMDc3MTU_34407bf6-b871-4dba-90bf-f5f971ae4c0f">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f4502c99efb4e1192389a486b24fec4_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi0xMC0xLTEtMjA3NzE1_6d0e7ad0-bc35-4261-b4d7-9ed6110035c9">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi0xMi0xLTEtMjA3NzE1_2cfde3ea-bdec-4d25-a03a-7a8e2af6dc2a">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd2d65e95c5455ba33597d7af92fae1_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy0yLTEtMS0yMDc3MTU_2244f2a1-7be3-4d32-b529-0a4092dee970">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de88d59e31147e89b39381c09c53f91_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy00LTEtMS0yMDc3MTU_b697506a-e25c-4edb-bd95-d0104ca5918c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieda7c01115f14fb48e402b3e7a8d7854_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy02LTEtMS0yMDc3MTU_2eeafbde-afa1-48f0-bd6b-596e036c521c">581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd272b84eca74392a824eff8a9e1189e_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy04LTEtMS0yMDc3MTU_c481f8a7-15bf-41ce-a67f-adf13b5a93ec">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2463be0b4714169986c616ff3005117_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy0xMC0xLTEtMjA3NzE1_fc8c3a40-a453-45dc-a52f-336905deeec7">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy0xMi0xLTEtMjA3NzE1_6dc0e40f-5cda-4b79-9077-c9a7707be7fa">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cd2d65e95c5455ba33597d7af92fae1_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC0yLTEtMS0yMDc3MTU_82218ee6-bf78-48ef-ad82-37610c2fba64">162</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6de88d59e31147e89b39381c09c53f91_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC00LTEtMS0yMDc3MTU_d778236c-7bdd-4ab2-b3d7-d5da09edcaf1">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieda7c01115f14fb48e402b3e7a8d7854_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC02LTEtMS0yMDc3MTU_333f3a67-9442-474e-9c5f-d0cccdf6dca9">599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd272b84eca74392a824eff8a9e1189e_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC04LTEtMS0yMDc3MTU_78b712e8-ba6f-4892-b4e6-1f43de2d48cd">359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2463be0b4714169986c616ff3005117_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC0xMC0xLTEtMjA3NzE1_33e3e39e-e461-4afd-be5c-dbc664803588">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC0xMi0xLTEtMjA3NzE1_4144483a-ca9b-49ca-b2a4-ca3becf86d4a">1,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c1aa2507e474247b21581cd979cbf95_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS0yLTEtMS0yMDc3MTU_849fc2db-9c1a-47ea-b73c-91b068cbabe8">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec8b23fc6b3d427ebf6b56614132eabc_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS00LTEtMS0yMDc3MTU_9f5ad2ff-516a-4d05-97bc-02e5dc68b53b">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie930191b929c4961b8ea3b30d8630a7d_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS02LTEtMS0yMDc3MTU_6d33f429-dcc7-478f-94ab-2565445cebd1">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d287acf3b954277b424a867b92331d4_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS04LTEtMS0yMDc3MTU_d2b013a3-fb60-4861-9390-98c264524ed3">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c5df1eca1d6410e9c23987eab19795d_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS0xMC0xLTEtMjA3NzE1_ef8ce70d-3b66-4c8b-81a7-cc3e527391dd">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS0xMi0xLTEtMjA3NzE1_49d93463-bfe1-4e5a-befd-677b9f0efb4d">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i9fea59117d2a4ea787d736618e348ab1_I20220331" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNTE3NQ_43b48308-3095-4dcd-baeb-45ba0d49406f">37</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i399b542872cf4b8a95bc8a36570e3ecd_I20220101" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNTE4Mg_e60b8358-46c7-40b6-bcaa-7dace6a41986">36</ix:nonFraction>&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were <ix:nonFraction unitRef="usd" contextRef="i6b5563f26ef24b288a82a1f6a3909255_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfMTA5OTUxMTYzNTQxNg_da7e29f6-b350-4005-95bd-912a7758c6e0">no</ix:nonFraction> price appreciation credits during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ0Ng_59a14949-59dd-4849-8a6f-47eb72afd7bf" continuedAt="icae6c3f94e2746aa893c73b3cfbe47b4" escape="true">The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2023 and 2022 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><ix:continuation id="icae6c3f94e2746aa893c73b3cfbe47b4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMS0xLTEtMS0yMDc3MTU_91000e58-ba87-4ed9-a1e8-0f64cee4420c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMS0zLTEtMS0yMDc3MTU_11092c47-8489-4dc6-859f-4a8b7b675103">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMi0xLTEtMS0yMDc3MTU_95d624d6-0318-49a3-8d51-d3928467c4ef">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMi0zLTEtMS0yMDc3MTU_f2a1e53b-12c9-470f-821a-b532a0f1469a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMy0xLTEtMS0yMDc3MTU_26940c00-03f6-495a-b2f4-b9643d4d12ad">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMy0zLTEtMS0yMDc3MTU_af84db91-e49f-462a-8774-cd1353831758">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNC0xLTEtMS0yMDc3MTU_0b98ec24-c4b9-4ed4-8cd7-fe02a39ff2a2">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNC0zLTEtMS0yMDc3MTU_a751a007-c170-4abe-8313-0bf8546eaa29">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNS0xLTEtMS0yMDc3MTU_00ffc909-ee8c-4d88-8cfc-ac2863b79c66">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNS0zLTEtMS0yMDc3MTU_5d85796a-000e-4a0c-bb96-bd25c45e77c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNi0xLTEtMS0yMDc3MTU_6a9cdc70-a687-4d5b-bcc0-19c27de0f6c1">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNi0zLTEtMS0yMDc3MTU_c5c2c099-21e1-4d85-8628-273f98d8ee6a">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_49"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="bhc:LicensingAgreementsAndAcquisitionDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMjY3OQ_d0d0bd3c-35b3-4524-a2fd-d0e85a8c2baa" continuedAt="i516ac3439c444deaa668607cd27d3256" escape="true">LICENSING AGREEMENTS AND ACQUISITION</ix:nonNumeric></span></div><ix:continuation id="i516ac3439c444deaa668607cd27d3256"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2023, Bausch + Lomb acquired AcuFocus, Inc., an ophthalmic medical device company, for an up-front payment of $<ix:nonFraction unitRef="usd" contextRef="i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMTA5OTUxMTY0MjUzMg_899a2740-a9fc-4bbb-b291-85da69b95543">35</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ib72c99bc651a43d89f88a30576ef0099_D20230101-20230131" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMjE5OTAyMzI3MTMwNA_f7755b91-11d4-4786-912e-4bb215170842">31</ix:nonFraction>&#160;million of which was paid in January 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the remaining purchase price to be paid within <ix:nonNumeric contextRef="i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117" name="bhc:BusinessAcquisitionMaximumTermForRemainingPayment" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMjE5OTAyMzI3MTMxNg_040920f2-a24b-4b63-b88f-1ffb4876e601">18</ix:nonNumeric> months following the transaction, less any amounts that are the subject of any indemnification claims</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The acquisition was made to acquire certain small aperture intraocular technology for the treatment of certain cataract conditions. Additional contingent payments may be payable upon achievement of future sales milestones. Bausch + Lomb recorded an initial acquisition-related contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI4OTI3_aa090677-03f5-4764-a291-b2e414922e53">5</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this transaction, recorded within the Condensed Consolidated Balance Sheets are Intangibles, net of $<ix:nonFraction unitRef="usd" contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI3Nzc5_fa1fa343-50aa-4a92-9221-e4849076009a">28</ix:nonFraction>&#160;million, Goodwill of $<ix:nonFraction unitRef="usd" contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI3NzM1_8bc95aaa-1863-44e3-b6b7-31f2b58d6f99">2</ix:nonFraction>&#160;million, other assets of $<ix:nonFraction unitRef="usd" contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI5MjE0_65e29399-2c4a-4277-b555-4de80dec0cca">11</ix:nonFraction>&#160;million and liabilities of $<ix:nonFraction unitRef="usd" contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI3NzQ4_00a3ce9d-a6e0-40f6-83c9-f09da21d0f79">2</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_52"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMjY0OQ_afec9a45-1319-47e1-b0b0-df634414fc49" continuedAt="ide5f54023f5c4764ae4c83708c598a92" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS </ix:nonNumeric></span></div><ix:continuation id="ide5f54023f5c4764ae4c83708c598a92"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i274f7bd9f55d4414ae43d99e682cd28a_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfNzMz_44ce6fe4-9fa7-4721-a685-8aba182acbee">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7994dfc403646e5bff69630f9cc9aa6_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfNzQw_ea403393-c6dd-4a40-b93f-ac93eb06aed6">3</ix:nonFraction>&#160;million of restructuring and integration costs during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities relating to the B+L Separation. In 2022, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and, in 2022, Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and, in 2022, preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and, in 2022, the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for Bausch + Lomb. Included in Restructuring, integration, separation and IPO costs for the three months ended March 31, 2023 and 2022 are separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="i47206664dbc844039797dc32726a84f4_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMTkxNg_bb95c317-c4b1-4550-8d31-02010c72afaa">1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie718797acbb14934a88039b0b7639ab6_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMTkyMw_64f6cd6f-d86f-4daf-97ad-916efb14c8e9">10</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur incremental costs with respect to the B+L Separation. During 2022, the Company also incurred incremental costs indirectly related to the suspended Solta IPO. These separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the three months ended March 31, 2023 and 2022 are separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="i47206664dbc844039797dc32726a84f4_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMjQ2OQ_9c056d75-dbe9-40d6-8f71-149562274179">6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie718797acbb14934a88039b0b7639ab6_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMjQ3Ng_89ca104a-8660-4c7f-a0e7-6827c4eaa45f">24</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_55"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTk0Mg_a8d9f02b-f28f-49f6-91c1-4826eb74a052" continuedAt="ibd54acabb20d49fabda6f66633c52604" escape="true">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="ibd54acabb20d49fabda6f66633c52604" continuedAt="i325123b9103e487287c9d720f5c50ffd"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis </span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTkyOQ_9e8f58d2-3bfa-4e09-9105-0216a4cbd604" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ac642717c94b2bb1846110be0fc60d_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0yLTEtMS0yMDc3MTU_8d133ab9-baa5-4cd6-8cc9-663cc481010f">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7219dc1016d84387a28c86b12d9cf065_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy00LTEtMS0yMDc3MTU_f334fde2-fd5a-4ccc-b2a9-3834c2626f22">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ecdb94ccdc9431b9447675875213cc0_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy02LTEtMS0yMDc3MTU_39190d00-10c7-4e89-b84e-a8e97997b07e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy04LTEtMS0yMDc3MTU_def19daf-9a9d-4a65-b2eb-5a9e8c3ed3f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xMC0xLTEtMjA3NzE1_43533543-2698-4698-a3dc-e9c348361e4c">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa5ab43fca470998ef4bc73c508195_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xMi0xLTEtMjA3NzE1_850ed123-c76a-4c2d-8118-605d1423fc97">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05beb5b79d2d4d1786504e1574156b9d_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xNC0xLTEtMjA3NzE1_fa9add61-d516-436e-8fbe-fa9706c5cb2e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a57514fe2b45cc95ad51616dde5842_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xNi0xLTEtMjA3NzE1_ecc2166d-cd4a-42f6-a9d4-23f9d9846976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ac642717c94b2bb1846110be0fc60d_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0yLTEtMS0yMDc3MTU_54ef143e-af48-4056-9b28-95ed9886c1f2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7219dc1016d84387a28c86b12d9cf065_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC00LTEtMS0yMDc3MTU_40d8f761-f934-4ac4-9f57-983e89ad0237">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ecdb94ccdc9431b9447675875213cc0_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC02LTEtMS0yMDc3MTU_34dea761-00a2-47a2-b9bb-3bc4a0f09c9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC04LTEtMS0yMDc3MTU_3321724c-c786-4140-8d26-b6dccf03c648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xMC0xLTEtMjA3NzE1_7970f702-d78b-49ea-8d2b-9bad9dc29834">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa5ab43fca470998ef4bc73c508195_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xMi0xLTEtMjA3NzE1_f8c1ecb9-30e1-4fb7-9fbe-55167b453ada">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05beb5b79d2d4d1786504e1574156b9d_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xNC0xLTEtMjA3NzE1_5d66f3bd-6f57-410e-905c-0c8026096e5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a57514fe2b45cc95ad51616dde5842_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xNi0xLTEtMjA3NzE1_525f74a7-502c-4adb-9980-3781efbc2b6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8571f31f2d94cbcaa0a6cf746cebae6_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0yLTEtMS0yMDc3MTU_55d14670-10ad-4e91-9648-6380335a321a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08edcda8013b411a8ae514fb186572f3_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS00LTEtMS0yMDc3MTU_fa55420b-90c4-4ee1-b5cc-5397564537c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7702b9b65346fdbe57769e179c3810_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS02LTEtMS0yMDc3MTU_1ff0e214-0ff8-4893-87b2-8b1e19c8de23">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0daaca70154c40aeaacadd2265003e58_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS04LTEtMS0yMDc3MTU_a721fe82-093d-44e9-9041-5096711554ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9716709350419c83c375cd1e7f06dd_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xMC0xLTEtMjA3NzE1_a9e08e65-75e7-4429-9c80-18585aae2f12">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2d1c1b6390420dbae526e06c3bf460_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xMi0xLTEtMjA3NzE1_0fc1246d-3bac-43ae-982f-3df42aaa9ea7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0830e0c16af34c70b916f4b40dd82c53_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xNC0xLTEtMjA3NzE1_80d9b918-6fac-4f95-8d4b-0f3f599e3185">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7e1e14aa134850b3ef64a8fc34014e_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xNi0xLTEtMjA3NzE1_9df53728-8510-4296-9619-de4f267b0278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ac642717c94b2bb1846110be0fc60d_I20230331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0yLTEtMS0yMDc3MTU_212ab73c-fcb4-482b-aaf5-3d1a97bf89e8">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7219dc1016d84387a28c86b12d9cf065_I20230331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC00LTEtMS0yMDc3MTU_10efde86-025a-49a0-98a7-2dc7015aba91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ecdb94ccdc9431b9447675875213cc0_I20230331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC02LTEtMS0yMDc3MTU_17d6a4ee-01a3-4f8d-9aba-8ce8ae3db437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC04LTEtMS0yMDc3MTU_ba0a4672-b4b6-4e9c-9437-e19f4fbb55b3">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xMC0xLTEtMjA3NzE1_e9b97713-ca70-4ce6-bb74-251e8a2865a5">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifffa5ab43fca470998ef4bc73c508195_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xMi0xLTEtMjA3NzE1_210f0c32-b365-4064-a464-4ebe835cf5a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05beb5b79d2d4d1786504e1574156b9d_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xNC0xLTEtMjA3NzE1_1a619910-5404-4fc3-9c87-c6faab042410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a57514fe2b45cc95ad51616dde5842_I20221231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xNi0xLTEtMjA3NzE1_d64e068f-b189-4fbd-ba27-383a072ba662">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia244db96c1c640908fc33b4da08106d9_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0yLTEtMS0yMjkyMzk_96e759f1-831e-45d6-a3fe-333df1862a10">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f2aa66d564423a8584754ff4101e8c_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS00LTEtMS0yMjkyMzk_5b19bd7a-8ef6-4798-adac-20cb0e3e41d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba72009cea324aec8b99aef7cc724d7a_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS02LTEtMS0yMjkyMzk_1771b6f1-f7be-4db8-b989-2124cbd181d2">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee7e52beb8e43fda8b440f37c8ebe57_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS04LTEtMS0yMjkyMzk_46f486a3-1948-4d1d-9592-b9d081accd17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc061681ca144219826ecd1f58d340a_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMC0xLTEtMjI5MjM5_8a235c98-1115-4072-9356-3609196e2d37">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf1769e6ad7e4ee4ba7d31d32deaa20b_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMi0xLTEtMjI5MjM5_f5e73425-17d5-4e9b-b04d-1cdb2542e698">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11e5b05711c41bc94278235adbc4f4c_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNC0xLTEtMjI5MjM5_182605b8-0837-42fa-a192-479b75532b5b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28a74559e034fe78617f85992188d35_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNi0xLTEtMjI5MjM5_b4eaf799-3cf4-4ddd-b9b5-ef78e2a06b38">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8571f31f2d94cbcaa0a6cf746cebae6_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0yLTEtMS0yMDc3MTU_2bb9923b-9c0a-45d7-aec7-f21f256f628a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08edcda8013b411a8ae514fb186572f3_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS00LTEtMS0yMDc3MTU_5b95f5b2-abee-4a51-bdf0-825423569312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7702b9b65346fdbe57769e179c3810_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS02LTEtMS0yMDc3MTU_94fb100b-77c7-4bab-8068-8fde115e24a8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0daaca70154c40aeaacadd2265003e58_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS04LTEtMS0yMDc3MTU_d7d7603c-1aa4-403f-8689-e570116f1aff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc9716709350419c83c375cd1e7f06dd_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMC0xLTEtMjA3NzE1_6cbf7cb8-e964-4763-855e-1a5d81e4aea9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e2d1c1b6390420dbae526e06c3bf460_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMi0xLTEtMjA3NzE1_2b2c7e5f-6268-48ec-80bd-bce2e5151804">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0830e0c16af34c70b916f4b40dd82c53_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNC0xLTEtMjA3NzE1_322b22d3-9914-48e3-b110-c41ac01866a8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7e1e14aa134850b3ef64a8fc34014e_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNi0xLTEtMjA3NzE1_e07c0c6c-9de3-4939-9ba3-5f6ae24bfde9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfMTQyOQ_8754f48b-8cee-47d1-a1bb-879e3f768460">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Condensed Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash as presented in the Condensed Consolidated Balance Sheet as of March 31, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="i095b974a4eda46539b55e501e35cecd5_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfMTczNg_ea3b1093-1278-43a7-9a7c-e4d146cc374c">358</ix:nonFraction>&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operating, investing and financing activities of Bausch + Lomb is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 assets or liabilities during the three months ended March 31, 2023.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i325123b9103e487287c9d720f5c50ffd" continuedAt="i1525118aeeca4d69b8fb67eefaec94b4"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i6ecae6a4337c43a6a5d0f8fb9b2a8820_I20220930" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfMzQ5Nw_16890e3b-f98f-4434-810f-91f2ce8e15de">1,000</ix:nonFraction>&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Condensed Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Condensed Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualify for and have been designated as a hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Condensed Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the periods presented. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Condensed Consolidated Statements of Operations.</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTkzNQ_7b42b086-e20b-4a16-8a25-d0e38cd7d9ef" continuedAt="i114355436f114fa696261898faa9aaef" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with Bausch + Lomb&#8217;s cross-currency swaps as included in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022 are as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"></td><td style="width:70.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.563%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72f352e9aecb43c082504ada58284827_I20230331" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMS0xLTEtMS0yMjkyNzE_91b107dd-f61e-4933-9d8f-73490aff44dd">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibebb6d14814347889239321501ae010a_I20221231" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMS0yLTEtMS0yMDc3MTU_950eaa23-dad1-48cb-8306-7f103d20690d">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7d14de197c840548e735b7c5dccffd4_I20230331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMi0xLTEtMS0yMjkyNzE_24ce63a4-bb66-4f40-980c-fe5edac99c3f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5134dadb2714e1785041a8064f00e00_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMi0yLTEtMS0yMDc3MTU_4d02ed0b-1d33-4950-9283-3edfb50e24f1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf6e5891da834960a8eb4d5a50ad53f2_I20230331" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMy0xLTEtMS0yMjkyNzE_cce220cd-5a33-4560-9f24-4bc9c1bda6c9">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieba2db723f4a453284cf02585362f5f9_I20221231" decimals="-6" sign="-" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMy0yLTEtMS0yMDc3MTU_200a2689-cef5-4f29-b4c9-0be6d56e7eaf">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTk1NQ_9edbc7d0-12a0-4a65-aa32-a43805693390" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Condensed Consolidated Statements of Comprehensive Loss and the Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.626%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccb47312bd346279aaf43b1d2624d18_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMi0yLTEtMS0yMDc3MTU_1a7adb7e-2c45-4e6a-af78-2a3c2cfdf280">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95be04917e9242a4b3ab893073a4e5ac_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMi00LTEtMS0yMDc3MTU_f693d8be-b073-4ce4-965e-c94cad17e50c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d884c3b238b4a9484042a7ec80e4c08_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMy0yLTEtMS0yMDc3MTU_bc0a9ff8-0cd2-4fb0-b6ef-8a2576a7ed4b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e0459eac81b48d391a6ba5f7a204bc9_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMy00LTEtMS0yMDc3MTU_bf11a75f-0e92-4e7e-b2e6-8aa900e2c9dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portion of the cross-currency swaps were ineffective for the three months ended March 31, 2023. During the three months ended March 31, 2023, the Company received $<ix:nonFraction unitRef="usd" contextRef="i6a9fc2637fe14e8da7c94ff2d6063b4f_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfNTQ5NzU1ODMwMDUy_047fe844-c724-42dd-a26e-2dd2ad899868">6</ix:nonFraction>&#160;million in interest settlements, which are reported as investing activities in the Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company&#8217;s outstanding foreign currency exchange contracts had an aggregate notional amount of $<ix:nonFraction unitRef="usd" contextRef="i1660d479841841a083afc611c4742172_I20230331" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfNzMwMQ_4edd6ab3-ac86-42da-944f-3ee2ca6f2ee9">548</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Condensed Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i1525118aeeca4d69b8fb67eefaec94b4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Condensed Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Condensed Consolidated Statements of Cash Flows. </span></div><ix:continuation id="i114355436f114fa696261898faa9aaef"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.443%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab4bebd84ef941c29f23b2b4ac6c05a9_I20230331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMS0xLTEtMS0yMDc3MTU_1b7c0024-5bb9-4140-b70c-cc96a14d1923">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a6e400c24a6461b88808840db8e4b5e_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMS0zLTEtMS0yMDc3MTU_10d69b85-b333-4e90-9296-bf6dbbcadc7e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22eb775dada74a4cbae4ccbc53d12e07_I20230331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMi0xLTEtMS0yMDc3MTU_7926755b-ceb5-4946-b698-453397a7e3b5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056164fc33e8477cbf8aadaeb9855ca2_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMi0zLTEtMS0yMDc3MTU_bb5b60dc-da40-4b3b-b9f6-933cc94dfd42">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1660d479841841a083afc611c4742172_I20230331" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMy0xLTEtMS0yMDc3MTU_24f5eae5-92e0-44ba-afd8-ea5af395ced1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6357772b0f77447aac759696baca2658_I20221231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMy0zLTEtMS0yMDc3MTU_3f85aa65-8765-4833-ba40-a9bfe8df90af">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTkzNw_c7013362-8b1e-4fb9-bb8b-dce153df27da" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Condensed Consolidated Statements of Operations and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.477%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMi0xLTEtMS0yMDc3MTU_6be46128-12e4-4be2-baee-115cdd2bae28">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibfd26c8ad7914e708774f00d667fddae_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMi0zLTEtMS0yMDc3MTU_10b40c4d-f28b-4f53-a4c6-dc60cc27485f">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMy0xLTEtMS0yMDc3MTU_040fd67f-f435-4ba9-9373-6628561e2112">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd26c8ad7914e708774f00d667fddae_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMy0zLTEtMS0yMDc3MTU_caa074ba-2f3d-42ed-9217-91aac1661f5e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At March&#160;31, 2023, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="i82576bfa08994cd9af972d7222b8c478_I20230331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTM1OQ_3ec38490-b000-4068-8e82-bdc2a2401889">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="if9f1fb1cd13846c38b5c4a4cafd8a808_I20230331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTM2NQ_af6c8923-d650-4f32-b6a9-6fc5c9611ef1">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="rate" contextRef="ia20a127e123344f5a9df3c653c0441ff_I20230331" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTQyMw_35aa3ed8-ccb0-42fb-8a74-73a5b8b77c71">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at March&#160;31, 2023.</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTk0NA_a8871cb8-b4a6-4bb0-875c-e773e1cd58aa" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:70.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.401%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMi00LTEtMS0yMDc3MTU_17c27443-9725-4e0f-b16e-94d79264daaa">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMi04LTEtMS0yMDc3MTU_0e85cbef-9cbd-493c-93d7-f39399969196">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d7b079169584b7b827bc3ad599a02a0_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNC0yLTEtMS0yMDc3MTU_913524d9-a386-451b-bf15-29cdd43036d9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i147a77a2853541b8ac642c9ce50dfb79_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNC02LTEtMS0yMDc3MTU_53861959-b893-4d91-9f38-4bc9da43a7ec">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7363eb7130846d498238f0c9266f211_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNS0yLTEtMS0yMDc3MTU_b5cbbb22-e679-4142-aba1-506fca5e0add">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f59cd43aff447ff9034642bf45fa138_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNS02LTEtMS0yMDc3MTU_3dc6cf85-1970-4bad-9b3b-6864ef0ecdf4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi0wLTEtMS0yMDc3MTU_7cfa70ac-334c-427f-800c-3fa168193578"><ix:nonNumeric contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" name="bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi0wLTEtMS0yMDc3MTU_8c92d0fe-96d4-437e-acb8-9797f035ca76">Acquisition-related contingent consideration</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi00LTEtMS0yMDc3MTU_343a57d0-de0f-4860-a87b-8fbf959b3642">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi04LTEtMS0yMDc3MTU_ebb6774e-9560-4d22-acb8-ebbb71ac323b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AcuFocus Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy00LTEtMS0yMzU3NDU_61063194-fff3-4566-b10b-57cf81156950">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy04LTEtMS0yMzU3NDc_5c363857-17c0-4197-9c62-bf484a4e25cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy00LTEtMS0yMDc3MTU_0a6456df-224a-4a91-8d7a-98bfbbcbada5">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy04LTEtMS0yMDc3MTU_c879d63c-7523-4399-894b-1fc400a6923d">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTAtNC0xLTEtMjA3NzE1_4d7b2520-f6b2-42cc-833e-d90d5d539580">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTAtOC0xLTEtMjA3NzE1_43a7505c-36fe-4fbd-9ea9-abf63214d7b0">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTEtNC0xLTEtMjA3NzE1_4910cb38-e2c8-402e-be37-76c508c46bee">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTEtOC0xLTEtMjA3NzE1_c8dbc769-629b-441d-a71e-b400ba4e16f9">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTItNC0xLTEtMjA3NzE1_742db7c4-68a9-478f-a3bd-01409d155526">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTItOC0xLTEtMjA3NzE1_571f0fc3-4c1d-49a6-82f3-ed68e7e456e4">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of March&#160;31, 2023 and December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i3e658e3f4fe444859560086bf4a59a49_I20230331" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTgwNw_fc5d5e9b-8fba-4dd1-9e3d-3b4bb940ab34">13,367</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i28204be5e8ef457b9c492f5b766ac878_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTgxNA_9595caef-43a8-4168-9b2b-0f9d60b27d1f">14,011</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_58"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RleHRyZWdpb246ODRhZmNhZmU3MzQxNDE1MmExY2YzMTAyMjk0NjY4ZjRfNTc_0497984c-1266-446e-8f3b-ef59b0a44275" continuedAt="ic202e32fc9694cb8beff17b1cc7c5ffb" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="ic202e32fc9694cb8beff17b1cc7c5ffb"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RleHRyZWdpb246ODRhZmNhZmU3MzQxNDE1MmExY2YzMTAyMjk0NjY4ZjRfNDg_3673ee16-be19-4908-8a2e-f0d9b650b8f3" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMS0yLTEtMS0yMDc3MTU_d72e7309-6569-41cc-be02-8765bdec840c">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMS00LTEtMS0yMDc3MTU_96eb5a51-a9ae-4ceb-bbc1-6c2abbba339d">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMi0yLTEtMS0yMDc3MTU_c13283aa-b89d-4a61-b0a8-5f1714a0de8d">123</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMi00LTEtMS0yMDc3MTU_08c5506c-0ba2-4179-a1f9-644fe262651c">98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMy0yLTEtMS0yMDc3MTU_8d2d344a-0212-4cd9-ad5c-575d6502cd5a">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMy00LTEtMS0yMDc3MTU_77a11edb-0a38-4912-95ae-5369821498f6">666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfNC0yLTEtMS0yMDc3MTU_c6e9a178-15b6-4272-a703-b575a8ca55dc">1,222</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfNC00LTEtMS0yMDc3MTU_ac52b91f-d71b-4fb0-b10f-77a5be68fa1f">1,090</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_61"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5Njk_ba75d253-8b3f-4837-89b8-324ed7f8e943" continuedAt="iee9672ae8680486ea998640cc60bd76c" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="iee9672ae8680486ea998640cc60bd76c" continuedAt="ib62135cef7ea4c1d89602b99ccd1bb80"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5ODg_a3ebce96-b3fb-49df-84e3-340b4d863896" escape="true"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5OTY_4ac906bf-c927-4f19-985d-94b88f4492b9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.872%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06b415e61b344bdb2ccda942b08f59b_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy0yLTEtMS0yMDc3MTU_b95d6a39-de9c-4f38-927d-ecbae0c138f0">20,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id06b415e61b344bdb2ccda942b08f59b_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy00LTEtMS0yMDc3MTU_b48bcb97-d88a-40bd-9eee-1739e8afc5e7">17,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06b415e61b344bdb2ccda942b08f59b_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy02LTEtMS0yMDc3MTU_e0fbf759-f4e2-4f28-8d4f-7e772587d590">3,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48125eb5f60a4e3fa677f9dba896c944_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy04LTEtMS0yMDc3MTU_486f6444-69de-45e2-b0bf-62d245727105">20,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48125eb5f60a4e3fa677f9dba896c944_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy0xMC0xLTEtMjA3NzE1_b138a910-f32d-4f2f-86bd-79f50ca36c4d">17,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48125eb5f60a4e3fa677f9dba896c944_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy0xMi0xLTEtMjA3NzE1_18946acb-7986-47e8-a2d4-f3136784295c">3,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC0yLTEtMS0yMDc3MTU_73b87664-aa22-4d89-aa2f-cc1321ad7cec">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC00LTEtMS0yMDc3MTU_7006c6bd-b674-4445-8cfa-c6df00b50d93">571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC02LTEtMS0yMDc3MTU_3e6f1020-2eef-4f8c-b80e-867b33cea7fb">333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5705188337dd4a7f9f61104a2f18967b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC04LTEtMS0yMDc3MTU_cc38dddf-fd6d-4c32-8c1f-a93bd3d3dc21">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5705188337dd4a7f9f61104a2f18967b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC0xMC0xLTEtMjA3NzE1_bf17c788-318b-4f57-8f09-4623f81e1b3e">542</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5705188337dd4a7f9f61104a2f18967b_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC0xMi0xLTEtMjA3NzE1_3fa5e53f-81d1-4f86-8063-8824f8b2972c">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2610664ed984b688dd611a19b847b62_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS0yLTEtMS0yMDc3MTU_1543950f-ac14-44a7-a275-c21998dea984">3,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2610664ed984b688dd611a19b847b62_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS00LTEtMS0yMDc3MTU_5fa18252-3a92-415d-8dee-ad769fd11d1e">3,265</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2610664ed984b688dd611a19b847b62_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS02LTEtMS0yMDc3MTU_d60a8a1e-2ffd-490e-b051-4f732c895b78">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84330219b21546d7b29a854334867cd0_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS04LTEtMS0yMDc3MTU_c035d3f1-9d2a-4836-aa26-8ea0426d37f2">3,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84330219b21546d7b29a854334867cd0_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS0xMC0xLTEtMjA3NzE1_1ae69649-4644-44de-aef7-e37ae6788e47">3,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84330219b21546d7b29a854334867cd0_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS0xMi0xLTEtMjA3NzE1_3e55546a-c06d-4b51-bbf3-28c9f03d95e6">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi0yLTEtMS0yMDc3MTU_7746f5c9-0f2d-4532-9ac2-f23e2db3608e">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi00LTEtMS0yMDc3MTU_2a26b011-fca9-42d7-a97a-bb3a7cac577a">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi02LTEtMS0yMDc3MTU_bd810da6-997c-41f7-a314-fc6f47572a69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0d15fc2eafe4f60beb93612549521a7_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi04LTEtMS0yMDc3MTU_c63e6a86-5e4a-4365-b832-c5bdc669d1a9">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0d15fc2eafe4f60beb93612549521a7_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi0xMC0xLTEtMjA3NzE1_90dd83f8-7ad9-4801-9681-a6d34fa6b21d">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0d15fc2eafe4f60beb93612549521a7_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi0xMi0xLTEtMjA3NzE1_ade84c92-1268-4156-95c5-939959f64828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b48c13c21214c678ad36cf685b3b072_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy0yLTEtMS0yMDc3MTU_16c74d08-f637-4735-bd64-ca0bc5ef3469">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b48c13c21214c678ad36cf685b3b072_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy00LTEtMS0yMDc3MTU_396689bc-676a-4eec-9111-f08cd7b252e7">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b48c13c21214c678ad36cf685b3b072_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy02LTEtMS0yMDc3MTU_9733a91b-17bf-4549-a2e8-9123e0d2f289">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd0103274754e1fb33a46edcf042268_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy04LTEtMS0yMDc3MTU_41400443-dfe7-462c-9a77-93a5af7a848e">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2dd0103274754e1fb33a46edcf042268_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy0xMC0xLTEtMjA3NzE1_2fdb077a-1fa8-4480-8324-d9ece4e28423">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dd0103274754e1fb33a46edcf042268_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy0xMi0xLTEtMjA3NzE1_380dbfee-bcfa-4af6-8039-31ba09790295">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC0yLTEtMS0yMDc3MTU_0066eab6-5765-4bc8-933f-07f6b84b06fc">25,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC00LTEtMS0yMDc3MTU_7922d72a-1659-446c-9416-293a8139dc47">21,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC02LTEtMS0yMDc3MTU_ca3acf25-4687-4587-943a-e623fb6ed366">3,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC04LTEtMS0yMDc3MTU_bfffb01c-06dc-4e0f-ae3a-f324bf90c636">25,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC0xMC0xLTEtMjA3NzE1_5fb79f80-c02b-481e-8614-ab8b64e61aa6">21,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC0xMi0xLTEtMjA3NzE1_58d041bc-9930-4588-8fe7-a99abe93d578">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da26cfaf00043bdbba7864b5a155ec6_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS0yLTEtMS0yMDc3MTU_0f6add69-e8bf-4b09-b1f7-70c0693ac530">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da26cfaf00043bdbba7864b5a155ec6_I20230331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS02LTEtMS0yMDc3MTU_5aa352b8-6c1c-46b7-b004-12771601efc2">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa692efa530140f8a1a881ba8a8249c5_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS04LTEtMS0yMDc3MTU_95645cf6-0eeb-477d-9819-3faa42bbff18">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa692efa530140f8a1a881ba8a8249c5_I20221231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS0xMi0xLTEtMjA3NzE1_bedc1be0-fa77-4676-b9bb-e65a7d27d5ff">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtMi0xLTEtMjA3NzE1_c6c4e7ab-8608-40e8-92d2-998a50f427ce">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtNC0xLTEtMjA3NzE1_118c8f6b-20de-4443-b32e-dea37e5a8d32">21,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtNi0xLTEtMjA3NzE1_7f5c897d-fe9e-418f-9788-1e06ec7ff745">5,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtOC0xLTEtMjA3NzE1_bc98027b-abad-4be6-9ba9-a602944d5c52">27,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtMTAtMS0xLTIwNzcxNQ_3314033a-aa54-41bc-b5ec-868535d91a63">21,334</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtMTItMS0xLTIwNzcxNQ_0e846760-7e0c-4f7b-b861-3d1ce474b2a6">5,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Condensed Consolidated Statements of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses and research and development expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments for the three months ended March 31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfNjY3_24f79745-d93c-429e-837d-9274e034293b">13</ix:nonFraction>&#160;million and include impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="i818c74f66a48498dba0c587f79830579_D20230101-20230331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfNzAy_c47e2872-26b8-44b6-9756-276fa9efa73b">8</ix:nonFraction>&#160;million, in aggregate, attributable to certain trade names no longer in use and (ii) $<ix:nonFraction unitRef="usd" contextRef="ifbe4581fb4234dbdafb70170994354db_D20230101-20230331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfODA2_7edfcc71-cc89-4b1b-ab63-9eb62fd49197">5</ix:nonFraction>&#160;million, related to the discontinuance of a certain product line. Asset impairments for the three months ended March 31, 2022 were $<ix:nonFraction unitRef="usd" contextRef="idf755e2bc874449e82907e0d22cf8c11_D20220101-20220331" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM2ODI5Nw_13f145ba-a1f9-48a6-bb1b-a917bfcf9e0e">8</ix:nonFraction>&#160;million due to discontinuances and decreases in the forecasted sales of certain product lines. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets included in the unaudited Condensed Consolidated Balance Sheets had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i08e744695a9e45b9b9ad55074d322f8a_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfOTg1_ffaeede0-0189-415e-9dbb-91189de59739">2,559</ix:nonFraction>&#160;million and an estimated remaining useful life of <ix:nonNumeric contextRef="i1fafe0032cba4aa1a32eca01ef3aca20_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMTAzMA_668999ac-dce8-4a13-9763-0871bff3f2eb">57</ix:nonNumeric> months as of March 31, 2023. On August 10, 2022, a court held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) were invalid (the &#8220;Norwich Legal Decision&#8221;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Paragraph IV Proceedings&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="ib62135cef7ea4c1d89602b99ccd1bb80" continuedAt="i777e7f7d853d41dbabcb0e2850c686f2"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that, in the third quarter of 2022, the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets for potential impairment using different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. This assessment resulted in <ix:nonFraction unitRef="usd" contextRef="i8a66af6adc904896a8ff0e7c2c1bd921_D20220930-20220930" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMTA5OTUxMTcxNDY2OQ_abdd6687-677a-457f-bcb4-a28c830047e1">no</ix:nonFraction> impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets as of September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From September 30, 2022 through the first quarter of 2023 there were no material changes to the facts and circumstances of the Norwich Legal Decision or to actual or expected business performance for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on these factors, <ix:nonFraction unitRef="usd" contextRef="i1fafe0032cba4aa1a32eca01ef3aca20_D20230101-20230331" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1ODI0Mw_5ce530f9-b02b-4fb6-8df9-e492911d0df5">no</ix:nonFraction> impairment to the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was identified as of March 31, 2023. The Company also determined that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be material to the results of operations of the Company in the period or periods in which they were to occur.</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5NzU_5c7698ce-9188-4332-8cde-a125ee63f51b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2023 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.833%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0yLTEtMS0yMDc3MTU_fc3d000a-293a-4397-bf7c-2792e75d8e0c">756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS00LTEtMS0yMDc3MTU_4ee84736-fafe-40c5-afe7-5254ccac9307">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS02LTEtMS0yMDc3MTU_5ba71f1f-3476-4f7d-a326-ef0b391c6c48">801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS04LTEtMS0yMDc3MTU_2ec82e05-505b-4a41-a2dc-146c26820336">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xMC0xLTEtMjA3NzE1_066d06ca-f599-4dbe-a072-4f136e9e3977">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xMi0xLTEtMjA3NzE1_92ca3e90-6e3a-4fb2-bc8d-958a64fd809b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xNC0xLTEtMjA3NzE1_0b31378b-87b2-4262-a9d4-98219c055485">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xNi0xLTEtMjA3NzE1_c8b17a48-ddba-41b9-8d28-ae20c4f7c669">3,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjgwMDE_e7abcf1a-8e6d-4fb0-a5b6-2c90e4b57a44" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 and the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.298%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.465%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dermatology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6bf825c7324cacac00e1ebf2a1c71e_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS00LTEtMS0yMDc3MTU_dae78aca-b771-4281-b16a-16c25f9b3749">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179f309e60d44d41af3ca366ec893b8b_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS02LTEtMS0yMDc3MTU_3bc24e8b-5f3d-40b9-b979-5f6875f8ee54">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i778f77cb42414cb5ac34f18b66605477_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS04LTEtMS0yMDc3MTU_edefaa86-24b0-46f7-a22c-189c4e643f03">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa6d2cd08c24125aa6dc092aad37002_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xMC0xLTEtMjA3NzE1_f65a45f8-bc01-4072-9120-3eb3f2dbb9ab">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9d39794e57948c0b3f7a07a43885d87_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xMi0xLTEtMjA3NzE1_9a891f3b-784f-45a1-97f1-8ceed9386392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb32f84fce124fcdbdda1eb3094fee46_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xNC0xLTEtMjA3NzE1_e1dbf5d4-757c-4cc7-9c08-339e0bfa94d1">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xNi0xLTEtMjA3NzE1_0fe1eaeb-f106-4201-88f4-ba48a376b6d8">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi00LTEtMS0yMDc3MTU_83d4ce94-f4ff-4e80-a8f4-1798c0772fe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi02LTEtMS0yMDc3MTU_b11383ed-9b1e-4753-9f66-0be85f98ebea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi04LTEtMS0yMDc3MTU_dba947b0-2ceb-42d8-ba70-e8bfd0733df3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xMC0xLTEtMjA3NzE1_2bd6b4c0-099d-4344-b34a-8f50fac2bdca">798</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xMi0xLTEtMjA3NzE1_85eb1f2b-f8d8-435e-af58-3422c3ad0dbf">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xNC0xLTEtMjA3NzE1_b6c2b8f1-cdab-4208-8cb6-d0dae5f5b585">683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xNi0xLTEtMjA3NzE1_6bd1a17c-5f9b-4789-8e32-3b98dac69be7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy00LTEtMS0yMjkzMDA_d26cf755-3a8d-4f69-8125-0e9895fb3efe">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy02LTEtMS0yMjkzMDA_23572250-32e3-40cf-a9e1-cbee3597d8ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy04LTEtMS0yMjkzMDA_0f369d38-b276-43ea-be74-6ba032efab8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMC0xLTEtMjI5MzAw_ef3a7518-3270-4082-8b29-c943ec05fb33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMi0xLTEtMjI5MzAw_c3c6ebeb-8d42-4c43-8d7b-6a26aeec6379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNC0xLTEtMjI5MzAw_62d2dcd5-aab4-4af5-8f2e-02345b21381e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNi0xLTEtMjI5MzAw_fd36cb66-f4cd-413a-8030-fdfa8efb4751">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy00LTEtMS0yMDc3MTU_9523ed38-0ffa-4a59-a5f6-aeb5c0cf7dd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy02LTEtMS0yMDc3MTU_6e6749a9-86a3-46a9-9d8d-93778401e91a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy04LTEtMS0yMDc3MTU_3b544553-92d3-4d42-a5d8-7612f84cb4e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMC0xLTEtMjA3NzE1_c7d34680-acfc-4f74-a342-04175416d42d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMi0xLTEtMjA3NzE1_ba4080b7-4c80-463d-ac3d-b08d911cd0fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNC0xLTEtMjA3NzE1_4b509188-f410-4f85-9d0c-91b374b81ac3">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNi0xLTEtMjA3NzE1_e3b2dd7d-35a9-433e-bce2-dced974124f5">824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC00LTEtMS0yMDc3MTU_a1f2650f-b950-4ada-8970-637163d55a58">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC02LTEtMS0yMDc3MTU_3bd2913b-a99d-4fd8-afdf-07e32d5c1851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC04LTEtMS0yMDc3MTU_0402fd9f-7218-4c14-a890-66f2bf9a6d64">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xMC0xLTEtMjA3NzE1_64495627-aae2-436b-a1e4-dcba38461a8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xMi0xLTEtMjA3NzE1_4c26c2f3-c28d-45de-bbb4-0f89f35449bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xNC0xLTEtMjA3NzE1_750f5fb8-ee2f-4876-a728-3be17c4b8b09">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xNi0xLTEtMjA3NzE1_059930e5-3515-4a4f-b6c6-ff3692fa3e76">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52bba3d92b045cd9377b763545b3f6b_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS00LTEtMS0yMDc3MTU_2091bf15-3e3a-420c-b791-981d33b16081">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53fcd851b0d54c2dbe32c186e8d2ecb0_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS02LTEtMS0yMDc3MTU_2fc4e4cc-5de9-4752-b210-ac2bd4b72524">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c329081547a4cdf98e1aa393d8972f9_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS04LTEtMS0yMDc3MTU_bfee8db1-1394-4e89-8353-b122f90840c3">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2455a2fae6ad431e922a0ba988eb6a34_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xMC0xLTEtMjA3NzE1_8640a294-154e-48db-b074-0566da69307a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f2a2fe52aa458190c6047336e73de4_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xMi0xLTEtMjA3NzE1_f5f703bb-d2f3-4690-8ee5-8fbf1169f97d">115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659a2f673c4a4411ab26d25784b4be92_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xNC0xLTEtMjA3NzE1_fffe2ef3-9a61-4ed8-87c2-be06ed542f2c">2,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xNi0xLTEtMjA3NzE1_252aae70-bbee-4993-8847-c34ffb54be18">11,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi00LTEtMS0yMDc3MTU_b759d671-4104-4a08-919a-252b10e3ff3e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi02LTEtMS0yMDc3MTU_b3a6e0ec-4548-4c49-afd8-d7e2a0f15aff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if298046fc580453c82cae116d877a880_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi04LTEtMS0yMDc3MTU_76e53676-d3af-48ca-885a-9a7ef014a508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a6d2460268490a812b6a04661c6a65_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xMC0xLTEtMjA3NzE1_d8c0875e-9405-4573-9201-542b1bc51aa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xMi0xLTEtMjA3NzE1_4e401564-b517-4f22-9351-fec6c51dc488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xNC0xLTEtMjA3NzE1_2e2e7127-0e2c-4a7b-998a-360f6339fcaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xNi0xLTEtMjA3NzE1_80806805-dd6d-4a89-90e2-e01c433528d0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC00LTEtMS0yMDc3MTU_680a3a3f-41c2-4736-af6e-36996ee5e1e2">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC02LTEtMS0yMDc3MTU_7d317d2d-2905-444c-b180-20ea46fceebe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if298046fc580453c82cae116d877a880_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC04LTEtMS0yMDc3MTU_7ddf1670-9c49-4d9a-a3a6-27391c1549c7">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a6d2460268490a812b6a04661c6a65_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xMC0xLTEtMjA3NzE1_aad96c10-dff8-4d26-b1fe-681ea7dd28c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xMi0xLTEtMjA3NzE1_55a73e14-3472-4d62-a17e-ac19d20cd1b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xNC0xLTEtMjA3NzE1_382733eb-4094-461b-a3ee-ae2886291799">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xNi0xLTEtMjA3NzE1_2f15b347-b252-44b5-973c-cbe0a84d8f69">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic769315b03e548d48d1dd48f1f5ce5a2_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS00LTEtMS0yMDc3MTU_c457fde5-3dd9-4a77-807c-83a2f44913bf">5,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc08a22ed7434483b9c22e1d5222d8b0_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS02LTEtMS0yMDc3MTU_defe0230-0789-42a0-9f3c-deb6e8ce0d88">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8bc248d85e49df8afec2958aab8781_I20230331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS04LTEtMS0yMDc3MTU_41096970-2b33-4cef-af84-92dc6196a786">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294049ce13fc4119883d1b65b4fb4e3f_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xMC0xLTEtMjA3NzE1_e36d5639-4985-4726-b6b5-95a9c3fa1796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c81e913fa06452b960a94c4319affd4_I20230331" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xMi0xLTEtMjA3NzE1_07f545be-21bf-4b17-a568-90690ac0981b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dd72c321919418dbd266cd1519b7af3_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xNC0xLTEtMjA3NzE1_4afd7b9e-4568-4cff-8c67-3022649ed579">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xNi0xLTEtMjA3NzE1_e92285df-0452-446b-803e-0872940c0e2e">11,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i777e7f7d853d41dbabcb0e2850c686f2" continuedAt="i88bd1b96c1a84d3f967a645a817762ee"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such charges could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Dermatology (formerly Ortho Dermatologics) reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i4f49db76bb9048269a4225f0617c7e08_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ4Ng_b14440e5-6c5c-4c67-94b1-9c938b324a58">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i4f49db76bb9048269a4225f0617c7e08_I20220331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ5MA_64b9c49f-1cd4-4840-9d06-6c08b3ea7c5f">9</ix:nonFraction>%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk-free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Dermatology reporting unit was less than <ix:nonFraction unitRef="number" contextRef="i4f49db76bb9048269a4225f0617c7e08_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ5NA_1e7102b2-8565-448f-b45b-eade07366c8e">2</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="id6075831fea84e2eb08c47c4f0c4d29b_D20220101-20220331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ5Nw_f266d8c1-812d-42c9-9119-9078a783429b">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Dermatology reporting unit as of March 31, 2022. Given the limited headroom of the Dermatology reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Dermatology reporting unit as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Dermatology reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="id40329b767834642890bfb55575f5122_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUwNg_1a75cf3a-d324-4f56-b55d-899ae79fbe42">1</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="id40329b767834642890bfb55575f5122_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUxMA_caf17932-895e-4a25-8bc0-4dd36d0391c6">10</ix:nonFraction>%. The discount rate had increased <ix:nonFraction unitRef="number" contextRef="id40329b767834642890bfb55575f5122_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUxNQ_43d122c4-36a8-42ec-87c9-9aedc6b3b4a3">1</ix:nonFraction>% since the assessment performed as of March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk-free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Dermatology reporting unit exceeded its fair value as of June 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="if2e632bea1f6478b9fa7efc4a42012da_D20220401-20220630" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUxOQ_e537ae38-acfd-4993-ab1e-7d7daadaeb03">83</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the date Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which as of June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the <ix:nonFraction unitRef="reporting_unit" contextRef="i9aa533c5f43d49389b83002df6cdf881_D20220506-20220630" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUzMQ_e11e61e7-f39a-4f55-8818-f162a3a5e5b5">three</ix:nonFraction> reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized the Company&#8217;s most recent cash flow projections for each of its reporting units as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i88bd1b96c1a84d3f967a645a817762ee" continuedAt="if39032d6e4414dd3bd9f9d59d1ed77a1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="iab9c3331e15a44048291c40dafad29a2_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU0Mg_f2478573-198e-4325-9b3e-593ab27afb05">2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7b85418b2df045ccaf777f6a153cd251_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU0Ng_0540dac8-ff4a-44eb-b80c-fb638be9cecf">3</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="iab9c3331e15a44048291c40dafad29a2_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU1MA_ba2c5868-0342-4024-bae4-e6b8fc70ec46">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7b85418b2df045ccaf777f6a153cd251_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU1Ng_3a373dd1-343c-4fe2-8d17-fb7d5a49897f">11.5</ix:nonFraction>%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than <ix:nonFraction unitRef="number" contextRef="iff9524a8dec942a8bde2eb81616907d3_I20220630" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU2Mw_b19bfe52-a5a6-4b84-969c-f5d937687d97">25</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i2ae7f8afd93140b892be236df15ed51f_D20220506-20220630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU2Nw_b9a5cf16-ffcd-4d39-a0b7-4b8e130b3321">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Dermatology reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Dermatology reporting unit at June 30, 2022. Based on the impairment of goodwill recognized in the second quarter of 2022 for the Dermatology reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Dermatology reporting unit as revised in the third quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Dermatology reporting unit includes, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="iad75129d06c348f0be0dddaa52c9ed51_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU3Ng_3e19b5be-8dd2-48d9-996c-a8eafa3cad4c">1</ix:nonFraction>% and the discount rate increased from <ix:nonFraction unitRef="number" contextRef="id40329b767834642890bfb55575f5122_I20220630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU4MA_cbeb3668-36bd-4164-b252-3aef00b53669">10.0</ix:nonFraction>% at June 30, 2022 to <ix:nonFraction unitRef="number" contextRef="iad75129d06c348f0be0dddaa52c9ed51_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU4Nw_80eeb470-a628-4688-aff2-efdca39a5ff6">10.5</ix:nonFraction>% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Dermatology reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="ia0f99abdbe264be492c1ab50a81c5fa7_D20220701-20220930" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU5NA_93cd5458-c87e-43e8-a8ec-2258b749a6b2">119</ix:nonFraction>&#160;million for the three months ended September 30, 2022. As of September 30, 2022, the Dermatology reporting unit had remaining goodwill of $<ix:nonFraction unitRef="usd" contextRef="iad75129d06c348f0be0dddaa52c9ed51_I20220930" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYwOA_89c2cc78-b5c2-4c47-902b-5c4354622854">480</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately <ix:nonFraction unitRef="number" contextRef="i370ee4cf54624da09da5e76a026c3802_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYyMg_079bd995-b0f9-4bc6-b2bd-23f4a07697b5">80</ix:nonFraction>% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i41f572ad45a949229f9b0322d3dfb46d_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYyNw_7f32192f-1c42-4d1f-b413-268c01f7ca88">2.5</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="i9c9e3a1139454651b2a0528c0e2b983c_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYzMw_001f90bd-bb30-48ae-91d0-08e95dde4402">9.75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i84e42d2305b3476a936b8caf47cb8b60_I20220930" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY0MA_ae31a6e8-a82e-46f2-8d18-0a3ec787980b">10.0</ix:nonFraction>%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore <ix:nonFraction unitRef="usd" contextRef="i45fcaa6d1e16450c95f03e1749bb60ac_D20220701-20220930" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY0Ng_623ab493-b3ce-4c18-ae72-2211eb007435">no</ix:nonFraction> impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than <ix:nonFraction unitRef="number" contextRef="i41f572ad45a949229f9b0322d3dfb46d_I20220930" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY1NQ_ac3a9f8a-c3c6-460e-88b2-16f95b83afc1">5</ix:nonFraction>%.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, no events occurred, or circumstances changed during the period October 1, 2021 (the date of the last annual impairment test) through September 30, 2022, that indicated that the fair value of any reporting unit, other than the Dermatology reporting unit, the Salix reporting unit and the reporting units of the Bausch + Lomb segment, might be below their respective carrying values.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="if39032d6e4414dd3bd9f9d59d1ed77a1" continuedAt="ie6c67ffdd6d642a980ba37269258a934"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, the Company conducted its annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2022, management believed that, it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurology and Other </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands, health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. The nature of the Neurology and Other reporting unit&#8217;s product portfolio, which includes branded generic pharmaceuticals, is by its nature impacted by these changing market dynamics. As a result, the Company has begun taking steps to: (i) reassess its pricing strategies, (ii) re-evaluate its marketing and promotional efforts and (iii) reduce its cost structure, and has revised its long-term forecasts for the Neurology and Other reporting unit to reflect these developments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Neurology and Other reporting unit utilized the most recent cash flow projections for the reporting unit as revised in the fourth quarter of 2022 to reflect current market conditions and current trends in business performance. The quantitative assessment utilized a long-term growth rate of -<ix:nonFraction unitRef="number" contextRef="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231" decimals="INF" sign="-" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY1OQ_b0071e04-c66f-4dd0-94d9-cf34cd115ced">2.5</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY2Ng_d61445fc-85a4-448e-b35e-15f008624792">10.25</ix:nonFraction>% in the estimation of the reporting unit&#8217;s fair value. As a result of the revisions to its long-term expectations for these and other factors, goodwill for the Neurology and Other reporting unit was impaired during the Company&#8217;s most recent annual impairment test reflecting its best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value test, the carrying value of the Neurology and Other reporting unit exceeded its fair value as of October 1, 2022, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="if400b9a66b464bc39f29a0744063105e_D20221001-20221001" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY3NA_dc8ade3b-f815-4c65-92a0-e62e466e3343">622</ix:nonFraction>&#160;million. As of December 31, 2022, the Neurology and Other reporting unit had remaining goodwill of $<ix:nonFraction unitRef="usd" contextRef="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY4OA_4d24b04e-fdfe-4b32-8a0b-591c6f28dee5">1,439</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative assessment utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i4230998f842f4bbc82a0ea680d4b577b_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcxOQ_7b4b3efc-175d-4e02-9296-8f7f9243f916">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id8d9d9cd168d4fe98734f508386e2be0_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcyNQ_c83c7ccf-b568-469b-b0a0-b6671edb523c">3.0</ix:nonFraction>% and discount rates of <ix:nonFraction unitRef="number" contextRef="i4230998f842f4bbc82a0ea680d4b577b_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcwNA_6d614613-022d-4de2-bc37-fadc86079b33">9.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id8d9d9cd168d4fe98734f508386e2be0_I20221231" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcxMQ_2182293b-f71e-4b91-ac0e-2bcec19819ce">12.25</ix:nonFraction>% in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its respective carrying value by more than <ix:nonFraction unitRef="number" contextRef="icfc0cbc0a72349eeb0612d5fd6410c80_I20221231" decimals="INF" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDczMQ_a59f1178-b0cd-44ba-ad41-9291a24e0755">25</ix:nonFraction>% and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i063a380689344325b47343a660c9c908_D20221001-20221231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDczNQ_0730c23a-9151-407b-abdb-18b73440f37d">no</ix:nonFraction> impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period October 1, 2022 through December 31, 2022, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Dermatology and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and any such charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment of goodwill in the third quarter of 2022, the Dermatology reporting unit had no headroom on September 30, 2022, and as such, the Company continued to monitor the market conditions impacting the Dermatology reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company evaluated the reporting unit&#8217;s performance as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Dermatology reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. </span></div></ix:continuation><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="ie6c67ffdd6d642a980ba37269258a934"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the quantitative fair value testing performed in the third quarter of 2022, the Salix reporting unit had limited headroom as of September 30, 2022 and, as such, the Company continued to monitor the potential impacts of changes in the Norwich Legal Decision and market conditions on the valuation of the Salix reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2022, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#8217;s assessment as to a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to January 2028, if they are able to launch one at all. The Company also evaluated the reporting unit&#8217;s performance in the fourth quarter as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Salix reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2023 Interim Assessment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Dermatology, Neurology and Other, and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and any such charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through March&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5NTc_59a41ce8-03df-418c-b71a-7781f9111ad0">5,004</ix:nonFraction> million.</span></div></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_64"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RleHRyZWdpb246M2Y0ZGE0ODRiYTgwNDJiNGEyMDc2YTE2ZjA0MjQ2YmJfOTY_11368d00-306c-48a1-9e69-b1d406aa329c" continuedAt="i02ae934513d2448ea424677a97914384" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i02ae934513d2448ea424677a97914384"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RleHRyZWdpb246M2Y0ZGE0ODRiYTgwNDJiNGEyMDc2YTE2ZjA0MjQ2YmJfOTk_6ed1bb3e-df1c-4da1-8256-743dc7e1dcff" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS0yLTEtMS0yMjczNzQ_ae050973-f0d6-480d-823a-cdb3439c2350">914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS00LTEtMS0yMjczNzY_427420e0-c07b-4cc5-8cc4-503fce454285">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMi0yLTEtMS0yMjczNzQ_23e2bbc7-7faf-48cd-8e32-e998086e702f">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMi00LTEtMS0yMjczNzY_a1f2f7c2-3945-4e72-bae0-0b015bbd50c7">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS0yLTEtMS0yMDc3MTU_243314ec-1d63-40ca-a91f-a0260b66c42b">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS00LTEtMS0yMDc3MTU_6b2a4bd0-bec6-4460-9af8-d621d86a5fe2">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC0yLTEtMS0yMTkyNjc_f4b038fb-b99a-4417-bb5b-8cffb2266e39">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC00LTEtMS0yMTkyNjc_466ed9f0-d6ca-4ea9-9ec1-551c53470079">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC0yLTEtMS0yMDc3MTU_e4794daf-ba3a-4a6f-9a8e-28a76b55c2a5">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC00LTEtMS0yMDc3MTU_d8ccdd31-1263-418b-8103-82a231ff06bb">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNi0yLTEtMS0yMDc3MTU_b8770480-eb92-4244-bf0f-2438d573485a">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNi00LTEtMS0yMDc3MTU_852240f0-8cf6-4e29-ae3f-eade730944b6">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNy0yLTEtMS0yMDc3MTU_6637db2c-c977-4404-a527-d033c6f9bf1f">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNy00LTEtMS0yMDc3MTU_81b6d494-d026-4d3c-97a0-144bdc68252e">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfOC0yLTEtMS0yMDc3MTU_ae39469f-72c8-49f2-a6f2-ef0501ca92d4">2,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfOC00LTEtMS0yMDc3MTU_927db464-8f24-44cb-bccb-2a53019a05fa">2,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_67"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5ODQ_25a02d35-b734-464f-bf81-0768e424d26e" continuedAt="i70737d58a1fd43bfa6c4663a77231726" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i70737d58a1fd43bfa6c4663a77231726" continuedAt="i50e40013b822421b896cdb52ff59ce15"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5OTI_b9d08bdb-9d60-4915-a2f7-04c71c78de9a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2263e23bd8e642778b2df9b8853237be_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC00LTEtMS0yMDc3MTU_a0eb1276-60e3-492b-b566-5f2a24a29524">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2263e23bd8e642778b2df9b8853237be_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC02LTEtMS0yMDc3MTU_3edaf28a-32b2-4c0f-8872-1728c8bcc4cd">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81245af4c6a84955ba0724a4c0e69852_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC04LTEtMS0yMDc3MTU_c9012608-1f4e-4469-ad3b-80b456462afe">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81245af4c6a84955ba0724a4c0e69852_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC0xMC0xLTEtMjA3NzE1_c97c0b12-2e17-4d45-97c0-27f7fb977a95">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5c0b0ff6ea4e92a88b245ac951ddde_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS00LTEtMS0yMDc3MTU_563f11c9-3c5a-4b85-931f-22b1277e3e2c">2,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5c0b0ff6ea4e92a88b245ac951ddde_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS02LTEtMS0yMDc3MTU_7cee4802-4937-4493-a5fb-41cb956c4301">2,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52924d69272c4ce08a9238494afb5ce1_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS04LTEtMS0yMDc3MTU_4b202b34-b9c7-430f-8b86-1fdb03308390">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52924d69272c4ce08a9238494afb5ce1_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS0xMC0xLTEtMjA3NzE1_d4aeb149-11c6-4de3-951a-c48d1097036f">2,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73805f2008b0493784b73a6e474d0511_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtNC0xLTEtMjA3NzE1_b3e1dce3-3826-460b-bc24-1a6aa372a9df">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73805f2008b0493784b73a6e474d0511_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtNi0xLTEtMjA3NzE1_3f67fac1-0bfa-4374-a543-9a52fe6c391e">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e66b94be8048c395bd7d7ffcc1ac3e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtOC0xLTEtMjA3NzE1_9e0997aa-1b63-4a99-b9e7-289b5b1371a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e66b94be8048c395bd7d7ffcc1ac3e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtMTAtMS0xLTIwNzcxNQ_f7f868e7-4e5e-4abc-8f05-537dacc71cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f96c4977bdf4527aca21c11e00b2edf_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItNC0xLTEtMjA3NzE1_39474983-7264-4967-b6e0-550332e9796a">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f96c4977bdf4527aca21c11e00b2edf_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItNi0xLTEtMjA3NzE1_c11c5ec3-9744-4ec5-bf86-66530880183c">2,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304f673759f44464b17361dc1fe3b487_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItOC0xLTEtMjA3NzE1_5d62d83b-f282-4c3e-9f05-257344687611">2,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i304f673759f44464b17361dc1fe3b487_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItMTAtMS0xLTIwNzcxNQ_db59cef1-6e49-495f-8da5-f3bf3cb28308">2,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibacd0f91a9214e0fbe96138d126d5254_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246OGUyZWY0ZTBhNDM5NGFjODk5ZWM2ZWJjNDYxNDU5YjVfNA_6b06fed8-09e4-477c-a994-41618831d036">5.50</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibacd0f91a9214e0fbe96138d126d5254_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtNC0xLTEtMjA3NzE1_ce9120ee-d0b5-4246-9041-0b0dd35e202b">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibacd0f91a9214e0fbe96138d126d5254_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtNi0xLTEtMjA3NzE1_560c6a63-2faa-4f05-8945-d4a97dc57757">1,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7b5fbd1e7f4531a59766d450386804_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtOC0xLTEtMjA3NzE1_e914bc91-f5d4-4027-8541-61f6def3a527">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d7b5fbd1e7f4531a59766d450386804_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtMTAtMS0xLTIwNzcxNQ_f0c4f8d2-289c-4c10-9901-64763f5a16fb">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d37517b7d6b4cbc982519aae076487f_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246N2Y1NTZhZmZkMzc0NGU0YzhmOWNmMDZjZDUzNGVlODJfNA_8e3bf8b6-5c60-40f3-96c7-cc8619b93ec8">6.125</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d37517b7d6b4cbc982519aae076487f_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtNC0xLTEtMjA3NzE1_f896068f-4d21-476e-be77-41d602b0100b">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d37517b7d6b4cbc982519aae076487f_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtNi0xLTEtMjA3NzE1_05837872-108a-4984-9535-ca5a5046db14">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e85debb9de747678b7cdb6f20a35b55_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtOC0xLTEtMjA3NzE1_dd9482e2-cde1-4959-83a1-03514f8da12b">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e85debb9de747678b7cdb6f20a35b55_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtMTAtMS0xLTIwNzcxNQ_d47343f1-f38b-4dfc-be6b-a500597c9cff">987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib53b662a6d4d41fead56abf94df3152b_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246YTZmOWYyZjUxM2VjNGMxMTk2NzJmYTk4OWY4NWE2ZjhfNA_8a188fba-b0c4-4f20-9a5c-56fe1fee2974">5.75</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53b662a6d4d41fead56abf94df3152b_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtNC0xLTEtMjA3NzE1_4069cdad-dd62-4dd8-807e-f780639cf6c5">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53b662a6d4d41fead56abf94df3152b_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtNi0xLTEtMjA3NzE1_d6cd8fab-bc78-4080-a4a1-7104ea4a7144">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d56d7f093844549b20bc3e68c8d823_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtOC0xLTEtMjA3NzE1_fff51f55-672e-430f-8691-eec8cf777581">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d56d7f093844549b20bc3e68c8d823_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtMTAtMS0xLTIwNzcxNQ_780cef90-f996-45e9-8938-bb08594b0a35">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5bfca85fb4024a6b94e76897fbe51927_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctMC0xLTEtMjA3NzE1L3RleHRyZWdpb246N2IwZmYyOGNlYzdhNDUyN2E3NjkzYjY2Y2ExNDA4ZWNfNA_32db420e-9b7f-4172-80da-4ea4dd43d38e">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfca85fb4024a6b94e76897fbe51927_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctNC0xLTEtMjA3NzE1_aa8f31b4-0fb5-4dc6-bdc5-9732c4a924d2">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bfca85fb4024a6b94e76897fbe51927_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctNi0xLTEtMjA3NzE1_1bdb2ba3-c9f1-4264-896e-69a441831255">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fce4dedbd8421eb73bafb553597896_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctOC0xLTEtMjA3NzE1_4cd27939-6a47-4e98-9329-892cd0c43448">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fce4dedbd8421eb73bafb553597896_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctMTAtMS0xLTIwNzcxNQ_47a625dd-9c01-4756-90a6-6e1eda6c4e7a">1,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246ZTY1ZGU5NjQxY2I4NDUxZWExZWFjNzNhZGJiOWM4ZDNfNA_7f145cd5-f54b-44b4-ac7b-b3bbd45f26d1">11.00</ix:nonFraction>% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtNC0xLTEtMjA3NzE1_8c2f555e-a22b-4232-a808-865d2a108abb">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtNi0xLTEtMjA3NzE1_934fb64c-5f97-4ab7-a0ec-04104f5eb53a">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19dd2ee808a54032b36dcaee1eacb64f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtOC0xLTEtMjA3NzE1_e36fc1b6-268e-4d15-8577-31937e42f42a">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19dd2ee808a54032b36dcaee1eacb64f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtMTAtMS0xLTIwNzcxNQ_e15e976d-23f2-4149-b073-d3b41fd24b42">2,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktMC0xLTEtMjA3NzE1L3RleHRyZWdpb246N2Y2YWUzZGZiY2U5NGE1YmFkZDVkZTY0MDBiNGFkOGNfNA_b435feb6-c761-4f22-95bc-b407f0e9bc86">14.00</ix:nonFraction>% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktNC0xLTEtMjA3NzE1_7595a357-8420-42bf-a423-2ac3d8b317f1">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktNi0xLTEtMjA3NzE1_8972d4e1-de6b-4088-bfce-c13bce9cc912">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552ec672b451433a9e90f1b3839c487f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktOC0xLTEtMjA3NzE1_5fe96d1a-e725-4d35-98f9-8253641d656a">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552ec672b451433a9e90f1b3839c487f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktMTAtMS0xLTIwNzcxNQ_6e81a7f1-e652-4ef5-ba85-67b5a80907e7">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NzliNThkOGQwYWE2NDgwY2IxZTEzMzVhNWRjNGNjNGFfNA_d1da07f7-c68b-47f1-8cb6-541430308fd9">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtNC0xLTEtMjA3NzE1_46ccf221-a10f-441c-a069-79f5c7e437f7">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtNi0xLTEtMjA3NzE1_07df050b-6221-46cb-a015-4d9a19d7888d">1,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57b9dc8ffac4b9b9b063a8ef1df4a6a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtOC0xLTEtMjA3NzE1_4814d638-2a57-4572-b58d-15fc2ad455dc">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if57b9dc8ffac4b9b9b063a8ef1df4a6a_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtMTAtMS0xLTIwNzcxNQ_13b2abc1-7a1e-4a36-b6d3-1d827ffdd273">1,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4de0d68bab3b4961969accc3d866508c_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246YjZhY2UwOWFlNjJiNDFlY2I5ZThhYzlkMTZlNjViMzRfNA_7b9e049c-2939-4663-8647-3ae9eca0216b">9.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de0d68bab3b4961969accc3d866508c_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtNC0xLTEtMjA3NzE1_4e80c5c3-a050-4b68-b6bd-9e271f18c35a">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4de0d68bab3b4961969accc3d866508c_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtNi0xLTEtMjA3NzE1_d34146d6-1c1c-4d76-bc85-ec7724a751cb">952</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69eca3a5c1014c4fb4646db720b2ce73_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtOC0xLTEtMjA3NzE1_401339f0-9f20-4677-8e9a-f2a8f1b94a1a">959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69eca3a5c1014c4fb4646db720b2ce73_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtMTAtMS0xLTIwNzcxNQ_ec72dcd0-83b7-4f81-b1b5-0cd01e86cd53">951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d865df747b04091979d8849df30eb08_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246YzE4MzI4MzY3YjBhNDgwNWE5NTI3NDZmZmFhMWE5NzZfNA_672f9982-6201-4244-b389-9c43d5a01f70">9.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d865df747b04091979d8849df30eb08_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtNC0xLTEtMjA3NzE1_8fa71876-454e-4c09-b0fc-151e50215726">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d865df747b04091979d8849df30eb08_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtNi0xLTEtMjA3NzE1_a819f5aa-22ed-41c0-841e-0e5294d34a0d">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5d88c4fc174c4ba4624f3bda26b88f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtOC0xLTEtMjA3NzE1_f158ed3a-58e0-4af2-8b0a-c9e0327f2a20">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5d88c4fc174c4ba4624f3bda26b88f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtMTAtMS0xLTIwNzcxNQ_1142228b-cfa2-4ea3-b83a-5476bf051144">737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i95707314425842cd82eb737ebe900f57_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NWViMTYwYmRhMWZkNDdiYWI4NjkxYTQxNzU5MTk5ZjNfNA_62af9bda-a955-4b18-a605-19050f718854">8.50</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95707314425842cd82eb737ebe900f57_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtNC0xLTEtMjA3NzE1_ee71e44d-4a5f-4887-9f15-7f9f1235f99b">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95707314425842cd82eb737ebe900f57_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtNi0xLTEtMjA3NzE1_77e37a41-45cc-4ed3-9f36-a2acb25d406d">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d21d625b784308ba11c8058938ddbe_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtOC0xLTEtMjA3NzE1_211a91bf-6a1f-4a76-8915-54864c07b8a6">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d21d625b784308ba11c8058938ddbe_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtMTAtMS0xLTIwNzcxNQ_eba9a44a-a989-4679-98ad-75f18359c009">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i798ef0f209fb49009a6ca1d36a285f67_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246OThjYTlhY2MyZDZlNGJiN2EwYzI0YmFmN2EyNDdkNThfNA_dd25b366-93a5-4072-95d8-d2a82d2fd024">7.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798ef0f209fb49009a6ca1d36a285f67_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtNC0xLTEtMjA3NzE1_41fc640a-541b-45ad-bb9b-f47633f28894">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i798ef0f209fb49009a6ca1d36a285f67_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtNi0xLTEtMjA3NzE1_ed63cf32-2056-41aa-bb1c-92d62edc0743">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a65dde3c3aa45549c7496b96199b6f8_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtOC0xLTEtMjA3NzE1_04a6cfc6-012b-4085-accf-e40d2d7a252f">171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a65dde3c3aa45549c7496b96199b6f8_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtMTAtMS0xLTIwNzcxNQ_1ab1826c-d3c4-4971-a0a4-bc19a5b04656">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd0cd3f81eb14fbb885bef7666346a89_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NDNmYWFhYzY5NThkNDU5MGFmNmQ1M2FhZjUzOWY1ZjBfNA_02096e6b-ddcb-417b-8418-e91bfe20d7aa">5.00</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0cd3f81eb14fbb885bef7666346a89_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctNC0xLTEtMjA3NzE1_52e69f41-84e4-4fa3-a475-bce6db4704a7">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0cd3f81eb14fbb885bef7666346a89_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctNi0xLTEtMjA3NzE1_9283fc7c-50c7-4e1a-a13f-5c49778f0ffa">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3ed0b49365444fad700d85b63bf260_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctOC0xLTEtMjA3NzE1_bd0ee41d-23bd-42e9-bd82-2ab14aa270bb">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3ed0b49365444fad700d85b63bf260_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctMTAtMS0xLTIwNzcxNQ_f960d0a3-ba2b-4ad4-86a9-42e818728b09">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50270179827249f7adf2f7e4718cc6cb_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246MjQwNzkwMzdjYmJlNDM1MWI2NGI2NjFhZjgzMjk4OTdfNA_735685e1-fd01-48ed-a090-1daf9d1511ac">6.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50270179827249f7adf2f7e4718cc6cb_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtNC0xLTEtMjA3NzE1_3bf5e973-9f0b-46e2-8492-bbb2630b071d">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50270179827249f7adf2f7e4718cc6cb_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtNi0xLTEtMjA3NzE1_69997a5c-a382-4f76-9a52-72fb3a460f71">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff54ecadaabf473d8116b32464b6b6a7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtOC0xLTEtMjA3NzE1_0ee97204-9cbb-4761-bd23-e6250e28c5a4">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff54ecadaabf473d8116b32464b6b6a7_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtMTAtMS0xLTIwNzcxNQ_d754ec01-3825-4a2e-a8b9-9c0ae64ed344">813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktMC0xLTEtMjA3NzE1_fc1f601a-30b9-4984-afce-f8b3c24d0b65">5.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktNC0xLTEtMjA3NzE1_fec31d44-0585-4288-a0b0-e549d05f2d32">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktNi0xLTEtMjA3NzE1_f67507c2-aa3d-4557-b32a-abbafd63e4e5">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7af656ef0f457484bd906468e5c84f_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktOC0xLTEtMjA3NzE1_a581d02d-694c-42c7-bd80-118997c6d55e">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a7af656ef0f457484bd906468e5c84f_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktMTAtMS0xLTIwNzcxNQ_bbd1be48-d915-41ee-9899-65d41a652f95">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ae1e47647b4e16abae2c02f07359b3_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NDNjYWYxYmMxMzMzNDI3Yjk2YTAzMmYwY2JjMGY1MTlfNA_eb0a1b58-1ca9-41db-92de-d6c6822cb72e">7.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ae1e47647b4e16abae2c02f07359b3_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtNC0xLTEtMjA3NzE1_31ad8ef7-769c-4728-bb53-6d9c1b976980">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ae1e47647b4e16abae2c02f07359b3_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtNi0xLTEtMjA3NzE1_52e84f0f-8d58-469b-830a-5d1969528946">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98cbac4569eb4a4897d65431dc5af7a6_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtOC0xLTEtMjA3NzE1_003d0bd6-fdad-43cf-9afe-0d16d8bd1516">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98cbac4569eb4a4897d65431dc5af7a6_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtMTAtMS0xLTIwNzcxNQ_97646730-7125-4b32-a111-b8b790f0c11d">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i513ab91ef61a48c09cebf7bccfcc7994_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NjZmYTMwZDMyYzM0NGQ2YWEyNDM5NTY4ZjM5YjFlYWJfNA_a38f0550-fb83-4074-ad22-89c2f4f7597e">5.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513ab91ef61a48c09cebf7bccfcc7994_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtNC0xLTEtMjA3NzE1_b38a08eb-b07c-47ab-9ef4-876a2ae696b8">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i513ab91ef61a48c09cebf7bccfcc7994_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtNi0xLTEtMjA3NzE1_03760f0e-4016-47f3-8d28-c6632f0af5ea">772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d700d6fa904cbabe449baab21de04e_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtOC0xLTEtMjA3NzE1_073f6622-c50f-4095-9d32-db8247f792c5">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d700d6fa904cbabe449baab21de04e_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtMTAtMS0xLTIwNzcxNQ_d2028ee0-23c8-43c7-aac7-fdf7659912bd">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItMC0xLTEtMjA3NzE1_88dcdc71-74ea-4300-ac9d-7f26ac5cf47e">5.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItNC0xLTEtMjA3NzE1_0ca40d85-4280-495e-8d99-1a919ea02062">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItNi0xLTEtMjA3NzE1_369a616e-8300-4185-bc86-a50ea78dc5bf">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573bed6abe6342a9a2cca0beda4b3a3d_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItOC0xLTEtMjA3NzE1_0bfdc73d-ff26-4974-9b6e-098153e6fc16">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573bed6abe6342a9a2cca0beda4b3a3d_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItMTAtMS0xLTIwNzcxNQ_ff761ef5-ce0f-49d0-8284-840982bed5ad">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7970cd462c4d338f9b250f47fc2cc7_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtNC0xLTEtMjA3NzE1_9d21b596-871a-44a4-86d3-07521f26e442">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf7970cd462c4d338f9b250f47fc2cc7_I20230331" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtNi0xLTEtMjA3NzE1_431af295-afa3-46cc-ab86-4cf1422486eb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2b7f1301cd4d6580b57be2d9bceba4_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtOC0xLTEtMjA3NzE1_f959d39a-09e4-4781-aefe-6148d9603d14">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e2b7f1301cd4d6580b57be2d9bceba4_I20221231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtMTAtMS0xLTIwNzcxNQ_323dc1c1-a290-4677-ac91-72f946c15bf2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtNC0xLTEtMjA3NzE1_48203210-5e4a-4d91-aec2-e4c54ee1c81e">19,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtNi0xLTEtMjA3NzE1_f7c59c01-6f1c-4e1f-bb1a-48d2c669d2c0">20,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtOC0xLTEtMjA3NzE1_e13d79bf-4cd9-4b11-a245-4bb3790bf476">19,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtMTAtMS0xLTIwNzcxNQ_3f03e21f-af71-42fa-9995-90916ac1209f">20,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzUtNi0xLTEtMjA3NzE1_99e2f1b4-fdce-4caa-89bf-61292bd8d474">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzUtMTAtMS0xLTIwNzcxNQ_1132080c-5e0e-496b-a9a7-34f313aa2470">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzYtNi0xLTEtMjA3NzE1_85b2c59d-c4d9-46c7-b434-a4cc4632c438">20,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzYtMTAtMS0xLTIwNzcxNQ_e8bda97d-d817-4c99-8152-cd8e12973c5c">20,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNDEx_24bdc09e-5663-442a-853f-9a7a2a4036f9">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of March&#160;31, 2023, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="i6d23cbe1712d416fb576aaa815a0484b_I20230331" decimals="-6" name="bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQwMA_2ec3f019-b301-454f-a0bd-f63525f4b125">9,700</ix:nonFraction>&#160;million (although such availability is subject to the Company&#8217;s compliance with a <ix:nonFraction unitRef="number" contextRef="i0f2be8ab73b940ed95457d1d1dafe5af_I20230331" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQ3Nw_baca9bdf-c77b-4075-96d8-85a14dfa881c">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i50e40013b822421b896cdb52ff59ce15" continuedAt="icea9944cebd147f7b539bce257dcf9ef"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i0f2be8ab73b940ed95457d1d1dafe5af_I20230331" decimals="INF" name="bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcwNw_43284904-2dd1-4e13-b9a7-2fcaadc4bacd">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#8220;Exchange Offer&#8221;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $<ix:nonFraction unitRef="usd" contextRef="if7d45443ba5c4563bf3b25ec62964df1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjg0NA_f5370a51-820c-4885-9089-70012df35887">5,594</ix:nonFraction>&#160;million as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i5debb458ebf44991aaa7a159d30b758f_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjkzNw_594d7e6c-6c14-4cb0-9164-3a96d6eaa8d5">3,125</ix:nonFraction>&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $<ix:nonFraction unitRef="usd" contextRef="i5debb458ebf44991aaa7a159d30b758f_I20220930" decimals="INF" name="bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzA0Mg_c85f209b-5c17-4f6a-950c-0280c58d9355">2,469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $<ix:nonFraction unitRef="usd" contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzEwOQ_ef805005-f373-423d-9a7d-1eaea8dce2f7">1,774</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzE0OQ_ebca46a8-742b-461d-a803-9acd67ae951f">11.00</ix:nonFraction>% First Lien Secured Notes due 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzE5Mg_96f09445-7e44-4491-b6af-46a08dab5e94">11.00</ix:nonFraction>% First Lien Secured Notes&#8221;) issued by the Company, (ii) $<ix:nonFraction unitRef="usd" contextRef="i17d52fbe0aac4ea784789ee582df1295_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzI1MA_d59e5368-4244-45b5-b8ac-cd77c80ff74b">352</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="i17d52fbe0aac4ea784789ee582df1295_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzI5MA_f09bf0bf-ec30-4b33-b9b2-e70575bc0a6b">14.00</ix:nonFraction>% Second Lien Secured Notes due 2030 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i17d52fbe0aac4ea784789ee582df1295_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzMzNA_dff46df1-876b-40d5-bc4f-67c5e9967377">14.00</ix:nonFraction>% Second Lien Secured Notes&#8221; and, together with the <ix:nonFraction unitRef="number" contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM4Nw_66d21910-0abe-4c0a-8b20-c36a8f1619ba">11.00</ix:nonFraction>% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $<ix:nonFraction unitRef="usd" contextRef="i903eec80383246d8b63564df58e178c8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzQ3Nw_785b683e-eb19-4a02-88cf-39207e8731da">999</ix:nonFraction>&#160;million in aggregate principal amount of new <ix:nonFraction unitRef="number" contextRef="i903eec80383246d8b63564df58e178c8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzUxNw_7c01a166-d002-4b3e-b0e9-0b30cca70e22">9.00</ix:nonFraction>% Senior Secured Notes due 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i903eec80383246d8b63564df58e178c8_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzU1Ng_72c22b67-5533-4b7a-b42c-7850a2651322">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes&#8221; and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds <ix:nonFraction unitRef="number" contextRef="i248fddc88f4a495caa1b4df3c4650cee_I20220930" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzgwMg_6df7afe0-ef5f-42a4-a6ff-fda21bfe47be">38.6</ix:nonFraction>% of the issued and outstanding common shares of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#8217;s Condensed Consolidated Balance Sheets</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium recorded on the New Secured Notes was $<ix:nonFraction unitRef="usd" contextRef="i837a88fd5e964623b1aadc43f080279c_I20221231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjE5OTAyMzMxMzI4MA_1adb2c2e-b099-4176-a49d-8491cb062ab8">1,835</ix:nonFraction>&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. During the first quarter of 2023, the Company made contractual interest payments of $<ix:nonFraction unitRef="usd" contextRef="i8a389a27060343e5b22dc6da4936a17a_D20230101-20230331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODY4MzEz_0280af06-2f31-4799-a2dd-de9e5145a971">128</ix:nonFraction>&#160;million related to the New Secured Notes, of which $<ix:nonFraction unitRef="usd" contextRef="i8a389a27060343e5b22dc6da4936a17a_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODY4MzI3_274bd015-ec46-404a-af90-dfae3063ecf7">111</ix:nonFraction>&#160;million was recorded as a reduction of the premium. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;). Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="icbfe4cdc452d465ebd08f232cee67b17_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNzQ4MQ_27c0b5c9-fcc7-45aa-8b5e-d1d6238d75ba">1,225</ix:nonFraction> million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $<ix:nonFraction unitRef="usd" contextRef="if38bd752f2804e82b66372aac33a299b_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNzgzMg_13460a37-c7d9-4ac6-a0b3-9724e6ae0b62">4,565</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i36d1ec0044004c3e9a1bd3cdc1fdd988_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNzgzOQ_7cb53941-8f5b-4d32-bb3e-9f0097a13061">1,500</ix:nonFraction> million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="icea9944cebd147f7b539bce257dcf9ef" continuedAt="icc5a2f45816c43a2bc887d0f52fc3e73"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ib2a4f5fc4d13488fa1eb6879e85815a5_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODQzNg_1566d55b-fde9-4766-b50d-0fa590a9b2e8">2,500</ix:nonFraction>&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODU0MQ_43e3d793-80be-466d-9f08-703ea0b12c5d">975</ix:nonFraction>&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is <ix:nonNumeric contextRef="if6aef544f55e4d479ca0c5fdb0d3ac29_D20220510-20220510" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODY1Ng_ff2962ea-d4ea-424f-8e4b-95185fe418ef">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODgwOQ_59c17294-4899-4f90-9cf1-b62513d83712">1,000</ix:nonFraction>&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of March 31, 2023, the Company had drawn $<ix:nonFraction unitRef="usd" contextRef="i2263e23bd8e642778b2df9b8853237be_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzNTM0_053c054b-3cad-4bff-8b24-3d97ec689a93">395</ix:nonFraction>&#160;million and had $<ix:nonFraction unitRef="usd" contextRef="i69b14ba8ead54d019ac598383a31b62d_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzNTQ4_14805d52-e0ae-4ebb-9021-fbf61573e3e1">23</ix:nonFraction>&#160;million of issued and outstanding letters of credit on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus <ix:nonFraction unitRef="number" contextRef="iae292b83994f4eaa9429e631a6fdf509_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTAwNDA_720ac605-5aaa-4e79-9aa0-ff98186f052b">1.00</ix:nonFraction>% (or if such rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="i1aa16e6b0d894c1dada5fbfacfcbe3c9_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTAwODg_73ae2068-b691-4fb4-ba8d-0236e646527f">1.50</ix:nonFraction>%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than <ix:nonFraction unitRef="number" contextRef="icc18552483b945af9947da7d748f3797_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTAyMTE_483d89b6-e799-4642-8d18-f7be4b961ad3">0.50</ix:nonFraction>% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of <ix:nonFraction unitRef="number" contextRef="i941c4bbefa5240ef85c8e4f4ab0ca948_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTA0NjQ_5b81d311-76c8-4d2e-a345-174670b9c0b8">0.00</ix:nonFraction>% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of <ix:nonFraction unitRef="number" contextRef="ib4c6dcc61b60403380d1c1c8b2e65827_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTA5MDM_541213b8-124b-4da8-af41-a4402bfc5f44">0.00</ix:nonFraction>% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from <ix:nonFraction unitRef="number" contextRef="i941c4bbefa5240ef85c8e4f4ab0ca948_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEwMzU_67705680-6221-47a6-8527-282b7cc4c97a">0.10</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i10b0cd89c2794a4a8c71d587e55cec38_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEwMzg_9fefe3c6-9140-469a-a67a-aff2a08a97cd">0.25</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="i1aa16e6b0d894c1dada5fbfacfcbe3c9_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTExMzI_f9d4b133-bb38-4072-98ed-a726cdab4f8c">5.25</ix:nonFraction>% for term SOFR rate loans and <ix:nonFraction unitRef="number" contextRef="i9c472af859db4ef39a87c178260df1d4_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTExNjQ_ac0451ea-7933-44de-9170-43d0e10d2aa3">4.25</ix:nonFraction>% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from <ix:nonFraction unitRef="number" contextRef="i3e11f388f2ee40dcbd589e6df1e9378c_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzMDQ_d11f7cf7-5bd2-45eb-8a6f-3bae64cd0309">4.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6752a30275734197a62fc5a9b8672ce1_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzMTA_7b8043ca-6074-4472-80aa-86efb994e9f2">5.25</ix:nonFraction>% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ief7bb320564f4aceb4edc483cb34a747_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzNzU_f9a7baa3-e9f8-4090-a02c-8635ebec3917">3.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i577454bd748e4d5a8c05a2a6ddfbd23a_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzODE_197d17d2-d2b9-4181-abd2-b7a5563de159">4.25</ix:nonFraction>% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i3948c6f5951248dfa12e05ac7dbbe705_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTE1MTA_3d850af6-7b89-4ab6-885c-e7449e56af61">0.25</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9e21098d0ad2484097856f68e1b275a2_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTE1MTM_6ac98732-f6ad-4749-b5d4-fa9e1761cde3">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTIzMDM_d49b8631-e56c-4403-a9d8-1e1080bc2069">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) <ix:nonFraction unitRef="number" contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTI0NjY_b2604d9f-dec4-462f-90d7-932f963db6b6">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTI2MDc_9bbbbb0c-c0e2-4066-b2f8-a98bc172d294">50</ix:nonFraction>% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTI3Njg_9511892c-7eb6-4f38-bab5-8a57249aa7b7">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="ib2a4f5fc4d13488fa1eb6879e85815a5_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTMwMDM_8ce6fe0a-7cc0-444d-8c0b-fedfe4278e26">5.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="if0cbf9921846406db6bd00b95257c769_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTMwMjA_4127b252-e490-400a-a3d6-b6ddf078ecd7">125</ix:nonFraction>&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of March&#160;31, 2023, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $<ix:nonFraction unitRef="usd" contextRef="icd9fcf0826bd4e36b2683c1eebfca266_D20230331-20230331" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTMyOTk_3fa9276f-033c-4ae2-b75d-341257c13ceb">469</ix:nonFraction>&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $<ix:nonFraction unitRef="usd" contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM0NDU_3036f51c-e45b-4136-940f-b0e755728472">1,000</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="if6aef544f55e4d479ca0c5fdb0d3ac29_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM0NTI_901843f2-c6a7-437a-9d5d-a7b054706379">40</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i56fcb41cb5a94e678206e69414bc0b5d_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM3NTc_a6af77fb-dc44-4a9e-8a69-7a33f1aa8519">3.50</ix:nonFraction>:1.00, and, in the case of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="icc5a2f45816c43a2bc887d0f52fc3e73" continuedAt="id72de8f504f7499dab39cbc8732e4c42"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="if2d58899a97e4cab97bd1a214b38f6cb_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM4NTI_042c3175-c072-4b9a-881c-40753f9d47d8">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM5MDc_8681b52f-1003-451b-b54f-b6686af96053">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than <ix:nonFraction unitRef="number" contextRef="i84889b9489a14e36877c0478bea79508_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQ2MTQ_99cfe1e6-0400-4670-a2e7-28455dbc3d4d">7.60</ix:nonFraction>:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions that were designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds approximately <ix:nonFraction unitRef="number" contextRef="i6c18712f4b5d49ac81d008a300ff10e9_D20221129-20221129" decimals="2" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjE5OTAyMzMxMzI5Ng_4cceba36-65e7-4414-94fc-94f9f35319f9">89</ix:nonFraction>% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are unrestricted subsidiaries of the Company and, as a result, are not subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $<ix:nonFraction unitRef="usd" contextRef="ib21fed5341d54d0e89405e700d2488cd_I20220510" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQ5OTI_70084623-6b52-4631-accf-aacda9d91154">2,500</ix:nonFraction>&#160;million with a <ix:nonNumeric contextRef="i70d7dc79e80f485e9b0e3247e4c85728_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5NzU_af75a741-a66e-4053-941b-9f3dc7ceb2e8">five-year</ix:nonNumeric> term to maturity (the &#8220;B+L Term Facility&#8221;) and a <ix:nonNumeric contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5OTg_8a2b14f9-d891-4ed8-91e2-d292f716c6fd">five-year</ix:nonNumeric> revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i3edcc26eaf534e8eb544ca874238a97e_I20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTUwOTY_0348629c-b869-4e28-ad6e-f018cfaf5afa">500</ix:nonFraction>&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of March&#160;31, 2023, the B+L Revolving Credit Facility had $<ix:nonFraction unitRef="usd" contextRef="i73805f2008b0493784b73a6e474d0511_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjE5OTAyMzMxMzQ0OQ_b4eb65be-7923-4f67-9854-9549c801475f">100</ix:nonFraction>&#160;million of outstanding borrowings, $<ix:nonFraction unitRef="usd" contextRef="i1dd01cd11a7445c4a00b066d23512c4f_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzODE5_9d2c7a72-a345-494c-8554-5b8db01d1925">24</ix:nonFraction>&#160;million of issued and outstanding letters of credit and remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i73805f2008b0493784b73a6e474d0511_I20230331" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzODMy_30d96ab2-f8f9-4499-bb4c-5d8d03f759a9">376</ix:nonFraction>&#160;million under its Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of any other subsidiaries of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than <ix:nonFraction unitRef="number" contextRef="i8621c3667fbf460daa121b9c4ae610ed_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTY4MjI_1bbaaf1c-4aa0-48e9-b79c-de4bfa7e7fe0">0.00</ix:nonFraction>% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than <ix:nonFraction unitRef="number" contextRef="ie155f835e73f43c0a0a7a12dcfe3ddb7_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTY5MzQ_97b30c28-a014-41aa-a54a-52d1bc7fb57c">1.00</ix:nonFraction>% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i510257e58ffa4decb28c62ab425bbac7_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcwNjk_576c3689-b3de-4852-b96d-7b51b6421710">0.10</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between <ix:nonFraction unitRef="number" contextRef="i0248ec1e93ba4d7ea8d09b465512a94f_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcxODI_c5d83383-da07-4d77-8608-60ca639d3957">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1922ecd18a2e46a48b9820d0ee052834_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcxODg_d0f500d0-94eb-45eb-9d68-d911ee3f8229">1.75</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i9e35bf60d1c341548e91652443b6c303_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcyODI_b31115e4-3a02-49ba-895a-2d70ed4e1663">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id29818a3e24849c9872d1d9f53ab8b00_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcyODg_06e207f6-1c52-47fe-9107-6fa172264089">2.75</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of Standard &amp; Poor&#8217;s, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between <ix:nonFraction unitRef="number" contextRef="if67b7c28c9224ebf8f9b868d72b01bf9_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc2ODI_82ac0ec0-3f33-4028-8db4-03bf29439d38">0.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6520558979e64b11a055e7cb64fefcb3_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc2ODg_5968df55-a49f-4a60-bedc-a7b6516a09d6">0.475</ix:nonFraction>% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between <ix:nonFraction unitRef="number" contextRef="i07b28056246f43a38618df0e494a97e4_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc3ODI_dbf8c104-a2a1-4f0c-a3be-f624c577e38e">1.015</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3f67059f3db74cc48b901c7b97bad681_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc3ODg_ef97a816-ca75-466f-9c5b-42aca668c9c5">1.475</ix:nonFraction>% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc5NTA_f93fdde7-2701-4c22-adc5-301d46473d93">0.25</ix:nonFraction>% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between <ix:nonFraction unitRef="number" contextRef="ia22c0fcb53a541a5b34a13bce7623b83_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTgxMjI_e51ba08e-9e22-43c2-a821-2e81cb584054">0.110</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i10bb7c9cf0764db899519673b3e54aa0_D20220510-20220510" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTgxMjg_2be75a5f-ed47-4622-b8df-1c52fcd78a62">0.275</ix:nonFraction>% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="i2a2772683b4144eb8f2ccc0181cce01e_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTg4MjY_f57e24c6-c276-4254-aca6-3d5f5667a03f">3.25</ix:nonFraction>% or (ii) a U.S. dollar base rate, plus an applicable margin of <ix:nonFraction unitRef="number" contextRef="ia7f2841ca1e44cdc95d5d3f351c569c0_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTg4OTE_089eb2e2-6aa4-42c0-bb9f-6334065e5297">2.25</ix:nonFraction>% (provided, however, that the term SOFR-based rate shall be no less than <ix:nonFraction unitRef="number" contextRef="i79f18a15a09b463389c535fe19ade465_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTg5NjY_748a5564-67d4-4473-81bf-c5f1b06c42b5">0.50</ix:nonFraction>% per annum at any time and the U.S. dollar </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="id72de8f504f7499dab39cbc8732e4c42" continuedAt="ia7f1f0bd060548e1858806a33fe29f92"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">base rate shall not be lower than <ix:nonFraction unitRef="number" contextRef="ib0cba2f234984f27bed6d219b8e46492_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTkwNDU_2d556417-7c89-4967-89b6-0173e367267e">1.50</ix:nonFraction>% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="i2a2772683b4144eb8f2ccc0181cce01e_D20220510-20220510" decimals="INF" name="bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTkxMzk_fa3ff459-742d-4a21-8a0e-22e88d40b1c3">0.10</ix:nonFraction>%. The stated rate of interest under the Term Facility at March&#160;31, 2023 was <ix:nonFraction unitRef="number" contextRef="i2f96c4977bdf4527aca21c11e00b2edf_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTkyMDU_41e0a6db-ab53-4aad-87c3-578182937a3f">8.46</ix:nonFraction>% per annum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) <ix:nonFraction unitRef="number" contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk0NTY_5d389e54-b5b9-462c-b61f-b6ce5fe7e140">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) <ix:nonFraction unitRef="number" contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk2NTM_43a18996-7e44-45f9-ba52-d877d58db7c5">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) <ix:nonFraction unitRef="number" contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk3ODU_28a8ab59-8e2c-49d5-888d-63c2695a1242">50</ix:nonFraction>% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) <ix:nonFraction unitRef="number" contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk5Mzc_c921b1ed-f53d-4bb3-8bdb-db6ed6c41f6e">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is <ix:nonFraction unitRef="number" contextRef="ib21fed5341d54d0e89405e700d2488cd_I20220510" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjAxOTc_5dcc62be-0715-45a8-9ff0-8aca6b038e3d">1.00</ix:nonFraction>% per annum, or $<ix:nonFraction unitRef="usd" contextRef="i70d7dc79e80f485e9b0e3247e4c85728_D20220510-20220510" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjAyMTQ_d7624889-e4d6-4c7f-8ae9-3af06a25dde3">25</ix:nonFraction>&#160;million, and the first quarterly installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of March&#160;31, 2023, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $<ix:nonFraction unitRef="usd" contextRef="iba4accda99c8474fb514ff5e90f2c9c5_D20230101-20230331" decimals="-6" name="bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjA0NTU_add23be9-324e-40ac-9e56-68add53476bf">100</ix:nonFraction>&#160;million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="id65c9d3aa0e147cbbacd4d3353c0d376_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjA4NDc_8435b32f-c333-43df-9e9b-e73ee40be2a9">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjI5OTE_aa970314-9ee5-4746-a8d0-e51f301583fc">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjQ4MDM_1c2f9082-e928-4634-a76b-e356b4981a76">6.125</ix:nonFraction>% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjQ5MDM_7085e4fa-1410-4d96-b42f-dc3207b27f0d">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjQ5MzY_81570c11-df37-440c-9fab-e53b74076a1c">6.125</ix:nonFraction>% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjUzMzg_81570c11-df37-440c-9fab-e53b74076a1c">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i547ceb5147ad4e2db654418ebe7f7568_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjU3MTc_5e87e565-8617-432e-9728-f212a70e3eb6">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i52c91df8447249489b14e04f36239c8d_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjU4MzQ_7b364223-a94a-4050-a025-b1b1c4c03938">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYwMzI_965f5ba0-7e7e-43f0-9188-cdb68b63ec19">11.00</ix:nonFraction>% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of <ix:nonFraction unitRef="number" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYxMTM_2ca6b081-cd16-4ad7-93f2-b2b5ae73e414">11.00</ix:nonFraction>% per year that is payable semi-annually in arrears on each March 30 and September 30. The <ix:nonFraction unitRef="number" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYxOTg_1e2985e1-ce49-42c0-bdeb-a131a1be9991">11.00</ix:nonFraction>% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to <ix:nonFraction unitRef="number" contextRef="ie985a1f2ae2940ddaae3a79acd52e7d2_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYyOTU_5bfb9c21-c2d6-424f-8418-b606754c80a0">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="ia7f1f0bd060548e1858806a33fe29f92" continuedAt="i4687ed19244745c6a1e9954be4d62917"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the <ix:nonFraction unitRef="number" contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY0NTg_f691862d-8ed8-4d5c-bfaa-8cc64ea4c18e">11.00</ix:nonFraction>% First Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY1MDE_ec24595f-002b-4cc1-9aca-2d800f6be8d2">14.00</ix:nonFraction>% Second Lien Secured Notes mature on October 15, 2030, and have a stated interest of <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY1ODE_2261758b-aec4-4f08-998e-f11df37ea72e">14.00</ix:nonFraction>% per year that is payable semi-annually in arrears on each April 15 and October 15. The <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY2NjQ_311c68cf-b112-4011-bf62-a83c8c7c6f6b">14.00</ix:nonFraction>% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY4Mjg_5707cc94-1b52-41df-a434-3b75ed2d4b83">14.00</ix:nonFraction>% Second Lien Secured Notes indenture. In addition, some or all of the <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY5MDA_9f1baf9d-80fd-474e-9a20-27f61ba4deca">14.00</ix:nonFraction>% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to <ix:nonFraction unitRef="number" contextRef="if0760722bf5d4183839a587492c1db15_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY5OTE_3e896990-a0d2-401c-abcf-c978c08fc47b">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjcxNTQ_d51f8d35-1601-4a53-aad6-daf0f64ae2c3">14.00</ix:nonFraction>% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to <ix:nonFraction unitRef="number" contextRef="i860c8720321c489a82c36ce3d3e91c8a_D20230101-20230331" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjcyMzk_8eee0f6f-5c10-4c26-99c6-2ee5fcd1faf6">40</ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjcyODM_68a7ec08-1afb-4d9b-8091-3db605dd693b">14.00</ix:nonFraction>% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc0MTk_4b21be76-1b1c-4af4-aaef-50d362cb2a02">14.00</ix:nonFraction>% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc0NTk_bfe4e377-b2a1-45cf-812b-fc4e29f5d952">9.00</ix:nonFraction>% Intermediate Holdco Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc1MDc_290da399-aa0b-42cb-be7e-7928ead98398">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc1OTU_49a52332-2d1f-4b7b-af31-63c4fade2d20">9.00</ix:nonFraction>% per year that is payable semi-annually in arrears on each January 30 and July 30. The <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc2Nzc_9120af08-8873-40f0-a47c-e36770f603bf">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc4NDM_33c2750a-4b0d-40fd-b8f6-d1c547cf6f88">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc4OTY_8f5dbbde-4382-42e3-8f85-f8150e24c98e">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of March 31, 2023 were comprised of <ix:nonFraction unitRef="number" contextRef="id094eccb229a4fd2b63155f5f349149b_I20230331" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjgxOTc_f07b1f2a-cc3d-4fee-8c5e-3ba8325f2679">38.6</ix:nonFraction>% of the issued and outstanding common shares of Bausch + Lomb Corporation. The <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjgyNzg_15f3d302-d215-4e44-a610-f72ab8c73db3">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjg2Mjg_8f5dbbde-4382-42e3-8f85-f8150e24c98e">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes under the <ix:nonFraction unitRef="number" contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjg2NzU_8f5dbbde-4382-42e3-8f85-f8150e24c98e">9.00</ix:nonFraction>% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i089a9da68a994aa6a72f9953208ab0d3_D20230101-20230331" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzAwMDc_39cc3420-108f-4c31-ae71-ec3979c6a8c2">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, on May 10, 2022, the Company using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of <ix:nonFraction unitRef="number" contextRef="i970ab9f80f5f40959c2ab1571822b0d8_D20220510-20220510" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzEyNjY_7c736efc-2ccd-4f38-ad83-3fdcfeb48de6">101.021</ix:nonFraction>% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A. The April 2025 Unsecured Notes were redeemed on May 16, 2022 and were accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of March&#160;31, 2023 and December&#160;31, 2022 was <ix:nonFraction unitRef="number" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzIzNzY_4a4116af-c341-4af8-8fb9-2a8550fbcaed">7.87</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzIzODM_143ca549-caae-4149-b509-2e5e74db6a89">7.74</ix:nonFraction>%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements for 2023 and in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i4687ed19244745c6a1e9954be4d62917"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5ODI_4eb830c7-3b44-41ee-b48a-7dd662a32a39" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2023, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMS0xLTEtMS0yMDc3MTU_b2522b48-4934-470f-9c2e-4f36fb3211c3">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMi0xLTEtMS0yMDc3MTU_eefdd04e-e2f2-40b3-a748-2652ae249cd8">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMy0xLTEtMS0yMDc3MTU_a3215e31-f1ac-45ff-8d97-1451102b9bfe">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNC0xLTEtMS0yMDc3MTU_bd0359f6-9f74-48bd-9fe6-7ae127f9ed58">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNS0xLTEtMS0yMDc3MTU_44487fce-51c0-4ba7-ab75-31011be2bc51">6,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNi0xLTEtMS0yMDc3MTU_572ea5b2-cab7-4aba-87ff-b27195860abb">4,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNy0xLTEtMS0yMDc3MTU_facf4a5c-f9f3-48f2-9ea8-91b2120ef84a">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfOC0xLTEtMS0yMDc3MTU_7fc2a04b-7acd-49fb-baed-22749e5a2748">19,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" sign="-" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfOS0xLTEtMS0yMDc3MTU_9711e22c-897b-42df-ae56-9fc60cfa9d4a">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMTAtMS0xLTEtMjA3NzE1_f7c59c01-6f1c-4e1f-bb1a-48d2c669d2c0">20,653</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_76"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODM4Ng_ccf4305b-2e64-4d24-af21-e23239bfe389" continuedAt="i26b8f73047364bbda4ec070d2a34fbb7" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i26b8f73047364bbda4ec070d2a34fbb7" continuedAt="i94f2cfd9b3704c2791ab12d01cd84692"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved Bausch Health&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced Bausch Health&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was initially equal to <ix:nonFraction unitRef="shares" contextRef="i85b588e044c940eca8328840cfc28748_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNDg5_17676023-19d3-4fef-a36c-b8697255a48f">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="i85b588e044c940eca8328840cfc28748_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODQ5_2f88d222-ea60-4f01-8c6e-d70cf00c7fd9">20,000,000</ix:nonFraction> common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional <ix:nonFraction unitRef="shares" contextRef="i3c45857d12dd4d23981e438c843ec5cc_D20220621-20220621" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTQwMQ_69a432c6-c3fa-40d3-8e6a-dc1d4de6fa3f">11,500,000</ix:nonFraction> common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i9a72442b14b74396a03e29bc48cf80d5_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTQ1Mw_c07f5c30-cca7-4212-9e9f-670bbad5e3cd">9,527,000</ix:nonFraction> common shares were available for future grants under the Amended and Restated 2014 Plan as of March&#160;31, 2023. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on generating operating cash flow while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that vest: (i) upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;), (iii) upon attainment of Adjusted Operating Cash Flow, as defined in each applicable award agreement, and a Relative Total Shareholder Return modifier performance metric and (iv) fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to retain and incentivize certain members of the Company&#8217;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#8220;Retention RSU Grant&#8221;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzEyOA_7d8122c2-092a-4cd8-b6dd-b57d32d9fc25">three</span> anniversaries of the grant date based on continuous employment with Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to May 5, 2022, Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb participated in Bausch Health&#8217;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of <ix:nonFraction unitRef="shares" contextRef="ia05b5bf3a3e34503a29b0b66b71f201e_I20220505" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzQ4Ng_45ea6103-70db-4629-80d3-eabb14bc05c9">28,000,000</ix:nonFraction> common shares of Bausch + Lomb were originally authorized under the B+L Plan. Effective April 24, 2023, the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i94f2cfd9b3704c2791ab12d01cd84692" continuedAt="i4a3c505bfed74a8f85cacad9fb491780"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders of Bausch + Lomb approved an amendment and restatement to the B+L Plan to increase the number of shares authorized for issuance thereunder by an additional <ix:nonFraction unitRef="shares" contextRef="ieb50a893b673454784c495a665d8a5a8_D20230424-20230424" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNTQ5NzU1ODM3NTAx_c34ff608-1523-4be9-8c1e-e99df33a1f94">10,000,000</ix:nonFraction> common shares, resulting in an aggregate <ix:nonFraction unitRef="shares" contextRef="i3863db1d928d4e059096c4ab578fc383_I20230424" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNTQ5NzU1ODUyNzg3_4d70c787-cf88-4f59-969e-d88218a2984a">38,000,000</ix:nonFraction> common shares of Bausch + Lomb authorized for issuance under the Plan (the &#8220;Plan Amendment&#8221;). The B+L Plan provides for the grant of various types of awards including RSUs, restricted stock, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of <ix:nonNumeric contextRef="i8868f6921a25423eaf40a6f726a3c0f9_D20220505-20220505" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzkwOA_fca1bc3e-7c2e-449b-819a-61a6fefe0db2">ten years</ix:nonNumeric> and a <ix:nonNumeric contextRef="i8868f6921a25423eaf40a6f726a3c0f9_D20220505-20220505" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODM5NQ_ebff93df-62cf-4dc5-bae2-f63e12688c98">three-year</ix:nonNumeric> vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i095b974a4eda46539b55e501e35cecd5_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNzQ1MQ_d13e77de-8dea-4b06-8223-4a9bc52c4267">9,300,000</ix:nonFraction> Bausch + Lomb common shares were available for future grants as of March&#160;31, 2023. This does not include the additional <ix:nonFraction unitRef="shares" contextRef="ieb50a893b673454784c495a665d8a5a8_D20230424-20230424" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNTQ5NzU1ODUyMjgx_a9ab04a3-ff96-4301-9b8e-8f56983933b6">10,000,000</ix:nonFraction> common shares authorized for issuance under the Plan Amendment. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s focus on enhancing its revenue growth while maintaining focus on total shareholder return over the long-term. In addition to stock options and RSUs, during the first quarter of 2023, performance restricted share units (&#8220;PSUs&#8221;) were also granted. The PSUs are comprised of awards that vest upon: (i) achievement of certain share price appreciation conditions, including absolute and relative TSR and (ii) attainment of certain performance targets that are based on </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s Organic Revenue Growth. If </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s performance is below a specified performance level, no common shares will be paid. Each vested PSU represents the right of a holder to receive a number of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s common shares up to a specified maximum. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR PSU granted was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the Organic Revenue Growth PSUs is estimated based on the trading price of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s common shares on the date of grant. Expense recognized for the Organic Revenue Growth PSUs in each reporting period reflects </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s latest estimate of Organic Revenue Growth in determining the number of PSUs that are expected to vest. If the Organic Revenue Growth PSUs do not ultimately vest due to the Organic Revenue Growth targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, Bausch + Lomb announced the appointment of Brent Saunders as its Chief Executive Officer, effective March 6, 2023. Pursuant to Mr. Saunders&#8217; employment agreement, on February 23, 2023, Mr. Saunders was granted the following equity grants: <ix:nonFraction unitRef="shares" contextRef="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTU4MA_72678dd8-833e-4185-9982-1706fcdfd233">750,000</ix:nonFraction> PSUs, <ix:nonFraction unitRef="shares" contextRef="i7a7df102d4344988ae96ebc9a50e6c5f_D20230306-20230306" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTU5MA_e442b67c-c406-479c-b003-ca8708587c7a">1,318,681</ix:nonFraction> stock options and <ix:nonFraction unitRef="shares" contextRef="id24036d8d6074ecdacda84c97de2156f_D20230306-20230306" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTU5OQ_561c530f-abdd-4f31-88ed-51c79acdc100">375,000</ix:nonFraction> RSUs. The RSUs are scheduled to vest <ix:nonFraction unitRef="number" contextRef="i57dc496593aa4b0eb2e9577518a5942f_D20230306-20230306" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTYxNw_ffde8ac3-d5d1-4473-aea7-1799cb965340">50</ix:nonFraction>% on the second anniversary of the grant date and the remaining <ix:nonFraction unitRef="number" contextRef="i7e8032e2d6aa4162adae2cb4b0bb8097_D20230306-20230306" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTYyMg_1696517c-3a24-44d9-b39c-5a1035b2dfd8">50</ix:nonFraction>% on the third anniversary of the grant date. The stock options are scheduled to vest in equal one-third installments on each of the first three anniversaries of the grant date. The PSUs vest on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDI0NA_b622811e-eab0-4467-ba1f-ded7a871e35c">four</span>th anniversary from grant date based on Bausch + Lomb&#8217;s achievement of absolute share price hurdles, or upon achievement of absolute and relative TSR hurdles in relation to the S&amp;P 500 Index during the <ix:nonNumeric contextRef="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDIyOQ_c2684581-be4e-442c-b57f-d1f7666752cf">four-year</ix:nonNumeric> performance period.</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODQwMg_eefcd3b8-7a90-4875-9b1a-413373e5b85c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company&#8217;s share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.429%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMi0yLTEtMS0yMDc3MTU_6521c4dd-81d2-4163-9640-a8395df5e982">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMi00LTEtMS0yMDc3MTU_dc593fcc-3edf-4267-9f2d-35efd43dfa3e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2c3fa275d2440c596a3bed71d4c3b85_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMy0yLTEtMS0yMDc3MTU_62f01a23-7342-4c4d-bd88-646a571937dd">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ed2192fcc941a696c261e49cf75b05_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMy00LTEtMS0yMDc3MTU_204a756d-de0a-4051-bee9-7425bf616cd0">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNC0yLTEtMS0yMDc3MTU_ed418b09-42f6-474f-be75-edce7e63aa1b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNC00LTEtMS0yMDc3MTU_03172189-d97d-4460-a08e-1abf443e0e61">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406d990fd1d347fe9b57aac1683865e7_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNi0yLTEtMS0yMDc3MTU_877328ed-1d3a-41ef-a78e-1a6568d489d7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68adcae65fa245a48869470ea3438264_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNi00LTEtMS0yMDc3MTU_ffab2dca-94cf-4754-b269-d44f8dbe762e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i666b40934018485093be0f36415a1be9_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNy0yLTEtMS0yMDc3MTU_a09f01de-92e5-4633-a8c5-a0683cc7ed03">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac84c79811c44f82877f5606d96b198a_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNy00LTEtMS0yMDc3MTU_7c297dc5-7a57-441a-9fde-384122070a50">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfOC0yLTEtMS0yMDc3MTU_7aa230aa-a899-480c-a7dd-2a25d3e419b4">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfOC00LTEtMS0yMDc3MTU_95a32731-5eb2-4391-a6fb-7465bc68ce6b">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i4a3c505bfed74a8f85cacad9fb491780"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODQwMw_07ca8c6d-536e-469e-a54d-e5adeda6d947" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the three months ended March 31, 2023 and 2022 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMy0xLTEtMS0yMDc3MTU_fd5614d2-e7df-49cd-a2b1-73108303897a">999,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMy0zLTEtMS0yMDc3MTU_e74ec52a-583f-4b19-93f4-fec2583e39ca">2,545,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNC0xLTEtMS0yMDc3MTU_70214da9-7055-43a0-8e20-cc00a51b0358">9.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNC0zLTEtMS0yMDc3MTU_877af579-af03-4a3e-84dc-80af77432551">24.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNS0xLTEtMS0yMDc3MTU_9bb70724-a68a-46aa-bd49-9b5d4025a6de">4.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNS0zLTEtMS0yMDc3MTU_8d62944e-47f6-4824-8062-6458eee4be7d">6.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb261569c3d84cc38298b5c87946b5a9_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNy0xLTEtMS0yMDc3MTU_f69929d4-0a8d-4de3-bf2a-51052a44d2d7">4,133,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic545e6c12b6344cf81caeedddfb12a1d_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNy0zLTEtMS0yMDc3MTU_d74965bb-eb05-4732-9103-4a5bd2a7b458">1,662,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibb261569c3d84cc38298b5c87946b5a9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfOC0xLTEtMS0yMDc3MTU_f014c51a-d3a1-4c90-87c9-b58d4280ccd9">9.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic545e6c12b6344cf81caeedddfb12a1d_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfOC0zLTEtMS0yMDc3MTU_b72cbd1a-862a-4894-8b35-bd39806a83af">24.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Operating Cash Flow performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6e00e72db8d42a6b5461ecf16e5d5a6_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTAtMS0xLTEtMjA3NzE1_b0f4fb5f-68c0-4d6f-a3bd-aa6c13f65027">647,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad26ab4e7aaa42cead89d21e59618776_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTAtMy0xLTEtMjA3NzE1_92f7734b-0816-41bf-81e1-815ae60df679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6e00e72db8d42a6b5461ecf16e5d5a6_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTEtMS0xLTEtMjA3NzE1_29f943ff-861e-4bb0-9678-a9edc3ac0243">10.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iad26ab4e7aaa42cead89d21e59618776_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTEtMy0xLTEtMjA3NzE1_ea6a506d-dfc9-4508-b5b2-7e39d5750978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjAtMS0xLTEtMjA3NzE1_5f76aa99-db87-4862-bdcd-fbcc94beb64e">2,679,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjAtMy0xLTEtMjA3NzE1_b0bda31e-0295-4990-9bf7-a603df623b7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjEtMS0xLTEtMjA3NzE1_83bd474a-87b5-4860-8015-99dc8a3759ec">18.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjEtMy0xLTEtMjA3NzE1_13016adc-8120-424f-8d7d-16a073bffadf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjItMS0xLTEtMjA3NzE1_b23ab6fd-c0e8-4c0e-8621-12479dcfa708">5.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjItMy0xLTEtMjA3NzE1_3c5b6bce-07f5-4aa1-93b4-f9aed64ecdd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id19de0acd56e49d687b026d53ef417fa_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjQtMS0xLTEtMjA3NzE1_4e5e6b5a-ca37-4c19-9005-ae8a1901094b">2,358,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4df47c6c0de44dfa8ac7d75e4c88624a_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjQtMy0xLTEtMjA3NzE1_748dbeff-45d8-41a4-b3e6-59e48378342e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id19de0acd56e49d687b026d53ef417fa_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjUtMS0xLTEtMjA3NzE1_30b73ece-233b-4225-b89b-93372d0719e4">18.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4df47c6c0de44dfa8ac7d75e4c88624a_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjUtMy0xLTEtMjA3NzE1_ac297adc-2d0f-4c88-937f-69f1115e12bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6511364c8e784a6ea61cc24f22c25e3f_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjctMS0xLTEtMjMyNzk4_3399e0cc-04c3-4229-b0af-67c4ea4b8949">1,175,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibda9a2e4a2b849239f2f10392436563f_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjctMy0xLTEtMjMyNzk4_de42a618-4f25-4a69-90c8-a23d1fdca6cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6511364c8e784a6ea61cc24f22c25e3f_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjgtMS0xLTEtMjMyNzk4_b467d9dd-8ae1-4757-9c27-5707a76a3432">27.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibda9a2e4a2b849239f2f10392436563f_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjgtMy0xLTEtMjMyNzk4_a5494ed7-de2c-48a9-b535-c37d632ad9a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organic Revenue Growth performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76926d6eb76743fb893fda0b5ee0cd1a_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzAtMS0xLTEtMjMyNzk4_172ed4b3-01cb-4b55-a6ca-2e4bd3388be2">142,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icdfbb4a76db045fd9ebe9fb23d5d7ecf_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzAtMy0xLTEtMjMyNzk4_c12f8dd3-1108-4443-80d7-d23b20c8e8ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i76926d6eb76743fb893fda0b5ee0cd1a_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzEtMS0xLTEtMjMyNzk4_0dc76fc0-9b74-4f6f-baa9-e8867e8e1721">17.96</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icdfbb4a76db045fd9ebe9fb23d5d7ecf_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzEtMy0xLTEtMjMyNzk4_8ee8308c-f19f-4778-8629-8dad2aa19498">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODA1Mg_73416286-5558-4403-a550-e75721736ba8">216</ix:nonFraction> million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODExNA_9fb91f05-914d-4c12-ba60-d2609b2a3577">2.31</ix:nonNumeric> years.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $<ix:nonFraction unitRef="usd" contextRef="i095b974a4eda46539b55e501e35cecd5_I20230331" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODMxMA_1c7c94c3-cef7-440f-a2a2-23cb8ab8f0e2">118</ix:nonFraction>&#160;million, which will be amortized over a weighted-average period of <ix:nonNumeric contextRef="i38c3d0bb2bf64e46be06eed20ec48919_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODM3Mg_e4c02222-c4ce-490e-95cf-0d2fd7269a2e">2.49</ix:nonNumeric> years.</span></div></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_82"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RleHRyZWdpb246OGUyMWQ3ZjBhMDMwNDgwZWE4M2MzYTNlYmZjOWNjMjFfNzY2_65b590a9-1336-447a-b9bc-73df5bb66fb0" continuedAt="ia795b92e35c14ece97c523696131cd87" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="ia795b92e35c14ece97c523696131cd87"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RleHRyZWdpb246OGUyMWQ3ZjBhMDMwNDgwZWE4M2MzYTNlYmZjOWNjMjFfNzY0_89b7204a-ad8d-4ef3-ab63-695be5b32877" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ffe0c3f62ab46708e444bc96954e538_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMS0yLTEtMS0yMDc3MTU_de765631-289b-4d72-a90b-813a6d026e6c">1,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie78900a84c814e17a0700f44d77a770a_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMS00LTEtMS0yMDc3MTU_202e1b29-7297-4ef6-856f-f205ec969f54">2,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08ba76927daa47f698849aaa8387e768_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMy0yLTEtMS0yMDc3MTU_a6023f4b-879c-4e6e-872f-a9bc81e8bf06">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcf8da1fe72640db95834f27357c5bde_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMy00LTEtMS0yMDc3MTU_b98a8eb1-55b2-4eb1-9afd-cd83be57bc21">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bbac5f0d9d24f8a8f825099f3394fec_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfNC0yLTEtMS0yMDc3MTU_82b2e88f-1bbf-4f12-a12f-16c5bb682be6">1,989</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e558abb1f7e4945be1efbb15c0857e4_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfNC00LTEtMS0yMDc3MTU_ef88f713-2c26-4e50-bbef-45a624dd1edc">2,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, in the second quarter of 2022, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $<ix:nonFraction unitRef="usd" contextRef="i23d3136d31994fbdb7cb150bafef9389_D20220401-20220630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RleHRyZWdpb246OGUyMWQ3ZjBhMDMwNDgwZWE4M2MzYTNlYmZjOWNjMjFfNzIz_d739bf3a-da80-48e0-94cf-f93d3c80dd16">137</ix:nonFraction>&#160;million to equity attributable to the Company.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_85"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RleHRyZWdpb246NGJiMWRlMzlhYzRlNGQ0YmE2ODA2ZjhjZWQ5YTQxNjlfMjMz_f1ba6a53-9bb5-489d-b106-281162f28654" continuedAt="i1123c5fe2eff468086105ae68464eccc" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="i1123c5fe2eff468086105ae68464eccc"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RleHRyZWdpb246NGJiMWRlMzlhYzRlNGQ0YmE2ODA2ZjhjZWQ5YTQxNjlfMjM2_f655415b-d6d9-4a9e-929c-a8283ea37419" continuedAt="i64d1f1a2b2234de080b61dc5b860f1c6" escape="true">Research and development costs consist of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><ix:continuation id="i64d1f1a2b2234de080b61dc5b860f1c6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMi0yLTEtMS0yMDc3MTU_6b93ff91-67d4-47e3-81ba-b25ffeaee724">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMi00LTEtMS0yMDc3MTU_9f45b810-8714-42fa-a697-ed3339fa86c5">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMy0yLTEtMS0yMDc3MTU_91fe5c6d-540b-4162-980d-6f9d43c5165f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMy00LTEtMS0yMDc3MTU_222d4550-854c-4c7b-bbce-28b3da3bc91b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfNC0yLTEtMS0yMDc3MTU_b3f03d0c-469c-498a-8c18-504fddbad972">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfNC00LTEtMS0yMDc3MTU_ad3b3d3e-23f9-415b-8490-2770626d7df6">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_88"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RleHRyZWdpb246NmQ5NTgyMjgxNjRkNDM4MzgxNDUyODZkZDQ3NDJlZWVfMjE3_1a81bfe9-e0ec-4abd-bdb8-ca28a3a0cb20" continuedAt="ib63114ee6b624305abf544d3dda7352b" escape="true">OTHER EXPENSE, NET</ix:nonNumeric></span></div><ix:continuation id="ib63114ee6b624305abf544d3dda7352b"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RleHRyZWdpb246NmQ5NTgyMjgxNjRkNDM4MzgxNDUyODZkZDQ3NDJlZWVfMjE5_34d31de0-cfcf-4fa5-b3f8-0e632eb33bb7" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:77.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.948%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMi0yLTEtMS0yMDc3MTU_2f4b9773-36dd-4904-bf94-aa2039557ace">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMi00LTEtMS0yMDc3MTU_cfb906e2-b04a-4c78-9c31-cf13a31675bd">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMy0yLTEtMS0yMDc3MTU_3105f677-d055-4d9a-bd90-ecc24ea90911">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMy00LTEtMS0yMDc3MTU_61632955-4c1e-4fad-a512-595f203dabaf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfNy0yLTEtMS0yMDc3MTU_cd96d496-9c3e-4beb-8177-ff57458ff60c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfNy00LTEtMS0yMDc3MTU_d04e7d35-16c8-41e2-bc1d-be3c4b56c041">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, Litigation and other matters primarily relates to an insurance recovery regarding a certain litigation matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration expense for the three months ended March 31, 2023, primarily includes adjustments to reflect the changes in estimates of the future royalty and milestone payments related to a branded product.</span></div></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_91"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfOTA0MA_b23cb45f-68c8-4c7f-8e03-274a00adaff8" continuedAt="i3db2c1868aa24d6ea6148f32c1880342" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i3db2c1868aa24d6ea6148f32c1880342" continuedAt="i6574faec19ce494686d964f774837dd5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for the three months ended March 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNzA2_5d582135-bced-4993-96c1-8ade01a915af">73</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNzI3_84736619-ec6a-4a59-a45f-575d4ad469d0">13</ix:nonFraction>&#160;million of income tax benefit for the Company&#8217;s ordinary loss for the three months ended March 31, 2023 and (ii) $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfODA2_a2c65405-1fb1-48c5-8fc6-881d0db4a3b0">86</ix:nonFraction> million of net income tax expense for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxSettlements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfODc1_54913849-c566-44f5-9ca0-7c642b716b8e">41</ix:nonFraction>&#160;million of net income tax expense related to final and potential settlements of various tax audits in the first quarter of 2023, (b) $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfOTYx_8283ba33-baac-411e-a956-32aec53a349c">18</ix:nonFraction>&#160;million of income tax expense related to changes in uncertain tax positions, (c) $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMTAzMQ_21b189a2-9d32-49ea-9af0-7f392db3979c">18</ix:nonFraction>&#160;million of income tax expense associated with the establishment of a valuation allowance against deferred tax assets of B+L&#8217;s Canadian parent and (d) $<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI4MDM1NQ_1db81cb3-7d71-4920-807f-d4d7fc5e693e">6</ix:nonFraction>&#160;million of income tax expense associated with stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the three months ended March 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMTExNQ_dc181c69-be22-4194-a2bf-8b0a6df1f1ad">16</ix:nonFraction> million and included: (i) $<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjYyMw_335afc71-08af-45b5-9504-93840f754a2e">14</ix:nonFraction>&#160;million of income tax expense for the Company&#8217;s ordinary loss for the three months ended March 31, 2022 and (ii) $<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjYzNg_0fdd066d-7ac6-4bcf-9022-b47033254090">30</ix:nonFraction>&#160;million of net income tax benefit for discrete items, which includes: (a) $<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjY0OQ_48a8cbd3-1741-497b-8cbc-efdaade4d6a4">36</ix:nonFraction>&#160;million of net income tax benefit recognized for changes in uncertain tax positions and (b) a $<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjY2Mg_43fe5f65-672c-44de-ae3f-b39ffc25bcae">6</ix:nonFraction>&#160;million tax provision associated with the filing of certain tax returns. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was approximately $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjEyNw_1376ee25-9cf2-48d0-8395-62c642247740"><ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjEyNw_20b1920e-e53e-422a-9447-b86d81fef6ed">2,000</ix:nonFraction></ix:nonFraction> million as of March&#160;31, 2023 and December&#160;31, 2022. The Company will continue to assess the need for valuation allowances on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTY5Ng_a6ad3a48-007f-4d10-8a1c-8230b44c9817">901</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTcwMw_c7b55b6e-0878-454a-ac62-9aeff4d457be">881</ix:nonFraction> million, respectively, of unrecognized tax benefits, which included $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTc2Ng_9e12636e-480a-4fbf-9fa1-e6c9a7f2fc8c">41</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i57d70860978f416995c6e78078eb91fe_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTc3Mw_d834efba-5de6-44c8-ae3e-0c6d61890d33">32</ix:nonFraction> million of interest and penalties, respectively. Of the total unrecognized tax benefits as of March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTg2Ng_49938909-87c8-41a6-bee3-1c784d7018b9">402</ix:nonFraction> million would reduce the Company&#8217;s effective tax rate, if recognized. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i6574faec19ce494686d964f774837dd5"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at March&#160;31, 2023 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNjA3Mg_d53927be-c038-471c-850a-416e5cf27216">5</ix:nonFraction> million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. In the first quarter of 2023, the Company recorded income tax expense related to prior year withholding tax returns.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2021, the Canadian federal government delivered its 2021 budget which contained proposed measures related to limitations on interest deductibility and changes in relation to international taxation. Draft legislative proposals pertaining to interest deductibility were initially released for public comment on February 4, 2022, with revised legislative proposals subsequently released on November 3, 2022. The proposed rules on interest deductibility are expected to be effective no earlier than January 1, 2024. The proposed rules and their application are complex and could have a material adverse impact on our consolidated effective tax rate and financial results in future years if enacted as drafted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the &#8220;IRS&#8221;) previously completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company&#8217;s taxable income as a result of these examinations. However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. The Company&#8217;s annual tax filings for 2015 and 2016 and short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017 is currently under IRS examination. As part of its examination, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss resulting from its internal restructuring. The Company previously contested this proposed tax deficiency through the IRS administrative appeals process and if necessary, will continue to contest any proposed tax deficiency through appropriate litigation. Accordingly, no income tax provision had been recorded as of December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="i19848514ed9a48b79bf2c5a2c418cae9_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI4MjYwNw_6cba510b-e39f-424c-8174-1f6a9f669fc5">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, as part of an alternative dispute resolution process with the IRS, the Company reached a tentative settlement on the 2017 Capital Loss. This tentative settlement is subject to further review and approvals before it is finalized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In anticipation of the finalization of this settlement agreement the Company has recorded an estimate for the impact of the settlement during the first quarter of 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Condensed Consolidated Financial Statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022 the Company&#8217;s affiliate in the Netherlands received an assessment from the Luxembourg Tax Authorities as successor in interest to its affiliate in Luxembourg for tax years 2018 &#8211; 2019 for &#8364;<ix:nonFraction unitRef="eur" contextRef="i0e7f6f3cf8d14cc58d92cb9b35e61a89_D20221108-20221108" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI4MDM4MQ_37cf270b-0635-4acc-96e0-017dbec5551f">272</ix:nonFraction>&#160;million. The Company is vigorously defending its position and has not recorded any reserves for this assessment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Luxembourg are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Condensed Consolidated Financial Statements.</span></div></ix:continuation><div id="i403fd8161ca64d5ab28658fcd748a8e4_94"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfMTI4OQ_a0aab60b-5b44-4d86-8bc6-9d8ab680e31b" continuedAt="ie4971f6109fb4dd6b6123052e01f8244" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ie4971f6109fb4dd6b6123052e01f8244" continuedAt="ie288552142ff4a5d88a8a8bd3f3ea7f8"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfMTMwNQ_b4ff2d3e-b39c-4872-81f2-e291b4e7b113" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:78.660%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMi01LTEtMS0yMDc3MTU_6ca67acf-d220-4a90-a850-ff16a2e187f4">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMi03LTEtMS0yMDc3MTU_f673ade8-f303-4505-af57-0231c568cef8">69</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy01LTEtMS0yMDc3MTU_7111d1bc-58a2-49d8-a934-5e5b684291a9"><ix:nonFraction unitRef="shares" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy01LTEtMS0yMDc3MTU_7a77166b-daf2-4880-8f02-3ce576155160">363.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy03LTEtMS0yMDc3MTU_3b37c142-7b89-4edd-b849-bfa6c7adf67f"><ix:nonFraction unitRef="shares" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy03LTEtMS0yMDc3MTU_f9a9a8d6-52ed-4b00-a907-67ae700cf7c1">360.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi01LTEtMS0yMTkwMzg_5d2a9f8d-2120-4754-be0f-d5cce55aac30"><ix:nonFraction unitRef="usdPerShare" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi01LTEtMS0yMTkwMzg_759a968e-fbfe-45db-96aa-3f9fac613b69">0.55</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi03LTEtMS0yMTkwMzg_950d4ee7-017b-47c3-bc7d-013f8fd32d09"><ix:nonFraction unitRef="usdPerShare" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi03LTEtMS0yMTkwMzg_f8c5825f-96a7-4d96-a310-852ed5263f8b">0.19</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie288552142ff4a5d88a8a8bd3f3ea7f8" continuedAt="i4724171c49aa47869df300613deccd73">During the three months ended March 31, 2023 and 2022, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="i5eb53786821248ca8b1f2d53e1c01d20_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNDg2_622ea9cc-7791-4a33-a365-3694efabd520">3,426,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icb496022dc8e4cf08fe49993684b187c_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNDkz_fadd9d0c-eb61-4133-9214-18f8cc4188bc">3,600,000</ix:nonFraction> common shares for the three months ended March 31, 2023 and 2022, respectively.</ix:continuation></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4724171c49aa47869df300613deccd73">During the three months ended March 31, 2023 and 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="iaebb38b5c93f4c928fa764fbd3fde9ce_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNjM1_b5f2c0a2-92c1-4b83-be9f-0abb463e6ccd">17,636,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i81b6547380c64dd2a50784794125d70e_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNjQy_47856a25-9289-416d-adca-b8eb5e3e11d4">9,332,000</ix:nonFraction> common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended March 31, 2023 and 2022, an additional <ix:nonFraction unitRef="shares" contextRef="i519005c4e8bf4fa49fe850dc4fd0f0ff_D20230101-20230331" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfMTEzOQ_cea0ea52-ff9c-4da0-a441-d8a38171d465">90,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iabca2dedff2549f2a26e0f9e0fc903e9_D20220101-20220331" decimals="-3" name="bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNTQ5NzU1ODE1NTk2_c83099d8-afce-45bd-b7b8-4c77b88c13c2">156,000</ix:nonFraction> performance-based RSUs, respectively, were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</ix:continuation> </span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_97"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNjE0NTc_aceb7d19-d06e-48ed-9d35-998714de5e78" continuedAt="i0995bd5243664a26918f990deb15ad38" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="i0995bd5243664a26918f990deb15ad38" continuedAt="ie41da7437dfa425ea19148f6e81e7105"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of March 31, 2023, the Company&#8217;s Condensed Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331" decimals="-6" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTM2Ng_04c4b143-28b6-4c52-966a-aee9713ba6f0">326</ix:nonFraction> million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Iowa &#8211; re OrthoDerm</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a Civil Investigative Demand in May 2021 from the Civil Division of the United States Department of Justice and the United States Attorney&#8217;s Office for the District of Iowa, requesting documents and other information concerning the sales and marketing of Bryhali</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Siliq</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#8220;Securities Class Action Settlement&#8221;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, <ix:nonFraction unitRef="case" contextRef="if51c4186ebf842d9bc523ee7341ac28b_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI4Nw_a8bbd258-f7cf-4d3e-8c9e-180e728745e6">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="ie41da7437dfa425ea19148f6e81e7105" continuedAt="i91927149632a45588e42d3a317932e9d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="if51c4186ebf842d9bc523ee7341ac28b_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI5Ng_9a33eac2-fb92-46cd-9fa3-80c9b36a17b7">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="ifc7b2df681304b2890b3963d6767bdca_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjMwNg_2c88e7f4-624b-4d55-ab1e-cdc4e23b30da">1,210</ix:nonFraction>&#160;million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments were paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. During 2022, the Company&#8217;s rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjMyMQ_6bb97edf-5d9d-4123-8c07-de420207895f">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed on February 23, 2023. <ix:nonFraction unitRef="case" contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjMzOA_e31639c2-cb17-464b-93e8-c358ab749aa8">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM1MQ_a15dfcc8-6f75-4aec-94ed-f6d4f3740b68">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM2OA_3ce70c2d-a0fd-4d79-a6dc-a97925a59103">twenty-one</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Aly opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="i4673169a9f5042a890348f2de0d3b0de_D20150101-20151231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTE0NjM_1e286be5-d4f3-4114-b655-8f5ba4f2f954">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of <ix:nonFraction unitRef="action" contextRef="i458f2edb3ff040f987cabd221cc1abb6_D20230101-20230331" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTE2ODE_3dff5662-7616-4df9-857f-3c67ca9f3601">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company and the </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i91927149632a45588e42d3a317932e9d" continuedAt="ie8144e79279b48dba666805f73ef87d6"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February&#160;23, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="ia0de8367b153476aa320c433be6e8642_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTMyNDQ_e6be60f4-5b10-4236-9e21-4cfc978d855b">94,000,000</ix:nonFraction> plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i39bb1640622d4df192d462ee18b711d5_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM4Mw_4e58c495-727d-47e7-ae29-4e51557399c4">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="number_business" contextRef="i9f50f038b4734b508b66b728e2f90a2b_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM5MQ_983c7a51-035c-4c67-993a-02d13cf2956d">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="ie8144e79279b48dba666805f73ef87d6" continuedAt="i81a88998aca345f3bca00535de0cf738"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="ic47ec016d3f14e9687e6fd9195affb3e_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI0NjA3_90fa0cfa-a213-4ac6-b6c9-b8a7d3ff57af">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="i1f2bdc093e6f469e94ae4f92c6ae44c9_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI2NTc4_506a873e-0885-40ac-8a6a-d8e0d5e19778">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="i1f2bdc093e6f469e94ae4f92c6ae44c9_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI2Njk1_5382eabc-efcb-4fff-aeff-c984673a100e">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="i1bbfea8bf36146258594bca2c1b2d4fa_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI2OTMz_8c5227ff-563d-44d0-86cb-aaf3eedee284">213</ix:nonFraction>&#160;million. The Company has resolved its insurance claims with respect to the Allergan Securities Litigation against the Hartford Fire Insurance Company but its claims against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="i770a218322c748019334a4cf693ddec3_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQwMA_0d1fb276-0563-464d-b64b-2871bfc19c1f">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, <ix:nonFraction unitRef="case" contextRef="i5fef41f4b68f4a788694d3e96118dc2d_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ0OA_5c0755ae-a870-45cb-abb8-6f76dd4c040c">eight</ix:nonFraction> (8) putative antitrust class actions and <ix:nonFraction unitRef="case" contextRef="i005975800f4b45b88a890051cc8ed460_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ1OQ_9fdd412f-d308-4541-ab5f-e167fa397aa0">four</ix:nonFraction> (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. <ix:nonFraction unitRef="case" contextRef="i09d4ece01b0b4cbe82efb645a38a84ad_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ2OA_7cd6d787-7d12-4729-b9b5-d3607c0b4c8a">Three</ix:nonFraction> (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i81a88998aca345f3bca00535de0cf738" continuedAt="i568141f409aa4634b43285aa96b98259"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. <ix:nonFraction unitRef="case" contextRef="i945b95d4642547dc948d93764b9fa34e_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ3OQ_6279870e-f536-462f-a27e-d5737498e3cb">Three</ix:nonFraction> (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="i57a59221634247afa741a3029a821408_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ5MQ_b4569c96-9482-47db-b8ba-037e3f038b27">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i568141f409aa4634b43285aa96b98259" continuedAt="id6de5409be854ccc80478e3c8deee5f1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above), Humana Inc. (&#8220;Humana&#8221;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022. On November 28, 2022, the Court consolidated this action with the State Court Action for trial and pretrial purposes (the &#8220;Consolidated State Case&#8221;). Trial is currently scheduled to start in January 2024 in the Consolidated State Case.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain intellectual property litigation proceedings in the United States and Canada, including as arising from claims filed against the Company or by the Company (or that the Company anticipates filing within the required time periods) related to certain products sold by or on behalf of the Company, which may be in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers, where such products include Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 200 mg and 550 mg, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the U.S. Food and Drug Administration (&#8220;FDA&#8221;)&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i176472c9a91947a58428394faa66f2cc_D20200326-20200326" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjUwNQ_10b56081-d515-4f3a-b82f-a65945f3b9f4">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 27 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August 10, 2022, (the &#8220;Norwich Legal Decision&#8221;), finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid. The Norwich Legal Decision prevents FDA approval of Norwich&#8217;s 550 mg ANDA until October 2029. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. Following the Company&#8217;s appeal, Norwich claimed to have removed the HE indication from its existing ANDA and then filed a motion in the District Court requesting modification of the Norwich Legal Decision to permit the FDA to approve their ANDA before October 2029. The Company opposed this motion and awaits a decision on the motion from the District Court. In January 2023, the U.S. Patent Office issued U.S. Patent No. 11,564,912 (the &#8220;&#8217;912 Patent&#8221;) directed to IBS-D, which was then listed in the FDA&#8217;s Orange Book for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On April 28, 2023, the Company received a new Notice of Paragraph IV Certification from Norwich asserting that claims of the &#8216;912 Patent are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, or </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="id6de5409be854ccc80478e3c8deee5f1" continuedAt="i982242cf83124f508098b688413b1815"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, under the existing Norwich ANDA. Any suit brought against the existing Norwich ANDA under the &#8216;912 Patent is not believed to result in a new 30-month stay of approval. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a <ix:nonNumeric contextRef="i3b70ae48ac824b238ebdfb47f23616a7_D20220721-20220721" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjUyMg_bb6d9fa9-763d-4493-8c5a-93d0e75dafd5">30</ix:nonNumeric>-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a <ix:nonNumeric contextRef="if9c399e8c9cd4e7ca1b0299006f338c2_D20210401-20210430" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjUzOA_89b2bd8b-d115-4ba0-b538-f904fef2b37a">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company commenced litigation against Aurobindo Pharma Limited (&#8220;Auro&#8221;) alleging patent infringement by Auro&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Auro, in which it asserted that the U.S. patent listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Auro&#8217;s generic plecanatide tablets, 3 mg. The filing of this suit triggered a <ix:nonNumeric contextRef="i24d679a98f75427f88c6ebe76a942e45_D20230101-20230131" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU0Ng_fba4c20e-fa29-49a4-827e-39dbbc173367">30</ix:nonNumeric>-month stay of the approval of the Auro ANDA for plecanatide tablets. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against <ix:nonFraction unitRef="defendant" contextRef="if6350305849648ffb0d2318c6a4aff11_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI1Mg_59abf97f-7485-4276-965a-5fdc748e953c">19</ix:nonFraction> named defendants in <ix:nonFraction unitRef="proceeding" contextRef="if6350305849648ffb0d2318c6a4aff11_D20210301-20210331" decimals="INF" name="bhc:GainContingencyNumberOfProceedings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI1Ng_443072e7-a86e-4b8d-916f-f474d73b3744">16</ix:nonFraction> proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. <ix:nonFraction unitRef="defendant" contextRef="i4d5d5d30a78743fcbe52b8144e75f596_D20230101-20230331" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI1OQ_6076ad69-b66f-4cce-bf59-e2f0e0ce55ef">Twelve</ix:nonFraction> of these proceedings were subsequently settled; <ix:nonFraction unitRef="defendant" contextRef="i52f2f806ddb64cfc8ebb70476e207aae_D20230101-20230331" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI3OQ_ab6b647e-07e4-4bce-b8cf-2f0018e3f8d2">two</ix:nonFraction> resulted in a default. As of the date of this filing, there are <ix:nonFraction unitRef="defendant" contextRef="i88b0c4fb144a4119b0353b9e796c5864_D20230504-20230504" decimals="INF" name="bhc:GainContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI3MQ_b7c48bb5-4616-4e25-bed6-cea8acfad754">two</ix:nonFraction> ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 4:22-cv-00914-AGF (E.D. Mo.) and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-GBW-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 8, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-00739-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i982242cf83124f508098b688413b1815" continuedAt="i60d25d71b9b14cd796ca38a2c32e308d"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="i26816d2d301f4b2e814b747046bafd99_D20210910-20210910" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU1NA_eb1f3e81-3f7b-4566-964c-0aec3b0cc0a1">30</ix:nonNumeric>-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a <ix:nonNumeric contextRef="id1a1acd7be5d4003ac3ff92ab403c379_D20220202-20220202" name="bhc:GainContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU2Mg_8e5c4d6d-f42f-4464-ad65-2299289f5bef">30</ix:nonNumeric>-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2026 through 2035. In 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. <ix:nonFraction unitRef="lawsuit" contextRef="i48e4a619c05e48ffb995b93d387f88e3_D20230101-20230331" decimals="INF" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU2OQ_aca9b2b3-a903-4bfa-a4a0-3b6636dd0b58">Three</ix:nonFraction> lawsuits are pending in Canada regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Apotex Inc. and Pharmascience Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On October 12, 2022, MSN also filed a petition for IPR of U.S. Patent No. 7,041,786 and the PTAB then issued a decision on December 14, 2022, instituting MSN&#8217;s IPR and joining it with Mylan&#8217;s IPR. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. In the Company&#8217;s favor, the PTAB issued decisions on Jan. 4, 2022, denying Mylan&#8217;s petitions.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, <ix:nonFraction unitRef="case" contextRef="i993f123539934cffbde85472ef746930_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU5MA_8998102d-cb34-4fad-a708-288b5ecbf15e">twenty-six</ix:nonFraction> (26) of such product liability suits currently remain pending. In <ix:nonFraction unitRef="case" contextRef="i9b05eff1ebcf4f5b980a23bd07d03ae4_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU4MA_ac1da66b-29f1-40cc-9cfc-592a0ac201d8">three</ix:nonFraction> (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. <ix:nonFraction unitRef="case" contextRef="ief2eb449f9874ce181c5a5a55b53420a_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYwNQ_f1ad1e3d-c281-46ee-ad2d-1df4d8bf5d4f">Twenty-five</ix:nonFraction> (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i60d25d71b9b14cd796ca38a2c32e308d" continuedAt="i7ad80e167b29425d98ffac4d5cd72f88"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="case" contextRef="i879843cb6d494828a7a39d54b19d72ca_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYyMg_4726e20e-392b-42cf-a34b-afe0beaf596b">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="i6a43da3b1f6244ca9940203efc29fea7_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYzMA_c552c96e-576f-4368-a735-d535847dca88">one</ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="ib68a72c1f5224ee9b35a0e482c1dadbb_I20230331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYzOA_7df32555-c5a5-42f7-944d-6c441063bed7">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of <ix:nonNumeric contextRef="ic2b286567c0d4c80b0020c5f649deaeb_D20211101-20211130" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjY0Ng_316de531-b663-49a3-9bfe-7b5d194d45b5">60</ix:nonNumeric> days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the <ix:nonNumeric contextRef="i9efca43066164f5f8a7d4d69da63efec_D20211201-20211231" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjY1Nw_a0ff2188-7017-4d5e-8ce4-c3a6b408e10d">60</ix:nonNumeric>-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022, which it later extended indefinitely. The order denying the motions to dismiss and the order extending the preliminary injunction were subject to appeal and the Bankruptcy Court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022. On January 30, 2023, a unanimous three-judge Third Circuit Court of Appeals panel issued its decision directing the Bankruptcy Court to dismiss LTL&#8217;s bankruptcy case, concluding that LTL was not in financial distress and could not file a bankruptcy case in good faith. LTL requested a rehearing and on March 22, 2023, the Third Circuit denied LTL&#8217;s rehearing request. Thereafter LTL moved for a stay of the mandate of the Third Circuit&#8217;s dismissal decision while LTL sought review by the Supreme Court. On March 31, 2023, the Third Circuit denied LTL&#8217;s stay motion. At that juncture, the Bankruptcy Court determined it appropriate to discontinue the proceedings pending there, and on April 4, 2023, entered orders dismissing the bankruptcy case and related adversary proceedings and terminating the preliminary injunction.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, on April 4, 2023, LTL re-filed for chapter 11 in the Bankruptcy Court and again commenced an adversary proceeding seeking a preliminary injunction enjoining substantially all cases subject to the indemnification agreement. The Bankruptcy Court granted a temporary restraining order enjoining litigation against the &#8220;Protected Parties&#8221; including the Bausch entities. The Bankruptcy Court held a hearing on April 18, 2023, to consider the preliminary injunction, and on April 20, 2023, the Bankruptcy Court ordered a preliminary injunction solely on a limited basis to enjoin the commencement or continuation of any trial against any Protected Party (including the Bausch entities). The injunction does not enjoin the commencement of a new suit or any discovery or pre-trial activity in pending suits. The talc claimants have sought to have the decision certified for direct appeal to the Third Circuit. Additionally, the Bankruptcy Court will be ordering the parties to continue mediation, and will consider proposals for mediators, a Future Claims Representative, and a fee examiner at a hearing scheduled for May 3, 2023. On April 24, 2023, the talc claimants filed a motion to dismiss the newly filed Chapter 11 case and a hearing is scheduled for May 22, 2023. Meanwhile, LTL has stated that it intends to file a plan of reorganization by May 14, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the bankruptcy case is ultimately dismissed, the Company&#8217;s position vis a vis J&amp;J would return to the status quo prior to the filing. The litigation against the Company and other defendants will no longer be stayed, and LTL and J&amp;J will continue to have indemnification obligations running to the Company and its affiliates for Shower-to-Shower related product liability litigation.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any cases proceed during the pendency of the bankruptcy case, or if the case is ultimately dismissed, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i7ad80e167b29425d98ffac4d5cd72f88" continuedAt="if4c18feab3414c2b95c9034ddb773c6c"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that the future potential separation of Bausch + Lomb from the Company by distribution of Bausch + Lomb stock to the Company&#8217;s shareholders would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. On April 29, 2022, Plaintiffs filed a motion to remand. On November 29, 2022, the District Court granted Plaintiffs&#8217; remand motion and the case was remanded to the Superior Court. On December 8, 2022, Plaintiffs filed a proposed Order to Show Cause and motion for a preliminary injunction, and sought interim relief including expedited discovery. On December 13, 2022, the Court denied Plaintiffs&#8217; proposed Order to Show Cause and stayed discovery pending the resolution of the Company and Bausch + Lomb&#8217;s forthcoming motions to dismiss, while instructing the Company to provide certain notice to Plaintiffs of the intended completion of the distribution referenced above under certain circumstances. On December 22, 2022, Plaintiffs filed an amended complaint which, among other things, added claims seeking injunctive relief. On January 11, 2023, the Company and Bausch + Lomb moved to dismiss the amended complaint. Briefing was complete on February 24, 2023, and the motion to dismiss was heard on March 3, 2023. On April 3, 2023, the court issued a decision granting in part and denying in part the motion to dismiss. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and asked the Ninth Circuit to continue to stay this action while the bankruptcy preliminary injunction remained in place. On January 20, 2023, the Ninth Circuit extended the stay until February 17, 2023. On February 17, 2023, Johnson &amp; Johnson requested the court afford it sixty (<ix:nonNumeric contextRef="i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzUwNTcwOA_b787f3fe-d656-4ba9-9478-6405de01effc">60</ix:nonNumeric>) days &#8211; until April 18, 2023, or seven (<ix:nonNumeric contextRef="i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217" name="bhc:LossContingencyStayOfApprovalMotionToExtendPeriodTwo" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzUwNTcyMw_0410cf36-8ab0-4e7f-9ec5-97b3e1e02d5c">7</ix:nonNumeric>) days following any lifting of the LTL Bankruptcy Court&#8217;s preliminary injunction &#8211; whichever comes earliest &#8211; to provide an additional status report about the bankruptcy proceeding and the Third Circuit dismissal for which LTL has requested a rehearing. On April 7, 2023, Johnson &amp; Johnson Consumer Inc. filed a status report regarding the bankruptcy proceeding advising the Court of the dismissal of the prior bankruptcy proceeding and the filing of the second bankruptcy proceeding, as well as the preliminary </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="if4c18feab3414c2b95c9034ddb773c6c" continuedAt="ia76c12f7bd46418da604064f7020b837"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunction and stay order, and requesting the stay of the appeal remain in place until May 10, 2023. The Ninth Circuit has not yet acted on that request.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial was scheduled to begin on May 30, 2023, until the case was stayed by an interlocutory appeal to the New Mexico Supreme Court by Johnson &amp; Johnson.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the New Mexico Attorney General from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction. The New Mexico and Mississippi Attorneys General appealed the order granting the preliminary injunction and sought direct appeal to the Third Circuit. The Bankruptcy Court certified the matter for direct appeal to the Third Circuit Court of Appeals. Following the Third Circuit&#8217;s decision requiring dismissal of the main bankruptcy proceeding, and its subsequent denials of LTL&#8217;s requests for a rehearing or a stay pending disposition by the Supreme Court, on April 4, 2023, the Bankruptcy Court entered orders dismissing the bankruptcy case and related adversary proceedings. However, also on April 4, 2023, LTL re-filed for chapter 11 in the Bankruptcy Court and again sought a preliminary injunction, though it does not currently include this lawsuit. The Bankruptcy Court did not grant the broad preliminary injunction requested and, instead, issued a preliminary injunction solely on a limited basis to enjoin the commencement or continuation of any trial against any Protected Party. However, this action remains stayed due to a separate September 13, 2022, stay order from the New Mexico Supreme Court in a pending appeal from a Motion to Compel filed by Johnson &amp; Johnson. Accordingly, at this time this matter remains stayed pending the outcome of that appeal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="i0e4af957468b4b74a17f3a7d3f6e1b6d_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDUwNDM4_7fbf1604-2afb-43e0-8d48-4950eba13c7a">30</ix:nonFraction>&#160;million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 11, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="ia80385ad9ebe4c0bb7c80610f3bae724_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjY5MA_b5b84b50-50ed-432c-9a2b-3f5c99fff3ab">23</ix:nonFraction>&#160;million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia76c12f7bd46418da604064f7020b837">Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</ix:continuation></span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_100"></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2MzQ_0e484c23-6ab9-4f47-b48e-8dc936f79702" continuedAt="i9eac64c0c0ba45469d752b5a20ef33f5" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="i9eac64c0c0ba45469d752b5a20ef33f5" continuedAt="id83a34df865b49ae89001b04101059e4"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately <ix:nonFraction unitRef="number" contextRef="i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzIxMTM_4d006ffc-7b13-40bd-8149-373fc49cd932"><ix:nonFraction unitRef="number" contextRef="i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzIxMTM_756c060e-3107-4ca6-b45b-0aa841a347ea">80</ix:nonFraction></ix:nonFraction>% of the Salix segment&#8217;s revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Diversified (formerly Diversified Products) segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="id83a34df865b49ae89001b04101059e4" continuedAt="i81c02cdd986642baae0242ea6f40e067"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2NjQ_39ca2654-602b-4c02-ba9d-366f79744302" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:78.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8c6d648ece4cb38926e0893d4d16cb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzMtMS0xLTEtMjA3NzE1_5fdd7860-2583-4352-838b-c20c8bcae121">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa7faccfc9e4b2ca204f3c85a970f69_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzMtMy0xLTEtMjA3NzE1_6074a41b-8340-432a-a6ba-5bcba34b67f3">464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023a58638ddd46eca36de268fb813f97_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzQtMS0xLTEtMjA3NzE1_e5d63f6e-0826-453a-ac79-51d86b476dab">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be070c32a5a4c1ba81697834d0ed884_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzQtMy0xLTEtMjA3NzE1_d98c6c09-ece8-4b9c-a5fa-cac35bae4534">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4f39f4056646cc9b55c92a148ec539_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzUtMS0xLTEtMjA3NzE1_23ce5dbb-0903-4181-9595-ff50110f9ddb">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcb8713c7af444fb8b6d03e82848ff6_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzUtMy0xLTEtMjA3NzE1_3eeb807b-a3e5-451a-a948-57dd30931df8">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46df43952df846588596009246e5d41d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzYtMS0xLTEtMjA3NzE1_b56dd571-d9f4-4a29-8f65-1fe136037685">197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24da3a29fc44884abed656c976f1185_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzYtMy0xLTEtMjA3NzE1_4e08b90a-1b97-4394-aebd-93ed707b12d1">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5067f998a0774347a1ba8dddd05e828d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzctMS0xLTEtMjA3NzE1_135c65dd-641f-40c7-99d3-2408f80fc4a1">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84476c66acf64d629d1829a442bdd45f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzctMy0xLTEtMjA3NzE1_4a4f8225-78e9-4e18-8cf2-7d267858fd4b">889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzgtMS0xLTEtMjA3NzE1_41e5e067-186f-494b-a06f-9f11c7200750">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844e35405a554f25b15ab800349871ec_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzgtMy0xLTEtMjA3NzE1_51209caf-fc0c-4e2c-b4df-74b56514ebbf">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide8c6d648ece4cb38926e0893d4d16cb_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEwLTEtMS0xLTIwNzcxNQ_4480965b-4ea6-4679-834d-bf7eb7cdd27d">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa7faccfc9e4b2ca204f3c85a970f69_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEwLTMtMS0xLTIwNzcxNQ_ae8c624f-a4a6-4ea1-969a-e95c6a74ef0b">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023a58638ddd46eca36de268fb813f97_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzExLTEtMS0xLTIwNzcxNQ_b808590c-da1e-41a8-9b49-b905813e8447">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6be070c32a5a4c1ba81697834d0ed884_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzExLTMtMS0xLTIwNzcxNQ_b8644fd4-ba7f-43df-8a80-9abdcd765e7c">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4f39f4056646cc9b55c92a148ec539_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEyLTEtMS0xLTIwNzcxNQ_f30288ff-fbf0-4f0f-944f-a64a8f9ec2fd">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedcb8713c7af444fb8b6d03e82848ff6_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEyLTMtMS0xLTIwNzcxNQ_be6bcb49-980d-4a2d-a46c-19c3cab60e59">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46df43952df846588596009246e5d41d_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEzLTEtMS0xLTIwNzcxNQ_e68ca3ea-eade-4a06-a224-aef32915c95c">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24da3a29fc44884abed656c976f1185_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEzLTMtMS0xLTIwNzcxNQ_3a42603d-3cbd-4b4f-a6d0-edc60a39cb8f">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5067f998a0774347a1ba8dddd05e828d_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE0LTEtMS0xLTIwNzcxNQ_8259485e-4b52-4b8f-a371-235c35146d5e">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84476c66acf64d629d1829a442bdd45f_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE0LTMtMS0xLTIwNzcxNQ_aab5f083-3fa6-4f79-a0e4-bbe57b20d6ae">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE1LTEtMS0xLTIwNzcxNQ_41cdf442-938a-475c-ba2f-48e1e86857da">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844e35405a554f25b15ab800349871ec_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE1LTMtMS0xLTIwNzcxNQ_702fe2ea-6d2c-4012-ae7a-2b4b46c655f9">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c0d405070e646faa7642b41b7cf60bc_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE2LTEtMS0xLTIwNzcxNQ_17de08c9-e3ef-4982-a719-70e1d0106a81">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i291a59d0cc7a41f998a11690ab1a3fc2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE2LTMtMS0xLTIwNzcxNQ_9c3a4d59-d4b0-4d45-805a-286f9b908a75">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE3LTEtMS0xLTIwNzcxNQ_11827f98-b330-4b7f-9211-253ae69a8658">273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE3LTMtMS0xLTIwNzcxNQ_fbd9a0ca-be56-4f70-9613-5269af6720d2">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE5LTEtMS0xLTIwNzcxNQ_f226030e-fa1c-4819-aff6-8774ed71c867">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE5LTMtMS0xLTIwNzcxNQ_922823f6-6a29-4e9c-a209-9f3f07b57efb">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIwLTEtMS0xLTIwNzcxNQ_1654bd41-7993-4564-9105-89009d8a6cb2">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIwLTMtMS0xLTIwNzcxNQ_5997e04b-037e-4bf6-8279-b051838f480e">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIxLTEtMS0xLTIwNzcxNQ_41ff1c02-39a5-4a6d-b5ff-d76305c926d0">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIxLTMtMS0xLTIwNzcxNQ_4c87aaf6-b98c-4548-8dd0-e5f28cfc474a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIyLTEtMS0xLTIwNzcxNQ_c30ddd69-63a8-415c-8fa3-009f6ddb6be2">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIyLTMtMS0xLTIwNzcxNQ_134aced4-5393-498d-a5dc-0780097e340b">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIzLTEtMS0xLTIwNzcxNQ_936fff83-3a17-45db-8765-fc7de8c609b5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIzLTMtMS0xLTIwNzcxNQ_51bfcf01-4a9f-4f07-8076-d0bcd27b1008">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI0LTEtMS0xLTIwNzcxNQ_11f087de-0b39-4de1-92c5-8b82c1b84eaf">307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpenseDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI0LTMtMS0xLTIwNzcxNQ_511016de-58b5-41b2-a700-3a1222eb9455">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI2LTEtMS0xLTIwNzcxNQ_eda20f24-1c0d-4262-80b5-d4f02fa22be3">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI2LTMtMS0xLTIwNzcxNQ_e9ee3d62-bf03-42a1-8016-6d5b04ed0ebf">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI3LTEtMS0xLTIwNzcxNQ_9209143f-b104-40e3-8ada-61809c5aefd6">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI3LTMtMS0xLTIwNzcxNQ_ec758731-ce5a-473d-97a1-a6ea05ea41e6">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i81c02cdd986642baae0242ea6f40e067" continuedAt="i78a38da5a041420d94b693063562d6e1"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2NDU_a8169e50-d962-4b0b-9f0a-910fb9155a6d" escape="true"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:29.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if231378ef6374003b9b4b0a7109a7cd7_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItMS0xLTEtMjA3NzE1_28216689-532a-4254-bb13-05ba671032d6">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95a4bade0b5f449babad9d26acb96982_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItMy0xLTEtMjA3NzE1_726ccfc3-ea93-4ba0-9aa0-2700e9260cb0">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac1d18d3c5e49c2bfc56953bf92f5c6_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItNS0xLTEtMjA3NzE1_68b47c9b-d2c8-4948-880c-34ee19c62d74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f2d378c39e4f668000688f3e489870_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItNy0xLTEtMjA3NzE1_78ccd702-3019-4ade-aebc-ce2f0452faee">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7dd91b590f846dd9b290718829cfd6a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItOS0xLTEtMjA3NzE1_85d34d96-bd3f-4bce-8992-934f70a5c5bc">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b225b3f8b0746bfb199706e955676a9_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItMTEtMS0xLTIwNzcxNQ_c1636b9b-16ad-4e25-9f7b-e2c7dec9a55e">823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id89d66db36c64eceab4715ffe59e84a5_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtMS0xLTEtMjA3NzE1_20a6531b-2116-4c83-9683-bc76b9bb2f14">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8743518cdefc482a9aa2ddf769e627d3_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtMy0xLTEtMjA3NzE1_64f87eb0-ecce-424d-8186-0774f0a3a0f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc1d8878ec541b1826e3e74d410810e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtNS0xLTEtMjA3NzE1_4545c7eb-2344-4928-9056-04cfddedc836">73</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c847d919d274b11b0a404d202cae423_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtNy0xLTEtMjA3NzE1_b0d8b8cc-66dd-46fd-9031-353dbd94f32a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39116494adc049f9a0fbb011b1049e08_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtOS0xLTEtMjA3NzE1_56bb72f0-1932-46a4-a2bd-5ce66d22afb4">406</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5866e33824490488ff419bebdbb6ef_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtMTEtMS0xLTIwNzcxNQ_d1141e9d-64bf-4287-b9bc-b618b7fd6e60">479</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8662c383a6524d2ea7cd1a7de3a66edd_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtMS0xLTEtMjA3NzE1_a33c4e18-b529-4630-b209-b8e65bb65726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia643f63ceee34dc993fdef9436ce2e49_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtMy0xLTEtMjA3NzE1_399916e6-7151-4d70-96a7-b676162b53ac">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a5eb1f6967e48d08f792876eb21bd30_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtNS0xLTEtMjA3NzE1_cea41f09-1ec9-4dbb-8b29-e95a3fcf3ca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239109b0a39046aa954f3569a8c23d66_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtNy0xLTEtMjA3NzE1_fe2bd927-9275-45e9-85f6-e72ab025ae5d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8d23297ea6d4d9baf0ea77a0ff9cf17_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtOS0xLTEtMjA3NzE1_1c9dc658-92b9-448f-981f-061689951ec2">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42629885d170479c82e079fcc16ce6af_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtMTEtMS0xLTIwNzcxNQ_7e254f0b-c4e6-4ae5-a22a-8076eb46893e">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30903274eb934e56a09474d3bcc6a0e1_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtMS0xLTEtMjA3NzE1_01cd45ef-4e41-41c8-b7e6-9e4634b3941c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i295b427c6e5842fcb723434d6f3a5a70_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtMy0xLTEtMjA3NzE1_1766eab6-9210-4b58-b75d-1bdde7d198c2">138</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i324909a15d044fbfa04c98f71ac58540_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtNS0xLTEtMjA3NzE1_78486aff-8ae5-42d6-b5ea-227257bf6d3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e5c70cdd5da42c8a415fdc4ee3a7406_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtNy0xLTEtMjA3NzE1_5a377035-1479-4038-9767-6d9e1777944e">27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05fec92c81a743af8199d506c268b2b6_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtOS0xLTEtMjA3NzE1_dd1b83a6-c9d6-4877-a7be-de1dcabfe17f">61</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a76d1cc780742139bbe99625081f16e_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtMTEtMS0xLTIwNzcxNQ_4ab15218-a8fb-41ac-a7a8-1ed674374930">226</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb0507fddbe4ccab01b0ef5a88ce5d1_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtMS0xLTEtMjA3NzE1_89e0db9b-d981-4d84-af6f-4e11cf53b33d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92ca67bd6ac74e69949d588a28fb81f3_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtMy0xLTEtMjA3NzE1_6f849afe-2bdc-45ed-86b7-092a3bceace2">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0507fe44b91427c8643ec0c7610c2bb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtNS0xLTEtMjA3NzE1_675e21e7-a916-4307-b9a1-c1ade8274d1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c93ea65ff5e4ed7b39b1bf2ffc5657f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtNy0xLTEtMjA3NzE1_4e2f0d20-d113-4468-96bb-c75f39b1cade">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6774d58be5dd408890835ff4f0d2deeb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtOS0xLTEtMjA3NzE1_ab3a1d5e-dc7a-4309-92b7-74f78564cb21">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de643ea5a37490db8249b80a35d9852_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtMTEtMS0xLTIwNzcxNQ_757b261c-5d6c-4328-9b9d-bb5aaacf53bc">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctMS0xLTEtMjA3NzE1_13b9bf49-a248-4f2e-a7ef-007c846f03fe">496</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if298046fc580453c82cae116d877a880_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctMy0xLTEtMjA3NzE1_00a56ea4-8093-4b4c-b87d-2c6c3fb83ed6">247</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctNS0xLTEtMjA3NzE1_6dc4d0ff-6a9e-4716-9159-e09adcc043b8">73</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctNy0xLTEtMjA3NzE1_9586a11d-a6fa-4b06-bbdd-2322fed788ac">197</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctOS0xLTEtMjA3NzE1_faaedeee-79ba-4a3f-8496-6c1e33bcb507">931</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctMTEtMS0xLTIwNzcxNQ_a53aa89d-d415-469c-ab3b-756d493325dd">1,944</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d81a5cdc4704a17830a70621a701a43_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTEtMS0xLTIwNzcxNQ_3862b497-6b58-48da-b9db-349f1dbe993f">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0092c04e97d44cc7b8e987d7db42f7fb_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTMtMS0xLTIwNzcxNQ_6f24ffc1-37fd-4cf4-a611-b14cc9826928">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b4496691294c8ab8af9894359f523e_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTUtMS0xLTIwNzcxNQ_01b91b84-7ffc-4df8-851f-659bf7565069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67a9b004e36401d8688fc07e50d19a4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTctMS0xLTIwNzcxNQ_4348ca5b-a8d6-430f-841f-7f7a3b00308a">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d7bed392714c149189fa93868f8a48_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTktMS0xLTIwNzcxNQ_00059b4d-f53d-45d8-b5f5-5da379c50290">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82cb62cbef5f4deca4f2e8e3e580d3f5_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTExLTEtMS0yMDc3MTU_dfbc11d5-8123-45e7-b301-2db5f9052fbc">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9a2611542a49d9bc16e7aa4527978d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTEtMS0xLTIwNzcxNQ_b7e42e12-4453-4172-bb26-d84370f8cc4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56013d342ab744dca87c96542224d7e9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTMtMS0xLTIwNzcxNQ_76e2e8ff-59af-4daf-ad00-f871fbca39f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88fa31de50ca45b6a6a7b566720bcf21_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTUtMS0xLTIwNzcxNQ_d0cb7374-c776-4f0d-8dd1-8e9b88393e0b">72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6f318f371c4cbb8d697ce6f04abbb9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTctMS0xLTIwNzcxNQ_ee39bb93-c22d-4226-965d-ae8df566f0ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26e30d1cbd3240e3bfa7140161b77af8_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTktMS0xLTIwNzcxNQ_c8bef661-a9ba-46e3-b457-6055011ef614">386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b3e2d64225341b0baf9cc892bc9fd23_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTExLTEtMS0yMDc3MTU_ee3ef4f2-ed3b-40a0-8973-dd17c4b85ee1">458</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4924f823451e44f3b29db4603696acb0_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTEtMS0xLTIwNzcxNQ_1676b8c3-d905-4f16-867c-2d078b4cb9e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78fdb3892eb45d4b6b4521c1d544510_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTMtMS0xLTIwNzcxNQ_006caccb-806a-4b5a-8ff1-5969fe2ebf99">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf234d805c8b4bf18c742891e6f5b611_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTUtMS0xLTIwNzcxNQ_732ee920-d178-4032-aef6-92efcadde788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13033d3d942041598d62836da3fc1150_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTctMS0xLTIwNzcxNQ_f3229097-88d2-4182-a7e7-c321f282abb8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a6ba62744a40428a6ebad3dd21ae27_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTktMS0xLTIwNzcxNQ_d234e77d-6dce-40f1-a319-929d485ab0f9">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6956da0da306428e9c7adf2d607c14ed_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTExLTEtMS0yMDc3MTU_25341c45-0b81-4d17-b03d-929c471d45eb">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i954aadc6d7e24b478f75085b14eb996d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTEtMS0xLTIwNzcxNQ_857447a6-ebd8-4d57-99af-80100cb066d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice48058f29044c469949c88a452cb9bd_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTMtMS0xLTIwNzcxNQ_5cee5de9-21d3-4a33-8780-d31915464078">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15d3638d8904493b1d72ff76791bcb8_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTUtMS0xLTIwNzcxNQ_ef41d21f-195d-4026-9a39-2e257706d038">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ae1eb1ecc54f668ec2295f497fe096_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTctMS0xLTIwNzcxNQ_baf66bfd-0aec-4dce-ab15-fe0a49c7cac6">36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e328edc701b4e18a474924165dee258_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTktMS0xLTIwNzcxNQ_cd973470-950d-4e92-bcf0-2a8ce4f4e3db">54</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015bfad0089f4e8fb03abd4e78cccd35_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTExLTEtMS0yMDc3MTU_8ed7eb3b-a809-496e-ae89-4a96ef8fcded">223</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if576ecdebb9d4e7ea72213c7c3d64c5f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTEtMS0xLTIwNzcxNQ_9affd5e8-f0eb-4480-845a-143217f41e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8814d42191f44bb4856713e244453471_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTMtMS0xLTIwNzcxNQ_3972caad-fb7c-44cf-ab34-e7fa504e55f6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba18df505885492da7aa2619531de2b2_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTUtMS0xLTIwNzcxNQ_36275903-abd0-4049-b40a-2c944a626d89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92b667bc7804456b38e70fa08da5099_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTctMS0xLTIwNzcxNQ_349faadd-ec53-46ab-b120-1063aea64ab1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb0e6403a294c32ae63824bc6e1c102_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTktMS0xLTIwNzcxNQ_e92720ae-8215-4789-b9fa-21468f2b5901">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8101afe6ef64e7d899f1670a46f8de9_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTExLTEtMS0yMDc3MTU_d261821c-8771-424d-9c95-7be8dfd2daa3">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice4470b739f04d39a1886b3405bfed9f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTEtMS0xLTIwNzcxNQ_1f2474b9-2c0e-4614-8801-f25b3bf1ab5f">464</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i284ff13718b143468083c69139f95230_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTMtMS0xLTIwNzcxNQ_c5f4941a-fbe3-4568-974b-e39eaa9db6fb">244</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d85c2876042450a967e14abaddd63cc_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTUtMS0xLTIwNzcxNQ_e054db11-d36d-459a-8f98-6570f8a8bfcf">72</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdbe909a002041d9bac599bf26407059_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTctMS0xLTIwNzcxNQ_26770aab-89ab-47f5-bf61-61d9cd38e216">249</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36a4000ae884c6883a2abeb82097b07_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTktMS0xLTIwNzcxNQ_485340e2-827e-4dc4-8313-1e0160dd96cb">889</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTExLTEtMS0yMDc3MTU_ec877c88-beaa-4619-87f9-884ccf5a169a">1,918</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top <ix:nonFraction unitRef="product" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyMjE_0ea611f2-84df-46c1-8a7c-e07c1617ac25"><ix:nonFraction unitRef="product" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyMjE_df160381-0216-47f1-a8fa-42857846bd1e">ten</ix:nonFraction></ix:nonFraction> products for the three months ended March 31, 2023 and 2022 represented <ix:nonFraction unitRef="number" contextRef="ib4db0b41aa7f45ffbc8ed78d848702cd_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyNTY_78f9f7e5-d04c-4c48-a0a6-502184e64e40">48</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="idccd693104244d1e850fcf6797ba4971_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyNjM_b83e9ff6-c390-4f3a-9368-74d0e3600506">47</ix:nonFraction>% of total revenues for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2MjA_a6aa2ffe-8896-433e-ae2e-fc1a9e6a5f93" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:78.060%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.944%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34eb56c13bb140ba8a8a420a15ef17ba_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzItNS0xLTEtMjA3NzE1_a3c86521-4f63-4252-98c2-3a947f9ec74a">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2544c5919fe1473d9274d0f8c6f34aba_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzItNy0xLTEtMjA3NzE1_fb3f7ede-9e78-486b-b5d6-5103b436a9a9">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd68bfa811af4e1f80cef02be120e2ef_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzMtNS0xLTEtMjA3NzE1_67aec372-0eb7-434c-8ff8-56294cc7a69b">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f840f01d0d48f58279fe4612f1e496_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzMtNy0xLTEtMjA3NzE1_dacbaeb8-3d60-40fb-9706-e970cad23ddf">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab38f7e31c74f2c8d237669db709e1d_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzQtNS0xLTEtMjA3NzE1_65f54016-098d-45b8-a4fa-4c894b9c69b7">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a6fa5e6dc44421b695211384e133e5_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzQtNy0xLTEtMjA3NzE1_c06bf27d-0962-4f4f-a792-96161e2ae8a4">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e193566415d44f1b34e042c627e3a6a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzUtNS0xLTEtMjA3NzE1_dbc215b1-f086-4f30-9871-3584fc4c8ca8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5c293c01084dc9ada28fd87e45e84f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzUtNy0xLTEtMjA3NzE1_2abcced5-1c56-4966-b9a7-bcb75992360a">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56aa6955c9e4050b0a86980dfe8ef9c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzYtNS0xLTEtMjA3NzE1_9f9d9952-df51-4221-a25c-ee5469fd48d9">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35c155e8345e4852a74a094f971e33b4_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzYtNy0xLTEtMjA3NzE1_c4204b9f-78a1-49f4-8e1d-e208c10fc2b2">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe94207c53504992b03639c875317423_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzctNS0xLTEtMjA3NzE1_ab948853-a871-48b9-9a0f-96db1209227b">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b71032da9c24495bd516ea636fbb96a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzctNy0xLTEtMjA3NzE1_1beab48e-5841-487a-ae2c-5451771cc210">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f0b8edeace144f9838fb73ef992a4bf_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzgtNS0xLTEtMjA3NzE1_7984b54b-b470-4999-ac4b-61b225d0978f">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia525c6b1240948b7ac3d8f4ff68a197a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzgtNy0xLTEtMjA3NzE1_03f7aa45-d72e-43ec-b377-a6c51641540d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i228b85d7ce4e492abb7d118eda50756f_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzktNS0xLTEtMjA3NzE1_687a5079-9a65-41af-b883-010788947f5c">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4208ff78234d48a6b95a64d673fb7301_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzktNy0xLTEtMjA3NzE1_8e0b45de-0432-4319-8bf5-6bdcb74838a8">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i490f355f2ecc4859b9a79fb726c9eab2_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEwLTUtMS0xLTIwNzcxNQ_d6ca0437-78cd-4ff4-9103-877d1a766735">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4991ff736cbb4e52a8b67af6a4dd540d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEwLTctMS0xLTIwNzcxNQ_0fa5a535-d87d-4653-86d4-41073401a6b8">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62501d6a5964b1fb2ce175fd8d9ab7a_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzExLTUtMS0xLTIwNzcxNQ_5b58f539-4678-45ab-a17a-f8ed29339ba6">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf32169d53448eaa447c6c6a95ff0ee_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzExLTctMS0xLTIwNzcxNQ_d6e22f5d-a816-4212-a00b-191a8acf1764">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0ec5f9323645c896a31a7b9d2c0ffc_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEyLTUtMS0xLTIwNzcxNQ_fb008817-4817-4cb0-9e6a-e70d918ee878">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7febcf7dfef54f08a344f4e803874e80_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEyLTctMS0xLTIwNzcxNQ_fc6016e9-0c86-4386-ae59-75deb9e9b455">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269a979c418a4bc98d8b0cfceca3b1df_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEzLTUtMS0xLTIwNzcxNQ_bebdb628-a4d3-4fad-92f8-92a8598b236e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3eef7c95b3471bad3220dc8f4e560d_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEzLTctMS0xLTIwNzcxNQ_0d0f1dbe-37ad-497a-880b-00bc7ac3dd8f">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i470bfc29961247a9b005e84b7140ad3c_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE0LTUtMS0xLTIwNzcxNQ_d2a068f5-3e77-4aa8-a5e9-ba02910aa4d2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c45e66c585145df8939a8f99dceb756_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE0LTctMS0xLTIwNzcxNQ_16d7685f-353c-49e9-ab0e-c6a1ca5d7427">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020c8cc6877448239e19574641b420c0_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE1LTUtMS0xLTIwNzcxNQ_1e14d5f1-e8a4-4c10-b0be-f39d46c74265">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb78d4f9fa147ca952eee7a47399459_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE1LTctMS0xLTIwNzcxNQ_b38ac8f5-eace-4021-a993-2c7cd2bcfa5f">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE2LTUtMS0xLTIwNzcxNQ_6d6fb590-54ec-43c6-acab-217d45bccbc2">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE2LTctMS0xLTIwNzcxNQ_4475023a-b5c2-414f-9f1c-a5f5a3c8697f">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div></div><ix:continuation id="i78a38da5a041420d94b693063562d6e1"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2NDY_8a4b33c6-8668-4511-a2de-2d9e2355eb19" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i53c0c9f9a29c4194a26ee2fc5d2a2278_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzItMS0xLTEtMjA3NzE1_5dab22fd-a772-4b01-b7a5-64525ec2e5c3">19</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e7e267a0214438590a982060fcfc8e9_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzItMy0xLTEtMjA3NzE1_f985d5cd-1a76-4ffd-95d4-1ac5c2952ba5">18</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdbf70eb870c4f4c96edf59101416ef8_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzMtMS0xLTEtMjA3NzE1_673ea522-bc87-439a-a949-49f538ea8b3a">14</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i940b858ec7d04ba6b3901bcdc58f422f_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzMtMy0xLTEtMjA3NzE1_fb40a6ea-6c93-486c-a220-eaad726a6ecd">14</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia377fd0a03cc4bc29b88b780401b204b_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzQtMS0xLTEtMjA3NzE1_fa3af1ec-7e3d-45fb-a3b5-d2fab87cf7f8">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia318e977ae6f4e10a9742bbf5ef4c757_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzQtMy0xLTEtMjA3NzE1_fb08546a-e9ce-429e-89ba-a8985b825cc0">13</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_106"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of&#160;Operations</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context otherwise indicates, as used in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;Bausch Health,&#8221; and similar terms refer to Bausch Health Companies Inc. and its subsidiaries, taken together. This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should be read in conjunction with the unaudited interim Condensed Consolidated Financial Statements and the related notes (the &#8220;Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) included elsewhere in this Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2023 (this &#8220;Form 10-Q&#8221;). The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of The Securities Act of 1933, as amended, and Section 21E of The Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning of applicable Canadian securities laws (collectively &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our accompanying unaudited interim Condensed Consolidated Financial Statements as of March&#160;31, 2023 and for the three months ended March 31, 2023 and 2022 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the United States Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial statements, and should be read in conjunction with our Consolidated Financial Statements for the year ended December&#160;31, 2022, which were included in our Annual Report on Form 10-K filed on February&#160;23, 2023. In our opinion, the unaudited interim Condensed Consolidated Financial Statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair statement of the financial condition, results of operations and cash flows for the periods indicated. Additional company information is available on SEDAR at </span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the SEC website at&#160;</span><span style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted. Certain defined terms used herein have the meaning ascribed to them in the Financial Statements. </span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_112"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and aesthetic medical devices, and, through our approximately 89% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. Our products are marketed directly or indirectly in approximately 100 countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products falls into five reportable segments: (i) Salix, (ii) International, (iii) Solta Medical, (iv) Diversified (formerly Diversified Products) and (v) Bausch + Lomb. The following is a brief description of the Company&#8217;s segments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) Dermatology (formerly Ortho Dermatologics) products, (iii) generic pharmaceutical products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:4.5pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our reportable segments, see the subsection &#8220; &#8212; Segment Revenues and Profits&#8221; of Note 18, &#8220;SEGMENT INFORMATION&#8221; to our unaudited interim Condensed Consolidated Financial Statements. </span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_121"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye health business consisting of our Bausch + Lomb global Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporation (&#8220;Bausch + Lomb&#8221; or &#8220;B+L&#8221;) from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On May 5, 2022, the registration statement related to the initial public offering of Bausch +Lomb (the &#8220;B+L IPO&#8221;) was declared effective, and B+L&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, B+L was an indirect wholly-owned subsidiary of Bausch Health. On May 10, 2022, a wholly owned subsidiary of the Bausch Health sold 35,000,000 common shares of B+L pursuant to the B+L IPO. Upon the closing of the B+L IPO and after giving effect to the subsequent partial exercise of the over-allotment option by the underwriters, Bausch Health indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 89% of B+L&#8217;s outstanding common shares as of the date of this filing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continue to believe that completing the B+L Separation makes strategic sense. The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. We continue to evaluate all relevant factors and considerations related to the B+L Separation, including the effect of the Norwich Legal Decision (see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Condensed Consolidated Financial Statements) on the B+L Separation.&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Separation, if consummated, will result in two separate, independent companies:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Health excluding Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, hepatology, dermatology, neurology and international pharmaceuticals, and aesthetic medical devices. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics, and aesthetic medical devices businesses; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated eye health company built on the iconic Bausch + Lomb brand and long history of innovation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As independent entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs. Further, the B+L Separation will allow us and the market to compare the operating results of each entity with other peer companies. Although management believes the B+L Separation will unlock value, there can be no assurance that it will be successful in doing so.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors &#8212; Risk Relating to the B+L Separation&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023, for additional risks relating to the B+L Separation.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Focus on Value and Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to execute on a multi-year plan designed to transform and bring out value in our Company, which includes focus on, among other factors, our: product portfolio, infrastructure, geographic footprint, capital structure and risk management. We believe that these and other actions we have taken have helped to focus our operations and improve our capital structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. In line with this focus on our core businesses, we have: (i) made measurable progress in effectively managing our capital structure, including taking actions to reduce the principal balances of our long-term debt, (ii) directed capital allocation to drive growth within these core businesses, (iii) divested assets to improve our capital structure and simplify our business, (iv) resolved certain of the Company&#8217;s legacy litigation matters originating back to 2015 and prior, (v) increased our efforts to improve patient access and (vi) continued to invest in sustainable growth drivers to position us for long-term growth.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other actions we have taken to transform our Company, have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters. We believe that these measures, along with our continued commitment to improving people&#8217;s lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our eye health and pharmaceutical businesses.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement of the B+L Separation, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, as such, it is a primary objective of our plan of separation. For additional details on the B+L Separation, see &#8220;Separation of the Bausch + Lomb Eye Health Business&#8221; in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our unaudited interim Condensed Consolidated Financial Statements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Managing Our Capital Structure in 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we reduced the aggregate principal amount of our debt obligations by approximately $3,800&#160;million, as we: (i) utilized the net proceeds from the B+L IPO which closed on May 10, 2022, to make repayments of debt, (ii) reduced our debt through open market repurchases of debt with a principal value of approximately $927 million for approximately $550 million, (iii) extended the maturities of our debt through refinancing and (iv) completed an exchange offer which reduced the outstanding principal balance of our debt by $2,469&#160;million by exchanging $5,594&#160;million of aggregate principal value of existing unsecured senior notes (the &#8220;Existing Unsecured Senior Notes&#8221;) for newly issued secured notes with an aggregate principal balance of $3,125&#160;million (the &#8220;Exchange Offer&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The B+L IPO, 2022 Notes Issuance and Credit Agreement Refinancing - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L IPO, we completed a series of transactions in support of our commitment to improve our liquidity, reduce our leverage and better capitalize the two business entities post-separation. These transactions included:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 10, 2022, the Company issued $1,000 million aggregate principal amount of 6.125% Senior Secured Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due February 2027 (the &#8220;February 2027 Secured Notes&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 10, 2022: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The B+L IPO closed, with aggregate net proceeds (including the partial exercise of the over-allotment option by the underwriters), after deducting underwriting commissions, of approximately $675&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company entered into the 2022 Amended Credit Agreement as defined and discussed in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements. The 2022 Amended Credit Agreement consists of new term loans of $2,500 million and a revolving credit facility of $975 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bausch + Lomb entered into the B+L Credit Agreement, as defined and discussed in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements. The B+L Credit Agreement provides for a five-year term loan facility in an initial principal amount of $2,500 million and also provides for a five-year revolving credit facility of $500 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from these transactions, along with cash on hand, allowed us to: (i) repay certain amounts outstanding under our then existing June 2025 Term Loan B Facility and November 2025 Term Loan B Facility (each as defined and discussed in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements, (ii) replace our existing revolving credit facility which was due to mature in 2023, with revolving credit facilities that mature in 2027, (iii) redeem in full all of our then outstanding 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221;) and (iv) replace our then remaining amounts outstanding under our June 2025 Term Loan B Facility and November 2025 Term Loan B Facility with term loan facilities that were to expire in 2027. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Extinguishment of Debt - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, through a series of transactions we repurchased and retired outstanding senior unsecured notes with an aggregate par value of $927 million in the open market for approximately $550 million using: (i) the net proceeds from the partial exercise of the over-allotment option in the B+L IPO by the underwriters, after deducting underwriting commissions, (ii) amounts available under our revolving credit facility and (iii) cash on hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Offer - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in further detail below under &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221;, we made the strategic decision based on the fair value of our Senior Unsecured Notes to undertake the Exchange Offer in September 2022. We exchanged certain validly tendered existing senior unsecured notes, with an aggregate outstanding principal balance of approximately $5,594&#160;million with maturities of 2025 through 2031 for newly issued senior secured notes, with an aggregate principal balance of approximately $3,125 million with maturities of 2028 and 2030. After fees and expenses, the Exchange Offer reduced the principal balances of our outstanding debt obligations by $2,469 million and extended the maturities of approximately $2,400 million of principal balances coming due during the years 2025 through 2027 to the years 2028 and 2030.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#8220;11.00% First Lien Secured Notes&#8221;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#8220;14.00% Second Lien Secured Notes&#8221;, and, together with the 11.00% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#8220;9.00% </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intermediate Holdco Secured Notes&#8221;, and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of our principal balances of debt obligations as of March 31, 2023 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:19.176%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.962%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.122%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions improve our overall capitalization and leverage. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements and &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; below for additional discussion of these matters. Cash requirements for future debt repayments including interest can be found in &#8220;&#8212; Liquidity and Capital Resources &#8212; Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Continue to Manage our Capital Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. The Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_130"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is also driven by our long-term growth strategies. We allocate resources to promote our core businesses globally through: (i) strategic acquisitions, (ii) research and development (&#8220;R&amp;D&#8221;) investment, (iii) strategic licensing agreements and (iv) strategic investments in our infrastructure. We believe that the outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_136"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&amp;D Investment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We search for new product opportunities through internal development and strategic licensing agreements, that, if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&amp;D organization focuses on the development of products through clinical trials. As of December 31, 2022, approximately 1,300 dedicated R&amp;D and quality assurance employees in 25 R&amp;D facilities were involved in our R&amp;D efforts internally.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had approximately 100 projects in our global pipeline. Certain core internal R&amp;D projects that have received a significant portion of our R&amp;D investment in current and prior periods are listed below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gastrointestinal </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Rifaximin - </span></div><div style="padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Two global Phase 3 studies for the use of a rifaximin soluble solid dispersion (&#8220;SSD&#8221;) formulation for the prevention of overt hepatic encephalopathy (&#8220;OHE&#8221;) in patients with early decompensation in liver cirrhosis (RED-C) have commenced and are actively enrolling. Based on the top line results of a Phase 2 study, patients receiving 40 mg twice daily showed a statistically significant separation from placebo. We have completed scientific advisory meetings with the Medicines Evaluation Board in the Netherlands and with Health Canada, with plans to meet with authorities in Japan and China later this year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Recently received orphan drug designation for sickle cell disease. A phase 2 study with novel dosage formulation is currently enrolling patients for the treatment of sickle cell disease.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:49.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or &#8220;SIBO&#8221;, is continuing in 2023 and will be validated in an upcoming clinical trial.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Amiselimod (S1P modulator) - A Phase 2 study to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis is actively enrolling and is expected to finish later in 2023.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Next generation Clear + Brilliant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;laser designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths with submissions in Europe and Canada planned in 2024, and in Asia Pacific markets in 2025. Also, Next Generation Fraxel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fractionated laser device for skin resurfacing is planned for FDA submission later in 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Internal Development Project (&#8220;IDP&#8221;) 120 - An acne product with a fixed combination of mutually incompatible ingredients: benzoyl peroxide and tretinoin. Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. The FDA has accepted our New Drug Application (&#8220;NDA&#8221;) with an October 20, 2023 Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) date. We also have plans for a Canada submission in the second quarter of 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. To date, SiHy Daily has been launched in approximately 25 countries, under the branded name INFUSE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ultra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY and AQUALOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. Bausch + Lomb plans to launch its SiHy Daily lenses into additional countries throughout 2023 and expects to launch a multi-focal and toric lens in 2023 and 2024, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">LUMIFY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. To date, Bausch + Lomb has launched and acquired the right to launch Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in various countries. Bausch + Lomb also has several innovative new line extension formulations under development, including Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Illuminations which, Bausch + Lomb expects to launch soon, Lumify Preservative Free, for which an NDA is expected to be submitted to the FDA during 2023 and Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Allergy, for which an NDA is expected to be submitted to the FDA during 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb is expanding its portfolio of premium intraocular lenses (&#8220;IOL&#8221;) built on the enVista</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with Aspire</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Monofocal Plus), Envy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trifocal and BEYOND</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (extended depth of focus (&#8220;EDOF&#8221;)) optical designs with two options: non-Toric and Toric for astigmatism patients. Bausch + Lomb expects that they will be commercialized together with a new preloaded EyeGility inserter. Bausch + Lomb anticipates launching Monofocal Plus, Trifocal and EDOF optical designs for presbyopia in the U.S. in 2023, 2024 and 2025/2026, respectively.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_139"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&amp;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_133"></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Acquisitions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as &#8220;bolt on&#8221; acquisitions. In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During January 2023, Bausch + Lomb acquired AcuFocus, Inc., an ophthalmic medical device company that has delivered small aperture intraocular technology to address the diverse unmet needs in eye care. The IC-8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Apthera&#8482; IOL was approved by the FDA in July 2022 as the first and only small aperture non-toric EDOF IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and wish to address presbyopia at the same time. Bausch + Lomb believes the IC-8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Apthera&#8482; EDOF IOL will bolster its surgical portfolio by enhancing the IOL offerings, which is a strategic area of focus for Bausch + Lomb.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_148"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Team</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We formed the Patient Access and Pricing Team which is committed to maintaining patients ability to access our branded prescription pharmaceutical products. All future pricing actions will be subject to review by the Patient Access and Pricing Team. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to supporting patients through our Patient Assistance Program which offers free medication for patients who meet income and other eligibility criteria. If approved, patients receive their Bausch Health prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The cash-pay program was adopted to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings. This program is currently limited to a select group of our brands and offered through our unique telemedicine platform which allows for patients to choose direct delivery to their home or to use a pharmacy of their choice. This program is designed to connect patients with dermatologists and provide patients both a predictable customer experience and a predictable cost for their dermatology health care needs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Under our brand fulfillment arrangement with Walgreen Co. (&#8220;Walgreens&#8221;), we make certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_151"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market. Our investment in R&amp;D reflects our commitment to drive organic growth through internal development of new products and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. We continue to make strategic investments to drive revenue growth and build our R&amp;D pipeline to ultimately bring products that serve patient needs. We believe we have a robust pipeline that not only provides for the next generation of our existing products but is also poised to bring new products to market. To that end, we have identified key growth drivers across all our business segments and where we see significant opportunity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Focus on Core Business in 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain focused on growth, through innovation increasing the size, breadth and depth of our product pipeline through R&amp;D and strategic business development.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our key investment priorities for 2023 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing investment in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to further capitalize on the value of the infrastructure we have built around these products to extend our market share. We are increasing our investment in Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> direct-to-consumer (&#8220;DTC&#8221;) advertising and new sales force capabilities. We also continue to invest in our product line. Our rifaximin SSD formulation, is under development for the prevention of OHE and other complications in patients with early decompensation in liver cirrhosis (RED-C). The drug candidate is administered orally, and is a next-generation rifaximin formulation that acts by targeting beta-subunit of bacterial DNA-dependent RNA polymerase.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our International product portfolio consists of several new launches including Ryaltris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for moderate to severe seasonal allergic rhinitis and Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an aerosol foam for distal ulcerative colitis in Canada. We are also pursuing opportunities in the dermatology markets globally for products that address acne, atopic dermatitis, psoriasis and onychomycosis. To address these and other opportunities we continue to invest in the training and expansion of our sales and marketing teams.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - More than 70% of our Solta Medical business revenues come from consumables, which we believe results in a durable business model. We continue to invest in expanding our presence in key markets, including broadening the reach of our DTC campaigns in the U.S., the expansion of Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> FLX and the strengthening of our sales force in the U.S. and Europe.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We continue to seek out ways to bring out value in our promoted and nonpromoted products within our Diversified portfolios. In 2023 we anticipate making additional investments in the marketing and advertising of Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as the only approved major depressive disorder product for Seasonal Affective Disorder, and also expanding our consumer awareness campaign for Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, in support of our established acne product portfolio we also have a project in our pipeline, IDP-126, which is a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. The FDA has accepted our NDA with an October 20, 2023 PDUFA date. In our generics portfolio, we are focused on effectively managing this portfolio of non-promoted products. In our Dentistry business, we are increasing our investments in Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> direct to patient activation and awareness campaigns. </span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_154"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Trends</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends. The matters discussed in this section contain forward-looking statements. Please see &#8220;Forward-Looking Statements&#8221; at the end of Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for additional information.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_157"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. As military activity and sanctions against Russia, Belarus and specific areas of Ukraine have continued, the war has increasingly affected economic and global financial markets and exacerbated ongoing economic challenges, including issues such as high levels of inflation and global supply-chain disruption. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues attributable to Russia, Ukraine and Belarus, in the aggregate, were approximately $37 million and $29 million for three months ended March 31, 2023 and 2022, respectively. The Company does not have any research or manufacturing facilities in Russia, Ukraine or Belarus. To date, the Russia-Ukraine war has not had a material impact on our business, however we are not able to determine the ultimate future direct or indirect impacts this war may have on our business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other risks relating to our international business, see Item 1A. &#8220;Risk Factors &#8212; Risk Relating to the Russia and Ukraine conflict&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_160"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Update </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the outbreak of the omicron variant in China resulted in government enforced lockdowns and other social restrictions, which impacted our ability to conduct business as usual in certain regions in China, particularly Shanghai. The lockdowns in China had impacted the demand for certain products, particularly B+L&#8217;s Vision care and our Solta Medical products, as shelter in place orders limited the demand and need for the use of contact lenses and related products as well as for aesthetic medical treatments. Additionally, government enforced lockdowns caused certain businesses to suspend operations, creating distribution and other logistic issues for the distribution of our products and the sourcing for a limited number of raw materials. These lockdowns began to ease during the fourth quarter of 2022 and our revenues in China for the three months ended March 31, 2023 and 2022 were $88&#160;million and $103&#160;million, respectively, a decrease of $15&#160;million. To date, we have dealt with these issues in China with only a minimal impact on our manufacturing and distribution processes and we continue to monitor the impact of COVID-19 on all aspects of our business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. &#8220;Risk Factors &#8212; Risk Relating to COVID-19&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_169"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. Many of these changes focus on health care cost containment, which result in pricing pressures relating to the sales and reimbursements of healthcare products. The Biden Administration and Congress continue to focus on health care cost containment which could result in legislative and regulatory changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we continue to face various proposed health care pricing changes and regulations from governments throughout the world in locations in which we operate our business. These proposed changes may also continue to result in pricing pressures relating to sales, promotions and reimbursement of our product portfolio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rule-making and guidance published by the U.S. Department of Health and Human Services, the FDA, and applicable foreign governments in locations in which we operate; however, at this time, it is unclear the effect these matters may have on our businesses.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_172"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2023 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2023 or in later years. Following a loss of exclusivity (&#8220;LOE&#8221;) of and/or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic (&#8220;AG&#8221;) of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 through 2027 LOE Branded Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and/or competitive information, we have identified branded products that we believe could begin facing potential LOE and/or generic competition in the U.S. during the years 2023 through 2027. These products and year of expected LOE include, but are not limited to, Aplenzin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2026), Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2026), Noritate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2023), Onexton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2023), Prolensa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2023), Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foam (2023) and Xerese</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2023). These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and/or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the U.S. and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Condensed Consolidated Financial Statements elsewhere in this Form 10-Q, as well as Note 20, &#8220;LEGAL PROCEEDINGS&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023 for further details regarding certain infringement proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending the Company&#8217;s patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company&#8217;s pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future. We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A &#8220;Risk Factors&#8221; of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on our competition risks.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_175"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. In August 2022, we received a non-compliant rating from Health Canada related to our pharmaceutical manufacturing facility in Laval, Quebec. This rating was received without any restrictive conditions on plant operations so the production of important treatments for Canadians and for export was able to continue without interruption. A subsequent inspection of the Laval facility by Health Canada during March 2023 resulted in the issuance of a compliant rating.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and all operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_178"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides selected unaudited financial information for the three months ended March 31, 2023 and 2022: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.286%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of the Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the three months ended March 31, 2023 and 2022 were $1,944 million and $1,918 million, respectively, an increase of $26 million, or 1%. The increase was primarily due to growth in: (i) the Bausch + Lomb segment driven by improved net pricing and higher volumes and (ii) the Salix segment driven by higher volumes partially offset by: (i) lower revenues in our Diversified segment and (ii) the unfavorable impact of foreign currencies, primarily in Europe and Asia.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for the three months ended March 31, 2023 and 2022 was $175 million and $285&#160;million, respectively, and included non-cash charges for Depreciation and amortization of intangible assets of $319 million and $352 million, Asset impairments of $13 million and $8 million and Share-based compensation of $41&#160;million and $32 million, respectively. The decrease in our operating results of $110 million reflects, among other factors:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (Product sales revenue less Cost of goods sold, excluding amortization and impairments of intangible assets) of $5 million;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in selling, general and administrative (&#8220;SG&amp;A&#8221;) of $103 million primarily attributable to: (i) higher compensation expenses, (ii) higher advertising and promotion expenses and (iii) certain administrative expenses, partially offset by the favorable impact of foreign currencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&amp;D expenses of $16 million primarily attributable to higher spend on certain Salix projects;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $37 million primarily attributable to fully amortized intangible assets no longer being amortized in 2023;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Asset impairments of $5 million during the three months ended March 31, 2023; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an unfavorable change in Other expense, net of $21 million, primarily attributable to adjustments to reflect changes in estimates of the liability for Acquisition-related contingent consideration.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss before income taxes for the three months ended March 31, 2023 and 2022 was $136 million and $82&#160;million, respectively, an increase of $54 million. The increase in our Loss before income taxes is primarily attributable to the decrease in our operating results of $110 million, as previously discussed, partially offset by a decrease in Interest expense of $55 million. The decrease in interest expense is due to the impact of the accounting treatment for a portion of interest payments on the New Secured Notes, which reduced reported interest expense by $74 million relative to contractual interest cost. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health for the three months ended March 31, 2023 and 2022 was $201&#160;million and $69&#160;million, respectively, an increase of $132 million. This was primarily due to the increase in our Loss before income taxes of $54 million as previously discussed, and an unfavorable change in income taxes of $89 million.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_184"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited operating results for the three months ended March 31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:0.8pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.619%"><tr><td style="width:1.0%"></td><td style="width:70.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.436%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.867%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Provision for) benefit from income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_187"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three Months Ended March 31, 2023 Compared to the Three Months Ended March 31, 2022 </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue which is derived primarily from contract manufacturing for third parties and which is not material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $1,944 million and $1,918 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $26 million, or 1%. The increase was primarily due to: (i) an increase in volumes of $78 million in the Salix, Bausch + Lomb and Solta Medical segments and (ii) incremental sales attributable to acquisitions of $2 million, partially offset by: (i) the unfavorable impact of foreign currencies of $40 million, primarily in Europe and Asia, (ii) a decrease in net realized pricing of $9 million and (iii) the impact of divestitures and discontinuations of $5 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our segment revenues and segment profits for the three months ended March 31, 2023, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits.&#8221;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 3, &#8220;REVENUE RECOGNITION&#8221; to our unaudited interim Condensed Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available. Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate. Provisions recorded to reduce gross product sales to net product sales and revenues for the three months ended March 31, 2023 and 2022 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 41.7% and 40.0% for the three months ended March 31, 2023 and 2022, respectively, an increase of 1.7 percentage points due primarily to the following factors: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns were higher primarily due to reductions in the estimates of variable consideration for sales returns related to past sales in 2022. The Company continues to focus on maximizing operational efficiencies and actions to reduce product returns, including, but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due to an increase in gross product sales and higher rebate rates for certain branded products such as Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by lower gross product sales for certain branded products such as Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .06%, Retin-A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Microsphere .08% and Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were lower primarily due to lower gross product sales of certain generic products such as Nifediac and certain branded generics such as Apriso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Targretin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Cuprimine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG. These decreases were partially offset by: (i) increased gross product sales of our GI products Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) higher chargeback rates for certain generics and branded generics; and</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were higher primarily due to higher gross product sales of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Price appreciation credits are offset against distribution service fees when due to wholesalers. There were no price appreciation credits for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes: manufacturing and packaging; the cost of products we purchase from third parties; royalty payments we make to third parties; depreciation of manufacturing facilities and equipment; and lower of cost or market adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $572 million and $536 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $36 million, or 7%. The increase was primarily driven by the increase in volumes as previously discussed, partially offset by: (i) lower unfavorable manufacturing variances and (ii) the favorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of product sales revenue were 29.8% and 28.3% for the three months ended March 31, 2023 and 2022, respectively, an increase of 1.5 percentage points. Cost of goods sold as a percentage of product sales revenue was unfavorably impacted by: (i) changes in product mix, (ii) inflationary pressures and (iii) lower net realized pricing, as discussed above, partially offset by: (i) lower unfavorable manufacturing variances and (ii) the favorable impact of foreign currencies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses primarily include: employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions; certain outside legal fees and consultancy costs; product promotion expenses; overhead and occupancy costs; depreciation of corporate facilities and equipment; and other general and administrative costs. The Company has incurred, and expects to continue to incur incremental costs with respect to the B+L Separation. During 2022, the Company also incurred incremental costs indirectly related to the suspended Solta IPO. These separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses were $725 million and $622 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $103 million, or 17%. The increase was primarily attributable to higher: (i) advertising and promotion, (ii) compensation and (iii) certain administrative expenses, due in part to incremental costs associated with the separation of certain functions in connection with the B+L Separation. These increases were partially offset by: (i) lower separation-related and IPO-related costs and (ii) the favorable impact of foreign currencies. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include: employee compensation costs; overhead and occupancy costs; depreciation of research and development facilities and equipment; clinical trial costs; clinical manufacturing and scale-up costs; and other third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include: employee compensation costs; overhead and occupancy costs; amortization of software; and other third-party costs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses were $143 million and $127 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $16 million, or 13%. The increase was primarily attributable to higher spend on certain Salix projects. R&amp;D expenses as a percentage of Product sales were approximately 7% for each of the three months ended March 31, 2023 and 2022. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 1 to 20 years. Management continually assesses the useful lives related to the Company&#8217;s long-lived assets to reflect the most current assumptions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $273 million and $310 million for the three months ended March 31, 2023 and 2022, respectively, a decrease of $37 million. The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Condensed Consolidated Financial Statements for further details related to our intangible assets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset impairments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Condensed Consolidated Statements of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses and research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments were $13 million and $8 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $5 million. Asset impairments for the three months ended March 31, 2023 of $13 million was related to $8&#160;million, in aggregate, attributable to certain trade names no longer in use and $5&#160;million, related to the discontinuance of a certain product line. Asset impairments for the three months ended March 31, 2022 were $8 million due to discontinuances and decreases in the forecasted sales of certain product lines. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Foam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- On April 12, 2023, the FDA approved an ANDA, submitted by a competitor, for a budesonide (a steroid (cortisone-like) medicine) foam to help treat mild to moderate active ulcerative colitis. This product is a generic version of our Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foam product. Revenues for our branded Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foam product were $2 million for the three months ended March 31, 2023 and $6 million and $7 million for the years 2022 and 2021, respectively. As of March 31, 2023, our intangible assets associated with Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foam have a net book value of approximately $45 million. We continue to evaluate the potential impacts of this generic entrant on our business strategy for our Uceris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Foam product. It is possible that any changes to our business strategy and related forecast for this product could result in impairment charges in one or more future periods, and such charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Condensed Consolidated Financial Statements for further details related to our intangible assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $10 million and $13 million for the three months ended March 31, 2023 and 2022, respectively, a decrease of $3 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $9 million and $3&#160;million for the three months ended March 31, 2023 and 2022, respectively. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur costs associated with activities relating to the B+L Separation. In 2022, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and, in 2022, Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and, in 2022, preparing for </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the ongoing B+L Separation and, in 2022, the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb. Separation and IPO costs were $1&#160;million and $10&#160;million for the three months ended March 31, 2023 and 2022, respectively. The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements for further details regarding these actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the three months ended March 31, 2023 and 2022 consists of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, Litigation and other matters primarily relates to an insurance recovery regarding a certain litigation matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of better than expected performance of a branded product during the three months ended March 31, 2023, the Company has revised its long-term sales forecast for that product. Acquisition-related contingent consideration expense for the three months ended March 31, 2023, primarily includes adjustments to reflect the changes in estimates of the future royalty and milestone payments related to that branded product. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization and write-off of debt discounts, premiums and debt issuance costs under our credit facilities and notes as well as the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company&#8217;s cross-currency swaps.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $307 million and $362 million, and included non-cash amortization and write-offs of debt premiums, discounts and deferred issuance costs of $11 million and $14 million, for the three months ended March 31, 2023 and 2022, respectively. Interest expense for the three months ended March 31, 2023 decreased $55 million, or 15%, as compared to the three months ended March 31, 2022, primarily attributable to: (i) the accounting for contractual interest payments on the New Secured Notes, portions of which are recorded as a reduction of related premiums and not as interest expense, which reduced interest expense by $74 million relative to contractual interest cost and (ii) the impact of lower outstanding debt balances in 2023 as compared to 2022, partially offset by higher interest rates. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest as of March&#160;31, 2023 and 2022 was 7.87% and 5.97%, respectively. The increase in the weighted average stated rate of interest of 190 bps is primarily attributable to the New Secured Notes and higher interest rates on our variable rate debt. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements and the section titled &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; for further details.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other primarily includes: (i) translation gains/losses on intercompany loans and third-party liabilities and (ii) the gain/loss due to foreign currency exchange contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a loss of $10&#160;million and $7&#160;million for the three months ended March 31, 2023 and 2022, respectively, an unfavorable net change of $3&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $73 million for the three months ended March 31, 2023, as compared to a benefit from income taxes of $16 million for the three months ended March 31, 2022, an unfavorable change of $89&#160;million. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended March 31, 2023 differs from the statutory Canadian income tax rate primarily due to: (i) the tax provision generated from our annualized mix of earnings by jurisdiction, (ii) the recording of valuation allowances on entities for which no tax benefit of losses is expected and (iii) the discrete treatment of certain tax matters, primarily related to: (a) final and potential settlements of tax audits accrued in the first quarter of 2023, (b) changes in uncertain tax positions, (c) the establishment of a valuation allowance on B+L&#8217;s Canadian parent and (d) changes to the tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate for the three months ended March 31, 2022 differs from the statutory Canadian income tax rate primarily due to: (i) the recording of valuation allowances on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to: (a) changes in uncertain tax positions, (b) adjustments for book to income tax return provisions and (c) a tax deduction for stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15, &#8220;INCOME TAXES&#8221; to our unaudited interim Condensed Consolidated Financial Statements for further details.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_190"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.15pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical aesthetic medical devices. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified (formerly Diversified Products) segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 18, &#8220;SEGMENT INFORMATION&#8221; to our unaudited interim Condensed Consolidated Financial Statements for a reconciliation of segment profit to Loss before income taxes.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues, and the period-over-period changes in segment revenues for the three months ended March 31, 2023 and 2022. The following table also presents segment profits, segment profits as a percentage of segment revenues and the period-over-period changes in segment profits for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits / Segment Profit Margins</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue (non-GAAP) and change in organic revenue (non-GAAP), are defined as GAAP Revenue and change in GAAP revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments, and the Company in total. The Company believes that providing these measures is useful to investors as they provide a supplemental period-to-period comparison.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustments to GAAP Revenue and changes in GAAP revenue to determine organic revenue (non-GAAP) and changes in organic revenue (non-GAAP) are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and organic growth/change exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and the period-over-period changes in organic revenue (non-GAAP) for the three months ended March 31, 2023 and 2022 by segment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:13.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.270%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.037%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in<br/>Organic Revenue (Non-GAAP)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Exchange Rates</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br/>as<br/>Reported</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Divestitures <br/>and Discontinuations</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pct.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line. Revenues from our Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line accounted for approximately 80% of the Salix segment revenues for each of the three months ended March 31, 2023 and 2022. No other single product group represents 10% or more of the Salix segment product sales. Salix segment revenue for the three months ended March 31, 2023 and 2022 was $496 million and $464 million, respectively, an increase of $32 million, or 7%. The increase is attributable to an increase in volumes of $50 million, primarily driven by Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, partially offset by a decrease in net realized pricing of $18 million primarily attributable to reductions in 2022 of the estimates of variable consideration for sales returns related to past sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit for the three months ended March 31, 2023 and 2022 was $314&#160;million and $322&#160;million, respectively, a decrease of $8&#160;million, or 2%. The decrease was primarily driven by higher: (i) advertising and promotion, (ii) selling and (iii) R&amp;D expenses, partially offset by an increase in contribution attributable to the increase in revenues, as previously discussed. The increase in Salix&#8217;s operating expenses is primarily attributable to our investments in: (i) DTC advertising for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) new sales force capabilities and (iii) R&amp;D expense, including for our global RED-C program, a Phase 3 study for our formulation of rifaximin SSD for the prevention of HE and other complications with early decompensated liver cirrhosis, as previously discussed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $247 million and $244 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $3 million, or 1%. The increase was primarily attributable to increase in net realized pricing of $12 million, partially offset by the unfavorable impact of foreign currencies of $6 million, primarily in Europe and the impact of divestitures and discontinuations of $3 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for the three months ended March 31, 2023 and 2022 was $77 million and $91&#160;million, respectively, a decrease of $14 million, or 15%. The decrease was primarily attributable to an increase in General and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment includes the Thermage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for approximately 80% of the Solta Medical segment revenues for each of the three months ended March 31, 2023 and 2022. No other single product group represents 10% or more of the Solta Medical segment revenues. The Solta Medical segment revenue for the three months ended March 31, 2023 and 2022 was $73&#160;million and $72&#160;million, respectively, an increase of $1&#160;million, or 1%. The increase was primarily attributable to higher volumes of $4 million, partially offset by the unfavorable impact of foreign currencies of $3&#160;million. The increase in volumes is primarily attributable to the Asia-Pacific region excluding China, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by the impact of government enforced COVID-19 pandemic related shutdowns in China, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit for the three months ended March 31, 2023 and 2022 was $36 million and $35&#160;million, respectively, an increase of $1 million, or 3%. The increase was primarily attributable to the increase in revenues, as previously discussed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Segment Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified segment revenue for the three months ended March 31, 2023 and 2022 was $197 million and $249 million, respectively, a decrease of $52 million, or 21%. The decrease was primarily driven by decreases in: (i) net realized pricing of $34 million and (ii) volumes of $18 million, across our Neurology and other, Dermatology and Generics businesses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Segment Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified segment profit for the three months ended March 31, 2023 and 2022 was $107 million and $158&#160;million, respectively, a decrease of $51 million, or 32%. The decrease was primarily driven by lower contribution attributable to the net decrease in revenues, as previously discussed, partially offset by lower general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its product sales. The Bausch + Lomb segment revenue was $931 million and $889 million for the three months ended March 31, 2023 and 2022, respectively, an increase of $42 million, or 5%. The increase was attributable to: (i) increase in volumes of $42 million, (ii) net realized pricing of $31 million primarily within the Vision Care business and (iii) incremental sales attributable to acquisitions of $2 million within the Surgical business, partially offset by: (i) the unfavorable impact of foreign currencies across the Bausch + Lomb international businesses of $31 million, primarily in Asia and Europe and (ii) the impact of divestitures and discontinuations of $2 million, related to the discontinuation of certain products within the Surgical business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit for the three months ended March 31, 2023 and 2022 was $211&#160;million and $206&#160;million, respectively, an increase of $5 million, or 2%. The increase was primarily driven by higher contribution, attributable to the increase in revenues, as previously discussed, partially offset by an increase in selling expenses, attributable to higher warehousing and distribution costs, primarily driven by inflationary pressures.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_199"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:69.838%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in) operating activities before changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(401)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,528)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,929)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided operating activities was $154 million for the three months ended March 31, 2023, as compared to net cash used in operating activities of $63 million for the three months ended March 31, 2022, an increase of $217 million. The increase was attributable to the increase in Cash provided by operating activities before changes in operating assets and liabilities, partially offset by the reduction in cash from Changes in operating assets and liabilities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities before changes in operating assets and liabilities was $215 million for the three months ended March 31, 2023, as compared to Cash used in operating activities before changes in operating assets and liabilities of $79 million for the three months ended March 31 2022, an increase of $294 million. The increase is primarily attributable to: (i) a decrease in payments of accrued legal settlements related to the Glumetza Antitrust Litigation paid during the first quarter of 2022, (ii) changes in business performance and (iii) lower payments of interest included in Operating Activities as, due to the accounting treatment for the debt exchange, the portion of contractual interest payments on the New Secured Notes which reduce the premium on the New Secured Notes is reported as a Financing activity. During the three months ended March 31, 2023, contractual interest payments on the New Secured Notes allocated to the reduction of the recorded premium were $111&#160;million and are included in Cash flows from financing activities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $61 million for the three months ended March 31, 2023, as compared to a net increase in cash of $16 million for the three months ended March 31, 2022, a decrease of $77 million. During the three months ended March 31, 2023, Changes in operating assets and liabilities were negatively impacted by: (i) an increase in inventories of $128 million and (ii) the timing of other payments in the ordinary course of business of $41&#160;million, partially offset by the timing of collection of trade receivables of $108 million. During the three months ended March 31, 2022, Changes in operating assets and liabilities was positively impacted by: (i) the collection of trade receivables of $197 million and (ii) an increase in accrued interest due to timing of payments of $44&#160;million, partially offset by: (i) the timing of other payments in the ordinary course of business of $152&#160;million and (ii) an increase in inventories of $73 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $78 million for the three months ended March 31, 2023 and was primarily driven by Purchases of property, plant and equipment of $47 million and acquisitions and other investments of $31 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $56 million for the three months ended March 31, 2022 and was primarily driven by Purchases of property, plant and equipment of $46 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $142 million for the three months ended March 31, 2023 and was primarily driven by the repayment of long-term debt of $279 million which includes: (i) the $111&#160;million of contractual interest </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments on the New Secured Notes allocated to the reduction of the recorded premiums, as discussed above, (ii) the repayment of $130 million of amounts outstanding under our 2027 Revolving Credit Facility and (iii) payments of $37 million on the Term Loan B Facilities, partially offset by draws under the 2027 Revolving Credit Facility and the B+L Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $468 million for the three months ended March 31, 2022 and was primarily driven by the issuance of long-term debt, net of discounts, of $986 million of February 2027 Secured Notes, partially offset by the repayment of long-term debt of $485 million related to: (i) the repayment of the outstanding balance under its 2023 Revolving Credit Facility and (ii) the repayment of long-term debt of $200 million of its June 2025 Term Loan B Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements for additional information regarding the financing activities described above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity or equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for at least the twelve months following the issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance, repurchase or exchange existing debt or issue equity or equity-linked securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash as presented in the Condensed Consolidated Balance Sheet as of March 31, 2023 includes $358&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operating, investing and financing activities of Bausch + Lomb is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $20,653 million and $20,766 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively. Aggregate contractual principal amounts due under our debt obligations were $19,097 million and $19,110 million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, a decrease of $13 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements for additional information regarding long term debt.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for the Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. As a result of the application of this accounting, the difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. The portion of each contractual interest payment allocated to reduce the recorded premium is determined as the difference between the payment due and the calculated interest at the effective interest rate of the underlying carry amount of the associated note. During the first quarter of 2023, the Company made contractual interest payments of $128&#160;million related to the New Secured Notes, of which $111&#160;million was recorded as a reduction of the recorded premium. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future scheduled contractual interest payments of the New Secured Notes. Contractual interest payments will be allocated to the reduction of the recorded premium and interest expense as presented below. The amount of interest which reduces the recorded premium will be reported as a financing activity in the Condensed Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.608%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.493%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes due 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes due 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00% Intermediate Holdco Secured Notes due 2028 </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments recorded as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reduction of recorded premium</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes (as defined in Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our unaudited interim Condensed Consolidated Financial Statements) issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the 2022 Amended Credit Agreement. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the 2022 Amended Credit Agreement. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. In connection with the closing of the B+L IPO, the discharge of the April 2025 Unsecured Notes Indenture and the related release under the 2022 Amended Credit Agreement described above, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $12,875 million and total liabilities of $5,526 million as of March 31, 2023, and revenues of $1,036 million and operating income of $3 million for the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Availability Under Revolving Credit Facilities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, May&#160;4, 2023, there were $445&#160;million of outstanding borrowings, $23&#160;million of issued and outstanding letters of credit and approximately $507&#160;million of remaining availability under the 2027 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this filing, May&#160;4, 2023, there were $100 million of outstanding borrowings, $24 million of issued and outstanding letters of credit and $376 million remaining availability under the B+L Revolving Credit Facility. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of any other subsidiaries of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our 2022 Amended Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our 2022 Amended Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s indentures. In connection therewith, Bausch + Lomb and its subsidiaries are unrestricted subsidiaries of the Company and, as a result, are not subject to the covenants under the relevant Bausch Health indentures, and the earnings and debt of Bausch + Lomb, as defined in the relevant indentures, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the Company was in compliance with its financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations for at least the twelve months following the date of issuance of this Form 10-Q.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to seek to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common shares of Bausch + Lomb, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for the Exchange Offer results in the New Secured Notes being carried at a premium relative to their principal amount and will result in no interest expense to be recorded in our financial statements for a significant portion of the New Secured Notes. Therefore, interest expense recorded in our financial statements will differ significantly from the contractual interest rates of the New Secured Notes and term loan facilities. The weighted average interest rate of our debt as reported in our financial statements and the weighted average stated rate of interest was 6.26% and 7.87%, respectively, as of March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and it continues to be a primary objective of our plan of separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Rating</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;4, 2023, the credit ratings and outlook from Moody&#8217;s, Standard &amp; Poor&#8217;s (&#8220;S&amp;P&#8217;s&#8221;) and Fitch for certain outstanding obligations of the Company were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:15.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caa1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ca</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard &amp; Poor&#8217;s</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC+</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Negative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Positive</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fitch</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No Outlook</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BB-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rating Watch Evolving</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Bausch Health Companies Inc. -</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> During the first quarter of 2023, S&amp;P&#8217;s lowered our corporate ratings one notch and changed its outlook to negative. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Bausch + Lomb Corporation - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no changes to the corporate credit ratings of Bausch + Lomb Corporation during the first quarter of 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_202"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material effect on our results of operations, financial condition, capital expenditures, liquidity or capital resources. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our cash requirements for the remainder of 2023 are for debt service. Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and/or to make strategic acquisitions. We regularly consider licensing and acquisition opportunities within our core therapeutic areas, some of which could be sizable.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of March&#160;31, 2023, we expect our primary cash requirements during the remainder of 2023 to include:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments and interest payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Based on our debt portfolio as of May&#160;4, 2023, we anticipate making mandatory amortization and interest payments of approximately $1,189&#160;million during the period April 1, 2023 through December 31, 2023. We have, and in the future may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $230 million for property, plant and equipment during the period April 1, 2023 through December 31, 2023;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration payments of approximately $80&#160;million during the period April 1, 2023 through December 31, 2023. These payments include a potential $45 million payment in connection with our agreement with Novaliq GmbH should the FDA approve our NDA for NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGM. If approved, we anticipate launching NOV03 in the U.S. in the second half of 2023; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $6&#160;million during the period April 1, 2023 through December 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings. As of March 31, 2023, the Company&#8217;s Condensed Consolidated Balance Sheet includes accrued loss contingencies of $326 million related to matters which are both probable and reasonably estimable, however, a reliable estimate of the period in which the remaining loss contingencies will be payable, if&#160;ever, cannot be made. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Condensed Consolidated Financial Statements for further details. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 4, &#8220;LICENSING AGREEMENTS AND ACQUISITION&#8221; to our unaudited interim Condensed Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company had unrecognized tax benefits totaling $901 million, of which, $5&#160;million is expected to be realized during the remainder of 2023, however a reliable estimate of the period in which the remaining uncertain tax positions will be payable, if&#160;ever, cannot be made. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Repurchases of Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, we may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the contractual obligations disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Off-Balance Sheet Arrangements and Contractual Obligations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares trade on the New&#160;York Stock Exchange and the Toronto Stock Exchange under the symbol &#8220;BHC&#8221;. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At April&#160;28, 2023, we had 363,723,880 issued and outstanding common shares. In addition, as of April&#160;28, 2023, we had outstanding 11,659,087 stock options and 11,168,222 time-based restricted share units that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 735,711 performance-based restricted share units that represent the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. A maximum of 1,471,423 common shares could be issued upon vesting of the performance-based restricted share units outstanding.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_208"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our financial statements, and which require management&#8217;s most subjective and complex judgment due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. Management has reassessed the critical accounting policies and estimates as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Critical Accounting Policies and Estimates&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023, and determined that there were no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Goodwill Assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No events occurred, or circumstances changed during the three months ended March 31, 2023, that indicated that the fair value of any reporting unit might be below its respective carrying value. However, as a result of certain market conditions, macroeconomic factors and other business specific related factors that existed in 2022, the Company continues to monitor changes in the facts and circumstances which may impact the fair value of its Dermatology, Salix and Neurology and other reporting units.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment of goodwill in 2022, the Dermatology reporting unit had no headroom on September 30, 2022. As such, we continue to monitor conditions which may impact the valuation of the reporting unit including the reporting unit&#8217;s performance and revisions, if any, to its long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. Our current evaluation of these matters supports our previous expectations for the long-term business performance. Additionally, based on reference interest rates as of March 31, 2023, the Company concluded that discount rates would not have increased as compared to the discount rate used in determining the fair value as of September 30, 2022 when the unit was last tested. Based on our evaluation, we have not identified any changes in facts or circumstances that would suggest that it is more likely than not that the fair value of this reporting unit is less than its carrying value. However, given the limited headroom for this reporting unit, if market conditions deteriorate, or if we are unable to execute on our strategies, it may be necessary to record impairment charges in the future and those charges could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the quantitative fair value testing performed in 2022, the Salix reporting unit had limited headroom as of September 30, 2022. As such, we continue to monitor conditions which may impact the valuation of the reporting unit including the potential impacts of changes in the facts and circumstances of the Norwich Legal Decision, the reporting unit&#8217;s performance and revisions, if any, to its long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. During the period September 30, 2022 through March 31, 2023, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#8217;s assessment as to a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to January 2028, if they are able to launch one at all. Our current evaluation of these matters supports our previous expectations for the long-term business performance. Additionally, based on reference interest rates, the Company concluded that discount rates would not have increased as compared to the discount rate used in determining the fair value as of September 30, 2022 when the unit was last tested. Based on our evaluation, we have not identified any changes in facts or circumstances that would suggest that it is more likely than not that the fair value of this reporting unit is less than its carrying value. However, </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">given the limited headroom for this reporting unit, if we receive a negative outcome to the Norwich Legal Decision, if market conditions deteriorate or if we are unable to execute on our strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurology and Other </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment of goodwill in 2022, the Neurology and Other reporting unit had no headroom on October 1, 2022. As such, we continue to monitor conditions which may impact the valuation of the reporting unit including the reporting unit&#8217;s performance and revisions, if any, to its long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. Our current evaluation of these matters supports our previous expectations for the long-term business performance. Additionally, based on reference interest rates, the Company concluded that discount rates would not have increased as compared to the discount rate used in determining the fair value as of October 1, 2022 when the reporting unit was last tested. Based on our evaluation, we have not identified any changes in facts or circumstances that would suggest that it is more likely than not that the fair value of this reporting unit is less than its carrying value. However, if market conditions deteriorate, or if we are unable to execute on our strategies, it may be necessary to record impairment charges in the future and those charges could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our unaudited interim Condensed Consolidated Financial Statements for further details related to goodwill. </span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_211"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_214"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-Q contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things: our business strategy, business plans and prospects and forecasts and changes thereto; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products; anticipated revenues for our products; expected research and development (&#8220;R&amp;D&#8221;) and marketing spend; our expected primary cash and working capital requirements for this fiscal year and beyond; the Company&#8217;s plans for continued improvement in operational efficiency and the anticipated impact of such plans; our liquidity and our ability to satisfy our debt maturities as they become due; our ability to reduce debt levels; our ability to comply with the financial and other covenants contained in the 2022 Amended Credit Agreement and senior notes indentures; the ability of our subsidiary, Bausch + Lomb, to comply with the financial and other covenants contained in the B+L Credit Agreement; the impact of our distribution, fulfillment and other third-party arrangements; proposed pricing actions; exposure to foreign currency exchange rate changes and interest rate changes; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings; the anticipated impact of the adoption of new accounting standards; general market conditions; our expectations regarding our financial performance, including revenues, expenses, gross margins and income&#160;taxes; our impairment assessments, including the assumptions used therein and the results thereof; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic; the anticipated impact from the ongoing conflict between Russia and Ukraine; and the Company&#8217;s plan to separate its eye health business, including the structure and timing of completing such separation transaction.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. All of the statements in this Form&#160;10-Q that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse impact on our business and operations resulting from the ongoing conflict between Russia and Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants and subvariants), COVID-19 vaccine immunization rates, the emergence of variant and subvariant strains of COVID-19, the resurgence of the COVID-19 virus and variant and subvariant strains thereof (including, but not limited to, the recent resurgence of COVID-19 cases) and any resulting reinstitution of lockdowns and other restrictions, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including, but not limited to, its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition, costs (which may increase) and revenue and margins (both of which may decrease);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges the Company faces as a result of the closing of the B+L IPO, including the transitional services being provided by and to Bausch + Lomb, any potential, actual or perceived conflict of interest of some of our directors and officers because of their equity ownership in Bausch + Lomb and/or because they also serve as directors or officers of Bausch + Lomb and our ability to timely consolidate the financial results of the Bausch + Lomb business; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the B+L Separation, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the B+L Separation, the expected timing of completion of the B+L Separation and its terms, the Company&#8217;s ability to complete the B+L Separation considering the various conditions to the completion of the B+L Separation (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and applicable shareholder and stock exchange approvals), that market or other conditions are no longer favorable to completing the B+L Separation, that the previously announced planned Solta IPO has been suspended, that the Norwich Legal Decision (see &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Paragraph IV Proceedings&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221; to our unaudited interim Condensed Consolidated Financial Statements) may affect the timing of, or our ability to complete the B+L Separation, that applicable shareholder, stock exchange, regulatory or other approvals are not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of, or following, the B+L Separation, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and/or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency and/or the Internal Revenue Service will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the B+L Separation (some of which are beyond their control), limitations on the Company&#8217;s ability to sell a portion of the Company&#8217;s interest in Bausch + Lomb in order to maintain the tax-free status of the B+L Separation (including due to dilution from B+L&#8217;s issuance of share-based compensation awards), other potential tax or other liabilities that may arise as a result of the B+L Separation, the potential dissynergy costs resulting from the B+L Separation, the impact of the B+L Separation on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any B+L Separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing litigation and potential additional litigation, claims, challenges and/or regulatory investigations challenging or otherwise relating to the B+L IPO and the B+L Separation and the costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action and certain opt-out actions in Canada relating to the previously settled class </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2023 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the FDA and equivalent agencies outside of the U.S. and the results thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our senior notes indentures, the 2027 Revolving Credit Facility, the 2022 Amended Credit Agreement, the B+L Credit Agreement and other current or future credit and/or debt agreements, including the ability of Bausch + Lomb to comply with its covenants and obligations under the B+L Credit Agreement, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2027 Revolving Credit Facility, Bausch + Lomb&#8217;s ability to draw down under the revolving credit facility under the B+L Credit Agreement and restrictions on our ability to make certain investments and other restricted payments;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or the 2022 Amended Credit Agreement (and other current or future credit and/or debt agreements) and our ability, if any, to cure or obtain waivers of such default;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2023 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things: (i) a failure to meet the financial and/or other covenants contained in the 2022 Amended Credit Agreement, senior notes indentures and/or the B+L Credit Agreement (and other current or future credit and/or debt agreements) and/or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit directors, executives and other key&#160;employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">factors impacting our ability to stabilize and reposition our Dermatology business to generate additional value, including the success of recently launched products and the approval of pipeline products (and the timing of such approvals);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our 2022 Amended Credit Agreement, the B+L Credit Agreement, our senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products; the impact of obtaining or maintaining such reimbursement on the price and sales of our products; and the launch and implementation of any new pharma-care or dental-care program or related spending by the Canadian federal government;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our eligibility for benefits under tax treaties and the availability of low effective tax rates for the business profits of certain of our subsidiaries;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate; </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations);</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions, including rates of inflation, and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the U.S. and China;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of the ongoing conflict between Russia and Ukraine and the export controls, sanctions and other restrictive actions that have been or may be imposed by the U.S., Canada and other countries against governmental and other entities in Russia, Belarus and parts of Ukraine;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the impact of the United States-Mexico-Canada Agreement (&#8220;USMCA&#8221;) and any potential changes to other trade agreements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith) and the impact of the Norwich Legal Decision on, among other things, our business results, financial results, and the B+L Separation;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully appeal the decision of the U.S. District Court for the District of Delaware in the Company&#8217;s lawsuit against Norwich in connection with Norwich&#8217;s ANDA and challenge Norwich&#8217;s ability to achieve a modified ANDA that avoids the August 10, 2022 final judgement by the District Court and omits the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hepatic encephalopathy (&#8220;HE&#8221;) indication and HE safety data;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fact that a substantial amount of our revenues are derived from the Xifaxan</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, and that we may be materially impacted by the entry of a generic rifaximin product earlier than January 2028, including the risk of a competitor launching a generic rifaximin at risk prior to a final unappealable decision;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co., including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and/or recalls or withdrawals of products from the&#160;market;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and/or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and/or export laws, worldwide environmental laws and regulation and privacy and security regulations;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the current administration;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any plans for the Company&#8217;s aesthetic medical business;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February 23, 2023 and risks detailed from time to time in our other filings with the SEC and the CSA, as well as our ability to anticipate and manage the risks associated with the&#160;foregoing.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February 23, 2023, under Item&#160;1A. &#8220;Risk Factors&#8221;, under Item 1A. &#8220;Risk Factors&#8221; of Part II of this Form 10-Q and in the Company&#8217;s other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-Q or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_217"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;Quantitative and&#160;Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as indicated below under &#8220;&#8212; Interest Rate Risk&#8221; and &#8220;&#8212; Inflation Risk&#8221;, there have been no material changes to our exposures to market risks as disclosed in Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Quantitative and Qualitative Disclosures About Market Risks&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, we had $13,715&#160;million and $5,382&#160;million in outstanding aggregate principal amount of fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of March&#160;31, 2023 was $8,679&#160;million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $277&#160;million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $273&#160;million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-point increase in interest rates would have an annualized pre-tax effect of approximately $54&#160;million in our Condensed Consolidated Statements of Operations and Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Risk</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some markets.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_220"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Controls and&#160;Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer (&#8220;CEO&#8221;) and Chief Financial Officer (&#8220;CFO&#8221;), has evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023. Based on this evaluation, our CEO and CFO concluded that our disclosure controls and procedures were effective as of March&#160;31, 2023. </span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_223"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2023, we implemented a new enterprise resource planning (&#8220;ERP&#8221;) system for our U.S. and Ireland operations as part of our effort to upgrade and/or replace our ERP systems. The implementation resulted in certain changes to our processes related to financial reporting that have required us to effect certain modifications to our internal control over financial reporting. These changes to our processes have been and will continue to be subject to our evaluation of the operating effectiveness of internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the first quarter of 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_226"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_229"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;Legal Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information concerning legal proceedings, reference is made to Note 17, &#8220;LEGAL PROCEEDINGS&#8221; to&#160;the unaudited interim Condensed Consolidated Financial Statements included elsewhere in this Form&#160;10-Q.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_232"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors as disclosed in Item 1A. &#8220;Risk Factors&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_235"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of equity securities by the Company during the three months ended March 31, 2023.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_238"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_241"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;Mine Safety Disclosures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_244"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;Other Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_247"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:2pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;Exhibits </span></div><div style="margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:8.674%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101formofpsuagreeme.htm">10.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit101formofpsuagreeme.htm">Form of PSU Award Agreement</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8224;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12023.htm">31.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311q12023.htm">Certification of the Chief Executive Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12023.htm">31.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312q12023.htm">Certification of the Chief Financial Officer pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12023.htm">32.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321q12023.htm">Certificate of the Chief Executive Officer of Bausch Health Companies&#160;Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12023.htm">32.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322q12023.htm">Certificate of the Chief Financial Officer of Bausch Health Companies Inc. pursuant to 18&#160;U.S.C. &#167;&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*     Filed herewith.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i403fd8161ca64d5ab28658fcd748a8e4_250"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Bausch Health Companies&#160;Inc.</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ THOMAS J. APPIO</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio<br/>Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ TOM G.VADAKETH</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tom G. Vadaketh<br/>Executive Vice President, <br/>Chief Financial Officer <br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101formofpsuagreeme.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ife7f43a7319b47bd863062e94731a8bb_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Bausch Health Companies Inc.<br>Form of Share Unit Grant Agreement (Performance Vesting) <br>(Performance Restricted Share Units)<br>(2014 Omnibus Incentive Plan, as amended and restated, effective as of June 21, 2022)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Bausch Health Companies Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to Section 7(c) of the Company&#8217;s 2014 Omnibus Incentive Plan, as amended and restated, effective as of June 21, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), hereby awards to you a Share Unit Award in the form of performance restricted share units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in the target amount set forth below that are convertible into Common Shares in accordance with the terms set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  This Award is subject to all of the terms and conditions as set forth herein (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and in the Plan, which is incorporated herein in its entirety.  Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.  In the event of any conflict between the terms in the Agreement and the Plan, the terms of the Plan shall control.  For the avoidance of doubt, any terms contained in the Agreement but are not in the Plan shall not constitute a conflict and such terms in the Agreement shall control.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Participant&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Target Number of PSUs&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;<br></font></div><div style="padding-left:85.5pt;text-indent:-85.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The details of your Award are as follows.</font></div><div style="padding-left:85.5pt;text-indent:-85.5pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Consideration.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consideration for this Award is satisfied by your services to the Company and its Subsidiaries and complying with the terms of this Agreement, including the restrictive covenants set forth in Sections 8 and 9. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Vesting&#59; Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">In General. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The target number of PSUs granted to you hereunder (as set forth above) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Target PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may be earned between 0% and 200% based on the level of attainment of the service-based vesting condition (set forth in Section 2(b) below) and the performance-based vesting condition (set forth in Section 2(c) below). The date on which both of the service-based vesting condition and the performance-based vesting condition applicable to your Award are satisfied shall be referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Service-Based Vesting Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to the provisions of the Plan and the acceleration provisions contained herein, the Earned PSUs (as defined below) (if any) will vest (as to service) on the third anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;that (i) you must not have experienced a Termination of Service prior to the Service Vesting Date (unless otherwise vested upon your Termination of Service pursuant to Sections 2(d) through (f) and subject to Section 3) and (ii) you continue to comply with the restrictive covenants set forth in Sections 8 and 9. Any PSUs that did not become vested prior to your Termination of Service or that do not become vested according to the provisions in this Section 2 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall be forfeited immediately following the date of your Termination of Service, without any consideration thereto. Settlement of vested Awards shall be pursuant to Section 3 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Performance-Based Vesting Condition. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The number of PSUs that are earned and become eligible to vest pursuant to this Award (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Earned PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be equal to (A) the number of Target PSUs, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (B) the Performance Goal Payout Percentage </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (C) the rTSR Modifier Percentage. Any PSUs that do not become Earned PSUs in accordance with this Agreement as of the end of the Performance Period shall be immediately forfeited and cancelled, without the payment of any consideration therefor. Notwithstanding anything to the contrary herein, in no event will the Earned PSUs exceed 200% of the Target PSUs.</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt;text-decoration:underline">Adjusted Operating Cash Flow Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Committee shall establish the Adjusted Operating Cash Flow Performance Goal (including a schedule setting forth the threshold, target and maximum performance levels and corresponding goal achievement percentages (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Payout Matrix</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) for each Annual Measurement Period during the Performance Period. The specific Adjusted Operating Cash Flow Performance Goal and Performance Payout Matrix for each Annual Measurement Period during the Performance Period will be provided to you in a separate notification.  Following the end of each Annual Measurement Period in the Performance Period, the Committee will determine the level of achievement of the Adjusted Operating Cash Flow Performance Goal for such Annual Measurement Period and the corresponding achievement percentage of the Award for such Annual Measurement Period in accordance with the Performance Payout Matrix established for such Annual Measurement Period (with interpolation, on a mathematical straight-line basis, to reflect attained performance between defined ends of the applicable spectrum) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Adjusted Operating Cash Flow Performance Goal Achievement Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). At the end of the Performance Period, the Adjusted Operating Cash Flow Performance Goal Achievement Percentage for each Annual Measurement Period in the Performance Period will be averaged (such average, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Average Operating Cash Flow Performance Goal Achievement Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which will be used to calculate the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Goal Payout Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; in accordance with the table below (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that there shall be interpolation, on a mathematical straight-line basis, to derive any Average Operating Cash Flow Performance Goal Achievement Percentage not expressly forth in the table below including, for the avoidance of doubt, for achievement of Average Operating Cash Flow Performance Goal Achievement Percentage below &#91;  &#93;%)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="padding-left:40.64pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.692%"><tr><td style="width:1.0%"></td><td style="width:52.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:1.44pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Average Operating Cash Flow Performance Goal Achievement Percentage (%)</font></td><td colspan="3" style="background-color:#bfbfbf;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;text-indent:1.44pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Goal Payout Percentage (%)</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event that, with respect to any Annual Measurement Period, the Adjusted Operating Cash Flow Performance Goal Achievement Percentage falls at a level below the applicable performance threshold level for such Annual Measurement Period, the Adjusted Operating Cash Flow Performance Goal Achievement Percentage for such Annual Measurement Period shall be 0%&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, (i) if the Adjusted Operating Cash Flow Performance Goal Achievement Percentage for any other Annual Measurement Period during the Performance Period is achieved at or above the threshold performance level for such Annual Measurement Period, the Performance Goal Payout Percentage will be determined in accordance with the table set forth above and (ii) if the Adjusted Operating Cash Flow Performance Goal Achievement Percentage falls at a level below the threshold performance level for all three Annual Measurement Periods, the Performance Goal Payout Percentage will be 0% (and the Award be forfeited in its entirety), regardless of the level of achievement of the rTSR Modifier Percentage.  For the avoidance of doubt, (i) in no event will the calculation of a positive Adjusted Operating Cash Flow Performance Goal Achievement Percentage for any Annual Measurement Period be construed to guarantee that any Common Shares will be distributed to you on the Settlement Date (as defined below) and (ii)  the achievement percentages for each Annual Measurement Period are determined solely for purposes of determining the Average Operating Cash Flow Performance Goal Achievement Percentage for the Performance Period.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">rTSR Modifier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">rTSR Modifier Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be determined as follows (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that there shall be interpolation, on a mathematical straight-line basis, to derive any rTSR Modifier Percentage not expressly forth in the below)&#58; </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:19.36pt">If the Company TSR Percentile Ranking is at or below the &#91;   &#93; percentile, then the rTSR Modifier Percentage will be &#91;   &#93;%&#59;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">If the Company TSR Percentile Ranking is at the &#91;    &#93; percentile, then the rTSR Modifier Percentage will be &#91;    &#93;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.02pt">If the Company TSR Percentile Ranking is at or above the &#91;   &#93; percentile, then the rTSR Modifier Percentage will be &#91;    &#93;%.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. For purposes of this Agreement, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Adjusted Operating Cash Flow</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, for any Annual Measurement Period, the amount of net cash provided by operating activities for such Annual Measurement Period, as determined in accordance with U.S. GAAP, and adjusted, if at all, as a result of events or circumstances, as determined by the Committee.</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Adjusted Operating Cash Flow Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the level of performance that must be attained with respect to the Company&#8217;s Adjusted Operating Cash Flow for an Annual Measurement Period. The Committee shall provide how the Adjusted Operating Cash Flow </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Goal will be adjusted, if at all, as a result of events or circumstances, as determined by the Committee.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(C)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Annual Measurement Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each of the three calendar years during the Performance Period.  The first Annual Measurement period begins on &#91;    &#93; and ends on &#91;    &#93; .  The second Annual Measurement Period begins on &#91;    &#93; and ends on December &#91;     &#93;. The third Annual Measurement period begins on &#91;     &#93; and ends on &#91;     &#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(D)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company TSR Percentile Ranking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the percentile ranking of the Company&#8217;s TSR relative to the TSR of the Comparator Companies, rounded to the whole nearest percentile, as determined by the Committee. In determining the Company TSR Percentile Ranking, in the event that the Company&#8217;s TSR is equal to the TSR of one or more Comparator Companies, the Company TSR Percentile Ranking will be determined by ranking the Company&#8217;s TSR as being greater than such applicable Comparator Company.  </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(E)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Comparator Companies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, collectively, (i) all of the companies which comprise the Russell 1000 Pharmaceutical and Biotechnology Index as of the first day of the Performance Period and (ii) all of the companies which comprise the NYSE Arca Pharmaceutical Index (&#94;DRG) as of the first day of the Performance Period, in each case other than (x) the Company and (y) any companies that cease to exist as of the end of the Performance Period by virtue of having been acquired, merged into another company or subject to a similar fundamental transaction.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(F)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period beginning on &#91;     &#93; and ending on &#91;     &#93;.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(G)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to the Company or any Comparator Company, as applicable, the change in the fair market value per share of common stock of the Company or such Comparator Company, as applicable, including the pre-tax value of any dividends or other distributions per share for any dividend record dates that occur during the Performance Period (with the value of such dividends or distributions determined by treating them as reinvested in additional shares of common stock at the closing market price on the applicable ex-dividend date), calculated as the percentage difference (whether positive or negative) between the average of the closing price per share of the common stock of the Company or such Comparator Company, as applicable, for (i) the last 20 consecutive trading days immediately preceding the first day of the Performance Period and (ii) the last 20 consecutive trading days ending on the last trading day of the Performance Period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">plus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> the pre-tax value of any dividends or other distributions per share for any dividend record </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">dates that occur during the Performance Period, assuming reinvestment thereof in common stock as described above)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for the avoidance of doubt, with respect to the Company, the value of any common shares of Bausch + Lomb Corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">B+L</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that are distributed to shareholders of the Company in connection with the Company&#8217;s spinoff distribution of B+L shall be deemed reinvested in additional Common Shares, to the extent such spin-off distribution occurs during the Performance Period.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Vesting Acceleration Upon Termination of Service due to Death or Disability, due to Retirement or a Termination of Service without Cause or for Good Reason.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event that you experience a Termination of Service due to your death or Disability or Retirement, by the Company without Cause, or by you for Good Reason, the Target PSUs will remain outstanding and will be eligible to be earned and vest based on actual achievement of the applicable performance-based vesting conditions determined as of the end of the Performance Period in accordance Section 2(c) of this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that the number of your Earned PSUs (if any) that may become vested will be prorated based on a fraction, the numerator of which is the number of days from the first day of the Performance Period through the date of your Termination of Service, and the denominator of which is 1,096&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided further </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that (i) in the event of your Termination of Service due to Retirement, or by the Company without Cause or by you for Good Reason, you have been employed by the Company or one of its Subsidiaries for at least twelve (12) months following the Grant Date, (ii) in the event of your Termination of Service by the Company without Cause or by you for Good Reason, you deliver to the Company, and fail to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following the date of your Termination of Service and (iii) you comply with the restrictive covenants set forth in Sections 8 and 9. Notwithstanding the foregoing,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in the event your Termination of Service occurs as a result of the entity for which you are employed ceasing to qualify as a Subsidiary prior to the twelve (12)-month anniversary of the Grant Date, the requirement to be employed by the Company or one of its Subsidiaries for at least twelve (12) months as set forth in clause (i) above shall not apply and one-third (1&#47;3) of the Target PSUs will remain outstanding and will be eligible to be earned and vest based on actual achievement of the applicable performance-based vesting conditions determined as of the end of the Performance Period in accordance with Section 2(c) of this Agreement (and, for the avoidance of doubt, the remaining two-thirds (2&#47;3rds) of the Target PSUs shall be immediately forfeited and cancelled as of the date of your Termination of Service) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Divestiture Treatment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Unless otherwise defined in your employment agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means your Termination of Service on or after the date on which you attain age 55 and your age plus your years of service with the Company and its Subsidiaries total at least 65, and your Termination of Service was not for Cause (and your Retirement has not occurred at a time when grounds for a Termination of Service for Cause exists).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Treatment of Award in Event of Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the foregoing and any other provisions of the Plan to the contrary, in the event of a Change of Control&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">the performance-based vesting conditions set forth in Section 2(c) shall be deemed achieved at the target performance levels (for the avoidance of doubt, the Performance Goal Payout Percentage and the rTSR Modifier Percentage shall each be deemed equal to 100%)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">if this Award of PSUs is assumed or substituted (as described in Section 11(a)(iii) of the Plan) in connection with such Change of Control, then (A) the number of PSUs will be adjusted in accordance with Section 6(f) of the Plan, and (B) in the event you experience a Termination of Service by the Company (or the acquiring entity or its affiliates) without Cause or by you for Good Reason, in each case within the twelve (12) month period immediately following such Change of Control (or during the six month period prior to a Change of Control if such Termination of Service was in contemplation of, and directly related to, the Change of Control), then a pro rata portion of the Target PSUs will vest as of the date of such Termination of Service based on a fraction, the numerator of which is the number of days from the first day of the Performance Period through the date of your Termination of Service, and the denominator of which is 1,096&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that you deliver to the Company, and fail to revoke, a signed release of claims acceptable to the Company within fifty-five (55) days following the date of your Termination of Service&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">if this Award of PSUs is not assumed or substituted (as described in Section 11(a)(iii) of the Plan) in connection with such Change of Control, then a pro rata portion of the Target PSUs will vest as of immediately prior to such Change of Control based on a fraction, the numerator of which is the number of days from the first day of the Performance Period through the date of such Change of Control, and the denominator of which is 1,096.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Distribution of Common Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company will deliver to you a number of Common Shares vested in accordance with the provisions of Section 2 of this Agreement (plus any Common Shares resulting from dividend equivalents credited with respect to this Award in accordance with Section 6 of this Agreement) as soon as administratively practicable after the applicable Vesting Date, but in no event later than March 15 of the calendar year following the year in which such Common Shares become vested (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Settlement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, notwithstanding anything in the Plan or this Agreement to the contrary, any remaining right to a distribution of the Common Shares will be forfeited in the event of your Termination of Service by the Company for Cause prior to the date on which the Common Shares are distributed to you or if you violate any post-employment obligation that you may have to the Company or any of its Subsidiaries, including the restrictive covenants set forth in Sections 8 and 9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Number of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The number of Common Shares subject to your Award may be adjusted from time to time in accordance with Section 6(f) of the Plan.  The Company will establish a bookkeeping account to reflect the number of PSUs standing to your credit from time to time.  However, you will not be deemed to be the holder of, or to have any of the rights of a shareholder with respect to, any Common Shares subject to your Award (including but not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">limited to shareholder voting rights) unless and until the shares have been delivered to you in accordance with Section 3 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Common Share Ownership Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You agree to comply with any Common Share ownership requirements adopted by the Company applicable to you, which shall be on the same terms as similarly situated executives of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The bookkeeping account maintained for the Award granted pursuant to this Agreement shall, until the Vesting Date or the termination and cancellation or forfeiture of the Award pursuant to the terms of the Plan, be allocated additional PSUs on the payment date of dividends on the Company&#8217;s Common Shares.  Such dividends will be converted into a number of additional Common Shares covered by the PSUs equal to the quotient of (i) the aggregate amount or value of the dividends paid with respect to that number of Common Shares equal to the number of shares covered by the PSUs divided by (ii) the Market Price per Common Share on the payment date for such dividend.  Any such additional PSUs shall vest in accordance with, and subject to, the same terms as the PSUs granted under this Agreement (including the performance-based vesting conditions set forth in Section 2(c)).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Disclosure and Ownership of Intellectual Property. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You acknowledge and agree that any intellectual property, including, without limitation, works, materials, inventions, invention disclosures, invention registrations, patent rights, trademarks, service marks, trade names, trade dress, logos, domain names, copyrights, design rights, mask works, software, apparatus, technology, data, trade secrets, know-how and all other intellectual property and proprietary rights recognized by any applicable law of any jurisdiction, that you create, discover, conceive, reduce to practice, develop or acquire during the course of your employment or service, either alone or jointly with others, (i) using any equipment, supplies, facilities, trade secrets, know-how or other Confidential Information of the Company or any of its affiliates, (ii) that results from any work performed for the Company or any of its affiliates and&#47;or (iii) that otherwise relates to the Company&#8217;s or any of its affiliates&#8217; business or actual or demonstrably anticipated research or development (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is and shall remain the exclusive property of the Company or the affiliate of the Company, as applicable, that is your employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) whether registered or otherwise exploited or not.  In furtherance of the foregoing, you hereby assign, transfer, convey and deliver to the Employer your entire right, title and interest in and to any and all such Company Intellectual Property.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Work Made for Hire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You acknowledge and agree that, with respect to any Company Intellectual Property that may qualify as a Work Made For Hire as defined in 17 U.S.C. &#167; 101 or other applicable law, such Company Intellectual Property is and will be deemed a Work Made for Hire and the Employer will have the sole and exclusive right to the copyright (or, in the event that any such Company Intellectual Property does not qualify as a Work Made for Hire, the copyright and all other rights thereto are hereby automatically assigned to the Employer as above).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You agree to record all activities undertaken in the course of your employment and to disclose promptly in writing to the Employer any and all Company Intellectual Property.  You agree that you will give the Company or any of its affiliates all reasonable assistance and execute all documents necessary to assist with enabling the Company or any of its affiliates to prosecute, perfect, register, record, enforce and defend any and all of their rights in and to any Company Intellectual Property and Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. If your principal work location is in California, Illinois, Kansas, Minnesota or Washington State, the provisions regarding your assignment of Company Intellectual Property to the Employer in Sections 7(a) and (b) of this Agreement may not apply to certain inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Non-Assignable Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) as specified in the statutory code of the applicable state.  You acknowledge having received notification regarding such Non-Assignable Inventions pursuant to such states&#8217; codes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If, in the course of your employment with the Employer, you use any intellectual property that is solely or jointly owned by you or licensed to you, with the right to sub-license (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prior Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you hereby grant to the Company and its affiliates a worldwide, non-exclusive, irrevocable, perpetual, fully paid-up and royalty-free license (with rights to sublicense through multiple tiers of sublicensees) to use, reproduce, modify, make derivative works of, publicly perform, publicly display, make, have made, sell, offer for sale, import and otherwise exploit such Prior Intellectual Property for any purpose.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Waiver of Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To the extent you may do so under applicable law, you hereby waive and agree never to assert any Moral Rights that you may have in or with respect to any Company Intellectual Property, even after termination of any work on behalf of the Company or its affiliates. As used in this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Moral Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any rights to claim authorship of a work, to object to or prevent the modification or destruction of a work, or to withdraw from circulation or control the publication or distribution of a work, and any similar right, existing under any applicable law of any jurisdiction, regardless of whether or not such right is denominated or generally referred to as a &#8220;moral right.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Section 7 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Records and Confidential Data. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In consideration of the PSUs issued to you pursuant to this Agreement, subject to Sections 8(e) and 8(f), you agree to be bound by the covenant of confidentiality set forth in this Section 8 with respect to any and all Confidential Information (as defined below) disclosed or made available to you or of which you have otherwise become aware, whether before, on or after the date hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Ownership&#59; Recognition of Company&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You acknowledge that in connection with the performance of your duties, the Company will make available to you, or you will have access to, certain Confidential Information of the Company and its affiliates. You acknowledge and agree that any and all Confidential Information you learned or obtained during the course of your employment or service by the Company or any of its affiliates or otherwise, whether developed by you alone or in conjunction with others or otherwise, shall be and is the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">sole and exclusive property of the Employer. No license or other right to any Confidential Information is granted to you under this Agreement.  To the extent that you acquire any right, title or interest in or to any Confidential Information, you hereby assign, transfer, convey and deliver to the Employer all such right, title and interest in and to such Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to Sections 8(e) and 8(f), you (i)&#160;will keep all Confidential Information strictly confidential, (ii)&#160;will not use Confidential Information in any manner which is detrimental to the Company or its affiliates, (iii)&#160;will not use Confidential Information other than in connection with the discharge of your duties to the Company and its affiliates, (iv)&#160;will safeguard any and all Confidential Information from unauthorized disclosure, and (v)&#160;will not disclose, publish, use, transfer or otherwise disseminate any Confidential Information to any person or entity without the Employer&#8217;s express prior written consent, except as may be necessary to perform your duties as an employee of the Company or its affiliates for the benefit of the Company or its affiliates. You may, however, disclose Confidential Information to the extent it is in response to a valid order of a court or other governmental authority or to otherwise comply with applicable law&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that, subject to your protections under Sections 8(e) and 8(f) below, you shall first give notice to the Employer and reasonably cooperate with the Employer to obtain a protective order or other measures preserving the confidential treatment of such Confidential Information and requiring that the information or documents so disclosed be used only for the purposes for which the order was issued or is otherwise required by applicable law. For the avoidance of doubt, nothing in this Section 8(b) shall prevent you from exercising any legally protected whistleblower rights (including under Rule 21F under the Exchange Act), and you shall not be required to first give notice to the Employer when you are exercising your legally protected whistleblower rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Disposition of Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Following your Termination of Service or upon the Company&#8217;s request, you will return to the Company all copies of any and all Confidential Information in your custody, possession or control (including all copies of any analyses, compilations, studies or other documents prepared by you or for your use containing or reflecting any Confidential Information). Alternatively, with the Company&#8217;s prior written consent, you may destroy such Confidential Information. Within five (5) business days of your Termination of Service or such request by the Company, you shall deliver to the Company a document certifying that such written Confidential Information has been returned or destroyed in accordance with this Section 8(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Confidential Information. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any and all non-public, proprietary or other confidential information of the Company or its affiliates disclosed to you, to which you have access, or of which you otherwise become aware, in each case whether in oral, written, graphic or machine readable form, including, without limitation, (i)&#160;know-how, trade secrets, inventions, discoveries, concepts, information, works, materials, processes, methods, data, software, programs, apparatus, designs and the like, and any other intellectual property the value of which is contingent upon maintaining the confidentiality thereof, (ii)&#160;information regarding the business of the Company or its affiliates, including its products, services, budgets, contracts, reports, investigations, experiments, research, work in progress, drawings, designs, plans, proposals, codes, marketing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and sales programs, client lists, client mailing lists, supplier lists, financial projections, cost summaries, pricing formulae, marketing studies relating to prospective business opportunities, and all other concepts, ideas, materials, or information prepared or performed for or by the Company or its affiliates, (iii)&#160;information regarding the skills and compensation of the employees, contractors, and any other service providers of the Company or its affiliates, (iv)&#160;the existence of any business discussions, negotiations, or agreements between the Company or its affiliates and any third party, (v)&#160;all documents and other work product generated by you which contain, comment upon, or relate in any way to any information disclosed by the Company or its affiliates, (vi) all third-party information held in confidence by the Company or its affiliates, and (vii) the terms and conditions of this Agreement. For purposes of this Agreement, the Confidential Information shall not include and your obligation shall not extend to (i) information which is generally available to the public and (ii) information obtained by you other than pursuant to or in connection with your employment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Defend Trade Secrets Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Pursuant to Section 7 of the Defend Trade Secrets Act of 2016 (which added 18 U.S.C. &#167; 1833(b)), you and the Company acknowledge and agree that you shall not have criminal or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a federal, State, or local government official, either directly or indirectly, or to an attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law&#59; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition and without limiting the preceding sentence, if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and may use the trade secret information in the court proceeding, if you (x) file any document containing the trade secret under seal and (y) do not disclose the trade secret, except pursuant to court order. Nothing in this Agreement is intended to conflict with 18 U.S.C. &#167;1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Whistleblower Protections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding the foregoing, nothing in this Agreement precludes or otherwise limits your ability to communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or any other federal, state or local governmental agency or commission or self-regulatory organization (each such agency, commission or organization, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Government Agency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) organization regarding possible legal violations, without disclosure to the Company.  The Company may not retaliate against you for any of these activities, and nothing in this Agreement requires you to waive any monetary award or other relief that you might become entitled to from the SEC or any other Government Agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">This Section 8 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Covenant Not to Solicit, Not to Compete and Not to Disparage. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In consideration of the PSUs issued to you pursuant to this Agreement, you agree to be bound by the covenants of non-solicitation, non-competition and non-disparagement set forth in this Section 9.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Covenant Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To protect the Confidential Information and other trade secrets of the Company and its affiliates, you agree, during the period of your employment with or service to the Company and for a period of twelve (12) months thereafter (or, if greater, the period set forth in your employment or service agreement) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), not to solicit, hire or participate in or assist in any way in the solicitation or hire of any employees of the Company or any of its Subsidiaries (or any person who was an employee of the Company or any of its Subsidiaries during the 6-month period preceding such action). For purposes of this covenant, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means directly or indirectly influencing or attempting to influence employees of the Company to become employed with any other person, partnership, firm, corporation or other entity. You agree that the covenants contained in this Section 9(a) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that solicitation through general advertising or the provision of references shall not constitute a breach of such obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.35pt">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. To protect the Confidential Information and other trade secrets of the Company and its affiliates, you agree, during the Restricted Period, not to engage in Prohibited Activities (as defined below) in any country in which the Company or its affiliates conduct business, or plan to conduct business, during the period of your employment or service. For the purposes of this Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prohibited Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means directly or indirectly engaging as an owner, employee, consultant or agent of any entity that derives more than 10% of its consolidated revenue from the development, manufacturing, marketing and&#47;or distribution (directly or indirectly) of branded or generic prescription or non-prescription pharmaceuticals or medical devices for treatments in the fields of neurology, dermatology, gastroenterology or dentistry&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that Prohibited Activities shall not mean (i) your investment in securities of a publicly-traded company equal to less than five (5%) percent of such company&#8217;s outstanding voting securities or (ii) serving as a member of a board of directors of a company provided that, for the avoidance of doubt, you comply with the obligations set forth in Sections 8 and 9(a) of this Agreement. You agree that the covenants contained in this Section 9(b) are reasonable and desirable to protect the Confidential Information of the Company and its affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Non-Disparagement Covenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You agree not to make written or oral statements about the Company or its affiliates or their directors, executive officers or non-executive officer employees that are negative or disparaging. Notwithstanding the foregoing, nothing in this Agreement shall preclude you from communicating or testifying truthfully to the extent required by law to any federal, state, provincial or local governmental agency or in response to a subpoena to testify issued by a court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">Your obligations under this Section 9 shall survive your Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Severability of Restrictive Covenants. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is the intent and desire of you and the Company that the restrictive provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies as applied in each jurisdiction in which enforcement is sought. If any particular provision of Sections 8 or 9 shall be determined to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">invalid or unenforceable, such provision shall be amended, without any action on the part of either party hereto, to delete therefrom the portion so determined to be invalid or unenforceable, such deletion to apply only with respect to the operation of such covenant in the particular jurisdiction in which such adjudication is made.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any provision of Sections 8 or 9 (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner that will give effect to the terms of such Section or part of such Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Remedies for Breach of Obligations Under Sections 8 and 9.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that the Company will suffer irreparable injury, not readily susceptible to valuation in monetary damages, if you breach any obligation under Sections 8 or 9. Accordingly, you agree that the Company will be entitled, in addition to any other available remedies, to obtain preliminary and permanent injunctive relief against any breach or prospective breach by you of your obligations under Sections 8 or 9. Without limiting other forms of relief available to the Company, in the event of your breach of any of your obligations under Sections 8 or 9, your Award will be forfeited for no consideration and, if payment in respect of your Award has been made, you will be obligated to return the proceeds to the Company. You agree that process in any or all of those actions or proceedings may be served by registered mail, addressed to the last address provided by you to the Company, or in any other manner authorized by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Clawback. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is subject to Section 12 of the Plan, any policy the Company has adopted or will adopt regarding the recovery of incentive compensation and any additional clawback provisions as required by law or applicable listing rules.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Compliance with Section 409A of the Internal Revenue Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Award is intended to comply with Section 409A of the Code to the extent subject thereto or to otherwise be exempt from Section 409A of the Code, and shall be interpreted in accordance with this intent and Section 409A of the Code and treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Grant Date.  Notwithstanding any provision in the Plan to the contrary, no payment or distribution under this Plan that constitutes an item of deferred compensation under Section 409A of the Code and becomes payable by reason of your Termination of Service with the Company shall be made to you until your Termination of Service constitutes a separation from service within the meaning of Section 409A of the Code.  For purposes of this Award, each amount to be paid or benefit to be provided shall be construed as a separate identified payment for purposes of Section 409A of the Code.  Notwithstanding any provision in the Plan to the contrary, if you are a specified employee within the meaning of Section 409A of the Code, then to the extent necessary to avoid the imposition of taxes under Section 409A of the Code, you shall not be entitled to any payments upon your Termination of Service until the earlier of&#58;  (i) the expiration of the six (6)-month period measured from the date of your separation from service or (ii) the date of your death.  Upon the expiration of the applicable waiting period set forth in the preceding sentence, all payments and benefits deferred pursuant to this Section 13 (whether they would have otherwise been payable in a single lump sum or in installments in the absence of such deferral) shall be paid to you in a lump sum as soon as practicable, but in no event later than sixty (60) calendar days, following such expired period, and any remaining </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">payments due under this Award will be paid in accordance with the normal payment dates specified for them herein.  Notwithstanding any provision of the Plan to the contrary, in no event shall the Company or any affiliate be liable to you on account of an Award&#8217;s failure to (i) qualify for favorable U.S. or foreign tax treatment or (ii) avoid adverse tax treatment under U.S. or foreign law, including, without limitation, Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Securities Law Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You may not be issued any Common Shares under your Award unless the Common Shares are either (i) then registered under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), or (ii) the Company has determined that such issuance would be exempt from the registration requirements of the Securities Act.  Your Award must also comply with other applicable laws and regulations governing the Award, and you shall not receive such shares if the Company determines that such receipt would not be in material compliance with such laws and regulations. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Restrictive Legends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Common Shares issued under your Award shall be endorsed with appropriate legends, if any, determined by the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Except as otherwise permitted by the Committee in accordance with the terms of the Plan, your Award is not transferable, except by will or by the laws of descent and distribution.  Notwithstanding the foregoing, by delivering written notice to the Company, in the form prescribed by the Company, you may designate a third party who, in the event of your death, will thereafter be entitled to receive any distribution of Common Shares pursuant to Section 3 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Award Not a Service Contract</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Your Award is not an employment or service contract, and nothing in your Award will be deemed to create in any way whatsoever any obligation on your part to continue in the service of the Company or an affiliate, or on the part of the Company or an affiliate to continue such service.  In addition, nothing in your Award will obligate the Company or an affiliate, their respective shareholders, boards of directors or employees to continue any relationship that you might have as an employee of the Company or an affiliate. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Unsecured Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Your Award is unfunded, and as a holder of PSUs, you will be considered an unsecured creditor of the Company with respect to the Company&#8217;s obligation, if any, to issue Common Shares pursuant to this Agreement.  You will not have voting or any other rights as a shareholder of the Company with respect to the Common Shares subject to your Award until such Common Shares are issued to you pursuant to Section 3 of this Agreement.  Upon such issuance, you will obtain full voting and other rights as a shareholder of the Company.  Nothing contained in this Agreement, and no action taken pursuant to its provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Withholding Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On or before the time you receive a distribution of Common Shares pursuant to your Award, or at any time thereafter as requested by the Company, you hereby authorize any required withholding from the Common Shares, payroll and any other amounts payable or issuable to you and&#47;or otherwise agree to make adequate provision in cash </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for any sums that can be withheld to satisfy the federal, state, local and foreign tax withholding obligations of the Company or any affiliate which arise in connection with your Award (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Withholding Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  The Company shall (i) withhold, from Common Shares otherwise issuable upon settlement of the Award, a portion of the Common Shares with an aggregate Market Price (measured as of the date Common Shares are delivered pursuant to Section 3) equal to the amount of the applicable withholding taxes&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the number of such Common Shares so withheld shall not exceed the maximum amount that can be withheld to satisfy the Company&#8217;s required tax withholding obligations and (ii) make a cash payment equal to such fair market value directly to the appropriate taxing authorities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notices provided for in your Award or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address you provided to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The headings of the Sections in this Agreement are inserted for convenience only and will not be deemed to constitute a part of this Agreement or to affect the meaning of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing in this Agreement shall restrict the Committee&#8217;s (or its applicable delegate&#8217;s) ability to exercise its discretionary authority pursuant to Section 4 of the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that no such action may, without your consent, adversely affect your rights under your Award and this Agreement.  Without limiting the foregoing, the Board (or appropriate committee thereof) reserves the right to change, by written notice to you, the provisions of this Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant as a result of any change in applicable laws or regulations or any future law, regulation, ruling, or judicial decision&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that any such change will be applicable only to rights relating to that portion of the Award which is then subject to restrictions as provided herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The rights and obligations of the Company under your Award will be transferable by the Company to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company&#8217;s successors and assigns. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">You agree upon request to execute any further documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">You acknowledge and agree that you have reviewed your Award in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your Award and fully understand all provisions of your Award.  This Agreement and the Plan contain the entire agreement and understanding among the parties as to the subject matter hereof, and supersede any other agreements or representations, oral or otherwise, express or implied, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with respect to the subject matter hereof (including, without limitation, the provisions in your employment letter with respect thereto).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">This Agreement will be subject to all applicable laws, rules, and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">All obligations of the Company under the Plan and this Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the business and&#47;or assets of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Governing Plan Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Your Award is subject to all the provisions of the Plan, the provisions of which are hereby made a part of your Award, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan.  In the event of any conflict between the provisions of your Award and those of the Plan, the provisions of the Plan will control&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, for avoidance of doubt, terms contained in the Agreement but not in the Plan shall not constitute a conflict and such terms in the Agreement shall control.  The Committee will have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation, and application of the Plan as are consistent therewith and to interpret or revoke any such rules.  All actions taken and all interpretations and determinations made by the Committee will be final and binding upon you, the Company, and all other interested persons.  No member of the Board or the Committee will be personally liable for any action, determination, or interpretation made in good faith with respect to the Plan or this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Effect on Other Employee Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The value of the Award subject to this Agreement will not be included as compensation, earnings, salaries, or other similar terms used when calculating the employee&#8217;s benefits under any employee benefit plan sponsored by the Company or any affiliate except as such plan otherwise expressly provides.  The Company expressly reserves its rights to amend, modify, or terminate any of the Company&#8217;s or any affiliate&#8217;s employee benefit plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The interpretation, performance and enforcement of this Agreement will be governed by the laws of the Province of Ontario and the laws of Canada. Each of the parties submits to the exclusive jurisdiction of the state courts within the State of New Jersey. In any issue, claim, demand, action, cause of action, suit or proceeding arising out of, or relating to, this Agreement, each of the parties agrees that all claims in respect of the action or proceeding may be heard and determined in any such court, and agrees not to bring any action or proceeding arising out of, relating to, based on or in connection with this Agreement in any other court. Each of the parties waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security that might be required of any other party with respect thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If all or any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Appendices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions in this Agreement, the PSUs shall be subject to any special terms and conditions for employees outside the United States set forth in Appendix A and Appendix B attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Appendices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Further, if you relocate to one of the countries included in Appendix B, the special terms and conditions for such country will apply to you to the extent that the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendices constitutes part of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CKNOWLEDGEMENTS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. By accepting this Award, you hereby consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third-party designated by the Company.</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bausch Health Companies Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Restricted Share Unit Award Agreement (Performance Vesting)<br>(Performance Restricted Share Units)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2014 Omnibus Incentive Plan)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Additional Terms and Conditions For Employees Outside the United States </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes additional terms and conditions that govern the Award granted to you under the Plan if you are a Participant and reside and&#47;or work in a country outside the United States of America (or later relocate to such a country).  Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Plan and&#47;or the Agreement to which this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is attached.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> constitutes part of the Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Withholding Obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The following provisions supplement Section 19 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that, regardless of any action taken by the Company or, if different, your employer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable or deemed applicable to you (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is and remains your responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  You further acknowledge that the Company and the Employer (a) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award or the underlying Common Shares, and (b) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result.  Further, if you are subject to Tax-Related Items in more than one jurisdiction, you acknowledge that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Prior to any applicable taxable or tax withholding event, you authorize the Company and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by any of the methods referred to in Section 19 of the Agreement.  In addition, you authorize withholding from proceeds of the sale of Common Shares acquired upon vesting of the PSUs either through a voluntary sale, or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization without further consent by you).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may withhold or account for Tax-Related Items by considering  statutory or other  withholding rates, including minimum or maximum withholding rates applicable in your jurisdiction. In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the Common Share equivalent), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">withholding, you may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Company and&#47;or the Employer.  If the obligation for Tax-Related Items is satisfied by withholding in Common Shares, for tax purposes, you will be deemed to have been issued the full number of Common Shares subject to the vested Award, notwithstanding that a number of the Shares is held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Finally, if requested by the Company, you agree to pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described.  The Company may refuse to issue or deliver the Common Shares or the proceeds of the sale of Common Shares, if you fail to comply with your obligations in connection with the Tax-Related Items.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Accelerated Vesting upon a Termination of Employment due to Retirement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The following provision supplements Section 2(d) of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Plan or the Agreement, if the Company receives a legal opinion that there has been a legal judgment and&#47;or legal development in your jurisdiction that likely would result in the favorable treatment that applies to the PSUs as a result of your Retirement or you reaching a certain age being deemed unlawful and&#47;or discriminatory, the favorable treatment shall not apply and you shall be treated in accordance with the remaining provisions of Section 2 of the Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Disclosure and Ownership of Inventions and Intellectual Property. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The following provision supplements Section 7 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything to the contrary in the Plan or the Agreement, this Section 7 shall not apply if you work and&#47;or reside in France or Germany.  Moreover, this Section 7 shall not apply if you work and&#47;or reside in any other jurisdiction in which the Company determines that the provisions of this Section 7 would be deemed unlawful or invalid.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following provision replaces in its entirety Section 16 of the Agreement&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your Award and any interest therein shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than by will or by the applicable laws of descent and distribution. </font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In accepting the grant of the PSUs, you acknowledge, understand and agree that&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">the grant of the PSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of restricted share units, or benefits in lieu of restricted share units, even if restricted share units have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">all decisions with respect to future restricted share unit or other grants, if any, will be at the sole discretion of the Company&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">you are voluntarily participating in the Plan&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">the PSUs and any Common Shares acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">the PSUs and any Common Shares acquired under the Plan, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including, but limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-term service awards, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">the future value of the Common Shares underlying the PSUs is unknown, indeterminable, and cannot be predicted with certainty&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">unless otherwise agreed with the Company in writing, the PSUs and any Common Shares acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, any service you may provide as a director of a Subsidiary&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">neither the Company, the Employer, nor any other Subsidiary will be liable for any foreign exchange rate fluctuation between any local currency and the U.S. dollar that may affect the value of the PSUs, any amounts due to you pursuant to the vesting of the PSUs or the subsequent sale of any Common Shares acquired upon vesting&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">no claim or entitlement to compensation or damages shall arise from forfeiture of the PSUs resulting from the termination of your employment with the Employer (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment or service agreement, if any)&#59; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">the Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying Common Shares&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">you should consult with your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Data Privacy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The following provisions applies to Eligible Recipients in the European Union (&#8220;EU&#8221;)&#47;European Economic Area (&#8220;EEA&#8221;), in Switzerland, and in the United Kingdom (&#8220;U.K.&#8221;)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address, email address and telephone number, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Common Shares or directorships held in the Company, details of all PSUs or any other entitlement to Common Shares awarded, canceled, exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;), for the purpose of implementing, administering and managing the Plan.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that this Data will be processed in accordance with the Employee notice notified to you in local language in 2018 and available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;valeantvision.valeant.corp.vrx&#47;Europe&#47;Pages&#47;Compliance.aspx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan.  You understand that these recipients of Data may be located in other countries, such as the United States, which may afford a lower level of data protection and judicial redress than your country.  This is necessary to perform this Agreement and to implement the Plan.  You understand that you may request a list with the names and addresses of any potential recipients of Data by contacting your local Human Resources Representative.  You understand that the Company and the recipients assisting the Company (presently or in the future) receive, possess, use, retain and transfer Data, in electronic or other form, for the purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that you may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data, in any case without cost, by contacting in writing your local Human Resources Representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.35pt">The following provisions applies to Eligible Recipients outside the EU&#47;EEA, outside Switzerland, and outside the U.K.&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">By accepting the Award, you hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this Agreement and any other grant materials by and among, as applicable, the Company, your Employer and any other Subsidiary for the exclusive purpose of implementing, administering and managing your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address, email address and telephone number, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Common Shares or directorships held in the Company, details of all PSUs or any other entitlement to Common Shares awarded, canceled, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">exercised, vested, unvested or outstanding in your favor (&#8220;Data&#8221;), for the exclusive purpose of implementing, administering and managing the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">You understand that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan.  You understand that these recipients of Data may be located in the United States or elsewhere, and that the recipients&#8217; country (e.g., the United States) may have different data privacy laws and protections than your country.  You understand that you may request a list with the names and addresses of any potential recipients of Data by contacting your local Human Resources Representative.  You authorize the Company and the recipients assisting the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan.  You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan.  You understand that you may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local Human Resources Representative.  Further, you understand that you are providing the consents herein on a purely voluntary basis.  If you do not consent, or if you later seek to revoke the consents, your employment or service with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the consents is that the Company would not be able to grant PSUs or other equity awards to you or administer or maintain such awards.  Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan.  For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local Human Resources Representative.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Finally, upon request of the Company, you agree to provide an executed data privacy consent form to the Company (or any other agreements or consents that may be requested by the Company) that the Company may deem necessary to obtain from you for the purpose of administering your participation in the Plan in compliance with the data privacy laws in your country, either now or in the future.  You understand and agree that you will not be able to participate in the Plan if you fail to provide any such consent or agreement requested by the Company.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Electronic Delivery and Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Language.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You acknowledge that you are sufficiently proficient in the English language or have had an opportunity to consult with an advisor proficient in the English language, so as to enable you to understand the terms and conditions of the Agreement and other Plan-related materials.  Furthermore, if you have received this Agreement or any other document </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:18pt">Insider Trading&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge that, depending on your country of residence, the broker&#8217;s country, or the country in which Common Shares are listed, you may be subject to insider trading and&#47;or market abuse laws which may affect your ability to accept, acquire, sell or otherwise dispose of Common Shares, rights to such Common Shares (e.g., PSUs) or rights linked to the value of Common Shares under the Plan during such times as you are considered to have &#8220;material nonpublic information&#8221; or &#8220;insider information&#8221; regarding the Company (as defined by the laws or regulations in the relevant jurisdiction).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Company&#8217;s insider trading policy, and the requirements of applicable laws may or may not be consistent with the terms of the Company&#8217;s insider trading policy.  You acknowledge that it is your responsibility to comply with any applicable restrictions, and that you should speak to your personal advisor on this matter.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Foreign Asset&#47;Account Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You acknowledge that there may be certain foreign asset and&#47;or account reporting requirements which may affect your ability to acquire or hold Common Shares acquired under the Plan or cash received from participating in the Plan (including from any dividends paid on Common Shares acquired under the Plan) in a bank or brokerage account outside your country.  You may be required to report such accounts, assets or transactions to the tax or other authorities in your country.  You also may be required to repatriate sale proceeds from the sale of Common Shares or other funds received as a result of participation in the Plan to your country through a designated bank or broker within a certain time after receipt.  You acknowledge that it is your responsibility to be compliant with such regulations, and should consult your personal legal advisor for any details.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bausch Health Companies Inc.<br>Form of Restricted Share Unit Award Agreement (Performance Vesting)<br>(Performance Restricted Share Units)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2014 Omnibus Incentive Plan)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Country-Specific Terms</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> includes additional terms and conditions that govern the Award granted to you under the Plan if you reside in one of the countries listed below.  Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Plan and&#47;or the Agreement to which this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> is attached.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Canada</font></div><div style="margin-bottom:12pt;margin-top:1.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Distribution of Common Shares.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following provision supplements Section 3 of the Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any discretion contained in the Plan or the Agreement, PSUs will be settled in Common Shares only, not cash.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">The following provisions apply if you are a resident of Quebec</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">French Language Documents. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A French translation of the Agreement, the Plan and certain other documents related to the PSUs will be made available to you as soon as reasonably practicable. You understand that, from time to time, additional information related to the PSUs may be provided in English and such information may not be immediately available in French. However, upon request, the Company will provide a translation of such information into French as soon as reasonably practicable.  Notwithstanding anything to the contrary in the Agreement, and unless you indicate otherwise, the French translation of the Agreement and certain other documents related to the PSUs will govern the PSUs and your participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Privacy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This provision supplements Section 6(b) of Appendix A&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You hereby authorize the Company and the Company&#8217;s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan.  You further authorize the Company, the Employer, any Subsidiary or any stock plan service provider selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors.  You further authorize the Company and the Employer to record such information and to keep such information in your employee file. You acknowledge that your personal information, including sensitive personal information, may be transferred or disclosed outside of the province of Quebec, including to the United States.  If applicable, you also acknowledge that the Company, the Employer, and other parties involved in the administration of the Plan may use technology for profiling purposes and to make automated decisions that may have an impact on you or the administration of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exhibit311q12023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if04a40da49174b5aabbddb50ba0499fb_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"><tr><td style="width:1.0%"></td><td style="width:5.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.693%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exhibit312q12023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i76e09a72f26b473484c77c00886b71d7_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom G.Vadaketh, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this&#160;report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as&#160;defined in Exchange Act Rules&#160;13a-15(e) and&#160;15d-15(e)) and internal control over financial reporting (as&#160;defined in Exchange Act Rules&#160;13a-15(f) and&#160;15d-15(f)) for the Company and&#160;have&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being&#160;prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.&#160;&#160;&#160;&#160;Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The Company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or&#160;persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.727%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM G. VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom G. Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exhibit321q12023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iab33ed9ddb1c49df8205b43c67ba8c2d_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas J. Appio, Chief Executive Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended March&#160;31, 2023 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; THOMAS J. APPIO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>exhibit322q12023.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i75e983080b6f452b8ee28a117435c403_1"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:10pt;margin-top:10pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18&#160;U.S.C. &#167;&#160;1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tom G. Vadaketh, Executive Vice-President, Chief Financial Officer of Bausch Health Companies&#160;Inc. (the&#160;&#8220;Company&#8221;), certify, pursuant to 18&#160;U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my&#160;knowledge&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Quarterly Report on Form&#160;10-Q of the Company for the quarter ended March&#160;31, 2023 (the&#160;&#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59;&#160;and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the&#160;Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.382%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 4, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; TOM G. VADAKETH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Tom G. Vadaketh</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer<br>(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by&#160;reference.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the U.S.&#160;Securities and Exchange Commission or its staff upon&#160;request.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>bhc-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:15d8a82e-3541-4c94-ac5d-dc1f963a0c8b,g:acd10879-3b31-4117-a8f7-2a1c419d7f06-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000008 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITION" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION">
        <link:definition>0000010 - Disclosure - REVENUE RECOGNITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDACQUISITION" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITION">
        <link:definition>0000011 - Disclosure - LICENSING AGREEMENTS AND ACQUISITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS">
        <link:definition>0000013 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>0000014 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>0000016 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>0000017 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>0000018 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>0000019 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>0000020 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET">
        <link:definition>0000021 - Disclosure - OTHER EXPENSE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>0000022 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000023 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>0000024 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>0000025 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONTables" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables">
        <link:definition>0000027 - Disclosure - REVENUE RECOGNITION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables">
        <link:definition>0000028 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>0000029 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>0000030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>0000031 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>0000032 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>0000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>0000034 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>0000035 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables">
        <link:definition>0000036 - Disclosure - OTHER EXPENSE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>0000037 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>0000038 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>0000039 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>0000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails">
        <link:definition>0000041 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
        <link:definition>0000042 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails">
        <link:definition>0000043 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails">
        <link:definition>0000044 - Disclosure - LICENSING AGREEMENTS AND ACQUISITION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>0000045 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000046 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>0000047 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>0000048 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000049 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>0000050 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>0000051 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000052 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>0000053 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
        <link:definition>0000054 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
        <link:definition>0000055 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
        <link:definition>0000056 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESComponentsofInventoriesDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails">
        <link:definition>0000057 - Disclosure - INVENTORIES - Components of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
        <link:definition>0000058 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>0000059 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>0000060 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
        <link:definition>0000061 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails">
        <link:definition>0000062 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>0000063 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>0000064 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSExchangeOfferDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails">
        <link:definition>0000065 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>0000066 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>0000067 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>0000068 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>0000069 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails">
        <link:definition>0000070 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>0000071 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>0000072 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
        <link:definition>0000073 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>0000074 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
        <link:definition>0000075 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails">
        <link:definition>0000076 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETSummaryofOtherExpenseNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails">
        <link:definition>0000077 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>0000078 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails">
        <link:definition>0000079 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails">
        <link:definition>0000080 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSLegalProceedsDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsDetails">
        <link:definition>0000081 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
        <link:definition>0000082 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSAntitrustDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails">
        <link:definition>0000083 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSIntellectualPropertyDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails">
        <link:definition>0000084 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSProductLiabilityDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails">
        <link:definition>0000085 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSGeneralCivilActionsDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails">
        <link:definition>0000086 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>0000087 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
        <link:definition>0000088 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONDisaggregationofRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails">
        <link:definition>0000089 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails_1" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1">
        <link:definition>0000090 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
        <link:definition>0000091 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>0000092 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A1375209BCLtdMember" abstract="true" name="A1375209BCLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TradeNamesNoLongerUsedMember" abstract="true" name="TradeNamesNoLongerUsedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueMay2027Member" abstract="true" name="RevolvingCreditFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainContingencyStayOfApprovalPeriod" abstract="false" name="GainContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" abstract="false" name="DebtInstrumentCreditSpreadAdjustmentOnVariableRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" abstract="true" name="SeniorSecured1100NotesFirstLienDueSeptember2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EuropeInterbankOfferedRateEURIBORMember" abstract="true" name="EuropeInterbankOfferedRateEURIBORMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" abstract="true" name="VisionCareSurgicalAndOphthalmicReportingUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" abstract="true" name="BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SOFRCDORAndEURIBORRatesMember" abstract="true" name="SOFRCDORAndEURIBORRatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" abstract="false" name="RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueFebruary2027Member" abstract="true" name="RevolvingCreditFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" abstract="true" name="SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiversifiedSegmentMember" abstract="true" name="DiversifiedSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilityMember" abstract="true" name="SeniorSecuredCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" abstract="false" name="DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SalixReportingUnitMember" abstract="true" name="SalixReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_RICOClassActionsLitigationMember" abstract="true" name="RICOClassActionsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DefaultJudgementMember" abstract="true" name="DefaultJudgementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfDefendants" abstract="false" name="GainContingencyNumberOfDefendants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsLupinANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DermatologySegmentMember" abstract="true" name="DermatologySegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxYear2018AndTaxYear2019Member" abstract="true" name="TaxYear2018AndTaxYear2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ExchangeOfferMember" abstract="true" name="ExchangeOfferMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" abstract="true" name="PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_CaliforniaProposition65RelatedMatterLitigationMember" abstract="true" name="CaliforniaProposition65RelatedMatterLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantComplianceSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" abstract="true" name="CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NeurologyAndOtherReportingUnitMember" abstract="true" name="NeurologyAndOtherReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" abstract="true" name="USDollarBaseRateAndCanadianDollarPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" abstract="false" name="FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" abstract="true" name="OmnibusIncentivePlan2014RetentionRSUGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TroubledDebtRestructuringDebtorTypeAxis" abstract="true" name="TroubledDebtRestructuringDebtorTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_GainContingencyNumberOfProceedings" abstract="false" name="GainContingencyNumberOfProceedings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PerformanceRestrictedShareUnitsMember" abstract="true" name="PerformanceRestrictedShareUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" abstract="false" name="LicensingAgreementsAndAcquisitionDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueFebruary2027Member" abstract="true" name="TermLoanBFacilityDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriodTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_XifaxanBrandedProductsMember" abstract="true" name="XifaxanBrandedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DermatologyReportingUnitMember" abstract="true" name="DermatologyReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AcuFocusIncAcquisitionMember" abstract="true" name="AcuFocusIncAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" abstract="false" name="PaymentsToAcquireBusinessesAndForOtherInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PreserVisionAREDSPatentLitigationMember" abstract="true" name="PreserVisionAREDSPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" abstract="false" name="SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" abstract="true" name="SeniorSecured1400NotesSecondLienDueOctober2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" abstract="false" name="LossContingencyStayOfApprovalMotionToExtendPeriodOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionMaximumTermForRemainingPayment" abstract="false" name="BusinessAcquisitionMaximumTermForRemainingPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SOFRCDOREURIBORAndSONIARatesMember" abstract="true" name="SOFRCDOREURIBORAndSONIARatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A1261229BCLtdMember" abstract="true" name="A1261229BCLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A2022OmnibusIncentivePlanMember" abstract="true" name="A2022OmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" abstract="true" name="FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" abstract="false" name="DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NorwichPharmaceuticalsIncLitigationMember" abstract="true" name="NorwichPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SoltaMedicalSegmentMember" abstract="true" name="SoltaMedicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermFacilityDueMay2027Member" abstract="true" name="TermFacilityDueMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AurobindoPharmaLimitedLitigationMember" abstract="true" name="AurobindoPharmaLimitedLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" abstract="true" name="LumifyParagraphIVProceedingsSlaybackANDALitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TroubledDebtRestructuringDebtorTypeDomain" abstract="true" name="TroubledDebtRestructuringDebtorTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentCovenantAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaroPharmaceuticalsIncLitigationMember" abstract="true" name="TaroPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>bhc-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:15d8a82e-3541-4c94-ac5d-dc1f963a0c8b,g:acd10879-3b31-4117-a8f7-2a1c419d7f06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_61077592-a7df-4fdc-b60f-92b8e9e70b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_28c04288-dcaa-44f8-a322-6d014552f700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61077592-a7df-4fdc-b60f-92b8e9e70b8f" xlink:to="loc_us-gaap_CommonStockValue_28c04288-dcaa-44f8-a322-6d014552f700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24b3837d-3b8e-4529-b8b6-d2030fc75743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61077592-a7df-4fdc-b60f-92b8e9e70b8f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24b3837d-3b8e-4529-b8b6-d2030fc75743" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b39392ba-cd4f-4c7a-971b-0f7f60b40b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61077592-a7df-4fdc-b60f-92b8e9e70b8f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b39392ba-cd4f-4c7a-971b-0f7f60b40b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_469ccbc0-d9cc-4597-8a0e-ea6dfe15c9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_61077592-a7df-4fdc-b60f-92b8e9e70b8f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_469ccbc0-d9cc-4597-8a0e-ea6dfe15c9be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcee29ea-d153-4009-8bc7-f68869153405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_824c7d83-c925-43aa-af1e-e19999fd6fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcee29ea-d153-4009-8bc7-f68869153405" xlink:to="loc_us-gaap_Liabilities_824c7d83-c925-43aa-af1e-e19999fd6fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e38caec-bc68-4ac6-bbf3-83f3137bf0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcee29ea-d153-4009-8bc7-f68869153405" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6e38caec-bc68-4ac6-bbf3-83f3137bf0c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_891f01f4-ac0b-408f-ae48-c230a714d277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_bcee29ea-d153-4009-8bc7-f68869153405" xlink:to="loc_us-gaap_CommitmentsAndContingencies_891f01f4-ac0b-408f-ae48-c230a714d277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_74a99051-df86-4e79-917e-ad44cbc96bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_229099fe-61d4-43d6-899c-b05e48055dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_74a99051-df86-4e79-917e-ad44cbc96bc4" xlink:to="loc_us-gaap_AccountsPayableCurrent_229099fe-61d4-43d6-899c-b05e48055dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b7418119-1cd4-491a-b5f8-f61180f129ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_74a99051-df86-4e79-917e-ad44cbc96bc4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b7418119-1cd4-491a-b5f8-f61180f129ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d28ad5ff-408f-4d3e-b438-7c8cd1dced1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_74a99051-df86-4e79-917e-ad44cbc96bc4" xlink:to="loc_us-gaap_LongTermDebtCurrent_d28ad5ff-408f-4d3e-b438-7c8cd1dced1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6ea012e6-f408-440a-8c56-302d9c3c1ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4eb8f7b2-b23e-4447-8b95-3fc334b1c545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea012e6-f408-440a-8c56-302d9c3c1ea4" xlink:to="loc_us-gaap_LiabilitiesCurrent_4eb8f7b2-b23e-4447-8b95-3fc334b1c545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_63f324f0-04ee-47da-986f-f005ec69b936" xlink:href="bhc-20230331.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea012e6-f408-440a-8c56-302d9c3c1ea4" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_63f324f0-04ee-47da-986f-f005ec69b936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_71dee562-cc74-40d7-a30b-81e5dda84a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea012e6-f408-440a-8c56-302d9c3c1ea4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_71dee562-cc74-40d7-a30b-81e5dda84a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7ec16bc9-c20f-4218-bcb6-dfbdc7ac9926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea012e6-f408-440a-8c56-302d9c3c1ea4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7ec16bc9-c20f-4218-bcb6-dfbdc7ac9926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_05bd43ff-d40b-4a74-a47f-1d0d91a58271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6ea012e6-f408-440a-8c56-302d9c3c1ea4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_05bd43ff-d40b-4a74-a47f-1d0d91a58271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f546a684-cdfe-44c9-9644-0ff8859568cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cce7f31c-d575-4c9a-9df4-3c7563f8e0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f546a684-cdfe-44c9-9644-0ff8859568cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cce7f31c-d575-4c9a-9df4-3c7563f8e0f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_752cf7d6-247c-4716-a4d2-de82288b8271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f546a684-cdfe-44c9-9644-0ff8859568cf" xlink:to="loc_us-gaap_RestrictedCashCurrent_752cf7d6-247c-4716-a4d2-de82288b8271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_57737cc8-09b0-44ab-8ce4-b84f4ded56fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f546a684-cdfe-44c9-9644-0ff8859568cf" xlink:to="loc_us-gaap_ReceivablesNetCurrent_57737cc8-09b0-44ab-8ce4-b84f4ded56fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_92acfd1c-feab-42fd-ad63-1d242e63c9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f546a684-cdfe-44c9-9644-0ff8859568cf" xlink:to="loc_us-gaap_InventoryNet_92acfd1c-feab-42fd-ad63-1d242e63c9bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_79fe02c3-f89a-46ca-8ff7-2a429650f7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f546a684-cdfe-44c9-9644-0ff8859568cf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_79fe02c3-f89a-46ca-8ff7-2a429650f7bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e50caf8-7abb-4383-931d-2c724e3d1b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6511fcbe-6ab9-4199-97ae-fb95bc763539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e50caf8-7abb-4383-931d-2c724e3d1b9c" xlink:to="loc_us-gaap_StockholdersEquity_6511fcbe-6ab9-4199-97ae-fb95bc763539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e0e92c5a-1469-4d3a-bc9a-4980ff2be2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3e50caf8-7abb-4383-931d-2c724e3d1b9c" xlink:to="loc_us-gaap_MinorityInterest_e0e92c5a-1469-4d3a-bc9a-4980ff2be2c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_62a7c033-de44-4119-895d-e60506514307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:to="loc_us-gaap_AssetsCurrent_62a7c033-de44-4119-895d-e60506514307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e989a2a-4f77-4e4d-a84d-d810848396d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e989a2a-4f77-4e4d-a84d-d810848396d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4379b894-2116-4d8c-a97d-52683ff6b3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4379b894-2116-4d8c-a97d-52683ff6b3dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_65eec6d7-5569-4f5f-b8bf-27cb217f1953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:to="loc_us-gaap_Goodwill_65eec6d7-5569-4f5f-b8bf-27cb217f1953" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae3fd9b4-5058-40bb-87b6-3a0a30b2978c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_ae3fd9b4-5058-40bb-87b6-3a0a30b2978c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_72b47ff4-499a-43c3-a0fd-d7b23e816263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ca7905aa-548a-48aa-9452-f676472ff3c4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_72b47ff4-499a-43c3-a0fd-d7b23e816263" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d6695060-f98d-4d1a-ae78-21ab7047ea20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bbe63db-e849-46d4-9816-38e4badc6168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d6695060-f98d-4d1a-ae78-21ab7047ea20" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bbe63db-e849-46d4-9816-38e4badc6168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f2c44b35-61ea-4dde-a0d6-7858788e8073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_d6695060-f98d-4d1a-ae78-21ab7047ea20" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f2c44b35-61ea-4dde-a0d6-7858788e8073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8873aaf3-3475-4d13-806b-d0316344b8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ae431915-9761-4a91-8091-02a2ec1b032f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8873aaf3-3475-4d13-806b-d0316344b8fe" xlink:to="loc_us-gaap_OperatingIncomeLoss_ae431915-9761-4a91-8091-02a2ec1b032f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_486391f1-2ccf-48d5-9fb8-2f8049c42e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8873aaf3-3475-4d13-806b-d0316344b8fe" xlink:to="loc_us-gaap_InvestmentIncomeInterest_486391f1-2ccf-48d5-9fb8-2f8049c42e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_b62b181a-01f5-4ddb-ad2c-59cb65109d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8873aaf3-3475-4d13-806b-d0316344b8fe" xlink:to="loc_us-gaap_InterestExpenseDebt_b62b181a-01f5-4ddb-ad2c-59cb65109d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_73e08035-2434-486b-abe9-6782c8b7e666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8873aaf3-3475-4d13-806b-d0316344b8fe" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_73e08035-2434-486b-abe9-6782c8b7e666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2c77fa79-32dd-4fb3-a780-2e857fa7141a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2c77fa79-32dd-4fb3-a780-2e857fa7141a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00544e7c-94c3-4459-86d5-c2909a69ae33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00544e7c-94c3-4459-86d5-c2909a69ae33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9e5ceb66-e2ab-43c2-a16d-9191a05e2442" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9e5ceb66-e2ab-43c2-a16d-9191a05e2442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_bd463128-507f-4a17-ae7e-9e197f83f0ab" xlink:href="bhc-20230331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_bd463128-507f-4a17-ae7e-9e197f83f0ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_490bb158-b5ae-44b5-a60b-070c8903bd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_us-gaap_AssetImpairmentCharges_490bb158-b5ae-44b5-a60b-070c8903bd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_755402b0-8ea8-4628-ab05-0a57804fd1ba" xlink:href="bhc-20230331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_755402b0-8ea8-4628-ab05-0a57804fd1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_3d9628d8-f9f7-43e2-a824-762a85fc18df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_3ebd97c4-c9cb-4ec9-aece-01b57756860d" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_3d9628d8-f9f7-43e2-a824-762a85fc18df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83e6a1a4-3568-4067-8ef4-b8c939a4cf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7e12cafc-5380-4997-9ee2-5be5ed6b4f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_83e6a1a4-3568-4067-8ef4-b8c939a4cf5e" xlink:to="loc_us-gaap_ProfitLoss_7e12cafc-5380-4997-9ee2-5be5ed6b4f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d31edec3-d6ed-4173-8709-449291e2d2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_83e6a1a4-3568-4067-8ef4-b8c939a4cf5e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d31edec3-d6ed-4173-8709-449291e2d2be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_623282da-cc5c-4439-a466-b86d30d9b953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0900deea-afab-4bf3-8562-3e5986020980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_623282da-cc5c-4439-a466-b86d30d9b953" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0900deea-afab-4bf3-8562-3e5986020980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_ee5d5478-9e60-4785-aa99-0b3e8d56a3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_623282da-cc5c-4439-a466-b86d30d9b953" xlink:to="loc_us-gaap_CostsAndExpenses_ee5d5478-9e60-4785-aa99-0b3e8d56a3fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_51e83e5e-4f9e-44ec-b59e-7e6b8e342d51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_35e183e2-b201-4224-9c64-05b096192fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51e83e5e-4f9e-44ec-b59e-7e6b8e342d51" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_35e183e2-b201-4224-9c64-05b096192fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_99d352dd-e91f-4b5f-9ebe-05aafa88678f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_51e83e5e-4f9e-44ec-b59e-7e6b8e342d51" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_99d352dd-e91f-4b5f-9ebe-05aafa88678f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6f302d9-4fed-41ea-bd21-815f39a6f0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a6ea3d4c-f2e6-402b-9097-7cdfa554366b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6f302d9-4fed-41ea-bd21-815f39a6f0f5" xlink:to="loc_us-gaap_ProfitLoss_a6ea3d4c-f2e6-402b-9097-7cdfa554366b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ca00f44-65c6-4b3f-966f-466a215a0478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f6f302d9-4fed-41ea-bd21-815f39a6f0f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2ca00f44-65c6-4b3f-966f-466a215a0478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f38dbc5d-ed57-456d-9bb1-e92abafd21ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f5a59a41-8e68-4313-b8a3-c8ccea0184b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f38dbc5d-ed57-456d-9bb1-e92abafd21ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f5a59a41-8e68-4313-b8a3-c8ccea0184b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_468c41dd-c5bd-4a67-91f5-40ff8f2c2f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_f38dbc5d-ed57-456d-9bb1-e92abafd21ac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_468c41dd-c5bd-4a67-91f5-40ff8f2c2f7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_106bcad7-5f4a-4b8a-bd0b-1a5a2223c85d" xlink:href="bhc-20230331.xsd#bhc_PaymentsToAcquireBusinessesAndForOtherInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:to="loc_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_106bcad7-5f4a-4b8a-bd0b-1a5a2223c85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0eead49f-0a36-4f77-bed2-70591c346aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0eead49f-0a36-4f77-bed2-70591c346aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fcd58e06-79ae-43ea-a4cf-3755c996f584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fcd58e06-79ae-43ea-a4cf-3755c996f584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_85dd33bd-da5b-403d-af69-a79576252cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_85dd33bd-da5b-403d-af69-a79576252cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5120d444-d50d-4381-ae82-b82686ffe3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_5120d444-d50d-4381-ae82-b82686ffe3d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_778baf0b-aa6e-4e70-b61a-fc93c63fdd49" xlink:href="bhc-20230331.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de60cd60-aebe-4df8-bd9a-570fcdafad9f" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_778baf0b-aa6e-4e70-b61a-fc93c63fdd49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18cb904c-ab79-4c5c-92bd-e1141056ac77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cd7ba61-1d8b-40c8-9798-452cf9d251b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18cb904c-ab79-4c5c-92bd-e1141056ac77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cd7ba61-1d8b-40c8-9798-452cf9d251b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d1a4efe6-dff6-4411-92be-ae986127f123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18cb904c-ab79-4c5c-92bd-e1141056ac77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d1a4efe6-dff6-4411-92be-ae986127f123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e5da0370-3141-4c85-aaa7-7fb24df95ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18cb904c-ab79-4c5c-92bd-e1141056ac77" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e5da0370-3141-4c85-aaa7-7fb24df95ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42a33f71-07d3-4685-93cc-0baffb308936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_18cb904c-ab79-4c5c-92bd-e1141056ac77" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_42a33f71-07d3-4685-93cc-0baffb308936" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d5bad260-1e68-4c11-98a0-3d6d25a0be7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d5bad260-1e68-4c11-98a0-3d6d25a0be7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f7f0c221-b3e8-4079-8e06-4736991d7c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f7f0c221-b3e8-4079-8e06-4736991d7c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9a0a7ece-4536-47b7-85a6-c2e5048b9d11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9a0a7ece-4536-47b7-85a6-c2e5048b9d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_73e9c9e5-212a-4e18-92b7-c6b4bc0e775a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_73e9c9e5-212a-4e18-92b7-c6b4bc0e775a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2618d75a-3ccc-4f15-a0aa-22d5742dda6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2618d75a-3ccc-4f15-a0aa-22d5742dda6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3bac5852-d74a-4a39-9002-cfde9d588e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8cd63d6e-4360-4c48-beb5-5989454be4d1" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3bac5852-d74a-4a39-9002-cfde9d588e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_487a7a62-f175-464b-9577-af90ba9faeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5eea9c7f-f1dd-4ef4-bf9c-a740434f54de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_487a7a62-f175-464b-9577-af90ba9faeb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5eea9c7f-f1dd-4ef4-bf9c-a740434f54de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_50db9765-23e2-49ad-bed1-451349892aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_487a7a62-f175-464b-9577-af90ba9faeb8" xlink:to="loc_us-gaap_RestrictedCashCurrent_50db9765-23e2-49ad-bed1-451349892aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4c175e40-2349-4639-a25a-47a721564e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_ProfitLoss_4c175e40-2349-4639-a25a-47a721564e01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b7427a2a-0ac3-414e-9241-b7f147e06180" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_DepreciationAndAmortization_b7427a2a-0ac3-414e-9241-b7f147e06180" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79ec9022-e436-48cc-a8a7-03b3ca5a0267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_79ec9022-e436-48cc-a8a7-03b3ca5a0267" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3cd22b54-5e6c-4181-96b9-a031e46b8028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_AssetImpairmentCharges_3cd22b54-5e6c-4181-96b9-a031e46b8028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_713333f9-3f2f-4864-ac37-c1a482648e3d" xlink:href="bhc-20230331.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_713333f9-3f2f-4864-ac37-c1a482648e3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_b26e8725-1a4e-44f6-8e3a-6180ccf97314" xlink:href="bhc-20230331.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_b26e8725-1a4e-44f6-8e3a-6180ccf97314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_1728e3fb-dc6e-413a-8890-2185967d2d76" xlink:href="bhc-20230331.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_1728e3fb-dc6e-413a-8890-2185967d2d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_69c9734a-f809-4618-8fd9-2bd6231d708c" xlink:href="bhc-20230331.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_69c9734a-f809-4618-8fd9-2bd6231d708c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_a9d31a00-44e5-4146-986a-8111b7afec3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_a9d31a00-44e5-4146-986a-8111b7afec3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_47e404cc-8f9f-48d3-a8d5-9867fd97754c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_ShareBasedCompensation_47e404cc-8f9f-48d3-a8d5-9867fd97754c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_53ce9c66-72ac-41db-84db-e03fd9a0d04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_53ce9c66-72ac-41db-84db-e03fd9a0d04f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_fad8b35c-378f-4d0d-81ff-82cd07e051b2" xlink:href="bhc-20230331.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_bhc_DerivativeGainExcludedComponent_fad8b35c-378f-4d0d-81ff-82cd07e051b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0013fcd7-e892-4ed5-9cbd-04337cbaa3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0013fcd7-e892-4ed5-9cbd-04337cbaa3d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a9d6f02-a0dc-4476-98a2-c8143044ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1a9d6f02-a0dc-4476-98a2-c8143044ba1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_548a744a-3cd0-438c-8d29-ad8509932497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_548a744a-3cd0-438c-8d29-ad8509932497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fe76a5b8-5fb8-4927-a491-365ef93a509f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fe76a5b8-5fb8-4927-a491-365ef93a509f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3b0a4ba4-3cac-4e5b-ba9b-a7568cf4002c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e86a7bf3-e2e4-4d19-8d77-4867515710f6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3b0a4ba4-3cac-4e5b-ba9b-a7568cf4002c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5291913b-fba5-4126-912c-7dfefd7e7e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_98b90c34-df74-44cb-8777-64ab4a41696b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5291913b-fba5-4126-912c-7dfefd7e7e2f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_98b90c34-df74-44cb-8777-64ab4a41696b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c7338f2a-88d3-4fa1-b086-8f04a328c75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5291913b-fba5-4126-912c-7dfefd7e7e2f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c7338f2a-88d3-4fa1-b086-8f04a328c75c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_e35abdcb-fc7e-472d-8417-b8f6bebe0a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_66b3bea3-e096-4230-a3f9-d8b9c8ae372c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e35abdcb-fc7e-472d-8417-b8f6bebe0a07" xlink:to="loc_us-gaap_InventoryRawMaterials_66b3bea3-e096-4230-a3f9-d8b9c8ae372c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_47530d30-c131-41ea-8a7d-9ecbfabba5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e35abdcb-fc7e-472d-8417-b8f6bebe0a07" xlink:to="loc_us-gaap_InventoryWorkInProcess_47530d30-c131-41ea-8a7d-9ecbfabba5dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_941313be-1d36-4bda-ac8c-7eb5ccf74ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_e35abdcb-fc7e-472d-8417-b8f6bebe0a07" xlink:to="loc_us-gaap_InventoryFinishedGoods_941313be-1d36-4bda-ac8c-7eb5ccf74ffc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_847f4474-4e46-4300-8a56-d3bc39869f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_273d12ba-8911-452b-b713-32aef5e4d5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_847f4474-4e46-4300-8a56-d3bc39869f49" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_273d12ba-8911-452b-b713-32aef5e4d5bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8733d2f1-0d69-4f9f-a197-6865c00c5c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_847f4474-4e46-4300-8a56-d3bc39869f49" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8733d2f1-0d69-4f9f-a197-6865c00c5c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20fedeeb-159d-4698-9622-35ee1e681c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a279f40-dc88-4caf-a0db-3437f23077ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20fedeeb-159d-4698-9622-35ee1e681c13" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a279f40-dc88-4caf-a0db-3437f23077ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_82d952cd-cf58-4849-9138-36194a9666cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_20fedeeb-159d-4698-9622-35ee1e681c13" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_82d952cd-cf58-4849-9138-36194a9666cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2f610da-7956-40aa-9b19-163911e9d6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c4362d47-d946-4ff3-9fc5-8f60ad33ac9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2f610da-7956-40aa-9b19-163911e9d6ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c4362d47-d946-4ff3-9fc5-8f60ad33ac9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8c4eb862-5928-4de9-b87e-7b577cc44ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2f610da-7956-40aa-9b19-163911e9d6ef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8c4eb862-5928-4de9-b87e-7b577cc44ac1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9a6f04ed-51dc-4adf-b897-05d44ed75995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_9a6f04ed-51dc-4adf-b897-05d44ed75995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09382e42-3cd6-4536-b93a-29d56e52bddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_09382e42-3cd6-4536-b93a-29d56e52bddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3727fca8-cd49-4194-a7fa-a5bca1cc6bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3727fca8-cd49-4194-a7fa-a5bca1cc6bbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_51e019ce-c21b-42c3-b658-a5b41c0eb69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_51e019ce-c21b-42c3-b658-a5b41c0eb69d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_753af0be-a5fd-4cde-95e4-856a4f5bc4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_753af0be-a5fd-4cde-95e4-856a4f5bc4f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4418abe7-da68-4f79-b985-3b82ebcac7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_4418abe7-da68-4f79-b985-3b82ebcac7a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e555a899-bb67-4560-8717-cabe790011e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5a8df530-7165-444b-be55-f5e4fe24c40e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e555a899-bb67-4560-8717-cabe790011e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_827d2397-c338-4636-b370-9dd49994bd3b" xlink:href="bhc-20230331.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_bhc_AccruedProductRebateCurrent_827d2397-c338-4636-b370-9dd49994bd3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_03b7eea5-c662-4a31-bd07-9ca1df7b250e" xlink:href="bhc-20230331.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_bhc_AccruedProductReturnCurrent_03b7eea5-c662-4a31-bd07-9ca1df7b250e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_be0376ef-c5e4-44f5-98de-c49ff8d08d7f" xlink:href="bhc-20230331.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_be0376ef-c5e4-44f5-98de-c49ff8d08d7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_53ed0f11-4164-4815-a49d-88a134fc4e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_53ed0f11-4164-4815-a49d-88a134fc4e04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_0967a6a1-10ed-46d1-8f9a-9850f99c60ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_us-gaap_InterestPayableCurrent_0967a6a1-10ed-46d1-8f9a-9850f99c60ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b1433c94-3854-4447-b49c-d40795bd9bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b1433c94-3854-4447-b49c-d40795bd9bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_058dee63-0129-4dfa-923e-37f46f453023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_617a222a-1e8b-453f-86df-857666c568ee" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_058dee63-0129-4dfa-923e-37f46f453023" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_283af295-804a-407a-83d5-51b3796d5478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_138ebc05-73a2-4d1f-b4cd-abbefbe147e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_283af295-804a-407a-83d5-51b3796d5478" xlink:to="loc_us-gaap_LongTermDebtCurrent_138ebc05-73a2-4d1f-b4cd-abbefbe147e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e6aa50e6-5f3f-4804-bb5f-394cb5a7cd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_283af295-804a-407a-83d5-51b3796d5478" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e6aa50e6-5f3f-4804-bb5f-394cb5a7cd73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_11a053ef-82f6-4fa4-b12f-4117d1aaca72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1ced3798-d109-46ee-9e91-67ae7b5214eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_11a053ef-82f6-4fa4-b12f-4117d1aaca72" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1ced3798-d109-46ee-9e91-67ae7b5214eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f343a674-1d10-4150-993b-ce861aa6a6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_11a053ef-82f6-4fa4-b12f-4117d1aaca72" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f343a674-1d10-4150-993b-ce861aa6a6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_47f72774-bf5a-4071-beeb-3fe96ec8e00f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_47f72774-bf5a-4071-beeb-3fe96ec8e00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d201ae45-6fd6-4d2a-b926-848af20e388c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d201ae45-6fd6-4d2a-b926-848af20e388c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_28f1f0f1-9fd7-46e8-b0c3-97f930398af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_28f1f0f1-9fd7-46e8-b0c3-97f930398af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_013f4dd1-e39a-451d-81c3-99197d577d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_013f4dd1-e39a-451d-81c3-99197d577d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_05afb76b-dae8-4df2-9111-72b30b1562fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_05afb76b-dae8-4df2-9111-72b30b1562fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a93bd6c8-ab73-4263-8194-e03a5c586d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a93bd6c8-ab73-4263-8194-e03a5c586d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a5ddbce7-2af4-4a9b-b107-f8f66226c879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_c1117448-72af-4df4-a7df-37007be57a4e" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_a5ddbce7-2af4-4a9b-b107-f8f66226c879" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5cda127d-9afd-456f-95b2-abc03bd0d327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_a2ca47c1-e95b-41c6-a261-863cad2d6315" xlink:href="bhc-20230331.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5cda127d-9afd-456f-95b2-abc03bd0d327" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_a2ca47c1-e95b-41c6-a261-863cad2d6315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_8d36531e-2c06-47f5-827d-b5c7dd5307a3" xlink:href="bhc-20230331.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5cda127d-9afd-456f-95b2-abc03bd0d327" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_8d36531e-2c06-47f5-827d-b5c7dd5307a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3e185a78-524f-44b5-afde-dd04976fe092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_805f199d-0dde-4370-ab21-fc2abf898e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3e185a78-524f-44b5-afde-dd04976fe092" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_805f199d-0dde-4370-ab21-fc2abf898e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ef436216-9d4e-40fd-9cb9-730346c54d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_3e185a78-524f-44b5-afde-dd04976fe092" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ef436216-9d4e-40fd-9cb9-730346c54d9b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>bhc-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:15d8a82e-3541-4c94-ac5d-dc1f963a0c8b,g:acd10879-3b31-4117-a8f7-2a1c419d7f06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i31706187dd484fa6a48a51569e03ec3f_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ff9e3dd4-bd71-4207-b4d5-88e17ca2af59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_RevenuesAbstract_ff9e3dd4-bd71-4207-b4d5-88e17ca2af59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad16ec17-b016-4e04-a6bd-ec08a5595c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_ff9e3dd4-bd71-4207-b4d5-88e17ca2af59" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad16ec17-b016-4e04-a6bd-ec08a5595c24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_00ff6f03-068c-4842-8491-9ff7fac7e28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_00ff6f03-068c-4842-8491-9ff7fac7e28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9f07a70-52fc-4439-8934-d4e4dd9aecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9f07a70-52fc-4439-8934-d4e4dd9aecb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5010d2fa-9a97-48e8-8040-ad30927f0406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5010d2fa-9a97-48e8-8040-ad30927f0406" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_d234a9c3-4f0e-40a0-bb65-1ab334b3ff91" xlink:href="bhc-20230331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_d234a9c3-4f0e-40a0-bb65-1ab334b3ff91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f113cfdf-2504-4ff3-9880-3698b866d146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_AssetImpairmentCharges_f113cfdf-2504-4ff3-9880-3698b866d146" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_887d42ef-6027-4054-a49f-9535eb8eb266" xlink:href="bhc-20230331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_887d42ef-6027-4054-a49f-9535eb8eb266" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9817914e-793d-4e31-b971-e6a2eabb05c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9817914e-793d-4e31-b971-e6a2eabb05c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_64541a5b-75ba-4468-9da5-dae132f539ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_CostsAndExpenses_64541a5b-75ba-4468-9da5-dae132f539ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3183d26e-1ab9-4148-8a56-90af1b086223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_OperatingIncomeLoss_3183d26e-1ab9-4148-8a56-90af1b086223" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7b92c5e7-af9a-479f-ba72-d5cdb8f8b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7b92c5e7-af9a-479f-ba72-d5cdb8f8b7c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_06524160-eae5-46fd-934d-6846fcb5c2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_InterestExpenseDebt_06524160-eae5-46fd-934d-6846fcb5c2f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_261f8565-30e0-457c-b2e8-dd6b81ef2c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_261f8565-30e0-457c-b2e8-dd6b81ef2c0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7235945e-bb4d-4268-b264-17389b812d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7235945e-bb4d-4268-b264-17389b812d60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_830330b4-f7e5-41a5-9629-89e3f149cf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_830330b4-f7e5-41a5-9629-89e3f149cf3d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39ee267c-aec2-4e37-92bd-68aa070f37ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_ProfitLoss_39ee267c-aec2-4e37-92bd-68aa070f37ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f45ab1a6-b1b5-4968-814a-36d5f986ceb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f45ab1a6-b1b5-4968-814a-36d5f986ceb6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59432d02-694a-42c9-91d7-c639a28a0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_NetIncomeLoss_59432d02-694a-42c9-91d7-c639a28a0a6a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_01125956-1b68-469e-8b8a-7f4c96f20c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_EarningsPerShareBasic_01125956-1b68-469e-8b8a-7f4c96f20c7a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f9dd015f-618a-4d0c-bcfc-5e3226d3b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f9dd015f-618a-4d0c-bcfc-5e3226d3b9d6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf8abcec-81dc-4a31-9dda-321e54c27b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf8abcec-81dc-4a31-9dda-321e54c27b0e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99f60f55-898d-479d-b213-443e1edd0f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99f60f55-898d-479d-b213-443e1edd0f05" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:to="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_46aa8713-151f-42f6-b4e1-024430a7b728_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:to="loc_srt_ProductsAndServicesDomain_46aa8713-151f-42f6-b4e1-024430a7b728_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:to="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2c3d93ba-92d4-4a1b-a2e2-4a1023e21807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:to="loc_us-gaap_ProductMember_2c3d93ba-92d4-4a1b-a2e2-4a1023e21807" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3400aecd-60ef-4292-801f-c55e5a38ee06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3400aecd-60ef-4292-801f-c55e5a38ee06" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="id708287f48424fb49896ff53227bc0bb_CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4735dd5-cce0-4cf5-b2c3-cb6a3c6f582d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d4735dd5-cce0-4cf5-b2c3-cb6a3c6f582d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_668b347b-23ed-4874-af5e-32a86faeeb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_CommonStockSharesIssued_668b347b-23ed-4874-af5e-32a86faeeb5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7b90d97-aa48-4b5b-a91a-6c387bd2a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7b90d97-aa48-4b5b-a91a-6c387bd2a8a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c8347eb1-c055-46fa-85c6-a308884c6952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c8347eb1-c055-46fa-85c6-a308884c6952" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3dda7f9a-23d7-4e0b-b7f3-c37d3601adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3dda7f9a-23d7-4e0b-b7f3-c37d3601adb4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8c95559-8ca0-42e3-879e-d842241985aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8c95559-8ca0-42e3-879e-d842241985aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_13d853b3-bada-494f-bf3b-dc930227adc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_13d853b3-bada-494f-bf3b-dc930227adc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2d90431a-7573-40af-876c-d1ce64956afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2d90431a-7573-40af-876c-d1ce64956afc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e90d7ed-927b-4e99-91cc-f626676062ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_ProfitLoss_5e90d7ed-927b-4e99-91cc-f626676062ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0683b469-fbac-44dc-a783-1af0b9da7f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0683b469-fbac-44dc-a783-1af0b9da7f75" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cbc94ea6-f2a4-4c26-abcb-260e263ca2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cef6ebd9-ffb5-4cdb-a5db-e4fa3fd40ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d4735dd5-cce0-4cf5-b2c3-cb6a3c6f582d" xlink:to="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f53491c9-5ddb-4e1e-be3e-cdbf824fc316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:to="loc_us-gaap_EquityComponentDomain_f53491c9-5ddb-4e1e-be3e-cdbf824fc316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:to="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:to="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4ff6003-f8bd-40b7-b553-6dda6693e4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_CommonStockMember_a4ff6003-f8bd-40b7-b553-6dda6693e4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7515ed49-9055-45ba-b7ea-cc81935867b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7515ed49-9055-45ba-b7ea-cc81935867b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_351edd40-d6e2-425d-a121-ebe187980e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_RetainedEarningsMember_351edd40-d6e2-425d-a121-ebe187980e65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f8fd5030-89f8-46dd-9e1e-68f7008521e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f8fd5030-89f8-46dd-9e1e-68f7008521e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_cab77ee6-5ec2-4ff4-933a-a02af2fb8f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:to="loc_us-gaap_NoncontrollingInterestMember_cab77ee6-5ec2-4ff4-933a-a02af2fb8f5b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended" id="i142cdbaaee7b4fbb80b304a336bf5c0b_DESCRIPTIONOFBUSINESSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_943d83eb-f22e-4db4-8f45-344504227bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_943d83eb-f22e-4db4-8f45-344504227bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_bd7f55f6-5920-4176-a957-e1914f26dd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_bd7f55f6-5920-4176-a957-e1914f26dd0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:to="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_85ff5e0a-fa5b-47e1-b450-69dd3561fc75_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:to="loc_srt_OwnershipDomain_85ff5e0a-fa5b-47e1-b450-69dd3561fc75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9a101b56-debc-4ec5-9dcf-4e7feb089aa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:to="loc_srt_OwnershipDomain_9a101b56-debc-4ec5-9dcf-4e7feb089aa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_b6c7e874-9ce4-459d-874a-ed837b770cb9" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_9a101b56-debc-4ec5-9dcf-4e7feb089aa7" xlink:to="loc_bhc_BauschLombMember_b6c7e874-9ce4-459d-874a-ed837b770cb9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended" id="ibbf555277b354d1bb62e2f5e9bf8d646_SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c2993c56-17de-44eb-a94f-69a9a953d7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c2993c56-17de-44eb-a94f-69a9a953d7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_850cfd39-c514-40b7-be1a-0a4b5e8177c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_850cfd39-c514-40b7-be1a-0a4b5e8177c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_65bbfd51-16da-4cb2-a33b-fe50f6627127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_65bbfd51-16da-4cb2-a33b-fe50f6627127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3069a890-666c-444d-b406-9310d6f830e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3069a890-666c-444d-b406-9310d6f830e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23312c71-08a8-4dde-af94-47de761567b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23312c71-08a8-4dde-af94-47de761567b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_afeee29d-0c10-42f0-a739-954d33df5769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23312c71-08a8-4dde-af94-47de761567b0" xlink:to="loc_us-gaap_IPOMember_afeee29d-0c10-42f0-a739-954d33df5769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:to="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b0635df5-aadf-4001-a2a8-37798f144762_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:to="loc_srt_OwnershipDomain_b0635df5-aadf-4001-a2a8-37798f144762_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c3977eb1-3470-4b20-905a-e8505ca2ff1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:to="loc_srt_OwnershipDomain_c3977eb1-3470-4b20-905a-e8505ca2ff1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e607860a-c7cf-4b59-a860-e89b995eb4ba" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_c3977eb1-3470-4b20-905a-e8505ca2ff1b" xlink:to="loc_bhc_BauschLombMember_e607860a-c7cf-4b59-a860-e89b995eb4ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended" id="ibfe205681af844d5b52dfe985518e0cb_REVENUERECOGNITIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f1a814b4-0cd5-4676-b3cd-97599222b2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_f1a814b4-0cd5-4676-b3cd-97599222b2be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb9e5080-8c82-4f61-ab94-46971f9c7904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb9e5080-8c82-4f61-ab94-46971f9c7904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6b6ae45-d749-4070-9d9f-139c69d196c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d6b6ae45-d749-4070-9d9f-139c69d196c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c020089-220b-47d8-b58c-15625cbb71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c020089-220b-47d8-b58c-15625cbb71a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_6733aa16-8b6e-46fe-b7e1-c9fd5f2f5fc5" xlink:href="bhc-20230331.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c020089-220b-47d8-b58c-15625cbb71a2" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_6733aa16-8b6e-46fe-b7e1-c9fd5f2f5fc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:to="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_380ef17b-05ae-4e5b-9c90-7667cc423640_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:to="loc_srt_ProductsAndServicesDomain_380ef17b-05ae-4e5b-9c90-7667cc423640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b93cd5f-dfe9-45b5-890f-2aa1b54619c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:to="loc_srt_ProductsAndServicesDomain_9b93cd5f-dfe9-45b5-890f-2aa1b54619c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_90ca3403-5fb5-48a2-80a2-9663b208dd26" xlink:href="bhc-20230331.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9b93cd5f-dfe9-45b5-890f-2aa1b54619c5" xlink:to="loc_bhc_PriceAppreciationCreditMember_90ca3403-5fb5-48a2-80a2-9663b208dd26" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended" id="i684a577be02443eeb81aaa3fe6d16e42_REVENUERECOGNITIONVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_94600bbb-4af3-4a7c-9952-779777a7fdd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_94600bbb-4af3-4a7c-9952-779777a7fdd0" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4648fe2f-64f3-41dc-a1fd-c31e16996761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4648fe2f-64f3-41dc-a1fd-c31e16996761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7a8ac968-ca49-4586-b19b-4f883271676a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7a8ac968-ca49-4586-b19b-4f883271676a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_948490d7-6ab8-479a-a893-41df0a7cd4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_948490d7-6ab8-479a-a893-41df0a7cd4f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6b4032b-24cd-4069-bd4f-042779f50080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_94600bbb-4af3-4a7c-9952-779777a7fdd0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_51f58c89-eb6a-4846-bbca-a76ba719f000_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_51f58c89-eb6a-4846-bbca-a76ba719f000_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_3d8de10d-4c4c-4d8c-aa2d-a4c0b534e656" xlink:href="bhc-20230331.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_3d8de10d-4c4c-4d8c-aa2d-a4c0b534e656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_2f3bb2ad-d21d-498e-a6e0-9d01ce82929e" xlink:href="bhc-20230331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_2f3bb2ad-d21d-498e-a6e0-9d01ce82929e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_cc65183f-833d-45d4-aa4e-df977aee8130" xlink:href="bhc-20230331.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForRebatesMember_cc65183f-833d-45d4-aa4e-df977aee8130" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_439c807a-cfb1-4f09-ae17-161d9309dd69" xlink:href="bhc-20230331.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForChargebacksMember_439c807a-cfb1-4f09-ae17-161d9309dd69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_84867274-86d0-48d5-a10d-210f26e0ea05" xlink:href="bhc-20230331.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForDistributionFeesMember_84867274-86d0-48d5-a10d-210f26e0ea05" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails" xlink:type="extended" id="iddd74643e5de46a89e10d9a8a56de559_LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_466b60ed-7133-4cc1-9658-810f57611f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_466b60ed-7133-4cc1-9658-810f57611f04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_41719d8b-95c5-4848-9e69-5737015bf154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_41719d8b-95c5-4848-9e69-5737015bf154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_1628f2ac-a19b-4636-a163-c44f191383c0" xlink:href="bhc-20230331.xsd#bhc_BusinessAcquisitionMaximumTermForRemainingPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_1628f2ac-a19b-4636-a163-c44f191383c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c3255bf6-1427-4ff1-8571-edead318ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c3255bf6-1427-4ff1-8571-edead318ea3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c0941935-3d83-462e-adb1-68fa2f794459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c0941935-3d83-462e-adb1-68fa2f794459" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bc757159-a8c2-441c-864a-f41b8109c46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_Goodwill_bc757159-a8c2-441c-864a-f41b8109c46f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_530160a5-4320-4c63-83f1-54b4f8556724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_530160a5-4320-4c63-83f1-54b4f8556724" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_99feb7ad-6def-4e87-886a-165d85dca269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_99feb7ad-6def-4e87-886a-165d85dca269" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_639437eb-9072-4877-a4e4-7a08c22c37fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_639437eb-9072-4877-a4e4-7a08c22c37fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d33d81d-6ae5-42fc-9863-a7df2ba526a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d33d81d-6ae5-42fc-9863-a7df2ba526a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcuFocusIncAcquisitionMember_b91c804c-4447-44b3-a418-5935f36b8e44" xlink:href="bhc-20230331.xsd#bhc_AcuFocusIncAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d33d81d-6ae5-42fc-9863-a7df2ba526a0" xlink:to="loc_bhc_AcuFocusIncAcquisitionMember_b91c804c-4447-44b3-a418-5935f36b8e44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:to="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_db54fc5d-7991-4448-903e-d3dad2e3a5c3_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:to="loc_dei_EntityDomain_db54fc5d-7991-4448-903e-d3dad2e3a5c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4e8a1714-88b8-47e4-afd9-37c894428f7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:to="loc_dei_EntityDomain_4e8a1714-88b8-47e4-afd9-37c894428f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_a5ca70d3-884c-470b-961f-ae047c9dbaf0" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4e8a1714-88b8-47e4-afd9-37c894428f7b" xlink:to="loc_bhc_BauschLombMember_a5ca70d3-884c-470b-961f-ae047c9dbaf0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="ia4acb4c5755246e181843fd4f0ea8c54_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0f0012b7-68a0-4926-a085-7932b6f10bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0f0012b7-68a0-4926-a085-7932b6f10bdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_47195d6f-de06-4d88-a4b0-3ce7e38d79ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_RestructuringCharges_47195d6f-de06-4d88-a4b0-3ce7e38d79ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cbc27bc6-abfa-4e74-b774-45c2b9341c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cbc27bc6-abfa-4e74-b774-45c2b9341c89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79928972-0de5-4af5-b373-1566513a71b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79928972-0de5-4af5-b373-1566513a71b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_43090080-98e6-4e7b-9a53-24a4dd12bdc5" xlink:href="bhc-20230331.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_43090080-98e6-4e7b-9a53-24a4dd12bdc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_db2becd4-c9d8-4279-9108-81a5dd1171d9" xlink:href="bhc-20230331.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_db2becd4-c9d8-4279-9108-81a5dd1171d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i2509aee1bbc844a0bf11aa42bba5afb7_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_92d6fa73-cfb8-4625-8026-5290a45474d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_92d6fa73-cfb8-4625-8026-5290a45474d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5bc7a1bd-ebec-4913-9918-fbfc6e56ba71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:to="loc_us-gaap_RestrictedCashCurrent_5bc7a1bd-ebec-4913-9918-fbfc6e56ba71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6aadba33-cbfc-49fc-b440-c93431703325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:to="loc_us-gaap_DerivativeAssets_6aadba33-cbfc-49fc-b440-c93431703325" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_89ef0466-4787-4ca0-b0e2-d502414e020f" xlink:href="bhc-20230331.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_89ef0466-4787-4ca0-b0e2-d502414e020f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d2e10663-08f1-48b6-b80c-c5863a653554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:to="loc_us-gaap_DerivativeLiabilities_d2e10663-08f1-48b6-b80c-c5863a653554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_613b512e-e03d-4548-9d18-92b07c149128_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_613b512e-e03d-4548-9d18-92b07c149128_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4be9bdbc-0893-44ae-ba37-656c14502f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4be9bdbc-0893-44ae-ba37-656c14502f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_04aab7d0-4dbb-412d-ab30-1aba04a4622f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4be9bdbc-0893-44ae-ba37-656c14502f16" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_04aab7d0-4dbb-412d-ab30-1aba04a4622f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_125e4875-8db3-4ccb-8cea-578f35415b76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_125e4875-8db3-4ccb-8cea-578f35415b76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_513825f9-77c2-4017-a500-8f270c230dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_513825f9-77c2-4017-a500-8f270c230dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_515c5f78-4573-48e3-a26f-085adf05a5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_515c5f78-4573-48e3-a26f-085adf05a5d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f9b86247-dd8e-4ae4-9f18-4a995b95fb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f9b86247-dd8e-4ae4-9f18-4a995b95fb66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1b1617af-2e8c-4d3e-bf1c-21b9f1deaf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:to="loc_us-gaap_CurrencySwapMember_1b1617af-2e8c-4d3e-bf1c-21b9f1deaf41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_48585e91-badb-4475-b189-0f4b8ac33565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:to="loc_us-gaap_ForeignExchangeContractMember_48585e91-badb-4475-b189-0f4b8ac33565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_849ae74c-df9f-4b63-bc0a-7c2d807b7990_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:to="loc_us-gaap_HedgingDesignationDomain_849ae74c-df9f-4b63-bc0a-7c2d807b7990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:to="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_7713432f-b9fa-416b-8236-a51426c4b760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:to="loc_us-gaap_NondesignatedMember_7713432f-b9fa-416b-8236-a51426c4b760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9076217e-0f7a-4d75-8c56-cd92dac872db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9076217e-0f7a-4d75-8c56-cd92dac872db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_07b31a32-ce0c-4cf7-930c-17a50a84a9e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_07b31a32-ce0c-4cf7-930c-17a50a84a9e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3d5d35f8-e923-460c-baf5-a18c63b41289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3d5d35f8-e923-460c-baf5-a18c63b41289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_60353176-88b6-49e1-bfed-161629f64ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3d5d35f8-e923-460c-baf5-a18c63b41289" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_60353176-88b6-49e1-bfed-161629f64ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0c7a4d1b-a2bb-440a-a757-7683e141d1e4_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:to="loc_dei_EntityDomain_0c7a4d1b-a2bb-440a-a757-7683e141d1e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e56bedab-6918-4683-86ed-4812e3469f14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:to="loc_dei_EntityDomain_e56bedab-6918-4683-86ed-4812e3469f14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_88ef6f2e-56cd-4aec-a815-92de35d859d9" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e56bedab-6918-4683-86ed-4812e3469f14" xlink:to="loc_bhc_BauschLombMember_88ef6f2e-56cd-4aec-a815-92de35d859d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="ieac030b8919f4bd78a934d5be6684f67_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_545ee922-d3c4-44f3-a61a-2355040915bd" xlink:href="bhc-20230331.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_545ee922-d3c4-44f3-a61a-2355040915bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28d12bc5-c198-40a9-b6b6-4306d98148e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28d12bc5-c198-40a9-b6b6-4306d98148e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_87a20c6d-83b3-43e1-9619-38125c5a99eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_87a20c6d-83b3-43e1-9619-38125c5a99eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_95b2803a-2d95-4887-8832-e6e6b71efd53_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:to="loc_srt_LitigationCaseTypeDomain_95b2803a-2d95-4887-8832-e6e6b71efd53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8f75b0c3-e423-48b6-a1b8-ab7c90f122d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:to="loc_srt_LitigationCaseTypeDomain_8f75b0c3-e423-48b6-a1b8-ab7c90f122d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_e67b251c-ffe2-4d52-8936-98be69d59ba7" xlink:href="bhc-20230331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_8f75b0c3-e423-48b6-a1b8-ab7c90f122d5" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_e67b251c-ffe2-4d52-8936-98be69d59ba7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_41d824d0-7ad9-46a7-a533-88143a50e1e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:to="loc_us-gaap_LitigationStatusDomain_41d824d0-7ad9-46a7-a533-88143a50e1e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_659b77b7-f1d1-40e0-b9eb-a7134b2d0f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:to="loc_us-gaap_LitigationStatusDomain_659b77b7-f1d1-40e0-b9eb-a7134b2d0f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_6f4c4f94-64b5-4295-a497-cf64c98f550b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_659b77b7-f1d1-40e0-b9eb-a7134b2d0f17" xlink:to="loc_us-gaap_SettledLitigationMember_6f4c4f94-64b5-4295-a497-cf64c98f550b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1e746c72-adc5-4805-b4c6-b4c9216c7067_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:to="loc_srt_SegmentGeographicalDomain_1e746c72-adc5-4805-b4c6-b4c9216c7067_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_555e5e7c-9238-48d6-8514-409773ca9956" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:to="loc_srt_SegmentGeographicalDomain_555e5e7c-9238-48d6-8514-409773ca9956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_77cfcba4-0472-4260-9962-b35df74766c2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_555e5e7c-9238-48d6-8514-409773ca9956" xlink:to="loc_stpr_NJ_77cfcba4-0472-4260-9962-b35df74766c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c84989c1-2741-45e5-9d74-026ada93b3a4_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:to="loc_dei_EntityDomain_c84989c1-2741-45e5-9d74-026ada93b3a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_acbe9339-a549-4007-b7b3-cce2716e3447" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:to="loc_dei_EntityDomain_acbe9339-a549-4007-b7b3-cce2716e3447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_0fb9f145-8b98-49c0-ac40-1610dc941a14" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_acbe9339-a549-4007-b7b3-cce2716e3447" xlink:to="loc_bhc_BauschLombMember_0fb9f145-8b98-49c0-ac40-1610dc941a14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="i7dfb29e566894c0e9bc384235187a0fc_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1171eb60-6740-422a-99b1-04f64b1937fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1171eb60-6740-422a-99b1-04f64b1937fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_86437346-3673-469e-bcc1-90efcbe54d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_86437346-3673-469e-bcc1-90efcbe54d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_01c2fe16-3f59-4bfe-8416-f76586b22421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:to="loc_us-gaap_HedgingRelationshipDomain_01c2fe16-3f59-4bfe-8416-f76586b22421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b183c712-12c3-4381-ae4c-9f6254c07061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b183c712-12c3-4381-ae4c-9f6254c07061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_58be7852-aa4a-4619-947f-d334b749b229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b183c712-12c3-4381-ae4c-9f6254c07061" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_58be7852-aa4a-4619-947f-d334b749b229" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_446b485d-697c-4d04-af38-0f87034ae195_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_446b485d-697c-4d04-af38-0f87034ae195_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7ae50824-e8dc-47ee-b9e9-5aa2d551d1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7ae50824-e8dc-47ee-b9e9-5aa2d551d1f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_c487ce62-7908-4f68-a2e6-b40512a35ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7ae50824-e8dc-47ee-b9e9-5aa2d551d1f3" xlink:to="loc_us-gaap_CurrencySwapMember_c487ce62-7908-4f68-a2e6-b40512a35ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_97d2585a-92c5-4193-b3ee-89e17f45ebde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:to="loc_us-gaap_HedgingDesignationDomain_97d2585a-92c5-4193-b3ee-89e17f45ebde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b6a3d8b1-b445-47f0-a4a6-2ed5aa9119c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:to="loc_us-gaap_HedgingDesignationDomain_b6a3d8b1-b445-47f0-a4a6-2ed5aa9119c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e960beeb-2868-493d-ad64-96820ea1ea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_b6a3d8b1-b445-47f0-a4a6-2ed5aa9119c1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e960beeb-2868-493d-ad64-96820ea1ea8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:to="loc_dei_EntityDomain_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_80681dcd-d464-46d0-97cb-639aa7207280" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:to="loc_dei_EntityDomain_80681dcd-d464-46d0-97cb-639aa7207280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e1a76651-0a09-465b-90d6-95cdecc8eeb5" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_80681dcd-d464-46d0-97cb-639aa7207280" xlink:to="loc_bhc_BauschLombMember_e1a76651-0a09-465b-90d6-95cdecc8eeb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="ia4547074d3584ee3be01166cb7ee79fe_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59061ef3-007e-493b-b21f-398387b7ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_d6c8f5e2-f3a0-4e39-982e-6aa8285fc8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59061ef3-007e-493b-b21f-398387b7ec4e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_d6c8f5e2-f3a0-4e39-982e-6aa8285fc8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59061ef3-007e-493b-b21f-398387b7ec4e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fbe93878-565e-45d3-abfb-3aaf91410998_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fbe93878-565e-45d3-abfb-3aaf91410998_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06ba00d2-a59f-4412-abd5-450b4a85d351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06ba00d2-a59f-4412-abd5-450b4a85d351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ec423ae2-1abf-4a12-9436-ef4f50e0507e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ec423ae2-1abf-4a12-9436-ef4f50e0507e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_53335f83-a6e4-410e-afda-ea3c18799f97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_53335f83-a6e4-410e-afda-ea3c18799f97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_46877843-0181-4e6d-b498-1b364f1a6988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_46877843-0181-4e6d-b498-1b364f1a6988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_da0faa30-7698-4655-825b-6aa4f5367bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_46877843-0181-4e6d-b498-1b364f1a6988" xlink:to="loc_us-gaap_CurrencySwapMember_da0faa30-7698-4655-825b-6aa4f5367bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5e1d602d-b737-4fe4-849d-7b888b6c07fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5e1d602d-b737-4fe4-849d-7b888b6c07fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_92a73975-26f6-4e40-bcd9-34b330c6833b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:to="loc_us-gaap_HedgingRelationshipDomain_92a73975-26f6-4e40-bcd9-34b330c6833b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f9ce90f7-6e7a-4ac5-876b-9abb7c884afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92a73975-26f6-4e40-bcd9-34b330c6833b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f9ce90f7-6e7a-4ac5-876b-9abb7c884afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6b71c3f3-e15c-418a-9836-152cb6ae7a81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:to="loc_us-gaap_HedgingDesignationDomain_6b71c3f3-e15c-418a-9836-152cb6ae7a81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e3e76670-e972-469a-abaa-fb38d89fcef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:to="loc_us-gaap_HedgingDesignationDomain_e3e76670-e972-469a-abaa-fb38d89fcef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b475c876-1cc1-49ba-aaa3-baaa86ad8c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_e3e76670-e972-469a-abaa-fb38d89fcef0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b475c876-1cc1-49ba-aaa3-baaa86ad8c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:to="loc_dei_EntityDomain_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_41ba1ad5-e5c6-48b7-af5e-081656e24bae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:to="loc_dei_EntityDomain_41ba1ad5-e5c6-48b7-af5e-081656e24bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c06139ec-cb0b-49ab-9af2-ebd553ae1371" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_41ba1ad5-e5c6-48b7-af5e-081656e24bae" xlink:to="loc_bhc_BauschLombMember_c06139ec-cb0b-49ab-9af2-ebd553ae1371" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="i93d85c3fe1ec4e4dbef32b27d2ebad22_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0a1ec2d0-2ea2-465b-9334-b35efcee80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0a1ec2d0-2ea2-465b-9334-b35efcee80bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_93a85477-3109-46f0-bd4d-24f5a7b8674a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_93a85477-3109-46f0-bd4d-24f5a7b8674a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7f7b076b-284f-4bc7-b5a1-81a2fabc956e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7f7b076b-284f-4bc7-b5a1-81a2fabc956e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_be8b2bb4-9084-4042-8e95-5a0e07534507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_be8b2bb4-9084-4042-8e95-5a0e07534507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8f5e4838-3fd3-4048-8c4a-955f42c69fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_be8b2bb4-9084-4042-8e95-5a0e07534507" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8f5e4838-3fd3-4048-8c4a-955f42c69fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_680653a2-4cfb-40b2-a933-5a49af70e31d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_680653a2-4cfb-40b2-a933-5a49af70e31d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94cb03dd-caac-4d90-8791-08bffc3b036b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94cb03dd-caac-4d90-8791-08bffc3b036b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_26b1f4ba-47c5-4cff-948b-e561ddbee2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94cb03dd-caac-4d90-8791-08bffc3b036b" xlink:to="loc_us-gaap_CurrencySwapMember_26b1f4ba-47c5-4cff-948b-e561ddbee2f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6065b64f-adf5-482b-83c5-f34f011d98cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:to="loc_us-gaap_HedgingDesignationDomain_6065b64f-adf5-482b-83c5-f34f011d98cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7d088e85-7f2f-4ef4-92f6-cacfc5719959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:to="loc_us-gaap_HedgingDesignationDomain_7d088e85-7f2f-4ef4-92f6-cacfc5719959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ac21b6f8-6220-43eb-a530-0c5e72e32ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7d088e85-7f2f-4ef4-92f6-cacfc5719959" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ac21b6f8-6220-43eb-a530-0c5e72e32ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_607c6f68-75d8-431f-994b-59130bbd7e2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_607c6f68-75d8-431f-994b-59130bbd7e2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51abdcf0-15ee-4f63-8785-91eedd56b141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51abdcf0-15ee-4f63-8785-91eedd56b141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_81fc3228-be2f-42f6-afda-c59d88d3cf61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51abdcf0-15ee-4f63-8785-91eedd56b141" xlink:to="loc_us-gaap_InterestExpenseMember_81fc3228-be2f-42f6-afda-c59d88d3cf61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="i74fb53ffd9534927a7f3a969fbfb64a3_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cac9b0ed-396c-4879-97e3-ce3eafa441f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_f7ba214c-d7fd-49a4-8f0e-4676232dd893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cac9b0ed-396c-4879-97e3-ce3eafa441f0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_f7ba214c-d7fd-49a4-8f0e-4676232dd893" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cac9b0ed-396c-4879-97e3-ce3eafa441f0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:to="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_8919ec6a-f915-4219-adca-3b56351c8b63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:to="loc_us-gaap_HedgingDesignationDomain_8919ec6a-f915-4219-adca-3b56351c8b63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7b91f058-d430-426c-8822-5b1ff7aa9068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:to="loc_us-gaap_HedgingDesignationDomain_7b91f058-d430-426c-8822-5b1ff7aa9068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a30e5c8b-dd06-49e8-85a1-0ea303d901cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7b91f058-d430-426c-8822-5b1ff7aa9068" xlink:to="loc_us-gaap_NondesignatedMember_a30e5c8b-dd06-49e8-85a1-0ea303d901cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_04c9fd1a-ab45-4c41-9078-71c6a65622d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_04c9fd1a-ab45-4c41-9078-71c6a65622d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e7b25113-96e1-40bb-a02c-9bac18ac56f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e7b25113-96e1-40bb-a02c-9bac18ac56f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fd2dec78-a155-413f-9dab-227d227c764f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e7b25113-96e1-40bb-a02c-9bac18ac56f6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fd2dec78-a155-413f-9dab-227d227c764f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="id55cc8e7de334ae4848e169a45286b63_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85dfe9f3-e869-4895-8a96-515d77e9c765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_f3c1a93f-bd42-4cf1-a5d1-8edc675b8fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85dfe9f3-e869-4895-8a96-515d77e9c765" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_f3c1a93f-bd42-4cf1-a5d1-8edc675b8fa4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85dfe9f3-e869-4895-8a96-515d77e9c765" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e5fcfc32-292e-4b75-9355-13d1a29be489_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e5fcfc32-292e-4b75-9355-13d1a29be489_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_d40b4959-6790-4269-a182-14dd36596560" xlink:href="bhc-20230331.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_d40b4959-6790-4269-a182-14dd36596560" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_af167c3c-b240-487b-8483-add083175b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_af167c3c-b240-487b-8483-add083175b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2d681e90-ae91-400d-9f55-2d2fd8002c6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2d681e90-ae91-400d-9f55-2d2fd8002c6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_181a2fa8-8f5a-46af-ae14-54b23133372b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_181a2fa8-8f5a-46af-ae14-54b23133372b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e93ce20e-3b2a-4317-849f-caa64274ec7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_181a2fa8-8f5a-46af-ae14-54b23133372b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e93ce20e-3b2a-4317-849f-caa64274ec7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_beacd44e-8935-4577-81d3-4d7edcb7e85c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:to="loc_us-gaap_HedgingDesignationDomain_beacd44e-8935-4577-81d3-4d7edcb7e85c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_833b8e62-8e09-4dcc-b75c-9c81e3991ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:to="loc_us-gaap_HedgingDesignationDomain_833b8e62-8e09-4dcc-b75c-9c81e3991ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a103d471-3ddb-45a5-a548-87c20131157a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_833b8e62-8e09-4dcc-b75c-9c81e3991ad8" xlink:to="loc_us-gaap_NondesignatedMember_a103d471-3ddb-45a5-a548-87c20131157a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="iac4e289f9dc4408890b26fcfb2f3c0cd_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2fd469e5-5f81-4c66-a382-2cd93065e655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2fd469e5-5f81-4c66-a382-2cd93065e655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3154caef-7990-491b-9889-6aec6262fb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3154caef-7990-491b-9889-6aec6262fb18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_b25082a7-2804-4c49-b815-37aacc459221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_b25082a7-2804-4c49-b815-37aacc459221" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3590646b-dc14-4a82-8a27-a65371da3a56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3590646b-dc14-4a82-8a27-a65371da3a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_36ff854a-d990-411b-bef5-605038e43d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_36ff854a-d990-411b-bef5-605038e43d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0d9aca4a-08cc-4bc5-8f9b-a7a42f6aabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_36ff854a-d990-411b-bef5-605038e43d89" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0d9aca4a-08cc-4bc5-8f9b-a7a42f6aabe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:to="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7fb37a1d-eee1-45f1-8571-0103058197cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:to="loc_us-gaap_HedgingDesignationDomain_7fb37a1d-eee1-45f1-8571-0103058197cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0747a089-f4a2-4cde-be95-c06aa9e253a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:to="loc_us-gaap_HedgingDesignationDomain_0747a089-f4a2-4cde-be95-c06aa9e253a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_df086aa1-c3a2-414b-8105-84b069b03c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0747a089-f4a2-4cde-be95-c06aa9e253a8" xlink:to="loc_us-gaap_NondesignatedMember_df086aa1-c3a2-414b-8105-84b069b03c35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended" id="id0080812253b4e9da5731980876175e2_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14d1afc6-987d-43c0-85d5-91c40549b921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_525355d3-290d-4a15-a170-f29a93c8fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14d1afc6-987d-43c0-85d5-91c40549b921" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_525355d3-290d-4a15-a170-f29a93c8fe83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14d1afc6-987d-43c0-85d5-91c40549b921" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_05fe523b-1bbf-477b-994a-b0f78787b398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_05fe523b-1bbf-477b-994a-b0f78787b398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75d7adf1-bd9a-4587-ba9e-3b7e57e3ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75d7adf1-bd9a-4587-ba9e-3b7e57e3ef6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_55a2227b-4f7c-4dff-abfa-920b0a0a9823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75d7adf1-bd9a-4587-ba9e-3b7e57e3ef6b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_55a2227b-4f7c-4dff-abfa-920b0a0a9823" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_865fe458-b786-4fc1-b77d-d7779c639034_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_865fe458-b786-4fc1-b77d-d7779c639034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4a3ff0b8-b699-46d7-8096-5bc44ba3f0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4a3ff0b8-b699-46d7-8096-5bc44ba3f0a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_f71f2fd7-6952-48b0-9c71-f4d2849d5620" xlink:href="bhc-20230331.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_f71f2fd7-6952-48b0-9c71-f4d2849d5620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab468ebd-48d3-424b-ad1b-a246b4e3089a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ab468ebd-48d3-424b-ad1b-a246b4e3089a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a699bed8-930a-40d3-9e92-b2ce5f420f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a699bed8-930a-40d3-9e92-b2ce5f420f0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fcdd85d2-b4a4-4371-b073-7f255b0844b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a699bed8-930a-40d3-9e92-b2ce5f420f0b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fcdd85d2-b4a4-4371-b073-7f255b0844b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81089ea6-f033-4440-b650-43e5272d1020_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:to="loc_srt_RangeMember_81089ea6-f033-4440-b650-43e5272d1020_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:to="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eddb8a6a-405f-4307-89de-44d64748a0b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:to="loc_srt_MinimumMember_eddb8a6a-405f-4307-89de-44d64748a0b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a62c23c-9e17-467c-b3d8-846225e2198a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:to="loc_srt_MaximumMember_3a62c23c-9e17-467c-b3d8-846225e2198a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended" id="idd135ba4e1494a07b48245bfd6b55789_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74e7a5ae-28ed-4948-97a3-a33aeee45b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74e7a5ae-28ed-4948-97a3-a33aeee45b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1d6c594e-b36c-4f01-ae9c-ee8797bc8576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1d6c594e-b36c-4f01-ae9c-ee8797bc8576" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f6e47ffe-0e60-4615-aa3d-f9d654fd58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f6e47ffe-0e60-4615-aa3d-f9d654fd58a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43bfca76-f54a-4961-882d-07e9258af2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43bfca76-f54a-4961-882d-07e9258af2ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0079f578-9b15-48b3-9049-77e3888ccfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0652ee7a-44a5-4acf-8261-fcef0346f658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0652ee7a-44a5-4acf-8261-fcef0346f658" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_02d815c0-41a3-477f-9127-7cf8d2997384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_02d815c0-41a3-477f-9127-7cf8d2997384" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_7acd3c2e-8548-4960-9811-d95475432efa" xlink:href="bhc-20230331.xsd#bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:to="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_7acd3c2e-8548-4960-9811-d95475432efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_71bb0c0c-7a38-4216-9bb3-018ae2dbc965_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_71bb0c0c-7a38-4216-9bb3-018ae2dbc965_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_92b6a799-652e-454e-a163-3a20bc2a4979" xlink:href="bhc-20230331.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_92b6a799-652e-454e-a163-3a20bc2a4979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_78ee1b71-47f6-4997-969f-ddbf3faad5a5" xlink:href="bhc-20230331.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_78ee1b71-47f6-4997-969f-ddbf3faad5a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended" id="i29321414927a47669033bd7890c730ad_FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e118e73-931a-41b9-9b20-c8133298458b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ec4eeba3-e204-4eb8-a699-e0af7d5b9786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e118e73-931a-41b9-9b20-c8133298458b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ec4eeba3-e204-4eb8-a699-e0af7d5b9786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e118e73-931a-41b9-9b20-c8133298458b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6af742de-fc7b-4ddd-b69d-b362e557fb4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6af742de-fc7b-4ddd-b69d-b362e557fb4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd7f1c07-23e3-43ea-9102-ccc63dfb0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd7f1c07-23e3-43ea-9102-ccc63dfb0ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_fdb94f16-3d58-42ae-a19e-329ac0a95c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd7f1c07-23e3-43ea-9102-ccc63dfb0ed6" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_fdb94f16-3d58-42ae-a19e-329ac0a95c23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70a976cf-37b7-457a-80e7-b49f0e1bdec5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_70a976cf-37b7-457a-80e7-b49f0e1bdec5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3999487a-cadc-4e64-b0c0-0081f2203f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3999487a-cadc-4e64-b0c0-0081f2203f98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_65f6449a-52ad-48fd-a336-13e8d6f31549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3999487a-cadc-4e64-b0c0-0081f2203f98" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_65f6449a-52ad-48fd-a336-13e8d6f31549" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended" id="if7b0ae35630447e59dbc2580234cdfed_INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:href="bhc-20230331.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8c03b6ab-c9f8-4992-9c0d-233e528f2a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8c03b6ab-c9f8-4992-9c0d-233e528f2a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aeb5dc86-5e7a-4480-b2fb-9dcd8708cbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aeb5dc86-5e7a-4480-b2fb-9dcd8708cbf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65195c48-c26f-4c7e-be6d-b1f9891c77f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65195c48-c26f-4c7e-be6d-b1f9891c77f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5faf455c-dba9-4b16-a2c7-79658dcce214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5faf455c-dba9-4b16-a2c7-79658dcce214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3a1744b8-0e82-48dc-9d52-03737efc2993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5faf455c-dba9-4b16-a2c7-79658dcce214" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3a1744b8-0e82-48dc-9d52-03737efc2993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b15f4f9d-82b9-4113-bd59-d600b2c914ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b15f4f9d-82b9-4113-bd59-d600b2c914ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83bf0bf2-626a-44af-885b-c8bb7e093dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83bf0bf2-626a-44af-885b-c8bb7e093dd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:href="bhc-20230331.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87251075-f102-4b1f-8ab1-f46befd3781a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87251075-f102-4b1f-8ab1-f46befd3781a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_bf7a8eed-5242-4033-8932-58db99a0f9f4" xlink:href="bhc-20230331.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_bhc_ProductBrandsMember_bf7a8eed-5242-4033-8932-58db99a0f9f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9ef136d8-e579-4f06-8f71-c39fc4072074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_us-gaap_TradeNamesMember_9ef136d8-e579-4f06-8f71-c39fc4072074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_84bb8c58-b8b4-48b6-9026-5ac2cb3e47f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_us-gaap_ContractualRightsMember_84bb8c58-b8b4-48b6-9026-5ac2cb3e47f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_f8d3060f-278c-4e0f-a576-5e843fc35e8e" xlink:href="bhc-20230331.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_bhc_PartnerRelationshipsMember_f8d3060f-278c-4e0f-a576-5e843fc35e8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_a863ea9a-131f-4b1e-9932-4403fe3325fa" xlink:href="bhc-20230331.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_bhc_OutLicensedTechnologyMember_a863ea9a-131f-4b1e-9932-4403fe3325fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57a26b5b-8224-471b-8398-4d086d2023ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_57a26b5b-8224-471b-8398-4d086d2023ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfe60c2c-b279-4ef5-b9c9-e31f13144310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfe60c2c-b279-4ef5-b9c9-e31f13144310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_a43c759f-588b-4249-88dd-8d25b92899a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfe60c2c-b279-4ef5-b9c9-e31f13144310" xlink:to="loc_us-gaap_TrademarksMember_a43c759f-588b-4249-88dd-8d25b92899a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="ie4c9a08a6c9b4b9a8a3e23827ffc7d42_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b9b22982-6e35-4f11-bf14-0f68f706154f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_AssetImpairmentCharges_b9b22982-6e35-4f11-bf14-0f68f706154f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7b815fa4-31f0-483a-b0ba-3fe36c395d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7b815fa4-31f0-483a-b0ba-3fe36c395d96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b7bb8c77-1421-4633-b245-20316360fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b7bb8c77-1421-4633-b245-20316360fe23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c6bcf814-43aa-4d4e-963a-35d9b963fe88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c6bcf814-43aa-4d4e-963a-35d9b963fe88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_5ae2943d-e7b6-4fb6-8e37-11e5f0745e27" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_5ae2943d-e7b6-4fb6-8e37-11e5f0745e27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_7db6ec33-481e-4a57-acc6-631751cd64ed" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_7db6ec33-481e-4a57-acc6-631751cd64ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_6f8a196a-3173-4a33-b4e6-0b91275e1f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_6f8a196a-3173-4a33-b4e6-0b91275e1f40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_54f0eaa7-ced9-4581-af75-17d535989a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_54f0eaa7-ced9-4581-af75-17d535989a72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_23ae0815-2a03-45cc-a0d1-de08e4a78e84" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_23ae0815-2a03-45cc-a0d1-de08e4a78e84" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_69d17cdf-d2e8-40e4-b89c-1d7d29598aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_NumberOfReportingUnits_69d17cdf-d2e8-40e4-b89c-1d7d29598aee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3dcb081e-72a1-4506-8f3b-04765fc4fefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_Goodwill_3dcb081e-72a1-4506-8f3b-04765fc4fefc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_49014b9c-a3cb-4fa5-8691-020e52f5952b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_49014b9c-a3cb-4fa5-8691-020e52f5952b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f1e88c5b-5104-49ef-9d82-d8230f8505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f1e88c5b-5104-49ef-9d82-d8230f8505ce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_07ccfac8-2046-4351-ae58-bbb342e81478_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_07ccfac8-2046-4351-ae58-bbb342e81478_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeNamesNoLongerUsedMember_5cb677c3-2028-458b-aee3-08f5fa75f962" xlink:href="bhc-20230331.xsd#bhc_TradeNamesNoLongerUsedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:to="loc_bhc_TradeNamesNoLongerUsedMember_5cb677c3-2028-458b-aee3-08f5fa75f962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_c7429472-e7e2-4baf-9bdc-d8d6f7cb32cf" xlink:href="bhc-20230331.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:to="loc_bhc_DiscontinuedProductLinesMember_c7429472-e7e2-4baf-9bdc-d8d6f7cb32cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_57063c39-4061-42fe-9466-a31cd54696fc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:to="loc_srt_ProductsAndServicesDomain_57063c39-4061-42fe-9466-a31cd54696fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32d06da3-b3b1-4056-99ca-7adb45327311" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:to="loc_srt_ProductsAndServicesDomain_32d06da3-b3b1-4056-99ca-7adb45327311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_3a892bcf-3b7d-4266-a38e-b29a468546a0" xlink:href="bhc-20230331.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_32d06da3-b3b1-4056-99ca-7adb45327311" xlink:to="loc_bhc_XifaxanBrandedProductsMember_3a892bcf-3b7d-4266-a38e-b29a468546a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9c8d049d-dc37-4c28-9e10-9d415a3bdf27_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:to="loc_srt_RangeMember_9c8d049d-dc37-4c28-9e10-9d415a3bdf27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:to="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f0e2659-d44c-4672-a72a-26055a72cabc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:to="loc_srt_MinimumMember_6f0e2659-d44c-4672-a72a-26055a72cabc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_607763a2-e0f4-49bb-b876-8876b91e5502" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:to="loc_srt_MaximumMember_607763a2-e0f4-49bb-b876-8876b91e5502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_d3248ea2-1f8a-405d-ac65-b73a82ee137a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:to="loc_us-gaap_ReportingUnitDomain_d3248ea2-1f8a-405d-ac65-b73a82ee137a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:to="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DermatologyReportingUnitMember_c7d1a543-7a71-406e-8389-55baf01558dc" xlink:href="bhc-20230331.xsd#bhc_DermatologyReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_DermatologyReportingUnitMember_c7d1a543-7a71-406e-8389-55baf01558dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_052eab52-2dc4-4105-9591-2d08a8e9195f" xlink:href="bhc-20230331.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_052eab52-2dc4-4105-9591-2d08a8e9195f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember_b9ba9825-c083-4824-bd53-5adc393438e7" xlink:href="bhc-20230331.xsd#bhc_SalixReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_SalixReportingUnitMember_b9ba9825-c083-4824-bd53-5adc393438e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NeurologyAndOtherReportingUnitMember_0114c33b-0a28-4f6d-b091-c8226f36431c" xlink:href="bhc-20230331.xsd#bhc_NeurologyAndOtherReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_NeurologyAndOtherReportingUnitMember_0114c33b-0a28-4f6d-b091-c8226f36431c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:to="loc_us-gaap_SegmentDomain_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3eda7d9b-fccc-4768-a762-205ac1e9ca93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:to="loc_us-gaap_SegmentDomain_3eda7d9b-fccc-4768-a762-205ac1e9ca93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_edcc7916-5e0d-4222-85db-28b7f626c433" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3eda7d9b-fccc-4768-a762-205ac1e9ca93" xlink:to="loc_bhc_SalixSegmentMember_edcc7916-5e0d-4222-85db-28b7f626c433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_23a71948-e63f-408c-b3db-38d8abb1ed39_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:to="loc_dei_EntityDomain_23a71948-e63f-408c-b3db-38d8abb1ed39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_491f7599-2f5d-4afa-8a56-2dd28481f09f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:to="loc_dei_EntityDomain_491f7599-2f5d-4afa-8a56-2dd28481f09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_20b28c8f-b90f-4ae3-999d-090d610dabea" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_491f7599-2f5d-4afa-8a56-2dd28481f09f" xlink:to="loc_bhc_BauschLombMember_20b28c8f-b90f-4ae3-999d-090d610dabea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a7e0108a-02fb-4db3-860e-8556397b3e48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a7e0108a-02fb-4db3-860e-8556397b3e48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0ffb0ef-d765-4f49-b745-69e8644581a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0ffb0ef-d765-4f49-b745-69e8644581a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_992e3612-c51f-4d4e-b3f1-e955ef9f5114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0ffb0ef-d765-4f49-b745-69e8644581a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_992e3612-c51f-4d4e-b3f1-e955ef9f5114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_af5d1dcb-7865-4478-8933-351416be6ea8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_af5d1dcb-7865-4478-8933-351416be6ea8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cbf42b01-832e-4046-9587-38ed63fe3440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cbf42b01-832e-4046-9587-38ed63fe3440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f8763fa7-fc16-49c3-ad7b-e84caf6c00e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cbf42b01-832e-4046-9587-38ed63fe3440" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f8763fa7-fc16-49c3-ad7b-e84caf6c00e8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended" id="ib6dca27382e54e8dbe99262fae4260c9_INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f5e4ebab-b2df-4935-a2fd-102e98cf5a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f5e4ebab-b2df-4935-a2fd-102e98cf5a10" xlink:to="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1496f8f9-c705-49e4-805a-407e3df4ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_Goodwill_1496f8f9-c705-49e4-805a-407e3df4ce78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_aeb0a2b8-2dea-467f-bd70-abdc43f989cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_aeb0a2b8-2dea-467f-bd70-abdc43f989cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ee283f62-fa44-48a3-bf67-a41aa73d2c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ee283f62-fa44-48a3-bf67-a41aa73d2c24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9b0d4751-ce8f-4965-b5d0-343b52cf196a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9b0d4751-ce8f-4965-b5d0-343b52cf196a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5f5a20eb-5d67-4231-92c0-0561fce798e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5f5a20eb-5d67-4231-92c0-0561fce798e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5abb3d33-54f7-4891-b529-0f940d9b98dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f5e4ebab-b2df-4935-a2fd-102e98cf5a10" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_91fd33d2-be48-44db-8ea4-67a68db2b155_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:to="loc_us-gaap_SegmentDomain_91fd33d2-be48-44db-8ea4-67a68db2b155_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:to="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_94912ca2-6b06-4336-8bad-b905403af51d" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_BauschLombMember_94912ca2-6b06-4336-8bad-b905403af51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_4102c7b6-90ad-42d4-8527-da48941b1aa8" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_SalixSegmentMember_4102c7b6-90ad-42d4-8527-da48941b1aa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_9871cc99-b673-4153-90ef-3d087b7ca835" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_InternationalRxMember_9871cc99-b673-4153-90ef-3d087b7ca835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DermatologySegmentMember_eee7590c-964e-4e0d-928a-3a4c8cf66999" xlink:href="bhc-20230331.xsd#bhc_DermatologySegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_DermatologySegmentMember_eee7590c-964e-4e0d-928a-3a4c8cf66999" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_d103fd8d-4efc-4a0f-ada8-6b72985e0503" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_SoltaMedicalSegmentMember_d103fd8d-4efc-4a0f-ada8-6b72985e0503" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember_3edb68be-b028-4088-9253-c9402c756065" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_DiversifiedSegmentMember_3edb68be-b028-4088-9253-c9402c756065" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="i8507cc501d744a178bb908f0ce751eb0_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_054163e0-c277-4813-b5dd-57dc24bdeffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_054163e0-c277-4813-b5dd-57dc24bdeffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_577b72a5-131a-4d58-b1b3-79a5a905a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_577b72a5-131a-4d58-b1b3-79a5a905a2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d3e50fa8-11d8-4677-bf16-a75524e1e787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_LongTermDebt_d3e50fa8-11d8-4677-bf16-a75524e1e787" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7fd97bfb-0ff0-4877-b25d-2e3345f91e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_LongTermDebtCurrent_7fd97bfb-0ff0-4877-b25d-2e3345f91e44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_50c3d3e0-9895-459c-ab3a-30a9a82ce01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_50c3d3e0-9895-459c-ab3a-30a9a82ce01c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a440a932-7f89-4e46-a70d-30a511ab92c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:to="loc_us-gaap_CreditFacilityDomain_a440a932-7f89-4e46-a70d-30a511ab92c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2cdc35f1-1ea3-44ab-b16f-400766b6928b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:to="loc_us-gaap_CreditFacilityDomain_2cdc35f1-1ea3-44ab-b16f-400766b6928b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0df10f6e-0890-457d-9cc5-75a9d2f35fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2cdc35f1-1ea3-44ab-b16f-400766b6928b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0df10f6e-0890-457d-9cc5-75a9d2f35fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfd98d4e-1752-430f-8434-1dbe28f08ee5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfd98d4e-1752-430f-8434-1dbe28f08ee5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d6e9ce0a-fe0c-4023-8260-3b9c394de49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:to="loc_us-gaap_SecuredDebtMember_d6e9ce0a-fe0c-4023-8260-3b9c394de49a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_38a0b8af-8ce7-49a3-a249-a914ba6edaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:to="loc_us-gaap_UnsecuredDebtMember_38a0b8af-8ce7-49a3-a249-a914ba6edaf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7acc2b0-89e6-40ba-8c36-502f18660afb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7acc2b0-89e6-40ba-8c36-502f18660afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_fb601c01-aad5-415c-ace3-3dcbb53f22ca" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_fb601c01-aad5-415c-ace3-3dcbb53f22ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_f0440614-98af-486f-99c8-e34fef616bf7" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_f0440614-98af-486f-99c8-e34fef616bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_a82be5b2-6dde-4db7-a6a1-5e1a8d8b8cf8" xlink:href="bhc-20230331.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_TermFacilityDueMay2027Member_a82be5b2-6dde-4db7-a6a1-5e1a8d8b8cf8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_1cf3b844-b9bd-4e3b-b130-0a86002bcc1e" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_1cf3b844-b9bd-4e3b-b130-0a86002bcc1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_97656ef1-5918-4e49-bb4a-61257313e870" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_97656ef1-5918-4e49-bb4a-61257313e870" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9eedc9e5-721f-4091-9843-06e939f84ae9" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9eedc9e5-721f-4091-9843-06e939f84ae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_3180fd94-62b1-4f8d-9586-3d14c13b76d6" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_3180fd94-62b1-4f8d-9586-3d14c13b76d6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_dd7ffa6d-3b39-4fde-917a-f85966b0e4f3" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_dd7ffa6d-3b39-4fde-917a-f85966b0e4f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_5d8745f5-e102-4324-9176-c90e8b6154c1" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_5d8745f5-e102-4324-9176-c90e8b6154c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_21c62e26-8db2-4ba3-b3a1-5b4db3124a5b" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_21c62e26-8db2-4ba3-b3a1-5b4db3124a5b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_a3ac2155-6069-4867-ba89-f21b97e96d20" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_a3ac2155-6069-4867-ba89-f21b97e96d20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_f61e962c-d197-48eb-a852-10f998853d9c" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_f61e962c-d197-48eb-a852-10f998853d9c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_fdf6564d-e218-4160-92e3-d5059b81c20e" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_fdf6564d-e218-4160-92e3-d5059b81c20e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_5166d8a5-8a70-47fb-a282-abd2a8a1ac53" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_5166d8a5-8a70-47fb-a282-abd2a8a1ac53" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_ead6bde9-5b8c-4d18-b707-4a33e8fa3f23" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_ead6bde9-5b8c-4d18-b707-4a33e8fa3f23" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_4c6e4ff2-504c-47f7-bcf7-35b3b768023c" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_4c6e4ff2-504c-47f7-bcf7-35b3b768023c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_001efb1e-f315-412f-bd37-cca234ef4f1e" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_001efb1e-f315-412f-bd37-cca234ef4f1e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_fed7e1ed-00f6-449f-a339-104c2c733577" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_fed7e1ed-00f6-449f-a339-104c2c733577" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_82471b65-a02a-4f58-a161-018dc8b99b91" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_82471b65-a02a-4f58-a161-018dc8b99b91" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_d4f2695a-935f-4200-912d-3f80de8e5e6c" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_d4f2695a-935f-4200-912d-3f80de8e5e6c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_edaa6e71-74ec-4f62-9d0f-a109cc862e56" xlink:href="bhc-20230331.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_OtherLongTermDebtMember_edaa6e71-74ec-4f62-9d0f-a109cc862e56" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_12b798e8-b872-4e96-8406-7ef4ff3eb5f2_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:to="loc_dei_EntityDomain_12b798e8-b872-4e96-8406-7ef4ff3eb5f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c05f7ed-72a0-4da4-bca1-40634481b2f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:to="loc_dei_EntityDomain_2c05f7ed-72a0-4da4-bca1-40634481b2f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_57729a03-043c-48d2-8a9e-e57611654a1e" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2c05f7ed-72a0-4da4-bca1-40634481b2f0" xlink:to="loc_bhc_BauschLombMember_57729a03-043c-48d2-8a9e-e57611654a1e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="i2b35e266f2d74b0280c255db6cf0452b_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e8f2326-90a3-4d2f-b7c3-c6da3ef61f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e8f2326-90a3-4d2f-b7c3-c6da3ef61f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_f2e3979c-c5a1-45b9-bcd0-527e3dd28c43" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_f2e3979c-c5a1-45b9-bcd0-527e3dd28c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_2a27304b-51fe-4ecf-b35c-86da548f634e" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_2a27304b-51fe-4ecf-b35c-86da548f634e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_fdcb22b5-6845-48c2-813c-d3bdb1fe92f3" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_fdcb22b5-6845-48c2-813c-d3bdb1fe92f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1009817e-8545-4a55-afda-1f89d7c26ab7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1009817e-8545-4a55-afda-1f89d7c26ab7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f982575c-7343-4b63-9600-839f0f89919d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f982575c-7343-4b63-9600-839f0f89919d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b4e5a10f-fc41-42ec-a2fb-af968872134e" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f982575c-7343-4b63-9600-839f0f89919d" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b4e5a10f-fc41-42ec-a2fb-af968872134e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d470241d-070c-44ad-9f55-2f724bf36336_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d470241d-070c-44ad-9f55-2f724bf36336_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_495946df-5ec4-4ba6-82e3-b101f8f9dd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_495946df-5ec4-4ba6-82e3-b101f8f9dd2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_50db57ac-bee1-4bc9-9cfe-5aebe1ac2bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_495946df-5ec4-4ba6-82e3-b101f8f9dd2e" xlink:to="loc_us-gaap_SecuredDebtMember_50db57ac-bee1-4bc9-9cfe-5aebe1ac2bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e2b39261-d97c-4a7f-88a6-2fbf86619a22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:to="loc_us-gaap_CreditFacilityDomain_e2b39261-d97c-4a7f-88a6-2fbf86619a22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:to="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_57ae9dd3-2f23-428f-9e55-3677fb4cf18b" xlink:href="bhc-20230331.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_57ae9dd3-2f23-428f-9e55-3677fb4cf18b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f381a49a-5ed9-4f1a-ae17-005319c5915d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f381a49a-5ed9-4f1a-ae17-005319c5915d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSExchangeOfferDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="extended" id="i3daa3227ffa14a27af384073a39f2d9f_FINANCINGARRANGEMENTSExchangeOfferDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9f7f528d-9ba7-4f99-a78d-420789a80e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9f7f528d-9ba7-4f99-a78d-420789a80e9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_728d44ce-41c4-4a89-ae0a-2aeb5e4353d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_728d44ce-41c4-4a89-ae0a-2aeb5e4353d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_55e4013d-108c-4a65-ae1e-68e6998c4054" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_55e4013d-108c-4a65-ae1e-68e6998c4054" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14541dc3-2fd9-4f46-9e4b-7c0924cce55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14541dc3-2fd9-4f46-9e4b-7c0924cce55e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_52fa048e-fbf5-4165-a0fb-9eb46b195850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_52fa048e-fbf5-4165-a0fb-9eb46b195850" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_8f163bfc-2bdb-4fbb-86f7-d2beda06c983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_8f163bfc-2bdb-4fbb-86f7-d2beda06c983" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_ef8280d3-c580-40b0-b47c-2786295788a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_InterestPaid_ef8280d3-c580-40b0-b47c-2786295788a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_914770fe-302d-4cb9-8be6-0c8823992ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_914770fe-302d-4cb9-8be6-0c8823992ecc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d175dcf8-c7b9-48e5-a228-8311a78715df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d175dcf8-c7b9-48e5-a228-8311a78715df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0779a3e9-b002-4709-b2cc-0f126ba74e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:to="loc_us-gaap_UnsecuredDebtMember_0779a3e9-b002-4709-b2cc-0f126ba74e70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2142552c-56bb-446e-9422-cc3ed9c678fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:to="loc_us-gaap_SecuredDebtMember_2142552c-56bb-446e-9422-cc3ed9c678fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_00a97ac1-71f3-418d-904f-2317cfdb2153_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_00a97ac1-71f3-418d-904f-2317cfdb2153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_853b9c5e-e5dd-424b-b817-ea4c7206201a" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_853b9c5e-e5dd-424b-b817-ea4c7206201a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_94dab19c-cc06-4a81-bc61-f961536e61e2" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_94dab19c-cc06-4a81-bc61-f961536e61e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_6a0da4bd-52af-4a15-9274-cc44f94ed2b9" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_6a0da4bd-52af-4a15-9274-cc44f94ed2b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_192f51ef-0243-4d36-b82e-27ce11d85e26_default" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_192f51ef-0243-4d36-b82e-27ce11d85e26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_0c938914-4ba1-47f0-a53c-c4042f95ecbb" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_0c938914-4ba1-47f0-a53c-c4042f95ecbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_23ce71aa-3ffd-4c38-a33e-74d679cf3534" xlink:href="bhc-20230331.xsd#bhc_ExchangeOfferMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_0c938914-4ba1-47f0-a53c-c4042f95ecbb" xlink:to="loc_bhc_ExchangeOfferMember_23ce71aa-3ffd-4c38-a33e-74d679cf3534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_011e8017-9ef3-4973-8296-b97ce4c87666_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:to="loc_srt_OwnershipDomain_011e8017-9ef3-4973-8296-b97ce4c87666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_352ee7aa-ce00-4275-8dc9-78dcda1c7cdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:to="loc_srt_OwnershipDomain_352ee7aa-ce00-4275-8dc9-78dcda1c7cdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_2f8b4ee4-7151-44b9-96f8-96f88808358d" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_352ee7aa-ce00-4275-8dc9-78dcda1c7cdd" xlink:to="loc_bhc_BauschLombMember_2f8b4ee4-7151-44b9-96f8-96f88808358d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5db1042d-4215-4bec-b5f8-4f704f7d767a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:to="loc_dei_EntityDomain_5db1042d-4215-4bec-b5f8-4f704f7d767a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_abfc7938-7e39-4db7-8086-85fde7759ff5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:to="loc_dei_EntityDomain_abfc7938-7e39-4db7-8086-85fde7759ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_d53d5665-bb92-4371-b59c-4865f6a1c854" xlink:href="bhc-20230331.xsd#bhc_A1375209BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_abfc7938-7e39-4db7-8086-85fde7759ff5" xlink:to="loc_bhc_A1375209BCLtdMember_d53d5665-bb92-4371-b59c-4865f6a1c854" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i584e6581ebab479a8f9456e4ed74c460_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e9f607-40c8-48f7-87a0-02cfe09a7d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e9f607-40c8-48f7-87a0-02cfe09a7d7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a61b540e-220d-4934-aa96-94fc416d42c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a61b540e-220d-4934-aa96-94fc416d42c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_5f273e17-68d3-4fa5-b0a9-6c543e4d401e" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_5f273e17-68d3-4fa5-b0a9-6c543e4d401e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_33897220-8148-475a-ba15-1c22cf9fcf67" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_33897220-8148-475a-ba15-1c22cf9fcf67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4c49ce9f-9145-40a5-bf28-5d59db627aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4c49ce9f-9145-40a5-bf28-5d59db627aec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_717c27a1-e91a-4d73-9291-b3bce1734148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LongTermDebt_717c27a1-e91a-4d73-9291-b3bce1734148" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0e7641c8-95e6-4988-aeee-13cfc5ef02eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0e7641c8-95e6-4988-aeee-13cfc5ef02eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_1528ae36-5fe8-4e5b-8557-6b1f0ac65a31" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_1528ae36-5fe8-4e5b-8557-6b1f0ac65a31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_b62c93d1-3363-4c00-9949-19a5584fa46c" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_b62c93d1-3363-4c00-9949-19a5584fa46c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36cc26c5-d87f-4076-ac87-58d32943b319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36cc26c5-d87f-4076-ac87-58d32943b319" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f5678f0f-11c7-4227-bea0-b308d62db31e" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f5678f0f-11c7-4227-bea0-b308d62db31e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_41d030fb-ec09-45ab-b6df-8e0deb8b7b66" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_41d030fb-ec09-45ab-b6df-8e0deb8b7b66" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_1544e9c6-8700-4c89-955b-56d2b0b88040" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_1544e9c6-8700-4c89-955b-56d2b0b88040" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_27577611-3265-4dfc-8972-0a6e56f7327d" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_27577611-3265-4dfc-8972-0a6e56f7327d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_b7f06778-1351-4680-999e-1b04d6bcb690" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_b7f06778-1351-4680-999e-1b04d6bcb690" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_dd26f0ce-577f-4674-9c0c-25b13ee49932" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_dd26f0ce-577f-4674-9c0c-25b13ee49932" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_e4550529-d17c-4328-9a8b-66e2e19ae6aa" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_e4550529-d17c-4328-9a8b-66e2e19ae6aa" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_4a1ba949-38ce-4afc-a5f6-0e63bacf820f" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_4a1ba949-38ce-4afc-a5f6-0e63bacf820f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_a1cf7a21-d24c-4afa-afac-8a577fc35992" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_a1cf7a21-d24c-4afa-afac-8a577fc35992" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_f38916a3-7983-4e00-b9b3-7b2a82556d36" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_f38916a3-7983-4e00-b9b3-7b2a82556d36" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_07bf7824-0faf-4cb9-b6a5-d31233961e8f" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_07bf7824-0faf-4cb9-b6a5-d31233961e8f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_5edc12e3-438e-4cae-93d2-65028903839d" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_5edc12e3-438e-4cae-93d2-65028903839d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_afccd4c2-9bb1-4fc3-8ad8-51a71ce899f0" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_afccd4c2-9bb1-4fc3-8ad8-51a71ce899f0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b1560b4d-2305-455f-bb90-b154f6618793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b1560b4d-2305-455f-bb90-b154f6618793" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_423112e7-cad5-4441-8e81-bd65799f2190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentTerm_423112e7-cad5-4441-8e81-bd65799f2190" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0050aa27-1d32-4a43-a199-3fff992c72a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0050aa27-1d32-4a43-a199-3fff992c72a0" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_509e02d9-1591-4cfd-89d6-7e96c62c3721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_509e02d9-1591-4cfd-89d6-7e96c62c3721" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_18ca2ba5-da01-43c2-95e2-2dd47fb88ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_18ca2ba5-da01-43c2-95e2-2dd47fb88ea5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_476e8047-a8f2-414d-a57d-22fbdc60fb79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:to="loc_us-gaap_CreditFacilityDomain_476e8047-a8f2-414d-a57d-22fbdc60fb79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:to="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_66a10154-35d4-44f3-89c3-bebe17b84482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_66a10154-35d4-44f3-89c3-bebe17b84482" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0b83811c-324e-4192-b0de-9ea83445ebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:to="loc_us-gaap_LetterOfCreditMember_0b83811c-324e-4192-b0de-9ea83445ebcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5eb1a8c0-05e5-43de-b8d2-c744719b1632" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5eb1a8c0-05e5-43de-b8d2-c744719b1632" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_869c7b57-4f98-430f-a9f5-d1bf791fa0a3" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_869c7b57-4f98-430f-a9f5-d1bf791fa0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_9c59f8c1-43ca-45e0-92af-06ea3e39f529" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_9c59f8c1-43ca-45e0-92af-06ea3e39f529" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_48a365a7-b9ea-426c-b39d-076092629cc6" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_48a365a7-b9ea-426c-b39d-076092629cc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0c5c9498-cda8-484f-ac1e-e6382bd174ea" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0c5c9498-cda8-484f-ac1e-e6382bd174ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_9a013b47-448f-4592-bb15-e4c05586b087" xlink:href="bhc-20230331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_9a013b47-448f-4592-bb15-e4c05586b087" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_4d38e7bd-9d26-4af5-a677-0b07a016377f" xlink:href="bhc-20230331.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_4d38e7bd-9d26-4af5-a677-0b07a016377f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_68addf3d-7b88-4e2e-a117-f5b9bdd7f565" xlink:href="bhc-20230331.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermFacilityDueMay2027Member_68addf3d-7b88-4e2e-a117-f5b9bdd7f565" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_d11295ed-a83e-461c-97bf-4bb4afac4498" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_d11295ed-a83e-461c-97bf-4bb4afac4498" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_8c628a50-1a31-45c2-96d7-705d28645ef7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:to="loc_us-gaap_VariableRateDomain_8c628a50-1a31-45c2-96d7-705d28645ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:to="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_24393eae-2f04-4cb8-a784-bf3635ff39a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_24393eae-2f04-4cb8-a784-bf3635ff39a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_86b8e00f-9a42-4bd3-aade-4e51c9df76a3" xlink:href="bhc-20230331.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_86b8e00f-9a42-4bd3-aade-4e51c9df76a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b4e753d9-0a5c-4da8-aaf9-c16dd87b5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b4e753d9-0a5c-4da8-aaf9-c16dd87b5cab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_d8f79445-7acf-478a-91cb-8b7a3c5909c1" xlink:href="bhc-20230331.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_d8f79445-7acf-478a-91cb-8b7a3c5909c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6ce6fe13-af68-451b-89c2-7522e68579c1" xlink:href="bhc-20230331.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6ce6fe13-af68-451b-89c2-7522e68579c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_8b6a9716-47b1-4262-87ce-c5ea14cfa7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_us-gaap_BaseRateMember_8b6a9716-47b1-4262-87ce-c5ea14cfa7b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_5c8fa2b4-a1e4-41ea-9f3f-9c9152c75256" xlink:href="bhc-20230331.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_5c8fa2b4-a1e4-41ea-9f3f-9c9152c75256" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_d9aa1f04-6951-4f0a-b39c-918a0427ff5f" xlink:href="bhc-20230331.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_d9aa1f04-6951-4f0a-b39c-918a0427ff5f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fb04083-e109-4222-b35a-0df9f988d758_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:to="loc_srt_RangeMember_5fb04083-e109-4222-b35a-0df9f988d758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:to="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f2021d3-37ff-46a8-b9f9-3fca4df3b28b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:to="loc_srt_MinimumMember_4f2021d3-37ff-46a8-b9f9-3fca4df3b28b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1f60b2b-e921-453e-876e-e5d45f6a6994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:to="loc_srt_MaximumMember_c1f60b2b-e921-453e-876e-e5d45f6a6994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d447aa7f-618d-4a68-8774-711ccd3628c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d447aa7f-618d-4a68-8774-711ccd3628c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_29338dea-aa79-4fbe-9360-3713c35e9bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:to="loc_us-gaap_SecuredDebtMember_29338dea-aa79-4fbe-9360-3713c35e9bb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_189096c9-cafd-474f-8e45-4d8d5120c98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:to="loc_us-gaap_UnsecuredDebtMember_189096c9-cafd-474f-8e45-4d8d5120c98b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d183433b-0edc-4f03-917a-b28b85a906be_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:to="loc_dei_EntityDomain_d183433b-0edc-4f03-917a-b28b85a906be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:to="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_0aa314cc-4bf3-49d6-a1e6-e62caaf35e88" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:to="loc_bhc_BauschLombMember_0aa314cc-4bf3-49d6-a1e6-e62caaf35e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember_f2e48b27-20a4-4c9b-a2e9-80731b5aec23" xlink:href="bhc-20230331.xsd#bhc_A1261229BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:to="loc_bhc_A1261229BCLtdMember_f2e48b27-20a4-4c9b-a2e9-80731b5aec23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c05efda7-2c68-4ad6-992e-f2e949ed0092_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:to="loc_srt_OwnershipDomain_c05efda7-2c68-4ad6-992e-f2e949ed0092_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_274da3c3-b600-4081-93de-836faf12da44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:to="loc_srt_OwnershipDomain_274da3c3-b600-4081-93de-836faf12da44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_4b34f29a-3111-428b-827d-6013df7c61e1" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_274da3c3-b600-4081-93de-836faf12da44" xlink:to="loc_bhc_BauschLombMember_4b34f29a-3111-428b-827d-6013df7c61e1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="ib683526911b84f258583d844f9747e75_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5b3f67-a611-493e-9ec9-4aac833234f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5b3f67-a611-493e-9ec9-4aac833234f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7b8a7f3d-f61e-406c-b03f-2849845f6d8a" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7b8a7f3d-f61e-406c-b03f-2849845f6d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1ab97f11-de01-4aa9-9928-7a69e76a47a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1ab97f11-de01-4aa9-9928-7a69e76a47a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a8e5aa60-6a16-4a2c-8f66-79e3f76ae703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a8e5aa60-6a16-4a2c-8f66-79e3f76ae703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_8cf83213-8228-469d-afb5-f0504f7e7527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_8cf83213-8228-469d-afb5-f0504f7e7527" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc411745-4e36-48b7-8aa0-be98ca7249eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc411745-4e36-48b7-8aa0-be98ca7249eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6cacf4f7-d883-428d-8161-9d74adaeb25a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6cacf4f7-d883-428d-8161-9d74adaeb25a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_f07f1b98-a7c6-42dd-b0cb-507a3389dfd7" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_f07f1b98-a7c6-42dd-b0cb-507a3389dfd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_10fdc900-fce8-42d7-b90c-ce95bd3911c5" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_10fdc900-fce8-42d7-b90c-ce95bd3911c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_2a493a0f-1486-44e3-be89-4679c7bba1f6" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_2a493a0f-1486-44e3-be89-4679c7bba1f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_77a0c3e8-a2a4-47f9-8b2a-738670b71a4a" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_77a0c3e8-a2a4-47f9-8b2a-738670b71a4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cc11373e-669f-4c83-8447-22f51dff2605" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cc11373e-669f-4c83-8447-22f51dff2605" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_749734e0-4e6b-4f0e-8634-7a24568a3a8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_749734e0-4e6b-4f0e-8634-7a24568a3a8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_72e4163f-abec-4c0a-91f5-c966887384b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:to="loc_us-gaap_UnsecuredDebtMember_72e4163f-abec-4c0a-91f5-c966887384b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ae199b25-afc5-4533-bf08-b2cfb3ecb809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:to="loc_us-gaap_SecuredDebtMember_ae199b25-afc5-4533-bf08-b2cfb3ecb809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_59a9baba-c3e3-4771-af54-0a65a8347add_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_59a9baba-c3e3-4771-af54-0a65a8347add_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_07e66cd8-4e0d-4477-9df6-0e840ad9c85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_07e66cd8-4e0d-4477-9df6-0e840ad9c85f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_304964fa-6c83-409f-885a-4a45602bde10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_304964fa-6c83-409f-885a-4a45602bde10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b04be272-58bb-4aa1-8239-4c94383b1be5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:to="loc_srt_RangeMember_b04be272-58bb-4aa1-8239-4c94383b1be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ac33100-823c-4d76-a900-29d1fbe9aa30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:to="loc_srt_RangeMember_1ac33100-823c-4d76-a900-29d1fbe9aa30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89224f8e-8b9a-4fb6-82bb-169bcdec0a88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1ac33100-823c-4d76-a900-29d1fbe9aa30" xlink:to="loc_srt_MaximumMember_89224f8e-8b9a-4fb6-82bb-169bcdec0a88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_36a7d74a-373d-453f-90bb-f0b427633d57_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:to="loc_srt_OwnershipDomain_36a7d74a-373d-453f-90bb-f0b427633d57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_45c11a04-0227-49e3-89b4-306cb68535d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:to="loc_srt_OwnershipDomain_45c11a04-0227-49e3-89b4-306cb68535d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_a4781ef1-1179-4561-92c6-1536a2f3cf1b" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_45c11a04-0227-49e3-89b4-306cb68535d9" xlink:to="loc_bhc_BauschLombMember_a4781ef1-1179-4561-92c6-1536a2f3cf1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:to="loc_dei_EntityDomain_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_86b505e6-3038-43c9-8856-2b4f3d63d87f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:to="loc_dei_EntityDomain_86b505e6-3038-43c9-8856-2b4f3d63d87f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_8f2f923e-bfb5-4a38-b6a9-484e1168ce81" xlink:href="bhc-20230331.xsd#bhc_A1375209BCLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_86b505e6-3038-43c9-8856-2b4f3d63d87f" xlink:to="loc_bhc_A1375209BCLtdMember_8f2f923e-bfb5-4a38-b6a9-484e1168ce81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="id531003cb8a04e238286ed56c735e830_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6e0f2f0d-b9d6-4add-9aab-444cf27f6fb2" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6e0f2f0d-b9d6-4add-9aab-444cf27f6fb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_50b02ec7-0d1e-4468-be58-3a6a732b26e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_50b02ec7-0d1e-4468-be58-3a6a732b26e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:to="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b596ac3a-46c7-473e-a377-76c50c990ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b596ac3a-46c7-473e-a377-76c50c990ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_8fa80f0b-5cda-4e3c-b608-aac560ba6fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b596ac3a-46c7-473e-a377-76c50c990ab9" xlink:to="loc_us-gaap_UnsecuredDebtMember_8fa80f0b-5cda-4e3c-b608-aac560ba6fe8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:to="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_555f06a2-8475-441f-8c0d-68c9a9a77eb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_555f06a2-8475-441f-8c0d-68c9a9a77eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7b6b711-b889-4a86-9ac3-cc6df3000a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7b6b711-b889-4a86-9ac3-cc6df3000a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_26693689-693a-4eda-aca2-8d5769f5ae16" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7b6b711-b889-4a86-9ac3-cc6df3000a04" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_26693689-693a-4eda-aca2-8d5769f5ae16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i1e3de94e41b7491a92adbff58884052a_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7a986361-b6bb-4684-b51a-7af246dd9866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7a986361-b6bb-4684-b51a-7af246dd9866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f394092-1f90-4fda-81eb-ec39ebb3dc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f394092-1f90-4fda-81eb-ec39ebb3dc4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a3b6d893-c180-4872-bb63-d2775855cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a3b6d893-c180-4872-bb63-d2775855cdce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38858389-e5ec-47e6-8f63-9a6bb3f6e4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38858389-e5ec-47e6-8f63-9a6bb3f6e4d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3466e32-f6d5-4ad1-bfab-7011296835a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3466e32-f6d5-4ad1-bfab-7011296835a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4007b223-5a02-41d7-9dd1-26e5857b1d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4007b223-5a02-41d7-9dd1-26e5857b1d8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d75061e-dd10-4f24-8199-7a803a9244d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d75061e-dd10-4f24-8199-7a803a9244d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe168b4-3b1d-43f9-a224-86c24c8db0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe168b4-3b1d-43f9-a224-86c24c8db0c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_88684f34-9214-42ff-811f-d3898ccfa310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_88684f34-9214-42ff-811f-d3898ccfa310" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_05d56a86-b504-4210-88e3-5f2db38ba94f" xlink:href="bhc-20230331.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_05d56a86-b504-4210-88e3-5f2db38ba94f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_156f017d-3fc7-413b-8849-5710112420e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_156f017d-3fc7-413b-8849-5710112420e0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_13f61726-27f3-4bb3-85b0-3a259b689239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_13f61726-27f3-4bb3-85b0-3a259b689239" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5518d392-edfe-4330-bc4a-aa73751a8e6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:to="loc_us-gaap_PlanNameDomain_5518d392-edfe-4330-bc4a-aa73751a8e6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:to="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_ba881e3f-0d8f-43e0-bc10-901fa70e724e" xlink:href="bhc-20230331.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_ba881e3f-0d8f-43e0-bc10-901fa70e724e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_7dcf61e8-ba63-4b53-a5c3-76671aaf8201" xlink:href="bhc-20230331.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member_ba881e3f-0d8f-43e0-bc10-901fa70e724e" xlink:to="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_7dcf61e8-ba63-4b53-a5c3-76671aaf8201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_ad132072-d2c7-4865-a8f6-4d77c792f966" xlink:href="bhc-20230331.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_ad132072-d2c7-4865-a8f6-4d77c792f966" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7177a76d-820b-4216-8a3c-8f7008a8a3df_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7177a76d-820b-4216-8a3c-8f7008a8a3df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_394c6d4b-1a82-4c15-9897-7dcb38134325" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:to="loc_srt_ChiefExecutiveOfficerMember_394c6d4b-1a82-4c15-9897-7dcb38134325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_74ef803e-9c27-4486-81be-9efc8968522c" xlink:href="bhc-20230331.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:to="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_74ef803e-9c27-4486-81be-9efc8968522c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_417a584e-15b2-4985-843e-3a84349fcd31_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_417a584e-15b2-4985-843e-3a84349fcd31_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6dce2956-d3f8-4def-b77c-b34a0da877a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6dce2956-d3f8-4def-b77c-b34a0da877a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5cf96d19-3ebb-4aa0-bfc8-d2157d450b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5cf96d19-3ebb-4aa0-bfc8-d2157d450b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceRestrictedShareUnitsMember_01d36e79-0562-42e8-8469-a42edcfadadf" xlink:href="bhc-20230331.xsd#bhc_PerformanceRestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:to="loc_bhc_PerformanceRestrictedShareUnitsMember_01d36e79-0562-42e8-8469-a42edcfadadf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_11172231-911a-4615-b557-f96245fad475_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:to="loc_dei_EntityDomain_11172231-911a-4615-b557-f96245fad475_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cb168851-908b-4904-a038-d13f3e306456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:to="loc_dei_EntityDomain_cb168851-908b-4904-a038-d13f3e306456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_28367d98-13c9-4bee-a163-ccdf6dd99374" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_cb168851-908b-4904-a038-d13f3e306456" xlink:to="loc_bhc_BauschLombMember_28367d98-13c9-4bee-a163-ccdf6dd99374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_2f38b953-7520-45f9-a76b-656bcfe191a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:to="loc_us-gaap_VestingDomain_2f38b953-7520-45f9-a76b-656bcfe191a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:to="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2fe6d012-6958-416f-bcab-5ff3a52f2a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2fe6d012-6958-416f-bcab-5ff3a52f2a10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ca2af273-975d-4378-bdaf-38172222ce28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ca2af273-975d-4378-bdaf-38172222ce28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3d0082f4-995b-4df2-bea6-cece5abdf3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3d0082f4-995b-4df2-bea6-cece5abdf3ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f8f56d04-0934-45d1-959b-bf3da1739a15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f8f56d04-0934-45d1-959b-bf3da1739a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bf3cbc50-5c14-4b60-8ef9-2d14c0b23a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bf3cbc50-5c14-4b60-8ef9-2d14c0b23a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_68e6e90b-e11d-4098-b339-cbef5db971a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bf3cbc50-5c14-4b60-8ef9-2d14c0b23a38" xlink:to="loc_us-gaap_SubsequentEventMember_68e6e90b-e11d-4098-b339-cbef5db971a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="i988ea3c373c14608913749d242e47918_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_96f336f7-74b9-4479-bea6-5f72f0b1d8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b18a30d2-cd2a-4b80-a2d5-1f7b90c914dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_96f336f7-74b9-4479-bea6-5f72f0b1d8ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b18a30d2-cd2a-4b80-a2d5-1f7b90c914dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_96f336f7-74b9-4479-bea6-5f72f0b1d8ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:to="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11f88853-7577-44a8-8a2f-59178ec39593_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_11f88853-7577-44a8-8a2f-59178ec39593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_26924c05-30cf-4d05-a02e-7c7f7b7f8e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_26924c05-30cf-4d05-a02e-7c7f7b7f8e07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0f4c39e1-7e73-4b1c-a494-39b2d16e7b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0f4c39e1-7e73-4b1c-a494-39b2d16e7b04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dcf67620-ef1d-409b-be41-4431c0d577b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dcf67620-ef1d-409b-be41-4431c0d577b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e2f3b65-fa71-490e-b314-cc64cb25213d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e2f3b65-fa71-490e-b314-cc64cb25213d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bec16b7a-fd0d-45d5-9e4c-e1b07e072977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bec16b7a-fd0d-45d5-9e4c-e1b07e072977" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended" id="ia91c321ea8d24bd598ae7acd1ba1e580_SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ce24dfc2-4221-472c-ab79-af2bb2ff38f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ce24dfc2-4221-472c-ab79-af2bb2ff38f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03e1911c-db3e-462b-ad15-29fe3db3501a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03e1911c-db3e-462b-ad15-29fe3db3501a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85d034e4-1476-4648-a160-83ade3223aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85d034e4-1476-4648-a160-83ade3223aa6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_972bd1e7-0d60-41cd-aea6-d34ef0703113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_972bd1e7-0d60-41cd-aea6-d34ef0703113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9ce3470-0c6e-435c-bb24-03df7431be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9ce3470-0c6e-435c-bb24-03df7431be50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:to="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9aacb7b-ec7c-4fad-ba98-338fae737056_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9aacb7b-ec7c-4fad-ba98-338fae737056_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8c349b04-1a68-4534-a6f1-7cc6dfa665a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8c349b04-1a68-4534-a6f1-7cc6dfa665a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_4411e1b6-1927-411b-a891-b901662662f6" xlink:href="bhc-20230331.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_TimeBasedRSUMember_4411e1b6-1927-411b-a891-b901662662f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_e0d706b2-240b-4344-ae89-1ff5ba16a5ee" xlink:href="bhc-20230331.xsd#bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_e0d706b2-240b-4344-ae89-1ff5ba16a5ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2ea0835-df06-4d6f-8369-defaff6dea87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2ea0835-df06-4d6f-8369-defaff6dea87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_fabd8719-a137-45f2-b9fb-15141758d198" xlink:href="bhc-20230331.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_fabd8719-a137-45f2-b9fb-15141758d198" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_ba9e8c50-f45f-488a-af0a-48d0689fa635" xlink:href="bhc-20230331.xsd#bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_ba9e8c50-f45f-488a-af0a-48d0689fa635" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:to="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b5075c14-7779-4513-aae5-d5367f328162_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:to="loc_dei_EntityDomain_b5075c14-7779-4513-aae5-d5367f328162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_94526b1f-3d80-407e-b0bd-ca1e532d8f34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:to="loc_dei_EntityDomain_94526b1f-3d80-407e-b0bd-ca1e532d8f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_eb81c581-571f-46a8-b84c-c52772836984" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_94526b1f-3d80-407e-b0bd-ca1e532d8f34" xlink:to="loc_bhc_BauschLombMember_eb81c581-571f-46a8-b84c-c52772836984" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="iba6fea45dabf4d83b4a9a31a24768a81_ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e93b32d-9348-49a8-b7cf-fc72dbecbed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1797148-0b23-4cd1-8f64-0d1d3769b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e93b32d-9348-49a8-b7cf-fc72dbecbed0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1797148-0b23-4cd1-8f64-0d1d3769b4df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e93b32d-9348-49a8-b7cf-fc72dbecbed0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7eb5c47b-4c95-462b-80e7-a06628c58fac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:to="loc_us-gaap_EquityComponentDomain_7eb5c47b-4c95-462b-80e7-a06628c58fac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:to="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f2ba7b3c-a263-4c52-a77f-bc8940a8b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f2ba7b3c-a263-4c52-a77f-bc8940a8b1a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_86672f3b-e7eb-4add-8e17-77eb4166f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_86672f3b-e7eb-4add-8e17-77eb4166f84d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d34e677-84c9-4a25-bbff-870e3fca9680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d34e677-84c9-4a25-bbff-870e3fca9680" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended" id="idb9888498fd14ebcacf768d264843973_ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4da51a33-3abc-47ac-8ade-67d7949c3421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_092d1356-a280-42ce-8d6e-19f5a75feae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4da51a33-3abc-47ac-8ade-67d7949c3421" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_092d1356-a280-42ce-8d6e-19f5a75feae6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4da51a33-3abc-47ac-8ade-67d7949c3421" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:to="loc_us-gaap_EquityComponentDomain_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad8e14a8-702a-4c5c-bbde-908a0098affe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:to="loc_us-gaap_EquityComponentDomain_ad8e14a8-702a-4c5c-bbde-908a0098affe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2bf2799f-6ca7-4d57-951e-80273cef041c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ad8e14a8-702a-4c5c-bbde-908a0098affe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2bf2799f-6ca7-4d57-951e-80273cef041c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i6f1a2d1d088446a08072c91db8b41ca6_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_56ca1e41-a96b-479d-9669-0de678ef6adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_56ca1e41-a96b-479d-9669-0de678ef6adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_de646ecf-e3b0-4ce8-90c3-5fd890334bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_de646ecf-e3b0-4ce8-90c3-5fd890334bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_f7e54761-cdc8-416e-b063-0d96c19467d5" xlink:href="bhc-20230331.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_f7e54761-cdc8-416e-b063-0d96c19467d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_49941baa-8d2b-4c1d-91f0-8c2ee371e680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_49941baa-8d2b-4c1d-91f0-8c2ee371e680" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_b5c4dc4d-1a80-46ef-81a4-76cdcbc6d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_b5c4dc4d-1a80-46ef-81a4-76cdcbc6d0f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_43b2b228-a7ab-4923-bbea-40818d1a6dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_43b2b228-a7ab-4923-bbea-40818d1a6dd5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ea6e64e1-9875-4d08-9666-bbd805c73226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ea6e64e1-9875-4d08-9666-bbd805c73226" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_11ef70de-e8fd-4868-83dd-4544d314f02a" xlink:href="bhc-20230331.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_11ef70de-e8fd-4868-83dd-4544d314f02a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b38f5ba5-9bad-49de-b775-b0111dd77953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b38f5ba5-9bad-49de-b775-b0111dd77953" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_97dcc9ed-bb80-4863-a805-25f52d282863" xlink:href="bhc-20230331.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_97dcc9ed-bb80-4863-a805-25f52d282863" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_64560493-6e7c-4b9d-a749-a68996ff9606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_64560493-6e7c-4b9d-a749-a68996ff9606" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d1b0d74-6353-4329-9e5c-af4d8d1a3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d1b0d74-6353-4329-9e5c-af4d8d1a3c3c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_760a5a43-391c-410f-b424-4840b224d976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_760a5a43-391c-410f-b424-4840b224d976" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_da6992f0-5772-41de-a6e7-3d81001b6d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_da6992f0-5772-41de-a6e7-3d81001b6d96" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f1399f4f-27a4-4c20-92fe-35ccbc579b66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f1399f4f-27a4-4c20-92fe-35ccbc579b66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_70b399fe-a391-4048-a00a-7888c672e48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_70b399fe-a391-4048-a00a-7888c672e48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_0ded9a8e-f5ef-4fb1-94ad-ec16af967fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_70b399fe-a391-4048-a00a-7888c672e48f" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_0ded9a8e-f5ef-4fb1-94ad-ec16af967fe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_97e49b57-f76f-4ef0-9538-dff3e53e58ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:to="loc_us-gaap_TaxPeriodDomain_97e49b57-f76f-4ef0-9538-dff3e53e58ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:to="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2014Member_36b1468d-a4b5-4b42-8e5f-16477ea18671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:to="loc_us-gaap_TaxYear2014Member_36b1468d-a4b5-4b42-8e5f-16477ea18671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2018AndTaxYear2019Member_517d0f59-e515-44b7-830b-9ddf237cf9f8" xlink:href="bhc-20230331.xsd#bhc_TaxYear2018AndTaxYear2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:to="loc_bhc_TaxYear2018AndTaxYear2019Member_517d0f59-e515-44b7-830b-9ddf237cf9f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76032d98-29b6-4583-9037-691fb0016477_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:to="loc_srt_RangeMember_76032d98-29b6-4583-9037-691fb0016477_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb051937-6d7d-48d5-811e-2d279dbd1fe4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:to="loc_srt_RangeMember_eb051937-6d7d-48d5-811e-2d279dbd1fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_adcf6c97-d9e7-45a7-9077-a6aaf158d25d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb051937-6d7d-48d5-811e-2d279dbd1fe4" xlink:to="loc_srt_MaximumMember_adcf6c97-d9e7-45a7-9077-a6aaf158d25d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended" id="i01a80d16b6f14c7a9b827fdbb5ca6d0c_EARNINGSLOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5228f27-c02d-453a-80db-81ad5e81260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5228f27-c02d-453a-80db-81ad5e81260c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_9903a750-dc2d-4ee5-9efa-169b6e750f8f" xlink:href="bhc-20230331.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_9903a750-dc2d-4ee5-9efa-169b6e750f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e2f869bf-c67d-4cef-904a-a9dba522bd3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e2f869bf-c67d-4cef-904a-a9dba522bd3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_4d94a414-594e-4892-a24e-6c8e112f775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:to="loc_us-gaap_StockCompensationPlanMember_4d94a414-594e-4892-a24e-6c8e112f775f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_b7278826-3719-4b31-9a5b-5afefcfbd7d8" xlink:href="bhc-20230331.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_b7278826-3719-4b31-9a5b-5afefcfbd7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_50c0853e-49ec-490c-9024-c674fb9d78b4" xlink:href="bhc-20230331.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_50c0853e-49ec-490c-9024-c674fb9d78b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended" id="i8da36a21bfd041b29bf0815824914519_LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_52af340b-ac18-4faf-a769-1c2925cad8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_52af340b-ac18-4faf-a769-1c2925cad8e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec9c6b3b-1cd4-48aa-a7e3-fd76ecdb3f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec9c6b3b-1cd4-48aa-a7e3-fd76ecdb3f4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_7c47ab12-8b08-42f6-8b25-24ce12cef6c5" xlink:href="bhc-20230331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_7c47ab12-8b08-42f6-8b25-24ce12cef6c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_55ad4dba-19b3-4fe9-a643-7da3f3616d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_55ad4dba-19b3-4fe9-a643-7da3f3616d98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_5619776a-4b91-4b43-b2e5-8bd0de3e12bc" xlink:href="bhc-20230331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_5619776a-4b91-4b43-b2e5-8bd0de3e12bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_51ca9616-3bd9-41e9-b129-17b026a91cba" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_51ca9616-3bd9-41e9-b129-17b026a91cba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_e67f78dd-6590-4d57-a601-4d8d28e42758" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_e67f78dd-6590-4d57-a601-4d8d28e42758" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_17ebd187-a221-46e6-8d70-52ef9fbf086b" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_17ebd187-a221-46e6-8d70-52ef9fbf086b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_c82a690f-f6e6-45d4-80bd-636b79625bb3" xlink:href="bhc-20230331.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_c82a690f-f6e6-45d4-80bd-636b79625bb3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aec1dee-c841-47d8-bd2d-a29af85067cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aec1dee-c841-47d8-bd2d-a29af85067cc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c1603dc8-99aa-444b-b2fd-c1864e1f288f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:to="loc_srt_LitigationCaseTypeDomain_c1603dc8-99aa-444b-b2fd-c1864e1f288f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:to="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_af07ea61-11f0-44f5-a73e-00fe68a5cf22" xlink:href="bhc-20230331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_af07ea61-11f0-44f5-a73e-00fe68a5cf22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_7a25c2a6-f384-49fa-817f-666582d3b565" xlink:href="bhc-20230331.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_7a25c2a6-f384-49fa-817f-666582d3b565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_b220ab22-b9b6-41e1-a71b-bf67fe34342b" xlink:href="bhc-20230331.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_RICOClassActionsLitigationMember_b220ab22-b9b6-41e1-a71b-bf67fe34342b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_0177135e-f3d0-42f5-8a53-2740f9873a8b" xlink:href="bhc-20230331.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_0177135e-f3d0-42f5-8a53-2740f9873a8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_4840490c-109a-4829-8212-87f589151379_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:to="loc_us-gaap_LitigationStatusDomain_4840490c-109a-4829-8212-87f589151379_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bf71b510-df67-4014-a9fc-e737c8ddacbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:to="loc_us-gaap_LitigationStatusDomain_bf71b510-df67-4014-a9fc-e737c8ddacbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_e3cd539e-1c16-405d-9c48-5b9f9696bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_bf71b510-df67-4014-a9fc-e737c8ddacbb" xlink:to="loc_us-gaap_SettledLitigationMember_e3cd539e-1c16-405d-9c48-5b9f9696bf37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d0612a74-4041-48b1-9ceb-fdf1b5467a9c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:to="loc_srt_SegmentGeographicalDomain_d0612a74-4041-48b1-9ceb-fdf1b5467a9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:to="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_dbdfd401-411f-4c20-bf69-ab0c37a250c1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:to="loc_stpr_NJ_dbdfd401-411f-4c20-bf69-ab0c37a250c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_4931b596-9fd2-43ef-87d1-4fba8e28d806" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:to="loc_country_CA_4931b596-9fd2-43ef-87d1-4fba8e28d806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_84c266ed-ce39-4ecd-8b44-7dd3e3305d67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:to="loc_us-gaap_LossContingencyNatureDomain_84c266ed-ce39-4ecd-8b44-7dd3e3305d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:to="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_e596acea-9730-4ac2-8563-c26c4d7b30f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_e596acea-9730-4ac2-8563-c26c4d7b30f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_1ef053e5-1de2-4147-9b74-9ecd4de432aa" xlink:href="bhc-20230331.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_1ef053e5-1de2-4147-9b74-9ecd4de432aa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended" id="i826ecc0702e14d0fa666effcd0628631_LEGALPROCEEDINGSAntitrustDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d07d4fcc-5f9b-4c2c-bbc8-6a5f967a4b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d07d4fcc-5f9b-4c2c-bbc8-6a5f967a4b78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_24aa0629-4446-429f-aead-6a0f2c975c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_24aa0629-4446-429f-aead-6a0f2c975c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:to="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2ec3db90-6c75-4a33-ac6b-b79223de3d46_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:to="loc_srt_LitigationCaseTypeDomain_2ec3db90-6c75-4a33-ac6b-b79223de3d46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:to="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_8a82488a-a94a-4ea8-b062-6e0d741af2a1" xlink:href="bhc-20230331.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_8a82488a-a94a-4ea8-b062-6e0d741af2a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_ba11f192-6bc2-4f47-b7bc-bc444e342d6b" xlink:href="bhc-20230331.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_ba11f192-6bc2-4f47-b7bc-bc444e342d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2df64295-2ef4-4d03-8902-b3eabd788811_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2df64295-2ef4-4d03-8902-b3eabd788811_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c60801d4-0ff5-46d9-afff-c9c172997c54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c60801d4-0ff5-46d9-afff-c9c172997c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_22d9ebd0-b351-4b5c-b5d7-15644c3156c0" xlink:href="bhc-20230331.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c60801d4-0ff5-46d9-afff-c9c172997c54" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_22d9ebd0-b351-4b5c-b5d7-15644c3156c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_e2908f3e-9f59-4603-a453-f9e68c4efc00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:to="loc_us-gaap_LitigationStatusDomain_e2908f3e-9f59-4603-a453-f9e68c4efc00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25e8ed7f-4b4d-468a-87c4-fff21ebfc386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:to="loc_us-gaap_LitigationStatusDomain_25e8ed7f-4b4d-468a-87c4-fff21ebfc386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_40d7ff56-366c-4144-9516-e56de898e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_25e8ed7f-4b4d-468a-87c4-fff21ebfc386" xlink:to="loc_us-gaap_PendingLitigationMember_40d7ff56-366c-4144-9516-e56de898e42b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended" id="i2c03c749cbe24581b09c2b42d6dc55ae_LEGALPROCEEDINGSIntellectualPropertyDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_94c271e6-2499-4003-b4a0-51e0dc661755" xlink:href="bhc-20230331.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_94c271e6-2499-4003-b4a0-51e0dc661755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_63d41b47-71d0-455a-8ad7-57102bda2df9" xlink:href="bhc-20230331.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_63d41b47-71d0-455a-8ad7-57102bda2df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings_33d90d76-c8db-4bb9-bb01-273c65a61808" xlink:href="bhc-20230331.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_bhc_GainContingencyNumberOfProceedings_33d90d76-c8db-4bb9-bb01-273c65a61808" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_0c3fa7b6-35c6-4aa9-8efd-c35333c3af1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_0c3fa7b6-35c6-4aa9-8efd-c35333c3af1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0803e743-527e-473c-99e0-02077b1300b1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:to="loc_srt_LitigationCaseTypeDomain_0803e743-527e-473c-99e0-02077b1300b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:to="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_08e8f7cd-59ba-45f5-b2ad-c74a148b9e54" xlink:href="bhc-20230331.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_08e8f7cd-59ba-45f5-b2ad-c74a148b9e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_c6956112-7cde-4102-b7cc-d68da9c3d9c3" xlink:href="bhc-20230331.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_c6956112-7cde-4102-b7cc-d68da9c3d9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_53b25891-5e11-4121-98e8-03ea6d833528" xlink:href="bhc-20230331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_53b25891-5e11-4121-98e8-03ea6d833528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AurobindoPharmaLimitedLitigationMember_bf748a59-efe4-49ec-ae13-8c2a1c3b850d" xlink:href="bhc-20230331.xsd#bhc_AurobindoPharmaLimitedLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_AurobindoPharmaLimitedLitigationMember_bf748a59-efe4-49ec-ae13-8c2a1c3b850d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_5d91bbe5-25c8-4d4d-99a3-03d95f55e52b" xlink:href="bhc-20230331.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_5d91bbe5-25c8-4d4d-99a3-03d95f55e52b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_265fcf25-b162-4935-ae63-94d9db1e4358" xlink:href="bhc-20230331.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_265fcf25-b162-4935-ae63-94d9db1e4358" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_22385fc6-623b-4b4d-8f88-b82cfbae98e8" xlink:href="bhc-20230331.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_22385fc6-623b-4b4d-8f88-b82cfbae98e8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_467f1fb6-1ad3-43d7-9fcf-5b1528d37aaf" xlink:href="bhc-20230331.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_ApotexIncLitigationMember_467f1fb6-1ad3-43d7-9fcf-5b1528d37aaf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_188c2743-7252-4484-a296-189aff51432b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:to="loc_srt_SegmentGeographicalDomain_188c2743-7252-4484-a296-189aff51432b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_de3f7892-94ae-48d0-bf6b-7c20bba964e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:to="loc_srt_SegmentGeographicalDomain_de3f7892-94ae-48d0-bf6b-7c20bba964e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_895f93d0-743e-4b44-9627-685a53cd039f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_de3f7892-94ae-48d0-bf6b-7c20bba964e4" xlink:to="loc_country_CA_895f93d0-743e-4b44-9627-685a53cd039f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:to="loc_us-gaap_LitigationStatusDomain_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:to="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f0621ec0-ed4c-4119-9281-9d7d00b2fa53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:to="loc_us-gaap_SettledLitigationMember_f0621ec0-ed4c-4119-9281-9d7d00b2fa53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_fab8a21b-4e9e-4543-ab48-443032d2d118" xlink:href="bhc-20230331.xsd#bhc_DefaultJudgementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:to="loc_bhc_DefaultJudgementMember_fab8a21b-4e9e-4543-ab48-443032d2d118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_bc83c2d5-1fbf-4d2c-a38d-33c82dd49e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:to="loc_us-gaap_PendingLitigationMember_bc83c2d5-1fbf-4d2c-a38d-33c82dd49e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:to="loc_dei_EntityDomain_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_acaf64d6-ec77-4eb9-a2fa-da67ae6b4afc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:to="loc_dei_EntityDomain_acaf64d6-ec77-4eb9-a2fa-da67ae6b4afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f960f73f-8875-4aad-88e0-8d89d1d32cb7" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_acaf64d6-ec77-4eb9-a2fa-da67ae6b4afc" xlink:to="loc_bhc_BauschLombMember_f960f73f-8875-4aad-88e0-8d89d1d32cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_486a7502-4a70-4df2-95d0-c4e93650679a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_486a7502-4a70-4df2-95d0-c4e93650679a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_68de5776-84b7-4ad2-94aa-68c19d4a7abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_486a7502-4a70-4df2-95d0-c4e93650679a" xlink:to="loc_us-gaap_SubsequentEventMember_68de5776-84b7-4ad2-94aa-68c19d4a7abc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended" id="i5a753996dd6d4bc6a43efe7b40df967e_LEGALPROCEEDINGSProductLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b445786f-702a-475b-ab19-73efa2435862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b445786f-702a-475b-ab19-73efa2435862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_e575d84c-292d-4941-8b24-29bd87ce5f00" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_e575d84c-292d-4941-8b24-29bd87ce5f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5113957f-57a0-4ef7-8981-1d3c91064928" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5113957f-57a0-4ef7-8981-1d3c91064928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ef59ae5a-5836-4f97-aa03-21012afc0e91_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:to="loc_srt_LitigationCaseTypeDomain_ef59ae5a-5836-4f97-aa03-21012afc0e91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_96fd19d7-cb29-47a2-b270-e09132c1b6eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:to="loc_srt_LitigationCaseTypeDomain_96fd19d7-cb29-47a2-b270-e09132c1b6eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_965caaee-ede8-46d8-8d9c-34a3f34490d5" xlink:href="bhc-20230331.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_96fd19d7-cb29-47a2-b270-e09132c1b6eb" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_965caaee-ede8-46d8-8d9c-34a3f34490d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_f078e50b-0a33-49dc-b2c1-da4ea105d140" xlink:href="bhc-20230331.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_965caaee-ede8-46d8-8d9c-34a3f34490d5" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_f078e50b-0a33-49dc-b2c1-da4ea105d140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_e68649b8-3513-4d44-93f2-a0fb809330a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:to="loc_us-gaap_LitigationStatusDomain_e68649b8-3513-4d44-93f2-a0fb809330a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7b232200-01ef-437d-a2e8-ba84f4653d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:to="loc_us-gaap_LitigationStatusDomain_7b232200-01ef-437d-a2e8-ba84f4653d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_7d237626-17a2-45d6-98f2-35d0b01cc8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_7b232200-01ef-437d-a2e8-ba84f4653d43" xlink:to="loc_us-gaap_PendingLitigationMember_7d237626-17a2-45d6-98f2-35d0b01cc8c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_57b29878-a151-46df-addd-5f2dc22aa2da" xlink:href="bhc-20230331.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PendingLitigationMember_7d237626-17a2-45d6-98f2-35d0b01cc8c9" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_57b29878-a151-46df-addd-5f2dc22aa2da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4a7c9c1a-b216-40fa-9f8d-6a31019c6503_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:to="loc_srt_SegmentGeographicalDomain_4a7c9c1a-b216-40fa-9f8d-6a31019c6503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:to="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_a0d2989e-0a45-4057-bd1b-5172c06e7bf4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:to="loc_country_CA_a0d2989e-0a45-4057-bd1b-5172c06e7bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_db9320d4-3801-40ee-a23d-25e80ba1058c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:to="loc_stpr_CA-BC_db9320d4-3801-40ee-a23d-25e80ba1058c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_9842ab10-bbe3-420d-b25f-301120eb6c9a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:to="loc_stpr_CA-QC_9842ab10-bbe3-420d-b25f-301120eb6c9a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended" id="ia052c8ee8585429db28550674f71480b_LEGALPROCEEDINGSGeneralCivilActionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_c01fd97d-6876-4041-8d6a-c2e70fd54d2c" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_c01fd97d-6876-4041-8d6a-c2e70fd54d2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_3774ab7a-b9be-4f9c-827b-d1a9c4650b39" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_3774ab7a-b9be-4f9c-827b-d1a9c4650b39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2cd57175-807d-42a1-8d13-df74624aafed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2cd57175-807d-42a1-8d13-df74624aafed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:to="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:to="loc_srt_LitigationCaseTypeDomain_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:to="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_8757a015-f8f4-4cc2-be28-11c6c4815796" xlink:href="bhc-20230331.xsd#bhc_CaliforniaProposition65RelatedMatterLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:to="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_8757a015-f8f4-4cc2-be28-11c6c4815796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_1db197cb-bcdf-4db0-b869-c2ec99716dd3" xlink:href="bhc-20230331.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_1db197cb-bcdf-4db0-b869-c2ec99716dd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a56d554d-abe4-4100-ad08-2e40cb04832b" xlink:href="bhc-20230331.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a56d554d-abe4-4100-ad08-2e40cb04832b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i91c67efc9efa40028ff1e52efe5e3629_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_236e3ece-c96b-48a9-a6e2-36eae6d06f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6b217f6c-830e-4a3a-8d70-eacb7eaccb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_236e3ece-c96b-48a9-a6e2-36eae6d06f65" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6b217f6c-830e-4a3a-8d70-eacb7eaccb60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_236e3ece-c96b-48a9-a6e2-36eae6d06f65" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_951cd25a-32c7-4465-ad9d-73a583f66246_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:to="loc_us-gaap_SegmentDomain_951cd25a-32c7-4465-ad9d-73a583f66246_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4b7b1f3a-30c9-4f23-9082-f8e8b9074d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:to="loc_us-gaap_SegmentDomain_4b7b1f3a-30c9-4f23-9082-f8e8b9074d38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_dfdaedce-e635-4e30-b141-17afeb509abc" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4b7b1f3a-30c9-4f23-9082-f8e8b9074d38" xlink:to="loc_bhc_SalixSegmentMember_dfdaedce-e635-4e30-b141-17afeb509abc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9412496c-d660-42f1-8246-7b527220d25d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:to="loc_srt_ProductsAndServicesDomain_9412496c-d660-42f1-8246-7b527220d25d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e95c5ca5-f33e-4ffb-b361-9e20190c9610" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:to="loc_srt_ProductsAndServicesDomain_e95c5ca5-f33e-4ffb-b361-9e20190c9610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_5d8ff723-d4c0-4124-8e2d-47e7c30b1671" xlink:href="bhc-20230331.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e95c5ca5-f33e-4ffb-b361-9e20190c9610" xlink:to="loc_bhc_XifaxanBrandedProductsMember_5d8ff723-d4c0-4124-8e2d-47e7c30b1671" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_560d67a7-7161-410f-8ab4-39ff315f979e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_560d67a7-7161-410f-8ab4-39ff315f979e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_452aa8ee-1936-46bc-b5ee-cc9bd367b978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_452aa8ee-1936-46bc-b5ee-cc9bd367b978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_10e82544-d6ba-4af4-8519-f2f11da65f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_452aa8ee-1936-46bc-b5ee-cc9bd367b978" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_10e82544-d6ba-4af4-8519-f2f11da65f2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_803089e6-2be7-4530-92c8-a0fd42fe0a6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_803089e6-2be7-4530-92c8-a0fd42fe0a6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3044af4c-a11e-4673-a0e9-24caf08c16b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3044af4c-a11e-4673-a0e9-24caf08c16b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0a8ff888-9737-438b-8cc0-be0c44018e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3044af4c-a11e-4673-a0e9-24caf08c16b7" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0a8ff888-9737-438b-8cc0-be0c44018e07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended" id="i2def6b286fff49c19e4e47d5db21bd4b_SEGMENTINFORMATIONSegmentRevenuesandProfitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41fe946b-c8d8-4d8c-9ab9-c7d42f30bcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41fe946b-c8d8-4d8c-9ab9-c7d42f30bcd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_60f269be-4410-42dc-a370-c79dc92a977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_OperatingIncomeLoss_60f269be-4410-42dc-a370-c79dc92a977e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_005e8b78-6540-45f8-95f5-50238a9b4824" xlink:href="bhc-20230331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_005e8b78-6540-45f8-95f5-50238a9b4824" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_34a7faa0-f52e-474a-87a2-e19d75663aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_AssetImpairmentCharges_34a7faa0-f52e-474a-87a2-e19d75663aac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_2444bb7a-e5c0-47b8-aed4-81f4c369f96d" xlink:href="bhc-20230331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_2444bb7a-e5c0-47b8-aed4-81f4c369f96d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_c9b36185-f03a-4801-bff3-438c17e667fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_c9b36185-f03a-4801-bff3-438c17e667fb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e8990a2d-d205-47a1-82df-38ce723b588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e8990a2d-d205-47a1-82df-38ce723b588d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7c19456d-c861-4005-8a36-55d5d4aa2022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_InterestExpenseDebt_7c19456d-c861-4005-8a36-55d5d4aa2022" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01659d22-0c0e-4968-936a-5e9c6ee4b862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01659d22-0c0e-4968-936a-5e9c6ee4b862" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0970aa9b-4727-49bf-8536-c319c4f3ccea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0970aa9b-4727-49bf-8536-c319c4f3ccea" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:to="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:to="loc_srt_ConsolidationItemsDomain_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:to="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_575f9b9e-3814-415d-a295-a5d26b32cdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:to="loc_us-gaap_OperatingSegmentsMember_575f9b9e-3814-415d-a295-a5d26b32cdc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d1cb3517-1e28-4e69-938a-c2446ea071f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d1cb3517-1e28-4e69-938a-c2446ea071f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0e1741d8-4118-491e-9c9f-d1d14e2648f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:to="loc_us-gaap_SegmentDomain_0e1741d8-4118-491e-9c9f-d1d14e2648f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:to="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_d033e27c-78ee-4589-bb6c-78865fd9af10" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_SalixSegmentMember_d033e27c-78ee-4589-bb6c-78865fd9af10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_4378298f-444d-4193-93c7-bef1e4e7d4d4" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_InternationalRxMember_4378298f-444d-4193-93c7-bef1e4e7d4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_cac21e1b-28ed-4ce2-b8d4-a09ed6c53046" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_SoltaMedicalSegmentMember_cac21e1b-28ed-4ce2-b8d4-a09ed6c53046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember_e83597cf-e8df-4963-aed1-c2a9a2eb67e3" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_DiversifiedSegmentMember_e83597cf-e8df-4963-aed1-c2a9a2eb67e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_ce17ea61-0302-4629-a8fb-026402498c79" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_BauschLombMember_ce17ea61-0302-4629-a8fb-026402498c79" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended" id="i4c7534b98e54474a8266844077a35cd7_SEGMENTINFORMATIONDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_298931cb-e0cb-40fb-b1ca-d26c54d61931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7051649-8077-4df1-a851-702640f84bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_298931cb-e0cb-40fb-b1ca-d26c54d61931" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7051649-8077-4df1-a851-702640f84bfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_298931cb-e0cb-40fb-b1ca-d26c54d61931" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:to="loc_us-gaap_SegmentDomain_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:to="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_750fc1b1-794d-4c6b-9808-dfe2bb35564e" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_SalixSegmentMember_750fc1b1-794d-4c6b-9808-dfe2bb35564e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_d34679fc-e135-4f3e-9665-587706b1d212" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_InternationalRxMember_d34679fc-e135-4f3e-9665-587706b1d212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_55726b29-4838-4916-a670-1fd83743acfb" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_SoltaMedicalSegmentMember_55726b29-4838-4916-a670-1fd83743acfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember_5eae6e26-988b-48bb-95ac-bc966da5f4d2" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_DiversifiedSegmentMember_5eae6e26-988b-48bb-95ac-bc966da5f4d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_ed14432b-1207-4c9f-b85a-ff9236fbcb47" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_BauschLombMember_ed14432b-1207-4c9f-b85a-ff9236fbcb47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:to="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_617fc945-edd5-45d9-942c-c91713742180_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:to="loc_srt_ProductsAndServicesDomain_617fc945-edd5-45d9-942c-c91713742180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:to="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_8c3022bc-7ef7-4531-81c8-ccbe79b17de5" xlink:href="bhc-20230331.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_PharmaceuticalProductsMember_8c3022bc-7ef7-4531-81c8-ccbe79b17de5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_28676fb8-b76f-4dd9-adc2-18f476c7d311" xlink:href="bhc-20230331.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_DeviceProductsMember_28676fb8-b76f-4dd9-adc2-18f476c7d311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_06f9b0df-4087-457f-8578-6bb61f0a1934" xlink:href="bhc-20230331.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_OvertheCounterProductsMember_06f9b0df-4087-457f-8578-6bb61f0a1934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_a7cdab35-f808-4c6a-9ee5-ea5c33fd2ce7" xlink:href="bhc-20230331.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_a7cdab35-f808-4c6a-9ee5-ea5c33fd2ce7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_adc54db8-c7fe-4ca2-9ba6-e8eb9356a253" xlink:href="bhc-20230331.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_OtherRevenuesMember_adc54db8-c7fe-4ca2-9ba6-e8eb9356a253" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended" id="i81590dac473f48e9af7cbad6e868407f_SEGMENTINFORMATIONNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_290d308e-d8a0-4abd-8bb0-3db4764dbbde" xlink:href="bhc-20230331.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_290d308e-d8a0-4abd-8bb0-3db4764dbbde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a24798c5-fea9-4ede-b228-3cb6c8a799a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a24798c5-fea9-4ede-b228-3cb6c8a799a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_269789a5-920d-4a10-8be4-414a05928f1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_269789a5-920d-4a10-8be4-414a05928f1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_568ec2ff-ead3-4a40-ae46-5303d1169626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_568ec2ff-ead3-4a40-ae46-5303d1169626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_fec4e8f6-5cf1-4f21-95c1-ed8754be4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_568ec2ff-ead3-4a40-ae46-5303d1169626" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_fec4e8f6-5cf1-4f21-95c1-ed8754be4d2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_60acf161-5542-4684-8dee-57920f6a5f7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_60acf161-5542-4684-8dee-57920f6a5f7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fb8e4373-aa80-49f2-a5e6-295cf3941ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fb8e4373-aa80-49f2-a5e6-295cf3941ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_1fba0b71-734e-4f5f-8a23-591238a2a7cc" xlink:href="bhc-20230331.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fb8e4373-aa80-49f2-a5e6-295cf3941ebd" xlink:to="loc_bhc_RevenuesNetMember_1fba0b71-734e-4f5f-8a23-591238a2a7cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b6316c65-b6d4-43ca-8351-60c6692cfc9c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:to="loc_srt_NameOfMajorCustomerDomain_b6316c65-b6d4-43ca-8351-60c6692cfc9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4095fcfb-0cdc-413a-b8b4-3fc9d4ffd69d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:to="loc_srt_NameOfMajorCustomerDomain_4095fcfb-0cdc-413a-b8b4-3fc9d4ffd69d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_f202f266-b0a7-40bc-a3c6-80c01f96754d" xlink:href="bhc-20230331.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4095fcfb-0cdc-413a-b8b4-3fc9d4ffd69d" xlink:to="loc_bhc_CustomerTopTenProductsMember_f202f266-b0a7-40bc-a3c6-80c01f96754d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended" id="ic42dab8629ce4e0090742dbac1e7592f_SEGMENTINFORMATIONRevenuebyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_09616393-7987-43c9-a815-ce0bc3577a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edd63b36-f3e9-4afa-8713-8cdeebcd510c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_09616393-7987-43c9-a815-ce0bc3577a22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edd63b36-f3e9-4afa-8713-8cdeebcd510c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_09616393-7987-43c9-a815-ce0bc3577a22" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:to="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_67c7d12f-be2e-4010-9d96-5d36733794dd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:to="loc_srt_SegmentGeographicalDomain_67c7d12f-be2e-4010-9d96-5d36733794dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:to="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_60f0490d-97ee-450d-a8b6-15b5e5885054" xlink:href="bhc-20230331.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_60f0490d-97ee-450d-a8b6-15b5e5885054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_33a97e0e-451f-43d2-bc4d-005a8d4fea69" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_CN_33a97e0e-451f-43d2-bc4d-005a8d4fea69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_853aec88-7efc-4d02-aea2-a3fb4c59a816" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_CA_853aec88-7efc-4d02-aea2-a3fb4c59a816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_63dd6db6-005c-4a1c-a0a5-63b17f4cbc45" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_PL_63dd6db6-005c-4a1c-a0a5-63b17f4cbc45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_38c32e19-d047-4008-a488-f664e03265fa" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_MX_38c32e19-d047-4008-a488-f664e03265fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ad9d9ae5-4af3-4033-8fcb-320563a65c12" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_FR_ad9d9ae5-4af3-4033-8fcb-320563a65c12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_7f1c71c0-faba-4510-9a76-09242708c2b8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_JP_7f1c71c0-faba-4510-9a76-09242708c2b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_49ac84df-2cc4-44a5-aa0a-7e17982340df" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_DE_49ac84df-2cc4-44a5-aa0a-7e17982340df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_a750c796-8135-4fc9-b120-e4f52287750a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_GB_a750c796-8135-4fc9-b120-e4f52287750a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_d01275fc-44a3-4c34-993c-c77d1df93936" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_RU_d01275fc-44a3-4c34-993c-c77d1df93936" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_6bd4ce83-be27-4482-a0e6-4455eb0e6947" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_ES_6bd4ce83-be27-4482-a0e6-4455eb0e6947" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_5c67c647-7591-4f48-9ec2-93a572c745d4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_IT_5c67c647-7591-4f48-9ec2-93a572c745d4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_9dd1d9a9-c99b-4885-aaea-d75114415945" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_KR_9dd1d9a9-c99b-4885-aaea-d75114415945" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_74fc569e-bc7a-4e51-a582-8680165a2c68" xlink:href="bhc-20230331.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_bhc_OtherCountriesMember_74fc569e-bc7a-4e51-a582-8680165a2c68" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="i3e96de92d2e243cf8293df627d99c47c_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_1e1a75fd-508f-4338-a6c3-a22f6b3c12b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_31ae5a15-d1ab-4558-8147-173594442b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_1e1a75fd-508f-4338-a6c3-a22f6b3c12b2" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_31ae5a15-d1ab-4558-8147-173594442b81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_1e1a75fd-508f-4338-a6c3-a22f6b3c12b2" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7f7a79e5-1a9c-484e-8d55-14defc79accd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7f7a79e5-1a9c-484e-8d55-14defc79accd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a33ee32a-0499-4eee-9568-e22304c65f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a33ee32a-0499-4eee-9568-e22304c65f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_a89210e3-5bb7-4e63-b6b5-45a0e9d1349e" xlink:href="bhc-20230331.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a33ee32a-0499-4eee-9568-e22304c65f5a" xlink:to="loc_bhc_RevenuesNetMember_a89210e3-5bb7-4e63-b6b5-45a0e9d1349e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5169a553-fda3-4706-a78b-25981f7b86f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5169a553-fda3-4706-a78b-25981f7b86f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_93db2555-1609-43a6-a483-f757ab912225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_93db2555-1609-43a6-a483-f757ab912225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_51444b1a-6eed-4a9f-842d-8519ccc312e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_93db2555-1609-43a6-a483-f757ab912225" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_51444b1a-6eed-4a9f-842d-8519ccc312e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_eb82bd46-a554-420e-9dc1-32f3821fc6a2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:to="loc_srt_NameOfMajorCustomerDomain_eb82bd46-a554-420e-9dc1-32f3821fc6a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:to="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_fb721db9-2d9b-4550-a8de-54ad4f6ca0f6" xlink:href="bhc-20230331.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_fb721db9-2d9b-4550-a8de-54ad4f6ca0f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_a04d063b-9d9d-4171-9327-4871bdb008a0" xlink:href="bhc-20230331.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:to="loc_bhc_McKessonCorporationMember_a04d063b-9d9d-4171-9327-4871bdb008a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_c98db0c1-1639-40ec-befa-541eaa359ff2" xlink:href="bhc-20230331.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:to="loc_bhc_CardinalHealthIncMember_c98db0c1-1639-40ec-befa-541eaa359ff2" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>bhc-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:15d8a82e-3541-4c94-ac5d-dc1f963a0c8b,g:acd10879-3b31-4117-a8f7-2a1c419d7f06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember_e609bf95-26dd-4aaa-ba15-148e6a7244bb_terseLabel_en-US" xlink:label="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Proposition 65 Related Matter Litigation</link:label>
    <link:label id="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember_label_en-US" xlink:label="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Proposition 65 Related Matter Litigation [Member]</link:label>
    <link:label id="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember_documentation_en-US" xlink:label="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Proposition 65 Related Matter Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:href="bhc-20230331.xsd#bhc_CaliforniaProposition65RelatedMatterLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:to="lab_bhc_CaliforniaProposition65RelatedMatterLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5d6ec95d-3759-4c59-a4a7-0dd86da70381_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7a814d5f-f47c-4e7f-83b8-0455307b0f3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_909ebcb1-c44b-4739-84dd-225769621849_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b4584dcb-f5fc-4070-9c01-c902a40f955a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b46f4624-6b45-4a8e-8642-cf8d30d99627_netLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_1393dd6f-f5a6-40b7-adf8-f4cd61f8bccd_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_ff1d921e-1c5e-4021-b0c8-655b19423891_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_da33d543-06d4-4587-a06f-6cd107ddec4e_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for expected credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_08086e17-f4f4-40d5-9c2f-dc618da0d48c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_dec266bd-c1aa-475f-984b-4fb8a2abdeff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_4204c6b9-663d-408b-bf03-31f2588bfecc_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_34a18b2d-398d-4027-ac67-5828d4c875b6_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_a0574c78-e2ec-4ba9-9df3-5eab923df606_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) for discrete items</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Discrete Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:href="bhc-20230331.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8175510e-02be-4df5-9524-cd7e544502a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9266ae6a-469e-4cbf-8e5b-c9da588d3613_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DermatologySegmentMember_9889d2ce-616c-4796-a0b8-768ff128873d_terseLabel_en-US" xlink:label="lab_bhc_DermatologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatology</link:label>
    <link:label id="lab_bhc_DermatologySegmentMember_label_en-US" xlink:label="lab_bhc_DermatologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatology Segment [Member]</link:label>
    <link:label id="lab_bhc_DermatologySegmentMember_documentation_en-US" xlink:label="lab_bhc_DermatologySegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatology Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DermatologySegmentMember" xlink:href="bhc-20230331.xsd#bhc_DermatologySegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DermatologySegmentMember" xlink:to="lab_bhc_DermatologySegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cf88e4b0-bc8a-4137-a7f1-9b11cd0830b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_3f8f0183-ac99-4ef1-9194-b2a55e6b35ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_55ae116f-f3e2-4f11-a2ce-946d21b003cd_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20230331.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_35cc1f91-10fc-4e84-82e6-7a7a8922b719_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_5ca34e38-0a42-4a37-b934-13702c281258_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_bbdcdb45-05c7-41c0-9c34-43776a7a4675_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_368f8709-4fac-4f3e-9c7f-faf0f91069db_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_8a106a70-442f-422e-a3cc-d8ae1232b332_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_1f195573-e07b-4e0d-a685-a86cf1206bf7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_83d444af-833b-4ae3-90b0-085be15dce85_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_2f1eb22e-8be9-475b-9de2-e66ad480f301_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_12e30054-49ea-41d5-9e26-6ef5983b60c8_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20230331.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_2e358e52-3acf-469c-901e-db7341731ffd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1207bd85-d6ca-47da-b87e-89418d3b1264_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_faf38d6f-fd82-4c9b-961b-2e7ade7d9083_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_b34f7286-4301-4992-9379-6a4d72949529_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_570c6386-6b2f-4e56-9820-279916bd0a8f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c14a97ac-7312-4167-b0bb-c18b58dfa52a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_0454c161-7d1a-4f90-9129-92c7f9296f95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue attributed to a geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_539f72ec-8957-4476-9dc9-ff353d5b322e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2c62e4e7-d1ac-4815-9418-e15c8c63ffc3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_67fcb299-3d70-4b49-bc2d-4defa6a74d09_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_59875a9b-0882-418e-b2b2-2f36ca8a39ae_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20230331.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_aba67072-4c3e-4dbd-b28c-c22c6a393a6a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_a89d09fc-6b9f-4b9e-b9a1-c828e8f5b37f_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_1b0b5b80-4721-4e9c-9e99-7757fd4f260f_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_f84b2ce6-d8da-465e-be1a-d7cc47cae3f9_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20230331.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_5bcf6551-4b91-4861-bb0b-e068f307d8cd_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20230331.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_83f378c3-d674-4a03-95d3-3335248d3cf7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_71dba0d5-61bd-48ee-b634-74802603e095_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c3965745-aa0f-4cf4-bf9a-78a72087910e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1d6cd8d8-39f4-419c-967c-0e08764c4a42_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares not included in the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1d4dfc60-7667-475c-9ac8-2a89772b51c6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_0c488bc2-c2f6-47cf-b642-cfa78e2f2fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_6e4a645b-2491-4e77-b32d-308f752cfdea_terseLabel_en-US" xlink:label="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organic Revenue Growth performance-based RSUs</link:label>
    <link:label id="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organic Revenue Growth Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organic Revenue Growth Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20230331.xsd#bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1f8de8f0-edfe-4a91-ade4-85e8f648938c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_b29b4675-157f-4311-81ee-f6b229603b2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_14aa5cb6-57ed-42ef-b549-538bd58295f4_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_c6ba4b17-f808-4e1a-b196-260f11b5563a_negatedLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20230331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_9da8e89f-8b82-40cf-99a4-9e6217929c87_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_4cb841d4-21f3-4d82-a963-d4e0886df7d6_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0466cb92-2c63-4150-8bb5-2be21b3f0357_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_ab320516-640c-4af0-ad30-c0069a5f5c27_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_e4ba42a3-12ee-4e2b-8069-044cea501984_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_8c9bed18-7160-4fe4-99f4-041feb78d8b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrecurring adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_8b4369aa-946f-452e-8bd9-3ef223aa9f2b_terseLabel_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_label_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar Base Rate and Canadian Dollar Prime Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:href="bhc-20230331.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:to="lab_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_b7958c18-7e85-4a58-b3e1-592ac7d53f42_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_0a1d37df-d372-4a2f-ab92-d9677483e441_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_319b13fb-e893-4ad8-9225-2b1f8d7327ec_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_e5a0b950-4325-42ab-882b-f0e3907ead07_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f42a0f63-ba9a-4b81-87a9-edbae4d79061_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense, establishment of stock valuation allowance on B+L's Canadian parent</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_e2f4c83c-eb56-4545-97cb-f92ce40cb942_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_07c2a997-5607-4cd6-9d1e-5c5a22796f1b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_86e4d369-cf87-4eb0-aa69-82e7b1e3990d_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20230331.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4b47b2de-dc21-4851-b7bf-c85dca5d52c8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_84aaf99a-bbee-4e8f-ab1e-0cca09402c46_terseLabel_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Axis]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_label_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Axis]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis_documentation_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:to="lab_bhc_TroubledDebtRestructuringDebtorTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_d60a2b40-8e4d-4dcc-97b4-8b25c356244f_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AurobindoPharmaLimitedLitigationMember_13eb3beb-ee94-4c87-ae2f-b3d9c163f820_terseLabel_en-US" xlink:label="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurobindo Pharma Limited Litigation</link:label>
    <link:label id="lab_bhc_AurobindoPharmaLimitedLitigationMember_label_en-US" xlink:label="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurobindo Pharma Limited Litigation [Member]</link:label>
    <link:label id="lab_bhc_AurobindoPharmaLimitedLitigationMember_documentation_en-US" xlink:label="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurobindo Pharma Limited Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AurobindoPharmaLimitedLitigationMember" xlink:href="bhc-20230331.xsd#bhc_AurobindoPharmaLimitedLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AurobindoPharmaLimitedLitigationMember" xlink:to="lab_bhc_AurobindoPharmaLimitedLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_94335f92-dab1-43f2-8b89-d1f1c78439fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2be4bc27-2003-4919-ae22-0292e07457e3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_73afafa7-5520-46d0-a709-eb607ca34abd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_e6c6c5d5-56d6-403d-9116-650ec78910f2_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3642a42b-a4d6-4ade-93a2-21f4b8bbdd6f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e6c69f1b-99e3-4d4e-abef-1fc185c651b3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_279b3c87-8ac7-4dbc-ba7c-f4ad9ad676b3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4e9414a7-4859-4c5d-9a92-f56a83ff2263_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c35dc1e5-e357-4ea0-ae5e-088c795308eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2014Member_2a02c129-78da-49f1-9a62-b55b8cbffe58_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2014</link:label>
    <link:label id="lab_us-gaap_TaxYear2014Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2014Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2014Member" xlink:to="lab_us-gaap_TaxYear2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2431571b-5179-4836-a43a-9de4c35c7369_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_8e69fda9-6bbc-44ab-a394-d8e79581c2e3_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2f58d42c-d098-4815-81fb-6df59704c4f9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_09492931-9bc4-4b78-96af-f285fc768b5f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_76ba3a33-be07-48e0-87b6-c6f665778ef3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_a14d530d-d02b-44aa-94cb-f3f55c8f1e26_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Segment Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_81257445-9354-48df-bc41-1059fe5f2c26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57ce18f0-bc0d-473c-b066-328897ac92f4_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixReportingUnitMember_5f56472e-3a18-41ce-a826-73dbc45d265b_terseLabel_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit</link:label>
    <link:label id="lab_bhc_SalixReportingUnitMember_label_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_SalixReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_SalixReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember" xlink:href="bhc-20230331.xsd#bhc_SalixReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixReportingUnitMember" xlink:to="lab_bhc_SalixReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a64903fe-5623-441f-a3f3-a5edf4b1ae66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_dd1e14d2-df9e-4399-8e1f-8c3b296c30ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) related to changes in uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_59948970-73fa-4c33-9b29-bf3498ebd948_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_ec5f8490-062e-479b-b4d3-372981451921_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_2b0531eb-85e8-4d6a-8a0c-7bb6841f1bf0_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20230331.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_149bb627-71ee-466f-b3d3-c05fc576ba9b_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries of amounts previously written off</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_76f0422f-1306-462b-b12d-0e6f31e7564e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_5f58d854-f887-4a12-b42c-dd879c815d0e_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDORAndEURIBORRatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR and EURIBOR Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:href="bhc-20230331.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDORAndEURIBORRatesMember" xlink:to="lab_bhc_SOFRCDORAndEURIBORRatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_15e06c9c-2075-4ff9-86f4-380702a127dd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0141451c-90b2-462d-bc57-d543d57a4c8e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_eb69bd5a-232b-465d-b165-70a8ddbdb7e8_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_4eb3aded-55ac-4b6a-b1bf-7569a7b4418b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_11db63b4-f1f3-4ad1-8919-b8ebc671cabd_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20230331.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ab5823d6-9764-4e13-9d6f-87c564af363a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_00d69c8d-090c-4c1d-abf4-b7845b311e99_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4969a7ab-91f7-4e45-8055-1458bdc8fa4a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcuFocusIncAcquisitionMember_026f67c4-ceb5-4b89-a8cb-850bc81bbf27_terseLabel_en-US" xlink:label="lab_bhc_AcuFocusIncAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AcuFocus, Inc. Acquisition</link:label>
    <link:label id="lab_bhc_AcuFocusIncAcquisitionMember_label_en-US" xlink:label="lab_bhc_AcuFocusIncAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AcuFocus, Inc. Acquisition [Member]</link:label>
    <link:label id="lab_bhc_AcuFocusIncAcquisitionMember_documentation_en-US" xlink:label="lab_bhc_AcuFocusIncAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AcuFocus, Inc. Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcuFocusIncAcquisitionMember" xlink:href="bhc-20230331.xsd#bhc_AcuFocusIncAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcuFocusIncAcquisitionMember" xlink:to="lab_bhc_AcuFocusIncAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_36608ff6-7eec-493c-8091-9b46b9c83ac9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reflect change in ownership interest in Bausch + Lomb</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_2f2351d3-a783-4b47-aaa1-a2dd91c44734_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments due to changes in estimates of other future payments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:href="bhc-20230331.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:to="lab_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_a4d68188-f626-442d-a0dc-cc5774c363c7_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Intermediate Holdco Senior Notes, Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:to="lab_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_724cf98f-6fdf-41d7-b35c-8f41c6c93d48_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:href="bhc-20230331.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d4a046cc-e8b8-4124-aba3-bfcd91f375fa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9d89c3b7-9615-4efd-a1c7-06352fa33fcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_56fc53a3-4765-4019-ad89-1e1514c782ef_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20230331.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_19561ebb-3713-4f0e-bec4-917ce341dbc1_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_73095231-32b6-4526-9521-c3862e6ef2a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_dffdcdaa-9cb9-45ab-9a39-791e86c0d369_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6d12a6be-5991-454d-b902-b7b823af1702_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_bd1645da-1ed4-44d2-98c2-f75911609d83_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR Rate</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_fd4ed400-b587-40e9-81e2-dfac0341cb9d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_6a85ee46-4a05-4cbd-ac02-92f1f6b8a495_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_13110aee-e346-4a0a-b6c4-7cda63068614_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_b14b7c11-29dc-40d4-92aa-8952b0f58031_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_169a1824-4342-4dc2-a2b5-c516a9cdab63_verboseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_61a44ee8-8fed-41fd-8653-fb3bc334411c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_325cb7cb-c19f-435b-bf4c-54c955dae72d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DermatologyReportingUnitMember_53a01414-4998-4f4f-90fa-6f2381e6dded_terseLabel_en-US" xlink:label="lab_bhc_DermatologyReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatology Reporting Unit</link:label>
    <link:label id="lab_bhc_DermatologyReportingUnitMember_label_en-US" xlink:label="lab_bhc_DermatologyReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatology Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_DermatologyReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_DermatologyReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dermatology Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DermatologyReportingUnitMember" xlink:href="bhc-20230331.xsd#bhc_DermatologyReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DermatologyReportingUnitMember" xlink:to="lab_bhc_DermatologyReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ed15f09e-d3b8-414e-aaf4-e18df2b516a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_a9fab44f-25b0-4a39-a41f-069bb0bfedc3_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, repayment term</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Maximum Term For Remaining Payment</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Maximum Term For Remaining Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionMaximumTermForRemainingPayment" xlink:href="bhc-20230331.xsd#bhc_BusinessAcquisitionMaximumTermForRemainingPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionMaximumTermForRemainingPayment" xlink:to="lab_bhc_BusinessAcquisitionMaximumTermForRemainingPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_18e2e4b3-db09-4a57-b6ae-4537683346e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_d9518f24-2471-4c93-96b9-a954bd15d546_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20230331.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_f0084e68-e0cf-43e6-a835-8cfdd7fee6cd_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20230331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_21c61b3d-d905-43b5-a560-0e9f8a26fb3f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a3283516-ddb3-4ba2-a6e3-07e18288d86a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_e3fffb50-6ea5-405e-9ef2-22731da141ce_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20230331.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_1973828a-76f1-475a-8c75-bf592ea1383a_terseLabel_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_label_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]</link:label>
    <link:label id="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_documentation_en-US" xlink:label="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:href="bhc-20230331.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:to="lab_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d084a693-2460-409b-af81-6bed73210936_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_d14d1573-4387-4283-ad79-4aef167ed062_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_a86971f8-926e-491b-b0c4-b4a86a5a22cc_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits pending</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_2f4ce3a6-d72a-48d5-bfb4-a08b9045257e_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_f8768aa3-773c-40d4-95ae-21a964413e44_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_87403e06-db48-458f-93c4-cb36573d3a23_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fc6c84a1-6cb5-4be8-8cbe-9f7238593505_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0a281841-d25b-47f9-88ce-5a0a61c3e8d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_7855f89d-277a-4985-942a-08dfab3d5eaa_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit spread adjustment (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_label_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:label id="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Credit Spread Adjustment on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:to="lab_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_98b55997-b999-4b77-b2b2-16de91aee061_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_bc869d17-0a2d-4d1c-bbb0-ff54bb71b944_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20230331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4adc3e6c-5286-4ced-b4b1-42925e1994bf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_35482dc8-e05b-4b80-9eed-dd2f987e6ccf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5821f4ee-d617-4311-a29d-fa9bbe803103_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_6956d4a8-9b4e-4a30-9540-bf479b97f362_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20230331.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_e1a78936-33c3-4c8b-bd84-f9c3a5d0cd10_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs charged against the allowance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_d01b89a6-8ebe-422c-b15b-71caa8bcd847_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_05390fa6-736d-4c8b-9dac-2c616bae0ae2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Stock Options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_dd7da075-1978-4f6c-9cf1-86216572f527_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount to be received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_82af02a1-d2df-4bf5-aef8-941adb38a7a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, premium</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedPremium_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1b4bba0e-6b80-4c14-9e46-35ba8dea7290_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_bdef500f-5873-4e0b-a2f1-8d0f14fd5377_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts in interest settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_51dab025-e291-483f-9d59-8385c99c2622_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_adb4144a-2bfb-4b05-ac4e-9fab37af6285_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_03fdcdc6-afd6-4edc-88d7-ef6360a57702_terseLabel_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_TaroPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taro Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:href="bhc-20230331.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_TaroPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c1b97005-3bc0-4b40-91cc-6d477469dbe5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a0d5aac3-8cf2-4d3d-b980-5485ccada2d3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_2235b817-c646-47ae-9cb2-8096506827d9_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_2ded18c6-a0b0-40ee-b3b3-bbd165981ceb_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_b75b16a5-98e3-4994-b57a-dd61a5aa2204_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_69027fc3-e6be-4e33-8642-51d82222beb1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_40bc5eaf-fd68-4982-9354-7e97d9f53178_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2661e66-e49f-4fbf-8b24-908d88f44ba5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9f94aa6a-31ae-4c29-83ac-1c9cce5e9974_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_9271860a-a2e6-4e37-bb13-b6df926077fd_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4b7c4bea-0b8c-445f-a85e-5093fa2a8af9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_f2e7a002-2dd3-40ac-8fe3-a9310a404d8d_terseLabel_en-US" xlink:label="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_label_en-US" xlink:label="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</link:label>
    <link:label id="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_documentation_en-US" xlink:label="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:href="bhc-20230331.xsd#bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:to="lab_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fea176b2-065c-423e-bf18-c51f637fd5aa_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_cef4c5f9-dff0-4e76-b734-9b3f16fede15_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e315ddbf-f2e4-4ec1-b66f-da7ae91a63ad_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_c01142c3-2363-4686-a66a-023d440ec597_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_0bb6fec0-b65a-4d7c-99a3-fc2a2ba46207_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e57d7bff-ee31-44d8-abdc-c8a6d9b1f97d_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5ea8d3e2-09cd-4999-9ea0-85aa18e4d2ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1c3f4281-1808-40b6-9ff8-7a7282569db0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_bf3ced5a-aa61-4d91-ba7e-cb8f69dd883c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_d93305d4-c95a-4110-ba82-40df77ee8a00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_1b034fb6-8a70-4370-af01-bc97ab98a6ef_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_460df3f4-9c1a-4ec5-90f7-5c88d868ef79_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_f4b9623f-c42e-45bc-abb4-02476bc74b8d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_dab7801b-adb7-4df3-aa23-1b242c6bd395_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ec0ef9ab-7c7c-4d1c-94e0-7003e03a0f65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_21491aae-3c43-415e-9a09-5b4bccc9ec11_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average service period over which compensation cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6f1cc869-29b6-47fe-9fae-8c92d05f5632_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_096a6748-a4a5-4adc-a872-4947509261b0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_9c59f14a-90b2-4108-9949-c5e18a48cdaa_terseLabel_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived and Indefinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="bhc-20230331.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_ec99fa94-224b-4ace-aade-ed84c523d081_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_381f4a55-0097-447e-b540-14cb59997bc5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_626820b7-f4d2-4141-ab93-c5d0f16f98b1_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.25% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_92996977-f570-44c6-ac08-7c352519a800_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5cbb3336-c954-48c2-ad89-f2527c03cc30_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_dad08ef5-9cc1-4663-9606-84275fb9694d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased debt, aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_0e279564-11f2-4c9f-be0f-9ec1ba3023dc_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_2e23e0ea-e964-49b8-b510-5b0c74b6e422_negatedTerseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20230331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_31099a4e-3d43-4ca1-bba2-3ce6b1fd4014_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_12b8d975-0d70-4f53-9126-325a415cb48a_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20230331.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_f24e68d2-7a5d-4f63-ba67-c1875b2dbdf1_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_GainContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:href="bhc-20230331.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_GainContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_d07412c9-3810-4ead-a8df-0f41fc2ebb63_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20230331.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_11bb5ef1-5a26-4481-91f1-626bfe562322_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_43e322e0-9f35-4381-b687-4589ecd2b062_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_a44cda95-805c-45e0-a4e2-0c12a0cfb83b_terseLabel_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_TermFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member" xlink:href="bhc-20230331.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermFacilityDueMay2027Member" xlink:to="lab_bhc_TermFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedSegmentMember_445339bf-15e5-42f6-b7d3-5dda89451c9b_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified</link:label>
    <link:label id="lab_bhc_DiversifiedSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedSegmentMember" xlink:to="lab_bhc_DiversifiedSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c806a389-0ba3-492f-abac-83b97f9fd891_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_65d91ae3-7e14-404b-8cd2-966c42d30309_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed but not yet served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_ef570d1b-8342-4649-9d80-00d8169e652f_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4efcc8a6-8560-4f79-8a94-e21eeb764e21_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a96b46f0-f51d-41f6-9deb-059630fd2a4c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_27b26cbe-9eba-417a-827c-bf7b4e7b8f34_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4d1a5666-5cbc-43e8-aae4-a968006d3d12_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_f6b74371-a098-4fae-a617-fdb3736a2618_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_700d41a2-8b3b-43bb-9c54-1c6f35a314ec_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_3711c0f3-04a8-4168-bbe0-ee04204c771f_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cf610f78-9347-47ed-9ad8-4ddaff435d48_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_6f11392a-c960-442d-b0bc-03730fc89d9e_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20230331.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_69e7fd60-c859-464b-b24f-8ae1c1d8d181_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1fed9360-b243-49e4-8094-4e0185fd35dd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3de7505d-744e-45ed-b964-d7114894e3cb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_6cd628bc-3b94-40ab-9211-2b9e167e33ec_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_d9f19c5d-edb1-4c1c-bd7a-5360b7a736b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_9326cecb-0b0c-4b98-863f-1f272bdeda93_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_db3c202b-e635-45e3-8807-14caae14f754_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_48ecc66c-62cc-42f7-b406-03c56f17493a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_65f5252d-d83f-4a15-9206-afdab1a2059f_terseLabel_en-US" xlink:label="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Operating Cash Flow performance-based RSUs</link:label>
    <link:label id="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Operating Cash Flow Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Operating Cash Flow Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20230331.xsd#bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_fc640316-9bdd-4616-8d1f-a385aaf27164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_09849bb1-ff7c-49d4-b5e3-6a2fd1d890e3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_54a6b128-146c-4f39-9161-658a4c27b1e1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_3fb27d7b-898d-44d9-8b8d-06f5a671e0eb_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20230331.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_15b38ea0-4821-437b-87f5-6e365a611efd_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20230331.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_7051dc6c-348e-47b4-8808-0db0258b8471_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR performance-based RSUs</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20230331.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_999b7cb7-08cf-4fec-9254-f9b9fdafb883_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e3e3c852-84cb-46a7-9057-8e0de79dac8d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_a4553258-e36d-4f83-be0b-cbd1d75abc25_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_aac397c4-63cd-4942-b8b1-4736c2e18b19_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_248b80d5-d3ea-4c3b-823d-5281a0c4d868_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of shares held</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_920eec3b-f704-4edb-8856-87cee3a19f94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss (income) attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_c14105d4-f379-4dba-89c7-e1f8329a8e24_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:to="lab_bhc_TermLoanBFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_43ca1235-9b30-4fa4-b76f-7c664a64d5aa_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_19211d81-e9c4-4d85-b7e2-99963db8abde_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_fa438633-1b64-4ee2-9b78-7906abc97dd5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_2063b37e-24a9-449b-92e1-e3bf954f37fc_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20230331.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c12cbef3-c155-42b7-9555-0be7bebdd03a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_9dc0073b-d55e-4391-ad5c-0e2022845956_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dce6690c-0454-4837-9778-6dd2a7495299_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_618801ef-f04b-4599-a7e4-d3d030cf45e1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d42482a3-1a7c-496c-88d0-a55d32b434cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_b76d5237-25a9-4ceb-ba69-255cd0ef28e1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_003b6493-4fd2-4ec0-b8ac-80436855bf7d_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cb132498-6208-4c48-a1ea-7707d7d03a44_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4bcde176-48fc-4461-ba20-50664a2cc9b4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4a372551-5232-4901-8411-793d42f80503_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2aa28b6b-a6c2-4c6f-beee-81e8aaebb5b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_1382ac1e-a30f-4730-a8b4-8fa44a146b52_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e693aba3-04b9-4c98-a9ba-af58042f33c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_aae3c066-7daf-41c4-b986-c3cdfd8c22e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_f727caca-30f0-4e31-bc7a-ae7265e6bf4c_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_00b27ff0-52a6-479b-bfb6-9628c5c4eb19_terseLabel_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers and Other Members of Leadership</link:label>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_label_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers And Other Members Of Leadership [Member]</link:label>
    <link:label id="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_documentation_en-US" xlink:label="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Executive Officers And Other Members Of Leadership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:href="bhc-20230331.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:to="lab_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_be3fa3e9-53de-44fb-960d-37eaa2469013_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20230331.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3fcd76c9-1987-46dd-b139-3d07eb514743_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_3cfd90db-e685-4df3-8f8f-b690094bf8e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c104ac7a-3f97-4a66-bb0a-b8aeb5593c70_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_d54d4a7f-52a9-4f25-8eb0-eeb146e06f23_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_33158e12-129c-4823-a840-62ed49ae568f_terseLabel_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations of Dismissal Submitted</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_label_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]</link:label>
    <link:label id="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_documentation_en-US" xlink:label="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation, Agreed Stipulations Of Dismissal Submitted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:href="bhc-20230331.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:to="lab_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_944c6c9d-41c4-4666-9be3-d02b45729c9d_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems" xlink:to="lab_us-gaap_ExtinguishmentOfDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0f951112-ab4b-41ec-ad61-742cc51d527e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_d05ea4fd-852b-4b3e-95fe-6a423a17c443_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20230331.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_1105c3d9-a408-40d2-8ba4-19ba4c406a59_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a7df21aa-3812-46f6-98dc-06be67d170b0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_222ad754-47c8-4824-8f3d-131427703ca4_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_62d97b07-69d7-493d-a9a4-d91b3d2bb470_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan, Retention RSU Grant</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014, Retention RSU Grant [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014, Retention RSU Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:href="bhc-20230331.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:to="lab_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_01fbad8e-e3d7-43e3-8a38-f94dcc5c9ce7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_897c6828-68b3-4f1d-847f-440756f06a2a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_225cbc17-7417-4941-b1ac-22bae6be0e4e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_13cde878-5f84-4807-9477-59a43b6061f6_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bb7e5ff6-3892-4b69-9e97-001f3b62d87f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2018AndTaxYear2019Member_9152adc1-bfd3-4733-943b-a17e1248bad0_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2018AndTaxYear2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Years 2018 and 2019</link:label>
    <link:label id="lab_bhc_TaxYear2018AndTaxYear2019Member_label_en-US" xlink:label="lab_bhc_TaxYear2018AndTaxYear2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2018 And Tax Year 2019 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2018AndTaxYear2019Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2018AndTaxYear2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2018 And Tax Year 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2018AndTaxYear2019Member" xlink:href="bhc-20230331.xsd#bhc_TaxYear2018AndTaxYear2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2018AndTaxYear2019Member" xlink:to="lab_bhc_TaxYear2018AndTaxYear2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_d185e5f4-2e45-4580-a2d5-22817f187f16_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_05d4df84-1a6c-4800-8ce5-c61c20941348_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20230331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_40e5e335-a954-4fcb-b7f0-614a4347d732_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_e559c6ab-ad0e-42c6-b2f2-fc0fee356c49_terseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense associated with filing certain tax returns</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:href="bhc-20230331.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_01faeeb2-835d-4d4b-87c9-96122e6ab1e9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e23b5b50-1168-4c91-abd7-dab5c03892e1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_8e7e3e62-e198-40b2-80b5-06c6d6b2c33d_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfDefendants_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants" xlink:href="bhc-20230331.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfDefendants" xlink:to="lab_bhc_GainContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cdce5049-b5c0-4f1c-bde4-ebe1d8d8c18c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d3bad097-b5fc-4553-8b91-cd245af01fc5_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_b3a0b82b-a083-4d35-9922-acb2bac06645_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20230331.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_3fbd16a8-3faa-405c-88cb-bc89095e6fd7_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20230331.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_1caea0bb-50f8-4f72-848c-074584cfa9f5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8b85a04c-0382-444a-950b-58edd5ff1ee1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d73d7a9b-78c8-42ed-b82e-d2c0847c819d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_26cbb241-33eb-4768-b525-eea5e52afb84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4456046b-5248-4ae5-b6dc-bcb8b912cf31_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_42b5ba11-049b-4c24-b3e2-fa415d1586a1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_fa4d49b5-6f4a-4144-95ea-fc552f8deff0_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_59076533-5544-4a35-b8cf-5c6013dfd8fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_33cd5721-308c-4c30-ab01-d63a6800e82b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7e54960e-0c18-4ad0-8648-b52c38927534_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_1266ac7a-be69-4ab1-9969-7c1a86edb63d_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_204ba2b7-0091-455c-a5dc-2111ed8f2cd1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4dc5bb78-979c-4f82-a338-988f27d1de80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7e72b1df-1a3a-4c25-b230-1748f1838634_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_361b078a-cef9-4dee-90a8-249ddde26671_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_ddb1791a-271a-4867-bf98-a86ca0547c61_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20230331.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6839c68e-fed4-4510-a7a2-53e77e6de263_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_d064a770-07e9-428d-af4e-6c4a390d6598_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_2ca90eae-71b4-4904-8de4-c9e9d19c3379_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_75a760ce-cc0f-4b65-a9ef-cc5147835c81_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_f8e640c0-e2a1-4974-abca-694ee87b70f6_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_43c89465-8751-4170-b3cc-378ab0f2bbb1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_7821d3b9-7c69-4c09-ada8-c82909a33b9f_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_344e7d80-9373-4244-bd99-d95d84cdb086_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments, net of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_ecb526f3-4361-4b4e-97a9-ee19ff46b858_verboseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based RSUs</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20230331.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_626e8f9b-e8cc-4898-b554-085da420a47d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_3947df8b-4cb2-4e0b-81e5-da3142531b83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_fb96c0b4-91ba-45ff-a37f-ab37d82c4a4e_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20230331.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_1cefdb2a-2fab-4874-9161-9df3dbd5dedc_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20230331.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_55a71710-2afe-41a5-85fa-996e4a5bb441_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_a744659f-e49e-4432-a767-abe865adefd3_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20230331.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_88f48be9-33f1-428c-8c6f-278433af9a7e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_fea24c66-82fe-4cd3-ad79-801b134e98e1_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_d5aa6fa7-71ab-4783-8b00-1619b78a3c12_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f1965325-635d-45f8-8991-a8fff3d1f016_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_5803e2aa-5183-445a-80f0-ebc61fc83f9b_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_bac5d53f-3eae-4990-90ad-262797599da0_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20230331.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_861cd879-cf14-48ce-95be-a725932c1511_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_label_en-US" xlink:label="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:to="lab_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_de80c119-4539-4b1b-bb5b-ac0136636314_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_00fbf853-0714-42e5-863d-6a1793ecec16_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_cf38f021-4625-4a6b-a4ac-ef395cf2f0b5_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B&amp;L Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_707145f6-d13c-4587-be96-dbd1d4ff3e4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e07f60bc-7ec6-46be-a10b-267ac5a5f730_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_1d6b3d0d-8b8f-4190-bc8d-a0cb1ea24d53_terseLabel_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_NorwichPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norwich Pharmaceuticals Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:href="bhc-20230331.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_NorwichPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_929be32e-05e1-469d-af46-91b56699728d_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4d12c763-050a-414a-9c0a-dc156fb72c3d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_4f6c1c33-ae12-4159-846a-18b0ab479d7e_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20230331.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_4c3aaee7-e150-4bf5-bd0b-19b0b84d0d49_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_fac08d49-eb8b-4db2-af82-100bfdb1a692_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b3ebdd8e-1a29-41cd-9d41-de745b1ed3c7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5706896b-c025-490b-b807-8d046d3b0b4f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_54662dcf-fbb3-4ed9-a5c2-fffec9fcd97d_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20230331.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_90e743aa-ebe5-49f4-9b9e-163a930527c8_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_5cc86747-9cfb-4f88-8588-caed13144171_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_09f553b2-fd03-467d-8d3c-16e7c5608f7f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0e47a14d-9e45-4bc1-b5fc-04d7ad530a9d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3ea54518-c96e-4248-b203-07dec22b7fc0_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_633d603b-9437-4510-b4c0-415aade9094c_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO-related costs included in selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_9b66efff-5b1a-4d96-a7fd-f28c35b55a0a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_7944cb70-3e9a-424f-8091-7e2453e78a9d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_25c32ecc-b1d8-424c-b884-40fdf52c2385_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_9e597c20-99a2-462f-9616-261049a0d771_terseLabel_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_label_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:label id="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain_documentation_en-US" xlink:label="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Troubled Debt Restructuring, Debtor, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:to="lab_bhc_TroubledDebtRestructuringDebtorTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_00bd4ba5-104d-4497-98b4-75d489453cf1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_0c858206-69e1-443e-8ffd-04e761fc4a78_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_d6fa6308-d30f-4a01-b834-8d86fbab45aa_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_71d8fca9-b9f4-4a2b-bafb-d5c10373919f_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_64faa493-0e52-4bfe-bbc3-057f14bdff6a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d5ec052d-524e-44d6-b4d4-b0996e8c70bb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c107002d-b6cf-4a00-a965-345d0117c955_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_eab860e8-d999-4dff-8391-930ce21bdba4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0a4fffdd-cd6d-4b47-bdfd-74861ff92e6a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f85e3291-6f3c-4291-9092-aae259ef6c4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ff06a0cd-6261-4330-a022-5932f923742d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_e985438e-cadd-4d30-bc04-559afe83ae0a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_06606498-ba10-4f91-9762-2f2dc4147893_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_fb8f7b19-6ee6-4a6e-82f1-a6a3317976e2_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_97072b09-48f1-431c-8ceb-b8f7eb47b935_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_d6d0e9cd-f813-43e6-a06e-c925fa38ec51_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20230331.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_62a78448-d911-499c-add5-e25eb7e3ea58_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Performance Period</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:href="bhc-20230331.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5779aa6a-296f-446b-bd21-867431753c2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_8aad7470-b273-4874-936e-1b07b576fcbf_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_56b56746-67f6-4c1a-8d76-eee87fbebc23_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_25b91feb-b169-4d62-9b52-b7245b4bc027_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_36bc489d-d074-4fb6-b94f-6b6ec5d7978a_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_73e3d375-34b3-4afa-8f39-8729ad1a2685_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L vested shares</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_c36a0473-034d-4720-a89f-1204824b1f04_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:href="bhc-20230331.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a8176f33-4eb1-40df-aa70-d5e8072c94bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_67e376be-395f-46b7-b772-2f80f1f01903_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of contingent payment obligations measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7bf3b8eb-b806-44bc-81b8-bbc4db8d97c5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d23bc0a1-30ff-4168-954e-d76f9acc1b1c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_c7a49522-ad4a-445c-a4ec-14708d474dd6_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Activities And Initial Public Offering Costs Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:href="bhc-20230331.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:to="lab_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8a3d8721-ca03-43d2-b174-249e358102e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_19767ed7-a351-4677-9efc-dfb104f0f6ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_06a3999b-9e69-4176-9288-ecd751872854_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20230331.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f3df004d-35b9-45be-b986-287a3bf035b1_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9cd8902e-8751-41b7-bc50-97a608277b03_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_458e2dd3-77ec-482b-87c1-bb57a655afff_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1b290acc-dce1-4673-a472-ad214553794d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1265d0ac-88a0-4096-bf1d-8b838d577816_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_966b30d2-6243-492f-a6b7-23d789fd2110_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bab8dfc7-0dbc-4339-99fb-545218af8f8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_248bb05c-e407-4d22-a177-1b61a153ee62_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_bb358d42-a04f-44c6-a289-b248a552663a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_fd066404-9c34-4645-abe3-ced069b45642_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2e640e13-9722-48a2-abac-8894934224f2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_1faf015a-4258-4ae4-9519-23aa96f73c1c_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20230331.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c49f4991-9b0b-4151-a7a2-76df450f4137_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_ff03fdd4-fffe-4c4f-bc8a-78f09af78595_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20230331.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cb8a101-c457-4e6f-ae45-63d31c746731_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cdd04afc-b74c-412a-a078-5588145c56aa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_a8637e31-e275-4d9e-bff5-915bcd370af1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_9464e008-9f29-40c7-9f48-90765d4438e2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_5ac9a876-e49d-41b3-9c23-e780cab7b625_terseLabel_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_label_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products [Member]</link:label>
    <link:label id="lab_bhc_XifaxanBrandedProductsMember_documentation_en-US" xlink:label="lab_bhc_XifaxanBrandedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xifaxan Branded Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember" xlink:href="bhc-20230331.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_XifaxanBrandedProductsMember" xlink:to="lab_bhc_XifaxanBrandedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_cd09799c-7258-4533-bba8-b1b1878837a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_fd0caaf6-b3d1-49be-9c47-2b2a3b5f3f7f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_63f8b25c-1fdd-4953-a8dc-444c78971e53_terseLabel_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg Inland Revenue</link:label>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_label_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg Inland Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:to="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_2344b2f6-c1da-4030-8ea4-74fc1198744f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_2f17cc73-bb06-4289-8be7-d99a8a293998_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_3fb1c92a-d52b-40fa-97db-e4d52143e424_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20230331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_77558080-a122-41ba-919a-c07d882eeb92_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_4d5c8166-c167-48df-823b-28f30702b65c_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.250% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_b8e218db-0a32-46d6-bb59-5839097231e6_terseLabel_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical and Ophthalmic Reporting Units</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_label_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units [Member]</link:label>
    <link:label id="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_documentation_en-US" xlink:label="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision Care, Surgical And Ophthalmic Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:href="bhc-20230331.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:to="lab_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f34e0909-ecae-4cc8-a14d-87f24a2b169e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 363,607,062 and 361,898,846 issued and outstanding at March 31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_36f15728-c6b2-4a49-96bf-457fb01f3a27_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20230331.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_af4852c4-d161-4082-8b46-da0d10756ae7_terseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs, Performance-based RSUs and Stock Options</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20230331.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_67761116-da57-4588-936a-fc80a819f2cd_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9fc676ef-0d50-4b62-b841-871fb6dad94b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_868edde6-46f8-4376-9c33-f801f9126ba9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_e6e86bd5-ad66-4934-a838-ae3ad32809c7_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20230331.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_73fa01f1-0d5e-4ccd-8413-776021e861c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5f15c49f-1d65-4b69-8ce5-32fd9500aea1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_60b575f8-b1c2-4d56-99d7-0139985be18b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_8803152f-2cc4-4c76-8b8d-c7f833bfaad5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_342a5b10-e6a4-41ac-b249-a087aef0cc83_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_6b1fb58f-37b9-40c6-a459-cc758458ae25_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, change in discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_ae7cf4ba-62b4-47e8-a56f-c4a7dc5546d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_ec1f585e-a22a-42b5-8e2e-a3a625945dbb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b879dd28-4b66-4e51-8388-9859ea3150b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_2599969a-4975-4655-981c-1fd2cf015ecc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A1375209BCLtdMember_fe3e1473-f76b-47fd-8ab3-0462d8c6f29d_terseLabel_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intermediate Holdco</link:label>
    <link:label id="lab_bhc_A1375209BCLtdMember_label_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1375209 B.C. Ltd. [Member]</link:label>
    <link:label id="lab_bhc_A1375209BCLtdMember_documentation_en-US" xlink:label="lab_bhc_A1375209BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1375209 B.C. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember" xlink:href="bhc-20230331.xsd#bhc_A1375209BCLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A1375209BCLtdMember" xlink:to="lab_bhc_A1375209BCLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_76cc349c-5f6a-40c1-ba9f-46f3c1d67878_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_34cdf754-4b87-49ba-bdb3-f7cf06f58931_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_19fb27e9-8ce7-4809-a305-179c75cca84e_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefit, amount possible to decrease in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_0c2ace1b-a4af-4138-a058-02f2712ce0d4_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78916749-960c-4a91-ba75-8925e27c646d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22dfe383-6f5e-41c1-ae43-50c0f92f4aa3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d82702f5-7821-45b6-8c7d-9a716837c66f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_45dea283-42a2-4363-aa0a-816c86a60b78_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due February 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2c640185-ef4b-4b1f-bc30-02e52a1a905e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_498504a6-7fdf-4ea7-983d-da75c1d470e5_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilityMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:href="bhc-20230331.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilityMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0e2cbc65-bf0e-4c86-89c5-8828a98fdb80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b33327ec-9f8d-4ea9-9452-ab2b291b9ae3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_27b58a49-c315-4800-b598-6d6d96abd408_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e7fa53ff-ccf7-4d41-af58-4facd7c6da6b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e849ffb1-714e-44f4-bf75-50ca281d7a2b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_600035b5-7fd9-44ea-9f16-4dad60d84e61_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bff77971-9f21-4bc0-9b2f-92c942be426a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_b94d2818-323d-40e0-8e5a-d7caa08ac3fe_terseLabel_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_label_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation [Member]</link:label>
    <link:label id="lab_bhc_PreserVisionAREDSPatentLitigationMember_documentation_en-US" xlink:label="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PreserVision&#174; AREDS Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:href="bhc-20230331.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PreserVisionAREDSPatentLitigationMember" xlink:to="lab_bhc_PreserVisionAREDSPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_87c75d12-b287-4638-bbdc-a22006db55bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of AcuFocus Inc.</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_1dc0bb22-9086-4b88-ac2f-2ee38e0038fe_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NeurologyAndOtherReportingUnitMember_adb08c1d-7205-45c5-a8c3-cbc90ee76d3a_terseLabel_en-US" xlink:label="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurology and Other Reporting Unit</link:label>
    <link:label id="lab_bhc_NeurologyAndOtherReportingUnitMember_label_en-US" xlink:label="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurology And Other Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_NeurologyAndOtherReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurology And Other Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NeurologyAndOtherReportingUnitMember" xlink:href="bhc-20230331.xsd#bhc_NeurologyAndOtherReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NeurologyAndOtherReportingUnitMember" xlink:to="lab_bhc_NeurologyAndOtherReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_6d25f30a-b3af-49a6-8b72-621af2dc1775_terseLabel_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_label_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan [Member]</link:label>
    <link:label id="lab_bhc_A2022OmnibusIncentivePlanMember_documentation_en-US" xlink:label="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Omnibus Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember" xlink:href="bhc-20230331.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A2022OmnibusIncentivePlanMember" xlink:to="lab_bhc_A2022OmnibusIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_bb2108f4-a1e5-4eb2-8021-aac9ee217ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8430a332-9bb2-4ba5-a06c-8e1af96bc3d3_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cc629f44-e021-4a79-bcbd-1a13a80e4a45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fc916215-db94-49f2-87d6-9d9ac95a40f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4acbea71-c473-4df2-9dfd-da4b694a3739_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_da77e193-344a-47f8-9d11-80d6dc92e606_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_d7c01eed-89d4-4d26-96f9-66415e52a7eb_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable rate, if rate not ascertainable (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_label_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:label id="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:to="lab_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_05550663-87ee-4511-92f2-f516cc587d16_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_499c6806-56ee-4420-9314-89e339322256_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2b453457-4380-468f-bf79-374a03622e22_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d8ef4555-0ad8-4a08-8c08-fe0db42fead6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_96c689cc-fc7b-469b-9ed1-2e701a7d315d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_944225cc-4776-41f8-bbec-16111d964d6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_KR_554cba3a-4adc-4623-84f4-05198a73da03_terseLabel_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">South Korea</link:label>
    <link:label id="lab_country_KR_label_en-US" xlink:label="lab_country_KR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KOREA, REPUBLIC OF</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KR" xlink:to="lab_country_KR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_5fe4b052-31eb-413d-bd17-92a299126690_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_04d9f565-327d-4661-83a6-a0f4b3baeea0_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of putative antitrust class actions filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6b4af782-2482-4071-8c97-a9de3c06e808_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ab8a98a4-aa55-4354-a54f-e873d50f6f3f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_c36f8317-5292-4131-94bb-14b6869808c2_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_19b59c46-7a79-4511-8855-085240d92a1a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_3f77bee5-5e80-4992-85b4-208a114a632e_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_6bd8cf4f-69d6-4425-bca1-f2fd189dd7f5_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_a17430f0-c770-4af2-a297-b5aefa15495d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_35e936be-f312-463a-97c3-cbc59fbadb91_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_8c96f260-5e33-430f-9557-26c34b8ac0a2_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:href="bhc-20230331.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_c284d430-ea38-40b6-ba8a-84ec0221e2bf_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4b662769-a5ed-48d0-8b24-a88493497e35_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_a1d3f7d9-2f6d-437e-8af7-18f6350d6cde_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_76508b15-f0e7-4bf3-9d4d-3471e11ef63b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aa939477-553d-4b5a-82f4-289d6550c323_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1e006a4a-44d0-42fa-ba7c-e5256e95dd5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_1bc1b887-9069-43ec-b6b8-bdd471b8e3a5_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20230331.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_1eec8cef-b91a-4cee-b546-f63f431ba824_negatedLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20230331.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_4747379f-b5fb-4d9f-ba98-e1cc63f98882_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_ac921ec6-ee96-4492-bb22-c58a5685d8bf_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_8ef0e718-f367-416c-9c65-60bfb05bcb29_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_e330f770-1f81-4874-9d39-b202c8558cbd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_408db45d-138c-4494-9643-d77cabd3f9c7_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2228e7a2-db82-431a-9475-2437b254231a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefaultJudgementMember_29524f0a-93b0-445e-8aaa-096c7ef2c826_terseLabel_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_label_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement [Member]</link:label>
    <link:label id="lab_bhc_DefaultJudgementMember_documentation_en-US" xlink:label="lab_bhc_DefaultJudgementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default Judgement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember" xlink:href="bhc-20230331.xsd#bhc_DefaultJudgementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefaultJudgementMember" xlink:to="lab_bhc_DefaultJudgementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_b1b808d3-4e10-4daf-8b2b-15846e4595b4_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20230331.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_2af4096f-63de-46cb-85f9-4ac300109f94_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_7b19c986-1261-4e87-9f1d-689f79e9cb21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_0622d50d-02ba-4297-aba3-25b521ad5474_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income Loss [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b87c355a-97e6-4833-8e0f-46c3cc102c24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized premiums, discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_5a280d48-aa96-4ee2-90d8-c4cf437125cd_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_915e072b-3150-46cb-8436-b4a93dbad0b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_2dbfe7b1-264d-430f-9b2a-11e9e8d6dc81_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_2989c2a6-2189-4a1e-978f-85a0bfd44032_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_bff114f8-816b-4c4b-81a9-a44f2cfcf055_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current accrued loss contingencies</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_90088b91-b39c-4968-8ab6-f5452f94b642_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B+L IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_70078b5e-769e-4caa-8844-2495fe923969_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_89876085-22d1-4a67-ae6e-7e1c59bdc69e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07ff7a07-4aef-4cac-b002-01fb722fc503_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and other</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_8fd84f29-ab0f-4a48-9fb2-da153e36cd1b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2bbb8829-e1ed-47d1-bf5d-5e041493e175_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ExchangeOfferMember_b999898a-808b-4a47-9e69-b4c1b74d3b4a_terseLabel_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer</link:label>
    <link:label id="lab_bhc_ExchangeOfferMember_label_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer [Member]</link:label>
    <link:label id="lab_bhc_ExchangeOfferMember_documentation_en-US" xlink:label="lab_bhc_ExchangeOfferMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember" xlink:href="bhc-20230331.xsd#bhc_ExchangeOfferMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ExchangeOfferMember" xlink:to="lab_bhc_ExchangeOfferMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_95994118-0f10-4475-a68f-69b538bc4303_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_95fff537-c7fd-4764-ba0f-c0279d3cd4eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8c7f7c33-e250-4941-88e3-9254a22d9c97_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cf45fc46-8f28-4980-9217-eb49a0723811_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_906740ad-d4cb-4e52-aef2-7391f4a0fabb_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_83935afe-8225-4b09-8e84-afad480dfcc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE, NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_fbda0c86-3ece-4c58-a374-d2e6eb76707e_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_536b39b2-d621-4c1c-9e15-f40cfb108ad8_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember" xlink:href="bhc-20230331.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsLitigationMember" xlink:to="lab_bhc_RICOClassActionsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_848a7ca4-2c78-4a76-8688-2b4e6aeb92e5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_742b2e5f-b5ce-4e17-817c-6971738bb07a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_72ecba79-fbed-4923-8fdc-8c534369b420_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8c340eb3-df3b-465e-9755-cd73e49c5782_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount drawn under credit facility</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_34f7ae7b-00b8-4fc2-95a1-c8a515546943_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_380f623d-420b-4a60-9cc2-2cd30444759b_terseLabel_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of proceedings</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_label_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Proceedings</link:label>
    <link:label id="lab_bhc_GainContingencyNumberOfProceedings_documentation_en-US" xlink:label="lab_bhc_GainContingencyNumberOfProceedings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Number Of Proceedings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings" xlink:href="bhc-20230331.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainContingencyNumberOfProceedings" xlink:to="lab_bhc_GainContingencyNumberOfProceedings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_190c1c28-bc5f-44a1-b428-12f346eef551_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a4e300b7-4743-40f2-a6c5-ce38fb9ba299_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_184f2301-7a03-47eb-93af-1b5c1b24f3d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0172d29c-eab3-412d-ba1f-7b917b6fcd64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c50b3b80-9874-4d29-9f73-c05f5d9aa28b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_47c73df3-05ee-4037-a7ae-e95d26b42f41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_74b7d1d1-475b-4c0d-89b1-9913d4810453_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_211bf830-f6bc-459a-9de4-af5b3e38a876_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_2c8779d4-21e3-4158-b99a-08c15bd5b3c1_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20230331.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_54277c3b-f775-41a7-babe-f82dfa3683d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_087ca4ab-fe9c-455a-b510-5ff28b20648e_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and RSUs</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6d1af70d-d894-4707-9e50-9fc56396f844_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_c611ec8c-cd4b-4540-91db-bb50c7185312_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_9938d66f-b874-4552-b884-de2bcfcc57f2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_5a777c68-9c5e-4a86-8126-debdd0293a58_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_35ce2674-13ed-48a1-934f-867464d9a5d5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_5071a507-395b-4914-93b9-87fe59b53edb_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_7f4e9a98-b79d-4e6d-9670-fdaf2febc67c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_fb8cc253-466f-447a-9b46-c4199e4c9c52_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f3c51925-13f9-4e12-a208-99c29c62bb90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f084b513-d41c-4bbd-8071-54c3d7f52fae_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_124b0ed2-378b-47eb-98fd-ddfe5c7e3d6b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_2e3cb285-cf53-4ff0-91fe-e9f69c27414c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_11c82918-94c4-44d9-b239-bcd96f1fda05_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:label id="lab_stpr_NJ_f8453e52-1b12-40b2-9ad5-5a8148c97b07_verboseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_21a0200f-1798-44e6-9be4-226fa824a4fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_556dad9b-4139-43d9-bc54-881be81e4459_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7e516ace-afbd-468b-838d-e4e1613c5b5f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_41c882a2-0027-4b42-a467-d06c424a8abf_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20230331.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_924ff63f-1692-4349-a2be-a85663bc3d78_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_fd77054e-5b93-4fa5-aae9-a33853687a5b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_137a7a06-89ff-4df4-92ee-93b18031e3b2_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_343aa84c-ac1e-4fc8-b25f-3977808a6f22_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_e1bcf8ae-cc0f-4b2a-84d8-0a5ffdf9b3a4_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20230331.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_a60c2c74-4270-4ed3-9ccd-3cb74787cd5d_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_ad6a31b5-1c97-4ec4-9213-d2f1c669a9a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt premium</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ad8cddb0-e151-4503-947d-d19a2c7d5e10_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_db8aada6-9ec2-434c-b01e-1ef003f41703_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_848980b8-f278-435b-bd50-a4cbd694e66a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_b542ae48-b9ee-4504-b150-e6c01dd1bb1f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_86e31f4c-8d6b-4fc2-bf47-ff5b0cd54bca_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_82e89abf-acd7-46e1-93b7-e7ae0fc9eb4a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_050e90f8-d1ae-4f40-9200-19e44fedda8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_17069c74-4c32-4a95-a047-b05801a05675_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b42b4906-c87d-4590-9f60-1686fd680701_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_d5405195-f1e9-431a-a33f-c080c133e8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_717dbbb3-1eb1-4f66-96c0-31a7ef92c170_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_0430e8bd-07e8-497e-b8a8-3e7b65d95864_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_a5d31338-eb86-4af2-b291-568058b86092_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation (including McKesson Specialty)</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20230331.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_285587d6-2f71-4a55-af42-7b28279bb824_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20230331.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6d859a66-f933-4aed-a8be-f2d767ed75b1_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_7b7fcb99-080e-4c66-8d69-19b2bc66aa26_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_bfb3da36-ba09-4023-803c-bba6aaf84f9c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_32b01f83-4828-4074-877a-00b049dcb467_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5b2695ba-0a4b-41e9-861a-9756f3e9895c_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_11979f79-b874-4795-b589-9a8dea094bfb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_80ed5cf4-f98e-49f1-a5a8-3b30b2abf210_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense associated with stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_06331327-217a-47e2-b10f-5be6a0534c0a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a6b8105a-14ac-4791-b15a-4783fb35c061_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_70808214-e923-4775-baf1-d3021a4664eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_92939daa-91c6-46ac-bf56-3915cdfac42e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for intangible and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_6a5628f6-8242-4bcc-8651-c77dba8313a0_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_247d266d-864c-4723-a98c-77a463144a8b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_4ff105ae-868f-48f8-850f-970510e53426_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_7d4e3f56-9164-42ac-8060-7bbd6a5612c0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_76063175-7e70-4670-b675-98a93548519e_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20230331.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_56819e1c-867f-40fe-925f-ff4a689c8cad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_df783fc9-ce4c-48d3-9354-64ac8f6c96bf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_2bd8b483-b827-4116-bca6-8c38dfe36361_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_d465af00-e5ba-4491-a53b-7e29438e8725_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation, and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_0d1b74b7-78d3-4c46-ace1-3c99fce54e4b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_36c50b76-ecb8-4c71-bc45-5687db4360e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A1261229BCLtdMember_b0e3afbf-edf6-4a9b-ac57-187d2c5c30ad_terseLabel_en-US" xlink:label="lab_bhc_A1261229BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1261229 B.C. Ltd.</link:label>
    <link:label id="lab_bhc_A1261229BCLtdMember_label_en-US" xlink:label="lab_bhc_A1261229BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1261229 B.C. Ltd. [Member]</link:label>
    <link:label id="lab_bhc_A1261229BCLtdMember_documentation_en-US" xlink:label="lab_bhc_A1261229BCLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1261229 B.C. Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember" xlink:href="bhc-20230331.xsd#bhc_A1261229BCLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A1261229BCLtdMember" xlink:to="lab_bhc_A1261229BCLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_7df6b562-b62f-419e-9be4-02e48907c074_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_ac5cfbe9-24d0-4688-83a1-d70dde6aa161_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_94703a46-8812-4c92-ac4c-b3aded7579e9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_3c862b7a-c087-4ae9-8168-6ad936b9bc92_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7ccc419a-75f1-45b6-adb8-464d79b6ad35_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_c9927fc9-629d-43c1-9848-3c729ddfbf82_terseLabel_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_label_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment [Member]</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_documentation_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SoltaMedicalSegmentMember" xlink:to="lab_bhc_SoltaMedicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_232bca8d-2d64-467d-a872-962f87406779_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8de0d624-c994-4b39-8f29-a9244008c07b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_420af9c3-5c49-47b7-8771-a45b52fb7389_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of reporting value, greater than its carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_fca55dfe-5142-4059-994e-c9dba36a5a6e_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20230331.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_317aaeba-a9ec-42f1-89d0-7eeca640a7ab_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_508aa458-7643-43df-bb62-6a763de1befb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_cd2ff690-3d73-4e51-bf65-fff7aa75ddef_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 18)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_25c5b7f7-157f-4131-b231-e4f949d126c4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_de09ab75-33a2-4f98-91e6-1d212eb1b798_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_085c7d38-73c7-47d1-b32f-7b3bc543addb_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20230331.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_cd6ecf03-2a90-41e6-8a1c-e9b4fa7b4e18_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20230331.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_154243f4-1743-4026-be40-6dc32e30800c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_f5ae53a8-713a-4448-9a04-404dabd6bb94_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_3248d942-50d7-456c-ac20-3bffdedeb8f2_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_f136aaf4-8b14-4a50-87f2-b59fa9f62f00_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_49179738-7f02-45db-870f-33faf8a8ef8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dc658717-a3e7-45e5-bf1c-86686c234b76_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aeca4491-d2a5-48a8-8a72-0ca7b701f2d0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_d270fe7d-be5c-41b6-8117-449f6521a3b7_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold for incremental borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_e48e5856-68ad-4aca-88e8-e05825399e00_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20230331.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_aad3f751-4d7f-464a-9464-dc1b47669db6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_62e91f40-0757-43f9-8dd4-6473d3c2c7e8_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivable and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20230331.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_be680582-676e-44cf-83f2-635e16e43c31_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_9546475b-23b2-40a0-96ff-c6c4029c6661_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_fa6c9bd3-eb56-444e-a0ea-b73266efb51f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_97a1055b-0826-4120-a1d8-fef4f2402c5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_20510da1-3e7f-4078-ac09-559f554398cf_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1ac492ce-5ef2-4368-a177-8ac6d725f5ea_negatedLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_def2c831-ea2e-43a0-ad16-9e6f981d0b87_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8d56b5ff-c972-40a5-9f23-1c75ee49f217_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_e7d7bfb0-d332-4759-9875-7ceb4b8ac674_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_db95951f-55fe-4ad4-af19-07fdc693506a_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueMay2027Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_a2c7a8b3-317a-4a97-b585-7400597920a9_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of outstanding principal</link:label>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_label_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</link:label>
    <link:label id="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:to="lab_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_e355b3f9-c754-4c49-88e8-41597e405c9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Extinguishment of Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:to="lab_us-gaap_ScheduleOfExtinguishmentOfDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_cd45c863-9b42-4821-ab6f-4ae16105c8ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_902cb0f6-1715-4975-99fd-e63a0fdb8df2_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_012bddd3-82e8-4664-afe1-e39f2155e8b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b4c79fac-e492-45d7-9c54-428a9de582b5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_8c789b55-c55b-4304-9613-26d5101f3d6f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_3e9c202b-eda5-4782-9e19-f0e8249ce3e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceRestrictedShareUnitsMember_c9363d6a-00da-4e06-9bfe-968fa6d821a4_terseLabel_en-US" xlink:label="lab_bhc_PerformanceRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_bhc_PerformanceRestrictedShareUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Share Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceRestrictedShareUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceRestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Share Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceRestrictedShareUnitsMember" xlink:href="bhc-20230331.xsd#bhc_PerformanceRestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceRestrictedShareUnitsMember" xlink:to="lab_bhc_PerformanceRestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_3add7a8c-2e87-4aed-991f-a39546bb5599_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_a7a4439e-2632-4d6c-9de7-c7d4f3aa5c9d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_c88ca6bd-1eb8-4931-89a8-6efab2a2cdb5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0c15aa48-5eef-45b2-9ea3-49426998c97d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_a0ad15da-44cb-4c29-96cf-cd64da83e8e8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8913458c-eb54-4da6-8345-fa100fed5be3_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_914b8e01-1f5e-4b70-9376-e402e4b396b8_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period one</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period One</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_6bf9951a-17f5-4536-993b-1337c3e1366e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_9c28ed92-9268-4f57-8f8b-6aef83369e3f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TradeNamesNoLongerUsedMember_01944a9d-b11d-4eaf-ad02-266e0a11502e_terseLabel_en-US" xlink:label="lab_bhc_TradeNamesNoLongerUsedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names No Longer Used</link:label>
    <link:label id="lab_bhc_TradeNamesNoLongerUsedMember_label_en-US" xlink:label="lab_bhc_TradeNamesNoLongerUsedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names No Longer Used [Member]</link:label>
    <link:label id="lab_bhc_TradeNamesNoLongerUsedMember_documentation_en-US" xlink:label="lab_bhc_TradeNamesNoLongerUsedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names No Longer Used</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeNamesNoLongerUsedMember" xlink:href="bhc-20230331.xsd#bhc_TradeNamesNoLongerUsedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TradeNamesNoLongerUsedMember" xlink:to="lab_bhc_TradeNamesNoLongerUsedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_cc4a0ea8-ba34-4824-8341-32c4a097524b_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">14.00% Second Lien Senior Notes, Due October 2030</link:label>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_label_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 14.00% Notes, Second Lien, Due October 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:to="lab_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_59a4132f-6532-425a-a2fe-eaf963cd0435_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_6c7fd093-765f-4b56-9105-a5d8052cbb5d_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_81cd078e-0601-428d-b4e7-b5644f1f6ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f0e2bd41-9bd8-4c66-a13a-b118a2d14e81_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_1e3f062d-be05-4fd8-8b71-d6b69ecb8a33_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20230331.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_4a01bd92-b040-472a-99b0-88871b220bc2_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_0ded86e6-33b7-4cb0-9efc-6a6098d7c7d0_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c3bbf239-679a-4e5a-a742-1e4af78f0097_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e9e043c5-b3c5-4e07-a6d6-5f12ea68cc4b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f5099c0f-030c-425c-9aa0-26dc84278b93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b3f2a90b-49d1-4149-b9e3-ea06bc0ae511_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_1ec6dd24-47a0-4a4b-8c96-cc06154cf7a3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits related to interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_90097620-e668-4371-a5e2-52aa0a965e34_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_79fffd90-8a8c-484d-99e9-11645d4bf095_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_2df585cd-f858-45f4-bbac-77d4e00ce784_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b8c2cfd8-006e-41b8-beb0-dc71288a398b_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_204332c4-bc63-4cc4-b134-29f090f5565d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_293e7d1e-012a-4c0c-b405-e062770aebc3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_31919cfe-ddab-4bc3-91db-b3975b718156_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_9e39eb49-b7ec-4d38-8b38-e00dce0b3df2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_15afe0a1-773b-4b10-803c-2da91777ad7f_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4888e166-e12e-4196-ba3f-5c0d26bf3469_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7a00302c-5482-4aa3-9004-f2332ec9edbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_435684ad-97db-4cd8-b1a7-28d3b2ceb803_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_7f5d5cff-5063-4571-a542-9e38845100b7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_44342abb-053b-4410-9132-afb3d49ce14b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_42680229-eb66-4859-851a-231664e300bf_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_464ec23a-9645-4e6b-909c-1c8686cef475_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of approval, motion to extend, period two</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period Two</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Motion To Extend, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:to="lab_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_b02fc2d6-9d7f-4ab3-9c90-5c6aa5915be6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_8e745fb6-bc57-4cb7-b64a-6e6feb214cd4_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20230331.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_bcb4ce5c-e017-40df-85cf-f714d4e92274_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20230331.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_600f69d0-91f5-4841-8c4a-576b5e0c95c4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_ac9357f1-4de0-4b4c-907f-be29d6b11ab7_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20230331.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_5aae596f-2726-4a5a-923b-5ddcdf01c448_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_1f8fdf5e-cb4d-43b8-ae30-e8d6ee78b115_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_a133f545-5851-4150-a6c6-e908f87b0e9d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_7cf52a81-2d18-4e58-885d-a5293241e70d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock plan, term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ed6be52d-0344-4f81-af2c-669b36f1ae35_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_65adc61f-973f-45c8-88b5-ab486f476f15_terseLabel_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EURIBOR</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_label_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR) [Member]</link:label>
    <link:label id="lab_bhc_EuropeInterbankOfferedRateEURIBORMember_documentation_en-US" xlink:label="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe Interbank Offered Rate (EURIBOR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:href="bhc-20230331.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:to="lab_bhc_EuropeInterbankOfferedRateEURIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_680a8e00-067a-4674-8a52-bd1d28d8a1d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of customers that accounted for 10% or more of total revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_dae993fa-22ee-4be0-b493-4f00357bbe4c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_8ebd3804-e805-4221-98c9-2b9a14b7f10f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_abd1ac95-9e50-41c7-9f8e-c6551d9cfa44_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_a21ceed0-f9a4-4d25-b594-07aae6d24d3c_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20230331.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_76f38a9d-de83-44fc-b949-b1905bcc95a3_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_fa947c8c-beb8-4ae3-bfa9-45a4e2b02300_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_e9d81be1-0e00-4a01-acdf-e8dbce9a42ea_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_bfae6874-7bc2-42f2-8bd9-13d9dd82c022_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c5635988-8f70-481b-b805-bd7d52b6ee4d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowings</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_975a6c03-ad37-434b-b15e-4286223c1aab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_3cbb9b9a-c5a7-4257-8e84-cb987f425580_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_83c526e5-4739-4883-907f-8a56321a0d7d_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20230331.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_80b3b367-0aa4-4dbf-ba52-df3d658c8b0b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_38b5a523-8f8c-4fa6-a1a4-ea08acf99c61_negatedTerseLabel_en-US" xlink:label="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and other investments</link:label>
    <link:label id="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_label_en-US" xlink:label="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Businesses And For Other Investments</link:label>
    <link:label id="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_documentation_en-US" xlink:label="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Businesses And For Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" xlink:href="bhc-20230331.xsd#bhc_PaymentsToAcquireBusinessesAndForOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" xlink:to="lab_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_401d5cec-4a77-4f63-82a4-c9d1d3198400_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_d4ef9f16-0788-4e91-a92b-b57c8b1f2f70_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_734514de-5e21-4cfe-b529-b103a30f5486_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20230331.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_93b94279-d948-4d42-9ebf-8459d18d64ca_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20230331.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_65ccc16e-f9a4-42c2-bd88-6dd390883d78_terseLabel_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_label_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates [Member]</link:label>
    <link:label id="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember_documentation_en-US" xlink:label="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR, CDOR, EURIBOR and SONIA Rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:href="bhc-20230331.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:to="lab_bhc_SOFRCDOREURIBORAndSONIARatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_3f212953-e5e4-455f-8311-ab4c0bdb4686_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a563ef5f-2e02-4106-9139-a2f41105fd2b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_e2e43c46-0014-4b78-b46b-79014e0fe1ae_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_abf39ec6-32c3-4c88-af4b-5a7f022ea704_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a5d32e87-4043-4809-bd2c-a54547732699_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_dbc1b296-14d7-4c4b-84c6-41998a7d2513_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_575f7df1-fa26-4205-a79d-a13c152b2cdb_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.500% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_c56fef32-5e1f-4df7-85cd-4a10b2612404_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_04b0a0b1-95bc-4ad2-8c9f-98e60e9c6b45_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20230331.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_d1220c7c-1bd6-4c4e-9961-5190a498191e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_16250480-1832-452c-81b5-ed67659e9da4_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_772ddf9c-b04b-42eb-a492-52e2da6ce977_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_2fdc031e-9256-4293-9428-7cf49a1bc8d2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0f8a09f-c152-4e15-a682-56f3ed41a552_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_63758dd3-dbf7-45a6-b299-ddc4f7f9649f_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20230331.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_b6e2c6ed-d32f-4845-86ed-c7b460428021_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_203e14bb-1bc6-445e-a531-a755a86d3f13_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2ffbada6-e271-4dde-b5ae-e42d8d36b697_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_9ec0cd9c-0e40-4535-8b8f-1b0fb79403dd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_cfdde3c2-c079-4f2c-b64e-ac9a844bb87c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3fa89c14-1d16-4993-9a1c-96e5567fddd0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_8a3098f3-6880-4bc8-b69c-14094ec01bcf_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20230331.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_7bda0a10-bbc2-4796-8cdf-5d4871f07e13_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20230331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0879630d-d8b6-4cd8-8d8e-f5246cfc5329_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_93509235-68c3-4274-803b-51991a171fd6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_122ca8da-dafb-4374-b861-8f3c46738954_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ece90a3e-6044-40a6-a174-0c9cab0a5023_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-front payment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_cd49f867-ece0-44ff-b35a-fee856a3194c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_a1dd603d-0fae-4f8a-8658-92b8b52d77a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_359587ff-8567-4db7-80c5-cd888026f791_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_8cc13242-b657-4701-9965-aaca776a5370_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_2c30cd5b-306d-40fb-b44b-7f9253c7f203_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_16e87d56-d576-4e69-8c1f-c2a923da1dc6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_edcbc829-2329-483b-ba62-be7983e7de3a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_434dd39a-9d41-42c6-91c9-b701ac9a767b_terseLabel_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of earnings per share, performance conditions not met (in shares)</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_label_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:label id="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_documentation_en-US" xlink:label="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:href="bhc-20230331.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:to="lab_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3732ee63-b9a8-46a2-b3f6-5ea1bed06bd4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bd4769ca-33d8-45b1-80c9-262375e421ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_02359c68-7987-493e-91e7-a164bf57ef53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense from final and potential settlement of various tax audits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_7f616b20-58ab-4daf-8229-9f34199dda26_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20230331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a4c3cc48-f8c8-4dc1-9804-2aaff16660b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_c0688ea5-c1b1-4067-92a6-f8b936848f50_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3a975727-eeee-4ec6-83b4-5b0a4033ff9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) on ordinary income (loss)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_8f5c79fe-ec68-437d-9814-c92a148fa6fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_b8948c36-7bdc-425a-a0f2-5b8897a8c5fc_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">11.00% First Lien Senior Notes, Due September 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 11.00% Notes, First Lien, Due September 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:to="lab_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e7d534bd-c090-4702-9368-910ba6dd5faa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_68d7cbd0-c8b6-4ecc-9c3e-f77631cc7e14_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4e82cc9e-b024-41eb-96c7-4117db3f8949_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3eeb6624-d4f8-4a03-a4c9-a78b3b141565_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_343428d9-1b26-4e92-a535-5f060530664d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_61ac6b72-19ae-4d2b-a785-ff355d6bf1f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_8f708f6d-aba2-4861-a115-8200af941f8c_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock_b8ee9401-4e86-4b65-863e-5724396c7ded_terseLabel_en-US" xlink:label="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSING AGREEMENTS AND ACQUISITION</link:label>
    <link:label id="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock_label_en-US" xlink:label="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Acquisition Disclosure [Text Block]</link:label>
    <link:label id="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock_documentation_en-US" xlink:label="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements And Acquisition Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" xlink:href="bhc-20230331.xsd#bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" xlink:to="lab_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ea76d70f-a03c-4ee9-837a-bdc01e051fb8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_89577b68-f425-4a03-914d-46a05740225b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_c6c151d9-ad0c-41c6-b3ce-477f43412d8a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_f191ce96-afcf-4be0-98d1-ee6b4e902eea_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_f5c53332-840e-41b7-967f-752a88c8f633_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b013cc61-5036-46c0-b972-1a24d18f3a78_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_fca84a54-05d6-4287-ad96-7a0485fe7a13_terseLabel_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, SOFR</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_label_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:href="bhc-20230331.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:to="lab_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_984126f5-47fb-4824-a183-52c2999f1b91_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_68151a58-6816-40de-a022-b0652407ff0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_211f3a39-6b00-4282-9650-760e3728f9cd_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20230331.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_399ec7ca-ee5f-4aaf-821b-bfef1f2c87bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_cb255d1b-15eb-4578-93cc-af791978de49_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_d413d672-e439-4eda-8b27-a1c54dcbfca0_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>bhc-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:15d8a82e-3541-4c94-ac5d-dc1f963a0c8b,g:acd10879-3b31-4117-a8f7-2a1c419d7f06-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="bhc-20230331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_234f2764-51fd-41a5-84fa-248d8e7b3f91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_DocumentType_234f2764-51fd-41a5-84fa-248d8e7b3f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0e97cf20-51a0-44a2-8784-d9006daa6b8b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_DocumentQuarterlyReport_0e97cf20-51a0-44a2-8784-d9006daa6b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fc87eaca-f341-48bb-83e0-78da80322bad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_DocumentPeriodEndDate_fc87eaca-f341-48bb-83e0-78da80322bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4b59ba93-c9cf-4d2e-9992-405bc507f1fe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_DocumentTransitionReport_4b59ba93-c9cf-4d2e-9992-405bc507f1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e8819816-42e3-4b6a-bfa1-7b7b154117ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityFileNumber_e8819816-42e3-4b6a-bfa1-7b7b154117ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a545d4b6-6647-47b0-8fa6-ec7c8451b01d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityRegistrantName_a545d4b6-6647-47b0-8fa6-ec7c8451b01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b17d9461-f1d5-4465-b020-9a531533187b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b17d9461-f1d5-4465-b020-9a531533187b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_066d1693-c745-49e8-94c2-bb17b073949d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityAddressCountry_066d1693-c745-49e8-94c2-bb17b073949d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dc537656-2cab-4288-88f4-17d208adc3e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityTaxIdentificationNumber_dc537656-2cab-4288-88f4-17d208adc3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_1f297a3a-673c-420f-a09c-1269fe8054e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityAddressAddressLine1_1f297a3a-673c-420f-a09c-1269fe8054e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bd627a23-a2a9-4483-ad04-cf4c62c64e6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityAddressCityOrTown_bd627a23-a2a9-4483-ad04-cf4c62c64e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f4bc7528-155d-4239-9a8c-14f02d857b26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityAddressStateOrProvince_f4bc7528-155d-4239-9a8c-14f02d857b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5cef762e-88df-4e87-b53e-c92436d75556" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityAddressPostalZipCode_5cef762e-88df-4e87-b53e-c92436d75556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_25d1f1f6-f8a7-4f75-97e6-8966cd89de35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_CityAreaCode_25d1f1f6-f8a7-4f75-97e6-8966cd89de35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6265f965-bc69-4b3b-a5af-df84dc6c06d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_LocalPhoneNumber_6265f965-bc69-4b3b-a5af-df84dc6c06d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cf4a8d5e-800e-4e5a-a809-60a6888efb3e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_Security12bTitle_cf4a8d5e-800e-4e5a-a809-60a6888efb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c48656dc-13f4-415b-a83e-0788697ad268" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_TradingSymbol_c48656dc-13f4-415b-a83e-0788697ad268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_78bf93b7-9883-4fe1-8659-741f56694a41" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_SecurityExchangeName_78bf93b7-9883-4fe1-8659-741f56694a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_62f4fa31-6d5f-4d45-9690-5d6197b30123" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityCurrentReportingStatus_62f4fa31-6d5f-4d45-9690-5d6197b30123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_96ad1b69-406e-41ea-b7ae-3cc4beff9540" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityInteractiveDataCurrent_96ad1b69-406e-41ea-b7ae-3cc4beff9540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0d8d61a9-5179-4ea5-8f57-84c469562f75" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityFilerCategory_0d8d61a9-5179-4ea5-8f57-84c469562f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c425a73c-91cd-4de8-8173-7ec779674990" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntitySmallBusiness_c425a73c-91cd-4de8-8173-7ec779674990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1f87250d-d942-4458-ad69-beab7d4314d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityEmergingGrowthCompany_1f87250d-d942-4458-ad69-beab7d4314d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8da86d04-3d23-4fb1-a30c-b633e44b3a54" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityShellCompany_8da86d04-3d23-4fb1-a30c-b633e44b3a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0aebbee8-d890-4d37-98f2-a3942c9cb564" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0aebbee8-d890-4d37-98f2-a3942c9cb564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_71236f39-a369-4422-a090-d48a941eae14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_EntityCentralIndexKey_71236f39-a369-4422-a090-d48a941eae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_be68b2f0-2e9d-4d78-8383-1664da0092a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_CurrentFiscalYearEndDate_be68b2f0-2e9d-4d78-8383-1664da0092a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9cbd4f12-3e51-4bba-a3a2-420657ffcdf5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_DocumentFiscalYearFocus_9cbd4f12-3e51-4bba-a3a2-420657ffcdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_83ad3b2b-1afb-49ba-8515-148a83ee3127" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_DocumentFiscalPeriodFocus_83ad3b2b-1afb-49ba-8515-148a83ee3127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_11a7f668-4da9-4f1b-8922-17f42a027ed8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bd4dac12-53d5-4dde-a53a-f3c8dda0bdfe" xlink:to="loc_dei_AmendmentFlag_11a7f668-4da9-4f1b-8922-17f42a027ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_59e74e1a-6794-4623-a5b7-5366c998d494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59e74e1a-6794-4623-a5b7-5366c998d494" xlink:to="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_02712578-b6fe-4cdc-aca7-010721288a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_02712578-b6fe-4cdc-aca7-010721288a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_809cd7ce-fc54-41c7-97b4-c391ea138a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:to="loc_us-gaap_RestrictedCashCurrent_809cd7ce-fc54-41c7-97b4-c391ea138a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_57f42a78-2503-4acb-8cea-5f83ab7e373d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:to="loc_us-gaap_ReceivablesNetCurrent_57f42a78-2503-4acb-8cea-5f83ab7e373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_192962bf-048c-4e65-afbb-e88a7e757f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:to="loc_us-gaap_InventoryNet_192962bf-048c-4e65-afbb-e88a7e757f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fcd0204-9029-4206-92a8-b239af1dcc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fcd0204-9029-4206-92a8-b239af1dcc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4459d49b-c37c-42bf-8c90-2ff0f11c1d84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_30269b4d-bc71-447f-a0b2-2f4405833757" xlink:to="loc_us-gaap_AssetsCurrent_4459d49b-c37c-42bf-8c90-2ff0f11c1d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1b694ab2-7133-4634-a633-fa91c9b6cd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1b694ab2-7133-4634-a633-fa91c9b6cd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f4309844-6d77-469d-a8ce-e541b39a94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f4309844-6d77-469d-a8ce-e541b39a94c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1927aad1-f81a-4f09-b3f8-243360b60b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_Goodwill_1927aad1-f81a-4f09-b3f8-243360b60b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_83528391-bda2-458a-a73c-cb8ca077b389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_83528391-bda2-458a-a73c-cb8ca077b389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ed1271ca-2db3-4fd9-88bb-2a116df69e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ed1271ca-2db3-4fd9-88bb-2a116df69e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_216a7dbd-a9ed-4b05-8362-33ebfe7eef97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ff65966c-14cb-4b66-b149-43fcf75e8b20" xlink:to="loc_us-gaap_Assets_216a7dbd-a9ed-4b05-8362-33ebfe7eef97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59e74e1a-6794-4623-a5b7-5366c998d494" xlink:to="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ce23be06-6e34-4837-8264-adbc3fba7741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ce23be06-6e34-4837-8264-adbc3fba7741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b5e212a2-ae3a-4b24-94d1-a532848262eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ce23be06-6e34-4837-8264-adbc3fba7741" xlink:to="loc_us-gaap_AccountsPayableCurrent_b5e212a2-ae3a-4b24-94d1-a532848262eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a06d2a83-2eb0-47f4-9a06-7fc37ae6b263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ce23be06-6e34-4837-8264-adbc3fba7741" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a06d2a83-2eb0-47f4-9a06-7fc37ae6b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_620f1496-27c4-477a-9270-1e946c9729f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ce23be06-6e34-4837-8264-adbc3fba7741" xlink:to="loc_us-gaap_LongTermDebtCurrent_620f1496-27c4-477a-9270-1e946c9729f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1e10c085-a31f-4826-b096-74b31a2fd069" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ce23be06-6e34-4837-8264-adbc3fba7741" xlink:to="loc_us-gaap_LiabilitiesCurrent_1e10c085-a31f-4826-b096-74b31a2fd069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_69a63947-5037-4dc3-8099-a4da4e93d712" xlink:href="bhc-20230331.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_69a63947-5037-4dc3-8099-a4da4e93d712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e90dcf1b-d48f-4003-854f-9e2c2d2554a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e90dcf1b-d48f-4003-854f-9e2c2d2554a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4f83c95b-53f9-4b92-8ab7-50013e0b812e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4f83c95b-53f9-4b92-8ab7-50013e0b812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_a8c1551d-c4d8-4a14-a0e0-605f68e72507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_a8c1551d-c4d8-4a14-a0e0-605f68e72507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_84770903-743e-4023-837c-dd8cdd6a727b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_0b4d8f69-6e64-4c93-8090-64687a106bcf" xlink:to="loc_us-gaap_Liabilities_84770903-743e-4023-837c-dd8cdd6a727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b2930f88-882d-4905-a869-bf50c307311a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59e74e1a-6794-4623-a5b7-5366c998d494" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b2930f88-882d-4905-a869-bf50c307311a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59e74e1a-6794-4623-a5b7-5366c998d494" xlink:to="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_926d2119-2f5f-43a0-8c33-8160c7628e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_CommonStockValue_926d2119-2f5f-43a0-8c33-8160c7628e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ceab9601-3e37-4bf6-91d2-c0cec7ac59e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ceab9601-3e37-4bf6-91d2-c0cec7ac59e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_54ccd8cd-7d31-44fb-8ac1-9a85da4ae4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_54ccd8cd-7d31-44fb-8ac1-9a85da4ae4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7511ed83-38ce-424b-9f11-8dd8a253616f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7511ed83-38ce-424b-9f11-8dd8a253616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b1ae972-641b-4872-8f63-288d4dcaa4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_StockholdersEquity_4b1ae972-641b-4872-8f63-288d4dcaa4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ba1c36c1-b1a6-438a-a348-84a3326949b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_MinorityInterest_ba1c36c1-b1a6-438a-a348-84a3326949b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_142a34c9-0865-440d-83d9-fcef27a741f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_13632ba9-8193-4d91-ad23-36b7db0857ad" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_142a34c9-0865-440d-83d9-fcef27a741f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bcc1265-2bef-4393-bc55-c01a1bc8209b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_59e74e1a-6794-4623-a5b7-5366c998d494" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0bcc1265-2bef-4393-bc55-c01a1bc8209b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7e4cdddf-f380-43cf-aa2b-f6ca56c7fd46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0dc103f8-7307-4a7f-9185-a9b8c2192096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e4cdddf-f380-43cf-aa2b-f6ca56c7fd46" xlink:to="loc_us-gaap_CommonStockSharesIssued_0dc103f8-7307-4a7f-9185-a9b8c2192096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0fdb82b5-47fa-4c78-905e-a22569d860e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7e4cdddf-f380-43cf-aa2b-f6ca56c7fd46" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0fdb82b5-47fa-4c78-905e-a22569d860e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b5a4b638-5b80-4cb2-9e19-77ec5e86610c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b5a4b638-5b80-4cb2-9e19-77ec5e86610c" xlink:to="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:to="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_46aa8713-151f-42f6-b4e1-024430a7b728" xlink:to="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_2c3d93ba-92d4-4a1b-a2e2-4a1023e21807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:to="loc_us-gaap_ProductMember_2c3d93ba-92d4-4a1b-a2e2-4a1023e21807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_3400aecd-60ef-4292-801f-c55e5a38ee06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d0f5322b-6dea-4acd-ba5a-c8ad45b914d4" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_3400aecd-60ef-4292-801f-c55e5a38ee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a5c0589b-8d4f-4880-9c6d-c60da98b640a" xlink:to="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_ff9e3dd4-bd71-4207-b4d5-88e17ca2af59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_RevenuesAbstract_ff9e3dd4-bd71-4207-b4d5-88e17ca2af59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad16ec17-b016-4e04-a6bd-ec08a5595c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_ff9e3dd4-bd71-4207-b4d5-88e17ca2af59" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad16ec17-b016-4e04-a6bd-ec08a5595c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_00ff6f03-068c-4842-8491-9ff7fac7e28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_00ff6f03-068c-4842-8491-9ff7fac7e28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9f07a70-52fc-4439-8934-d4e4dd9aecb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9f07a70-52fc-4439-8934-d4e4dd9aecb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5010d2fa-9a97-48e8-8040-ad30927f0406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5010d2fa-9a97-48e8-8040-ad30927f0406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_d234a9c3-4f0e-40a0-bb65-1ab334b3ff91" xlink:href="bhc-20230331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_d234a9c3-4f0e-40a0-bb65-1ab334b3ff91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f113cfdf-2504-4ff3-9880-3698b866d146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_AssetImpairmentCharges_f113cfdf-2504-4ff3-9880-3698b866d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_887d42ef-6027-4054-a49f-9535eb8eb266" xlink:href="bhc-20230331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_887d42ef-6027-4054-a49f-9535eb8eb266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9817914e-793d-4e31-b971-e6a2eabb05c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9817914e-793d-4e31-b971-e6a2eabb05c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_64541a5b-75ba-4468-9da5-dae132f539ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_782c2d9c-72e3-4c33-8055-283cd1def2e1" xlink:to="loc_us-gaap_CostsAndExpenses_64541a5b-75ba-4468-9da5-dae132f539ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3183d26e-1ab9-4148-8a56-90af1b086223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_OperatingIncomeLoss_3183d26e-1ab9-4148-8a56-90af1b086223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_7b92c5e7-af9a-479f-ba72-d5cdb8f8b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_7b92c5e7-af9a-479f-ba72-d5cdb8f8b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_06524160-eae5-46fd-934d-6846fcb5c2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_InterestExpenseDebt_06524160-eae5-46fd-934d-6846fcb5c2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_261f8565-30e0-457c-b2e8-dd6b81ef2c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_261f8565-30e0-457c-b2e8-dd6b81ef2c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7235945e-bb4d-4268-b264-17389b812d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7235945e-bb4d-4268-b264-17389b812d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_830330b4-f7e5-41a5-9629-89e3f149cf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_830330b4-f7e5-41a5-9629-89e3f149cf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_39ee267c-aec2-4e37-92bd-68aa070f37ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_ProfitLoss_39ee267c-aec2-4e37-92bd-68aa070f37ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f45ab1a6-b1b5-4968-814a-36d5f986ceb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f45ab1a6-b1b5-4968-814a-36d5f986ceb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_59432d02-694a-42c9-91d7-c639a28a0a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_NetIncomeLoss_59432d02-694a-42c9-91d7-c639a28a0a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_01125956-1b68-469e-8b8a-7f4c96f20c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_EarningsPerShareBasic_01125956-1b68-469e-8b8a-7f4c96f20c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f9dd015f-618a-4d0c-bcfc-5e3226d3b9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f9dd015f-618a-4d0c-bcfc-5e3226d3b9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf8abcec-81dc-4a31-9dda-321e54c27b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf8abcec-81dc-4a31-9dda-321e54c27b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99f60f55-898d-479d-b213-443e1edd0f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3e1f6403-17d9-4855-8fd0-d5ba8953709e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_99f60f55-898d-479d-b213-443e1edd0f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a8d67900-1af3-4c8d-acd5-05ee95d6963c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e300580e-bf17-41c3-960b-1979d11e6724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a8d67900-1af3-4c8d-acd5-05ee95d6963c" xlink:to="loc_us-gaap_ProfitLoss_e300580e-bf17-41c3-960b-1979d11e6724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a61c16d0-9d0a-4912-a298-34eaced6ce25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a8d67900-1af3-4c8d-acd5-05ee95d6963c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a61c16d0-9d0a-4912-a298-34eaced6ce25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_45012a62-4201-4581-997f-8c3263fe4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a61c16d0-9d0a-4912-a298-34eaced6ce25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_45012a62-4201-4581-997f-8c3263fe4ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_a3d5041d-39ca-40d0-b811-8b816a7a845a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a61c16d0-9d0a-4912-a298-34eaced6ce25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_a3d5041d-39ca-40d0-b811-8b816a7a845a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_28b321c9-01ad-4657-9b88-cb484ae6ba1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a61c16d0-9d0a-4912-a298-34eaced6ce25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_28b321c9-01ad-4657-9b88-cb484ae6ba1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81ba6691-7bce-4072-a0e9-d02cdd12ea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a8d67900-1af3-4c8d-acd5-05ee95d6963c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_81ba6691-7bce-4072-a0e9-d02cdd12ea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2697890f-16ac-4248-bb9c-da74ffba091b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a8d67900-1af3-4c8d-acd5-05ee95d6963c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2697890f-16ac-4248-bb9c-da74ffba091b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee649a74-dbe1-4e45-9aac-00210d554cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a8d67900-1af3-4c8d-acd5-05ee95d6963c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee649a74-dbe1-4e45-9aac-00210d554cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a44b8d58-2ed1-403f-a85b-bcc9af220758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a44b8d58-2ed1-403f-a85b-bcc9af220758" xlink:to="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f53491c9-5ddb-4e1e-be3e-cdbf824fc316" xlink:to="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:to="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a4ff6003-f8bd-40b7-b553-6dda6693e4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_CommonStockMember_a4ff6003-f8bd-40b7-b553-6dda6693e4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7515ed49-9055-45ba-b7ea-cc81935867b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7515ed49-9055-45ba-b7ea-cc81935867b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_351edd40-d6e2-425d-a121-ebe187980e65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_RetainedEarningsMember_351edd40-d6e2-425d-a121-ebe187980e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f8fd5030-89f8-46dd-9e1e-68f7008521e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_6abbbd82-97b5-49c2-8b4e-2aed084b87c5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f8fd5030-89f8-46dd-9e1e-68f7008521e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_cab77ee6-5ec2-4ff4-933a-a02af2fb8f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_53a51826-289d-4288-9b83-49874018e510" xlink:to="loc_us-gaap_NoncontrollingInterestMember_cab77ee6-5ec2-4ff4-933a-a02af2fb8f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d4735dd5-cce0-4cf5-b2c3-cb6a3c6f582d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e10866d5-3b26-42ed-befc-55044024317b" xlink:to="loc_us-gaap_StatementLineItems_d4735dd5-cce0-4cf5-b2c3-cb6a3c6f582d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d4735dd5-cce0-4cf5-b2c3-cb6a3c6f582d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_668b347b-23ed-4874-af5e-32a86faeeb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_CommonStockSharesIssued_668b347b-23ed-4874-af5e-32a86faeeb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7b90d97-aa48-4b5b-a91a-6c387bd2a8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f7b90d97-aa48-4b5b-a91a-6c387bd2a8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c8347eb1-c055-46fa-85c6-a308884c6952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_c8347eb1-c055-46fa-85c6-a308884c6952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3dda7f9a-23d7-4e0b-b7f3-c37d3601adb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3dda7f9a-23d7-4e0b-b7f3-c37d3601adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8c95559-8ca0-42e3-879e-d842241985aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8c95559-8ca0-42e3-879e-d842241985aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_13d853b3-bada-494f-bf3b-dc930227adc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_13d853b3-bada-494f-bf3b-dc930227adc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2d90431a-7573-40af-876c-d1ce64956afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_2d90431a-7573-40af-876c-d1ce64956afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5e90d7ed-927b-4e99-91cc-f626676062ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_ProfitLoss_5e90d7ed-927b-4e99-91cc-f626676062ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0683b469-fbac-44dc-a783-1af0b9da7f75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0683b469-fbac-44dc-a783-1af0b9da7f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cbc94ea6-f2a4-4c26-abcb-260e263ca2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_CommonStockSharesIssued_cbc94ea6-f2a4-4c26-abcb-260e263ca2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cef6ebd9-ffb5-4cdb-a5db-e4fa3fd40ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c9b68c22-174e-412c-8b7f-972077d7a53f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cef6ebd9-ffb5-4cdb-a5db-e4fa3fd40ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_936b1345-721b-4f7b-b3be-dab571421571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_936b1345-721b-4f7b-b3be-dab571421571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6cd3261f-3e5c-41f8-baef-a88b76f9a9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_936b1345-721b-4f7b-b3be-dab571421571" xlink:to="loc_us-gaap_ProfitLoss_6cd3261f-3e5c-41f8-baef-a88b76f9a9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_936b1345-721b-4f7b-b3be-dab571421571" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ddf1c93a-2c05-4752-a415-1e36171e26a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_DepreciationAndAmortization_ddf1c93a-2c05-4752-a415-1e36171e26a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_71667a13-834e-4014-9aae-6c1304562ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_71667a13-834e-4014-9aae-6c1304562ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_99cf555b-9db7-4f09-9789-0615b0ee7757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_AssetImpairmentCharges_99cf555b-9db7-4f09-9789-0615b0ee7757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_dc9e7af0-88de-4756-8076-8ec774653d38" xlink:href="bhc-20230331.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_dc9e7af0-88de-4756-8076-8ec774653d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_85d5976e-4fcd-4db5-a06a-a00871a47991" xlink:href="bhc-20230331.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_85d5976e-4fcd-4db5-a06a-a00871a47991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_9f58a385-25d4-4380-a044-b185d1039625" xlink:href="bhc-20230331.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_9f58a385-25d4-4380-a044-b185d1039625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_265d174c-7194-4e5e-94f5-05fdba4477b7" xlink:href="bhc-20230331.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_265d174c-7194-4e5e-94f5-05fdba4477b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_dc882e77-6272-4c02-8fdd-3d21996d1be2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_dc882e77-6272-4c02-8fdd-3d21996d1be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_07ebff1d-a8f5-4968-b06d-5ef0ae4eab36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_ShareBasedCompensation_07ebff1d-a8f5-4968-b06d-5ef0ae4eab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8be9b098-c1d7-457a-9112-6be7f0d6f273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_8be9b098-c1d7-457a-9112-6be7f0d6f273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_62e8de8b-1839-4cf3-b589-c56ed7f59346" xlink:href="bhc-20230331.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_bhc_DerivativeGainExcludedComponent_62e8de8b-1839-4cf3-b589-c56ed7f59346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_ff6da21b-5a49-4632-b112-65b2058b0422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_ff6da21b-5a49-4632-b112-65b2058b0422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a9e2f3-6733-4020-9ec4-dc6deee9a25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5cb5af2e-9f36-4704-8fff-306c7966a309" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a9e2f3-6733-4020-9ec4-dc6deee9a25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c2bf763-fac2-4e21-918f-d28bd4f9089f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a9e2f3-6733-4020-9ec4-dc6deee9a25f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0c2bf763-fac2-4e21-918f-d28bd4f9089f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_114c7ba7-b55a-40a3-9029-d84e09e0d5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a9e2f3-6733-4020-9ec4-dc6deee9a25f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_114c7ba7-b55a-40a3-9029-d84e09e0d5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75813d54-19b2-481b-9493-3c4da0819749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a9e2f3-6733-4020-9ec4-dc6deee9a25f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_75813d54-19b2-481b-9493-3c4da0819749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0e3efdc4-c6e6-4006-be69-b7cf8d9b911e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_63a9e2f3-6733-4020-9ec4-dc6deee9a25f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0e3efdc4-c6e6-4006-be69-b7cf8d9b911e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d91ddb2e-6576-40db-a790-b0ecc0a2997c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_936b1345-721b-4f7b-b3be-dab571421571" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d91ddb2e-6576-40db-a790-b0ecc0a2997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_7a3e1cbb-f410-4c91-a278-606ec382d787" xlink:href="bhc-20230331.xsd#bhc_PaymentsToAcquireBusinessesAndForOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments_7a3e1cbb-f410-4c91-a278-606ec382d787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9b6f170-145d-4673-8876-0755c40a6636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e9b6f170-145d-4673-8876-0755c40a6636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_526f6f6a-b09d-48b1-9ed7-ed6d30f60668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_526f6f6a-b09d-48b1-9ed7-ed6d30f60668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2ef3814b-4acb-46ca-b084-b787ed07c141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_2ef3814b-4acb-46ca-b084-b787ed07c141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_dd2f3a5e-39dc-4604-969c-aaeb5c1798a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_dd2f3a5e-39dc-4604-969c-aaeb5c1798a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_9002241d-9e70-4b5b-a190-028f604c9493" xlink:href="bhc-20230331.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_9002241d-9e70-4b5b-a190-028f604c9493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_306b63ce-9c1a-4dee-931f-b8a2fa55ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3631886e-fb87-4dc6-bf58-dc37beb76da7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_306b63ce-9c1a-4dee-931f-b8a2fa55ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4cd44e3-fdfc-46c8-9887-ef58618d729e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e4cd44e3-fdfc-46c8-9887-ef58618d729e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_91838d43-0bc4-45c2-8bf7-ae40779f8474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_91838d43-0bc4-45c2-8bf7-ae40779f8474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f547d1fe-0d34-46cd-b06e-2bb48a32d561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f547d1fe-0d34-46cd-b06e-2bb48a32d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e3cf1c7d-5a91-4b1f-b8ef-f827d1b952d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_e3cf1c7d-5a91-4b1f-b8ef-f827d1b952d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4cf7d9b9-44fb-436b-8bcd-0fa2abb73059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4cf7d9b9-44fb-436b-8bcd-0fa2abb73059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bfedf548-1556-42a3-9f44-805a60635755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bfedf548-1556-42a3-9f44-805a60635755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7a80057-4b0c-482b-9268-86eea181be1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_707a7ee7-e37b-4047-89d9-124d0c530e24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f7a80057-4b0c-482b-9268-86eea181be1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2557200c-e4ff-4b69-9844-acac1eb63b57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2557200c-e4ff-4b69-9844-acac1eb63b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_247de893-a423-438f-9278-03717edf4443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_247de893-a423-438f-9278-03717edf4443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fc64e62-4423-43a1-9d37-86439b3786d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9fc64e62-4423-43a1-9d37-86439b3786d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0f2c52b-3a2a-4e77-8a50-7de708184354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e0f2c52b-3a2a-4e77-8a50-7de708184354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ce50bcd-d9a8-432a-acf7-dc962bb36d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4ce50bcd-d9a8-432a-acf7-dc962bb36d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_bd0c0055-fe38-41f5-8a5a-adc3edc8c0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_RestrictedCashCurrent_bd0c0055-fe38-41f5-8a5a-adc3edc8c0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_adde2fb6-5550-47cd-928f-113151346994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_926e1383-e476-4c5a-8c70-1be84dea5f0c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_adde2fb6-5550-47cd-928f-113151346994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20230331.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84b66a4c-6841-4f49-822a-633bbbfb0c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_a2f11a23-1c46-4936-95ca-32c032c3d535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84b66a4c-6841-4f49-822a-633bbbfb0c99" xlink:to="loc_us-gaap_NatureOfOperations_a2f11a23-1c46-4936-95ca-32c032c3d535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20230331.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3eee81d-2d40-498c-8f7d-da0bdf09552f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f8646ffa-4436-4a9f-af41-a142c0d86d65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3eee81d-2d40-498c-8f7d-da0bdf09552f" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f8646ffa-4436-4a9f-af41-a142c0d86d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6701463-1079-41e6-b810-6c38e3f652d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d471b917-8fb0-4b97-a7c5-79fa07f37ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e6701463-1079-41e6-b810-6c38e3f652d4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d471b917-8fb0-4b97-a7c5-79fa07f37ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITION" xlink:type="simple" xlink:href="bhc-20230331.xsd#LICENSINGAGREEMENTSANDACQUISITION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d403de92-f5b2-4656-ba98-10a08a949c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock_23c1353b-0445-486a-8e10-fcfadf272565" xlink:href="bhc-20230331.xsd#bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d403de92-f5b2-4656-ba98-10a08a949c56" xlink:to="loc_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock_23c1353b-0445-486a-8e10-fcfadf272565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_99f27335-fe8a-4d94-8e24-603ee37783cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_d43813c3-fb4e-43ea-8d46-21692806be6f" xlink:href="bhc-20230331.xsd#bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_99f27335-fe8a-4d94-8e24-603ee37783cc" xlink:to="loc_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock_d43813c3-fb4e-43ea-8d46-21692806be6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_078d3fdf-6ca4-487c-9df7-fdbaf60a64c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2aa42f00-8231-4cd7-8dd3-1a5d6c48893d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_078d3fdf-6ca4-487c-9df7-fdbaf60a64c1" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2aa42f00-8231-4cd7-8dd3-1a5d6c48893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20230331.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_de019455-36fd-474e-8739-b70081d3f458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ca1e5c3a-f0ae-4c29-94eb-f65d6c0e4582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_de019455-36fd-474e-8739-b70081d3f458" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ca1e5c3a-f0ae-4c29-94eb-f65d6c0e4582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_448f8999-4fc0-496e-816a-222b9a2d230f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_457fab7c-8565-4422-bd5c-923e6981f448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_448f8999-4fc0-496e-816a-222b9a2d230f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_457fab7c-8565-4422-bd5c-923e6981f448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_921bf36b-a482-4492-b1cd-4af2dbef88e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_4abd1400-391f-4c20-bf67-dc87dd50f031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_921bf36b-a482-4492-b1cd-4af2dbef88e5" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_4abd1400-391f-4c20-bf67-dc87dd50f031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_668040d6-6158-4370-8c4b-49772082724b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_ee7b4380-9db8-47be-b5f1-7296dc70856c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_668040d6-6158-4370-8c4b-49772082724b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_ee7b4380-9db8-47be-b5f1-7296dc70856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1db8aa89-c54c-4f55-941d-b55c7c0f1ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a29aea76-6bb8-4683-918a-9ed0b6b3b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1db8aa89-c54c-4f55-941d-b55c7c0f1ddc" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a29aea76-6bb8-4683-918a-9ed0b6b3b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a9f7d3a3-ec20-4308-8299-62c0f0b9fd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_f26a08ae-9fec-4be0-a993-37b6bc77d71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a9f7d3a3-ec20-4308-8299-62c0f0b9fd5c" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_f26a08ae-9fec-4be0-a993-37b6bc77d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_d6509522-803d-4174-8c49-f49d9bcaff84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_fa15633b-c3fd-457a-9222-743d235af68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_d6509522-803d-4174-8c49-f49d9bcaff84" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_fa15633b-c3fd-457a-9222-743d235af68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20230331.xsd#OTHEREXPENSENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_17b75fcb-8786-4b8f-8fa3-948277dc16ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_dc77094d-17d4-4d48-a2ac-adead7ba1713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_17b75fcb-8786-4b8f-8fa3-948277dc16ba" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_dc77094d-17d4-4d48-a2ac-adead7ba1713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20230331.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_209b32a8-f069-4844-aa1c-50bb64bc8b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1f30cc8d-d5e7-4e74-b881-b4b431712022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_209b32a8-f069-4844-aa1c-50bb64bc8b89" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1f30cc8d-d5e7-4e74-b881-b4b431712022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20230331.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3a1e5757-cd4e-4caf-b19a-49da84f2e1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_be5e0a48-f8be-4544-bbe0-497622e044c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3a1e5757-cd4e-4caf-b19a-49da84f2e1a6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_be5e0a48-f8be-4544-bbe0-497622e044c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c42820d-ae8a-495d-9148-f5e4417e0294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_841cff5e-48ce-426a-86f2-ec8dba39d99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1c42820d-ae8a-495d-9148-f5e4417e0294" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_841cff5e-48ce-426a-86f2-ec8dba39d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a14ffb47-7854-4f68-8fd9-9586c9ba1f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_608057c2-7528-41b1-ada0-cb38c3da1225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a14ffb47-7854-4f68-8fd9-9586c9ba1f02" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_608057c2-7528-41b1-ada0-cb38c3da1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20230331.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9b5e9eec-59d1-429c-a556-5ac992206f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e9af0651-77d8-4186-9848-c6acf0cd04c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b5e9eec-59d1-429c-a556-5ac992206f2f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e9af0651-77d8-4186-9848-c6acf0cd04c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a0541bd2-a43f-401a-b41f-3995044d5c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b5e9eec-59d1-429c-a556-5ac992206f2f" xlink:to="loc_us-gaap_UseOfEstimates_a0541bd2-a43f-401a-b41f-3995044d5c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_fd58ed96-f88a-46fc-a204-26dea30dda80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b5e9eec-59d1-429c-a556-5ac992206f2f" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_fd58ed96-f88a-46fc-a204-26dea30dda80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f8b05e5c-8e3d-4798-bf35-571d7ec0f8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b5e9eec-59d1-429c-a556-5ac992206f2f" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f8b05e5c-8e3d-4798-bf35-571d7ec0f8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b8ce95d2-10c9-42c2-be69-71e2c3da269d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9b5e9eec-59d1-429c-a556-5ac992206f2f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b8ce95d2-10c9-42c2-be69-71e2c3da269d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97ede9a0-02dc-47fb-8ff5-ac1effb9e5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_cb0b0296-4085-4859-aced-90f5ff449b15" xlink:href="bhc-20230331.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97ede9a0-02dc-47fb-8ff5-ac1effb9e5bd" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_cb0b0296-4085-4859-aced-90f5ff449b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_cb5d9d9a-aca1-4ec3-8780-c2a25639a0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97ede9a0-02dc-47fb-8ff5-ac1effb9e5bd" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_cb5d9d9a-aca1-4ec3-8780-c2a25639a0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f92b48b5-c871-4da0-82db-7aa559f1da08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_80bcbffc-b79d-4130-8952-0c3233f41513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f92b48b5-c871-4da0-82db-7aa559f1da08" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_80bcbffc-b79d-4130-8952-0c3233f41513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_49fc885d-3ac3-49aa-b945-19b915e2d255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f92b48b5-c871-4da0-82db-7aa559f1da08" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_49fc885d-3ac3-49aa-b945-19b915e2d255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_070a5ae8-1b0f-40b6-a9b7-364670092d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f92b48b5-c871-4da0-82db-7aa559f1da08" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_070a5ae8-1b0f-40b6-a9b7-364670092d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_85f30ba1-e0c2-4e84-95b7-dd763c1bf3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f92b48b5-c871-4da0-82db-7aa559f1da08" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_85f30ba1-e0c2-4e84-95b7-dd763c1bf3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_47194197-de99-4b8a-89ef-03f474f79270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f92b48b5-c871-4da0-82db-7aa559f1da08" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_47194197-de99-4b8a-89ef-03f474f79270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5ca4f950-cae7-42ba-9f2d-31920cb1bf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c2fe25e0-904b-4da6-b8c7-c1d889fda939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5ca4f950-cae7-42ba-9f2d-31920cb1bf35" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c2fe25e0-904b-4da6-b8c7-c1d889fda939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_463bb197-0c0f-4f96-aa64-0f00c910ca35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_15ce976b-b7ac-4744-93f1-104c247e79fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_463bb197-0c0f-4f96-aa64-0f00c910ca35" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_15ce976b-b7ac-4744-93f1-104c247e79fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_33b7a050-8f81-4570-b2de-c58fab730a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_463bb197-0c0f-4f96-aa64-0f00c910ca35" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_33b7a050-8f81-4570-b2de-c58fab730a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4de46faf-983c-4702-871b-ca4be469b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_463bb197-0c0f-4f96-aa64-0f00c910ca35" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4de46faf-983c-4702-871b-ca4be469b05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_8048c1a9-d5ec-4621-b4b0-5a1fcf46af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_463bb197-0c0f-4f96-aa64-0f00c910ca35" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_8048c1a9-d5ec-4621-b4b0-5a1fcf46af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e0b797a4-6491-4b18-b004-80a86c963c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_75d6b7f5-c21d-4601-adae-ee8e7f422a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e0b797a4-6491-4b18-b004-80a86c963c1c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_75d6b7f5-c21d-4601-adae-ee8e7f422a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8178cc24-f909-4f22-b07c-3771c479e8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_515c6b4b-1225-4efc-9a23-ec5a227e6fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8178cc24-f909-4f22-b07c-3771c479e8c4" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_515c6b4b-1225-4efc-9a23-ec5a227e6fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fb8c36a5-b8b5-45b1-9b72-31b347e59928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8178cc24-f909-4f22-b07c-3771c479e8c4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fb8c36a5-b8b5-45b1-9b72-31b347e59928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5698f6f-05d5-4cad-b842-4cbbc35f5822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f18b9ead-ce1d-4332-aec8-935dcacb6242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5698f6f-05d5-4cad-b842-4cbbc35f5822" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f18b9ead-ce1d-4332-aec8-935dcacb6242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2311d623-fc15-4a49-bfa3-942144e511dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5698f6f-05d5-4cad-b842-4cbbc35f5822" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_2311d623-fc15-4a49-bfa3-942144e511dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8860d4b2-70e0-4f42-ab63-528eec36c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6a9d0c3f-3171-4879-b034-5550a300703c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_8860d4b2-70e0-4f42-ab63-528eec36c3f8" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_6a9d0c3f-3171-4879-b034-5550a300703c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_3edfacde-e23b-4ff2-8b57-100ee3194304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_cc386a74-79ea-428d-858c-9a422c58e0c5" xlink:href="bhc-20230331.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_3edfacde-e23b-4ff2-8b57-100ee3194304" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_cc386a74-79ea-428d-858c-9a422c58e0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#OTHEREXPENSENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7a06e804-bd11-471a-9d9e-aa8c28301198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_40910329-57ed-4e10-829a-37140d8a9ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7a06e804-bd11-471a-9d9e-aa8c28301198" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_40910329-57ed-4e10-829a-37140d8a9ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20230331.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5bff8d69-a8fe-48e2-998b-e79cedac8f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_da5e1422-2b75-4a91-814a-4b449fee20c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bff8d69-a8fe-48e2-998b-e79cedac8f61" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_da5e1422-2b75-4a91-814a-4b449fee20c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_120f9e71-1007-4b36-82ec-322def44c681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4572a985-9286-4fb8-9e34-4a99c689b13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_120f9e71-1007-4b36-82ec-322def44c681" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_4572a985-9286-4fb8-9e34-4a99c689b13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8b083b13-54f6-4381-b63b-9959ef58f846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_120f9e71-1007-4b36-82ec-322def44c681" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_8b083b13-54f6-4381-b63b-9959ef58f846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_53b92952-89ed-42a7-b804-14d7219f2ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_120f9e71-1007-4b36-82ec-322def44c681" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_53b92952-89ed-42a7-b804-14d7219f2ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b935267b-fe4e-41e5-9c54-135baa6d6a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_120f9e71-1007-4b36-82ec-322def44c681" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b935267b-fe4e-41e5-9c54-135baa6d6a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02acd128-6531-4ea2-98fe-27027fc52aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_00b95373-fdba-42e3-915f-c0d4827475c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02acd128-6531-4ea2-98fe-27027fc52aea" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_00b95373-fdba-42e3-915f-c0d4827475c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02acd128-6531-4ea2-98fe-27027fc52aea" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:to="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9a101b56-debc-4ec5-9dcf-4e7feb089aa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_85ff5e0a-fa5b-47e1-b450-69dd3561fc75" xlink:to="loc_srt_OwnershipDomain_9a101b56-debc-4ec5-9dcf-4e7feb089aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_b6c7e874-9ce4-459d-874a-ed837b770cb9" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_9a101b56-debc-4ec5-9dcf-4e7feb089aa7" xlink:to="loc_bhc_BauschLombMember_b6c7e874-9ce4-459d-874a-ed837b770cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable_0e9503be-0bcc-4f81-b8a6-9dd5e9511607" xlink:to="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_943d83eb-f22e-4db4-8f45-344504227bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_943d83eb-f22e-4db4-8f45-344504227bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_bd7f55f6-5920-4176-a957-e1914f26dd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems_672d3617-bb69-4a31-be4d-2d6d51c59a54" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_bd7f55f6-5920-4176-a957-e1914f26dd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_58a786f8-ae49-492c-9b20-b9c34f277cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_58a786f8-ae49-492c-9b20-b9c34f277cd2" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23312c71-08a8-4dde-af94-47de761567b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3069a890-666c-444d-b406-9310d6f830e4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23312c71-08a8-4dde-af94-47de761567b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_afeee29d-0c10-42f0-a739-954d33df5769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23312c71-08a8-4dde-af94-47de761567b0" xlink:to="loc_us-gaap_IPOMember_afeee29d-0c10-42f0-a739-954d33df5769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:to="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c3977eb1-3470-4b20-905a-e8505ca2ff1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b0635df5-aadf-4001-a2a8-37798f144762" xlink:to="loc_srt_OwnershipDomain_c3977eb1-3470-4b20-905a-e8505ca2ff1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e607860a-c7cf-4b59-a860-e89b995eb4ba" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_c3977eb1-3470-4b20-905a-e8505ca2ff1b" xlink:to="loc_bhc_BauschLombMember_e607860a-c7cf-4b59-a860-e89b995eb4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6f13a631-131d-4d70-b3b6-74d58a6a38a5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c2993c56-17de-44eb-a94f-69a9a953d7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c2993c56-17de-44eb-a94f-69a9a953d7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_850cfd39-c514-40b7-be1a-0a4b5e8177c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_850cfd39-c514-40b7-be1a-0a4b5e8177c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_65bbfd51-16da-4cb2-a33b-fe50f6627127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_46586061-9a7d-4ab0-8b80-fc63dcae26b6" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_65bbfd51-16da-4cb2-a33b-fe50f6627127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ada8d632-e310-4dcc-921f-94d63414db0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ada8d632-e310-4dcc-921f-94d63414db0f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c020089-220b-47d8-b58c-15625cbb71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d6b6ae45-d749-4070-9d9f-139c69d196c4" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c020089-220b-47d8-b58c-15625cbb71a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_6733aa16-8b6e-46fe-b7e1-c9fd5f2f5fc5" xlink:href="bhc-20230331.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_5c020089-220b-47d8-b58c-15625cbb71a2" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_6733aa16-8b6e-46fe-b7e1-c9fd5f2f5fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:to="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b93cd5f-dfe9-45b5-890f-2aa1b54619c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_380ef17b-05ae-4e5b-9c90-7667cc423640" xlink:to="loc_srt_ProductsAndServicesDomain_9b93cd5f-dfe9-45b5-890f-2aa1b54619c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_90ca3403-5fb5-48a2-80a2-9663b208dd26" xlink:href="bhc-20230331.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9b93cd5f-dfe9-45b5-890f-2aa1b54619c5" xlink:to="loc_bhc_PriceAppreciationCreditMember_90ca3403-5fb5-48a2-80a2-9663b208dd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_75a9d61a-1e5d-4a3d-9135-5f2398b03be4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_f1a814b4-0cd5-4676-b3cd-97599222b2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_f1a814b4-0cd5-4676-b3cd-97599222b2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb9e5080-8c82-4f61-ab94-46971f9c7904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_8850938e-ece4-42c4-8170-465fff901193" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb9e5080-8c82-4f61-ab94-46971f9c7904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITIONVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9713a85-f9ec-499f-bd24-fee9ea7d029a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f9713a85-f9ec-499f-bd24-fee9ea7d029a" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_51f58c89-eb6a-4846-bbca-a76ba719f000" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_3d8de10d-4c4c-4d8c-aa2d-a4c0b534e656" xlink:href="bhc-20230331.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_3d8de10d-4c4c-4d8c-aa2d-a4c0b534e656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_2f3bb2ad-d21d-498e-a6e0-9d01ce82929e" xlink:href="bhc-20230331.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_2f3bb2ad-d21d-498e-a6e0-9d01ce82929e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_cc65183f-833d-45d4-aa4e-df977aee8130" xlink:href="bhc-20230331.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForRebatesMember_cc65183f-833d-45d4-aa4e-df977aee8130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_439c807a-cfb1-4f09-ae17-161d9309dd69" xlink:href="bhc-20230331.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForChargebacksMember_439c807a-cfb1-4f09-ae17-161d9309dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_84867274-86d0-48d5-a10d-210f26e0ea05" xlink:href="bhc-20230331.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_f5dc0c75-9535-4a0b-b982-acde440aab11" xlink:to="loc_bhc_ReserveForDistributionFeesMember_84867274-86d0-48d5-a10d-210f26e0ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_94600bbb-4af3-4a7c-9952-779777a7fdd0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_23a0a44d-7dff-4f32-b1a2-697a807381ea" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_94600bbb-4af3-4a7c-9952-779777a7fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_94600bbb-4af3-4a7c-9952-779777a7fdd0" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_4648fe2f-64f3-41dc-a1fd-c31e16996761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_4648fe2f-64f3-41dc-a1fd-c31e16996761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7a8ac968-ca49-4586-b19b-4f883271676a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_7a8ac968-ca49-4586-b19b-4f883271676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_948490d7-6ab8-479a-a893-41df0a7cd4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_948490d7-6ab8-479a-a893-41df0a7cd4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6b4032b-24cd-4069-bd4f-042779f50080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_7344067b-0721-4e06-b42c-5a792cbfe220" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e6b4032b-24cd-4069-bd4f-042779f50080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19e05eb3-af5b-4c26-a968-9be27666b9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19e05eb3-af5b-4c26-a968-9be27666b9c7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_96fdb082-8df4-4608-91d7-66c971569948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_96fdb082-8df4-4608-91d7-66c971569948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_7b104009-0170-4a9c-b769-e8cd0c2b7230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_7b104009-0170-4a9c-b769-e8cd0c2b7230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_74425fa4-b955-46c0-a8a5-6777726da720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_74425fa4-b955-46c0-a8a5-6777726da720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_3a313db0-e95d-47b5-8ef1-7b0e7e37e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_3a313db0-e95d-47b5-8ef1-7b0e7e37e87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_00f9d6b1-a4ba-4745-ac02-33e6bc0c33a5" xlink:href="bhc-20230331.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_00f9d6b1-a4ba-4745-ac02-33e6bc0c33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f02d420b-e302-48ae-bd76-e1cc50c16e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_a0d80c80-7c03-4ac6-8261-265432c5e744" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_f02d420b-e302-48ae-bd76-e1cc50c16e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b453a64a-7ebd-47f3-b405-a31f12d97f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b453a64a-7ebd-47f3-b405-a31f12d97f21" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d33d81d-6ae5-42fc-9863-a7df2ba526a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_639437eb-9072-4877-a4e4-7a08c22c37fe" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d33d81d-6ae5-42fc-9863-a7df2ba526a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcuFocusIncAcquisitionMember_b91c804c-4447-44b3-a418-5935f36b8e44" xlink:href="bhc-20230331.xsd#bhc_AcuFocusIncAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d33d81d-6ae5-42fc-9863-a7df2ba526a0" xlink:to="loc_bhc_AcuFocusIncAcquisitionMember_b91c804c-4447-44b3-a418-5935f36b8e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:to="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4e8a1714-88b8-47e4-afd9-37c894428f7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_db54fc5d-7991-4448-903e-d3dad2e3a5c3" xlink:to="loc_dei_EntityDomain_4e8a1714-88b8-47e4-afd9-37c894428f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_a5ca70d3-884c-470b-961f-ae047c9dbaf0" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4e8a1714-88b8-47e4-afd9-37c894428f7b" xlink:to="loc_bhc_BauschLombMember_a5ca70d3-884c-470b-961f-ae047c9dbaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78c99741-0388-4a5e-b6a5-fd562ffdff19" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_466b60ed-7133-4cc1-9658-810f57611f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_466b60ed-7133-4cc1-9658-810f57611f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_41719d8b-95c5-4848-9e69-5737015bf154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_41719d8b-95c5-4848-9e69-5737015bf154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_1628f2ac-a19b-4636-a163-c44f191383c0" xlink:href="bhc-20230331.xsd#bhc_BusinessAcquisitionMaximumTermForRemainingPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_bhc_BusinessAcquisitionMaximumTermForRemainingPayment_1628f2ac-a19b-4636-a163-c44f191383c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c3255bf6-1427-4ff1-8571-edead318ea3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c3255bf6-1427-4ff1-8571-edead318ea3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c0941935-3d83-462e-adb1-68fa2f794459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c0941935-3d83-462e-adb1-68fa2f794459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bc757159-a8c2-441c-864a-f41b8109c46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_Goodwill_bc757159-a8c2-441c-864a-f41b8109c46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_530160a5-4320-4c63-83f1-54b4f8556724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_530160a5-4320-4c63-83f1-54b4f8556724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_99feb7ad-6def-4e87-886a-165d85dca269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_65b7c40b-c747-465e-8df1-8c345e65d01d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_99feb7ad-6def-4e87-886a-165d85dca269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d394e0c4-77f4-4331-9729-a5b837e80a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d394e0c4-77f4-4331-9729-a5b837e80a87" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_79928972-0de5-4af5-b373-1566513a71b3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_43090080-98e6-4e7b-9a53-24a4dd12bdc5" xlink:href="bhc-20230331.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_43090080-98e6-4e7b-9a53-24a4dd12bdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_db2becd4-c9d8-4279-9108-81a5dd1171d9" xlink:href="bhc-20230331.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_fcbcf1e6-cf4e-4efe-8b10-170bb9ecbca1" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_db2becd4-c9d8-4279-9108-81a5dd1171d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_109dfc50-1285-4be1-8edf-12b2aa2cf15c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0f0012b7-68a0-4926-a085-7932b6f10bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_0f0012b7-68a0-4926-a085-7932b6f10bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_47195d6f-de06-4d88-a4b0-3ce7e38d79ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_RestructuringCharges_47195d6f-de06-4d88-a4b0-3ce7e38d79ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cbc27bc6-abfa-4e74-b774-45c2b9341c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_ed5f37f0-99fe-4738-9717-dce1a59ef6e8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_cbc27bc6-abfa-4e74-b774-45c2b9341c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f1648db8-379d-4a99-a2af-16dde5bedce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f1648db8-379d-4a99-a2af-16dde5bedce6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4be9bdbc-0893-44ae-ba37-656c14502f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_613b512e-e03d-4548-9d18-92b07c149128" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4be9bdbc-0893-44ae-ba37-656c14502f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_04aab7d0-4dbb-412d-ab30-1aba04a4622f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4be9bdbc-0893-44ae-ba37-656c14502f16" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_04aab7d0-4dbb-412d-ab30-1aba04a4622f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_125e4875-8db3-4ccb-8cea-578f35415b76" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_513825f9-77c2-4017-a500-8f270c230dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_513825f9-77c2-4017-a500-8f270c230dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_515c5f78-4573-48e3-a26f-085adf05a5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_515c5f78-4573-48e3-a26f-085adf05a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f9b86247-dd8e-4ae4-9f18-4a995b95fb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9bc04233-ca01-41bd-b838-98c5beb00186" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f9b86247-dd8e-4ae4-9f18-4a995b95fb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fc56eec6-095a-4ab0-a5b0-ffa614cb36f9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1b1617af-2e8c-4d3e-bf1c-21b9f1deaf41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:to="loc_us-gaap_CurrencySwapMember_1b1617af-2e8c-4d3e-bf1c-21b9f1deaf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_48585e91-badb-4475-b189-0f4b8ac33565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cfe90100-c615-48b2-901a-c7cf1f5875f2" xlink:to="loc_us-gaap_ForeignExchangeContractMember_48585e91-badb-4475-b189-0f4b8ac33565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_849ae74c-df9f-4b63-bc0a-7c2d807b7990" xlink:to="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_7713432f-b9fa-416b-8236-a51426c4b760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:to="loc_us-gaap_NondesignatedMember_7713432f-b9fa-416b-8236-a51426c4b760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9076217e-0f7a-4d75-8c56-cd92dac872db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_69d0575a-9b12-4963-a68a-549887c67c4f" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_9076217e-0f7a-4d75-8c56-cd92dac872db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_3d5d35f8-e923-460c-baf5-a18c63b41289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_07b31a32-ce0c-4cf7-930c-17a50a84a9e2" xlink:to="loc_us-gaap_HedgingRelationshipDomain_3d5d35f8-e923-460c-baf5-a18c63b41289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_60353176-88b6-49e1-bfed-161629f64ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_3d5d35f8-e923-460c-baf5-a18c63b41289" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_60353176-88b6-49e1-bfed-161629f64ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e56bedab-6918-4683-86ed-4812e3469f14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0c7a4d1b-a2bb-440a-a757-7683e141d1e4" xlink:to="loc_dei_EntityDomain_e56bedab-6918-4683-86ed-4812e3469f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_88ef6f2e-56cd-4aec-a815-92de35d859d9" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e56bedab-6918-4683-86ed-4812e3469f14" xlink:to="loc_bhc_BauschLombMember_88ef6f2e-56cd-4aec-a815-92de35d859d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_080c320c-9242-4c17-bebf-97fe098414bc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_92d6fa73-cfb8-4625-8026-5290a45474d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_92d6fa73-cfb8-4625-8026-5290a45474d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5bc7a1bd-ebec-4913-9918-fbfc6e56ba71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:to="loc_us-gaap_RestrictedCashCurrent_5bc7a1bd-ebec-4913-9918-fbfc6e56ba71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6aadba33-cbfc-49fc-b440-c93431703325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53790909-0c9b-422d-8e79-480d148fccb8" xlink:to="loc_us-gaap_DerivativeAssets_6aadba33-cbfc-49fc-b440-c93431703325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9c7452e3-f0fd-4d04-a6cb-b7033b7b73b7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_89ef0466-4787-4ca0-b0e2-d502414e020f" xlink:href="bhc-20230331.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_89ef0466-4787-4ca0-b0e2-d502414e020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_d2e10663-08f1-48b6-b80c-c5863a653554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e8df8ce3-f8c8-4659-b0cb-bc1c77fda20c" xlink:to="loc_us-gaap_DerivativeLiabilities_d2e10663-08f1-48b6-b80c-c5863a653554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_730212e7-2640-41db-826a-942a765f6fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_730212e7-2640-41db-826a-942a765f6fa9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8f75b0c3-e423-48b6-a1b8-ab7c90f122d5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_95b2803a-2d95-4887-8832-e6e6b71efd53" xlink:to="loc_srt_LitigationCaseTypeDomain_8f75b0c3-e423-48b6-a1b8-ab7c90f122d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_e67b251c-ffe2-4d52-8936-98be69d59ba7" xlink:href="bhc-20230331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_8f75b0c3-e423-48b6-a1b8-ab7c90f122d5" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_e67b251c-ffe2-4d52-8936-98be69d59ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_659b77b7-f1d1-40e0-b9eb-a7134b2d0f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_41d824d0-7ad9-46a7-a533-88143a50e1e5" xlink:to="loc_us-gaap_LitigationStatusDomain_659b77b7-f1d1-40e0-b9eb-a7134b2d0f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_6f4c4f94-64b5-4295-a497-cf64c98f550b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_659b77b7-f1d1-40e0-b9eb-a7134b2d0f17" xlink:to="loc_us-gaap_SettledLitigationMember_6f4c4f94-64b5-4295-a497-cf64c98f550b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_555e5e7c-9238-48d6-8514-409773ca9956" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1e746c72-adc5-4805-b4c6-b4c9216c7067" xlink:to="loc_srt_SegmentGeographicalDomain_555e5e7c-9238-48d6-8514-409773ca9956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_77cfcba4-0472-4260-9962-b35df74766c2" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_555e5e7c-9238-48d6-8514-409773ca9956" xlink:to="loc_stpr_NJ_77cfcba4-0472-4260-9962-b35df74766c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_acbe9339-a549-4007-b7b3-cce2716e3447" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c84989c1-2741-45e5-9d74-026ada93b3a4" xlink:to="loc_dei_EntityDomain_acbe9339-a549-4007-b7b3-cce2716e3447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_0fb9f145-8b98-49c0-ac40-1610dc941a14" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_acbe9339-a549-4007-b7b3-cce2716e3447" xlink:to="loc_bhc_BauschLombMember_0fb9f145-8b98-49c0-ac40-1610dc941a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1fe6816f-fc3f-4ec0-b06e-5e904ea1c87c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_545ee922-d3c4-44f3-a61a-2355040915bd" xlink:href="bhc-20230331.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_545ee922-d3c4-44f3-a61a-2355040915bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28d12bc5-c198-40a9-b6b6-4306d98148e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28d12bc5-c198-40a9-b6b6-4306d98148e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_87a20c6d-83b3-43e1-9619-38125c5a99eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_73cc6337-82f4-4abc-b860-b99b224d31c4" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_87a20c6d-83b3-43e1-9619-38125c5a99eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4637d936-8640-466a-87f5-38143cb7cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4637d936-8640-466a-87f5-38143cb7cc7e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_b183c712-12c3-4381-ae4c-9f6254c07061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_01c2fe16-3f59-4bfe-8416-f76586b22421" xlink:to="loc_us-gaap_HedgingRelationshipDomain_b183c712-12c3-4381-ae4c-9f6254c07061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_58be7852-aa4a-4619-947f-d334b749b229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_b183c712-12c3-4381-ae4c-9f6254c07061" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_58be7852-aa4a-4619-947f-d334b749b229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7ae50824-e8dc-47ee-b9e9-5aa2d551d1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_446b485d-697c-4d04-af38-0f87034ae195" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7ae50824-e8dc-47ee-b9e9-5aa2d551d1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_c487ce62-7908-4f68-a2e6-b40512a35ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7ae50824-e8dc-47ee-b9e9-5aa2d551d1f3" xlink:to="loc_us-gaap_CurrencySwapMember_c487ce62-7908-4f68-a2e6-b40512a35ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b6a3d8b1-b445-47f0-a4a6-2ed5aa9119c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_97d2585a-92c5-4193-b3ee-89e17f45ebde" xlink:to="loc_us-gaap_HedgingDesignationDomain_b6a3d8b1-b445-47f0-a4a6-2ed5aa9119c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e960beeb-2868-493d-ad64-96820ea1ea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_b6a3d8b1-b445-47f0-a4a6-2ed5aa9119c1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e960beeb-2868-493d-ad64-96820ea1ea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_80681dcd-d464-46d0-97cb-639aa7207280" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a7f7d837-a0a6-4d1d-aa6c-7de0fbe20eac" xlink:to="loc_dei_EntityDomain_80681dcd-d464-46d0-97cb-639aa7207280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_e1a76651-0a09-465b-90d6-95cdecc8eeb5" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_80681dcd-d464-46d0-97cb-639aa7207280" xlink:to="loc_bhc_BauschLombMember_e1a76651-0a09-465b-90d6-95cdecc8eeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cee6f640-8f5b-4037-92d6-ef87e300fcbb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_1171eb60-6740-422a-99b1-04f64b1937fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:to="loc_us-gaap_DerivativeNotionalAmount_1171eb60-6740-422a-99b1-04f64b1937fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_86437346-3673-469e-bcc1-90efcbe54d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6defe73f-102a-44a5-808a-10eeced3fabc" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_86437346-3673-469e-bcc1-90efcbe54d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_412e9f1d-9ff7-46c2-bd01-ae606a5de4be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_412e9f1d-9ff7-46c2-bd01-ae606a5de4be" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fbe93878-565e-45d3-abfb-3aaf91410998" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06ba00d2-a59f-4412-abd5-450b4a85d351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_06ba00d2-a59f-4412-abd5-450b4a85d351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ec423ae2-1abf-4a12-9436-ef4f50e0507e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0282a9b4-70b0-487c-b8dd-7833cc1865e0" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ec423ae2-1abf-4a12-9436-ef4f50e0507e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_46877843-0181-4e6d-b498-1b364f1a6988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_53335f83-a6e4-410e-afda-ea3c18799f97" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_46877843-0181-4e6d-b498-1b364f1a6988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_da0faa30-7698-4655-825b-6aa4f5367bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_46877843-0181-4e6d-b498-1b364f1a6988" xlink:to="loc_us-gaap_CurrencySwapMember_da0faa30-7698-4655-825b-6aa4f5367bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_92a73975-26f6-4e40-bcd9-34b330c6833b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5e1d602d-b737-4fe4-849d-7b888b6c07fe" xlink:to="loc_us-gaap_HedgingRelationshipDomain_92a73975-26f6-4e40-bcd9-34b330c6833b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_f9ce90f7-6e7a-4ac5-876b-9abb7c884afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_92a73975-26f6-4e40-bcd9-34b330c6833b" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_f9ce90f7-6e7a-4ac5-876b-9abb7c884afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_e3e76670-e972-469a-abaa-fb38d89fcef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6b71c3f3-e15c-418a-9836-152cb6ae7a81" xlink:to="loc_us-gaap_HedgingDesignationDomain_e3e76670-e972-469a-abaa-fb38d89fcef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b475c876-1cc1-49ba-aaa3-baaa86ad8c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_e3e76670-e972-469a-abaa-fb38d89fcef0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b475c876-1cc1-49ba-aaa3-baaa86ad8c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_41ba1ad5-e5c6-48b7-af5e-081656e24bae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5fe7d5ca-fe97-4a7d-ae23-3bee3eaae34c" xlink:to="loc_dei_EntityDomain_41ba1ad5-e5c6-48b7-af5e-081656e24bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c06139ec-cb0b-49ab-9af2-ebd553ae1371" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_41ba1ad5-e5c6-48b7-af5e-081656e24bae" xlink:to="loc_bhc_BauschLombMember_c06139ec-cb0b-49ab-9af2-ebd553ae1371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59061ef3-007e-493b-b21f-398387b7ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4c8a7ccf-886e-48b3-b65e-16e470322cbc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59061ef3-007e-493b-b21f-398387b7ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_d6c8f5e2-f3a0-4e39-982e-6aa8285fc8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_59061ef3-007e-493b-b21f-398387b7ec4e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_d6c8f5e2-f3a0-4e39-982e-6aa8285fc8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c80a1722-f5f5-480b-b059-27b641deb953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c80a1722-f5f5-480b-b059-27b641deb953" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_be8b2bb4-9084-4042-8e95-5a0e07534507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7f7b076b-284f-4bc7-b5a1-81a2fabc956e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_be8b2bb4-9084-4042-8e95-5a0e07534507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8f5e4838-3fd3-4048-8c4a-955f42c69fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_be8b2bb4-9084-4042-8e95-5a0e07534507" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8f5e4838-3fd3-4048-8c4a-955f42c69fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_94cb03dd-caac-4d90-8791-08bffc3b036b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_680653a2-4cfb-40b2-a933-5a49af70e31d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_94cb03dd-caac-4d90-8791-08bffc3b036b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_26b1f4ba-47c5-4cff-948b-e561ddbee2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_94cb03dd-caac-4d90-8791-08bffc3b036b" xlink:to="loc_us-gaap_CurrencySwapMember_26b1f4ba-47c5-4cff-948b-e561ddbee2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7d088e85-7f2f-4ef4-92f6-cacfc5719959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_6065b64f-adf5-482b-83c5-f34f011d98cd" xlink:to="loc_us-gaap_HedgingDesignationDomain_7d088e85-7f2f-4ef4-92f6-cacfc5719959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ac21b6f8-6220-43eb-a530-0c5e72e32ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7d088e85-7f2f-4ef4-92f6-cacfc5719959" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ac21b6f8-6220-43eb-a530-0c5e72e32ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_51abdcf0-15ee-4f63-8785-91eedd56b141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_607c6f68-75d8-431f-994b-59130bbd7e2d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_51abdcf0-15ee-4f63-8785-91eedd56b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_81fc3228-be2f-42f6-afda-c59d88d3cf61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_51abdcf0-15ee-4f63-8785-91eedd56b141" xlink:to="loc_us-gaap_InterestExpenseMember_81fc3228-be2f-42f6-afda-c59d88d3cf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a137e6b1-b87b-4f73-b3ee-a6bd26c16c31" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0a1ec2d0-2ea2-465b-9334-b35efcee80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_0a1ec2d0-2ea2-465b-9334-b35efcee80bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_93a85477-3109-46f0-bd4d-24f5a7b8674a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2ef6e12e-0427-4846-ac13-c3f07daef681" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_93a85477-3109-46f0-bd4d-24f5a7b8674a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8a4b5ff5-2271-4a72-b065-928dd7e8990c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8a4b5ff5-2271-4a72-b065-928dd7e8990c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:to="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7b91f058-d430-426c-8822-5b1ff7aa9068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_8919ec6a-f915-4219-adca-3b56351c8b63" xlink:to="loc_us-gaap_HedgingDesignationDomain_7b91f058-d430-426c-8822-5b1ff7aa9068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a30e5c8b-dd06-49e8-85a1-0ea303d901cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7b91f058-d430-426c-8822-5b1ff7aa9068" xlink:to="loc_us-gaap_NondesignatedMember_a30e5c8b-dd06-49e8-85a1-0ea303d901cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e7b25113-96e1-40bb-a02c-9bac18ac56f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_04c9fd1a-ab45-4c41-9078-71c6a65622d2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e7b25113-96e1-40bb-a02c-9bac18ac56f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_fd2dec78-a155-413f-9dab-227d227c764f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e7b25113-96e1-40bb-a02c-9bac18ac56f6" xlink:to="loc_us-gaap_ForeignExchangeContractMember_fd2dec78-a155-413f-9dab-227d227c764f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cac9b0ed-396c-4879-97e3-ce3eafa441f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c26190b8-1dbc-43ec-8e54-e7ef746b0131" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cac9b0ed-396c-4879-97e3-ce3eafa441f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_f7ba214c-d7fd-49a4-8f0e-4676232dd893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cac9b0ed-396c-4879-97e3-ce3eafa441f0" xlink:to="loc_us-gaap_DerivativeNotionalAmount_f7ba214c-d7fd-49a4-8f0e-4676232dd893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e1758b6b-578e-48f6-8b79-11ca75f78ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e1758b6b-578e-48f6-8b79-11ca75f78ef8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e5fcfc32-292e-4b75-9355-13d1a29be489" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_d40b4959-6790-4269-a182-14dd36596560" xlink:href="bhc-20230331.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_d40b4959-6790-4269-a182-14dd36596560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_af167c3c-b240-487b-8483-add083175b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_8515d37e-90ab-4a94-b6a8-aca9b9e23cc3" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_af167c3c-b240-487b-8483-add083175b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_181a2fa8-8f5a-46af-ae14-54b23133372b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2d681e90-ae91-400d-9f55-2d2fd8002c6b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_181a2fa8-8f5a-46af-ae14-54b23133372b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_e93ce20e-3b2a-4317-849f-caa64274ec7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_181a2fa8-8f5a-46af-ae14-54b23133372b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_e93ce20e-3b2a-4317-849f-caa64274ec7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_833b8e62-8e09-4dcc-b75c-9c81e3991ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_beacd44e-8935-4577-81d3-4d7edcb7e85c" xlink:to="loc_us-gaap_HedgingDesignationDomain_833b8e62-8e09-4dcc-b75c-9c81e3991ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_a103d471-3ddb-45a5-a548-87c20131157a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_833b8e62-8e09-4dcc-b75c-9c81e3991ad8" xlink:to="loc_us-gaap_NondesignatedMember_a103d471-3ddb-45a5-a548-87c20131157a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85dfe9f3-e869-4895-8a96-515d77e9c765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_50da53e6-da07-4a86-8d98-674c143ce8a7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85dfe9f3-e869-4895-8a96-515d77e9c765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_f3c1a93f-bd42-4cf1-a5d1-8edc675b8fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_85dfe9f3-e869-4895-8a96-515d77e9c765" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_f3c1a93f-bd42-4cf1-a5d1-8edc675b8fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8578bd5b-7a86-4ce8-9151-39a1813caa9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8578bd5b-7a86-4ce8-9151-39a1813caa9e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_36ff854a-d990-411b-bef5-605038e43d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3590646b-dc14-4a82-8a27-a65371da3a56" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_36ff854a-d990-411b-bef5-605038e43d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0d9aca4a-08cc-4bc5-8f9b-a7a42f6aabe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_36ff854a-d990-411b-bef5-605038e43d89" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0d9aca4a-08cc-4bc5-8f9b-a7a42f6aabe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:to="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0747a089-f4a2-4cde-be95-c06aa9e253a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7fb37a1d-eee1-45f1-8571-0103058197cf" xlink:to="loc_us-gaap_HedgingDesignationDomain_0747a089-f4a2-4cde-be95-c06aa9e253a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_df086aa1-c3a2-414b-8105-84b069b03c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0747a089-f4a2-4cde-be95-c06aa9e253a8" xlink:to="loc_us-gaap_NondesignatedMember_df086aa1-c3a2-414b-8105-84b069b03c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e4234bee-6754-45f6-98b4-92a5fbf5f0c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2fd469e5-5f81-4c66-a382-2cd93065e655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2fd469e5-5f81-4c66-a382-2cd93065e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3154caef-7990-491b-9889-6aec6262fb18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3154caef-7990-491b-9889-6aec6262fb18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_b25082a7-2804-4c49-b815-37aacc459221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_cdf2a282-e961-488b-a886-0ec8e1449643" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain_b25082a7-2804-4c49-b815-37aacc459221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dd1f231e-809d-42b1-8ed6-7e5b1fa4ab66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dd1f231e-809d-42b1-8ed6-7e5b1fa4ab66" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_75d7adf1-bd9a-4587-ba9e-3b7e57e3ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_05fe523b-1bbf-477b-994a-b0f78787b398" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_75d7adf1-bd9a-4587-ba9e-3b7e57e3ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_55a2227b-4f7c-4dff-abfa-920b0a0a9823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_75d7adf1-bd9a-4587-ba9e-3b7e57e3ef6b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_55a2227b-4f7c-4dff-abfa-920b0a0a9823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_865fe458-b786-4fc1-b77d-d7779c639034" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4a3ff0b8-b699-46d7-8096-5bc44ba3f0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4a3ff0b8-b699-46d7-8096-5bc44ba3f0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_f71f2fd7-6952-48b0-9c71-f4d2849d5620" xlink:href="bhc-20230331.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_00387645-e576-4bc1-abf1-a2654d60bde1" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_f71f2fd7-6952-48b0-9c71-f4d2849d5620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a699bed8-930a-40d3-9e92-b2ce5f420f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ab468ebd-48d3-424b-ad1b-a246b4e3089a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a699bed8-930a-40d3-9e92-b2ce5f420f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_fcdd85d2-b4a4-4371-b073-7f255b0844b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a699bed8-930a-40d3-9e92-b2ce5f420f0b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_fcdd85d2-b4a4-4371-b073-7f255b0844b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_81089ea6-f033-4440-b650-43e5272d1020" xlink:to="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eddb8a6a-405f-4307-89de-44d64748a0b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:to="loc_srt_MinimumMember_eddb8a6a-405f-4307-89de-44d64748a0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3a62c23c-9e17-467c-b3d8-846225e2198a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f6d50475-aaf2-46ae-99be-1fdcfda07084" xlink:to="loc_srt_MaximumMember_3a62c23c-9e17-467c-b3d8-846225e2198a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14d1afc6-987d-43c0-85d5-91c40549b921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_22bb8358-c246-455d-8489-b14e794b1b3c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14d1afc6-987d-43c0-85d5-91c40549b921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_525355d3-290d-4a15-a170-f29a93c8fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_14d1afc6-987d-43c0-85d5-91c40549b921" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_525355d3-290d-4a15-a170-f29a93c8fe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5a1f7417-0354-4a67-a485-823cf2ed7012" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5a1f7417-0354-4a67-a485-823cf2ed7012" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_71bb0c0c-7a38-4216-9bb3-018ae2dbc965" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_92b6a799-652e-454e-a163-3a20bc2a4979" xlink:href="bhc-20230331.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_92b6a799-652e-454e-a163-3a20bc2a4979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_78ee1b71-47f6-4997-969f-ddbf3faad5a5" xlink:href="bhc-20230331.xsd#bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_08968705-1719-4339-bf2f-ab91cc6baeb3" xlink:to="loc_bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember_78ee1b71-47f6-4997-969f-ddbf3faad5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_8442869d-de83-4a74-925d-ce992ef24c29" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74e7a5ae-28ed-4948-97a3-a33aeee45b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_74e7a5ae-28ed-4948-97a3-a33aeee45b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1d6c594e-b36c-4f01-ae9c-ee8797bc8576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1d6c594e-b36c-4f01-ae9c-ee8797bc8576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f6e47ffe-0e60-4615-aa3d-f9d654fd58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f6e47ffe-0e60-4615-aa3d-f9d654fd58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43bfca76-f54a-4961-882d-07e9258af2ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43bfca76-f54a-4961-882d-07e9258af2ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0079f578-9b15-48b3-9049-77e3888ccfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0079f578-9b15-48b3-9049-77e3888ccfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0652ee7a-44a5-4acf-8261-fcef0346f658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0652ee7a-44a5-4acf-8261-fcef0346f658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_02d815c0-41a3-477f-9127-7cf8d2997384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c9d72948-a49d-4e68-b73e-e4e097f3f2ff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_02d815c0-41a3-477f-9127-7cf8d2997384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_7acd3c2e-8548-4960-9811-d95475432efa" xlink:href="bhc-20230331.xsd#bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_6ceefb25-219a-4131-98da-b17bbb4f2a33" xlink:to="loc_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag_7acd3c2e-8548-4960-9811-d95475432efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9ea39f35-947c-4b7b-b40e-fb0fdc11f2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9ea39f35-947c-4b7b-b40e-fb0fdc11f2c6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd7f1c07-23e3-43ea-9102-ccc63dfb0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_6af742de-fc7b-4ddd-b69d-b362e557fb4e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd7f1c07-23e3-43ea-9102-ccc63dfb0ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_fdb94f16-3d58-42ae-a19e-329ac0a95c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_dd7f1c07-23e3-43ea-9102-ccc63dfb0ed6" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_fdb94f16-3d58-42ae-a19e-329ac0a95c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3999487a-cadc-4e64-b0c0-0081f2203f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_70a976cf-37b7-457a-80e7-b49f0e1bdec5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3999487a-cadc-4e64-b0c0-0081f2203f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_65f6449a-52ad-48fd-a336-13e8d6f31549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3999487a-cadc-4e64-b0c0-0081f2203f98" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_65f6449a-52ad-48fd-a336-13e8d6f31549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e118e73-931a-41b9-9b20-c8133298458b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_79a96cbb-506d-4f2d-a577-d775e7933122" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e118e73-931a-41b9-9b20-c8133298458b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_ec4eeba3-e204-4eb8-a699-e0af7d5b9786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e118e73-931a-41b9-9b20-c8133298458b" xlink:to="loc_us-gaap_DebtInstrumentFairValue_ec4eeba3-e204-4eb8-a699-e0af7d5b9786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INVENTORIESComponentsofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bec4e895-4117-401f-a65f-16089e9d1681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_5fe3c237-5756-442e-8ab5-514889853d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bec4e895-4117-401f-a65f-16089e9d1681" xlink:to="loc_us-gaap_InventoryRawMaterials_5fe3c237-5756-442e-8ab5-514889853d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5e0eb5e4-5ad6-4ead-b27d-333b483b2676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bec4e895-4117-401f-a65f-16089e9d1681" xlink:to="loc_us-gaap_InventoryWorkInProcess_5e0eb5e4-5ad6-4ead-b27d-333b483b2676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_9163970a-d5b1-4a88-a6bd-f33d64d1e9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bec4e895-4117-401f-a65f-16089e9d1681" xlink:to="loc_us-gaap_InventoryFinishedGoods_9163970a-d5b1-4a88-a6bd-f33d64d1e9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d1b9e7f3-f13b-4aa4-ba50-87946c74fd79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bec4e895-4117-401f-a65f-16089e9d1681" xlink:to="loc_us-gaap_InventoryGross_d1b9e7f3-f13b-4aa4-ba50-87946c74fd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_57e653f9-7809-4219-95ee-2114ca14857e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:href="bhc-20230331.xsd#bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_57e653f9-7809-4219-95ee-2114ca14857e" xlink:to="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_87251075-f102-4b1f-8ab1-f46befd3781a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_bf7a8eed-5242-4033-8932-58db99a0f9f4" xlink:href="bhc-20230331.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_bhc_ProductBrandsMember_bf7a8eed-5242-4033-8932-58db99a0f9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_9ef136d8-e579-4f06-8f71-c39fc4072074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_us-gaap_TradeNamesMember_9ef136d8-e579-4f06-8f71-c39fc4072074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_84bb8c58-b8b4-48b6-9026-5ac2cb3e47f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_us-gaap_ContractualRightsMember_84bb8c58-b8b4-48b6-9026-5ac2cb3e47f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_f8d3060f-278c-4e0f-a576-5e843fc35e8e" xlink:href="bhc-20230331.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_bhc_PartnerRelationshipsMember_f8d3060f-278c-4e0f-a576-5e843fc35e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_a863ea9a-131f-4b1e-9932-4403fe3325fa" xlink:href="bhc-20230331.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2e482e8-13da-4afa-bd23-06b2ccbc77c3" xlink:to="loc_bhc_OutLicensedTechnologyMember_a863ea9a-131f-4b1e-9932-4403fe3325fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfe60c2c-b279-4ef5-b9c9-e31f13144310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_57a26b5b-8224-471b-8398-4d086d2023ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfe60c2c-b279-4ef5-b9c9-e31f13144310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_a43c759f-588b-4249-88dd-8d25b92899a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_dfe60c2c-b279-4ef5-b9c9-e31f13144310" xlink:to="loc_us-gaap_TrademarksMember_a43c759f-588b-4249-88dd-8d25b92899a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:href="bhc-20230331.xsd#bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable_4f31a524-d07e-45b9-9c25-617e6fc796fb" xlink:to="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8c03b6ab-c9f8-4992-9c0d-233e528f2a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8c03b6ab-c9f8-4992-9c0d-233e528f2a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aeb5dc86-5e7a-4480-b2fb-9dcd8708cbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aeb5dc86-5e7a-4480-b2fb-9dcd8708cbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65195c48-c26f-4c7e-be6d-b1f9891c77f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_c9135bc6-2003-465e-a0f8-4fb6f96407c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_65195c48-c26f-4c7e-be6d-b1f9891c77f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5faf455c-dba9-4b16-a2c7-79658dcce214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5faf455c-dba9-4b16-a2c7-79658dcce214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3a1744b8-0e82-48dc-9d52-03737efc2993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_5faf455c-dba9-4b16-a2c7-79658dcce214" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_3a1744b8-0e82-48dc-9d52-03737efc2993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_647bf4cf-e14c-46f4-8429-e51aee531d5d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b15f4f9d-82b9-4113-bd59-d600b2c914ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_b15f4f9d-82b9-4113-bd59-d600b2c914ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83bf0bf2-626a-44af-885b-c8bb7e093dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_a4d753c6-8457-4f1c-b58d-e85fd7a772be" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_83bf0bf2-626a-44af-885b-c8bb7e093dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bfea642f-1a83-4bd0-bf2b-f5e10583aef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bfea642f-1a83-4bd0-bf2b-f5e10583aef1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07ccfac8-2046-4351-ae58-bbb342e81478" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeNamesNoLongerUsedMember_5cb677c3-2028-458b-aee3-08f5fa75f962" xlink:href="bhc-20230331.xsd#bhc_TradeNamesNoLongerUsedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:to="loc_bhc_TradeNamesNoLongerUsedMember_5cb677c3-2028-458b-aee3-08f5fa75f962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_c7429472-e7e2-4baf-9bdc-d8d6f7cb32cf" xlink:href="bhc-20230331.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4191c8e8-198f-4495-894a-6b6833b8a56f" xlink:to="loc_bhc_DiscontinuedProductLinesMember_c7429472-e7e2-4baf-9bdc-d8d6f7cb32cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_32d06da3-b3b1-4056-99ca-7adb45327311" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_57063c39-4061-42fe-9466-a31cd54696fc" xlink:to="loc_srt_ProductsAndServicesDomain_32d06da3-b3b1-4056-99ca-7adb45327311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_3a892bcf-3b7d-4266-a38e-b29a468546a0" xlink:href="bhc-20230331.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_32d06da3-b3b1-4056-99ca-7adb45327311" xlink:to="loc_bhc_XifaxanBrandedProductsMember_3a892bcf-3b7d-4266-a38e-b29a468546a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9c8d049d-dc37-4c28-9e10-9d415a3bdf27" xlink:to="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f0e2659-d44c-4672-a72a-26055a72cabc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:to="loc_srt_MinimumMember_6f0e2659-d44c-4672-a72a-26055a72cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_607763a2-e0f4-49bb-b876-8876b91e5502" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7cf1393-1bcb-45ce-b2c6-d3477f0ff4e5" xlink:to="loc_srt_MaximumMember_607763a2-e0f4-49bb-b876-8876b91e5502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_d3248ea2-1f8a-405d-ac65-b73a82ee137a" xlink:to="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DermatologyReportingUnitMember_c7d1a543-7a71-406e-8389-55baf01558dc" xlink:href="bhc-20230331.xsd#bhc_DermatologyReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_DermatologyReportingUnitMember_c7d1a543-7a71-406e-8389-55baf01558dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_052eab52-2dc4-4105-9591-2d08a8e9195f" xlink:href="bhc-20230331.xsd#bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember_052eab52-2dc4-4105-9591-2d08a8e9195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixReportingUnitMember_b9ba9825-c083-4824-bd53-5adc393438e7" xlink:href="bhc-20230331.xsd#bhc_SalixReportingUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_SalixReportingUnitMember_b9ba9825-c083-4824-bd53-5adc393438e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NeurologyAndOtherReportingUnitMember_0114c33b-0a28-4f6d-b091-c8226f36431c" xlink:href="bhc-20230331.xsd#bhc_NeurologyAndOtherReportingUnitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_987e250e-cc98-42e0-ba4d-a96d90810ff7" xlink:to="loc_bhc_NeurologyAndOtherReportingUnitMember_0114c33b-0a28-4f6d-b091-c8226f36431c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3eda7d9b-fccc-4768-a762-205ac1e9ca93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8ff2427b-7d95-4c1a-8dcc-bba10d95bde8" xlink:to="loc_us-gaap_SegmentDomain_3eda7d9b-fccc-4768-a762-205ac1e9ca93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_edcc7916-5e0d-4222-85db-28b7f626c433" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3eda7d9b-fccc-4768-a762-205ac1e9ca93" xlink:to="loc_bhc_SalixSegmentMember_edcc7916-5e0d-4222-85db-28b7f626c433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_491f7599-2f5d-4afa-8a56-2dd28481f09f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_23a71948-e63f-408c-b3db-38d8abb1ed39" xlink:to="loc_dei_EntityDomain_491f7599-2f5d-4afa-8a56-2dd28481f09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_20b28c8f-b90f-4ae3-999d-090d610dabea" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_491f7599-2f5d-4afa-8a56-2dd28481f09f" xlink:to="loc_bhc_BauschLombMember_20b28c8f-b90f-4ae3-999d-090d610dabea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0ffb0ef-d765-4f49-b745-69e8644581a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a7e0108a-02fb-4db3-860e-8556397b3e48" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0ffb0ef-d765-4f49-b745-69e8644581a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_992e3612-c51f-4d4e-b3f1-e955ef9f5114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0ffb0ef-d765-4f49-b745-69e8644581a8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_992e3612-c51f-4d4e-b3f1-e955ef9f5114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cbf42b01-832e-4046-9587-38ed63fe3440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_af5d1dcb-7865-4478-8933-351416be6ea8" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cbf42b01-832e-4046-9587-38ed63fe3440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_f8763fa7-fc16-49c3-ad7b-e84caf6c00e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_cbf42b01-832e-4046-9587-38ed63fe3440" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_f8763fa7-fc16-49c3-ad7b-e84caf6c00e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1980d430-11bc-4d77-9d92-7cffb2d4fed9" xlink:to="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b9b22982-6e35-4f11-bf14-0f68f706154f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_AssetImpairmentCharges_b9b22982-6e35-4f11-bf14-0f68f706154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7b815fa4-31f0-483a-b0ba-3fe36c395d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7b815fa4-31f0-483a-b0ba-3fe36c395d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b7bb8c77-1421-4633-b245-20316360fe23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b7bb8c77-1421-4633-b245-20316360fe23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c6bcf814-43aa-4d4e-963a-35d9b963fe88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c6bcf814-43aa-4d4e-963a-35d9b963fe88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_5ae2943d-e7b6-4fb6-8e37-11e5f0745e27" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_5ae2943d-e7b6-4fb6-8e37-11e5f0745e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_7db6ec33-481e-4a57-acc6-631751cd64ed" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_7db6ec33-481e-4a57-acc6-631751cd64ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_6f8a196a-3173-4a33-b4e6-0b91275e1f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_6f8a196a-3173-4a33-b4e6-0b91275e1f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_54f0eaa7-ced9-4581-af75-17d535989a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_54f0eaa7-ced9-4581-af75-17d535989a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_23ae0815-2a03-45cc-a0d1-de08e4a78e84" xlink:href="bhc-20230331.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate_23ae0815-2a03-45cc-a0d1-de08e4a78e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_69d17cdf-d2e8-40e4-b89c-1d7d29598aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_NumberOfReportingUnits_69d17cdf-d2e8-40e4-b89c-1d7d29598aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3dcb081e-72a1-4506-8f3b-04765fc4fefc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_Goodwill_3dcb081e-72a1-4506-8f3b-04765fc4fefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_49014b9c-a3cb-4fa5-8691-020e52f5952b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_49014b9c-a3cb-4fa5-8691-020e52f5952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f1e88c5b-5104-49ef-9d82-d8230f8505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ce4c50c8-7f06-4c9a-ab7b-1be977cc19c3" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_f1e88c5b-5104-49ef-9d82-d8230f8505ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_64b54530-0b0f-42a4-9fb2-7be87281fe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_64b54530-0b0f-42a4-9fb2-7be87281fe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_92272297-63ac-4feb-98ed-a00aadefd830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_92272297-63ac-4feb-98ed-a00aadefd830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bd497dc8-cf13-481a-acf3-d52ba1718086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bd497dc8-cf13-481a-acf3-d52ba1718086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dee6e7be-d41b-4f98-ae50-72d70895c7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dee6e7be-d41b-4f98-ae50-72d70895c7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_126ea947-6f8a-4b9d-a29c-619c1c4fde59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_126ea947-6f8a-4b9d-a29c-619c1c4fde59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_28fe03a7-b682-4220-ac7b-88bc5237717c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_28fe03a7-b682-4220-ac7b-88bc5237717c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9d143cdf-63db-47d4-9236-2ca073046ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9d143cdf-63db-47d4-9236-2ca073046ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9362e53a-32d3-4b16-9fbb-d924851069f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b8277fff-a598-4523-86a1-e79502c9348a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9362e53a-32d3-4b16-9fbb-d924851069f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_388bd8f6-be47-4525-891e-5cc4d2dbd66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_388bd8f6-be47-4525-891e-5cc4d2dbd66c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_91fd33d2-be48-44db-8ea4-67a68db2b155" xlink:to="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_94912ca2-6b06-4336-8bad-b905403af51d" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_BauschLombMember_94912ca2-6b06-4336-8bad-b905403af51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_4102c7b6-90ad-42d4-8527-da48941b1aa8" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_SalixSegmentMember_4102c7b6-90ad-42d4-8527-da48941b1aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_9871cc99-b673-4153-90ef-3d087b7ca835" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_InternationalRxMember_9871cc99-b673-4153-90ef-3d087b7ca835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DermatologySegmentMember_eee7590c-964e-4e0d-928a-3a4c8cf66999" xlink:href="bhc-20230331.xsd#bhc_DermatologySegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_DermatologySegmentMember_eee7590c-964e-4e0d-928a-3a4c8cf66999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_d103fd8d-4efc-4a0f-ada8-6b72985e0503" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_SoltaMedicalSegmentMember_d103fd8d-4efc-4a0f-ada8-6b72985e0503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember_3edb68be-b028-4088-9253-c9402c756065" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3447ace7-4731-44ab-845b-fd79a72169a9" xlink:to="loc_bhc_DiversifiedSegmentMember_3edb68be-b028-4088-9253-c9402c756065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f5e4ebab-b2df-4935-a2fd-102e98cf5a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_b4f3e361-5d36-4037-9232-4023dd5575b8" xlink:to="loc_us-gaap_GoodwillLineItems_f5e4ebab-b2df-4935-a2fd-102e98cf5a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f5e4ebab-b2df-4935-a2fd-102e98cf5a10" xlink:to="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1496f8f9-c705-49e4-805a-407e3df4ce78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_Goodwill_1496f8f9-c705-49e4-805a-407e3df4ce78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_aeb0a2b8-2dea-467f-bd70-abdc43f989cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_aeb0a2b8-2dea-467f-bd70-abdc43f989cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_ee283f62-fa44-48a3-bf67-a41aa73d2c24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_ee283f62-fa44-48a3-bf67-a41aa73d2c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_9b0d4751-ce8f-4965-b5d0-343b52cf196a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_9b0d4751-ce8f-4965-b5d0-343b52cf196a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5f5a20eb-5d67-4231-92c0-0561fce798e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_5f5a20eb-5d67-4231-92c0-0561fce798e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5abb3d33-54f7-4891-b529-0f940d9b98dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_f05ad476-f8ed-413d-aa06-1f15dedc59c7" xlink:to="loc_us-gaap_Goodwill_5abb3d33-54f7-4891-b529-0f940d9b98dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_d302d91b-1084-43be-8c86-e71b6a8d9efd" xlink:href="bhc-20230331.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_bhc_AccruedProductRebateCurrent_d302d91b-1084-43be-8c86-e71b6a8d9efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_0624a576-dfc7-4470-b9af-94b16c34e58f" xlink:href="bhc-20230331.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_bhc_AccruedProductReturnCurrent_0624a576-dfc7-4470-b9af-94b16c34e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_02ebdd50-7078-4411-b306-ae8a010218f4" xlink:href="bhc-20230331.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_02ebdd50-7078-4411-b306-ae8a010218f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6029d3f7-def9-4de8-8970-7302737cadc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_6029d3f7-def9-4de8-8970-7302737cadc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_f9421a31-c386-49ff-8f69-9d780cd039bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_us-gaap_InterestPayableCurrent_f9421a31-c386-49ff-8f69-9d780cd039bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_bc7c5981-f252-45d6-a991-42b94dd17a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_bc7c5981-f252-45d6-a991-42b94dd17a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba708c20-8690-4b41-810e-fe301ce25663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ba708c20-8690-4b41-810e-fe301ce25663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_cbe52354-4efc-4db2-876f-b1f6cd0b17a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_768d9bb9-4f19-47da-a8e9-3c4c4f7d3df1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_cbe52354-4efc-4db2-876f-b1f6cd0b17a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_194b2b4d-ecbe-42e2-90de-752cc39bae46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_194b2b4d-ecbe-42e2-90de-752cc39bae46" xlink:to="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2cdc35f1-1ea3-44ab-b16f-400766b6928b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a440a932-7f89-4e46-a70d-30a511ab92c3" xlink:to="loc_us-gaap_CreditFacilityDomain_2cdc35f1-1ea3-44ab-b16f-400766b6928b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_0df10f6e-0890-457d-9cc5-75a9d2f35fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2cdc35f1-1ea3-44ab-b16f-400766b6928b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_0df10f6e-0890-457d-9cc5-75a9d2f35fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfd98d4e-1752-430f-8434-1dbe28f08ee5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_d6e9ce0a-fe0c-4023-8260-3b9c394de49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:to="loc_us-gaap_SecuredDebtMember_d6e9ce0a-fe0c-4023-8260-3b9c394de49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_38a0b8af-8ce7-49a3-a249-a914ba6edaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b9e9f767-d970-487d-888b-fe392aa6710d" xlink:to="loc_us-gaap_UnsecuredDebtMember_38a0b8af-8ce7-49a3-a249-a914ba6edaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e7acc2b0-89e6-40ba-8c36-502f18660afb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_fb601c01-aad5-415c-ace3-3dcbb53f22ca" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_fb601c01-aad5-415c-ace3-3dcbb53f22ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_f0440614-98af-486f-99c8-e34fef616bf7" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_f0440614-98af-486f-99c8-e34fef616bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_a82be5b2-6dde-4db7-a6a1-5e1a8d8b8cf8" xlink:href="bhc-20230331.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_TermFacilityDueMay2027Member_a82be5b2-6dde-4db7-a6a1-5e1a8d8b8cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_1cf3b844-b9bd-4e3b-b130-0a86002bcc1e" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_1cf3b844-b9bd-4e3b-b130-0a86002bcc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_97656ef1-5918-4e49-bb4a-61257313e870" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_97656ef1-5918-4e49-bb4a-61257313e870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9eedc9e5-721f-4091-9843-06e939f84ae9" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_9eedc9e5-721f-4091-9843-06e939f84ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_3180fd94-62b1-4f8d-9586-3d14c13b76d6" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_3180fd94-62b1-4f8d-9586-3d14c13b76d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_dd7ffa6d-3b39-4fde-917a-f85966b0e4f3" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_dd7ffa6d-3b39-4fde-917a-f85966b0e4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_5d8745f5-e102-4324-9176-c90e8b6154c1" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_5d8745f5-e102-4324-9176-c90e8b6154c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_21c62e26-8db2-4ba3-b3a1-5b4db3124a5b" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_21c62e26-8db2-4ba3-b3a1-5b4db3124a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_a3ac2155-6069-4867-ba89-f21b97e96d20" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_a3ac2155-6069-4867-ba89-f21b97e96d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_f61e962c-d197-48eb-a852-10f998853d9c" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_f61e962c-d197-48eb-a852-10f998853d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_fdf6564d-e218-4160-92e3-d5059b81c20e" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_fdf6564d-e218-4160-92e3-d5059b81c20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_5166d8a5-8a70-47fb-a282-abd2a8a1ac53" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_5166d8a5-8a70-47fb-a282-abd2a8a1ac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_ead6bde9-5b8c-4d18-b707-4a33e8fa3f23" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_ead6bde9-5b8c-4d18-b707-4a33e8fa3f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_4c6e4ff2-504c-47f7-bcf7-35b3b768023c" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_4c6e4ff2-504c-47f7-bcf7-35b3b768023c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_001efb1e-f315-412f-bd37-cca234ef4f1e" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_001efb1e-f315-412f-bd37-cca234ef4f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_fed7e1ed-00f6-449f-a339-104c2c733577" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_fed7e1ed-00f6-449f-a339-104c2c733577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_82471b65-a02a-4f58-a161-018dc8b99b91" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_82471b65-a02a-4f58-a161-018dc8b99b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_d4f2695a-935f-4200-912d-3f80de8e5e6c" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_d4f2695a-935f-4200-912d-3f80de8e5e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_edaa6e71-74ec-4f62-9d0f-a109cc862e56" xlink:href="bhc-20230331.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2fd767db-9707-48ba-9a97-32992c55b062" xlink:to="loc_bhc_OtherLongTermDebtMember_edaa6e71-74ec-4f62-9d0f-a109cc862e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2c05f7ed-72a0-4da4-bca1-40634481b2f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_12b798e8-b872-4e96-8406-7ef4ff3eb5f2" xlink:to="loc_dei_EntityDomain_2c05f7ed-72a0-4da4-bca1-40634481b2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_57729a03-043c-48d2-8a9e-e57611654a1e" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2c05f7ed-72a0-4da4-bca1-40634481b2f0" xlink:to="loc_bhc_BauschLombMember_57729a03-043c-48d2-8a9e-e57611654a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a740a4d7-7bf7-4738-a28f-5c6ea436f125" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_054163e0-c277-4813-b5dd-57dc24bdeffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_054163e0-c277-4813-b5dd-57dc24bdeffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_577b72a5-131a-4d58-b1b3-79a5a905a2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_577b72a5-131a-4d58-b1b3-79a5a905a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d3e50fa8-11d8-4677-bf16-a75524e1e787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_LongTermDebt_d3e50fa8-11d8-4677-bf16-a75524e1e787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7fd97bfb-0ff0-4877-b25d-2e3345f91e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_LongTermDebtCurrent_7fd97bfb-0ff0-4877-b25d-2e3345f91e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_50c3d3e0-9895-459c-ab3a-30a9a82ce01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce4b91b-09fd-4ad2-bdd1-168fddf11bcf" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_50c3d3e0-9895-459c-ab3a-30a9a82ce01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2398a637-a6c4-41d4-8739-d203be2ea9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2398a637-a6c4-41d4-8739-d203be2ea9c5" xlink:to="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_f982575c-7343-4b63-9600-839f0f89919d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1009817e-8545-4a55-afda-1f89d7c26ab7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_f982575c-7343-4b63-9600-839f0f89919d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b4e5a10f-fc41-42ec-a2fb-af968872134e" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_f982575c-7343-4b63-9600-839f0f89919d" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_b4e5a10f-fc41-42ec-a2fb-af968872134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_495946df-5ec4-4ba6-82e3-b101f8f9dd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d470241d-070c-44ad-9f55-2f724bf36336" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_495946df-5ec4-4ba6-82e3-b101f8f9dd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_50db57ac-bee1-4bc9-9cfe-5aebe1ac2bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_495946df-5ec4-4ba6-82e3-b101f8f9dd2e" xlink:to="loc_us-gaap_SecuredDebtMember_50db57ac-bee1-4bc9-9cfe-5aebe1ac2bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e2b39261-d97c-4a7f-88a6-2fbf86619a22" xlink:to="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilityMember_57ae9dd3-2f23-428f-9e55-3677fb4cf18b" xlink:href="bhc-20230331.xsd#bhc_SeniorSecuredCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:to="loc_bhc_SeniorSecuredCreditFacilityMember_57ae9dd3-2f23-428f-9e55-3677fb4cf18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_f381a49a-5ed9-4f1a-ae17-005319c5915d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5c9180d5-c648-499b-846e-94082c078f94" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_f381a49a-5ed9-4f1a-ae17-005319c5915d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8c056830-61fa-4b90-b654-2a3f38b2a3b9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e8f2326-90a3-4d2f-b7c3-c6da3ef61f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e8f2326-90a3-4d2f-b7c3-c6da3ef61f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_f2e3979c-c5a1-45b9-bcd0-527e3dd28c43" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments_f2e3979c-c5a1-45b9-bcd0-527e3dd28c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_2a27304b-51fe-4ecf-b35c-86da548f634e" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_2a27304b-51fe-4ecf-b35c-86da548f634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_fdcb22b5-6845-48c2-813c-d3bdb1fe92f3" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_959019bd-56ea-4876-be87-e5220d122650" xlink:to="loc_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio_fdcb22b5-6845-48c2-813c-d3bdb1fe92f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSExchangeOfferDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a266a112-56e0-4a7d-8895-a09ab8088cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExtinguishmentOfDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a266a112-56e0-4a7d-8895-a09ab8088cd2" xlink:to="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d175dcf8-c7b9-48e5-a228-8311a78715df" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0779a3e9-b002-4709-b2cc-0f126ba74e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:to="loc_us-gaap_UnsecuredDebtMember_0779a3e9-b002-4709-b2cc-0f126ba74e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_2142552c-56bb-446e-9422-cc3ed9c678fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_eb6e5715-3be8-47ea-981e-8c7c4b84312b" xlink:to="loc_us-gaap_SecuredDebtMember_2142552c-56bb-446e-9422-cc3ed9c678fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_00a97ac1-71f3-418d-904f-2317cfdb2153" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_853b9c5e-e5dd-424b-b817-ea4c7206201a" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_853b9c5e-e5dd-424b-b817-ea4c7206201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_94dab19c-cc06-4a81-bc61-f961536e61e2" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_94dab19c-cc06-4a81-bc61-f961536e61e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_6a0da4bd-52af-4a15-9274-cc44f94ed2b9" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_988c1ed8-479d-4958-aa29-5ec4f0fd134a" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_6a0da4bd-52af-4a15-9274-cc44f94ed2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_0c938914-4ba1-47f0-a53c-c4042f95ecbb" xlink:href="bhc-20230331.xsd#bhc_TroubledDebtRestructuringDebtorTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeAxis_192f51ef-0243-4d36-b82e-27ce11d85e26" xlink:to="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_0c938914-4ba1-47f0-a53c-c4042f95ecbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ExchangeOfferMember_23ce71aa-3ffd-4c38-a33e-74d679cf3534" xlink:href="bhc-20230331.xsd#bhc_ExchangeOfferMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_TroubledDebtRestructuringDebtorTypeDomain_0c938914-4ba1-47f0-a53c-c4042f95ecbb" xlink:to="loc_bhc_ExchangeOfferMember_23ce71aa-3ffd-4c38-a33e-74d679cf3534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_352ee7aa-ce00-4275-8dc9-78dcda1c7cdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_011e8017-9ef3-4973-8296-b97ce4c87666" xlink:to="loc_srt_OwnershipDomain_352ee7aa-ce00-4275-8dc9-78dcda1c7cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_2f8b4ee4-7151-44b9-96f8-96f88808358d" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_352ee7aa-ce00-4275-8dc9-78dcda1c7cdd" xlink:to="loc_bhc_BauschLombMember_2f8b4ee4-7151-44b9-96f8-96f88808358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_abfc7938-7e39-4db7-8086-85fde7759ff5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5db1042d-4215-4bec-b5f8-4f704f7d767a" xlink:to="loc_dei_EntityDomain_abfc7938-7e39-4db7-8086-85fde7759ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_d53d5665-bb92-4371-b59c-4865f6a1c854" xlink:href="bhc-20230331.xsd#bhc_A1375209BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_abfc7938-7e39-4db7-8086-85fde7759ff5" xlink:to="loc_bhc_A1375209BCLtdMember_d53d5665-bb92-4371-b59c-4865f6a1c854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfExtinguishmentOfDebtTable_d8b67383-ce37-410a-9549-89fd1a319005" xlink:to="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9f7f528d-9ba7-4f99-a78d-420789a80e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_9f7f528d-9ba7-4f99-a78d-420789a80e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_728d44ce-41c4-4a89-ae0a-2aeb5e4353d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_728d44ce-41c4-4a89-ae0a-2aeb5e4353d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_55e4013d-108c-4a65-ae1e-68e6998c4054" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal_55e4013d-108c-4a65-ae1e-68e6998c4054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14541dc3-2fd9-4f46-9e4b-7c0924cce55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_14541dc3-2fd9-4f46-9e4b-7c0924cce55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_52fa048e-fbf5-4165-a0fb-9eb46b195850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_52fa048e-fbf5-4165-a0fb-9eb46b195850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedPremium_8f163bfc-2bdb-4fbb-86f7-d2beda06c983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedPremium_8f163bfc-2bdb-4fbb-86f7-d2beda06c983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_ef8280d3-c580-40b0-b47c-2786295788a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_InterestPaid_ef8280d3-c580-40b0-b47c-2786295788a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_914770fe-302d-4cb9-8be6-0c8823992ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtLineItems_ddc48a50-ea43-4bba-b25f-284dc6ff1aa7" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_914770fe-302d-4cb9-8be6-0c8823992ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_397dcf8f-61c9-47db-b1c9-b462a2311adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_397dcf8f-61c9-47db-b1c9-b462a2311adf" xlink:to="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_476e8047-a8f2-414d-a57d-22fbdc60fb79" xlink:to="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_66a10154-35d4-44f3-89c3-bebe17b84482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_66a10154-35d4-44f3-89c3-bebe17b84482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_0b83811c-324e-4192-b0de-9ea83445ebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_b6fad605-0efe-43ed-afef-3b690525e05f" xlink:to="loc_us-gaap_LetterOfCreditMember_0b83811c-324e-4192-b0de-9ea83445ebcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe9e1821-d6e6-4a25-84a3-a7aa99df7a72" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5eb1a8c0-05e5-43de-b8d2-c744719b1632" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5eb1a8c0-05e5-43de-b8d2-c744719b1632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_869c7b57-4f98-430f-a9f5-d1bf791fa0a3" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_869c7b57-4f98-430f-a9f5-d1bf791fa0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_9c59f8c1-43ca-45e0-92af-06ea3e39f529" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_9c59f8c1-43ca-45e0-92af-06ea3e39f529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueFebruary2027Member_48a365a7-b9ea-426c-b39d-076092629cc6" xlink:href="bhc-20230331.xsd#bhc_TermLoanBFacilityDueFebruary2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermLoanBFacilityDueFebruary2027Member_48a365a7-b9ea-426c-b39d-076092629cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0c5c9498-cda8-484f-ac1e-e6382bd174ea" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_RevolvingCreditFacilityDueFebruary2027Member_0c5c9498-cda8-484f-ac1e-e6382bd174ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_9a013b47-448f-4592-bb15-e4c05586b087" xlink:href="bhc-20230331.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_9a013b47-448f-4592-bb15-e4c05586b087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_4d38e7bd-9d26-4af5-a677-0b07a016377f" xlink:href="bhc-20230331.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_4d38e7bd-9d26-4af5-a677-0b07a016377f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermFacilityDueMay2027Member_68addf3d-7b88-4e2e-a117-f5b9bdd7f565" xlink:href="bhc-20230331.xsd#bhc_TermFacilityDueMay2027Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_TermFacilityDueMay2027Member_68addf3d-7b88-4e2e-a117-f5b9bdd7f565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueMay2027Member_d11295ed-a83e-461c-97bf-4bb4afac4498" xlink:href="bhc-20230331.xsd#bhc_RevolvingCreditFacilityDueMay2027Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c95475ca-f8da-40f6-8013-60b7017007e8" xlink:to="loc_bhc_RevolvingCreditFacilityDueMay2027Member_d11295ed-a83e-461c-97bf-4bb4afac4498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_8c628a50-1a31-45c2-96d7-705d28645ef7" xlink:to="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_24393eae-2f04-4cb8-a784-bf3635ff39a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_24393eae-2f04-4cb8-a784-bf3635ff39a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_86b8e00f-9a42-4bd3-aade-4e51c9df76a3" xlink:href="bhc-20230331.xsd#bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember_86b8e00f-9a42-4bd3-aade-4e51c9df76a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b4e753d9-0a5c-4da8-aaf9-c16dd87b5cab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_b4e753d9-0a5c-4da8-aaf9-c16dd87b5cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_d8f79445-7acf-478a-91cb-8b7a3c5909c1" xlink:href="bhc-20230331.xsd#bhc_EuropeInterbankOfferedRateEURIBORMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_EuropeInterbankOfferedRateEURIBORMember_d8f79445-7acf-478a-91cb-8b7a3c5909c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6ce6fe13-af68-451b-89c2-7522e68579c1" xlink:href="bhc-20230331.xsd#bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember_6ce6fe13-af68-451b-89c2-7522e68579c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_8b6a9716-47b1-4262-87ce-c5ea14cfa7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_us-gaap_BaseRateMember_8b6a9716-47b1-4262-87ce-c5ea14cfa7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDORAndEURIBORRatesMember_5c8fa2b4-a1e4-41ea-9f3f-9c9152c75256" xlink:href="bhc-20230331.xsd#bhc_SOFRCDORAndEURIBORRatesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_SOFRCDORAndEURIBORRatesMember_5c8fa2b4-a1e4-41ea-9f3f-9c9152c75256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_d9aa1f04-6951-4f0a-b39c-918a0427ff5f" xlink:href="bhc-20230331.xsd#bhc_SOFRCDOREURIBORAndSONIARatesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_6d05cfeb-b4c8-4c03-9792-66aca8a68967" xlink:to="loc_bhc_SOFRCDOREURIBORAndSONIARatesMember_d9aa1f04-6951-4f0a-b39c-918a0427ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5fb04083-e109-4222-b35a-0df9f988d758" xlink:to="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4f2021d3-37ff-46a8-b9f9-3fca4df3b28b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:to="loc_srt_MinimumMember_4f2021d3-37ff-46a8-b9f9-3fca4df3b28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1f60b2b-e921-453e-876e-e5d45f6a6994" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb5f88db-b1db-4564-adbe-660c38ae0e55" xlink:to="loc_srt_MaximumMember_c1f60b2b-e921-453e-876e-e5d45f6a6994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d447aa7f-618d-4a68-8774-711ccd3628c2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_29338dea-aa79-4fbe-9360-3713c35e9bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:to="loc_us-gaap_SecuredDebtMember_29338dea-aa79-4fbe-9360-3713c35e9bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_189096c9-cafd-474f-8e45-4d8d5120c98b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c86e971f-4706-49a8-b6da-de8a996d7f21" xlink:to="loc_us-gaap_UnsecuredDebtMember_189096c9-cafd-474f-8e45-4d8d5120c98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d183433b-0edc-4f03-917a-b28b85a906be" xlink:to="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_0aa314cc-4bf3-49d6-a1e6-e62caaf35e88" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:to="loc_bhc_BauschLombMember_0aa314cc-4bf3-49d6-a1e6-e62caaf35e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1261229BCLtdMember_f2e48b27-20a4-4c9b-a2e9-80731b5aec23" xlink:href="bhc-20230331.xsd#bhc_A1261229BCLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1c79422c-ffc0-4896-b283-347de9b286f5" xlink:to="loc_bhc_A1261229BCLtdMember_f2e48b27-20a4-4c9b-a2e9-80731b5aec23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_274da3c3-b600-4081-93de-836faf12da44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c05efda7-2c68-4ad6-992e-f2e949ed0092" xlink:to="loc_srt_OwnershipDomain_274da3c3-b600-4081-93de-836faf12da44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_4b34f29a-3111-428b-827d-6013df7c61e1" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_274da3c3-b600-4081-93de-836faf12da44" xlink:to="loc_bhc_BauschLombMember_4b34f29a-3111-428b-827d-6013df7c61e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_82e04e22-5fdb-4760-b8aa-15e504565d39" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e9f607-40c8-48f7-87a0-02cfe09a7d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c9e9f607-40c8-48f7-87a0-02cfe09a7d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a61b540e-220d-4934-aa96-94fc416d42c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a61b540e-220d-4934-aa96-94fc416d42c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_5f273e17-68d3-4fa5-b0a9-6c543e4d401e" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_5f273e17-68d3-4fa5-b0a9-6c543e4d401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_33897220-8148-475a-ba15-1c22cf9fcf67" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_33897220-8148-475a-ba15-1c22cf9fcf67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_4c49ce9f-9145-40a5-bf28-5d59db627aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_4c49ce9f-9145-40a5-bf28-5d59db627aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_717c27a1-e91a-4d73-9291-b3bce1734148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LongTermDebt_717c27a1-e91a-4d73-9291-b3bce1734148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0e7641c8-95e6-4988-aeee-13cfc5ef02eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0e7641c8-95e6-4988-aeee-13cfc5ef02eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_1528ae36-5fe8-4e5b-8557-6b1f0ac65a31" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable_1528ae36-5fe8-4e5b-8557-6b1f0ac65a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_b62c93d1-3363-4c00-9949-19a5584fa46c" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate_b62c93d1-3363-4c00-9949-19a5584fa46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36cc26c5-d87f-4076-ac87-58d32943b319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_36cc26c5-d87f-4076-ac87-58d32943b319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f5678f0f-11c7-4227-bea0-b308d62db31e" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_f5678f0f-11c7-4227-bea0-b308d62db31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_41d030fb-ec09-45ab-b6df-8e0deb8b7b66" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_41d030fb-ec09-45ab-b6df-8e0deb8b7b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_1544e9c6-8700-4c89-955b-56d2b0b88040" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_1544e9c6-8700-4c89-955b-56d2b0b88040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_27577611-3265-4dfc-8972-0a6e56f7327d" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_27577611-3265-4dfc-8972-0a6e56f7327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_b7f06778-1351-4680-999e-1b04d6bcb690" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_b7f06778-1351-4680-999e-1b04d6bcb690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_dd26f0ce-577f-4674-9c0c-25b13ee49932" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_dd26f0ce-577f-4674-9c0c-25b13ee49932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_e4550529-d17c-4328-9a8b-66e2e19ae6aa" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization_e4550529-d17c-4328-9a8b-66e2e19ae6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_4a1ba949-38ce-4afc-a5f6-0e63bacf820f" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_4a1ba949-38ce-4afc-a5f6-0e63bacf820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_a1cf7a21-d24c-4afa-afac-8a577fc35992" xlink:href="bhc-20230331.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage_a1cf7a21-d24c-4afa-afac-8a577fc35992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_f38916a3-7983-4e00-b9b3-7b2a82556d36" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_f38916a3-7983-4e00-b9b3-7b2a82556d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_07bf7824-0faf-4cb9-b6a5-d31233961e8f" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_07bf7824-0faf-4cb9-b6a5-d31233961e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_5edc12e3-438e-4cae-93d2-65028903839d" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_5edc12e3-438e-4cae-93d2-65028903839d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_afccd4c2-9bb1-4fc3-8ad8-51a71ce899f0" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_afccd4c2-9bb1-4fc3-8ad8-51a71ce899f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b1560b4d-2305-455f-bb90-b154f6618793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_b1560b4d-2305-455f-bb90-b154f6618793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_423112e7-cad5-4441-8e81-bd65799f2190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentTerm_423112e7-cad5-4441-8e81-bd65799f2190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0050aa27-1d32-4a43-a199-3fff992c72a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_0050aa27-1d32-4a43-a199-3fff992c72a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_509e02d9-1591-4cfd-89d6-7e96c62c3721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_509e02d9-1591-4cfd-89d6-7e96c62c3721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_18ca2ba5-da01-43c2-95e2-2dd47fb88ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7b52b2fe-9cd0-412e-9a71-6ac7a229a2f8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_18ca2ba5-da01-43c2-95e2-2dd47fb88ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_efe440f9-4445-417c-8093-c9a9b68a6e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_efe440f9-4445-417c-8093-c9a9b68a6e86" xlink:to="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6cacf4f7-d883-428d-8161-9d74adaeb25a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_f07f1b98-a7c6-42dd-b0cb-507a3389dfd7" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_f07f1b98-a7c6-42dd-b0cb-507a3389dfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_10fdc900-fce8-42d7-b90c-ce95bd3911c5" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_10fdc900-fce8-42d7-b90c-ce95bd3911c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_2a493a0f-1486-44e3-be89-4679c7bba1f6" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member_2a493a0f-1486-44e3-be89-4679c7bba1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_77a0c3e8-a2a4-47f9-8b2a-738670b71a4a" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member_77a0c3e8-a2a4-47f9-8b2a-738670b71a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cc11373e-669f-4c83-8447-22f51dff2605" xlink:href="bhc-20230331.xsd#bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0482d493-2f76-4a89-a643-c5596dc1b261" xlink:to="loc_bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member_cc11373e-669f-4c83-8447-22f51dff2605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_749734e0-4e6b-4f0e-8634-7a24568a3a8d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_72e4163f-abec-4c0a-91f5-c966887384b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:to="loc_us-gaap_UnsecuredDebtMember_72e4163f-abec-4c0a-91f5-c966887384b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_ae199b25-afc5-4533-bf08-b2cfb3ecb809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0fdcf30c-41a8-48ce-b9d7-6c2fbfdbce23" xlink:to="loc_us-gaap_SecuredDebtMember_ae199b25-afc5-4533-bf08-b2cfb3ecb809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_59a9baba-c3e3-4771-af54-0a65a8347add" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_07e66cd8-4e0d-4477-9df6-0e840ad9c85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_07e66cd8-4e0d-4477-9df6-0e840ad9c85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_304964fa-6c83-409f-885a-4a45602bde10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_134c9719-ca07-41fa-b0df-4d2c20065699" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_304964fa-6c83-409f-885a-4a45602bde10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1ac33100-823c-4d76-a900-29d1fbe9aa30" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b04be272-58bb-4aa1-8239-4c94383b1be5" xlink:to="loc_srt_RangeMember_1ac33100-823c-4d76-a900-29d1fbe9aa30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_89224f8e-8b9a-4fb6-82bb-169bcdec0a88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1ac33100-823c-4d76-a900-29d1fbe9aa30" xlink:to="loc_srt_MaximumMember_89224f8e-8b9a-4fb6-82bb-169bcdec0a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_45c11a04-0227-49e3-89b4-306cb68535d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_36a7d74a-373d-453f-90bb-f0b427633d57" xlink:to="loc_srt_OwnershipDomain_45c11a04-0227-49e3-89b4-306cb68535d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_a4781ef1-1179-4561-92c6-1536a2f3cf1b" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_45c11a04-0227-49e3-89b4-306cb68535d9" xlink:to="loc_bhc_BauschLombMember_a4781ef1-1179-4561-92c6-1536a2f3cf1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_86b505e6-3038-43c9-8856-2b4f3d63d87f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3e4745a2-ef2b-4d9a-98c9-1e7050bb4941" xlink:to="loc_dei_EntityDomain_86b505e6-3038-43c9-8856-2b4f3d63d87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A1375209BCLtdMember_8f2f923e-bfb5-4a38-b6a9-484e1168ce81" xlink:href="bhc-20230331.xsd#bhc_A1375209BCLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_86b505e6-3038-43c9-8856-2b4f3d63d87f" xlink:to="loc_bhc_A1375209BCLtdMember_8f2f923e-bfb5-4a38-b6a9-484e1168ce81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d0f9d7ba-f1fc-4b29-99c8-44988993b886" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5b3f67-a611-493e-9ec9-4aac833234f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5a5b3f67-a611-493e-9ec9-4aac833234f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7b8a7f3d-f61e-406c-b03f-2849845f6d8a" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_7b8a7f3d-f61e-406c-b03f-2849845f6d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1ab97f11-de01-4aa9-9928-7a69e76a47a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1ab97f11-de01-4aa9-9928-7a69e76a47a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a8e5aa60-6a16-4a2c-8f66-79e3f76ae703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_a8e5aa60-6a16-4a2c-8f66-79e3f76ae703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_8cf83213-8228-469d-afb5-f0504f7e7527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_8cf83213-8228-469d-afb5-f0504f7e7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc411745-4e36-48b7-8aa0-be98ca7249eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4a5201e1-fafc-4c21-bf39-564dcde96fce" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_dc411745-4e36-48b7-8aa0-be98ca7249eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_df177950-e3ae-4c17-96fb-c4c8302e2986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_df177950-e3ae-4c17-96fb-c4c8302e2986" xlink:to="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b596ac3a-46c7-473e-a377-76c50c990ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d43c56b6-d4fc-4d90-8fe7-9d772f311bd6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b596ac3a-46c7-473e-a377-76c50c990ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_8fa80f0b-5cda-4e3c-b608-aac560ba6fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b596ac3a-46c7-473e-a377-76c50c990ab9" xlink:to="loc_us-gaap_UnsecuredDebtMember_8fa80f0b-5cda-4e3c-b608-aac560ba6fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:to="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e7b6b711-b889-4a86-9ac3-cc6df3000a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_555f06a2-8475-441f-8c0d-68c9a9a77eb4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e7b6b711-b889-4a86-9ac3-cc6df3000a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_26693689-693a-4eda-aca2-8d5769f5ae16" xlink:href="bhc-20230331.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e7b6b711-b889-4a86-9ac3-cc6df3000a04" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_26693689-693a-4eda-aca2-8d5769f5ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_34b3758e-b2b0-4454-b4a8-16233dc352c4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6e0f2f0d-b9d6-4add-9aab-444cf27f6fb2" xlink:href="bhc-20230331.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_6e0f2f0d-b9d6-4add-9aab-444cf27f6fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_50b02ec7-0d1e-4468-be58-3a6a732b26e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d3457ef3-3f8d-434c-b950-47677fcb18ee" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_50b02ec7-0d1e-4468-be58-3a6a732b26e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c1785227-e4e3-4063-8c44-b234dde414de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_2e9edb40-2280-46bf-ac91-86c62d92553f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1785227-e4e3-4063-8c44-b234dde414de" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_2e9edb40-2280-46bf-ac91-86c62d92553f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_94fab59c-b83a-40a0-8269-34a93b050fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_94fab59c-b83a-40a0-8269-34a93b050fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d923437a-20ec-430c-a7b3-3380d8f3fa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d923437a-20ec-430c-a7b3-3380d8f3fa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f1589fb5-2934-4464-bd3c-b02f95ffa392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_f1589fb5-2934-4464-bd3c-b02f95ffa392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bd047ad1-a8b6-482f-97e8-8e82a58dd540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bd047ad1-a8b6-482f-97e8-8e82a58dd540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f0ba9d3a-c2fc-4b02-bd04-df4985084d80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_f0ba9d3a-c2fc-4b02-bd04-df4985084d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4d796231-d48f-4975-aa8e-0c8f60a31f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4d796231-d48f-4975-aa8e-0c8f60a31f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2a3ab257-6aa4-40e7-be3c-fae248bbf75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_2a3ab257-6aa4-40e7-be3c-fae248bbf75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_776238ca-e1cf-4b1d-9801-6761dd0f9612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_776238ca-e1cf-4b1d-9801-6761dd0f9612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b21c75d1-cd77-4773-9555-c3307010a146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b21c75d1-cd77-4773-9555-c3307010a146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0be8e8de-f0e7-4ea5-9a9a-d90796014500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7fbc37ba-9ecc-4164-925c-0237819fa1ba" xlink:to="loc_us-gaap_LongTermDebt_0be8e8de-f0e7-4ea5-9a9a-d90796014500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f7340c-e21b-4def-ab0c-e922529a13ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f7340c-e21b-4def-ab0c-e922529a13ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5518d392-edfe-4330-bc4a-aa73751a8e6b" xlink:to="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_ba881e3f-0d8f-43e0-bc10-901fa70e724e" xlink:href="bhc-20230331.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_ba881e3f-0d8f-43e0-bc10-901fa70e724e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_7dcf61e8-ba63-4b53-a5c3-76671aaf8201" xlink:href="bhc-20230331.xsd#bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member_ba881e3f-0d8f-43e0-bc10-901fa70e724e" xlink:to="loc_bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember_7dcf61e8-ba63-4b53-a5c3-76671aaf8201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A2022OmnibusIncentivePlanMember_ad132072-d2c7-4865-a8f6-4d77c792f966" xlink:href="bhc-20230331.xsd#bhc_A2022OmnibusIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5f71503f-b06f-4d78-9268-1be59d7083f3" xlink:to="loc_bhc_A2022OmnibusIncentivePlanMember_ad132072-d2c7-4865-a8f6-4d77c792f966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7177a76d-820b-4216-8a3c-8f7008a8a3df" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_394c6d4b-1a82-4c15-9897-7dcb38134325" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:to="loc_srt_ChiefExecutiveOfficerMember_394c6d4b-1a82-4c15-9897-7dcb38134325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_74ef803e-9c27-4486-81be-9efc8968522c" xlink:href="bhc-20230331.xsd#bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_bd462d4c-9540-436c-8e4d-63ffe0a96366" xlink:to="loc_bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember_74ef803e-9c27-4486-81be-9efc8968522c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_417a584e-15b2-4985-843e-3a84349fcd31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6dce2956-d3f8-4def-b77c-b34a0da877a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6dce2956-d3f8-4def-b77c-b34a0da877a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5cf96d19-3ebb-4aa0-bfc8-d2157d450b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5cf96d19-3ebb-4aa0-bfc8-d2157d450b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceRestrictedShareUnitsMember_01d36e79-0562-42e8-8469-a42edcfadadf" xlink:href="bhc-20230331.xsd#bhc_PerformanceRestrictedShareUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a3f88d5c-0a1b-4a7f-ae02-6eb4ecce1996" xlink:to="loc_bhc_PerformanceRestrictedShareUnitsMember_01d36e79-0562-42e8-8469-a42edcfadadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cb168851-908b-4904-a038-d13f3e306456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_11172231-911a-4615-b557-f96245fad475" xlink:to="loc_dei_EntityDomain_cb168851-908b-4904-a038-d13f3e306456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_28367d98-13c9-4bee-a163-ccdf6dd99374" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_cb168851-908b-4904-a038-d13f3e306456" xlink:to="loc_bhc_BauschLombMember_28367d98-13c9-4bee-a163-ccdf6dd99374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2f38b953-7520-45f9-a76b-656bcfe191a3" xlink:to="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2fe6d012-6958-416f-bcab-5ff3a52f2a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_2fe6d012-6958-416f-bcab-5ff3a52f2a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ca2af273-975d-4378-bdaf-38172222ce28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ca2af273-975d-4378-bdaf-38172222ce28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3d0082f4-995b-4df2-bea6-cece5abdf3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_f2d43c80-df10-4f51-b24d-f8046ec079b6" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_3d0082f4-995b-4df2-bea6-cece5abdf3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bf3cbc50-5c14-4b60-8ef9-2d14c0b23a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f8f56d04-0934-45d1-959b-bf3da1739a15" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bf3cbc50-5c14-4b60-8ef9-2d14c0b23a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_68e6e90b-e11d-4098-b339-cbef5db971a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bf3cbc50-5c14-4b60-8ef9-2d14c0b23a38" xlink:to="loc_us-gaap_SubsequentEventMember_68e6e90b-e11d-4098-b339-cbef5db971a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8514dc74-57b3-473e-9bd6-8663df42a8c1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7a986361-b6bb-4684-b51a-7af246dd9866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7a986361-b6bb-4684-b51a-7af246dd9866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f394092-1f90-4fda-81eb-ec39ebb3dc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9f394092-1f90-4fda-81eb-ec39ebb3dc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a3b6d893-c180-4872-bb63-d2775855cdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a3b6d893-c180-4872-bb63-d2775855cdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38858389-e5ec-47e6-8f63-9a6bb3f6e4d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_38858389-e5ec-47e6-8f63-9a6bb3f6e4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3466e32-f6d5-4ad1-bfab-7011296835a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b3466e32-f6d5-4ad1-bfab-7011296835a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4007b223-5a02-41d7-9dd1-26e5857b1d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4007b223-5a02-41d7-9dd1-26e5857b1d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d75061e-dd10-4f24-8199-7a803a9244d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_3d75061e-dd10-4f24-8199-7a803a9244d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe168b4-3b1d-43f9-a224-86c24c8db0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fe168b4-3b1d-43f9-a224-86c24c8db0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_88684f34-9214-42ff-811f-d3898ccfa310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_88684f34-9214-42ff-811f-d3898ccfa310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_05d56a86-b504-4210-88e3-5f2db38ba94f" xlink:href="bhc-20230331.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_05d56a86-b504-4210-88e3-5f2db38ba94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_156f017d-3fc7-413b-8849-5710112420e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_156f017d-3fc7-413b-8849-5710112420e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_13f61726-27f3-4bb3-85b0-3a259b689239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9948bc5b-b6db-4e24-8cdb-793f7a0edff9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_13f61726-27f3-4bb3-85b0-3a259b689239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00c959eb-0ff8-4079-b172-86f4dcf0609a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_00c959eb-0ff8-4079-b172-86f4dcf0609a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:to="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_11f88853-7577-44a8-8a2f-59178ec39593" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_26924c05-30cf-4d05-a02e-7c7f7b7f8e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:to="loc_us-gaap_EmployeeStockOptionMember_26924c05-30cf-4d05-a02e-7c7f7b7f8e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0f4c39e1-7e73-4b1c-a494-39b2d16e7b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44fd1906-4185-484f-b58f-f03cbf1b16ba" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0f4c39e1-7e73-4b1c-a494-39b2d16e7b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dcf67620-ef1d-409b-be41-4431c0d577b9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e2f3b65-fa71-490e-b314-cc64cb25213d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8e2f3b65-fa71-490e-b314-cc64cb25213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bec16b7a-fd0d-45d5-9e4c-e1b07e072977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03fc18ab-005a-4266-90f6-ee9cfd4f4f52" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bec16b7a-fd0d-45d5-9e4c-e1b07e072977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_96f336f7-74b9-4479-bea6-5f72f0b1d8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_aac72f57-a59e-4946-8395-bd82b04f1ea3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_96f336f7-74b9-4479-bea6-5f72f0b1d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b18a30d2-cd2a-4b80-a2d5-1f7b90c914dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_96f336f7-74b9-4479-bea6-5f72f0b1d8ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b18a30d2-cd2a-4b80-a2d5-1f7b90c914dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e7d3e02-9041-4f3b-8485-672cc91fc66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2e7d3e02-9041-4f3b-8485-672cc91fc66a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:to="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e9aacb7b-ec7c-4fad-ba98-338fae737056" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8c349b04-1a68-4534-a6f1-7cc6dfa665a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8c349b04-1a68-4534-a6f1-7cc6dfa665a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_4411e1b6-1927-411b-a891-b901662662f6" xlink:href="bhc-20230331.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_TimeBasedRSUMember_4411e1b6-1927-411b-a891-b901662662f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_e0d706b2-240b-4344-ae89-1ff5ba16a5ee" xlink:href="bhc-20230331.xsd#bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember_e0d706b2-240b-4344-ae89-1ff5ba16a5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2ea0835-df06-4d6f-8369-defaff6dea87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2ea0835-df06-4d6f-8369-defaff6dea87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_fabd8719-a137-45f2-b9fb-15141758d198" xlink:href="bhc-20230331.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_fabd8719-a137-45f2-b9fb-15141758d198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_ba9e8c50-f45f-488a-af0a-48d0689fa635" xlink:href="bhc-20230331.xsd#bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2dd929ab-5bed-40b1-a2ee-447597dc095b" xlink:to="loc_bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember_ba9e8c50-f45f-488a-af0a-48d0689fa635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:to="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_94526b1f-3d80-407e-b0bd-ca1e532d8f34" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b5075c14-7779-4513-aae5-d5367f328162" xlink:to="loc_dei_EntityDomain_94526b1f-3d80-407e-b0bd-ca1e532d8f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_eb81c581-571f-46a8-b84c-c52772836984" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_94526b1f-3d80-407e-b0bd-ca1e532d8f34" xlink:to="loc_bhc_BauschLombMember_eb81c581-571f-46a8-b84c-c52772836984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5414fb0c-3eea-4f79-9d27-451338926b3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ce24dfc2-4221-472c-ab79-af2bb2ff38f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ce24dfc2-4221-472c-ab79-af2bb2ff38f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03e1911c-db3e-462b-ad15-29fe3db3501a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03e1911c-db3e-462b-ad15-29fe3db3501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85d034e4-1476-4648-a160-83ade3223aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract_142d8b4c-3e54-40f7-b153-137cdff6c187" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_85d034e4-1476-4648-a160-83ade3223aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c3572892-5528-49af-8791-581400f8cbb2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_972bd1e7-0d60-41cd-aea6-d34ef0703113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_972bd1e7-0d60-41cd-aea6-d34ef0703113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9ce3470-0c6e-435c-bb24-03df7431be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract_846b00aa-e6fb-40b5-bcfe-d5205e343ce8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d9ce3470-0c6e-435c-bb24-03df7431be50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9903d004-0925-46a5-9c10-c29d9da4d518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_9903d004-0925-46a5-9c10-c29d9da4d518" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7eb5c47b-4c95-462b-80e7-a06628c58fac" xlink:to="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f2ba7b3c-a263-4c52-a77f-bc8940a8b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_f2ba7b3c-a263-4c52-a77f-bc8940a8b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_86672f3b-e7eb-4add-8e17-77eb4166f84d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_86672f3b-e7eb-4add-8e17-77eb4166f84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d34e677-84c9-4a25-bbff-870e3fca9680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_32bfbc37-1cb0-4c99-8b6a-a49d55ecc078" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d34e677-84c9-4a25-bbff-870e3fca9680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e93b32d-9348-49a8-b7cf-fc72dbecbed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_68435240-6ecd-480f-81b3-34f9e0114b4a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e93b32d-9348-49a8-b7cf-fc72dbecbed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1797148-0b23-4cd1-8f64-0d1d3769b4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4e93b32d-9348-49a8-b7cf-fc72dbecbed0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a1797148-0b23-4cd1-8f64-0d1d3769b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2c1637af-52c7-48f6-ada3-8333d3b2d670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2c1637af-52c7-48f6-ada3-8333d3b2d670" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ad8e14a8-702a-4c5c-bbde-908a0098affe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6f8ff4dd-acbe-463e-8fa2-cce4604ed9f0" xlink:to="loc_us-gaap_EquityComponentDomain_ad8e14a8-702a-4c5c-bbde-908a0098affe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2bf2799f-6ca7-4d57-951e-80273cef041c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ad8e14a8-702a-4c5c-bbde-908a0098affe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2bf2799f-6ca7-4d57-951e-80273cef041c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4da51a33-3abc-47ac-8ade-67d7949c3421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8101117e-fb89-4ed0-9925-c25dbd7a5aff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4da51a33-3abc-47ac-8ade-67d7949c3421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_092d1356-a280-42ce-8d6e-19f5a75feae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_4da51a33-3abc-47ac-8ade-67d7949c3421" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_092d1356-a280-42ce-8d6e-19f5a75feae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_e80b7632-3562-41e8-9f82-bda37b315c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_3b440e5e-c50e-4a06-a177-9dedda3c7fce" xlink:href="bhc-20230331.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e80b7632-3562-41e8-9f82-bda37b315c37" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_3b440e5e-c50e-4a06-a177-9dedda3c7fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_593821b4-7ac4-473d-bd7e-7874117f96f9" xlink:href="bhc-20230331.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e80b7632-3562-41e8-9f82-bda37b315c37" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_593821b4-7ac4-473d-bd7e-7874117f96f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_69f2fcc0-f4e2-4b82-83ec-d477cdc346ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_e80b7632-3562-41e8-9f82-bda37b315c37" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_69f2fcc0-f4e2-4b82-83ec-d477cdc346ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#OTHEREXPENSENETSummaryofOtherExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0d7e4780-eff4-4828-b447-8d8f3e286107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_4338691d-ded5-4556-bd5c-c126dd1be838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0d7e4780-eff4-4828-b447-8d8f3e286107" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_4338691d-ded5-4556-bd5c-c126dd1be838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89626a66-9ebd-428e-b33a-4eccc1429bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0d7e4780-eff4-4828-b447-8d8f3e286107" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_89626a66-9ebd-428e-b33a-4eccc1429bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e852a57f-4e85-4924-a9ba-5c86d662c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0d7e4780-eff4-4828-b447-8d8f3e286107" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e852a57f-4e85-4924-a9ba-5c86d662c00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6c1861ef-2252-4368-af7b-c32fe8874387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6c1861ef-2252-4368-af7b-c32fe8874387" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_70b399fe-a391-4048-a00a-7888c672e48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f1399f4f-27a4-4c20-92fe-35ccbc579b66" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_70b399fe-a391-4048-a00a-7888c672e48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_0ded9a8e-f5ef-4fb1-94ad-ec16af967fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_70b399fe-a391-4048-a00a-7888c672e48f" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_0ded9a8e-f5ef-4fb1-94ad-ec16af967fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_97e49b57-f76f-4ef0-9538-dff3e53e58ff" xlink:to="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2014Member_36b1468d-a4b5-4b42-8e5f-16477ea18671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:to="loc_us-gaap_TaxYear2014Member_36b1468d-a4b5-4b42-8e5f-16477ea18671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2018AndTaxYear2019Member_517d0f59-e515-44b7-830b-9ddf237cf9f8" xlink:href="bhc-20230331.xsd#bhc_TaxYear2018AndTaxYear2019Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_15d06ca9-3f76-42d2-af30-175c3eeb6f8b" xlink:to="loc_bhc_TaxYear2018AndTaxYear2019Member_517d0f59-e515-44b7-830b-9ddf237cf9f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb051937-6d7d-48d5-811e-2d279dbd1fe4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76032d98-29b6-4583-9037-691fb0016477" xlink:to="loc_srt_RangeMember_eb051937-6d7d-48d5-811e-2d279dbd1fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_adcf6c97-d9e7-45a7-9077-a6aaf158d25d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb051937-6d7d-48d5-811e-2d279dbd1fe4" xlink:to="loc_srt_MaximumMember_adcf6c97-d9e7-45a7-9077-a6aaf158d25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_ee571e07-cbd3-42c0-a5d3-0394d7ac67d6" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_56ca1e41-a96b-479d-9669-0de678ef6adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_56ca1e41-a96b-479d-9669-0de678ef6adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_de646ecf-e3b0-4ce8-90c3-5fd890334bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_de646ecf-e3b0-4ce8-90c3-5fd890334bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_f7e54761-cdc8-416e-b063-0d96c19467d5" xlink:href="bhc-20230331.xsd#bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount_f7e54761-cdc8-416e-b063-0d96c19467d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_49941baa-8d2b-4c1d-91f0-8c2ee371e680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_49941baa-8d2b-4c1d-91f0-8c2ee371e680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_b5c4dc4d-1a80-46ef-81a4-76cdcbc6d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_b5c4dc4d-1a80-46ef-81a4-76cdcbc6d0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_43b2b228-a7ab-4923-bbea-40818d1a6dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_43b2b228-a7ab-4923-bbea-40818d1a6dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ea6e64e1-9875-4d08-9666-bbd805c73226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ea6e64e1-9875-4d08-9666-bbd805c73226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_11ef70de-e8fd-4868-83dd-4544d314f02a" xlink:href="bhc-20230331.xsd#bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount_11ef70de-e8fd-4868-83dd-4544d314f02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b38f5ba5-9bad-49de-b775-b0111dd77953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b38f5ba5-9bad-49de-b775-b0111dd77953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_97dcc9ed-bb80-4863-a805-25f52d282863" xlink:href="bhc-20230331.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_97dcc9ed-bb80-4863-a805-25f52d282863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_64560493-6e7c-4b9d-a749-a68996ff9606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_64560493-6e7c-4b9d-a749-a68996ff9606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d1b0d74-6353-4329-9e5c-af4d8d1a3c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d1b0d74-6353-4329-9e5c-af4d8d1a3c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_760a5a43-391c-410f-b424-4840b224d976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_760a5a43-391c-410f-b424-4840b224d976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_da6992f0-5772-41de-a6e7-3d81001b6d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_108a65a2-a4cb-49e8-b0d5-9d2d85c1e24e" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_da6992f0-5772-41de-a6e7-3d81001b6d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_225c389e-4a4f-4615-8364-8d565047ef76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac81a869-49a1-4d56-ab72-60f34a600156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_225c389e-4a4f-4615-8364-8d565047ef76" xlink:to="loc_us-gaap_NetIncomeLoss_ac81a869-49a1-4d56-ab72-60f34a600156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8905a23-60a3-4bba-bde3-78221165de70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_225c389e-4a4f-4615-8364-8d565047ef76" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c8905a23-60a3-4bba-bde3-78221165de70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9b486c9-c9e7-4b89-baba-b7295c25d333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_225c389e-4a4f-4615-8364-8d565047ef76" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c9b486c9-c9e7-4b89-baba-b7295c25d333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f74e10de-329c-4c68-9700-1fe44cd69fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_225c389e-4a4f-4615-8364-8d565047ef76" xlink:to="loc_us-gaap_EarningsPerShareBasic_f74e10de-329c-4c68-9700-1fe44cd69fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a3276503-4e2a-430f-876f-d0f458165c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_225c389e-4a4f-4615-8364-8d565047ef76" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a3276503-4e2a-430f-876f-d0f458165c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#EARNINGSLOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_be4a5dd7-7ebf-4bb4-80a4-192abfb3f42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_be4a5dd7-7ebf-4bb4-80a4-192abfb3f42e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_e2f869bf-c67d-4cef-904a-a9dba522bd3a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_4d94a414-594e-4892-a24e-6c8e112f775f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:to="loc_us-gaap_StockCompensationPlanMember_4d94a414-594e-4892-a24e-6c8e112f775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_b7278826-3719-4b31-9a5b-5afefcfbd7d8" xlink:href="bhc-20230331.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_b7278826-3719-4b31-9a5b-5afefcfbd7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_50c0853e-49ec-490c-9024-c674fb9d78b4" xlink:href="bhc-20230331.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_00196839-2ddc-4ded-b460-fd138a9ca4ec" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_50c0853e-49ec-490c-9024-c674fb9d78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0552c0a-62a3-4ed5-a674-bb0f922b4a24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5228f27-c02d-453a-80db-81ad5e81260c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f5228f27-c02d-453a-80db-81ad5e81260c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_9903a750-dc2d-4ee5-9efa-169b6e750f8f" xlink:href="bhc-20230331.xsd#bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6d76b83f-b880-4327-a74a-50c072ad2161" xlink:to="loc_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount_9903a750-dc2d-4ee5-9efa-169b6e750f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSLegalProceedsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7fda88d4-18a0-4cba-92ef-c7ac23d7ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_74f60846-fabd-4b55-bfd3-5d5d1b09d639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7fda88d4-18a0-4cba-92ef-c7ac23d7ae58" xlink:to="loc_us-gaap_LitigationReserveCurrent_74f60846-fabd-4b55-bfd3-5d5d1b09d639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0288b64-2055-4254-a099-0366c253b992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d0288b64-2055-4254-a099-0366c253b992" xlink:to="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_c1603dc8-99aa-444b-b2fd-c1864e1f288f" xlink:to="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_af07ea61-11f0-44f5-a73e-00fe68a5cf22" xlink:href="bhc-20230331.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_af07ea61-11f0-44f5-a73e-00fe68a5cf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_7a25c2a6-f384-49fa-817f-666582d3b565" xlink:href="bhc-20230331.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_7a25c2a6-f384-49fa-817f-666582d3b565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_b220ab22-b9b6-41e1-a71b-bf67fe34342b" xlink:href="bhc-20230331.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_RICOClassActionsLitigationMember_b220ab22-b9b6-41e1-a71b-bf67fe34342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_0177135e-f3d0-42f5-8a53-2740f9873a8b" xlink:href="bhc-20230331.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f2fea423-d592-4c83-abe3-662057e4d24b" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_0177135e-f3d0-42f5-8a53-2740f9873a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_bf71b510-df67-4014-a9fc-e737c8ddacbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_4840490c-109a-4829-8212-87f589151379" xlink:to="loc_us-gaap_LitigationStatusDomain_bf71b510-df67-4014-a9fc-e737c8ddacbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_e3cd539e-1c16-405d-9c48-5b9f9696bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_bf71b510-df67-4014-a9fc-e737c8ddacbb" xlink:to="loc_us-gaap_SettledLitigationMember_e3cd539e-1c16-405d-9c48-5b9f9696bf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d0612a74-4041-48b1-9ceb-fdf1b5467a9c" xlink:to="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_dbdfd401-411f-4c20-bf69-ab0c37a250c1" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:to="loc_stpr_NJ_dbdfd401-411f-4c20-bf69-ab0c37a250c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_4931b596-9fd2-43ef-87d1-4fba8e28d806" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_46375890-bc72-4e93-82ce-9615c9d3a7ae" xlink:to="loc_country_CA_4931b596-9fd2-43ef-87d1-4fba8e28d806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_84c266ed-ce39-4ecd-8b44-7dd3e3305d67" xlink:to="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_e596acea-9730-4ac2-8563-c26c4d7b30f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_e596acea-9730-4ac2-8563-c26c4d7b30f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_1ef053e5-1de2-4147-9b74-9ecd4de432aa" xlink:href="bhc-20230331.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_44165682-4ed0-423b-82d4-e838ba441db4" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_1ef053e5-1de2-4147-9b74-9ecd4de432aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ad3d820b-3920-4d0b-8c06-b93789f35a14" xlink:to="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_52af340b-ac18-4faf-a769-1c2925cad8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_52af340b-ac18-4faf-a769-1c2925cad8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec9c6b3b-1cd4-48aa-a7e3-fd76ecdb3f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ec9c6b3b-1cd4-48aa-a7e3-fd76ecdb3f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_7c47ab12-8b08-42f6-8b25-24ce12cef6c5" xlink:href="bhc-20230331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_7c47ab12-8b08-42f6-8b25-24ce12cef6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_55ad4dba-19b3-4fe9-a643-7da3f3616d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_55ad4dba-19b3-4fe9-a643-7da3f3616d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_5619776a-4b91-4b43-b2e5-8bd0de3e12bc" xlink:href="bhc-20230331.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_5619776a-4b91-4b43-b2e5-8bd0de3e12bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_51ca9616-3bd9-41e9-b129-17b026a91cba" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_51ca9616-3bd9-41e9-b129-17b026a91cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_e67f78dd-6590-4d57-a601-4d8d28e42758" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_e67f78dd-6590-4d57-a601-4d8d28e42758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_17ebd187-a221-46e6-8d70-52ef9fbf086b" xlink:href="bhc-20230331.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_17ebd187-a221-46e6-8d70-52ef9fbf086b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_c82a690f-f6e6-45d4-80bd-636b79625bb3" xlink:href="bhc-20230331.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_c82a690f-f6e6-45d4-80bd-636b79625bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aec1dee-c841-47d8-bd2d-a29af85067cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c2120649-e680-4649-944d-8ef0adc21216" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3aec1dee-c841-47d8-bd2d-a29af85067cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSAntitrustDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6192066-88f7-4b87-8873-8b8201a976a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c6192066-88f7-4b87-8873-8b8201a976a8" xlink:to="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2ec3db90-6c75-4a33-ac6b-b79223de3d46" xlink:to="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_8a82488a-a94a-4ea8-b062-6e0d741af2a1" xlink:href="bhc-20230331.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_8a82488a-a94a-4ea8-b062-6e0d741af2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_ba11f192-6bc2-4f47-b7bc-bc444e342d6b" xlink:href="bhc-20230331.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_d90910cd-677b-4ebb-9c6b-3b208e25249a" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_ba11f192-6bc2-4f47-b7bc-bc444e342d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c60801d4-0ff5-46d9-afff-c9c172997c54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2df64295-2ef4-4d03-8902-b3eabd788811" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c60801d4-0ff5-46d9-afff-c9c172997c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_22d9ebd0-b351-4b5c-b5d7-15644c3156c0" xlink:href="bhc-20230331.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c60801d4-0ff5-46d9-afff-c9c172997c54" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_22d9ebd0-b351-4b5c-b5d7-15644c3156c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_25e8ed7f-4b4d-468a-87c4-fff21ebfc386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_e2908f3e-9f59-4603-a453-f9e68c4efc00" xlink:to="loc_us-gaap_LitigationStatusDomain_25e8ed7f-4b4d-468a-87c4-fff21ebfc386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_40d7ff56-366c-4144-9516-e56de898e42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_25e8ed7f-4b4d-468a-87c4-fff21ebfc386" xlink:to="loc_us-gaap_PendingLitigationMember_40d7ff56-366c-4144-9516-e56de898e42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e52c32d1-8b04-4602-b2b9-72fd181a275f" xlink:to="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d07d4fcc-5f9b-4c2c-bbc8-6a5f967a4b78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_d07d4fcc-5f9b-4c2c-bbc8-6a5f967a4b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_24aa0629-4446-429f-aead-6a0f2c975c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_fa1169ae-413c-4638-aaf4-b2cf3e915b17" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_24aa0629-4446-429f-aead-6a0f2c975c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSIntellectualPropertyDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8db7acda-8fbb-4668-b1f0-60880d6a53cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8db7acda-8fbb-4668-b1f0-60880d6a53cc" xlink:to="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_0803e743-527e-473c-99e0-02077b1300b1" xlink:to="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_08e8f7cd-59ba-45f5-b2ad-c74a148b9e54" xlink:href="bhc-20230331.xsd#bhc_NorwichPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_NorwichPharmaceuticalsIncLitigationMember_08e8f7cd-59ba-45f5-b2ad-c74a148b9e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaroPharmaceuticalsIncLitigationMember_c6956112-7cde-4102-b7cc-d68da9c3d9c3" xlink:href="bhc-20230331.xsd#bhc_TaroPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_TaroPharmaceuticalsIncLitigationMember_c6956112-7cde-4102-b7cc-d68da9c3d9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_53b25891-5e11-4121-98e8-03ea6d833528" xlink:href="bhc-20230331.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_53b25891-5e11-4121-98e8-03ea6d833528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AurobindoPharmaLimitedLitigationMember_bf748a59-efe4-49ec-ae13-8c2a1c3b850d" xlink:href="bhc-20230331.xsd#bhc_AurobindoPharmaLimitedLitigationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_AurobindoPharmaLimitedLitigationMember_bf748a59-efe4-49ec-ae13-8c2a1c3b850d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PreserVisionAREDSPatentLitigationMember_5d91bbe5-25c8-4d4d-99a3-03d95f55e52b" xlink:href="bhc-20230331.xsd#bhc_PreserVisionAREDSPatentLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_PreserVisionAREDSPatentLitigationMember_5d91bbe5-25c8-4d4d-99a3-03d95f55e52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_265fcf25-b162-4935-ae63-94d9db1e4358" xlink:href="bhc-20230331.xsd#bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember_265fcf25-b162-4935-ae63-94d9db1e4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_22385fc6-623b-4b4d-8f88-b82cfbae98e8" xlink:href="bhc-20230331.xsd#bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember_22385fc6-623b-4b4d-8f88-b82cfbae98e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_467f1fb6-1ad3-43d7-9fcf-5b1528d37aaf" xlink:href="bhc-20230331.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2c287caa-c2c8-447d-b18c-ae808367f7a6" xlink:to="loc_bhc_ApotexIncLitigationMember_467f1fb6-1ad3-43d7-9fcf-5b1528d37aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_de3f7892-94ae-48d0-bf6b-7c20bba964e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_188c2743-7252-4484-a296-189aff51432b" xlink:to="loc_srt_SegmentGeographicalDomain_de3f7892-94ae-48d0-bf6b-7c20bba964e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_895f93d0-743e-4b44-9627-685a53cd039f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_de3f7892-94ae-48d0-bf6b-7c20bba964e4" xlink:to="loc_country_CA_895f93d0-743e-4b44-9627-685a53cd039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_a87f04d6-fce1-4c80-ae36-99ec2abf4c0b" xlink:to="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f0621ec0-ed4c-4119-9281-9d7d00b2fa53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:to="loc_us-gaap_SettledLitigationMember_f0621ec0-ed4c-4119-9281-9d7d00b2fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefaultJudgementMember_fab8a21b-4e9e-4543-ab48-443032d2d118" xlink:href="bhc-20230331.xsd#bhc_DefaultJudgementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:to="loc_bhc_DefaultJudgementMember_fab8a21b-4e9e-4543-ab48-443032d2d118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_bc83c2d5-1fbf-4d2c-a38d-33c82dd49e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a92827b6-563d-43aa-9962-2282887904bf" xlink:to="loc_us-gaap_PendingLitigationMember_bc83c2d5-1fbf-4d2c-a38d-33c82dd49e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_acaf64d6-ec77-4eb9-a2fa-da67ae6b4afc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_34d0fbc3-53ce-4b65-9ba2-7245cdcd7976" xlink:to="loc_dei_EntityDomain_acaf64d6-ec77-4eb9-a2fa-da67ae6b4afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_f960f73f-8875-4aad-88e0-8d89d1d32cb7" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_acaf64d6-ec77-4eb9-a2fa-da67ae6b4afc" xlink:to="loc_bhc_BauschLombMember_f960f73f-8875-4aad-88e0-8d89d1d32cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_486a7502-4a70-4df2-95d0-c4e93650679a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_ef3ce88f-5ca7-451e-9bb4-05aad4858c4b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_486a7502-4a70-4df2-95d0-c4e93650679a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_68de5776-84b7-4ad2-94aa-68c19d4a7abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_486a7502-4a70-4df2-95d0-c4e93650679a" xlink:to="loc_us-gaap_SubsequentEventMember_68de5776-84b7-4ad2-94aa-68c19d4a7abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_f6ba04a6-e73a-4519-b228-d45ef2052137" xlink:to="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyStayOfApprovalPeriod_94c271e6-2499-4003-b4a0-51e0dc661755" xlink:href="bhc-20230331.xsd#bhc_GainContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_bhc_GainContingencyStayOfApprovalPeriod_94c271e6-2499-4003-b4a0-51e0dc661755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfDefendants_63d41b47-71d0-455a-8ad7-57102bda2df9" xlink:href="bhc-20230331.xsd#bhc_GainContingencyNumberOfDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_bhc_GainContingencyNumberOfDefendants_63d41b47-71d0-455a-8ad7-57102bda2df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainContingencyNumberOfProceedings_33d90d76-c8db-4bb9-bb01-273c65a61808" xlink:href="bhc-20230331.xsd#bhc_GainContingencyNumberOfProceedings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_bhc_GainContingencyNumberOfProceedings_33d90d76-c8db-4bb9-bb01-273c65a61808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_0c3fa7b6-35c6-4aa9-8efd-c35333c3af1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4d3dfdd6-eb33-46c2-88d2-b972ebaee28b" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_0c3fa7b6-35c6-4aa9-8efd-c35333c3af1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSProductLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_06d0e43d-a762-4b6c-a371-861cd10d0f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_06d0e43d-a762-4b6c-a371-861cd10d0f9b" xlink:to="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_96fd19d7-cb29-47a2-b270-e09132c1b6eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ef59ae5a-5836-4f97-aa03-21012afc0e91" xlink:to="loc_srt_LitigationCaseTypeDomain_96fd19d7-cb29-47a2-b270-e09132c1b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_965caaee-ede8-46d8-8d9c-34a3f34490d5" xlink:href="bhc-20230331.xsd#bhc_ShowerToShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_96fd19d7-cb29-47a2-b270-e09132c1b6eb" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_965caaee-ede8-46d8-8d9c-34a3f34490d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_f078e50b-0a33-49dc-b2c1-da4ea105d140" xlink:href="bhc-20230331.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationMember_965caaee-ede8-46d8-8d9c-34a3f34490d5" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_f078e50b-0a33-49dc-b2c1-da4ea105d140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_7b232200-01ef-437d-a2e8-ba84f4653d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_e68649b8-3513-4d44-93f2-a0fb809330a1" xlink:to="loc_us-gaap_LitigationStatusDomain_7b232200-01ef-437d-a2e8-ba84f4653d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_7d237626-17a2-45d6-98f2-35d0b01cc8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_7b232200-01ef-437d-a2e8-ba84f4653d43" xlink:to="loc_us-gaap_PendingLitigationMember_7d237626-17a2-45d6-98f2-35d0b01cc8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_57b29878-a151-46df-addd-5f2dc22aa2da" xlink:href="bhc-20230331.xsd#bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PendingLitigationMember_7d237626-17a2-45d6-98f2-35d0b01cc8c9" xlink:to="loc_bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember_57b29878-a151-46df-addd-5f2dc22aa2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4a7c9c1a-b216-40fa-9f8d-6a31019c6503" xlink:to="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_a0d2989e-0a45-4057-bd1b-5172c06e7bf4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:to="loc_country_CA_a0d2989e-0a45-4057-bd1b-5172c06e7bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_db9320d4-3801-40ee-a23d-25e80ba1058c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-BC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:to="loc_stpr_CA-BC_db9320d4-3801-40ee-a23d-25e80ba1058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_9842ab10-bbe3-420d-b25f-301120eb6c9a" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA-QC"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_98ba9d6b-0f55-4ffc-bca7-22334d65f32d" xlink:to="loc_stpr_CA-QC_9842ab10-bbe3-420d-b25f-301120eb6c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_cdb9b9ea-ce6e-4cbb-9d0c-db0b8fcb42cb" xlink:to="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b445786f-702a-475b-ab19-73efa2435862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b445786f-702a-475b-ab19-73efa2435862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_e575d84c-292d-4941-8b24-29bd87ce5f00" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_e575d84c-292d-4941-8b24-29bd87ce5f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5113957f-57a0-4ef7-8981-1d3c91064928" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bb5c59ab-028f-4550-9831-78f1e0115beb" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod_5113957f-57a0-4ef7-8981-1d3c91064928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#LEGALPROCEEDINGSGeneralCivilActionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dab654e4-629c-4cf3-9ee6-7ba2f593cb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dab654e4-629c-4cf3-9ee6-7ba2f593cb0f" xlink:to="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:to="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_db93bb13-5a4c-4337-a7cb-d7da3bc7aa79" xlink:to="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_8757a015-f8f4-4cc2-be28-11c6c4815796" xlink:href="bhc-20230331.xsd#bhc_CaliforniaProposition65RelatedMatterLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:to="loc_bhc_CaliforniaProposition65RelatedMatterLitigationMember_8757a015-f8f4-4cc2-be28-11c6c4815796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_1db197cb-bcdf-4db0-b869-c2ec99716dd3" xlink:href="bhc-20230331.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_1db197cb-bcdf-4db0-b869-c2ec99716dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a56d554d-abe4-4100-ad08-2e40cb04832b" xlink:href="bhc-20230331.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_c81870f8-6afc-4ed6-a4ce-3ca66c7deed1" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_a56d554d-abe4-4100-ad08-2e40cb04832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_aaf327d1-8f6b-44d1-9082-a0d2ad331d0a" xlink:to="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_c01fd97d-6876-4041-8d6a-c2e70fd54d2c" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne_c01fd97d-6876-4041-8d6a-c2e70fd54d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_3774ab7a-b9be-4f9c-827b-d1a9c4650b39" xlink:href="bhc-20230331.xsd#bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo_3774ab7a-b9be-4f9c-827b-d1a9c4650b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_2cd57175-807d-42a1-8d13-df74624aafed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_776fa822-f943-4d54-9e8e-7def111be4de" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_2cd57175-807d-42a1-8d13-df74624aafed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a2b8d335-56a1-4884-a0c4-f239fa95f2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a2b8d335-56a1-4884-a0c4-f239fa95f2bf" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4b7b1f3a-30c9-4f23-9082-f8e8b9074d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_951cd25a-32c7-4465-ad9d-73a583f66246" xlink:to="loc_us-gaap_SegmentDomain_4b7b1f3a-30c9-4f23-9082-f8e8b9074d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_dfdaedce-e635-4e30-b141-17afeb509abc" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4b7b1f3a-30c9-4f23-9082-f8e8b9074d38" xlink:to="loc_bhc_SalixSegmentMember_dfdaedce-e635-4e30-b141-17afeb509abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e95c5ca5-f33e-4ffb-b361-9e20190c9610" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9412496c-d660-42f1-8246-7b527220d25d" xlink:to="loc_srt_ProductsAndServicesDomain_e95c5ca5-f33e-4ffb-b361-9e20190c9610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_XifaxanBrandedProductsMember_5d8ff723-d4c0-4124-8e2d-47e7c30b1671" xlink:href="bhc-20230331.xsd#bhc_XifaxanBrandedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e95c5ca5-f33e-4ffb-b361-9e20190c9610" xlink:to="loc_bhc_XifaxanBrandedProductsMember_5d8ff723-d4c0-4124-8e2d-47e7c30b1671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_452aa8ee-1936-46bc-b5ee-cc9bd367b978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_560d67a7-7161-410f-8ab4-39ff315f979e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_452aa8ee-1936-46bc-b5ee-cc9bd367b978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_10e82544-d6ba-4af4-8519-f2f11da65f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_452aa8ee-1936-46bc-b5ee-cc9bd367b978" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember_10e82544-d6ba-4af4-8519-f2f11da65f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3044af4c-a11e-4673-a0e9-24caf08c16b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_803089e6-2be7-4530-92c8-a0fd42fe0a6d" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3044af4c-a11e-4673-a0e9-24caf08c16b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0a8ff888-9737-438b-8cc0-be0c44018e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3044af4c-a11e-4673-a0e9-24caf08c16b7" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0a8ff888-9737-438b-8cc0-be0c44018e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_236e3ece-c96b-48a9-a6e2-36eae6d06f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f40311a4-c935-4c2a-805a-b3d65c4276f0" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_236e3ece-c96b-48a9-a6e2-36eae6d06f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6b217f6c-830e-4a3a-8d70-eacb7eaccb60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_236e3ece-c96b-48a9-a6e2-36eae6d06f65" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6b217f6c-830e-4a3a-8d70-eacb7eaccb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a9ca74b2-f103-4fc9-aa7a-5abf09891c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a9ca74b2-f103-4fc9-aa7a-5abf09891c7c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:to="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_55ff82cc-c9f0-4cc6-967c-642ef30aa6f3" xlink:to="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_575f9b9e-3814-415d-a295-a5d26b32cdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:to="loc_us-gaap_OperatingSegmentsMember_575f9b9e-3814-415d-a295-a5d26b32cdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d1cb3517-1e28-4e69-938a-c2446ea071f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ae404c7b-7980-4167-9114-9ea4567818dc" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d1cb3517-1e28-4e69-938a-c2446ea071f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0e1741d8-4118-491e-9c9f-d1d14e2648f8" xlink:to="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_d033e27c-78ee-4589-bb6c-78865fd9af10" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_SalixSegmentMember_d033e27c-78ee-4589-bb6c-78865fd9af10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_4378298f-444d-4193-93c7-bef1e4e7d4d4" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_InternationalRxMember_4378298f-444d-4193-93c7-bef1e4e7d4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_cac21e1b-28ed-4ce2-b8d4-a09ed6c53046" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_SoltaMedicalSegmentMember_cac21e1b-28ed-4ce2-b8d4-a09ed6c53046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember_e83597cf-e8df-4963-aed1-c2a9a2eb67e3" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_DiversifiedSegmentMember_e83597cf-e8df-4963-aed1-c2a9a2eb67e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_ce17ea61-0302-4629-a8fb-026402498c79" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e6548c8b-61f5-44f5-85ac-1103788448d3" xlink:to="loc_bhc_BauschLombMember_ce17ea61-0302-4629-a8fb-026402498c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_adb25c0c-e9e7-493f-93df-8cbb65987bc4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41fe946b-c8d8-4d8c-9ab9-c7d42f30bcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_41fe946b-c8d8-4d8c-9ab9-c7d42f30bcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_60f269be-4410-42dc-a370-c79dc92a977e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_OperatingIncomeLoss_60f269be-4410-42dc-a370-c79dc92a977e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_005e8b78-6540-45f8-95f5-50238a9b4824" xlink:href="bhc-20230331.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_005e8b78-6540-45f8-95f5-50238a9b4824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_34a7faa0-f52e-474a-87a2-e19d75663aac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_AssetImpairmentCharges_34a7faa0-f52e-474a-87a2-e19d75663aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_2444bb7a-e5c0-47b8-aed4-81f4c369f96d" xlink:href="bhc-20230331.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_2444bb7a-e5c0-47b8-aed4-81f4c369f96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_c9b36185-f03a-4801-bff3-438c17e667fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_c9b36185-f03a-4801-bff3-438c17e667fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e8990a2d-d205-47a1-82df-38ce723b588d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e8990a2d-d205-47a1-82df-38ce723b588d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7c19456d-c861-4005-8a36-55d5d4aa2022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_InterestExpenseDebt_7c19456d-c861-4005-8a36-55d5d4aa2022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01659d22-0c0e-4968-936a-5e9c6ee4b862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_01659d22-0c0e-4968-936a-5e9c6ee4b862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0970aa9b-4727-49bf-8536-c319c4f3ccea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_91be1097-d8e4-44ee-87cf-cc99accac190" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0970aa9b-4727-49bf-8536-c319c4f3ccea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_22971e68-78be-4d50-9110-a9a8704ba4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_22971e68-78be-4d50-9110-a9a8704ba4ad" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0407d6c-bcc9-40a4-9906-c3f5e8d4b6c9" xlink:to="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_750fc1b1-794d-4c6b-9808-dfe2bb35564e" xlink:href="bhc-20230331.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_SalixSegmentMember_750fc1b1-794d-4c6b-9808-dfe2bb35564e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_d34679fc-e135-4f3e-9665-587706b1d212" xlink:href="bhc-20230331.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_InternationalRxMember_d34679fc-e135-4f3e-9665-587706b1d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_55726b29-4838-4916-a670-1fd83743acfb" xlink:href="bhc-20230331.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_SoltaMedicalSegmentMember_55726b29-4838-4916-a670-1fd83743acfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedSegmentMember_5eae6e26-988b-48bb-95ac-bc966da5f4d2" xlink:href="bhc-20230331.xsd#bhc_DiversifiedSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_DiversifiedSegmentMember_5eae6e26-988b-48bb-95ac-bc966da5f4d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_ed14432b-1207-4c9f-b85a-ff9236fbcb47" xlink:href="bhc-20230331.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cdae5110-b5b9-4fd6-8f6d-4bad20f75543" xlink:to="loc_bhc_BauschLombMember_ed14432b-1207-4c9f-b85a-ff9236fbcb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:to="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_617fc945-edd5-45d9-942c-c91713742180" xlink:to="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_8c3022bc-7ef7-4531-81c8-ccbe79b17de5" xlink:href="bhc-20230331.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_PharmaceuticalProductsMember_8c3022bc-7ef7-4531-81c8-ccbe79b17de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_28676fb8-b76f-4dd9-adc2-18f476c7d311" xlink:href="bhc-20230331.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_DeviceProductsMember_28676fb8-b76f-4dd9-adc2-18f476c7d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_06f9b0df-4087-457f-8578-6bb61f0a1934" xlink:href="bhc-20230331.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_OvertheCounterProductsMember_06f9b0df-4087-457f-8578-6bb61f0a1934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_a7cdab35-f808-4c6a-9ee5-ea5c33fd2ce7" xlink:href="bhc-20230331.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_a7cdab35-f808-4c6a-9ee5-ea5c33fd2ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_adc54db8-c7fe-4ca2-9ba6-e8eb9356a253" xlink:href="bhc-20230331.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ae0a419f-a952-411a-ac2d-9076513c1b8a" xlink:to="loc_bhc_OtherRevenuesMember_adc54db8-c7fe-4ca2-9ba6-e8eb9356a253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_298931cb-e0cb-40fb-b1ca-d26c54d61931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_18beb054-beba-4a0d-bdfc-ddab2472f318" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_298931cb-e0cb-40fb-b1ca-d26c54d61931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7051649-8077-4df1-a851-702640f84bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_298931cb-e0cb-40fb-b1ca-d26c54d61931" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b7051649-8077-4df1-a851-702640f84bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_18caf47f-919c-441a-b894-ac73d9ad7b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_18caf47f-919c-441a-b894-ac73d9ad7b33" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_568ec2ff-ead3-4a40-ae46-5303d1169626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_269789a5-920d-4a10-8be4-414a05928f1f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_568ec2ff-ead3-4a40-ae46-5303d1169626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_fec4e8f6-5cf1-4f21-95c1-ed8754be4d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_568ec2ff-ead3-4a40-ae46-5303d1169626" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_fec4e8f6-5cf1-4f21-95c1-ed8754be4d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fb8e4373-aa80-49f2-a5e6-295cf3941ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_60acf161-5542-4684-8dee-57920f6a5f7d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fb8e4373-aa80-49f2-a5e6-295cf3941ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_1fba0b71-734e-4f5f-8a23-591238a2a7cc" xlink:href="bhc-20230331.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fb8e4373-aa80-49f2-a5e6-295cf3941ebd" xlink:to="loc_bhc_RevenuesNetMember_1fba0b71-734e-4f5f-8a23-591238a2a7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4095fcfb-0cdc-413a-b8b4-3fc9d4ffd69d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b6316c65-b6d4-43ca-8351-60c6692cfc9c" xlink:to="loc_srt_NameOfMajorCustomerDomain_4095fcfb-0cdc-413a-b8b4-3fc9d4ffd69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_f202f266-b0a7-40bc-a3c6-80c01f96754d" xlink:href="bhc-20230331.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4095fcfb-0cdc-413a-b8b4-3fc9d4ffd69d" xlink:to="loc_bhc_CustomerTopTenProductsMember_f202f266-b0a7-40bc-a3c6-80c01f96754d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a23ee174-4b48-48cc-9e68-0f4566a0a706" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_290d308e-d8a0-4abd-8bb0-3db4764dbbde" xlink:href="bhc-20230331.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_290d308e-d8a0-4abd-8bb0-3db4764dbbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a24798c5-fea9-4ede-b228-3cb6c8a799a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5cd4cfa9-b346-4f7b-b959-1b80a41b2f00" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a24798c5-fea9-4ede-b228-3cb6c8a799a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4f7edb2c-9582-4af2-b1d1-082d20e4ce2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4f7edb2c-9582-4af2-b1d1-082d20e4ce2e" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:to="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_67c7d12f-be2e-4010-9d96-5d36733794dd" xlink:to="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_60f0490d-97ee-450d-a8b6-15b5e5885054" xlink:href="bhc-20230331.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_60f0490d-97ee-450d-a8b6-15b5e5885054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_33a97e0e-451f-43d2-bc4d-005a8d4fea69" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_CN_33a97e0e-451f-43d2-bc4d-005a8d4fea69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_853aec88-7efc-4d02-aea2-a3fb4c59a816" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_CA_853aec88-7efc-4d02-aea2-a3fb4c59a816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_63dd6db6-005c-4a1c-a0a5-63b17f4cbc45" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_PL_63dd6db6-005c-4a1c-a0a5-63b17f4cbc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_38c32e19-d047-4008-a488-f664e03265fa" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_MX_38c32e19-d047-4008-a488-f664e03265fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ad9d9ae5-4af3-4033-8fcb-320563a65c12" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_FR"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_FR_ad9d9ae5-4af3-4033-8fcb-320563a65c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_7f1c71c0-faba-4510-9a76-09242708c2b8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_JP_7f1c71c0-faba-4510-9a76-09242708c2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_49ac84df-2cc4-44a5-aa0a-7e17982340df" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_DE_49ac84df-2cc4-44a5-aa0a-7e17982340df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_a750c796-8135-4fc9-b120-e4f52287750a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_GB"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_GB_a750c796-8135-4fc9-b120-e4f52287750a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_d01275fc-44a3-4c34-993c-c77d1df93936" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_RU"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_RU_d01275fc-44a3-4c34-993c-c77d1df93936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_6bd4ce83-be27-4482-a0e6-4455eb0e6947" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_ES"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_ES_6bd4ce83-be27-4482-a0e6-4455eb0e6947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_5c67c647-7591-4f48-9ec2-93a572c745d4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IT"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_IT_5c67c647-7591-4f48-9ec2-93a572c745d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_KR_9dd1d9a9-c99b-4885-aaea-d75114415945" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KR"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_country_KR_9dd1d9a9-c99b-4885-aaea-d75114415945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_74fc569e-bc7a-4e51-a582-8680165a2c68" xlink:href="bhc-20230331.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4983771b-c889-4840-bcef-169099586bb2" xlink:to="loc_bhc_OtherCountriesMember_74fc569e-bc7a-4e51-a582-8680165a2c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_09616393-7987-43c9-a815-ce0bc3577a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_8a718e6f-c362-445f-94d0-a8e716cd76bd" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_09616393-7987-43c9-a815-ce0bc3577a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edd63b36-f3e9-4afa-8713-8cdeebcd510c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_09616393-7987-43c9-a815-ce0bc3577a22" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_edd63b36-f3e9-4afa-8713-8cdeebcd510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20230331.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_93b39de4-2236-44af-9d54-059ccb3d5a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_93b39de4-2236-44af-9d54-059ccb3d5a5f" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a33ee32a-0499-4eee-9568-e22304c65f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7f7a79e5-1a9c-484e-8d55-14defc79accd" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a33ee32a-0499-4eee-9568-e22304c65f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_a89210e3-5bb7-4e63-b6b5-45a0e9d1349e" xlink:href="bhc-20230331.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a33ee32a-0499-4eee-9568-e22304c65f5a" xlink:to="loc_bhc_RevenuesNetMember_a89210e3-5bb7-4e63-b6b5-45a0e9d1349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_93db2555-1609-43a6-a483-f757ab912225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5169a553-fda3-4706-a78b-25981f7b86f7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_93db2555-1609-43a6-a483-f757ab912225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_51444b1a-6eed-4a9f-842d-8519ccc312e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_93db2555-1609-43a6-a483-f757ab912225" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_51444b1a-6eed-4a9f-842d-8519ccc312e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_eb82bd46-a554-420e-9dc1-32f3821fc6a2" xlink:to="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_fb721db9-2d9b-4550-a8de-54ad4f6ca0f6" xlink:href="bhc-20230331.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_fb721db9-2d9b-4550-a8de-54ad4f6ca0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_a04d063b-9d9d-4171-9327-4871bdb008a0" xlink:href="bhc-20230331.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:to="loc_bhc_McKessonCorporationMember_a04d063b-9d9d-4171-9327-4871bdb008a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_c98db0c1-1639-40ec-befa-541eaa359ff2" xlink:href="bhc-20230331.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f2e0492c-ffae-4ea0-9c6e-1bbe91bf738d" xlink:to="loc_bhc_CardinalHealthIncMember_c98db0c1-1639-40ec-befa-541eaa359ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_1e1a75fd-508f-4338-a6c3-a22f6b3c12b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_d5f56b75-c953-4573-bc59-3ec08e6d8fab" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_1e1a75fd-508f-4338-a6c3-a22f6b3c12b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_31ae5a15-d1ab-4558-8147-173594442b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_1e1a75fd-508f-4338-a6c3-a22f6b3c12b2" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_31ae5a15-d1ab-4558-8147-173594442b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407849952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,723,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408245296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">776<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">4,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">11,579<span></span>
</td>
<td class="nump">11,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">2,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,445<span></span>
</td>
<td class="nump">25,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">2,916<span></span>
</td>
<td class="nump">2,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">3,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">20,207<span></span>
</td>
<td class="nump">20,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">25,300<span></span>
</td>
<td class="nump">25,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 18)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 363,607,062 and 361,898,846 issued and outstanding at March 31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">10,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(9,387)<span></span>
</td>
<td class="num">(9,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,989)<span></span>
</td>
<td class="num">(2,056)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; deficit</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 25,445<span></span>
</td>
<td class="nump">$ 25,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549409137232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued (in shares)</a></td>
<td class="nump">363,607,062<span></span>
</td>
<td class="nump">361,898,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">363,607,062<span></span>
</td>
<td class="nump">361,898,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549405123936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 1,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interest</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (201)<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">363.3<span></span>
</td>
<td class="nump">360.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">363.3<span></span>
</td>
<td class="nump">360.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,922<span></span>
</td>
<td class="nump">$ 1,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407831088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension and postretirement benefit plan adjustments, net of income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss (income) attributable to noncontrolling interest</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (134)<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408970272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders&#8217; Deficit</div></th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
<td class="num">$ (8,961)<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="nump">$ 10,373<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="num">(9,030)<span></span>
</td>
<td class="num">(1,974)<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">361,898,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 260<span></span>
</td>
<td class="num">(692)<span></span>
</td>
<td class="nump">$ 10,391<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="num">(9,186)<span></span>
</td>
<td class="num">(2,056)<span></span>
</td>
<td class="nump">952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Employee withholding taxes related to share-based awards</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">B+L vested shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">363,607,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="num">$ (800)<span></span>
</td>
<td class="nump">$ 10,405<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="num">$ (9,387)<span></span>
</td>
<td class="num">$ (1,989)<span></span>
</td>
<td class="nump">$ 945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549403935600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (209)<span></span>
</td>
<td class="num">$ (66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt premiums, discounts and issuance costs</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivable and inventories</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Adjustments to accrued legal settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">154<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments', window );">Acquisitions and other investments</a></td>
<td class="num">(31)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for intangible and other assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Interest settlements from cross-currency swaps</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(279)<span></span>
</td>
<td class="num">(485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of employee withholding taxes related to share-based awards</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(142)<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and other</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash and other settlement deposits, end of period</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">$ 2,460<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentsToAcquireBusinessesAndForOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Businesses And For Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentsToAcquireBusinessesAndForOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549415448320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#8220;Company&#8221; or &#8220;Bausch Health&#8221;) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#8220;GI&#8221;), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and aesthetic medical devices, and, through its approximately 89% ownership of Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company&#8217;s products are marketed directly or indirectly in approximately 100 countries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549415452624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;) on February&#160;23, 2023. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2022. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye Health Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its plan to separate its eye health business, consisting of its Bausch + Lomb global Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb Corporation (&#8220;Bausch + Lomb&#8221; or &#8220;B+L&#8221;) from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On May 5, 2022, the registration statement related to the initial public offering of Bausch +Lomb (the &#8220;B+L IPO&#8221;) was declared effective, and B+L&#8217;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#8220;BLCO&#8221; on May 6, 2022. Prior to the effectiveness of the registration statement, B+L was an indirect wholly-owned subsidiary of Bausch Health. On May 10, 2022, a wholly owned subsidiary of Bausch Health sold 35,000,000 common shares of B+L pursuant to the B+L IPO. Upon the closing of the B+L IPO and after giving effect to the subsequent partial exercise of the over-allotment option by the underwriters, Bausch Health indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 89% of B+L&#8217;s outstanding common shares as of March&#160;31, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all relevant factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221;) on the B+L Separation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company comprised of the Salix, International, Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical), and Solta Medical aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other than the effects of the B+L IPO described above, these unaudited Condensed Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412604272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue which is derived primarily from contract manufacturing for third parties and which is not material. See Note 18, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the three months ended March 31, 2023 and 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $40&#160;million as of March 31, 2023 and January 1, 2023, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $37 million and $36&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2023 and 2022 is as follows.</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549415568432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND ACQUISITION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock', window );">LICENSING AGREEMENTS AND ACQUISITION</a></td>
<td class="text">LICENSING AGREEMENTS AND ACQUISITION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2023, Bausch + Lomb acquired AcuFocus, Inc., an ophthalmic medical device company, for an up-front payment of $35&#160;million, $31&#160;million of which was paid in January 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the remaining purchase price to be paid within 18 months following the transaction, less any amounts that are the subject of any indemnification claims</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The acquisition was made to acquire certain small aperture intraocular technology for the treatment of certain cataract conditions. Additional contingent payments may be payable upon achievement of future sales milestones. Bausch + Lomb recorded an initial acquisition-related contingent consideration liability of $5&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this transaction, recorded within the Condensed Consolidated Balance Sheets are Intangibles, net of $28&#160;million, Goodwill of $2&#160;million, other assets of $11&#160;million and liabilities of $2&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing Agreements And Acquisition Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412690112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Integration Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $9 million and $3&#160;million of restructuring and integration costs during the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities relating to the B+L Separation. In 2022, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and, in 2022, Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and, in 2022, preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and, in 2022, the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for Bausch + Lomb. Included in Restructuring, integration, separation and IPO costs for the three months ended March 31, 2023 and 2022 are separation and IPO costs of $1&#160;million and $10&#160;million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and expects to continue to incur incremental costs with respect to the B+L Separation. During 2022, the Company also incurred incremental costs indirectly related to the suspended Solta IPO. These separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the three months ended March 31, 2023 and 2022 are separation-related and IPO-related costs of $6&#160;million and $24&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities And Initial Public Offering Costs Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411500096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Condensed Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash as presented in the Condensed Consolidated Balance Sheet as of March 31, 2023 includes $358&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operating, investing and financing activities of Bausch + Lomb is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 assets or liabilities during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps, with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Condensed Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#8217;s investment in certain Bausch + Lomb euro-denominated subsidiaries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Condensed Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb&#8217;s cross-currency swaps qualify for and have been designated as a hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Condensed Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the periods presented. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with Bausch + Lomb&#8217;s cross-currency swaps as included in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022 are as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:70.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Condensed Consolidated Statements of Comprehensive Loss and the Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.626%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No portion of the cross-currency swaps were ineffective for the three months ended March 31, 2023. During the three months ended March 31, 2023, the Company received $6&#160;million in interest settlements, which are reported as investing activities in the Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company&#8217;s outstanding foreign currency exchange contracts had an aggregate notional amount of $548&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#8217;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#8217;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Condensed Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#8217;s foreign currency exchange contracts are reported as a gain or loss </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Condensed Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Condensed Consolidated Statements of Cash Flows. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Condensed Consolidated Statements of Operations and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At March&#160;31, 2023, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#8217;s relative fair value at March&#160;31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:70.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AcuFocus Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of March&#160;31, 2023 and December&#160;31, 2022 was $13,367 million and $14,011 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412578336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549415568432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,653)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Condensed Consolidated Statements of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses and research and development expenses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments for the three months ended March 31, 2023 were $13&#160;million and include impairments of: (i) $8&#160;million, in aggregate, attributable to certain trade names no longer in use and (ii) $5&#160;million, related to the discontinuance of a certain product line. Asset impairments for the three months ended March 31, 2022 were $8&#160;million due to discontinuances and decreases in the forecasted sales of certain product lines. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets included in the unaudited Condensed Consolidated Balance Sheets had a carrying value of $2,559&#160;million and an estimated remaining useful life of 57 months as of March 31, 2023. On August 10, 2022, a court held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating inflammatory bowel syndrome with diarrhea (&#8220;IBS-D&#8221;) were invalid (the &#8220;Norwich Legal Decision&#8221;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Paragraph IV Proceedings&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that, in the third quarter of 2022, the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets for potential impairment using different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. This assessment resulted in no impairment of the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets as of September 30, 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From September 30, 2022 through the first quarter of 2023 there were no material changes to the facts and circumstances of the Norwich Legal Decision or to actual or expected business performance for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on these factors, no impairment to the carrying value of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was identified as of March 31, 2023. The Company also determined that no change to the remaining useful lives of its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> finite-lived intangible assets was required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be material to the results of operations of the Company in the period or periods in which they were to occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2023 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 and the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dermatology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#8217;s terminal value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit&#8217;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#8217;s and a market participant&#8217;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#8217;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such charges could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Dermatology (formerly Ortho Dermatologics) reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk-free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Dermatology reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2022 Interim Assessment </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Dermatology reporting unit as of March 31, 2022. Given the limited headroom of the Dermatology reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Dermatology reporting unit as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Dermatology reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate had increased 1% since the assessment performed as of March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk-free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Dermatology reporting unit exceeded its fair value as of June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period May 6, 2022 (the date Bausch + Lomb&#8217;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The equity markets negatively impacted the market price for Bausch + Lomb&#8217;s common stock which as of June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized the Company&#8217;s most recent cash flow projections for each of its reporting units as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value tests utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September 30, 2022 Interim Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Dermatology reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Dermatology reporting unit at June 30, 2022. Based on the impairment of goodwill recognized in the second quarter of 2022 for the Dermatology reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test utilized the Company&#8217;s most recent cash flow projections for the Dermatology reporting unit as revised in the third quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#8217;s discounted cash flow model for the Dermatology reporting unit includes, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of 1% and the discount rate increased from 10.0% at June 30, 2022 to 10.5% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Dermatology reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $119&#160;million for the three months ended September 30, 2022. As of September 30, 2022, the Dermatology reporting unit had remaining goodwill of $480&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intellectual property. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of Note 17, &#8220;LEGAL PROCEEDINGS&#8221; for details of this litigation matter and the Company&#8217;s response.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues represent approximately 80% of the Salix reporting unit&#8217;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, could impact the timing and extent of future revenues and cash flows associated with Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues are indicators that the Salix reporting unit&#8217;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#8217;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.0%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#8217;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#8217;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2022, no events occurred, or circumstances changed during the period October 1, 2021 (the date of the last annual impairment test) through September 30, 2022, that indicated that the fair value of any reporting unit, other than the Dermatology reporting unit, the Salix reporting unit and the reporting units of the Bausch + Lomb segment, might be below their respective carrying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Annual Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, the Company conducted its annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2022, management believed that, it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurology and Other </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands, health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. The nature of the Neurology and Other reporting unit&#8217;s product portfolio, which includes branded generic pharmaceuticals, is by its nature impacted by these changing market dynamics. As a result, the Company has begun taking steps to: (i) reassess its pricing strategies, (ii) re-evaluate its marketing and promotional efforts and (iii) reduce its cost structure, and has revised its long-term forecasts for the Neurology and Other reporting unit to reflect these developments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Neurology and Other reporting unit utilized the most recent cash flow projections for the reporting unit as revised in the fourth quarter of 2022 to reflect current market conditions and current trends in business performance. The quantitative assessment utilized a long-term growth rate of -2.5% and a discount rate of 10.25% in the estimation of the reporting unit&#8217;s fair value. As a result of the revisions to its long-term expectations for these and other factors, goodwill for the Neurology and Other reporting unit was impaired during the Company&#8217;s most recent annual impairment test reflecting its best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value test, the carrying value of the Neurology and Other reporting unit exceeded its fair value as of October 1, 2022, and the Company recognized a goodwill impairment of $622&#160;million. As of December 31, 2022, the Neurology and Other reporting unit had remaining goodwill of $1,439&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative assessment utilized long-term growth rates of 2.0% and 3.0% and discount rates of 9.50% and 12.25% in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its respective carrying value by more than 25% and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 31, 2022</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period October 1, 2022 through December 31, 2022, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Dermatology and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and any such charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dermatology</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the impairment of goodwill in the third quarter of 2022, the Dermatology reporting unit had no headroom on September 30, 2022, and as such, the Company continued to monitor the market conditions impacting the Dermatology reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company evaluated the reporting unit&#8217;s performance as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Dermatology reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salix</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the quantitative fair value testing performed in the third quarter of 2022, the Salix reporting unit had limited headroom as of September 30, 2022 and, as such, the Company continued to monitor the potential impacts of changes in the Norwich Legal Decision and market conditions on the valuation of the Salix reporting unit during the period October 1, 2022 through December 31, 2022. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December 31, 2022, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#8217;s assessment as to a competitor&#8217;s ability to launch a successful generic version to Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to January 2028, if they are able to launch one at all. The Company also evaluated the reporting unit&#8217;s performance in the fourth quarter as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#8217;s latest business strategies. This evaluation supported management&#8217;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Salix reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2023 Interim Assessment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Dermatology, Neurology and Other, and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and any such charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through March&#160;31, 2023 were $5,004 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412690112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549415568432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the 9.00% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of March&#160;31, 2023, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $9,700&#160;million (although such availability is subject to the Company&#8217;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#8220;Exchange Offer&#8221;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $5,594&#160;million as set forth in the table below (collectively, the &#8220;Existing Unsecured Senior Notes&#8221;) for $3,125&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $2,469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#8220;11.00% First Lien Secured Notes&#8221;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#8220;14.00% Second Lien Secured Notes&#8221; and, together with the 11.00% First Lien Secured Notes, the &#8220;New BHC Secured Notes&#8221;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#8220;9.00% Intermediate Holdco Secured Notes&#8221; and, together with the New BHC Secured Notes, the &#8220;New Secured Notes&#8221;) issued by 1375209 B.C. Ltd. (&#8220;Intermediate Holdco&#8221;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#8217;s Condensed Consolidated Balance Sheets</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. During the first quarter of 2023, the Company made contractual interest payments of $128&#160;million related to the New Secured Notes, of which $111&#160;million was recorded as a reduction of the premium. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2018 Restated Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;2018 Restated Credit Agreement&#8221;). Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the 2022 Amended Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#8220;Second Amendment&#8221;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#8220;2022 Amended Credit Agreement&#8221;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#8220;2027 Term Loan B Facility&#8221;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#8220;2027 Revolving Credit Facility&#8221;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#8220;Credit Agreement Refinancing&#8221;), along with certain of the Company&#8217;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of March 31, 2023, the Company had drawn $395&#160;million and had $23&#160;million of issued and outstanding letters of credit on the 2027 Revolving Credit Facility. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#8220;term SOFR rate&#8221;) for the interest period relevant to such borrowing</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#8217;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#8220;EURIBOR&#8221;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of March&#160;31, 2023, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $469&#160;million through December 2026.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions that were designed to facilitate the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds approximately 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#8217;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are unrestricted subsidiaries of the Company and, as a result, are not subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#8217;s financial maintenance covenant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Senior Secured Credit Facilities under the B+L Credit Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#8220;B+L Credit Agreement&#8221;, and the credit facilities thereunder, the &#8220;B+L Credit Facilities&#8221;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#8220;B+L Term Facility&#8221;) and a five-year revolving credit facility of $500&#160;million (the &#8220;B+L Revolving Credit Facility&#8221; and such financing, the &#8220;B+L Debt Financing&#8221;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of March&#160;31, 2023, the B+L Revolving Credit Facility had $100&#160;million of outstanding borrowings, $24&#160;million of issued and outstanding letters of credit and remaining availability of $376&#160;million under its Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#8217;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of any other subsidiaries of Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a term Secured Overnight Financing Rate (&#8220;SOFR&#8221;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either: (a) a Canadian Dollar Offered Rate (&#8220;CDOR&#8221;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#8220;SONIA&#8221;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#8217;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of Standard &amp; Poor&#8217;s, Moody&#8217;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#8220;IG Trigger&#8221;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#8217;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#8217;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#8217;s option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%. The stated rate of interest under the Term Facility at March&#160;31, 2023 was 8.46% per annum.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, and the first quarterly installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of March&#160;31, 2023, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $100&#160;million through March 2027, with the remaining term loan balance being due in May 2027.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). In connection with the closing of the B+L IPO, the redemption of the Company&#8217;s 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.125% Senior Secured Notes due 2027 - February 2022 Financing</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">New BHC Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 11.00% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of 11.00% per year that is payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 11.00% First Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 14.00% Second Lien Secured Notes mature on October 15, 2030, and have a stated interest of 14.00% per year that is payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#8220;make-whole&#8221; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.00% Intermediate Holdco Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of 9.00% per year that is payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of March 31, 2023 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#8217;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Redemption of April 2025 Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of the B+L IPO, on May 10, 2022, the Company using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A. The April 2025 Unsecured Notes were redeemed on May 16, 2022 and were accounted for as an extinguishment of debt. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The weighted average stated rate of interest for the Company&#8217;s outstanding debt obligations as of March&#160;31, 2023 and December&#160;31, 2022 was 7.87% and 7.74%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#8217;s financial statements for 2023 and in future periods will not be representative of the weighted average stated rate of interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2023, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,653&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412468224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch Health&#8217;s Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, shareholders approved Bausch Health&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;) which replaced Bausch Health&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was initially equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#8220;Amended and Restated 2014 Plan&#8221;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 9,527,000 common shares were available for future grants under the Amended and Restated 2014 Plan as of March&#160;31, 2023. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on generating operating cash flow while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#8220;RSUs&#8221;) and performance-based RSUs. Performance-based RSUs are comprised of awards that vest: (i) upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;), (iii) upon attainment of Adjusted Operating Cash Flow, as defined in each applicable award agreement, and a Relative Total Shareholder Return modifier performance metric and (iv) fully or partially upon attainment of certain goals that are linked to the B+L Separation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to retain and incentivize certain members of the Company&#8217;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#8220;Retention RSU Grant&#8221;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzEyOA_7d8122c2-092a-4cd8-b6dd-b57d32d9fc25">three</span> anniversaries of the grant date based on continuous employment with Bausch Health.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bausch + Lomb Long-Term Incentive Plan</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to May 5, 2022, Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb participated in Bausch Health&#8217;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#8220;B+L Plan&#8221;). A total of 28,000,000 common shares of Bausch + Lomb were originally authorized under the B+L Plan. Effective April 24, 2023, the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shareholders of Bausch + Lomb approved an amendment and restatement to the B+L Plan to increase the number of shares authorized for issuance thereunder by an additional 10,000,000 common shares, resulting in an aggregate 38,000,000 common shares of Bausch + Lomb authorized for issuance under the Plan (the &#8220;Plan Amendment&#8221;). The B+L Plan provides for the grant of various types of awards including RSUs, restricted stock, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 9,300,000 Bausch + Lomb common shares were available for future grants as of March&#160;31, 2023. This does not include the additional 10,000,000 common shares authorized for issuance under the Plan Amendment. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s focus on enhancing its revenue growth while maintaining focus on total shareholder return over the long-term. In addition to stock options and RSUs, during the first quarter of 2023, performance restricted share units (&#8220;PSUs&#8221;) were also granted. The PSUs are comprised of awards that vest upon: (i) achievement of certain share price appreciation conditions, including absolute and relative TSR and (ii) attainment of certain performance targets that are based on </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s Organic Revenue Growth. If </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s performance is below a specified performance level, no common shares will be paid. Each vested PSU represents the right of a holder to receive a number of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s common shares up to a specified maximum. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR PSU granted was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the Organic Revenue Growth PSUs is estimated based on the trading price of </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s common shares on the date of grant. Expense recognized for the Organic Revenue Growth PSUs in each reporting period reflects </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> + Lomb&#8217;s latest estimate of Organic Revenue Growth in determining the number of PSUs that are expected to vest. If the Organic Revenue Growth PSUs do not ultimately vest due to the Organic Revenue Growth targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, Bausch + Lomb announced the appointment of Brent Saunders as its Chief Executive Officer, effective March 6, 2023. Pursuant to Mr. Saunders&#8217; employment agreement, on February 23, 2023, Mr. Saunders was granted the following equity grants: 750,000 PSUs, 1,318,681 stock options and 375,000 RSUs. The RSUs are scheduled to vest 50% on the second anniversary of the grant date and the remaining 50% on the third anniversary of the grant date. The stock options are scheduled to vest in equal one-third installments on each of the first three anniversaries of the grant date. The PSUs vest on the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDI0NA_b622811e-eab0-4467-ba1f-ded7a871e35c">four</span>th anniversary from grant date based on Bausch + Lomb&#8217;s achievement of absolute share price hurdles, or upon achievement of absolute and relative TSR hurdles in relation to the S&amp;P 500 Index during the four-year performance period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company&#8217;s share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the three months ended March 31, 2023 and 2022 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Operating Cash Flow performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,358,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organic Revenue Growth performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $216 million, which will be amortized over a weighted-average period of 2.31 years.</span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $118&#160;million, which will be amortized over a weighted-average period of 2.49 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412555664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,971)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in the Company&#8217;s ownership interest in Bausch + Lomb, in the second quarter of 2022, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411411072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI https://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408967216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text">OTHER EXPENSE, NET<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:77.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.948%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, Litigation and other matters primarily relates to an insurance recovery regarding a certain litigation matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration expense for the three months ended March 31, 2023, primarily includes adjustments to reflect the changes in estimates of the future royalty and milestone payments related to a branded product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408623312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#8217;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#8217;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates and an evaluation of valuation allowances. The Company&#8217;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes for the three months ended March 31, 2023 was $73 million and included: (i) $13&#160;million of income tax benefit for the Company&#8217;s ordinary loss for the three months ended March 31, 2023 and (ii) $86 million of net income tax expense for discrete items, which includes: (a) $41&#160;million of net income tax expense related to final and potential settlements of various tax audits in the first quarter of 2023, (b) $18&#160;million of income tax expense related to changes in uncertain tax positions, (c) $18&#160;million of income tax expense associated with the establishment of a valuation allowance against deferred tax assets of B+L&#8217;s Canadian parent and (d) $6&#160;million of income tax expense associated with stock compensation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit from income taxes for the three months ended March 31, 2022 was $16 million and included: (i) $14&#160;million of income tax expense for the Company&#8217;s ordinary loss for the three months ended March 31, 2022 and (ii) $30&#160;million of net income tax benefit for discrete items, which includes: (a) $36&#160;million of net income tax benefit recognized for changes in uncertain tax positions and (b) a $6&#160;million tax provision associated with the filing of certain tax returns. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was approximately $2,000 million as of March&#160;31, 2023 and December&#160;31, 2022. The Company will continue to assess the need for valuation allowances on an ongoing basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December&#160;31, 2022, the Company had $901 million and $881 million, respectively, of unrecognized tax benefits, which included $41 million and $32 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of March&#160;31, 2023, $402 million would reduce the Company&#8217;s effective tax rate, if recognized. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at March&#160;31, 2023 could decrease by approximately $5 million in the next 12 months as a result of the resolution of certain tax audits and other events.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be under examination by the Canada Revenue Agency. In the first quarter of 2023, the Company recorded income tax expense related to prior year withholding tax returns.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 19, 2021, the Canadian federal government delivered its 2021 budget which contained proposed measures related to limitations on interest deductibility and changes in relation to international taxation. Draft legislative proposals pertaining to interest deductibility were initially released for public comment on February 4, 2022, with revised legislative proposals subsequently released on November 3, 2022. The proposed rules on interest deductibility are expected to be effective no earlier than January 1, 2024. The proposed rules and their application are complex and could have a material adverse impact on our consolidated effective tax rate and financial results in future years if enacted as drafted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the &#8220;IRS&#8221;) previously completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company&#8217;s taxable income as a result of these examinations. However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. The Company&#8217;s annual tax filings for 2015 and 2016 and short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#8217;s internal restructuring efforts during 2017 is currently under IRS examination. As part of its examination, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss resulting from its internal restructuring. The Company previously contested this proposed tax deficiency through the IRS administrative appeals process and if necessary, will continue to contest any proposed tax deficiency through appropriate litigation. Accordingly, no income tax provision had been recorded as of December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, as part of an alternative dispute resolution process with the IRS, the Company reached a tentative settlement on the 2017 Capital Loss. This tentative settlement is subject to further review and approvals before it is finalized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In anticipation of the finalization of this settlement agreement the Company has recorded an estimate for the impact of the settlement during the first quarter of 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Condensed Consolidated Financial Statements.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 8, 2022 the Company&#8217;s affiliate in the Netherlands received an assessment from the Luxembourg Tax Authorities as successor in interest to its affiliate in Luxembourg for tax years 2018 &#8211; 2019 for &#8364;272&#160;million. The Company is vigorously defending its position and has not recorded any reserves for this assessment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Luxembourg are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#8217;s Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411343504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:78.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>During the three months ended March 31, 2023 and 2022, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,426,000 and 3,600,000 common shares for the three months ended March 31, 2023 and 2022, respectively.During the three months ended March 31, 2023 and 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 17,636,000 and 9,332,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended March 31, 2023 and 2022, an additional 90,000 and 156,000 performance-based RSUs, respectively, were not included in the computation of diluted earnings per share as the required performance conditions had not been met.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412441264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of March 31, 2023, the Company&#8217;s Condensed Consolidated Balance Sheets includes accrued current loss contingencies of $326 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney&#8217;s Office for the District of Iowa &#8211; re OrthoDerm</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a Civil Investigative Demand in May 2021 from the Civil Division of the United States Department of Justice and the United States Attorney&#8217;s Office for the District of Iowa, requesting documents and other information concerning the sales and marketing of Bryhali</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Siliq</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - Opt-Out Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#8220;Securities Class Action Settlement&#8221;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#8220;Timber Hill&#8221;) filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#8217;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210&#160;million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments were paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. During 2022, the Company&#8217;s rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed on February 23, 2023. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Aly opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February&#160;23, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#8217; Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company&#8217;s Consolidated Financial Statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company has resolved its insurance claims with respect to the Allergan Securities Litigation against the Hartford Fire Insurance Company but its claims against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#8217;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;) (discussed in further detail below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see Glumetza State-Law Insurer Litigations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#8220;Company&#8221;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These lawsuits cover products of both Bausch + Lomb and the Company&#8217;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigations</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail above), Humana Inc. (&#8220;Humana&#8221;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed above, were deemed asserted in the State Court Action. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#8217; answers were filed on June 17, 2022. On November 28, 2022, the Court consolidated this action with the State Court Action for trial and pretrial purposes (the &#8220;Consolidated State Case&#8221;). Trial is currently scheduled to start in January 2024 in the Consolidated State Case.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims and intends to vigorously defend these matters.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain intellectual property litigation proceedings in the United States and Canada, including as arising from claims filed against the Company or by the Company (or that the Company anticipates filing within the required time periods) related to certain products sold by or on behalf of the Company, which may be in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers, where such products include Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 200 mg and 550 mg, Arazlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nuvessa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A. (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the U.S. Food and Drug Administration (&#8220;FDA&#8221;)&#8217;s Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 27 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August 10, 2022, (the &#8220;Norwich Legal Decision&#8221;), finding that the U.S. Patents protecting the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#8220;HE&#8221;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for treating IBS-D invalid. The Norwich Legal Decision prevents FDA approval of Norwich&#8217;s 550 mg ANDA until October 2029. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. Following the Company&#8217;s appeal, Norwich claimed to have removed the HE indication from its existing ANDA and then filed a motion in the District Court requesting modification of the Norwich Legal Decision to permit the FDA to approve their ANDA before October 2029. The Company opposed this motion and awaits a decision on the motion from the District Court. In January 2023, the U.S. Patent Office issued U.S. Patent No. 11,564,912 (the &#8220;&#8217;912 Patent&#8221;) directed to IBS-D, which was then listed in the FDA&#8217;s Orange Book for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On April 28, 2023, the Company received a new Notice of Paragraph IV Certification from Norwich asserting that claims of the &#8216;912 Patent are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, or </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, under the existing Norwich ANDA. Any suit brought against the existing Norwich ANDA under the &#8216;912 Patent is not believed to result in a new 30-month stay of approval. The Company remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#8217;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and triggering a 30-month stay of the approval of the Taro ANDA. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company commenced litigation against Aurobindo Pharma Limited (&#8220;Auro&#8221;) alleging patent infringement by Auro&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Auro, in which it asserted that the U.S. patent listed in the FDA&#8217;s Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Auro&#8217;s generic plecanatide tablets, 3 mg. The filing of this suit triggered a 30-month stay of the approval of the Auro ANDA for plecanatide tablets. </span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> AREDS Patent Litigation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#8220;AMD&#8221;). The PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp; Lomb Incorporated (&#8220;B&amp;L Inc.&#8221;) has filed patent infringement proceedings against 19 named defendants in 16 proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 4:22-cv-00914-AGF (E.D. Mo.) and (2) Bausch &amp; Lomb Inc. &amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-GBW-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation against Certain Ocuvite and PreserVision </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2021, ZeaVision, LLC (&#8220;ZeaVision&#8221;) filed a complaint for patent infringement against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#8217;s motion to stay all proceedings pending inter partes review. On July 8, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-00739-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Paragraph IV Proceedings</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2021, B&amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#8220;Slayback&#8221;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#8217;s generic drops, for which an ANDA has been filed by Slayback. B&amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#8220;Eye Therapies&#8221;). On September 10, 2021, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, B&amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#8220;Lupin&#8221;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate solution) drops (the &#8220;Lumify Patents&#8221;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#8217;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B&amp;L Inc. remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and B&amp;L Inc. intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes Review Proceedings at the U.S. Patent and Trademark Office</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company&#8217;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#8217;s branded pharmaceutical products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2026 through 2035. In 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada. All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. Three lawsuits are pending in Canada regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against Apotex Inc. and Pharmascience Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On October 12, 2022, MSN also filed a petition for IPR of U.S. Patent No. 7,041,786 and the PTAB then issued a decision on December 14, 2022, instituting MSN&#8217;s IPR and joining it with Mylan&#8217;s IPR. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. In the Company&#8217;s favor, the PTAB issued decisions on Jan. 4, 2022, denying Mylan&#8217;s petitions.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-six (26) of such product liability suits currently remain pending. In three (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-five (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2021, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as to the Company.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#8220;Bankruptcy Court&#8221;), and substantially all cases related to Johnson &amp; Johnson&#8217;s talc liability were stayed for a period of 60 days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#8217;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability through at least June 29, 2022, which it later extended indefinitely. The order denying the motions to dismiss and the order extending the preliminary injunction were subject to appeal and the Bankruptcy Court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022. On January 30, 2023, a unanimous three-judge Third Circuit Court of Appeals panel issued its decision directing the Bankruptcy Court to dismiss LTL&#8217;s bankruptcy case, concluding that LTL was not in financial distress and could not file a bankruptcy case in good faith. LTL requested a rehearing and on March 22, 2023, the Third Circuit denied LTL&#8217;s rehearing request. Thereafter LTL moved for a stay of the mandate of the Third Circuit&#8217;s dismissal decision while LTL sought review by the Supreme Court. On March 31, 2023, the Third Circuit denied LTL&#8217;s stay motion. At that juncture, the Bankruptcy Court determined it appropriate to discontinue the proceedings pending there, and on April 4, 2023, entered orders dismissing the bankruptcy case and related adversary proceedings and terminating the preliminary injunction.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, on April 4, 2023, LTL re-filed for chapter 11 in the Bankruptcy Court and again commenced an adversary proceeding seeking a preliminary injunction enjoining substantially all cases subject to the indemnification agreement. The Bankruptcy Court granted a temporary restraining order enjoining litigation against the &#8220;Protected Parties&#8221; including the Bausch entities. The Bankruptcy Court held a hearing on April 18, 2023, to consider the preliminary injunction, and on April 20, 2023, the Bankruptcy Court ordered a preliminary injunction solely on a limited basis to enjoin the commencement or continuation of any trial against any Protected Party (including the Bausch entities). The injunction does not enjoin the commencement of a new suit or any discovery or pre-trial activity in pending suits. The talc claimants have sought to have the decision certified for direct appeal to the Third Circuit. Additionally, the Bankruptcy Court will be ordering the parties to continue mediation, and will consider proposals for mediators, a Future Claims Representative, and a fee examiner at a hearing scheduled for May 3, 2023. On April 24, 2023, the talc claimants filed a motion to dismiss the newly filed Chapter 11 case and a hearing is scheduled for May 22, 2023. Meanwhile, LTL has stated that it intends to file a plan of reorganization by May 14, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the bankruptcy case is ultimately dismissed, the Company&#8217;s position vis a vis J&amp;J would return to the status quo prior to the filing. The litigation against the Company and other defendants will no longer be stayed, and LTL and J&amp;J will continue to have indemnification obligations running to the Company and its affiliates for Shower-to-Shower related product liability litigation.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any cases proceed during the pendency of the bankruptcy case, or if the case is ultimately dismissed, it is the Company&#8217;s expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu</span><span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">it</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#8217;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that the future potential separation of Bausch + Lomb from the Company by distribution of Bausch + Lomb stock to the Company&#8217;s shareholders would leave the Company with inadequate financial resources to satisfy these plaintiffs&#8217; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#8217;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. On April 29, 2022, Plaintiffs filed a motion to remand. On November 29, 2022, the District Court granted Plaintiffs&#8217; remand motion and the case was remanded to the Superior Court. On December 8, 2022, Plaintiffs filed a proposed Order to Show Cause and motion for a preliminary injunction, and sought interim relief including expedited discovery. On December 13, 2022, the Court denied Plaintiffs&#8217; proposed Order to Show Cause and stayed discovery pending the resolution of the Company and Bausch + Lomb&#8217;s forthcoming motions to dismiss, while instructing the Company to provide certain notice to Plaintiffs of the intended completion of the distribution referenced above under certain circumstances. On December 22, 2022, Plaintiffs filed an amended complaint which, among other things, added claims seeking injunctive relief. On January 11, 2023, the Company and Bausch + Lomb moved to dismiss the amended complaint. Briefing was complete on February 24, 2023, and the motion to dismiss was heard on March 3, 2023. On April 3, 2023, the court issued a decision granting in part and denying in part the motion to dismiss. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (Gutierrez, et al. v. Johnson &amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#8217; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the stay. Johnson &amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and asked the Ninth Circuit to continue to stay this action while the bankruptcy preliminary injunction remained in place. On January 20, 2023, the Ninth Circuit extended the stay until February 17, 2023. On February 17, 2023, Johnson &amp; Johnson requested the court afford it sixty (60) days &#8211; until April 18, 2023, or seven (7) days following any lifting of the LTL Bankruptcy Court&#8217;s preliminary injunction &#8211; whichever comes earliest &#8211; to provide an additional status report about the bankruptcy proceeding and the Third Circuit dismissal for which LTL has requested a rehearing. On April 7, 2023, Johnson &amp; Johnson Consumer Inc. filed a status report regarding the bankruptcy proceeding advising the Court of the dismissal of the prior bankruptcy proceeding and the filing of the second bankruptcy proceeding, as well as the preliminary </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunction and stay order, and requesting the stay of the appeal remain in place until May 10, 2023. The Ninth Circuit has not yet acted on that request.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial was scheduled to begin on May 30, 2023, until the case was stayed by an interlocutory appeal to the New Mexico Supreme Court by Johnson &amp; Johnson.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the New Mexico Attorney General from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction. The New Mexico and Mississippi Attorneys General appealed the order granting the preliminary injunction and sought direct appeal to the Third Circuit. The Bankruptcy Court certified the matter for direct appeal to the Third Circuit Court of Appeals. Following the Third Circuit&#8217;s decision requiring dismissal of the main bankruptcy proceeding, and its subsequent denials of LTL&#8217;s requests for a rehearing or a stay pending disposition by the Supreme Court, on April 4, 2023, the Bankruptcy Court entered orders dismissing the bankruptcy case and related adversary proceedings. However, also on April 4, 2023, LTL re-filed for chapter 11 in the Bankruptcy Court and again sought a preliminary injunction, though it does not currently include this lawsuit. The Bankruptcy Court did not grant the broad preliminary injunction requested and, instead, issued a preliminary injunction solely on a limited basis to enjoin the commencement or continuation of any trial against any Protected Party. However, this action remains stayed due to a separate September 13, 2022, stay order from the New Mexico Supreme Court in a pending appeal from a Motion to Compel filed by Johnson &amp; Johnson. Accordingly, at this time this matter remains stayed pending the outcome of that appeal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30&#160;million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 11, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23&#160;million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch </span></div>Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412500656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales in the U.S. of GI products. Sales of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line represented approximately 80% of the Salix segment&#8217;s revenues.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta Medical aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt">The Diversified (formerly Diversified Products) segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profits</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:78.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.947%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Segment and Product Category </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:29.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The top ten products for the three months ended March 31, 2023 and 2022 represented 48% and 47% of total revenues for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:78.060%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408350752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;) and the Canadian Securities Administrators (the &#8220;CSA&#8221;) on February&#160;23, 2023. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#8217;s audited Consolidated Financial Statements for the year ended December&#160;31, 2022. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#8217;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the unaudited Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, and </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s results of operations and financial position could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">REVENUE RECOGNITION <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue which is derived primarily from contract manufacturing for third parties and which is not material. See Note 18, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#8217;s products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412452592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the activity and ending balances of the Company&#8217;s variable consideration provisions for the three months ended March 31, 2023 and 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,453)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $40&#160;million as of March 31, 2023 and January 1, 2023, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.616%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provisions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(359)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balances, March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,892&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2023 and 2022 is as follows.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for expected credit losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs charged against the allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries of amounts previously written off</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411366032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with Bausch + Lomb&#8217;s cross-currency swaps as included in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022 are as follows:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:70.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company&#8217;s foreign exchange contracts as included in the Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Condensed Consolidated Statements of Comprehensive Loss and the Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.626%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.443%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss recognized in Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company&#8217;s foreign exchange contracts on the Condensed Consolidated Statements of Operations and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.477%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:70.178%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments due to changes in estimates of other future payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of AcuFocus Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI https://asc.fasb.org/extlink&amp;oid=127000641&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412446080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549413571984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,653)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.872%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization<br/>and<br/>Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,902&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,265)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,653)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,134&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,334)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the remainder of 2023 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.833%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 and the year ended December&#160;31, 2022 were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.298%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.465%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.447%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.494%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dermatology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diversified</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(798)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(824)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,238&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412401184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities consist of:</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.740%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,988&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407769856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">2022 Amended Credit Agreement</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">B+L Credit Facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B+L Term Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.50% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.00% First Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.00% Second Lien Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9.00% Intermediate Holdco Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.50%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.00%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,766&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,207&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of long-term debt maturities</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of debt obligations for the remainder of 2023, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.383%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,962&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,097&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized premiums, discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,653&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407769856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components and classification of the Company&#8217;s share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2023 and 2022:</span></div><div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.429%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of share-based awards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards granted for the three months ended March 31, 2023 and 2022 consist of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch Health Share-Based Awards</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted Operating Cash Flow performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch+ Lomb Share-Based Awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average exercise price</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,358,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TSR performance-based RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Organic Revenue Growth performance-based RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412496176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss consists of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:69.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,971)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,056)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412382304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs consist of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549608868128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense, net</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:77.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.948%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412468224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of loss per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:</span></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:78.660%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.3&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.55)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408624752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:78.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.947%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and product category</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment and product category were as&#160;follows:</span></div><div style="margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"/><td style="width:29.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.475%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diversified</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenue attributed to a geographic region</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:78.060%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.944%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of customers that accounted for 10% or more of total revenue</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (including McKesson Specialty)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408699376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems', window );"><strong>Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="nump">89.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404445216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="nump">363,607,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,898,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,449,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">B+L IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549409559248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,828,000,000<span></span>
</td>
<td class="nump">$ 1,892,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,910,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,863,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">1,944,000,000<span></span>
</td>
<td class="nump">1,918,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">$ 37,000,000<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549409099120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">$ 1,910<span></span>
</td>
<td class="nump">$ 1,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(1,453)<span></span>
</td>
<td class="num">(1,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(729)<span></span>
</td>
<td class="num">(599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(487)<span></span>
</td>
<td class="num">(359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve beginning balance</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provisions</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Reserve ending balance</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404013392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Beginning balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for expected credit losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs charged against the allowance</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries of amounts previously written off</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Ending balance</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407968320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSING AGREEMENTS AND ACQUISITION - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,579<span></span>
</td>
<td class="nump">$ 11,547<span></span>
</td>
<td class="nump">$ 12,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_AcuFocusIncAcquisitionMember', window );">AcuFocus, Inc. Acquisition | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Up-front payment</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionMaximumTermForRemainingPayment', window );">Purchase price, repayment term</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets, net</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionMaximumTermForRemainingPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Maximum Term For Remaining Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionMaximumTermForRemainingPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_AcuFocusIncAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_AcuFocusIncAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408292960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Costs incurred</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation, and IPO costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Separation and IPO-related costs included in selling, general and administrative expenses</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404791424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Cross-currency swaps | Designated as Hedging Instrument | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407929408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2019</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="nump">$ 1,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | NEW JERSEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash and other settlement deposits</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407857120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details) - Cross-currency swaps - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Receipts in interest settlement of cross-currency swaps</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Designated as Hedging Instrument | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549409510896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - Bausch + Lomb - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404008592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - Net Investment Hedging - Cross-currency swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Loss recognized in Other comprehensive loss</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404388240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 548,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407973712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Net fair value</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411585440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) related to changes in fair value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain', window );">Gain related to settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407820352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details) - Recurring basis - Level&#160;3<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>rate</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Measurement Input, Weighted Average Risk-Adjusted Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate</a></td>
<td class="nump">0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408261952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Acquisition of AcuFocus Inc.</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments/Settlements</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion included in Accrued and other current liabilities</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag', window );">Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</a></td>
<td class="text">Acquisition-related contingent consideration<span></span>
</td>
<td class="text">Acquisition-related contingent consideration<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember', window );">Fair value adjustments due to changes in estimates of other future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412391536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring adjustment | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 13,367<span></span>
</td>
<td class="nump">$ 14,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407516736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Components of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventories</a></td>
<td class="nump">$ 1,222<span></span>
</td>
<td class="nump">$ 1,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408984288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,507<span></span>
</td>
<td class="nump">$ 25,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(21,653)<span></span>
</td>
<td class="num">(21,334)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,854<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Total intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,205<span></span>
</td>
<td class="nump">27,134<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">5,552<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">B&amp;L Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">20,902<span></span>
</td>
<td class="nump">20,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(17,471)<span></span>
</td>
<td class="num">(17,196)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">3,431<span></span>
</td>
<td class="nump">3,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">904<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(571)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">3,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,265)<span></span>
</td>
<td class="num">(3,251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-lived intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549402018704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,854,000,000<span></span>
</td>
<td class="nump">$ 4,102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,102,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">824,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,579,000,000<span></span>
</td>
<td class="nump">11,547,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,547,000,000<span></span>
</td>
<td class="nump">$ 12,457,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,004,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">$ 3,159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,159,000,000<span></span>
</td>
<td class="nump">$ 3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_DermatologyReportingUnitMember', window );">Dermatology Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,000,000<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, change in discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember', window );">Vision Care, Surgical and Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember', window );">Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Fair value of reporting value, greater than its carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember', window );">Neurology and Other Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 622,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Vision Care, Surgical and Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Vision Care, Surgical and Ophthalmic Reporting Units | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Salix Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,559,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">57 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember', window );">Xifaxan Branded Products | Salix | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_TradeNamesNoLongerUsedMember', window );">Trade Names No Longer Used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_DermatologyReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_DermatologyReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_SalixReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_NeurologyAndOtherReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_TradeNamesNoLongerUsedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_TradeNamesNoLongerUsedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549500967440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 3,854<span></span>
</td>
<td class="nump">$ 4,102<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401837392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 11,547<span></span>
</td>
<td class="nump">$ 12,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">30<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">11,579<span></span>
</td>
<td class="nump">11,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">5,262<span></span>
</td>
<td class="nump">5,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">3,159<span></span>
</td>
<td class="nump">3,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">22<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DermatologySegmentMember', window );">Dermatology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(798)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">2,238<span></span>
</td>
<td class="nump">2,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 2,238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DermatologySegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DermatologySegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404431200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">$ 914<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 2,916<span></span>
</td>
<td class="nump">$ 2,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401651648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 19,097<span></span>
</td>
<td class="nump">$ 19,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">20,653<span></span>
</td>
<td class="nump">20,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">20,207<span></span>
</td>
<td class="nump">20,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">2,406<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,363<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,481<span></span>
</td>
<td class="nump">2,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,436<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 5.500% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,680<span></span>
</td>
<td class="nump">1,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 6.125% Senior Notes Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 5.750% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,584<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 11.00% First Lien Senior Notes, Due September 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,774<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="nump">2,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 14.00% Second Lien Senior Notes, Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 711<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 9.00% Intermediate Holdco Senior Notes, Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,397<span></span>
</td>
<td class="nump">1,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 9.00% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 959<span></span>
</td>
<td class="nump">959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 952<span></span>
</td>
<td class="nump">951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 9.250% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 737<span></span>
</td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 8.50% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 171<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.00% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 6.25% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 821<span></span>
</td>
<td class="nump">821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.00% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 7.25% Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.25% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 779<span></span>
</td>
<td class="nump">779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | 5.25% Senior Notes Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 462<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407860928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember', window );">Senior Secured Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 9,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member', window );">9.00% Intermediate Holdco Senior Notes, Due January 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bhc_SeniorSecuredCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404652624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Exchange Offer (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="nump">38.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember', window );">Exchange Offer | Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased debt, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal', window );">Reduction of outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Debt instrument, premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Contractual interest paid</a></td>
<td class="nump">$ 128,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt premium</a></td>
<td class="nump">$ 111,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 11.00% First Lien Senior Notes, Due September 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 11.00% First Lien Senior Notes, Due September 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,774,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 14.00% Second Lien Senior Notes, Due October 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 14.00% Second Lien Senior Notes, Due October 2030 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 9.00% Intermediate Holdco Senior Notes, Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Notes | 9.00% Intermediate Holdco Senior Notes, Due January 2028 | Exchange Offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtLineItems', window );"><strong>Extinguishment of Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1375209BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1375209BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TroubledDebtRestructuringDebtorTypeAxis=bhc_ExchangeOfferMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549398633056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">$ 19,097,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,097,000,000<span></span>
</td>
<td class="nump">$ 19,110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 20,653,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,653,000,000<span></span>
</td>
<td class="nump">20,766,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_A1261229BCLtdMember', window );">1261229 B.C. Ltd. | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">$ 2,406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,406,000,000<span></span>
</td>
<td class="nump">2,437,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">2,363,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,363,000,000<span></span>
</td>
<td class="nump">2,392,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="nump">469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Federal Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Base Rate Factor, SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | SOFR Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable', window );">Variable rate, if rate not ascertainable (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member', window );">Term Loan B Facility Due February 2027 | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember', window );">New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">2,481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,481,000,000<span></span>
</td>
<td class="nump">2,488,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 2,436,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,436,000,000<span></span>
</td>
<td class="nump">2,439,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization', window );">Remaining quarterly amortization payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate Factor, SOFR | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | Base Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.015%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member', window );">Term Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.475%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">$ 395,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 395,000,000<span></span>
</td>
<td class="nump">470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">395,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,000,000<span></span>
</td>
<td class="nump">470,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Threshold for incremental borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage', window );">Incremental borrowings interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | EURIBOR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR, CDOR and EURIBOR Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due February 2027 | SOFR, CDOR and EURIBOR Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowings</a></td>
<td class="nump">376,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.275%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate', window );">Credit spread adjustment (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | U.S. Dollar Base Rate and Canadian Dollar Prime Rate | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Minimum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Facility Due May 2027 | SOFR, CDOR, EURIBOR and SONIA Rates | Maximum | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Credit Facility Due February 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Revolving Credit Facility Due May 2027 | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Amount drawn under credit facility</a></td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Credit Spread Adjustment on Variable Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Remaining Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1261229BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1261229BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDOREURIBORAndSONIARatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_EuropeInterbankOfferedRateEURIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_SOFRCDORAndEURIBORRatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549398571200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Intermediate Holdco</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member', window );">6.125% Senior Notes Due April 2025 | Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">6.125% Senior Notes Due February 2027 | Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member', window );">11.00% First Lien Senior Notes, Due September 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member', window );">11.00% First Lien Senior Notes, Due September 2028 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes, Due October 2030 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes, Due October 2030 | Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member', window );">14.00% Second Lien Senior Notes, Due October 2030 | Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member', window );">9.00% Intermediate Holdco Senior Notes, Due January 2028 | Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_A1375209BCLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_A1375209BCLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408295792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 10, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price (as a percent)</a></td>
<td class="nump">101.021%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407766160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">7.87%<span></span>
</td>
<td class="nump">7.74%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411512864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">2,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">6,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">4,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt obligations</a></td>
<td class="nump">19,097<span></span>
</td>
<td class="nump">$ 19,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized premiums, discounts and issuance costs</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 20,653<span></span>
</td>
<td class="nump">$ 20,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549405085888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2023</div></th>
<th class="th"><div>Mar. 06, 2023</div></th>
<th class="th"><div>Sep. 05, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>May 05, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average service period over which compensation cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,358,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember', window );">2014 Plan, Retention RSU Grant | Certain Executive Officers and Other Members of Leadership | RSUs | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Bausch + Lomb | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum shares authorized (in shares)</a></td>
<td class="nump">38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Incentive stock plan, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,318,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | Stock options | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | Stock options | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | Stock options | Bausch + Lomb | Vesting Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | RSUs | Bausch + Lomb | Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember', window );">2022 Omnibus Incentive Plan | Chief Executive Officer | PSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_A2022OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_PerformanceRestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_PerformanceRestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401560048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408558560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">2,545<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 24.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 4.87<span></span>
</td>
<td class="nump">$ 6.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract', window );"><strong>Stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,679<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price (in usd per share)</a></td>
<td class="nump">$ 18.27<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 5.52<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>Other Than Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 9.18<span></span>
</td>
<td class="nump">$ 24.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember', window );">Adjusted Operating Cash Flow performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>Other Than Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">647<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 10.57<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>Other Than Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,358<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 18.04<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR performance-based RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>Other Than Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 27.65<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember', window );">Organic Revenue Growth performance-based RSUs | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract', window );"><strong>Other Than Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in usd per share)</a></td>
<td class="nump">$ 17.96<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401813840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,971)<span></span>
</td>
<td class="num">(2,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (1,989)<span></span>
</td>
<td class="num">$ (2,056)<span></span>
</td>
<td class="num">$ (1,974)<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412460864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Adjustment to reflect change in ownership interest in Bausch + Lomb</a></td>
<td class="nump">$ 137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408316288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development costs</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407746880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Summary of Other Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404746992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 08, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit) from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="num">$ (16,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) on ordinary income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,000,000)<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount', window );">Income tax expense (benefit) for discrete items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,000,000<span></span>
</td>
<td class="num">(30,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Income tax expense from final and potential settlement of various tax audits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Income tax expense (benefit) related to changes in uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Income tax expense, establishment of stock valuation allowance on B+L's Canadian parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Income tax expense associated with stock compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount', window );">Income tax expense associated with filing certain tax returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits related to interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Unrecognized tax benefit, amount possible to decrease in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member', window );">Tax Year 2014 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg Inland Revenue | Tax Years 2018 and 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination | &#8364;</a></td>
<td class="nump">&#8364; 272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Discrete Items, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2018AndTaxYear2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2018AndTaxYear2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407678240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (201)<span></span>
</td>
<td class="num">$ (69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">363.3<span></span>
</td>
<td class="nump">360.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares outstanding (in shares)</a></td>
<td class="nump">363.3<span></span>
</td>
<td class="nump">360.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)</a></td>
<td class="num">$ (0.55)<span></span>
</td>
<td class="num">$ (0.19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404644528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Options and RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">3,426<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Time-based RSUs, Performance-based RSUs and Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive effect of potential common shares (in shares)</a></td>
<td class="nump">17,636<span></span>
</td>
<td class="nump">9,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-dilutive shares not included in the computation of diluted earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount', window );">Excluded from computation of earnings per share, performance conditions not met (in shares)</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549412641600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Legal Proceeds (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Current accrued loss contingencies</a></td>
<td class="nump">$ 326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401739216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>group </div>
<div>case </div>
<div>action</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>number_business</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors filing action | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">US Securities Litigation | Settled Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of suits filed but not yet served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Settled Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember', window );">RICO Class Actions Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount to be received | $</a></td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549408536720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Antitrust (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, agreed to pay | $</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of putative antitrust class actions filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407525744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Intellectual Property (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 04, 2023 </div>
<div>defendant</div>
</th>
<th class="th"><div>Jul. 21, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Sep. 10, 2021</div></th>
<th class="th"><div>Mar. 26, 2020</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>defendant </div>
<div>proceeding</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>defendant </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember', window );">Norwich Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember', window );">Taro Pharmaceuticals Inc. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember', window );">Aurobindo Pharma Limited Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfProceedings', window );">Number of proceedings | proceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Settled Litigation | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Default Judgement | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember', window );">PreserVision&#174; AREDS Patent Litigation | Pending Litigation | Bausch + Lomb | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyNumberOfDefendants', window );">Number of defendants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember', window );">Lumify Paragraph I V Proceedings Slayback ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember', window );">Lumify Paragraph I V Proceedings Lupin ANDA Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_GainContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of lawsuits pending | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyNumberOfProceedings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number Of Proceedings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyNumberOfProceedings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_NorwichPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_TaroPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_AurobindoPharmaLimitedLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PreserVisionAREDSPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_DefaultJudgementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407948496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Product Liability (Details) - case<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of approval, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod', window );">Stay of approval, motion to extend, period</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | BRITISH COLUMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | QUEBEC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation, Agreed Stipulations of Dismissal Submitted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of lawsuits pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549411156992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - General Civil Actions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Jan. 28, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CaliforniaProposition65RelatedMatterLitigationMember', window );">California Proposition 65 Related Matter Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne', window );">Stay of approval, motion to extend, period one</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo', window );">Stay of approval, motion to extend, period two</a></td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Motion To Extend, Period Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CaliforniaProposition65RelatedMatterLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CaliforniaProposition65RelatedMatterLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407356624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Xifaxan Branded Products | Revenue from Contract with Customer, Segment Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_XifaxanBrandedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549404051856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 1,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="num">(273)<span></span>
</td>
<td class="num">(310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(307)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(136)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">1,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">745<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Diversified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segment | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="num">$ (251)<span></span>
</td>
<td class="num">$ (194)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401354240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">823<span></span>
</td>
<td class="nump">834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember', window );">Diversified | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549407847344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details) - product<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember', window );">Product Concentration Risk | Revenues | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549401478416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenue by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 1,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">1,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140549413541472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Revenues - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">McKesson Corporation (including McKesson Specialty)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>bhc-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20230331.xsd" xlink:type="simple"/>
    <context id="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i62f07f63ca2d4846a0d70246d162c824_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i0498740aa6eb46ce88de603fe0598d20_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57d70860978f416995c6e78078eb91fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia19ded4922bb433e8435b8239b8ff307_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8c6e6704998497797963a331448aaea_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie687efc76f874ebeb1aae627bb6e171e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72d37d3e40784682946238eaa429b35e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i32b7e06a9d3a4aeb99dd497ebfb356f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i452d83aa9dde4d01b6869dd5703fdaf8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc3e9fd64df947f9a8f763d6cc90b963_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e558abb1f7e4945be1efbb15c0857e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib12545de9cf64750aa8d3591b5e00bc7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94c5658cc65a4a05b4ff0e04db19ee97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic6a8b96ed7f940c5845ec8d2f802a9d4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia3dd81794064434383ac1286a5053baf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i808b863dada9457f923ca993a3bea323_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic162d17ac63741d18133d43351ec92b7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40ddc921f07a4aeeacf02c27134db643_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i66672939efa64ce0a7f6175881cc8e7b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie8ba4914a69d4cb8b1fc752df5873883_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8a2f6084f5a4426387b1bdba497c5c63_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7bbac5f0d9d24f8a8f825099f3394fec_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i946e14205ef041e8972492d11be8775d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i371252488c904680b474dfac8b94f900_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f7f8f2ef85a49f4afe5effddaa485c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaf9314740a5046e6b7fbcde6a1225413_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c02450191db423fbdddbea92953f1fa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fcf82d8c82b4464bcd33142e1f338cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8902b132c274ce980a60fe03aa09c6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82e229d35290440d93fbde9447d92bd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ce9f18c7cd9441ba37c871b38e9c09e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibcbd578c19014c70a67ef1fb87173055_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1b2462e77bf46ba99a8e0c38ea11630_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e3484672c1b4b38a05983fa5254b458_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id04b8551dc9c4d889a6e5fd80cbc09f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6f710c703f87477bb1995e048a1ad4c3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i080749f8173b49ce89929a1cd63c2560_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib63d0633dd2449069f3d40c923633c0b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i77426eee8f534f118cfa729bb49d9f39_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i21c3f3c6b4a24d8cb42af4f8458f66e6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i479ac929919e4b9391ed384f3e44de72_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63bf7af9472e4ef792681b0e8c4f7da0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4c8c5d995a3747e29d7c4e9cef2e105f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i7e0c7a0e030f4effa3695934ea837e9f_I20220601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="i7a49d1ee9a464f5db7a10d853a1a1349_D20230331-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2e45b6ebd3b048e894cd2c2e5aedafa4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie10c054fa2de4824aef49eafab2b651e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i135bc17430224f338814ab96077762d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief70a603ee11466f94467c535a3e3125_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i823782cb59e242d194dab1df20d01ab8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bd82fd1b04c4ca5a90663181d0b9281_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1fe64f13b6ba4162ae7430acb9dbf957_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i20c4dfdc7ef14cc9bc3a3ac6abfe8664_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i42e80003bff24d46bd9d4b8a36e49cd0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3840f2154ebb4758a2ccbd787ed21972_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6e0087ac09e4486ea85863d74934cc18_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if83655d1435547e9a88be7c0a6a44473_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c661f0c33684c05ba82c765639b2da8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifcaaa7bc80ae4f49a0ec057d07433721_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0dfb70e0fd024446818c699b54888111_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i391ac9a452be4bdcb904867d4fb45391_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if1fb66cbda4b4013887d1e87c53164eb_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i318586ad088847fe9e02f2dbe2f1d9be_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8290334f6ddb49b48369b500e2a37633_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57521c3e1fc6438c83e45eed46549020_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80ef4ad0b68c4cc98d683b6b92852ec3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic21e95c278304743bdfd808b5bcf88c0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f4502c99efb4e1192389a486b24fec4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0cd2d65e95c5455ba33597d7af92fae1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6de88d59e31147e89b39381c09c53f91_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieda7c01115f14fb48e402b3e7a8d7854_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifd272b84eca74392a824eff8a9e1189e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2463be0b4714169986c616ff3005117_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c1aa2507e474247b21581cd979cbf95_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iec8b23fc6b3d427ebf6b56614132eabc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie930191b929c4961b8ea3b30d8630a7d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6d287acf3b954277b424a867b92331d4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2c5df1eca1d6410e9c23987eab19795d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9fea59117d2a4ea787d736618e348ab1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i399b542872cf4b8a95bc8a36570e3ecd_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i6b5563f26ef24b288a82a1f6a3909255_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:AcuFocusIncAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="ib72c99bc651a43d89f88a30576ef0099_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:AcuFocusIncAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="ibda71fa1050f4cd99d1b0487cabdc232_I20230117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:AcuFocusIncAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-17</instant>
        </period>
    </context>
    <context id="i274f7bd9f55d4414ae43d99e682cd28a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if7994dfc403646e5bff69630f9cc9aa6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47206664dbc844039797dc32726a84f4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie718797acbb14934a88039b0b7639ab6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i06ac642717c94b2bb1846110be0fc60d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7219dc1016d84387a28c86b12d9cf065_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ecdb94ccdc9431b9447675875213cc0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifffa5ab43fca470998ef4bc73c508195_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05beb5b79d2d4d1786504e1574156b9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i97a57514fe2b45cc95ad51616dde5842_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8571f31f2d94cbcaa0a6cf746cebae6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i08edcda8013b411a8ae514fb186572f3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9d7702b9b65346fdbe57769e179c3810_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0daaca70154c40aeaacadd2265003e58_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc9716709350419c83c375cd1e7f06dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e2d1c1b6390420dbae526e06c3bf460_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0830e0c16af34c70b916f4b40dd82c53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d7e1e14aa134850b3ef64a8fc34014e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia244db96c1c640908fc33b4da08106d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54f2aa66d564423a8584754ff4101e8c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iba72009cea324aec8b99aef7cc724d7a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibee7e52beb8e43fda8b440f37c8ebe57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iedc061681ca144219826ecd1f58d340a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf1769e6ad7e4ee4ba7d31d32deaa20b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia11e5b05711c41bc94278235adbc4f4c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id28a74559e034fe78617f85992188d35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i095b974a4eda46539b55e501e35cecd5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6ecae6a4337c43a6a5d0f8fb9b2a8820_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i72f352e9aecb43c082504ada58284827_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibebb6d14814347889239321501ae010a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7d14de197c840548e735b7c5dccffd4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if5134dadb2714e1785041a8064f00e00_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf6e5891da834960a8eb4d5a50ad53f2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieba2db723f4a453284cf02585362f5f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibccb47312bd346279aaf43b1d2624d18_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95be04917e9242a4b3ab893073a4e5ac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d884c3b238b4a9484042a7ec80e4c08_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9e0459eac81b48d391a6ba5f7a204bc9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a9fc2637fe14e8da7c94ff2d6063b4f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1660d479841841a083afc611c4742172_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iab4bebd84ef941c29f23b2b4ac6c05a9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7a6e400c24a6461b88808840db8e4b5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i22eb775dada74a4cbae4ccbc53d12e07_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i056164fc33e8477cbf8aadaeb9855ca2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6357772b0f77447aac759696baca2658_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibfd26c8ad7914e708774f00d667fddae_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i82576bfa08994cd9af972d7222b8c478_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if9f1fb1cd13846c38b5c4a4cafd8a808_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia20a127e123344f5a9df3c653c0441ff_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0d7b079169584b7b827bc3ad599a02a0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i147a77a2853541b8ac642c9ce50dfb79_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie7363eb7130846d498238f0c9266f211_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f59cd43aff447ff9034642bf45fa138_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e658e3f4fe444859560086bf4a59a49_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i28204be5e8ef457b9c492f5b766ac878_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id06b415e61b344bdb2ccda942b08f59b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i48125eb5f60a4e3fa677f9dba896c944_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5705188337dd4a7f9f61104a2f18967b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2610664ed984b688dd611a19b847b62_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84330219b21546d7b29a854334867cd0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if0d15fc2eafe4f60beb93612549521a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b48c13c21214c678ad36cf685b3b072_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2dd0103274754e1fb33a46edcf042268_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3da26cfaf00043bdbba7864b5a155ec6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaa692efa530140f8a1a881ba8a8249c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i818c74f66a48498dba0c587f79830579_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:TradeNamesNoLongerUsedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifbe4581fb4234dbdafb70170994354db_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idf755e2bc874449e82907e0d22cf8c11_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08e744695a9e45b9b9ad55074d322f8a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1fafe0032cba4aa1a32eca01ef3aca20_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8a66af6adc904896a8ff0e7c2c1bd921_D20220930-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9b6bf825c7324cacac00e1ebf2a1c71e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i179f309e60d44d41af3ca366ec893b8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i778f77cb42414cb5ac34f18b66605477_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffa6d2cd08c24125aa6dc092aad37002_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9d39794e57948c0b3f7a07a43885d87_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb32f84fce124fcdbdda1eb3094fee46_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id52bba3d92b045cd9377b763545b3f6b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53fcd851b0d54c2dbe32c186e8d2ecb0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5c329081547a4cdf98e1aa393d8972f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2455a2fae6ad431e922a0ba988eb6a34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05f2a2fe52aa458190c6047336e73de4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i659a2f673c4a4411ab26d25784b4be92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if298046fc580453c82cae116d877a880_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40a6d2460268490a812b6a04661c6a65_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic769315b03e548d48d1dd48f1f5ce5a2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc08a22ed7434483b9c22e1d5222d8b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c8bc248d85e49df8afec2958aab8781_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i294049ce13fc4119883d1b65b4fb4e3f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DermatologySegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9c81e913fa06452b960a94c4319affd4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4dd72c321919418dbd266cd1519b7af3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4f49db76bb9048269a4225f0617c7e08_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id6075831fea84e2eb08c47c4f0c4d29b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id40329b767834642890bfb55575f5122_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if2e632bea1f6478b9fa7efc4a42012da_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9aa533c5f43d49389b83002df6cdf881_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iab9c3331e15a44048291c40dafad29a2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7b85418b2df045ccaf777f6a153cd251_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iff9524a8dec942a8bde2eb81616907d3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ae7f8afd93140b892be236df15ed51f_D20220506-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-06</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iad75129d06c348f0be0dddaa52c9ed51_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia0f99abdbe264be492c1ab50a81c5fa7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:DermatologyReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i370ee4cf54624da09da5e76a026c3802_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41f572ad45a949229f9b0322d3dfb46d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c9e3a1139454651b2a0528c0e2b983c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i84e42d2305b3476a936b8caf47cb8b60_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i45fcaa6d1e16450c95f03e1749bb60ac_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:SalixReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if400b9a66b464bc39f29a0744063105e_D20221001-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:NeurologyAndOtherReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="i4230998f842f4bbc82a0ea680d4b577b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8d9d9cd168d4fe98734f508386e2be0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfc0cbc0a72349eeb0612d5fd6410c80_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i063a380689344325b47343a660c9c908_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:VisionCareSurgicalAndOphthalmicReportingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2263e23bd8e642778b2df9b8853237be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i81245af4c6a84955ba0724a4c0e69852_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb5c0b0ff6ea4e92a88b245ac951ddde_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i52924d69272c4ce08a9238494afb5ce1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i73805f2008b0493784b73a6e474d0511_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i14e66b94be8048c395bd7d7ffcc1ac3e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2f96c4977bdf4527aca21c11e00b2edf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i304f673759f44464b17361dc1fe3b487_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibacd0f91a9214e0fbe96138d126d5254_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d7b5fbd1e7f4531a59766d450386804_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d37517b7d6b4cbc982519aae076487f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9e85debb9de747678b7cdb6f20a35b55_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib53b662a6d4d41fead56abf94df3152b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i59d56d7f093844549b20bc3e68c8d823_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bfca85fb4024a6b94e76897fbe51927_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19fce4dedbd8421eb73bafb553597896_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i016ac45dbd954b42a38d2dbcdf824196_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19dd2ee808a54032b36dcaee1eacb64f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a5b69b0416d497d8056a590118b802a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i552ec672b451433a9e90f1b3839c487f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i05ac9da4a9e044b0b3404afa13818036_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if57b9dc8ffac4b9b9b063a8ef1df4a6a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4de0d68bab3b4961969accc3d866508c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i69eca3a5c1014c4fb4646db720b2ce73_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d865df747b04091979d8849df30eb08_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3f5d88c4fc174c4ba4624f3bda26b88f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95707314425842cd82eb737ebe900f57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i99d21d625b784308ba11c8058938ddbe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i798ef0f209fb49009a6ca1d36a285f67_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1a65dde3c3aa45549c7496b96199b6f8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd0cd3f81eb14fbb885bef7666346a89_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ied3ed0b49365444fad700d85b63bf260_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i50270179827249f7adf2f7e4718cc6cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iff54ecadaabf473d8116b32464b6b6a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2a7af656ef0f457484bd906468e5c84f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1ae1e47647b4e16abae2c02f07359b3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i98cbac4569eb4a4897d65431dc5af7a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i513ab91ef61a48c09cebf7bccfcc7994_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i80d700d6fa904cbabe449baab21de04e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i573bed6abe6342a9a2cca0beda4b3a3d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf7970cd462c4d338f9b250f47fc2cc7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2e2b7f1301cd4d6580b57be2d9bceba4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d23cbe1712d416fb576aaa815a0484b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bhc:SeniorSecuredCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0f2be8ab73b940ed95457d1d1dafe5af_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7d45443ba5c4563bf3b25ec62964df1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5debb458ebf44991aaa7a159d30b758f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i65c38375327d4fa899cba5594e9d68b1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i17d52fbe0aac4ea784789ee582df1295_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i903eec80383246d8b63564df58e178c8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i248fddc88f4a495caa1b4df3c4650cee_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i837a88fd5e964623b1aadc43f080279c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a389a27060343e5b22dc6da4936a17a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bhc:TroubledDebtRestructuringDebtorTypeAxis">bhc:ExchangeOfferMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icbfe4cdc452d465ebd08f232cee67b17_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="if38bd752f2804e82b66372aac33a299b_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i36d1ec0044004c3e9a1bd3cdc1fdd988_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="ib2a4f5fc4d13488fa1eb6879e85815a5_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i74a383df89994d61aacc54ce4b2086ff_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="if6aef544f55e4d479ca0c5fdb0d3ac29_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i69b14ba8ead54d019ac598383a31b62d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iae292b83994f4eaa9429e631a6fdf509_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1aa16e6b0d894c1dada5fbfacfcbe3c9_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="icc18552483b945af9947da7d748f3797_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i941c4bbefa5240ef85c8e4f4ab0ca948_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib4c6dcc61b60403380d1c1c8b2e65827_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:EuropeInterbankOfferedRateEURIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i10b0cd89c2794a4a8c71d587e55cec38_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9c472af859db4ef39a87c178260df1d4_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3e11f388f2ee40dcbd589e6df1e9378c_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6752a30275734197a62fc5a9b8672ce1_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDORAndEURIBORRatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ief7bb320564f4aceb4edc483cb34a747_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i577454bd748e4d5a8c05a2a6ddfbd23a_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3948c6f5951248dfa12e05ac7dbbe705_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9e21098d0ad2484097856f68e1b275a2_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if0cbf9921846406db6bd00b95257c769_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="icd9fcf0826bd4e36b2683c1eebfca266_D20230331-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i56fcb41cb5a94e678206e69414bc0b5d_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="if2d58899a97e4cab97bd1a214b38f6cb_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i84889b9489a14e36877c0478bea79508_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6c18712f4b5d49ac81d008a300ff10e9_D20221129-20221129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1261229BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="ib21fed5341d54d0e89405e700d2488cd_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i70d7dc79e80f485e9b0e3247e4c85728_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3edcc26eaf534e8eb544ca874238a97e_I20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-10</instant>
        </period>
    </context>
    <context id="i1dd01cd11a7445c4a00b066d23512c4f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8621c3667fbf460daa121b9c4ae610ed_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ie155f835e73f43c0a0a7a12dcfe3ddb7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i510257e58ffa4decb28c62ab425bbac7_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i0248ec1e93ba4d7ea8d09b465512a94f_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i1922ecd18a2e46a48b9820d0ee052834_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i9e35bf60d1c341548e91652443b6c303_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id29818a3e24849c9872d1d9f53ab8b00_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="if67b7c28c9224ebf8f9b868d72b01bf9_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i6520558979e64b11a055e7cb64fefcb3_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:USDollarBaseRateAndCanadianDollarPrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i07b28056246f43a38618df0e494a97e4_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i3f67059f3db74cc48b901c7b97bad681_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:SOFRCDOREURIBORAndSONIARatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia22c0fcb53a541a5b34a13bce7623b83_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i10bb7c9cf0764db899519673b3e54aa0_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i2a2772683b4144eb8f2ccc0181cce01e_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ia7f2841ca1e44cdc95d5d3f351c569c0_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i79f18a15a09b463389c535fe19ade465_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="ib0cba2f234984f27bed6d219b8e46492_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="iba4accda99c8474fb514ff5e90f2c9c5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermFacilityDueMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id65c9d3aa0e147cbbacd4d3353c0d376_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i031f71ba66044feeb7830f5561dbd4bb_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="i547ceb5147ad4e2db654418ebe7f7568_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="i52c91df8447249489b14e04f36239c8d_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="ie985a1f2ae2940ddaae3a79acd52e7d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1100NotesFirstLienDueSeptember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if0760722bf5d4183839a587492c1db15_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i860c8720321c489a82c36ce3d3e91c8a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured1400NotesSecondLienDueOctober2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id094eccb229a4fd2b63155f5f349149b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:A1375209BCLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i089a9da68a994aa6a72f9953208ab0d3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i970ab9f80f5f40959c2ab1571822b0d8_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i67fe16b7aeb642b693472e36f685e38b_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="i85b588e044c940eca8328840cfc28748_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="i3c45857d12dd4d23981e438c843ec5cc_D20220621-20220621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-21</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <context id="i9a72442b14b74396a03e29bc48cf80d5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id4cb8742033349bdafbfd0dbe5122c94_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="ia05b5bf3a3e34503a29b0b66b71f201e_I20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-05</instant>
        </period>
    </context>
    <context id="ieb50a893b673454784c495a665d8a5a8_D20230424-20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-24</startDate>
            <endDate>2023-04-24</endDate>
        </period>
    </context>
    <context id="i3863db1d928d4e059096c4ab578fc383_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i8868f6921a25423eaf40a6f726a3c0f9_D20220505-20220505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-05</startDate>
            <endDate>2022-05-05</endDate>
        </period>
    </context>
    <context id="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceRestrictedShareUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i7a7df102d4344988ae96ebc9a50e6c5f_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="id24036d8d6074ecdacda84c97de2156f_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i57dc496593aa4b0eb2e9577518a5942f_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i7e8032e2d6aa4162adae2cb4b0bb8097_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2c3fa275d2440c596a3bed71d4c3b85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id2ed2192fcc941a696c261e49cf75b05_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i406d990fd1d347fe9b57aac1683865e7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i68adcae65fa245a48869470ea3438264_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i666b40934018485093be0f36415a1be9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac84c79811c44f82877f5606d96b198a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibb261569c3d84cc38298b5c87946b5a9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic545e6c12b6344cf81caeedddfb12a1d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib6e00e72db8d42a6b5461ecf16e5d5a6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad26ab4e7aaa42cead89d21e59618776_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id19de0acd56e49d687b026d53ef417fa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4df47c6c0de44dfa8ac7d75e4c88624a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6511364c8e784a6ea61cc24f22c25e3f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibda9a2e4a2b849239f2f10392436563f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i76926d6eb76743fb893fda0b5ee0cd1a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icdfbb4a76db045fd9ebe9fb23d5d7ecf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38c3d0bb2bf64e46be06eed20ec48919_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i698b41841b3b43b49795ffc3a7917a63_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="ife9b18a3d3a749e8b7ea0da438e8d116_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="ib4f57ee4d6844129b313a85678998a48_D20220905-20220905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:CertainExecutiveOfficersAndOtherMembersOfLeadershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014RetentionRSUGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-05</startDate>
            <endDate>2022-09-05</endDate>
        </period>
    </context>
    <context id="i3b21867a93d5434bb4b2455d1f6434d2_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i1a35d63101ac4254a8698cf3aee3959f_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i6160a9c0226049118b1c6eadb8592be1_D20230306-20230306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:A2022OmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-06</startDate>
            <endDate>2023-03-06</endDate>
        </period>
    </context>
    <context id="i3ffe0c3f62ab46708e444bc96954e538_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie78900a84c814e17a0700f44d77a770a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i08ba76927daa47f698849aaa8387e768_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifcf8da1fe72640db95834f27357c5bde_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i23d3136d31994fbdb7cb150bafef9389_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i19848514ed9a48b79bf2c5a2c418cae9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e7f6f3cf8d14cc58d92cb9b35e61a89_D20221108-20221108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2018AndTaxYear2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-08</startDate>
            <endDate>2022-11-08</endDate>
        </period>
    </context>
    <context id="i5eb53786821248ca8b1f2d53e1c01d20_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icb496022dc8e4cf08fe49993684b187c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaebb38b5c93f4c928fa764fbd3fde9ce_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81b6547380c64dd2a50784794125d70e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i519005c4e8bf4fa49fe850dc4fd0f0ff_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iabca2dedff2549f2a26e0f9e0fc903e9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if51c4186ebf842d9bc523ee7341ac28b_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="ifc7b2df681304b2890b3963d6767bdca_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4673169a9f5042a890348f2de0d3b0de_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i458f2edb3ff040f987cabd221cc1abb6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia0de8367b153476aa320c433be6e8642_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i39bb1640622d4df192d462ee18b711d5_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i9f50f038b4734b508b66b728e2f90a2b_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="ic47ec016d3f14e9687e6fd9195affb3e_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="i1f2bdc093e6f469e94ae4f92c6ae44c9_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="i1bbfea8bf36146258594bca2c1b2d4fa_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="i770a218322c748019334a4cf693ddec3_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="i5fef41f4b68f4a788694d3e96118dc2d_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i005975800f4b45b88a890051cc8ed460_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i09d4ece01b0b4cbe82efb645a38a84ad_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i945b95d4642547dc948d93764b9fa34e_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i57a59221634247afa741a3029a821408_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="i176472c9a91947a58428394faa66f2cc_D20200326-20200326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:NorwichPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-03-26</endDate>
        </period>
    </context>
    <context id="i3b70ae48ac824b238ebdfb47f23616a7_D20220721-20220721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:TaroPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-21</endDate>
        </period>
    </context>
    <context id="if9c399e8c9cd4e7ca1b0299006f338c2_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i24d679a98f75427f88c6ebe76a942e45_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:AurobindoPharmaLimitedLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="if6350305849648ffb0d2318c6a4aff11_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d5d5d30a78743fcbe52b8144e75f596_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i52f2f806ddb64cfc8ebb70476e207aae_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:DefaultJudgementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88b0c4fb144a4119b0353b9e796c5864_D20230504-20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PreserVisionAREDSPatentLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="i26816d2d301f4b2e814b747046bafd99_D20210910-20210910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsSlaybackANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="id1a1acd7be5d4003ac3ff92ab403c379_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LumifyParagraphIVProceedingsLupinANDALitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i48e4a619c05e48ffb995b93d387f88e3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i993f123539934cffbde85472ef746930_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9b05eff1ebcf4f5b980a23bd07d03ae4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">bhc:PendingLitigationAgreedStipulationsOfDismissalSubmittedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief2eb449f9874ce181c5a5a55b53420a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i879843cb6d494828a7a39d54b19d72ca_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6a43da3b1f6244ca9940203efc29fea7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib68a72c1f5224ee9b35a0e482c1dadbb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic2b286567c0d4c80b0020c5f649deaeb_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i9efca43066164f5f8a7d4d69da63efec_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CaliforniaProposition65RelatedMatterLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="i0e4af957468b4b74a17f3a7d3f6e1b6d_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="ia80385ad9ebe4c0bb7c80610f3bae724_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:XifaxanBrandedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerSegmentBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide8c6d648ece4cb38926e0893d4d16cb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3fa7faccfc9e4b2ca204f3c85a970f69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i023a58638ddd46eca36de268fb813f97_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6be070c32a5a4c1ba81697834d0ed884_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d4f39f4056646cc9b55c92a148ec539_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iedcb8713c7af444fb8b6d03e82848ff6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46df43952df846588596009246e5d41d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id24da3a29fc44884abed656c976f1185_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5067f998a0774347a1ba8dddd05e828d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i84476c66acf64d629d1829a442bdd45f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i844e35405a554f25b15ab800349871ec_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4c0d405070e646faa7642b41b7cf60bc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i291a59d0cc7a41f998a11690ab1a3fc2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if231378ef6374003b9b4b0a7109a7cd7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95a4bade0b5f449babad9d26acb96982_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1ac1d18d3c5e49c2bfc56953bf92f5c6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i12f2d378c39e4f668000688f3e489870_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie7dd91b590f846dd9b290718829cfd6a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2b225b3f8b0746bfb199706e955676a9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id89d66db36c64eceab4715ffe59e84a5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8743518cdefc482a9aa2ddf769e627d3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbc1d8878ec541b1826e3e74d410810e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8c847d919d274b11b0a404d202cae423_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i39116494adc049f9a0fbb011b1049e08_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b5866e33824490488ff419bebdbb6ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8662c383a6524d2ea7cd1a7de3a66edd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia643f63ceee34dc993fdef9436ce2e49_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2a5eb1f6967e48d08f792876eb21bd30_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i239109b0a39046aa954f3569a8c23d66_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib8d23297ea6d4d9baf0ea77a0ff9cf17_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i42629885d170479c82e079fcc16ce6af_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i30903274eb934e56a09474d3bcc6a0e1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i295b427c6e5842fcb723434d6f3a5a70_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i324909a15d044fbfa04c98f71ac58540_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5e5c70cdd5da42c8a415fdc4ee3a7406_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i05fec92c81a743af8199d506c268b2b6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a76d1cc780742139bbe99625081f16e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ieeb0507fddbe4ccab01b0ef5a88ce5d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i92ca67bd6ac74e69949d588a28fb81f3_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id0507fe44b91427c8643ec0c7610c2bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c93ea65ff5e4ed7b39b1bf2ffc5657f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6774d58be5dd408890835ff4f0d2deeb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3de643ea5a37490db8249b80a35d9852_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d81a5cdc4704a17830a70621a701a43_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0092c04e97d44cc7b8e987d7db42f7fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3b4496691294c8ab8af9894359f523e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id67a9b004e36401d8688fc07e50d19a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib3d7bed392714c149189fa93868f8a48_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i82cb62cbef5f4deca4f2e8e3e580d3f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e9a2611542a49d9bc16e7aa4527978d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i56013d342ab744dca87c96542224d7e9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88fa31de50ca45b6a6a7b566720bcf21_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iae6f318f371c4cbb8d697ce6f04abbb9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26e30d1cbd3240e3bfa7140161b77af8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1b3e2d64225341b0baf9cc892bc9fd23_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4924f823451e44f3b29db4603696acb0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib78fdb3892eb45d4b6b4521c1d544510_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idf234d805c8b4bf18c742891e6f5b611_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13033d3d942041598d62836da3fc1150_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1a6ba62744a40428a6ebad3dd21ae27_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6956da0da306428e9c7adf2d607c14ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i954aadc6d7e24b478f75085b14eb996d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice48058f29044c469949c88a452cb9bd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if15d3638d8904493b1d72ff76791bcb8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25ae1eb1ecc54f668ec2295f497fe096_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7e328edc701b4e18a474924165dee258_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i015bfad0089f4e8fb03abd4e78cccd35_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if576ecdebb9d4e7ea72213c7c3d64c5f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8814d42191f44bb4856713e244453471_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba18df505885492da7aa2619531de2b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id92b667bc7804456b38e70fa08da5099_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iabb0e6403a294c32ae63824bc6e1c102_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic8101afe6ef64e7d899f1670a46f8de9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice4470b739f04d39a1886b3405bfed9f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i284ff13718b143468083c69139f95230_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d85c2876042450a967e14abaddd63cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibdbe909a002041d9bac599bf26407059_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic36a4000ae884c6883a2abeb82097b07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib4db0b41aa7f45ffbc8ed78d848702cd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idccd693104244d1e850fcf6797ba4971_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i34eb56c13bb140ba8a8a420a15ef17ba_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2544c5919fe1473d9274d0f8c6f34aba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idd68bfa811af4e1f80cef02be120e2ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i54f840f01d0d48f58279fe4612f1e496_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ab38f7e31c74f2c8d237669db709e1d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie5a6fa5e6dc44421b695211384e133e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e193566415d44f1b34e042c627e3a6a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2f5c293c01084dc9ada28fd87e45e84f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie56aa6955c9e4050b0a86980dfe8ef9c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i35c155e8345e4852a74a094f971e33b4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibe94207c53504992b03639c875317423_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2b71032da9c24495bd516ea636fbb96a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9f0b8edeace144f9838fb73ef992a4bf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia525c6b1240948b7ac3d8f4ff68a197a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i228b85d7ce4e492abb7d118eda50756f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4208ff78234d48a6b95a64d673fb7301_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i490f355f2ecc4859b9a79fb726c9eab2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4991ff736cbb4e52a8b67af6a4dd540d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia62501d6a5964b1fb2ce175fd8d9ab7a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icdf32169d53448eaa447c6c6a95ff0ee_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd0ec5f9323645c896a31a7b9d2c0ffc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7febcf7dfef54f08a344f4e803874e80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i269a979c418a4bc98d8b0cfceca3b1df_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifd3eef7c95b3471bad3220dc8f4e560d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i470bfc29961247a9b005e84b7140ad3c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c45e66c585145df8939a8f99dceb756_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i020c8cc6877448239e19574641b420c0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibeb78d4f9fa147ca952eee7a47399459_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i53c0c9f9a29c4194a26ee2fc5d2a2278_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2e7e267a0214438590a982060fcfc8e9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifdbf70eb870c4f4c96edf59101416ef8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i940b858ec7d04ba6b3901bcdc58f422f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia377fd0a03cc4bc29b88b780401b204b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia318e977ae6f4e10a9742bbf5ef4c757_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="number_business">
        <measure>bhc:number_business</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="defendant">
        <measure>bhc:defendant</measure>
    </unit>
    <unit id="proceeding">
        <measure>bhc:proceeding</measure>
    </unit>
    <unit id="lawsuit">
        <measure>bhc:lawsuit</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M18zLTEtMS0xLTIwNzcxNQ_92172b60-cc0b-46b2-87fa-2faff4f49b62">0000885590</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M180LTEtMS0xLTIwNzcxNQ_fbabfbf9-20f4-44e5-b73e-4cc5ef9bed34">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M181LTEtMS0xLTIwNzcxNQ_8ab8451a-e7b5-4c74-a720-e2f6370980e3">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M182LTEtMS0xLTIwNzcxNQ_ce6bb5da-be62-4b09-9d03-1796bfcc3133">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80L2ZyYWc6ZjI3YzQ2NTYxZThlNDFhODk3OGMxYzdjODNhYmYzNzEvdGFibGU6ZmY1ZWRiYjE5MGZkNDBlZTkxNTZmNWFlOTUxYmE5NDMvdGFibGVyYW5nZTpmZjVlZGJiMTkwZmQ0MGVlOTE1NmY1YWU5NTFiYTk0M183LTEtMS0xLTIwNzcxNQ_d0149991-f27c-49b8-ba8c-e0d883ce89cc">false</dei:AmendmentFlag>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i67fe16b7aeb642b693472e36f685e38b_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83MC9mcmFnOmMxNDRmMGIwNzlhODQ5ZTM5MzQwOTYzNjY4YmZkMGNmL3RhYmxlOjE2NDY4OTZiMDI3OTRmNzM4YmUzOTU2NDk1MTc3MjE2L3RhYmxlcmFuZ2U6MTY0Njg5NmIwMjc5NGY3MzhiZTM5NTY0OTUxNzcyMTZfMC0xLTEtMS0yMDc3MTU_481f7f80-a732-4464-bd62-9f7e0df3c93c"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id4cb8742033349bdafbfd0dbe5122c94_D20220905-20220905"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzEyOA_7d8122c2-092a-4cd8-b6dd-b57d32d9fc25">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDI0NA_b622811e-eab0-4467-ba1f-ded7a871e35c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i698b41841b3b43b49795ffc3a7917a63_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfNDIw_370e4722-2759-4f40-b1be-e73a2795ad7c"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ife9b18a3d3a749e8b7ea0da438e8d116_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfNDIz_6cee4566-84b1-4035-87e6-0a6b42318788"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib4f57ee4d6844129b313a85678998a48_D20220905-20220905"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfNDI2_f8529b49-4a61-43c1-a018-5ab2e8578242"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3b21867a93d5434bb4b2455d1f6434d2_D20230306-20230306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfMjE5OTAyMzI1NzcxOQ_2d5e4765-b16f-4474-96d2-d83dd1200faa"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i1a35d63101ac4254a8698cf3aee3959f_D20230306-20230306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfMjE5OTAyMzI1NzcyNw_9f31fdc8-b92e-44df-835b-8fc29c65c94c"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i6160a9c0226049118b1c6eadb8592be1_D20230306-20230306"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83OS9mcmFnOjM5MDA5NjQzYmZiNTQ0MTdiODMzMzY1Y2NkNjJmMWI5L3RleHRyZWdpb246MzkwMDk2NDNiZmI1NDQxN2I4MzMzNjVjY2Q2MmYxYjlfMjE5OTAyMzI1NzczNQ_458cdcc6-0d3f-48a1-b892-a1035d73fd47"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcw_f3183705-211b-4155-9172-99004cecc9af">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NDcyNmQ3ZGU2MDA2NGRmNzk3MDdhZGEwNDE3MzhmMDAvdGFibGVyYW5nZTo0NzI2ZDdkZTYwMDY0ZGY3OTcwN2FkYTA0MTczOGYwMF8wLTAtMS0xLTIwNzcxNQ_c1edfdf8-a82a-4037-8c2c-1b14b2a7ccd2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NDcyNmQ3ZGU2MDA2NGRmNzk3MDdhZGEwNDE3MzhmMDAvdGFibGVyYW5nZTo0NzI2ZDdkZTYwMDY0ZGY3OTcwN2FkYTA0MTczOGYwMF8xLTItMS0xLTIwNzcxNQ_2b1ef8c2-fc93-40cf-8deb-730159f419f7">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NDcyNmQ3ZGU2MDA2NGRmNzk3MDdhZGEwNDE3MzhmMDAvdGFibGVyYW5nZTo0NzI2ZDdkZTYwMDY0ZGY3OTcwN2FkYTA0MTczOGYwMF8zLTAtMS0xLTIwNzcxNQ_a9b7858f-62f8-4144-8bf4-b11f2184a43c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcx_20e15b6b-a25b-4d98-8991-9f8df0f0167b">001-14956</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY0_5443fab5-8f89-48f3-ae01-87347f2f49d3">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NzFhYThjZmUzNzcwNDJjN2IxN2MzOTJkMDA2MzIwYzEvdGFibGVyYW5nZTo3MWFhOGNmZTM3NzA0MmM3YjE3YzM5MmQwMDYzMjBjMV8wLTAtMS0xLTIwNzcxNQ_143502e1-b426-4881-ad40-a6e7f0b5bc11">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NzFhYThjZmUzNzcwNDJjN2IxN2MzOTJkMDA2MzIwYzEvdGFibGVyYW5nZTo3MWFhOGNmZTM3NzA0MmM3YjE3YzM5MmQwMDYzMjBjMV8wLTQtMS0xLTIwNzcxNQ_9ba3978d-a290-4049-875b-c78cf531a753">CA</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NzFhYThjZmUzNzcwNDJjN2IxN2MzOTJkMDA2MzIwYzEvdGFibGVyYW5nZTo3MWFhOGNmZTM3NzA0MmM3YjE3YzM5MmQwMDYzMjBjMV8wLTctMS0xLTIwNzcxNQ_b422c8f1-687a-43ee-bb5e-3acab1d265a8">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY1_bcab6baa-5360-436d-91ff-11ae7e7f8f32">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcy_380aedcb-b656-4f13-bdd0-67a0b8bb8021">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTcz_2dcfac19-9927-413e-b427-23582f96f056">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY2_b7061d40-78fd-498e-8ff1-6670374cb7f2">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY3_33696802-c744-4b6f-8c6a-8fb59978a5f6">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTYx_a9e12b4e-6add-42e8-8d7f-1bc2a2715428">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY4_14c1e438-50fb-4ee6-adfd-37fe50df0014">744-6792</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NTAyN2M3NTgzYzBiNGM3Mzk1YWEyYjgwYzY4ZWJkY2EvdGFibGVyYW5nZTo1MDI3Yzc1ODNjMGI0YzczOTVhYTJiODBjNjhlYmRjYV8xLTAtMS0xLTIwNzcxNQ_dba9e61d-0a8a-4b19-aced-7328496e474e">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NTAyN2M3NTgzYzBiNGM3Mzk1YWEyYjgwYzY4ZWJkY2EvdGFibGVyYW5nZTo1MDI3Yzc1ODNjMGI0YzczOTVhYTJiODBjNjhlYmRjYV8xLTEtMS0xLTIwNzcxNQ_75bb66a6-0acc-49e1-b50e-9bde5e9d1963">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6NTAyN2M3NTgzYzBiNGM3Mzk1YWEyYjgwYzY4ZWJkY2EvdGFibGVyYW5nZTo1MDI3Yzc1ODNjMGI0YzczOTVhYTJiODBjNjhlYmRjYV8xLTItMS0xLTIwNzcxNQ_474f8295-ffb8-45ca-89ee-bd204796f584">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTYy_0a8e9761-e81f-41dc-b2da-6055b8935328">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTY5_409265de-ede2-4e87-a671-2e43dfa8db48">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6OGQ4OWJmNzJlODgyNDFjNTgwNGI0ZWQ3MzVlZWQ0MDkvdGFibGVyYW5nZTo4ZDg5YmY3MmU4ODI0MWM1ODA0YjRlZDczNWVlZDQwOV8wLTAtMS0xLTIwNzcxNQ_405b2ea9-f161-438a-a545-18c69fcfec78">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6OGQ4OWJmNzJlODgyNDFjNTgwNGI0ZWQ3MzVlZWQ0MDkvdGFibGVyYW5nZTo4ZDg5YmY3MmU4ODI0MWM1ODA0YjRlZDczNWVlZDQwOV8wLTctMS0xLTIwNzcxNQ_8ef72948-0003-4289-a876-98b4127a9006">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGFibGU6OGQ4OWJmNzJlODgyNDFjNTgwNGI0ZWQ3MzVlZWQ0MDkvdGFibGVyYW5nZTo4ZDg5YmY3MmU4ODI0MWM1ODA0YjRlZDczNWVlZDQwOV8wLTktMS0xLTIwNzcxNQ_eb97f40b-f316-4873-89d6-8a307ff2fac5">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTYz_79236daa-754c-4008-a00d-ac38894f8fbb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i62f07f63ca2d4846a0d70246d162c824_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xL2ZyYWc6NGFlOTBiZjE2OWE3NDg5ZDhjMzMwMjFmNGY0ZmQ4ZjcvdGV4dHJlZ2lvbjo0YWU5MGJmMTY5YTc0ODlkOGMzMzAyMWY0ZjRmZDhmN18xOTI5_03d2080e-7877-40a7-aee2-02cb59f20b0c"
      unitRef="shares">363723880</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMy0xLTEtMS0yMDc3MTU_beca91c5-59c3-4c0f-a8a8-a026f942cd58"
      unitRef="usd">518000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMy0zLTEtMS0yMDc3MTU_d14f20f8-4268-4178-bb46-28e1a0311729"
      unitRef="usd">564000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNC0xLTEtMS0yMDc3MTU_dc3695b3-ed61-47ef-8f8d-41cb9b84dfe8"
      unitRef="usd">13000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNC0zLTEtMS0yMDc3MTU_27db9cbc-be6f-47b0-bdb5-d4f77c85ab74"
      unitRef="usd">27000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNS0xLTEtMS0yMDc3MTU_1e25689b-ca1d-467b-bb47-7bd618ae37f2"
      unitRef="usd">1688000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNS0zLTEtMS0yMDc3MTU_333de74a-0724-477c-a1db-1245db1b2154"
      unitRef="usd">1790000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNi0xLTEtMS0yMDc3MTU_bf623966-931f-4d5c-88c0-350f7dc5c062"
      unitRef="usd">1222000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNi0zLTEtMS0yMDc3MTU_c1937e2e-89de-4a63-ad05-8db8cc5a5520"
      unitRef="usd">1090000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNy0xLTEtMS0yMDc3MTU_b9b22924-8df4-4b22-8475-e507c44fcaf4"
      unitRef="usd">796000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfNy0zLTEtMS0yMDc3MTU_3cd9ecd8-2f00-4506-9d02-1ef725267ee0"
      unitRef="usd">776000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOC0xLTEtMS0yMDc3MTU_7a4b4eec-5cb1-4c62-a15c-e64e666fb45c"
      unitRef="usd">4237000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOC0zLTEtMS0yMDc3MTU_79cd9b85-036c-4849-adb8-7af8044ddd16"
      unitRef="usd">4247000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOS0xLTEtMS0yMDc3MTU_cd60600a-1390-4597-a314-cc502f6aab2f"
      unitRef="usd">1596000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfOS0zLTEtMS0yMDc3MTU_dae5416e-d82f-4d99-b77c-88f63d1dcfdd"
      unitRef="usd">1600000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTAtMS0xLTEtMjA3NzE1_3db0ab40-e0b2-4056-a464-e2998acd2cc6"
      unitRef="usd">5552000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTAtMy0xLTEtMjA3NzE1_8f90065b-034c-4341-b4f6-a16462d1f3cc"
      unitRef="usd">5800000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTEtMS0xLTEtMjA3NzE1_bf8687b3-c592-48a9-b4e0-ebc8b431a8ba"
      unitRef="usd">11579000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTEtMy0xLTEtMjA3NzE1_0e07a5d9-ba33-4cf6-9b4b-36b630c796f7"
      unitRef="usd">11547000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTItMS0xLTEtMjA3NzE1_1fab6476-f133-413d-83f2-d85853b71ab0"
      unitRef="usd">2163000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTItMy0xLTEtMjA3NzE1_933de959-e4eb-4fc9-b768-f8c99edfc8b7"
      unitRef="usd">2166000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTMtMS0xLTEtMjA3NzE1_7656639e-d9ac-4aba-9846-61a6f3bea259"
      unitRef="usd">318000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTMtMy0xLTEtMjA3NzE1_64d16a5b-edaf-4f78-8fea-d7ee67fc387e"
      unitRef="usd">326000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTQtMS0xLTEtMjA3NzE1_65ecc4f9-492d-4739-b3d7-45d5ffafcaab"
      unitRef="usd">25445000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTQtMy0xLTEtMjA3NzE1_c48797e1-ff09-4ede-bda2-5b8a242fc044"
      unitRef="usd">25686000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTctMS0xLTEtMjA3NzE1_e7ef111c-5010-45b4-928e-304614161791"
      unitRef="usd">561000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTctMy0xLTEtMjA3NzE1_f57c67a6-c465-4b40-a10e-e2ebd7abd2b0"
      unitRef="usd">521000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTgtMS0xLTEtMjA3NzE1_58cb1417-f6ff-41f9-bc22-d99efcb2f835"
      unitRef="usd">2916000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTgtMy0xLTEtMjA3NzE1_0853e00b-65af-494d-b130-f337e2666717"
      unitRef="usd">2988000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTktMS0xLTEtMjA3NzE1_99e2f1b4-fdce-4caa-89bf-61292bd8d474"
      unitRef="usd">446000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMTktMy0xLTEtMjA3NzE1_1132080c-5e0e-496b-a9a7-34f313aa2470"
      unitRef="usd">432000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjAtMS0xLTEtMjA3NzE1_84efd69c-2ce6-4b09-9e09-882946b94cfe"
      unitRef="usd">3923000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjAtMy0xLTEtMjA3NzE1_a602e829-bbe7-4ed2-94be-b17b2186704e"
      unitRef="usd">3941000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjEtMS0xLTEtMjA3NzE1_127cc900-ca21-4966-93fb-eb0093e18e82"
      unitRef="usd">219000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjEtMy0xLTEtMjA3NzE1_d0422475-2b4f-4b6d-be13-8f756efe6c45"
      unitRef="usd">208000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjItMS0xLTEtMjA3NzE1_b599f7f9-ea28-46e6-855e-d3b20a53ca4a"
      unitRef="usd">20207000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjItMy0xLTEtMjA3NzE1_5dcd2ac4-7d9b-4b85-b112-372d748af206"
      unitRef="usd">20334000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjMtMS0xLTEtMjA3NzE1_a9256b9f-f557-4690-8b89-518092585d24"
      unitRef="usd">205000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjMtMy0xLTEtMjA3NzE1_47b8895d-672b-452a-9283-700519e97d9d"
      unitRef="usd">202000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjQtMS0xLTEtMjA3NzE1_369dd59e-4df9-4bb8-b0e0-8bf98aa49c13"
      unitRef="usd">746000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjQtMy0xLTEtMjA3NzE1_c0a366ea-f770-40d8-a21c-be9a567c81b7"
      unitRef="usd">741000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjUtMS0xLTEtMjA3NzE1_d0fa272f-a7bd-44b0-8711-6e37680163d0"
      unitRef="usd">25300000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjUtMy0xLTEtMjA3NzE1_5cde4a46-3130-4a40-b367-14971210d147"
      unitRef="usd">25426000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjYtMS0xLTEtMjA3NzE1_e71ea39c-ea2c-47c9-b94c-cf9b490e1f40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjYtMy0xLTEtMjA3NzE1_af184c3a-aac4-4cd0-ae70-b7bc285c5db8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjI_4e212c75-eba1-4638-b580-df32362d1966"
      unitRef="shares">363607062</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjI_fb1a13fc-1510-4abc-a436-9d04e19de223"
      unitRef="shares">363607062</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjk_0913db0b-0361-4bad-8da9-0b5f6042ab89"
      unitRef="shares">361898846</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246M2EyNDQ3MmNiNTZiNDY3NGE5OWVkMGI5MmEzZGMyNzFfNjk_9d91e4de-10ec-4c1e-90bf-8033b719fb0a"
      unitRef="shares">361898846</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMS0xLTEtMjA3NzE1_97c98ff5-b8a6-48e5-a497-181f08cfbd64"
      unitRef="usd">10405000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjgtMy0xLTEtMjA3NzE1_9303dcc4-c2c5-4ab8-86d1-f5f5e95baf3f"
      unitRef="usd">10391000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjktMS0xLTEtMjA3NzE1_404f81ee-533a-4a27-993a-9cc1af01906d"
      unitRef="usd">171000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMjktMy0xLTEtMjA3NzE1_6cf4d775-94d0-47aa-861e-097973855b67"
      unitRef="usd">159000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzAtMS0xLTEtMjA3NzE1_15a80177-ff7e-4827-84a6-b7f757e03b09"
      unitRef="usd">-9387000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzAtMy0xLTEtMjA3NzE1_dc76dd48-8e3b-4977-bd56-f2809440a000"
      unitRef="usd">-9186000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzEtMS0xLTEtMjA3NzE1_1c46548f-c320-43d7-81be-bbda99c7f583"
      unitRef="usd">-1989000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzEtMy0xLTEtMjA3NzE1_9b71792a-ddbd-4955-aa20-5ac76465329c"
      unitRef="usd">-2056000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzItMS0xLTEtMjA3NzE1_80afacfe-0109-41ce-81c7-e45d84c5a879"
      unitRef="usd">-800000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzItMy0xLTEtMjA3NzE1_023d87ec-2520-4a3a-af66-6e1b7a48e555"
      unitRef="usd">-692000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzMtMS0xLTEtMjA3NzE1_3b13e93e-521c-4204-8c28-96ca5927d1b6"
      unitRef="usd">945000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzMtMy0xLTEtMjA3NzE1_8ff14440-46b3-4d48-975a-fabe4c4a0cc2"
      unitRef="usd">952000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzQtMS0xLTEtMjA3NzE1_e1dc2f90-e2b8-494d-a112-0d7cc278ca3b"
      unitRef="usd">145000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzQtMy0xLTEtMjA3NzE1_07a1bcf6-9bd5-44a7-8799-ac0aae790c64"
      unitRef="usd">260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzUtMS0xLTEtMjA3NzE1_d9dc83c4-83fc-497b-8312-13ce158d4e46"
      unitRef="usd">25445000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yMi9mcmFnOmRmMGNiZGE3MzE4MjQyYmViOWFlZmRmNWRiZTA1OGNlL3RhYmxlOjRiYzY0NzdkNjAzNjQ0YWZhZTEyMjdhZTRjYjA1MDY4L3RhYmxlcmFuZ2U6NGJjNjQ3N2Q2MDM2NDRhZmFlMTIyN2FlNGNiMDUwNjhfMzUtMy0xLTEtMjA3NzE1_2b93a175-cb75-4cab-94ac-91fcdff376a1"
      unitRef="usd">25686000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia19ded4922bb433e8435b8239b8ff307_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMy01LTEtMS0yMDc3MTU_25dd1f39-db1d-42c9-b70f-9c464f408409"
      unitRef="usd">1922000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8c6e6704998497797963a331448aaea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMy03LTEtMS0yMDc3MTU_ebb0833f-ff07-4d02-b6a6-86f9a7dd034a"
      unitRef="usd">1891000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie687efc76f874ebeb1aae627bb6e171e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNC01LTEtMS0yMDc3MTU_af0e0311-6047-4efe-9b52-092efb050921"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72d37d3e40784682946238eaa429b35e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNC03LTEtMS0yMDc3MTU_5c0d1076-7ac8-43e1-8f22-c58f350cb620"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNS01LTEtMS0yMDc3MTU_b4ab0497-dc14-4d7f-9977-1519cdd29539"
      unitRef="usd">1944000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNS03LTEtMS0yMDc3MTU_a62e8a30-d5c6-433a-97c3-8712221c871a"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia19ded4922bb433e8435b8239b8ff307_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNy01LTEtMS0yMDc3MTU_82e7f5a1-e1be-48a5-97db-c90d50fd4605"
      unitRef="usd">572000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie8c6e6704998497797963a331448aaea_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfNy03LTEtMS0yMDc3MTU_510f8942-17f9-44a9-9f0e-460893ff1d18"
      unitRef="usd">536000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie687efc76f874ebeb1aae627bb6e171e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOC01LTEtMS0yMDc3MTU_e1ac5962-3fc7-496b-b881-5876a7f85f27"
      unitRef="usd">10000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i72d37d3e40784682946238eaa429b35e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOC03LTEtMS0yMDc3MTU_26432013-ba5a-4bde-8f5d-607b5af0a264"
      unitRef="usd">15000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOS01LTEtMS0yMDc3MTU_df5e7fab-2726-4367-a5c9-4c54eecfee0f"
      unitRef="usd">725000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfOS03LTEtMS0yMDc3MTU_2b416a5f-8bf0-4f44-87d2-0f6e6f938e09"
      unitRef="usd">622000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTAtNS0xLTEtMjA3NzE1_b2fe57c5-7a92-47ec-9eec-e5be6e2686e7"
      unitRef="usd">143000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTAtNy0xLTEtMjA3NzE1_5c444ae7-c0b5-465a-8383-97b0e5379ff6"
      unitRef="usd">127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTEtNS0xLTEtMjA3NzE1_ba2a4374-2749-42fe-8c6e-d86ee29b3453"
      unitRef="usd">273000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTEtNy0xLTEtMjA3NzE1_88ac4d20-ce8e-4afc-a702-cb5a03ab8f23"
      unitRef="usd">310000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <us-gaap:AssetImpairmentCharges
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTMtNS0xLTEtMjA3NzE1_24f79745-d93c-429e-837d-9274e034293b"
      unitRef="usd">13000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTMtNy0xLTEtMjA3NzE1_ccd74831-f370-4e56-b81b-baceb3b5473e"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTQtNS0xLTEtMjA3NzE1_77275bce-2251-4ecf-a4bb-fc9a78cf345c"
      unitRef="usd">10000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTQtNy0xLTEtMjA3NzE1_97aa7ae4-3046-4e13-984f-b6c1046561cf"
      unitRef="usd">13000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTUtNS0xLTEtMjA3NzE1_f13c9e66-eb58-453e-8e31-dbbfe82f24f6"
      unitRef="usd">-23000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTUtNy0xLTEtMjA3NzE1_e7cdd115-96c9-4449-a6c9-5c40e40cf02a"
      unitRef="usd">-2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTctNS0xLTEtMjA3NzE1_61ada127-8f87-47c0-9e13-67eb65567d5d"
      unitRef="usd">1769000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTctNy0xLTEtMjA3NzE1_1f448cc7-fa8b-46a0-b75c-7ccc7c8d5188"
      unitRef="usd">1633000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTgtNS0xLTEtMjA3NzE1_77b64367-1991-4dff-9002-2d035e3fb850"
      unitRef="usd">175000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTgtNy0xLTEtMjA3NzE1_5ae87207-485c-4414-93e1-f15ff540ef1e"
      unitRef="usd">285000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTktNS0xLTEtMjA3NzE1_d4912071-2aad-454b-a506-295ca2426830"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMTktNy0xLTEtMjA3NzE1_5168c7c2-f852-4e43-baf8-10d399aea7cd"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjAtNS0xLTEtMjA3NzE1_d2ad3622-7664-43ad-acf9-ee12be2173d1"
      unitRef="usd">307000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjAtNy0xLTEtMjA3NzE1_98c710c9-7699-42a2-a108-cc3f3b287034"
      unitRef="usd">362000000</us-gaap:InterestExpenseDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjItNS0xLTEtMjA3NzE1_7fe6ee55-146a-448a-8295-2c158adadd5b"
      unitRef="usd">-10000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjItNy0xLTEtMjA3NzE1_fc9b46f6-6baa-41a6-8e6d-badd0089453b"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjMtNS0xLTEtMjA3NzE1_142bfcd8-b728-47ad-85ff-1dd1962e7f5d"
      unitRef="usd">-136000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjMtNy0xLTEtMjA3NzE1_5cb23cee-0f99-44b5-b75c-9f12e8a767e3"
      unitRef="usd">-82000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjQtNS0xLTEtMjA3NzE1_5d582135-bced-4993-96c1-8ade01a915af"
      unitRef="usd">73000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjQtNy0xLTEtMjA3NzE1_dc181c69-be22-4194-a2bf-8b0a6df1f1ad"
      unitRef="usd">-16000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjUtNS0xLTEtMjA3NzE1_159f250f-c82b-473f-9eb3-208f06f6dbc5"
      unitRef="usd">-209000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjUtNy0xLTEtMjA3NzE1_ee4be0c6-afca-4614-8737-771f88936c2b"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjYtNS0xLTEtMjA3NzE1_34d52762-c5a9-4966-8129-34e299872ad4"
      unitRef="usd">-8000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjYtNy0xLTEtMjA3NzE1_528863cf-fd73-4d1b-806f-15e9afc42a45"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjctNS0xLTEtMjA3NzE1_6f4998e0-e721-4359-baa1-4c47909656e9"
      unitRef="usd">-201000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMjctNy0xLTEtMjA3NzE1_2a2e0568-2300-4bbb-a801-71fd8bed73b4"
      unitRef="usd">-69000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNS0xLTEtMjA3NzE1_5d2a9f8d-2120-4754-be0f-d5cce55aac30"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNS0xLTEtMjA3NzE1_759a968e-fbfe-45db-96aa-3f9fac613b69"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNy0xLTEtMjA3NzE1_950d4ee7-017b-47c3-bc7d-013f8fd32d09"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzAtNy0xLTEtMjA3NzE1_f8c5825f-96a7-4d96-a310-852ed5263f8b"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNS0xLTEtMjE5MDAx_7111d1bc-58a2-49d8-a934-5e5b684291a9"
      unitRef="shares">363300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNS0xLTEtMjE5MDAx_7a77166b-daf2-4880-8f02-3ce576155160"
      unitRef="shares">363300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNy0xLTEtMjE5MDAx_3b37c142-7b89-4edd-b849-bfa6c7adf67f"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yNS9mcmFnOjEwODUyYmU2ZDEwNjQ2ZDY4NTQ3YzRiMDcyNjMyYTk5L3RhYmxlOjFiZTQ3ODE4NTAwOTQwYjdhNzBhODBkMzdiNGIwNDhjL3RhYmxlcmFuZ2U6MWJlNDc4MTg1MDA5NDBiN2E3MGE4MGQzN2I0YjA0OGNfMzQtNy0xLTEtMjE5MDAx_f9a9a8d6-52ed-4b00-a907-67ae700cf7c1"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfMi01LTEtMS0yMDc3MTU_5f52adb8-5365-4a65-855a-40060dd3ff65"
      unitRef="usd">-209000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfMi03LTEtMS0yMDc3MTU_0a160bbd-e547-4c2e-b197-cc228e439421"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNC01LTEtMS0yMDc3MTU_0396b36c-91fa-4471-879e-07187f55db0c"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNC03LTEtMS0yMDc3MTU_957cbf25-ba1f-4a60-b332-f879943ce3b4"
      unitRef="usd">-56000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNS01LTEtMS0yMDc3MTU_a1c32124-f249-40df-9346-90d45c34fd7d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNS03LTEtMS0yMDc3MTU_6f80ebaf-3b8f-46a7-9c1b-94f07d0007cd"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNi01LTEtMS0yMDc3MTU_5d37f972-7520-40ac-8c65-04f536bfce20"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNi03LTEtMS0yMDc3MTU_e195b18d-954c-4a58-88b0-0a8c9e5592c6"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNy01LTEtMS0yMDc3MTU_f96a668b-8f80-4a07-8b0c-948b4829a184"
      unitRef="usd">-144000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfNy03LTEtMS0yMDc3MTU_024e2ad1-a30d-49ce-b65d-e0cb06bcc02c"
      unitRef="usd">-116000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOC01LTEtMS0yMDc3MTU_ccd9c894-c49d-4b37-8995-256a185d1322"
      unitRef="usd">-10000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOC03LTEtMS0yMDc3MTU_9e4e69a4-eefa-4fe8-a74d-0df4ded75ebe"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOS01LTEtMS0yMDc3MTU_f76f7258-e15a-4c00-9544-cbe136e4c772"
      unitRef="usd">-134000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8yOC9mcmFnOmQxMjZmM2Q0M2FkZTRlYzBiZTZlOWMyNWI4YzRlN2FmL3RhYmxlOjE1ODlhYjgxMGQ4NDQzY2M4MDc2NDUwOTI3MDc2Mjc2L3RhYmxlcmFuZ2U6MTU4OWFiODEwZDg0NDNjYzgwNzY0NTA5MjcwNzYyNzZfOS03LTEtMS0yMDc3MTU_9e631101-e156-439b-8278-7b504798b96c"
      unitRef="usd">-119000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i32b7e06a9d3a4aeb99dd497ebfb356f9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMi0xLTEtMjA3NzE1_bc91f6c3-ea42-4217-9988-82e045851ef9"
      unitRef="shares">361900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i32b7e06a9d3a4aeb99dd497ebfb356f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtNC0xLTEtMjA3NzE1_40c7b5cd-b854-40f5-8925-727a7d41a037"
      unitRef="usd">10391000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i452d83aa9dde4d01b6869dd5703fdaf8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtNi0xLTEtMjA3NzE1_68da8887-6ee2-4025-bfe1-453cbcf26b5d"
      unitRef="usd">159000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc3e9fd64df947f9a8f763d6cc90b963_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtOC0xLTEtMjA3NzE1_d963a480-45fe-411a-8b0a-1e958ca85fcf"
      unitRef="usd">-9186000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e558abb1f7e4945be1efbb15c0857e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTAtMS0xLTIwNzcxNQ_70c0e09c-2616-4543-b62c-f84e32ce1a59"
      unitRef="usd">-2056000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib12545de9cf64750aa8d3591b5e00bc7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTItMS0xLTIwNzcxNQ_536ba151-3443-4a5d-8715-ab7fdf61afb1"
      unitRef="usd">-692000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i94c5658cc65a4a05b4ff0e04db19ee97_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTQtMS0xLTIwNzcxNQ_386bb514-c013-4698-98b9-a6c2a5157a20"
      unitRef="usd">952000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMjgtMTYtMS0xLTIwNzcxNQ_9ef2c31d-a477-4f37-a9c1-dc471b3b5b3b"
      unitRef="usd">260000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic6a8b96ed7f940c5845ec8d2f802a9d4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtMi0xLTEtMjA3NzE1_53d8b811-a39a-4c64-96a3-912edc96dcc2"
      unitRef="shares">1700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic6a8b96ed7f940c5845ec8d2f802a9d4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtNC0xLTEtMjA3NzE1_61fedd09-5ac2-44be-967b-cc91a60d6d0f"
      unitRef="usd">14000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtNi0xLTEtMjA3NzE1_cce4e5d5-b145-48eb-8209-2816e30b054a"
      unitRef="usd">-14000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzAtMTYtMS0xLTIwNzcxNQ_7aa9ddf4-ed2a-43f9-8525-724daf2897f9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzEtNi0xLTEtMjA3NzE1_82007c21-ece0-48c5-bcaa-b5a08660c5ed"
      unitRef="usd">41000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzEtMTItMS0xLTIwNzcxNQ_cdc4e4c2-64c0-4e1a-af6e-4c3394636fde"
      unitRef="usd">41000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzEtMTYtMS0xLTIwNzcxNQ_4eaed946-8950-4744-9219-31c54b7554ae"
      unitRef="usd">41000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzItNi0xLTEtMjA3NzE1_6e1691b8-241e-4741-9bde-774b05bcdd40"
      unitRef="usd">12000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzItMTItMS0xLTIwNzcxNQ_12cccb86-6886-4f38-9481-3b19eed81a34"
      unitRef="usd">12000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzItMTYtMS0xLTIwNzcxNQ_bcf79616-bc95-44e9-bd2a-6502940c107a"
      unitRef="usd">12000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i68ad4632312a47caba8495e9ad5c4daf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtNi0xLTEtMjM4NjYz_48275131-4e0c-477e-beaf-7a2a45cc5f31"
      unitRef="usd">-3000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTItMS0xLTIzODU3MA_417245b9-2b15-4a43-8d7a-311c523e71ea"
      unitRef="usd">-3000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i808b863dada9457f923ca993a3bea323_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzMtMTQtMS0xLTIwNzcxNQ_6c4fddc0-2fd7-45c7-bb91-e5caceffe5b7"
      unitRef="usd">3000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzMtMTYtMS0xLTIwNzcxNQ_2775f5fc-fd37-457c-b81e-c89de3138409"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss
      contextRef="ic162d17ac63741d18133d43351ec92b7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtOC0xLTEtMjA3NzE1_160f501c-e07b-4f32-a3f8-7b8ae9d79efa"
      unitRef="usd">-201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTItMS0xLTIwNzcxNQ_ba74735b-3a16-454d-bb30-3c677759e6ff"
      unitRef="usd">-201000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i808b863dada9457f923ca993a3bea323_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTQtMS0xLTIwNzcxNQ_f575b77c-f88e-455d-bbf1-964f3e7b5e3f"
      unitRef="usd">-8000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzQtMTYtMS0xLTIwNzcxNQ_8cafb275-6d7e-4f25-8b88-67c0bf46dda2"
      unitRef="usd">-209000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i40ddc921f07a4aeeacf02c27134db643_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTAtMS0xLTIwNzcxNQ_3c8d6aa2-d1c4-42df-956b-ca81cbfdde3e"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia3dd81794064434383ac1286a5053baf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTItMS0xLTIwNzcxNQ_d5091e73-7909-475b-a572-8e5581117151"
      unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i808b863dada9457f923ca993a3bea323_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTQtMS0xLTIwNzcxNQ_94656f3e-b4c9-45c7-a767-a8ef65c0e64b"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzUtMTYtMS0xLTIwNzcxNQ_a98ca305-90be-424f-9744-ce4cc2e94b5a"
      unitRef="usd">65000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i66672939efa64ce0a7f6175881cc8e7b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMi0xLTEtMjA3NzE1_03fe481e-03ec-4dbb-8502-69aaabbfd29d"
      unitRef="shares">363600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66672939efa64ce0a7f6175881cc8e7b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtNC0xLTEtMjA3NzE1_a8095ba5-ca65-4c5e-acb3-1a5973ebb6f2"
      unitRef="usd">10405000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8ba4914a69d4cb8b1fc752df5873883_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtNi0xLTEtMjA3NzE1_1519dfd0-defe-4c2b-8316-ef78ca8e5a05"
      unitRef="usd">171000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a2f6084f5a4426387b1bdba497c5c63_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtOC0xLTEtMjA3NzE1_80dc273d-ec5b-4569-8201-59d97c2f2a6a"
      unitRef="usd">-9387000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bbac5f0d9d24f8a8f825099f3394fec_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTAtMS0xLTIwNzcxNQ_e9c3af61-7a93-4dbb-99a4-ca5b5e113732"
      unitRef="usd">-1989000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i946e14205ef041e8972492d11be8775d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTItMS0xLTIwNzcxNQ_7a047af2-50c0-4b8c-9388-ef01fbdb3314"
      unitRef="usd">-800000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i371252488c904680b474dfac8b94f900_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTQtMS0xLTIwNzcxNQ_9d60cf8c-70b3-4cce-8f68-531bde0fc797"
      unitRef="usd">945000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzYtMTYtMS0xLTIwNzcxNQ_baf04ecb-358b-43a1-a211-bf31387e909f"
      unitRef="usd">145000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMi0xLTEtMjA3NzE1_34d13ea6-3ff1-4feb-ac4c-49d1b7b811ee"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktNC0xLTEtMjA3NzE1_1f06e0e9-22c1-41c7-a2bf-29be486d20d4"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f7f8f2ef85a49f4afe5effddaa485c8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktNi0xLTEtMjA3NzE1_0f2d0cd6-27a3-4a77-ba71-a6570dc41e77"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaf9314740a5046e6b7fbcde6a1225413_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktOC0xLTEtMjA3NzE1_dff4fcc5-411a-4c8f-8e1d-9505abfba130"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c02450191db423fbdddbea92953f1fa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTAtMS0xLTIwNzcxNQ_ba9f52d6-a94e-44bc-9e0f-0d6bccd3cf40"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fcf82d8c82b4464bcd33142e1f338cd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTItMS0xLTIwNzcxNQ_383df489-ec39-49d1-875c-9d7a91763bbc"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8902b132c274ce980a60fe03aa09c6f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTQtMS0xLTIwNzcxNQ_02f4d73c-f5c2-47b7-b854-24e2ebcc67c9"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfMzktMTYtMS0xLTIwNzcxNQ_e7000266-1764-49e9-8d77-cedac5f0f727"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1ce9f18c7cd9441ba37c871b38e9c09e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItMi0xLTEtMjI5MTk1_e60faca5-9d56-42b2-aede-a04da78fcb77"
      unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1ce9f18c7cd9441ba37c871b38e9c09e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItNC0xLTEtMjI5MTk1_13559d21-c4e6-4fa4-b246-1b2c71d853c3"
      unitRef="usd">56000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDEtNi0xLTEtMjA3NzE1_66e514a0-007e-43aa-9075-f5b7f9643f7c"
      unitRef="usd">-54000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDEtMTItMS0xLTIwNzcxNQ_82a0c8be-7da6-4d0f-af60-646e0cd84fac"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDEtMTYtMS0xLTIwNzcxNQ_a4814ab4-60fa-462b-b23e-f1e675614fd1"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItNi0xLTEtMjA3NzE1_a6585db0-dcd8-4c0a-b670-aabc0ce61a96"
      unitRef="usd">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItMTItMS0xLTIwNzcxNQ_2aba291a-7e1d-436a-899f-8cb45a345bab"
      unitRef="usd">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDItMTYtMS0xLTIwNzcxNQ_83bef0b8-c9f6-4a49-90cb-a0b2357b8b80"
      unitRef="usd">32000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1d2b6d09b8a84fe6a519bbef3b24f2de_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDQtNi0xLTEtMjI5MTk3_24072507-5087-47b0-be9b-c48f380a50f2"
      unitRef="usd">25000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDMtMTItMS0xLTIwNzcxNQ_ad93fb47-8bc9-49f5-9366-c1c3117044e1"
      unitRef="usd">25000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDMtMTYtMS0xLTIwNzcxNQ_8a67f625-fae1-4988-b47d-531d99c06211"
      unitRef="usd">25000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProfitLoss
      contextRef="ibcbd578c19014c70a67ef1fb87173055_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtOC0xLTEtMjA3NzE1_f52470c1-03ca-4de2-97e0-decbe48fe91c"
      unitRef="usd">-69000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtMTItMS0xLTIwNzcxNQ_d4ba786a-201f-4f44-a7e4-c59a8134d14c"
      unitRef="usd">-69000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib1b2462e77bf46ba99a8e0c38ea11630_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtMTQtMS0xLTIwNzcxNQ_e883a873-7265-42b6-ad6f-5ef814d0dc1a"
      unitRef="usd">3000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDUtMTYtMS0xLTIwNzcxNQ_118e1186-4190-48fd-b7d1-d317b6d3440b"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9e3484672c1b4b38a05983fa5254b458_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDYtMTAtMS0xLTIwNzcxNQ_78f2b4d5-8250-46ff-8a31-8f28899a473f"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2168a32f90e74120bf69aa8789094eed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDYtMTItMS0xLTIwNzcxNQ_c8ce6918-bb36-46ed-949b-021761d108f2"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDYtMTYtMS0xLTIwNzcxNQ_ac1b6aa5-2ae9-49f4-915f-03a85fe39d37"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="id04b8551dc9c4d889a6e5fd80cbc09f4_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMi0xLTEtMjA3NzE1_fa0d453f-3496-4198-9c37-812e454134f1"
      unitRef="shares">361300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id04b8551dc9c4d889a6e5fd80cbc09f4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctNC0xLTEtMjA3NzE1_1725d90c-4168-4af4-853d-06848d03a39f"
      unitRef="usd">10373000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f710c703f87477bb1995e048a1ad4c3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctNi0xLTEtMjA3NzE1_3e727bb0-3d53-4d95-8e79-af54c23e97f7"
      unitRef="usd">415000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i080749f8173b49ce89929a1cd63c2560_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctOC0xLTEtMjA3NzE1_ae9a58d6-fcea-4b47-b192-0033c2283db3"
      unitRef="usd">-9030000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib63d0633dd2449069f3d40c923633c0b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTAtMS0xLTIwNzcxNQ_033a85be-eb4e-4e91-a4c5-a0467ff79398"
      unitRef="usd">-1974000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77426eee8f534f118cfa729bb49d9f39_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTItMS0xLTIwNzcxNQ_e3d03f72-5099-49f5-9216-89ddfb39f162"
      unitRef="usd">-216000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21c3f3c6b4a24d8cb42af4f8458f66e6_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTQtMS0xLTIwNzcxNQ_350a71a8-7711-450d-bd44-d07ec8b4cfac"
      unitRef="usd">75000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zMS9mcmFnOmIzMWJhNTU3OWEwMDQwM2ViNzE4YjEwNzY4MTg2NWMwL3RhYmxlOmI0YjhhMmM3Zjk5MjQxMmI4ZmNiNDA2ODJhNzlmMzEzL3RhYmxlcmFuZ2U6YjRiOGEyYzdmOTkyNDEyYjhmY2I0MDY4MmE3OWYzMTNfNDctMTYtMS0xLTIwNzcxNQ_b13261fc-489d-4b0a-ad7d-c59f1caecb3e"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMy0xLTEtMS0yMDc3MTU_5f52adb8-5365-4a65-855a-40060dd3ff65"
      unitRef="usd">-209000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMy0zLTEtMS0yMDc3MTU_0a160bbd-e547-4c2e-b197-cc228e439421"
      unitRef="usd">-66000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNS0xLTEtMS0yMDc3MTU_509aa640-06d8-40b7-8f82-0ecec9fb956c"
      unitRef="usd">319000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNS0zLTEtMS0yMDc3MTU_b1e7d1c3-e4e8-471d-b0a4-34cf7e532662"
      unitRef="usd">352000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNi0xLTEtMS0yMDc3MTU_64bd3f72-c372-4b57-bd2f-3bd9225b50c2"
      unitRef="usd">11000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNi0zLTEtMS0yMDc3MTU_e8d59155-05e0-45ae-873e-c443bcf579d5"
      unitRef="usd">14000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNy0xLTEtMS0yMDc3MTU_24f79745-d93c-429e-837d-9274e034293b"
      unitRef="usd">13000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNy0zLTEtMS0yMDc3MTU_ccd74831-f370-4e56-b81b-baceb3b5473e"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfOS0xLTEtMS0yMDc3MTU_83d960df-a11f-432b-adb1-c66c520179b2"
      unitRef="usd">31000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfOS0zLTEtMS0yMDc3MTU_0f51727c-3851-4e3d-b1c9-dabe20709119"
      unitRef="usd">3000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTAtMS0xLTEtMjA3NzE1_4dd97471-3c4a-4e82-a4c6-490a51a0b71f"
      unitRef="usd">10000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTAtMy0xLTEtMjA3NzE1_fdcfe25c-ffd5-4977-b40e-fecf1f53f33b"
      unitRef="usd">14000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTEtMS0xLTEtMjA3NzE1_5807f1a6-19e1-461f-84a2-4d8ad6b21e1c"
      unitRef="usd">0</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTEtMy0xLTEtMjA3NzE1_e208e1d6-df3a-46ca-ac47-bd15170fe555"
      unitRef="usd">-83000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTMtMS0xLTEtMjA3NzE1_0083bc32-0037-4e2f-8bb7-d2f2143615b2"
      unitRef="usd">-1000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTMtMy0xLTEtMjA3NzE1_35018995-9b58-42c9-876c-e9e19f6d97ef"
      unitRef="usd">1000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTQtMS0xLTEtMjA3NzE1_d7e43bd6-5ff8-4a30-b8e2-3627fa96642c"
      unitRef="usd">1000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTQtMy0xLTEtMjA3NzE1_7a076f79-62b2-4425-8357-b8157a0693bf"
      unitRef="usd">360000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTUtMS0xLTEtMjA3NzE1_317c335c-9e53-4b85-9885-8dc5ed1fa6e6"
      unitRef="usd">41000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTUtMy0xLTEtMjA3NzE1_a0912cc7-068d-4f2e-b7a6-e119fd43acf0"
      unitRef="usd">32000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTYtMS0xLTEtMjA3NzE1_929997c0-2cbe-4878-9347-bc738801514f"
      unitRef="usd">-6000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTYtMy0xLTEtMjA3NzE1_1615f6ff-26cd-4ca7-b3ee-3e0a7c04abeb"
      unitRef="usd">2000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTctMS0xLTEtMjA3NzE1_29b7b72b-9fa7-4bd2-9c22-ef755d3b72c9"
      unitRef="usd">3000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMTctMy0xLTEtMjA3NzE1_ae26769d-cf44-4331-8ccd-b3c65a32c3a7"
      unitRef="usd">0</bhc:DerivativeGainExcludedComponent>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjEtMS0xLTEtMjA3NzE1_f7f836d2-8668-4c4e-b4b3-8c17db18f7d4"
      unitRef="usd">4000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjEtMy0xLTEtMjA3NzE1_5085211b-fa06-4458-86ed-597341bf6bc6"
      unitRef="usd">-10000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjMtMS0xLTEtMjA3NzE1_fbd2319a-ab8e-40c6-bbe3-e01126ef9e86"
      unitRef="usd">-108000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjMtMy0xLTEtMjA3NzE1_701ae1ce-068f-4068-932e-6033aa02e4ae"
      unitRef="usd">-197000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjQtMS0xLTEtMjA3NzE1_5a2dd4dd-ce8e-4b38-bd6d-97e24b76626e"
      unitRef="usd">128000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjQtMy0xLTEtMjA3NzE1_471c1117-4b18-4a32-8cac-a5406a470872"
      unitRef="usd">73000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjUtMS0xLTEtMjA3NzE1_d2a42607-cadb-41ac-93a0-ec8880352f68"
      unitRef="usd">33000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjUtMy0xLTEtMjA3NzE1_d7018efb-a89b-4d72-9cc9-e27fe4d5e7e5"
      unitRef="usd">33000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjYtMS0xLTEtMjA3NzE1_d2d8dc7b-3b61-4e82-b294-e11d21107af8"
      unitRef="usd">-8000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjYtMy0xLTEtMjA3NzE1_955eb239-0076-4035-a184-a90355bd314e"
      unitRef="usd">-75000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjctMS0xLTEtMjA3NzE1_5d57f54d-c677-44be-b7dc-c9d7e1461fec"
      unitRef="usd">154000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjctMy0xLTEtMjA3NzE1_a716947c-63ca-4ccf-bbc1-2009d2dd3291"
      unitRef="usd">-63000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <bhc:PaymentsToAcquireBusinessesAndForOtherInvestments
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMS0xLTEtMjMzNjg5_5bb855e1-ce3f-4710-9640-a1defc50d969"
      unitRef="usd">31000000</bhc:PaymentsToAcquireBusinessesAndForOtherInvestments>
    <bhc:PaymentsToAcquireBusinessesAndForOtherInvestments
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMy0xLTEtMjMzNjg5_ce72e119-1575-4058-bf24-fae2cdcf7070"
      unitRef="usd">0</bhc:PaymentsToAcquireBusinessesAndForOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMS0xLTEtMjA3NzE1_3320ea58-1e13-454a-bea2-4f0a4426aca0"
      unitRef="usd">47000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMjktMy0xLTEtMjA3NzE1_5776ae58-d042-4e7d-b446-18a813dea40c"
      unitRef="usd">46000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzAtMS0xLTEtMjA3NzE1_7ca7890e-94f4-401a-8184-3836600da458"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzAtMy0xLTEtMjA3NzE1_2e7f1a3b-5961-4a80-947f-be08076b8dfa"
      unitRef="usd">11000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzEtMS0xLTEtMjA3NzE1_a553cd8d-65dd-4168-afa1-244163c974bb"
      unitRef="usd">13000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzEtMy0xLTEtMjA3NzE1_e63f79a5-7088-491b-af6f-76cb02c44f26"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzItMS0xLTEtMjA3NzE1_09bcd488-8866-48b9-9b7b-29c61831a520"
      unitRef="usd">11000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzItMy0xLTEtMjA3NzE1_9aa1b753-6811-41f6-81da-b4b67a0ea6cd"
      unitRef="usd">6000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzQtMS0xLTEtMjA3NzE1_b51b990a-782f-438b-badc-6e1c651297cc"
      unitRef="usd">6000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzQtMy0xLTEtMjA3NzE1_5098cd54-15b7-4e02-a4d2-01f92787f985"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzUtMS0xLTEtMjA3NzE1_2b3769c1-c446-49f6-9c72-cde4b4b7b569"
      unitRef="usd">-78000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzUtMy0xLTEtMjA3NzE1_fb215f4b-f692-4a3e-925e-931cd02e3e00"
      unitRef="usd">-56000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzctMS0xLTEtMjA3NzE1_035ee789-0978-4281-9fe0-3035dec9c36d"
      unitRef="usd">155000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzctMy0xLTEtMjA3NzE1_82809ccc-8298-4ef5-857d-6922396a404f"
      unitRef="usd">986000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzgtMS0xLTEtMjA3NzE1_2bfb59b8-c8b5-4c76-840e-a895ea33d711"
      unitRef="usd">279000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfMzgtMy0xLTEtMjA3NzE1_6000f6db-927a-4957-ae01-2a723fe44628"
      unitRef="usd">485000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDItMS0xLTEtMjA3NzE1_f8941f08-b81c-4e9a-9880-3a0de0667a03"
      unitRef="usd">12000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDItMy0xLTEtMjA3NzE1_7b30bf31-477a-42e8-9ecf-a267f1cd4fe5"
      unitRef="usd">25000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDMtMS0xLTEtMjA3NzE1_283e168d-b4b1-4e31-8be4-0212d07dda57"
      unitRef="usd">7000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDMtMy0xLTEtMjA3NzE1_d646769c-bb26-42e4-a97b-08cd7a36be13"
      unitRef="usd">8000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDQtMS0xLTEtMjA3NzE1_bb21364f-2f59-4558-86eb-698f077c700e"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDQtMy0xLTEtMjA3NzE1_179dd780-7d9b-4105-85d9-428938564ce6"
      unitRef="usd">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDUtMS0xLTEtMjA3NzE1_e14cd510-7203-40c7-a69d-cab3d6f0ec0b"
      unitRef="usd">1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDUtMy0xLTEtMjA3NzE1_b5dfd338-7411-46a9-8d9e-1300f442b771"
      unitRef="usd">1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDYtMS0xLTEtMjA3NzE1_4151a393-d08c-4276-b19e-ea8ea53d6a33"
      unitRef="usd">-142000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDYtMy0xLTEtMjA3NzE1_9692991b-6e6f-4d11-9c51-a04cf9d7e4df"
      unitRef="usd">468000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDctMS0xLTEtMjA3NzE1_60005081-77bb-429e-b33b-671923740351"
      unitRef="usd">6000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDctMy0xLTEtMjA3NzE1_17cc5422-bbec-4dd1-b239-643f661ad666"
      unitRef="usd">-8000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDgtMS0xLTEtMjA3NzE1_539f61a8-3070-4955-b381-af455055ad5a"
      unitRef="usd">-60000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDgtMy0xLTEtMjA3NzE1_c0bed0d0-a165-4285-88b0-86edb5ecb3ae"
      unitRef="usd">341000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDktMS0xLTEtMjA3NzE1_4e2c98cb-5cb5-4f39-84b0-78921b161b95"
      unitRef="usd">591000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNDktMy0xLTEtMjA3NzE1_dbd67146-19f4-4f01-bdd7-b7aa4e971d9c"
      unitRef="usd">2119000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTAtMS0xLTEtMjA3NzE1_37fea78e-20a9-4879-9fd1-9730f0c4e972"
      unitRef="usd">531000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTAtMy0xLTEtMjA3NzE1_1818dd53-4193-46a2-b88a-15539dbae3c8"
      unitRef="usd">2460000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTEtMS0xLTEtMjA3NzE1_148e9aa7-edb3-4887-87b6-237b8175d0d1"
      unitRef="usd">518000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTEtMy0xLTEtMjA3NzE1_d6b3ed97-b53b-4d63-8837-2fc40c27eabb"
      unitRef="usd">1249000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTItMS0xLTEtMjA3NzE1_42b8d7f7-010d-41fe-ab86-4fa6ff126d9c"
      unitRef="usd">13000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTItMy0xLTEtMjA3NzE1_d2dd3eca-7809-42c4-9adb-7f7c5a026a3e"
      unitRef="usd">1211000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTQtMS0xLTEtMjA3NzE1_59f48ab2-a39e-463a-a890-be6dbc6b533e"
      unitRef="usd">531000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8zNC9mcmFnOmFmMjI0MTVhNTJhNjQ0MmE4MDEyMjkyYjkxMTNhMjM4L3RhYmxlOjUzNDE2Mjg4MGM5MjQwOGRiY2IzM2Q0YzYxNGRhMjBiL3RhYmxlcmFuZ2U6NTM0MTYyODgwYzkyNDA4ZGJjYjMzZDRjNjE0ZGEyMGJfNTQtMy0xLTEtMjA3NzE1_18aa7aae-7eaa-466b-a15d-c55a9ef4546f"
      unitRef="usd">2460000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80MC9mcmFnOjM1YjhhYTM1NjJiZTQ2Mjc5NTQyMTI1YWU2OTE5ZGRiL3RleHRyZWdpb246MzViOGFhMzU2MmJlNDYyNzk1NDIxMjVhZTY5MTlkZGJfNzkz_a749bf45-6fd4-4f61-ae30-7b343b1168b9">DESCRIPTION OF BUSINESS Bausch Health Companies Inc. (the&#160;&#x201c;Company&#x201d; or &#x201c;Bausch Health&#x201d;) is a global, diversified specialty pharmaceutical and medical device company that develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (&#x201c;GI&#x201d;), hepatology, neurology and dermatology, a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and aesthetic medical devices, and, through its approximately 89% ownership of Bausch + Lomb Corporation (&#x201c;Bausch + Lomb&#x201d;), branded, and branded generic pharmaceuticals, OTC products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment) in the therapeutic areas of eye health. The Company&#x2019;s products are marketed directly or indirectly in approximately 100 countries.</us-gaap:NatureOfOperations>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i63bf7af9472e4ef792681b0e8c4f7da0_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80MC9mcmFnOjM1YjhhYTM1NjJiZTQ2Mjc5NTQyMTI1YWU2OTE5ZGRiL3RleHRyZWdpb246MzViOGFhMzU2MmJlNDYyNzk1NDIxMjVhZTY5MTlkZGJfNDUz_1901135b-febd-4776-9627-c8b55697717a"
      unitRef="number">0.89</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80MC9mcmFnOjM1YjhhYTM1NjJiZTQ2Mjc5NTQyMTI1YWU2OTE5ZGRiL3RleHRyZWdpb246MzViOGFhMzU2MmJlNDYyNzk1NDIxMjVhZTY5MTlkZGJfNzc2_ab803e7e-1d1a-45b8-a949-efcb70bfab87"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAyMA_0b4a4803-76b8-4f06-a784-c29a3d5623de">SIGNIFICANT ACCOUNTING POLICIES &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the U.S Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the &#x201c;CSA&#x201d;) on February&#160;23, 2023. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2022. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye Health Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its plan to separate its eye health business, consisting of its Bausch + Lomb global Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb Corporation (&#x201c;Bausch + Lomb&#x201d; or &#x201c;B+L&#x201d;) from the remainder of Bausch Health Companies Inc. (the &#x201c;B+L Separation&#x201d;). On May 5, 2022, the registration statement related to the initial public offering of Bausch +Lomb (the &#x201c;B+L IPO&#x201d;) was declared effective, and B+L&#x2019;s common stock began trading on the New York Stock Exchange and the Toronto Stock Exchange, in each case under the ticker symbol &#x201c;BLCO&#x201d; on May 6, 2022. Prior to the effectiveness of the registration statement, B+L was an indirect wholly-owned subsidiary of Bausch Health. On May 10, 2022, a wholly owned subsidiary of Bausch Health sold 35,000,000 common shares of B+L pursuant to the B+L IPO. Upon the closing of the B+L IPO and after giving effect to the subsequent partial exercise of the over-allotment option by the underwriters, Bausch Health indirectly holds 310,449,643 common shares of Bausch + Lomb, which represents approximately 89% of B+L&#x2019;s outstanding common shares as of March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The completion of the B+L Separation is subject to the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals. The Company continues to evaluate all relevant factors and considerations related to completing the B+L Separation, including the effect of the Norwich Legal Decision (see&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 17, &#x201c;LEGAL PROCEEDINGS&#x201d;) on the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L IPO established two separate companies that include: (i) a diversified pharmaceutical company comprised of the Salix, International, Diversified (dentistry, neurology, medical dermatology and generics pharmaceutical), and Solta Medical aesthetic medical device businesses and (ii) a fully integrated eye health company which consists of the Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals businesses. Other than the effects of the B+L IPO described above, these unaudited Condensed Consolidated Financial Statements do not include any adjustments to give effect to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAyNw_dc29b2a4-50a8-404e-8964-609fc2e3ccec">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared by the Company in U.S. dollars and in accordance with&#160;U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;) for interim financial reporting, which do not conform in all respects to the requirements of U.S.&#160;GAAP for annual financial statements. Accordingly, these notes to the unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements prepared in accordance with U.S.&#160;GAAP that are contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the U.S Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and the Canadian Securities Administrators (the &#x201c;CSA&#x201d;) on February&#160;23, 2023. The unaudited Condensed Consolidated Financial Statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company&#x2019;s audited Consolidated Financial Statements for the year ended December&#160;31, 2022. The unaudited Condensed Consolidated Financial Statements reflect all normal and recurring adjustments necessary for a fair statement of the Company&#x2019;s financial position and results of operations for the interim periods. The operating results for the interim periods presented are not necessarily indicative of the results expected for the full&#160;year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i4c8c5d995a3747e29d7c4e9cef2e105f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMTA5OTUxMTY1MTE2Mg_d815f40d-3cba-4dc2-9d62-5699397a83ce"
      unitRef="shares">35000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7e0c7a0e030f4effa3695934ea837e9f_I20220601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMjE5OTAyMzI3OTEyNg_db3a5419-adcf-4174-80d2-70a8bb2c0720"
      unitRef="shares">310449643</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i7a49d1ee9a464f5db7a10d853a1a1349_D20230331-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMjE5OTAyMzI3OTEzOQ_0ce20ba3-52bb-4c50-8571-17691e331f8a"
      unitRef="number">0.89</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:UseOfEstimates
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAyNQ_2be4d0a6-a3eb-449c-8302-4d34b3381b23">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the unaudited Condensed Consolidated Financial Statements, management is required to make estimates and assumptions. The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s results of operations and financial position could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfOTAzOQ_e45f8a57-f6fd-4fc8-b4ea-5225e5551b79">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited Condensed Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80My9mcmFnOmMwMDcyODY4MWU3NzRmNTU4MGQ4OTU5ZjdiN2U1ZDJhL3RleHRyZWdpb246YzAwNzI4NjgxZTc3NGY1NTgwZDg5NTlmN2I3ZTVkMmFfMjE5OTAyMzI3OTczNQ_fa3df2e8-a361-43d4-9638-9e92797c9825">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ3Ng_84fda20c-b87d-4cad-92ce-867759e37631">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue which is derived primarily from contract manufacturing for third parties and which is not material. See Note 18, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $40&#160;million as of March 31, 2023 and January 1, 2023, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $37 million and $36&#160;million as of March 31, 2022 and January 1, 2022, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collateral (if any), and any relevant current and reasonably supportable future economic factors.&#160;Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2023 and 2022 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs charged against the allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries of amounts previously written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ4Mg_87b36d74-c612-4e48-9530-5e66921e2c52">REVENUE RECOGNITION &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of GI, hepatology, neurology, dermatology and eye health, that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic medical devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue which is derived primarily from contract manufacturing for third parties and which is not material. See Note 18, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenue which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160;The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers. Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company&#x2019;s products. This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period. The Company applies this method consistently for contracts with similar characteristics.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ2Mg_bb1d91d7-d5f8-4cbc-9290-de0ab26c709b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the activity and ending balances of the Company&#x2019;s variable consideration provisions for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $43 million and $40&#160;million as of March 31, 2023 and January 1, 2023, respectively, which are reflected as a reduction of Trade receivables, net in the Condensed Consolidated Balance Sheets. There were no price appreciation credits during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(162)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(599)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(359)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balances, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2e45b6ebd3b048e894cd2c2e5aedafa4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi0yLTEtMS0yMDc3MTU_8b9ae241-ff24-475f-8ec7-71c3c6018294"
      unitRef="usd">188000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie10c054fa2de4824aef49eafab2b651e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi00LTEtMS0yMDc3MTU_6e4489a4-a5a9-46c8-97ad-87073c387eb7"
      unitRef="usd">427000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i135bc17430224f338814ab96077762d3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi02LTEtMS0yMDc3MTU_3740b147-54bf-43cf-8e35-c6d12a87eede"
      unitRef="usd">1023000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ief70a603ee11466f94467c535a3e3125_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi04LTEtMS0yMDc3MTU_37935eb9-c156-4346-9f58-3f8cf0e7fa56"
      unitRef="usd">196000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i823782cb59e242d194dab1df20d01ab8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi0xMC0xLTEtMjA3NzE1_4657bba1-5ca7-4882-aca7-afac9be71136"
      unitRef="usd">76000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMi0xMi0xLTEtMjA3NzE1_d592a289-5f47-4903-a689-e8373e1cf2d7"
      unitRef="usd">1910000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i1bd82fd1b04c4ca5a90663181d0b9281_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy0yLTEtMS0yMDc3MTU_1cae38f6-e1cd-4726-9c58-2a7177d989f5"
      unitRef="usd">139000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i1fe64f13b6ba4162ae7430acb9dbf957_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy00LTEtMS0yMDc3MTU_5c4be8f9-932b-4886-a628-397a8b08188e"
      unitRef="usd">42000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i20c4dfdc7ef14cc9bc3a3ac6abfe8664_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy02LTEtMS0yMDc3MTU_78a5bf2b-f7b1-4f29-9353-5b40e92cfecf"
      unitRef="usd">664000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i42e80003bff24d46bd9d4b8a36e49cd0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy04LTEtMS0yMDc3MTU_f5069b90-e9fe-4ff0-a407-4730c6e5b50c"
      unitRef="usd">465000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i3840f2154ebb4758a2ccbd787ed21972_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy0xMC0xLTEtMjA3NzE1_2c7d4293-f6df-4146-a890-934b55bf4551"
      unitRef="usd">61000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfMy0xMi0xLTEtMjA3NzE1_43e60e6b-f92f-485f-a03d-0b245a1712c3"
      unitRef="usd">1371000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1bd82fd1b04c4ca5a90663181d0b9281_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC0yLTEtMS0yMDc3MTU_61ef3cae-9fa3-4810-b3d8-69d3124f0b8b"
      unitRef="usd">148000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1fe64f13b6ba4162ae7430acb9dbf957_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC00LTEtMS0yMDc3MTU_fe287927-c823-4472-b720-13fab5c86529"
      unitRef="usd">40000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i20c4dfdc7ef14cc9bc3a3ac6abfe8664_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC02LTEtMS0yMDc3MTU_2bcc3939-d3e5-4f07-8eee-e1b46b08538d"
      unitRef="usd">729000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i42e80003bff24d46bd9d4b8a36e49cd0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC04LTEtMS0yMDc3MTU_64b21892-386d-4ddd-b72d-cd91dc0d315b"
      unitRef="usd">487000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3840f2154ebb4758a2ccbd787ed21972_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC0xMC0xLTEtMjA3NzE1_08ac6f3e-1100-4d07-84e5-3062d2edc21a"
      unitRef="usd">49000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNC0xMi0xLTEtMjA3NzE1_b572ac5e-89e0-454e-8891-5991f058946e"
      unitRef="usd">1453000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6e0087ac09e4486ea85863d74934cc18_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS0yLTEtMS0yMDc3MTU_6ff190d9-debf-4e49-97c9-08b8f174c14e"
      unitRef="usd">179000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if83655d1435547e9a88be7c0a6a44473_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS00LTEtMS0yMDc3MTU_b705ca58-593c-4fd8-8b07-2ba8579e14a2"
      unitRef="usd">429000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9c661f0c33684c05ba82c765639b2da8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS02LTEtMS0yMDc3MTU_532702fc-d3a6-4732-af28-dc37554d6379"
      unitRef="usd">958000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifcaaa7bc80ae4f49a0ec057d07433721_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS04LTEtMS0yMDc3MTU_289491c0-2a1b-48be-b60c-07191035d171"
      unitRef="usd">174000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0dfb70e0fd024446818c699b54888111_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS0xMC0xLTEtMjA3NzE1_ef7f065c-5467-463c-a284-e79378d41a3c"
      unitRef="usd">88000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjZmM2I4OWFlOTRjNDQ5ODM4NzgxYTY1ODMxNGE3ODg1L3RhYmxlcmFuZ2U6NmYzYjg5YWU5NGM0NDk4Mzg3ODFhNjU4MzE0YTc4ODVfNS0xMi0xLTEtMjA3NzE1_e146d160-84b7-4328-be8c-244a35b8eab8"
      unitRef="usd">1828000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i391ac9a452be4bdcb904867d4fb45391_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNDg2Mw_40e6b6c0-9f59-4e66-a5a9-0baf06e81a16"
      unitRef="usd">43000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if1fb66cbda4b4013887d1e87c53164eb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNDg3MA_2b1320b1-1de3-45ab-8487-90078ff02e53"
      unitRef="usd">40000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i318586ad088847fe9e02f2dbe2f1d9be_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNTAxOQ_6daa8e65-65bb-4600-9651-b0b8c681246b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8290334f6ddb49b48369b500e2a37633_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi0yLTEtMS0yMDc3MTU_e1df7b59-3c95-43ca-8c91-959e4468a03b"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i57521c3e1fc6438c83e45eed46549020_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi00LTEtMS0yMDc3MTU_30465f18-9984-43b0-b0ec-9301aa1007b6"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i80ef4ad0b68c4cc98d683b6b92852ec3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi02LTEtMS0yMDc3MTU_cc067f8b-318a-46f5-8231-db4faca132f2"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic21e95c278304743bdfd808b5bcf88c0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi04LTEtMS0yMDc3MTU_34407bf6-b871-4dba-90bf-f5f971ae4c0f"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0f4502c99efb4e1192389a486b24fec4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi0xMC0xLTEtMjA3NzE1_6d0e7ad0-bc35-4261-b4d7-9ed6110035c9"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMi0xMi0xLTEtMjA3NzE1_2cfde3ea-bdec-4d25-a03a-7a8e2af6dc2a"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i0cd2d65e95c5455ba33597d7af92fae1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy0yLTEtMS0yMDc3MTU_2244f2a1-7be3-4d32-b529-0a4092dee970"
      unitRef="usd">134000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i6de88d59e31147e89b39381c09c53f91_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy00LTEtMS0yMDc3MTU_b697506a-e25c-4edb-bd95-d0104ca5918c"
      unitRef="usd">19000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ieda7c01115f14fb48e402b3e7a8d7854_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy02LTEtMS0yMDc3MTU_2eeafbde-afa1-48f0-bd6b-596e036c521c"
      unitRef="usd">581000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ifd272b84eca74392a824eff8a9e1189e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy04LTEtMS0yMDc3MTU_c481f8a7-15bf-41ce-a67f-adf13b5a93ec"
      unitRef="usd">471000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if2463be0b4714169986c616ff3005117_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy0xMC0xLTEtMjA3NzE1_fc8c3a40-a453-45dc-a52f-336905deeec7"
      unitRef="usd">51000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfMy0xMi0xLTEtMjA3NzE1_6dc0e40f-5cda-4b79-9077-c9a7707be7fa"
      unitRef="usd">1256000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i0cd2d65e95c5455ba33597d7af92fae1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC0yLTEtMS0yMDc3MTU_82218ee6-bf78-48ef-ad82-37610c2fba64"
      unitRef="usd">162000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i6de88d59e31147e89b39381c09c53f91_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC00LTEtMS0yMDc3MTU_d778236c-7bdd-4ab2-b3d7-d5da09edcaf1"
      unitRef="usd">54000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ieda7c01115f14fb48e402b3e7a8d7854_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC02LTEtMS0yMDc3MTU_333f3a67-9442-474e-9c5f-d0cccdf6dca9"
      unitRef="usd">599000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ifd272b84eca74392a824eff8a9e1189e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC04LTEtMS0yMDc3MTU_78b712e8-ba6f-4892-b4e6-1f43de2d48cd"
      unitRef="usd">359000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if2463be0b4714169986c616ff3005117_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC0xMC0xLTEtMjA3NzE1_33e3e39e-e461-4afd-be5c-dbc664803588"
      unitRef="usd">53000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNC0xMi0xLTEtMjA3NzE1_4144483a-ca9b-49ca-b2a4-ca3becf86d4a"
      unitRef="usd">1227000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i0c1aa2507e474247b21581cd979cbf95_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS0yLTEtMS0yMDc3MTU_849fc2db-9c1a-47ea-b73c-91b068cbabe8"
      unitRef="usd">194000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="iec8b23fc6b3d427ebf6b56614132eabc_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS00LTEtMS0yMDc3MTU_9f5ad2ff-516a-4d05-97bc-02e5dc68b53b"
      unitRef="usd">447000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie930191b929c4961b8ea3b30d8630a7d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS02LTEtMS0yMDc3MTU_6d33f429-dcc7-478f-94ab-2565445cebd1"
      unitRef="usd">926000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6d287acf3b954277b424a867b92331d4_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS04LTEtMS0yMDc3MTU_d2b013a3-fb60-4861-9390-98c264524ed3"
      unitRef="usd">282000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2c5df1eca1d6410e9c23987eab19795d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS0xMC0xLTEtMjA3NzE1_ef8ce70d-3b66-4c8b-81a7-cc3e527391dd"
      unitRef="usd">43000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOmRkZDg0YzcxZjdkNzQ0ODBhODQwMDg1MzEwZjJkY2RiL3RhYmxlcmFuZ2U6ZGRkODRjNzFmN2Q3NDQ4MGE4NDAwODUzMTBmMmRjZGJfNS0xMi0xLTEtMjA3NzE1_49d93463-bfe1-4e5a-befd-677b9f0efb4d"
      unitRef="usd">1892000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i9fea59117d2a4ea787d736618e348ab1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNTE3NQ_43b48308-3095-4dcd-baeb-45ba0d49406f"
      unitRef="usd">37000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i399b542872cf4b8a95bc8a36570e3ecd_I20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNTE4Mg_e60b8358-46c7-40b6-bcaa-7dace6a41986"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b5563f26ef24b288a82a1f6a3909255_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfMTA5OTUxMTYzNTQxNg_da7e29f6-b350-4005-95bd-912a7758c6e0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RleHRyZWdpb246MTBjMTc1MjExMmRhNGNkY2JlZjFhYThiYWFmMzc0OWJfNjQ0Ng_59a14949-59dd-4849-8a6f-47eb72afd7bf">The activity in the allowance for credit losses for trade receivables for the three months ended March 31, 2023 and 2022 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.830%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for expected credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs charged against the allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries of amounts previously written off&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMS0xLTEtMS0yMDc3MTU_91000e58-ba87-4ed9-a1e8-0f64cee4420c"
      unitRef="usd">33000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMS0zLTEtMS0yMDc3MTU_11092c47-8489-4dc6-859f-4a8b7b675103"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMi0xLTEtMS0yMDc3MTU_95d624d6-0318-49a3-8d51-d3928467c4ef"
      unitRef="usd">1000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMi0zLTEtMS0yMDc3MTU_f2a1e53b-12c9-470f-821a-b532a0f1469a"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMy0xLTEtMS0yMDc3MTU_26940c00-03f6-495a-b2f4-b9643d4d12ad"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfMy0zLTEtMS0yMDc3MTU_af84db91-e49f-462a-8774-cd1353831758"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNC0xLTEtMS0yMDc3MTU_0b98ec24-c4b9-4ed4-8cd7-fe02a39ff2a2"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNC0zLTEtMS0yMDc3MTU_a751a007-c170-4abe-8313-0bf8546eaa29"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNS0xLTEtMS0yMDc3MTU_00ffc909-ee8c-4d88-8cfc-ac2863b79c66"
      unitRef="usd">4000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNS0zLTEtMS0yMDc3MTU_5d85796a-000e-4a0c-bb96-bd25c45e77c0"
      unitRef="usd">0</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNi0xLTEtMS0yMDc3MTU_6a9cdc70-a687-4d5b-bcc0-19c27de0f6c1"
      unitRef="usd">32000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80Ni9mcmFnOjEwYzE3NTIxMTJkYTRjZGNiZWYxYWE4YmFhZjM3NDliL3RhYmxlOjllNWZiY2I5M2YyNjQxNzhhYzQ4ZjE3MTk1MDhjODI4L3RhYmxlcmFuZ2U6OWU1ZmJjYjkzZjI2NDE3OGFjNDhmMTcxOTUwOGM4MjhfNi0zLTEtMS0yMDc3MTU_c5c2c099-21e1-4d85-8628-273f98d8ee6a"
      unitRef="usd">38000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:LicensingAgreementsAndAcquisitionDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMjY3OQ_d0d0bd3c-35b3-4524-a2fd-d0e85a8c2baa">LICENSING AGREEMENTS AND ACQUISITION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions. The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 17, 2023, Bausch + Lomb acquired AcuFocus, Inc., an ophthalmic medical device company, for an up-front payment of $35&#160;million, $31&#160;million of which was paid in January 2023, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the remaining purchase price to be paid within 18 months following the transaction, less any amounts that are the subject of any indemnification claims&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The acquisition was made to acquire certain small aperture intraocular technology for the treatment of certain cataract conditions. Additional contingent payments may be payable upon achievement of future sales milestones. Bausch + Lomb recorded an initial acquisition-related contingent consideration liability of $5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this transaction, recorded within the Condensed Consolidated Balance Sheets are Intangibles, net of $28&#160;million, Goodwill of $2&#160;million, other assets of $11&#160;million and liabilities of $2&#160;million.&lt;/span&gt;&lt;/div&gt;</bhc:LicensingAgreementsAndAcquisitionDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMTA5OTUxMTY0MjUzMg_899a2740-a9fc-4bbb-b291-85da69b95543"
      unitRef="usd">35000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib72c99bc651a43d89f88a30576ef0099_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMjE5OTAyMzI3MTMwNA_f7755b91-11d4-4786-912e-4bb215170842"
      unitRef="usd">31000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <bhc:BusinessAcquisitionMaximumTermForRemainingPayment
      contextRef="i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfMjE5OTAyMzI3MTMxNg_040920f2-a24b-4b63-b88f-1ffb4876e601">P18M</bhc:BusinessAcquisitionMaximumTermForRemainingPayment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI4OTI3_aa090677-03f5-4764-a291-b2e414922e53"
      unitRef="usd">5000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI3Nzc5_fa1fa343-50aa-4a92-9221-e4849076009a"
      unitRef="usd">28000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI3NzM1_8bc95aaa-1863-44e3-b6b7-31f2b58d6f99"
      unitRef="usd">2000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI5MjE0_65e29399-2c4a-4277-b555-4de80dec0cca"
      unitRef="usd">11000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ibda71fa1050f4cd99d1b0487cabdc232_I20230117"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF80OS9mcmFnOjI4ZjUyZGQ1MTkxMDQyNTA5ODBiZThmOTQxYTY2OTk4L3RleHRyZWdpb246MjhmNTJkZDUxOTEwNDI1MDk4MGJlOGY5NDFhNjY5OThfNTQ5NzU1ODI3NzQ4_00a3ce9d-a6e0-40f6-83c9-f09da21d0f79"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMjY0OQ_afec9a45-1319-47e1-b0b0-df634414fc49">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS &lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and Integration Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implement cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $9 million and $3&#160;million of restructuring and integration costs during the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation Costs, Separation-related Costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and will incur, costs associated with activities relating to the B+L Separation. In 2022, the Company also incurred costs associated with activities relating to the Solta IPO, which was suspended in June 2022. These B+L Separation and Solta IPO activities include: (i) separating the Bausch + Lomb and, in 2022, Solta Medical businesses from the remainder of the Company, (ii) completing the B+L IPO and, in 2022, preparing for the suspended Solta IPO and (iii) the actions necessary for Bausch + Lomb to become an independent publicly traded entity. Separation and IPO costs are incremental costs directly related to the B+L Separation and, in 2022, the suspended Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for Bausch + Lomb. Included in Restructuring, integration, separation and IPO costs for the three months ended March 31, 2023 and 2022 are separation and IPO costs of $1&#160;million and $10&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and expects to continue to incur incremental costs with respect to the B+L Separation. During 2022, the Company also incurred incremental costs indirectly related to the suspended Solta IPO. These separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for the three months ended March 31, 2023 and 2022 are separation-related and IPO-related costs of $6&#160;million and $24&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges of these costs to complete the B+L Separation cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i274f7bd9f55d4414ae43d99e682cd28a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfNzMz_44ce6fe4-9fa7-4721-a685-8aba182acbee"
      unitRef="usd">9000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if7994dfc403646e5bff69630f9cc9aa6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfNzQw_ea403393-c6dd-4a40-b93f-ac93eb06aed6"
      unitRef="usd">3000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges
      contextRef="i47206664dbc844039797dc32726a84f4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMTkxNg_bb95c317-c4b1-4550-8d31-02010c72afaa"
      unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie718797acbb14934a88039b0b7639ab6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMTkyMw_64f6cd6f-d86f-4daf-97ad-916efb14c8e9"
      unitRef="usd">10000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i47206664dbc844039797dc32726a84f4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMjQ2OQ_9c056d75-dbe9-40d6-8f71-149562274179"
      unitRef="usd">6000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie718797acbb14934a88039b0b7639ab6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81Mi9mcmFnOmEzYmQ3NDlhNDExMzRjYzU4MGQyNDBmZjFiYzc0ZGRmL3RleHRyZWdpb246YTNiZDc0OWE0MTEzNGNjNTgwZDI0MGZmMWJjNzRkZGZfMjQ3Ng_89ca104a-8660-4c7f-a0e7-6827c4eaa45f"
      unitRef="usd">24000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTk0Mg_a8d9f02b-f28f-49f6-91c1-4826eb74a052">FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Condensed Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature. Cash, cash equivalents and restricted cash as presented in the Condensed Consolidated Balance Sheet as of March 31, 2023 includes $358&#160;million of cash, cash equivalents and restricted cash held by legal entities of Bausch + Lomb. Cash held by Bausch + Lomb legal entities and any future cash from the operating, investing and financing activities of Bausch + Lomb is expected to be retained by Bausch + Lomb entities and are generally not available to support the operations, investing and financing activities of other legal entities, including Bausch Health unless paid as a dividend which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 assets or liabilities during the three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, Bausch + Lomb entered into cross-currency swaps, with aggregate notional amounts of $1,000&#160;million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its Condensed Consolidated Financial Statements from fluctuation in exchange rates. The euro-denominated net investment being hedged is Bausch + Lomb&#x2019;s investment in certain Bausch + Lomb euro-denominated subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Condensed Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb&#x2019;s cross-currency swaps qualify for and have been designated as a hedge of the foreign currency exposure of a net investment in a foreign operation and are remeasured at each reporting date to reflect changes in their fair values. The fair value is determined via a mark-to-market analysis, using observable (Level 2) inputs. These inputs may include: (i) the foreign currency exchange spot rate between the euro and U.S. dollar, (ii) the interest rate yield curves in the euro and U.S. dollar and (iii) the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Condensed Consolidated Statements of Comprehensive Income (Loss) as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulative Comprehensive Income until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps were ineffective for the periods presented. Bausch + Lomb uses the spot method of assessing hedge effectiveness. Bausch + Lomb has elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as Interest expense in the Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with Bausch + Lomb&#x2019;s cross-currency swaps as included in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Condensed Consolidated Statements of Comprehensive Loss and the Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No portion of the cross-currency swaps were ineffective for the three months ended March 31, 2023. During the three months ended March 31, 2023, the Company received $6&#160;million in interest settlements, which are reported as investing activities in the Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, the Company&#x2019;s outstanding foreign currency exchange contracts had an aggregate notional amount of $548&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. The Company&#x2019;s foreign currency exchange contracts are economically hedging the foreign exchange exposure on certain of the Company&#x2019;s intercompany balances. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Condensed Consolidated Statements of Operations as part of Foreign exchange and other. Settlements of the Company&#x2019;s foreign currency exchange contracts are reported as a gain or loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the Condensed Consolidated Statements of Operations as part of Foreign exchange and other and reported as operating activities in the Condensed Consolidated Statements of Cash Flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Condensed Consolidated Statements of Operations and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At March&#160;31, 2023, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract&#x2019;s relative fair value at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of AcuFocus Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of March&#160;31, 2023 and December&#160;31, 2022 was $13,367 million and $14,011 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTkyOQ_9e8f58d2-3bfa-4e09-9105-0216a4cbd604">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.196%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i06ac642717c94b2bb1846110be0fc60d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0yLTEtMS0yMDc3MTU_8d133ab9-baa5-4cd6-8cc9-663cc481010f"
      unitRef="usd">45000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7219dc1016d84387a28c86b12d9cf065_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy00LTEtMS0yMDc3MTU_f334fde2-fd5a-4ccc-b2a9-3834c2626f22"
      unitRef="usd">36000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5ecdb94ccdc9431b9447675875213cc0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy02LTEtMS0yMDc3MTU_39190d00-10c7-4e89-b84e-a8e97997b07e"
      unitRef="usd">9000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy04LTEtMS0yMDc3MTU_def19daf-9a9d-4a65-b2eb-5a9e8c3ed3f4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xMC0xLTEtMjA3NzE1_43533543-2698-4698-a3dc-e9c348361e4c"
      unitRef="usd">94000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifffa5ab43fca470998ef4bc73c508195_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xMi0xLTEtMjA3NzE1_850ed123-c76a-4c2d-8118-605d1423fc97"
      unitRef="usd">85000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i05beb5b79d2d4d1786504e1574156b9d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xNC0xLTEtMjA3NzE1_fa9add61-d516-436e-8fbe-fa9706c5cb2e"
      unitRef="usd">9000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i97a57514fe2b45cc95ad51616dde5842_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfMy0xNi0xLTEtMjA3NzE1_ecc2166d-cd4a-42f6-a9d4-23f9d9846976"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCashCurrent
      contextRef="i06ac642717c94b2bb1846110be0fc60d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0yLTEtMS0yMDc3MTU_54ef143e-af48-4056-9b28-95ed9886c1f2"
      unitRef="usd">13000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7219dc1016d84387a28c86b12d9cf065_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC00LTEtMS0yMDc3MTU_40d8f761-f934-4ac4-9f57-983e89ad0237"
      unitRef="usd">13000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5ecdb94ccdc9431b9447675875213cc0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC02LTEtMS0yMDc3MTU_34dea761-00a2-47a2-b9bb-3bc4a0f09c9e"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC04LTEtMS0yMDc3MTU_3321724c-c786-4140-8d26-b6dccf03c648"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xMC0xLTEtMjA3NzE1_7970f702-d78b-49ea-8d2b-9bad9dc29834"
      unitRef="usd">27000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ifffa5ab43fca470998ef4bc73c508195_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xMi0xLTEtMjA3NzE1_f8c1ecb9-30e1-4fb7-9fbe-55167b453ada"
      unitRef="usd">27000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i05beb5b79d2d4d1786504e1574156b9d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xNC0xLTEtMjA3NzE1_5d66f3bd-6f57-410e-905c-0c8026096e5e"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i97a57514fe2b45cc95ad51616dde5842_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNC0xNi0xLTEtMjA3NzE1_525f74a7-502c-4adb-9980-3781efbc2b6f"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:DerivativeAssets
      contextRef="if8571f31f2d94cbcaa0a6cf746cebae6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0yLTEtMS0yMDc3MTU_55d14670-10ad-4e91-9648-6380335a321a"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i08edcda8013b411a8ae514fb186572f3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS00LTEtMS0yMDc3MTU_fa55420b-90c4-4ee1-b5cc-5397564537c2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9d7702b9b65346fdbe57769e179c3810_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS02LTEtMS0yMDc3MTU_1ff0e214-0ff8-4893-87b2-8b1e19c8de23"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0daaca70154c40aeaacadd2265003e58_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS04LTEtMS0yMDc3MTU_a721fe82-093d-44e9-9041-5096711554ae"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idc9716709350419c83c375cd1e7f06dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xMC0xLTEtMjA3NzE1_a9e08e65-75e7-4429-9c80-18585aae2f12"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7e2d1c1b6390420dbae526e06c3bf460_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xMi0xLTEtMjA3NzE1_0fc1246d-3bac-43ae-982f-3df42aaa9ea7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0830e0c16af34c70b916f4b40dd82c53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xNC0xLTEtMjA3NzE1_80d9b918-6fac-4f95-8d4b-0f3f599e3185"
      unitRef="usd">6000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0d7e1e14aa134850b3ef64a8fc34014e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfNS0xNi0xLTEtMjA3NzE1_9df53728-8510-4296-9619-de4f267b0278"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i06ac642717c94b2bb1846110be0fc60d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0yLTEtMS0yMDc3MTU_212ab73c-fcb4-482b-aaf5-3d1a97bf89e8"
      unitRef="usd">269000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i7219dc1016d84387a28c86b12d9cf065_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC00LTEtMS0yMDc3MTU_10efde86-025a-49a0-98a7-2dc7015aba91"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i5ecdb94ccdc9431b9447675875213cc0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC02LTEtMS0yMDc3MTU_17d6a4ee-01a3-4f8d-9aba-8ce8ae3db437"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i4215f9045d7a40cc8aa7a20f4e2e5750_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC04LTEtMS0yMDc3MTU_ba0a4672-b4b6-4e9c-9437-e19f4fbb55b3"
      unitRef="usd">269000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ib55bbfbf4c7a43cea45345828cbc3cb3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xMC0xLTEtMjA3NzE1_e9b97713-ca70-4ce6-bb74-251e8a2865a5"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ifffa5ab43fca470998ef4bc73c508195_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xMi0xLTEtMjA3NzE1_210f0c32-b365-4064-a464-4ebe835cf5a2"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i05beb5b79d2d4d1786504e1574156b9d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xNC0xLTEtMjA3NzE1_1a619910-5404-4fc3-9c87-c6faab042410"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i97a57514fe2b45cc95ad51616dde5842_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOC0xNi0xLTEtMjA3NzE1_d64e068f-b189-4fbd-ba27-383a072ba662"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="ia244db96c1c640908fc33b4da08106d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0yLTEtMS0yMjkyMzk_96e759f1-831e-45d6-a3fe-333df1862a10"
      unitRef="usd">48000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i54f2aa66d564423a8584754ff4101e8c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS00LTEtMS0yMjkyMzk_5b19bd7a-8ef6-4798-adac-20cb0e3e41d5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iba72009cea324aec8b99aef7cc724d7a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS02LTEtMS0yMjkyMzk_1771b6f1-f7be-4db8-b989-2124cbd181d2"
      unitRef="usd">48000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibee7e52beb8e43fda8b440f37c8ebe57_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS04LTEtMS0yMjkyMzk_46f486a3-1948-4d1d-9592-b9d081accd17"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iedc061681ca144219826ecd1f58d340a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMC0xLTEtMjI5MjM5_8a235c98-1115-4072-9356-3609196e2d37"
      unitRef="usd">39000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iaf1769e6ad7e4ee4ba7d31d32deaa20b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMi0xLTEtMjI5MjM5_f5e73425-17d5-4e9b-b04d-1cdb2542e698"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia11e5b05711c41bc94278235adbc4f4c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNC0xLTEtMjI5MjM5_182605b8-0837-42fa-a192-479b75532b5b"
      unitRef="usd">39000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id28a74559e034fe78617f85992188d35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNi0xLTEtMjI5MjM5_b4eaf799-3cf4-4ddd-b9b5-ef78e2a06b38"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if8571f31f2d94cbcaa0a6cf746cebae6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0yLTEtMS0yMDc3MTU_2bb9923b-9c0a-45d7-aec7-f21f256f628a"
      unitRef="usd">3000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i08edcda8013b411a8ae514fb186572f3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS00LTEtMS0yMDc3MTU_5b95f5b2-abee-4a51-bdf0-825423569312"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9d7702b9b65346fdbe57769e179c3810_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS02LTEtMS0yMDc3MTU_94fb100b-77c7-4bab-8068-8fde115e24a8"
      unitRef="usd">3000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0daaca70154c40aeaacadd2265003e58_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS04LTEtMS0yMDc3MTU_d7d7603c-1aa4-403f-8689-e570116f1aff"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idc9716709350419c83c375cd1e7f06dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMC0xLTEtMjA3NzE1_6cbf7cb8-e964-4763-855e-1a5d81e4aea9"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7e2d1c1b6390420dbae526e06c3bf460_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xMi0xLTEtMjA3NzE1_2b2c7e5f-6268-48ec-80bd-bce2e5151804"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0830e0c16af34c70b916f4b40dd82c53_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNC0xLTEtMjA3NzE1_322b22d3-9914-48e3-b110-c41ac01866a8"
      unitRef="usd">4000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0d7e1e14aa134850b3ef64a8fc34014e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmJlMDkyOTQwNDAwODRkZjFiOGIzODhkNzlkNThhOWFkL3RhYmxlcmFuZ2U6YmUwOTI5NDA0MDA4NGRmMWI4YjM4OGQ3OWQ1OGE5YWRfOS0xNi0xLTEtMjA3NzE1_e07c0c6c-9de3-4939-9ba3-5f6ae24bfde9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfMTQyOQ_8754f48b-8cee-47d1-a1bb-879e3f768460">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i095b974a4eda46539b55e501e35cecd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfMTczNg_ea3b1093-1278-43a7-9a7c-e4d146cc374c"
      unitRef="usd">358000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6ecae6a4337c43a6a5d0f8fb9b2a8820_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfMzQ5Nw_16890e3b-f98f-4434-810f-91f2ce8e15de"
      unitRef="usd">1000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTkzNQ_7b42b086-e20b-4a16-8a25-d0e38cd7d9ef">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with Bausch + Lomb&#x2019;s cross-currency swaps as included in the Condensed Consolidated Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company&#x2019;s foreign exchange contracts as included in the Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i72f352e9aecb43c082504ada58284827_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMS0xLTEtMS0yMjkyNzE_91b107dd-f61e-4933-9d8f-73490aff44dd"
      unitRef="usd">-51000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="ibebb6d14814347889239321501ae010a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMS0yLTEtMS0yMDc3MTU_950eaa23-dad1-48cb-8306-7f103d20690d"
      unitRef="usd">-45000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="ib7d14de197c840548e735b7c5dccffd4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMi0xLTEtMS0yMjkyNzE_24ce63a4-bb66-4f40-980c-fe5edac99c3f"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="if5134dadb2714e1785041a8064f00e00_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMi0yLTEtMS0yMDc3MTU_4d02ed0b-1d33-4950-9283-3edfb50e24f1"
      unitRef="usd">6000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="idf6e5891da834960a8eb4d5a50ad53f2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMy0xLTEtMS0yMjkyNzE_cce220cd-5a33-4560-9f24-4bc9c1bda6c9"
      unitRef="usd">-48000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="ieba2db723f4a453284cf02585362f5f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjIwZTViMGNjZGFkOTQ3NDk5MDRmNjRkYTg0YzE4Y2ExL3RhYmxlcmFuZ2U6MjBlNWIwY2NkYWQ5NDc0OTkwNGY2NGRhODRjMThjYTFfMy0yLTEtMS0yMDc3MTU_200a2689-cef5-4f29-b4c9-0be6d56e7eaf"
      unitRef="usd">-39000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTk1NQ_9edbc7d0-12a0-4a65-aa32-a43805693390">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Condensed Consolidated Statements of Comprehensive Loss and the Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ibccb47312bd346279aaf43b1d2624d18_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMi0yLTEtMS0yMDc3MTU_1a7adb7e-2c45-4e6a-af78-2a3c2cfdf280"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i95be04917e9242a4b3ab893073a4e5ac_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMi00LTEtMS0yMDc3MTU_f693d8be-b073-4ce4-965e-c94cad17e50c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i3d884c3b238b4a9484042a7ec80e4c08_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMy0yLTEtMS0yMDc3MTU_bc0a9ff8-0cd2-4fb0-b6ef-8a2576a7ed4b"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i9e0459eac81b48d391a6ba5f7a204bc9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOjA2MjYwYjJmY2EwOTQ0ZmFiMTc1ZGY0NDZhZGFhOWJjL3RhYmxlcmFuZ2U6MDYyNjBiMmZjYTA5NDRmYWIxNzVkZjQ0NmFkYWE5YmNfMy00LTEtMS0yMDc3MTU_bf11a75f-0e92-4e7e-b2e6-8aa900e2c9dd"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i6a9fc2637fe14e8da7c94ff2d6063b4f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfNTQ5NzU1ODMwMDUy_047fe844-c724-42dd-a26e-2dd2ad899868"
      unitRef="usd">-6000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i1660d479841841a083afc611c4742172_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfNzMwMQ_4edd6ab3-ac86-42da-944f-3ee2ca6f2ee9"
      unitRef="usd">548000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="iab4bebd84ef941c29f23b2b4ac6c05a9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMS0xLTEtMS0yMDc3MTU_1b7c0024-5bb9-4140-b70c-cc96a14d1923"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i7a6e400c24a6461b88808840db8e4b5e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMS0zLTEtMS0yMDc3MTU_10d69b85-b333-4e90-9296-bf6dbbcadc7e"
      unitRef="usd">4000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i22eb775dada74a4cbae4ccbc53d12e07_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMi0xLTEtMS0yMDc3MTU_7926755b-ceb5-4946-b698-453397a7e3b5"
      unitRef="usd">6000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i056164fc33e8477cbf8aadaeb9855ca2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMi0zLTEtMS0yMDc3MTU_bb5b60dc-da40-4b3b-b9f6-933cc94dfd42"
      unitRef="usd">6000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i1660d479841841a083afc611c4742172_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMy0xLTEtMS0yMDc3MTU_24f5eae5-92e0-44ba-afd8-ea5af395ced1"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="i6357772b0f77447aac759696baca2658_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmU4NjRjN2ZhMTE4NjQwYmFhOWRlZWE1ODY0YjA3YTFjL3RhYmxlcmFuZ2U6ZTg2NGM3ZmExMTg2NDBiYWE5ZGVlYTU4NjRiMDdhMWNfMy0zLTEtMS0yMDc3MTU_3f85aa65-8765-4833-ba40-a9bfe8df90af"
      unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTkzNw_c7013362-8b1e-4fb9-bb8b-dce153df27da">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company&#x2019;s foreign exchange contracts on the Condensed Consolidated Statements of Operations and the Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) gain related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMi0xLTEtMS0yMDc3MTU_6be46128-12e4-4be2-baee-115cdd2bae28"
      unitRef="usd">1000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ibfd26c8ad7914e708774f00d667fddae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMi0zLTEtMS0yMDc3MTU_10b40c4d-f28b-4f53-a4c6-dc60cc27485f"
      unitRef="usd">-7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMy0xLTEtMS0yMDc3MTU_040fd67f-f435-4ba9-9373-6628561e2112"
      unitRef="usd">5000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain
      contextRef="ibfd26c8ad7914e708774f00d667fddae_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmNkMjZmOGFmZDRjNTQ4OTk4N2IyY2MwODg0ZGY4NmVkL3RhYmxlcmFuZ2U6Y2QyNmY4YWZkNGM1NDg5OTg3YjJjYzA4ODRkZjg2ZWRfMy0zLTEtMS0yMDc3MTU_caa074ba-2f3d-42ed-9217-91aac1661f5e"
      unitRef="usd">7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i82576bfa08994cd9af972d7222b8c478_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTM1OQ_3ec38490-b000-4068-8e82-bdc2a2401889"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="if9f1fb1cd13846c38b5c4a4cafd8a808_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTM2NQ_af6c8923-d650-4f32-b6a9-6fc5c9611ef1"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia20a127e123344f5a9df3c653c0441ff_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTQyMw_35aa3ed8-ccb0-42fb-8a74-73a5b8b77c71"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTk0NA_a8871cb8-b4a6-4bb0-875c-e773e1cd58aa">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.366%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments due to changes in estimates of other future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition of AcuFocus Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMi00LTEtMS0yMDc3MTU_17c27443-9725-4e0f-b16e-94d79264daaa"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMi04LTEtMS0yMDc3MTU_0e85cbef-9cbd-493c-93d7-f39399969196"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0d7b079169584b7b827bc3ad599a02a0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNC0yLTEtMS0yMDc3MTU_913524d9-a386-451b-bf15-29cdd43036d9"
      unitRef="usd">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i147a77a2853541b8ac642c9ce50dfb79_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNC02LTEtMS0yMDc3MTU_53861959-b893-4d91-9f38-4bc9da43a7ec"
      unitRef="usd">4000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie7363eb7130846d498238f0c9266f211_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNS0yLTEtMS0yMDc3MTU_b5cbbb22-e679-4142-aba1-506fca5e0add"
      unitRef="usd">27000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i3f59cd43aff447ff9034642bf45fa138_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNS02LTEtMS0yMDc3MTU_3dc6cf85-1970-4bad-9b3b-6864ef0ecdf4"
      unitRef="usd">-1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi0wLTEtMS0yMDc3MTU_7cfa70ac-334c-427f-800c-3fa168193578">Acquisition-related contingent consideration</bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi0wLTEtMS0yMDc3MTU_8c92d0fe-96d4-437e-acb8-9797f035ca76">Acquisition-related contingent consideration</bhc:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi00LTEtMS0yMDc3MTU_343a57d0-de0f-4860-a87b-8fbf959b3642"
      unitRef="usd">31000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNi04LTEtMS0yMDc3MTU_ebb6774e-9560-4d22-acb8-ebbb71ac323b"
      unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy00LTEtMS0yMzU3NDU_61063194-fff3-4566-b10b-57cf81156950"
      unitRef="usd">5000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy04LTEtMS0yMzU3NDc_5c363857-17c0-4197-9c62-bf484a4e25cb"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy00LTEtMS0yMDc3MTU_0a6456df-224a-4a91-8d7a-98bfbbcbada5"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfNy04LTEtMS0yMDc3MTU_c879d63c-7523-4399-894b-1fc400a6923d"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTAtNC0xLTEtMjA3NzE1_4d7b2520-f6b2-42cc-833e-d90d5d539580"
      unitRef="usd">269000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTAtOC0xLTEtMjA3NzE1_43a7505c-36fe-4fbd-9ea9-abf63214d7b0"
      unitRef="usd">236000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTEtNC0xLTEtMjA3NzE1_4910cb38-e2c8-402e-be37-76c508c46bee"
      unitRef="usd">50000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTEtOC0xLTEtMjA3NzE1_c8dbc769-629b-441d-a71e-b400ba4e16f9"
      unitRef="usd">43000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTItNC0xLTEtMjA3NzE1_742db7c4-68a9-478f-a3bd-01409d155526"
      unitRef="usd">219000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i479ac929919e4b9391ed384f3e44de72_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RhYmxlOmYzMTc1MTgyM2VmYjRhNDc5MzBhMWYwODU3YjVhM2E2L3RhYmxlcmFuZ2U6ZjMxNzUxODIzZWZiNGE0NzkzMGExZjA4NTdiNWEzYTZfMTItOC0xLTEtMjA3NzE1_571f0fc3-4c1d-49a6-82f3-ed68e7e456e4"
      unitRef="usd">193000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3e658e3f4fe444859560086bf4a59a49_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTgwNw_fc5d5e9b-8fba-4dd1-9e3d-3b4bb940ab34"
      unitRef="usd">13367000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i28204be5e8ef457b9c492f5b766ac878_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81NS9mcmFnOjgwM2NkM2MzM2MzMzRiMDI4YjUyMzBjODk3Y2EzMzNhL3RleHRyZWdpb246ODAzY2QzYzMzYzMzNGIwMjhiNTIzMGM4OTdjYTMzM2FfOTgxNA_9595caef-43a8-4168-9b2b-0f9d60b27d1f"
      unitRef="usd">14011000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RleHRyZWdpb246ODRhZmNhZmU3MzQxNDE1MmExY2YzMTAyMjk0NjY4ZjRfNTc_0497984c-1266-446e-8f3b-ef59b0a44275">INVENTORIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RleHRyZWdpb246ODRhZmNhZmU3MzQxNDE1MmExY2YzMTAyMjk0NjY4ZjRfNDg_3673ee16-be19-4908-8a2e-f0d9b650b8f3">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMS0yLTEtMS0yMDc3MTU_d72e7309-6569-41cc-be02-8765bdec840c"
      unitRef="usd">378000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMS00LTEtMS0yMDc3MTU_96eb5a51-a9ae-4ceb-bbc1-6c2abbba339d"
      unitRef="usd">326000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMi0yLTEtMS0yMDc3MTU_c13283aa-b89d-4a61-b0a8-5f1714a0de8d"
      unitRef="usd">123000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMi00LTEtMS0yMDc3MTU_08c5506c-0ba2-4179-a1f9-644fe262651c"
      unitRef="usd">98000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMy0yLTEtMS0yMDc3MTU_8d2d344a-0212-4cd9-ad5c-575d6502cd5a"
      unitRef="usd">721000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfMy00LTEtMS0yMDc3MTU_77a11edb-0a38-4912-95ae-5369821498f6"
      unitRef="usd">666000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfNC0yLTEtMS0yMDc3MTU_c6e9a178-15b6-4272-a703-b575a8ca55dc"
      unitRef="usd">1222000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF81OC9mcmFnOjg0YWZjYWZlNzM0MTQxNTJhMWNmMzEwMjI5NDY2OGY0L3RhYmxlOjlmMmRkMDMxMDA4OTQxMzZiNGQ5MGNjNWIxOTNhN2I3L3RhYmxlcmFuZ2U6OWYyZGQwMzEwMDg5NDEzNmI0ZDkwY2M1YjE5M2E3YjdfNC00LTEtMS0yMDc3MTU_ac52b91f-d71b-4fb0-b10f-77a5be68fa1f"
      unitRef="usd">1090000000</us-gaap:InventoryGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5Njk_ba75d253-8b3f-4837-89b8-324ed7f8e943">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Condensed Consolidated Statements of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. The Company estimates the fair values of long-lived assets with finite lives using an undiscounted cash flow model which utilizes Level 3 unobservable inputs. The undiscounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, selling, general and administrative expenses and research and development expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments for the three months ended March 31, 2023 were $13&#160;million and include impairments of: (i) $8&#160;million, in aggregate, attributable to certain trade names no longer in use and (ii) $5&#160;million, related to the discontinuance of a certain product line. Asset impairments for the three months ended March 31, 2022 were $8&#160;million due to discontinuances and decreases in the forecasted sales of certain product lines. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets included in the unaudited Condensed Consolidated Balance Sheets had a carrying value of $2,559&#160;million and an estimated remaining useful life of 57 months as of March 31, 2023. On August 10, 2022, a court held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating inflammatory bowel syndrome with diarrhea (&#x201c;IBS-D&#x201d;) were invalid (the &#x201c;Norwich Legal Decision&#x201d;). On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property. See &#x201c;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&#x201d; of Note 17, &#x201c;LEGAL PROCEEDINGS&#x201d; for details of this litigation matter and the Company&#x2019;s response. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, could impact the timing and extent of future revenues and cash flows associated with Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that, in the third quarter of 2022, the ruling in the Norwich Legal Decision constituted an event requiring assessment of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets for potential impairment using different scenarios representing a range of different outcomes which address, among other things, the timing of when a competitor or competitors will be able to successfully launch a generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if they are able to launch one at all. This assessment resulted in no impairment of the carrying value of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From September 30, 2022 through the first quarter of 2023 there were no material changes to the facts and circumstances of the Norwich Legal Decision or to actual or expected business performance for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Based on these factors, no impairment to the carrying value of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets was identified as of March 31, 2023. The Company also determined that no change to the remaining useful lives of its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; finite-lived intangible assets was required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that the Norwich Legal Decision and other potential future developments: (i) may adversely impact the estimated future cash flows associated with these products, which could result in an impairment of the value of these intangible assets in one or more future periods and (ii) may result in shortened useful lives of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intangible assets, which would increase amortization expense in future periods. Any such impairment or shortening of the useful lives of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; could be material to the results of operations of the Company in the period or periods in which they were to occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2023 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 and the year ended December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dermatology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment. The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair value of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit&#x2019;s terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit&#x2019;s cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management&#x2019;s and a market participant&#x2019;s view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected loss of exclusivity to the Company&#x2019;s product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets. Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and such charges could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2022 Interim Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022, macroeconomic factors had impacted interest rates and the U.S. inflation rate was higher than previously expected. Given the limited headroom of the Dermatology (formerly Ortho Dermatologics) reporting unit as calculated on October 1, 2021, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 9%. The discount rate contemplated changes in the current macroeconomic conditions noting certain inputs such as the risk-free rate increased over the three months ended March 31, 2022, and was offset by decreases in other reporting unit specific risks during the same period. Based on the quantitative fair value test, the fair value of the Dermatology reporting unit was less than 2% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2022 Interim Assessment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dermatology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Dermatology reporting unit as of March 31, 2022. Given the limited headroom of the Dermatology reporting unit as calculated on March 31, 2022, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections for the Dermatology reporting unit as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#x2019;s discounted cash flow model for the Dermatology reporting unit included a range of potential outcomes for, among other matters, macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The quantitative fair value test utilized a long-term growth rate of 1% and a discount rate of 10%. The discount rate had increased 1% since the assessment performed as of March 31, 2022, as a result of changes in macroeconomic conditions, including an increase in the risk-free rate during the three months ended June 30, 2022. Based on the quantitative fair value test, the carrying value of the Dermatology reporting unit exceeded its fair value as of June 30, 2022, and the Company recognized a goodwill impairment of $83&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period May 6, 2022 (the date Bausch + Lomb&#x2019;s stock began trading publicly) through June 30, 2022, equity and bond markets were negatively impacted by various macroeconomic and geopolitical factors including, but not limited to: rising inflation rates in the U.S. and abroad, uncertainties created by the Russia/Ukraine conflict, interest rate volatility, COVID-19 related lockdowns and supply issues. The equity markets negatively impacted the market price for Bausch + Lomb&#x2019;s common stock which as of June 30, 2022 was trading below its IPO offering price. The Company believed that these facts and circumstances suggest the fair value of the three reporting units of the Bausch + Lomb segment could be less than their respective carrying amounts. Therefore, separate quantitative fair value tests were performed for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value tests utilized the Company&#x2019;s most recent cash flow projections for each of its reporting units as revised in the second quarter of 2022 which reflected current market conditions and current trends in business performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value tests utilized long-term growth rates of 2% and 3% and discount rates of 9.0% and 11.5%. After completing the testing, the fair value of each of these reporting units exceeded their respective carrying values by more than 25%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;September 30, 2022 Interim Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dermatology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2022, the Company continued to monitor the market conditions impacting the Dermatology reporting unit. Continued increases in interest rates and, to a lesser extent, higher than expected inflation in the U.S. and other macroeconomic factors impacted key assumptions used to value the Dermatology reporting unit at June 30, 2022. Based on the impairment of goodwill recognized in the second quarter of 2022 for the Dermatology reporting unit, the reporting unit had no headroom as calculated on June 30, 2022, and as such, the Company believed that these facts and circumstances suggested the fair value of the Dermatology reporting unit could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test utilized the Company&#x2019;s most recent cash flow projections for the Dermatology reporting unit as revised in the third quarter of 2022 which reflected current market conditions and current trends in business performance. The Company&#x2019;s discounted cash flow model for the Dermatology reporting unit includes, among other matters, volatility in many of the equity markets and pressures on market interest rates and macroeconomic factors such as changes in inflation for many commodities. The quantitative fair value test utilized a long-term growth rate of 1% and the discount rate increased from 10.0% at June 30, 2022 to 10.5% at September 30, 2022, which reflects the increases in market interest rates. Based on the quantitative fair value test, the carrying value of the Dermatology reporting unit exceeded its fair value at September 30, 2022, and the Company recognized a goodwill impairment of $119&#160;million for the three months ended September 30, 2022. As of September 30, 2022, the Dermatology reporting unit had remaining goodwill of $480&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salix &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 10, 2022, the Norwich Legal Decision was issued that held, among other matters, that certain U.S. Patents protecting the composition and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating IBS-D were invalid. On August 16, 2022, the Company appealed the Norwich Legal Decision and intends to vigorously defend its Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; intellectual property. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; of Note 17, &#x201c;LEGAL PROCEEDINGS&#x201d; for details of this litigation matter and the Company&#x2019;s response.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues represent approximately 80% of the Salix reporting unit&#x2019;s revenue. The ultimate outcome of the Norwich Legal Decision and other potential future related developments, including a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, could impact the timing and extent of future revenues and cash flows associated with Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As such, the Company believes that the uncertainty of the possible outcomes of the Norwich Legal Decision and the potential impact on Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; revenues are indicators that the Salix reporting unit&#x2019;s fair value could be less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed its quantitative fair value test using a probability-weighted discounted cash flow analysis, with a base case representing the Company&#x2019;s most recent cash flow projections as revised in the third quarter of 2022, as well as different scenarios representing a range of different outcomes which address, among other things, the range of possible outcomes of the Norwich Legal Decision and the timing of when a competitor or competitors could be able to successfully launch a generic version of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if they are able to launch one at all. The forecasted cash flows under each set of outcomes were discounted utilizing a long-term growth rate of 2.5% and discount rates of 9.75% and 10.0%. The Company assigned a probability weighting to each scenario reflecting its best estimate of likelihood of the outcome resulting in each scenario, and calculated a weighted average of the valuations derived from the discounted cash flows under each scenario using this probability weighting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the carrying value of the Salix reporting unit was less than its fair value as determined by the Company&#x2019;s probability-weighted discount valuation model and therefore no impairment was recorded as of September 30, 2022. However, as the Company&#x2019;s probability-weighted discount valuation includes certain scenarios under which the Company does not retain market exclusivity for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through January 2028, these probability-weighted fair values of the Salix reporting unit exceeded its carrying value by less than 5%.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2022, no events occurred, or circumstances changed during the period October 1, 2021 (the date of the last annual impairment test) through September 30, 2022, that indicated that the fair value of any reporting unit, other than the Dermatology reporting unit, the Salix reporting unit and the reporting units of the Bausch + Lomb segment, might be below their respective carrying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Annual Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s annual goodwill impairment test as of October 1, 2022, included performing separate quantitative fair value tests for the Neurology and Other reporting unit and the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment. For its remaining reporting units, the Company conducted its annual goodwill impairment test as of October 1, 2022, by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2022, management believed that, it was more likely than not that the carrying amounts of its remaining reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Neurology and Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Neurology and Other reporting unit operates in the United States, where shifting market dynamics, including changes in payer demands, health care legislation, and other regulations are contributing to increasing pressure for the reduction of healthcare costs, through both pricing of pharmaceutical products and/or directing patients to lower cost unbranded generic products. The nature of the Neurology and Other reporting unit&#x2019;s product portfolio, which includes branded generic pharmaceuticals, is by its nature impacted by these changing market dynamics. As a result, the Company has begun taking steps to: (i) reassess its pricing strategies, (ii) re-evaluate its marketing and promotional efforts and (iii) reduce its cost structure, and has revised its long-term forecasts for the Neurology and Other reporting unit to reflect these developments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test for the Neurology and Other reporting unit utilized the most recent cash flow projections for the reporting unit as revised in the fourth quarter of 2022 to reflect current market conditions and current trends in business performance. The quantitative assessment utilized a long-term growth rate of -2.5% and a discount rate of 10.25% in the estimation of the reporting unit&#x2019;s fair value. As a result of the revisions to its long-term expectations for these and other factors, goodwill for the Neurology and Other reporting unit was impaired during the Company&#x2019;s most recent annual impairment test reflecting its best estimate at that time of the outlook and risks of this business. Based on the quantitative fair value test, the carrying value of the Neurology and Other reporting unit exceeded its fair value as of October 1, 2022, and the Company recognized a goodwill impairment of $622&#160;million. As of December 31, 2022, the Neurology and Other reporting unit had remaining goodwill of $1,439&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The quantitative fair value test for the Vision Care, Surgical and Ophthalmic reporting units of the Bausch + Lomb segment utilized the most recent cash flow projections for each of the reporting units as revised in the fourth quarter of 2022 which reflected current market conditions and current trends in business performance. The quantitative assessment utilized long-term growth rates of 2.0% and 3.0% and discount rates of 9.50% and 12.25% in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its respective carrying value by more than 25% and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the period October 1, 2022 through December 31, 2022, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Dermatology and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and any such charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dermatology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the impairment of goodwill in the third quarter of 2022, the Dermatology reporting unit had no headroom on September 30, 2022, and as such, the Company continued to monitor the market conditions impacting the Dermatology reporting unit during the period October 1, 2022 through December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, the Company evaluated the reporting unit&#x2019;s performance as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#x2019;s latest business strategies. This evaluation supported management&#x2019;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rate used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Dermatology reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Salix&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the quantitative fair value testing performed in the third quarter of 2022, the Salix reporting unit had limited headroom as of September 30, 2022 and, as such, the Company continued to monitor the potential impacts of changes in the Norwich Legal Decision and market conditions on the valuation of the Salix reporting unit during the period October 1, 2022 through December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December 31, 2022, there were no material changes in the facts and circumstances of the Norwich Legal Decision, including management&#x2019;s assessment as to a competitor&#x2019;s ability to launch a successful generic version to Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; prior to January 2028, if they are able to launch one at all. The Company also evaluated the reporting unit&#x2019;s performance in the fourth quarter as well as its revised long-term forecasts in light of current market conditions, current trends in business performance and the expected impacts of management&#x2019;s latest business strategies. This evaluation supported management&#x2019;s previous expectations for long-term business performance. Additionally, based on corporate bond rates as of December 31, 2022, the Company concluded that discount rates would not have increased during the fourth quarter as compared to the discount rates used in determining the fair value of the reporting unit as of September 30, 2022. Based on these factors, management concluded that it was more likely than not that the carrying value of its Salix reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required during the quarter ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2023 Interim Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2023, the Company continued to monitor the market conditions and trends in business performance for all its reporting units, particularly as they pertain to the Dermatology, Neurology and Other, and Salix reporting units, and determined that, no events occurred, or circumstances changed that would indicate that the fair value of any reporting unit might be below its carrying value. However, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and any such charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through March&#160;31, 2023 were $5,004 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5ODg_a3ebce96-b3fb-49df-84e3-340b4d863896">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5OTY_4ac906bf-c927-4f19-985d-94b88f4492b9">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;br/&gt;and&lt;br/&gt;Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id06b415e61b344bdb2ccda942b08f59b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy0yLTEtMS0yMDc3MTU_b95d6a39-de9c-4f38-927d-ecbae0c138f0"
      unitRef="usd">20902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id06b415e61b344bdb2ccda942b08f59b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy00LTEtMS0yMDc3MTU_b48bcb97-d88a-40bd-9eee-1739e8afc5e7"
      unitRef="usd">17471000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id06b415e61b344bdb2ccda942b08f59b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy02LTEtMS0yMDc3MTU_e0fbf759-f4e2-4f28-8d4f-7e772587d590"
      unitRef="usd">3431000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i48125eb5f60a4e3fa677f9dba896c944_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy04LTEtMS0yMDc3MTU_486f6444-69de-45e2-b0bf-62d245727105"
      unitRef="usd">20840000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i48125eb5f60a4e3fa677f9dba896c944_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy0xMC0xLTEtMjA3NzE1_b138a910-f32d-4f2f-86bd-79f50ca36c4d"
      unitRef="usd">17196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i48125eb5f60a4e3fa677f9dba896c944_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMy0xMi0xLTEtMjA3NzE1_18946acb-7986-47e8-a2d4-f3136784295c"
      unitRef="usd">3644000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC0yLTEtMS0yMDc3MTU_73b87664-aa22-4d89-aa2f-cc1321ad7cec"
      unitRef="usd">904000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC00LTEtMS0yMDc3MTU_7006c6bd-b674-4445-8cfa-c6df00b50d93"
      unitRef="usd">571000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="icf7e45db3a55481b87f6c30b1f3d5fed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC02LTEtMS0yMDc3MTU_3e6f1020-2eef-4f8c-b80e-867b33cea7fb"
      unitRef="usd">333000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5705188337dd4a7f9f61104a2f18967b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC04LTEtMS0yMDc3MTU_cc38dddf-fd6d-4c32-8c1f-a93bd3d3dc21"
      unitRef="usd">899000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5705188337dd4a7f9f61104a2f18967b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC0xMC0xLTEtMjA3NzE1_bf17c788-318b-4f57-8f09-4623f81e1b3e"
      unitRef="usd">542000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5705188337dd4a7f9f61104a2f18967b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNC0xMi0xLTEtMjA3NzE1_3fa5e53f-81d1-4f86-8063-8824f8b2972c"
      unitRef="usd">357000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic2610664ed984b688dd611a19b847b62_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS0yLTEtMS0yMDc3MTU_1543950f-ac14-44a7-a275-c21998dea984"
      unitRef="usd">3350000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic2610664ed984b688dd611a19b847b62_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS00LTEtMS0yMDc3MTU_5fa18252-3a92-415d-8dee-ad769fd11d1e"
      unitRef="usd">3265000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic2610664ed984b688dd611a19b847b62_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS02LTEtMS0yMDc3MTU_d60a8a1e-2ffd-490e-b051-4f732c895b78"
      unitRef="usd">85000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i84330219b21546d7b29a854334867cd0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS04LTEtMS0yMDc3MTU_c035d3f1-9d2a-4836-aa26-8ea0426d37f2"
      unitRef="usd">3347000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i84330219b21546d7b29a854334867cd0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS0xMC0xLTEtMjA3NzE1_1ae69649-4644-44de-aef7-e37ae6788e47"
      unitRef="usd">3251000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i84330219b21546d7b29a854334867cd0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNS0xMi0xLTEtMjA3NzE1_3e55546a-c06d-4b51-bbf3-28c9f03d95e6"
      unitRef="usd">96000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi0yLTEtMS0yMDc3MTU_7746f5c9-0f2d-4532-9ac2-f23e2db3608e"
      unitRef="usd">150000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi00LTEtMS0yMDc3MTU_2a26b011-fca9-42d7-a97a-bb3a7cac577a"
      unitRef="usd">150000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iebbaf6a25af845ae92c8fa5bc306aba5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi02LTEtMS0yMDc3MTU_bd810da6-997c-41f7-a314-fc6f47572a69"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if0d15fc2eafe4f60beb93612549521a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi04LTEtMS0yMDc3MTU_c63e6a86-5e4a-4365-b832-c5bdc669d1a9"
      unitRef="usd">149000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if0d15fc2eafe4f60beb93612549521a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi0xMC0xLTEtMjA3NzE1_90dd83f8-7ad9-4801-9681-a6d34fa6b21d"
      unitRef="usd">149000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if0d15fc2eafe4f60beb93612549521a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNi0xMi0xLTEtMjA3NzE1_ade84c92-1268-4156-95c5-939959f64828"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i3b48c13c21214c678ad36cf685b3b072_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy0yLTEtMS0yMDc3MTU_16c74d08-f637-4735-bd64-ca0bc5ef3469"
      unitRef="usd">201000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i3b48c13c21214c678ad36cf685b3b072_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy00LTEtMS0yMDc3MTU_396689bc-676a-4eec-9111-f08cd7b252e7"
      unitRef="usd">196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i3b48c13c21214c678ad36cf685b3b072_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy02LTEtMS0yMDc3MTU_9733a91b-17bf-4549-a2e8-9123e0d2f289"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2dd0103274754e1fb33a46edcf042268_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy04LTEtMS0yMDc3MTU_41400443-dfe7-462c-9a77-93a5af7a848e"
      unitRef="usd">201000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2dd0103274754e1fb33a46edcf042268_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy0xMC0xLTEtMjA3NzE1_2fdb077a-1fa8-4480-8324-d9ece4e28423"
      unitRef="usd">196000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2dd0103274754e1fb33a46edcf042268_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfNy0xMi0xLTEtMjA3NzE1_380dbfee-bcfa-4af6-8039-31ba09790295"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC0yLTEtMS0yMDc3MTU_0066eab6-5765-4bc8-933f-07f6b84b06fc"
      unitRef="usd">25507000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC00LTEtMS0yMDc3MTU_7922d72a-1659-446c-9416-293a8139dc47"
      unitRef="usd">21653000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC02LTEtMS0yMDc3MTU_ca3acf25-4687-4587-943a-e623fb6ed366"
      unitRef="usd">3854000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC04LTEtMS0yMDc3MTU_bfffb01c-06dc-4e0f-ae3a-f324bf90c636"
      unitRef="usd">25436000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC0xMC0xLTEtMjA3NzE1_5fb79f80-c02b-481e-8614-ab8b64e61aa6"
      unitRef="usd">21334000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOC0xMi0xLTEtMjA3NzE1_58d041bc-9930-4588-8fe7-a99abe93d578"
      unitRef="usd">4102000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3da26cfaf00043bdbba7864b5a155ec6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS0yLTEtMS0yMDc3MTU_0f6add69-e8bf-4b09-b1f7-70c0693ac530"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i3da26cfaf00043bdbba7864b5a155ec6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS02LTEtMS0yMDc3MTU_5aa352b8-6c1c-46b7-b004-12771601efc2"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaa692efa530140f8a1a881ba8a8249c5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS04LTEtMS0yMDc3MTU_95645cf6-0eeb-477d-9819-3faa42bbff18"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaa692efa530140f8a1a881ba8a8249c5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfOS0xMi0xLTEtMjA3NzE1_bedc1be0-fa77-4676-b9bb-e65a7d27d5ff"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtMi0xLTEtMjA3NzE1_c6c4e7ab-8608-40e8-92d2-998a50f427ce"
      unitRef="usd">27205000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtNC0xLTEtMjA3NzE1_118c8f6b-20de-4443-b32e-dea37e5a8d32"
      unitRef="usd">21653000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtNi0xLTEtMjA3NzE1_7f5c897d-fe9e-418f-9788-1e06ec7ff745"
      unitRef="usd">5552000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtOC0xLTEtMjA3NzE1_bc98027b-abad-4be6-9ba9-a602944d5c52"
      unitRef="usd">27134000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtMTAtMS0xLTIwNzcxNQ_3314033a-aa54-41bc-b5ec-868535d91a63"
      unitRef="usd">21334000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZlZDIwYTAyYmM0OTQwMjJiMGQ1ZGIxYWUzNmJhMGRmL3RhYmxlcmFuZ2U6NmVkMjBhMDJiYzQ5NDAyMmIwZDVkYjFhZTM2YmEwZGZfMTAtMTItMS0xLTIwNzcxNQ_0e846760-7e0c-4f7b-b861-3d1ce474b2a6"
      unitRef="usd">5800000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetImpairmentCharges
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfNjY3_24f79745-d93c-429e-837d-9274e034293b"
      unitRef="usd">13000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i818c74f66a48498dba0c587f79830579_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfNzAy_c47e2872-26b8-44b6-9756-276fa9efa73b"
      unitRef="usd">8000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ifbe4581fb4234dbdafb70170994354db_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfODA2_7edfcc71-cc89-4b1b-ab63-9eb62fd49197"
      unitRef="usd">5000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="idf755e2bc874449e82907e0d22cf8c11_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM2ODI5Nw_13f145ba-a1f9-48a6-bb1b-a917bfcf9e0e"
      unitRef="usd">8000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i08e744695a9e45b9b9ad55074d322f8a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfOTg1_ffaeede0-0189-415e-9dbb-91189de59739"
      unitRef="usd">2559000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1fafe0032cba4aa1a32eca01ef3aca20_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMTAzMA_668999ac-dce8-4a13-9763-0871bff3f2eb">P57M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i8a66af6adc904896a8ff0e7c2c1bd921_D20220930-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMTA5OTUxMTcxNDY2OQ_abdd6687-677a-457f-bcb4-a28c830047e1"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i1fafe0032cba4aa1a32eca01ef3aca20_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1ODI0Mw_5ce530f9-b02b-4fb6-8df9-e492911d0df5"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5NzU_5c7698ce-9188-4332-8cde-a125ee63f51b">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the remainder of 2023 and each of the five succeeding years ending December&#160;31 and thereafter is as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0yLTEtMS0yMDc3MTU_fc3d000a-293a-4397-bf7c-2792e75d8e0c"
      unitRef="usd">756000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS00LTEtMS0yMDc3MTU_4ee84736-fafe-40c5-afe7-5254ccac9307"
      unitRef="usd">907000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS02LTEtMS0yMDc3MTU_5ba71f1f-3476-4f7d-a326-ef0b391c6c48"
      unitRef="usd">801000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS04LTEtMS0yMDc3MTU_2ec82e05-505b-4a41-a2dc-146c26820336"
      unitRef="usd">673000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xMC0xLTEtMjA3NzE1_066d06ca-f599-4dbe-a072-4f136e9e3977"
      unitRef="usd">636000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xMi0xLTEtMjA3NzE1_92ca3e90-6e3a-4fb2-bc8d-958a64fd809b"
      unitRef="usd">39000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xNC0xLTEtMjA3NzE1_0b31378b-87b2-4262-a9d4-98219c055485"
      unitRef="usd">42000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOmUyZjc3Y2U4Yzg4YTRlMDI4MmRkY2RiOWFiNWE5ZDQ2L3RhYmxlcmFuZ2U6ZTJmNzdjZThjODhhNGUwMjgyZGRjZGI5YWI1YTlkNDZfMS0xNi0xLTEtMjA3NzE1_c8b17a48-ddba-41b9-8d28-ae20c4f7c669"
      unitRef="usd">3854000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjgwMDE_e7abcf1a-8e6d-4fb0-a5b6-2c90e4b57a44">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the three months ended March 31, 2023 and the year ended December&#160;31, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.298%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.465%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.447%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Dermatology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(798)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(824)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i9b6bf825c7324cacac00e1ebf2a1c71e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS00LTEtMS0yMDc3MTU_dae78aca-b771-4281-b16a-16c25f9b3749"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i179f309e60d44d41af3ca366ec893b8b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS02LTEtMS0yMDc3MTU_3bc24e8b-5f3d-40b9-b979-5f6875f8ee54"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i778f77cb42414cb5ac34f18b66605477_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS04LTEtMS0yMDc3MTU_edefaa86-24b0-46f7-a22c-189c4e643f03"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iffa6d2cd08c24125aa6dc092aad37002_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xMC0xLTEtMjA3NzE1_f65a45f8-bc01-4072-9120-3eb3f2dbb9ab"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if9d39794e57948c0b3f7a07a43885d87_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xMi0xLTEtMjA3NzE1_9a891f3b-784f-45a1-97f1-8ceed9386392"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idb32f84fce124fcdbdda1eb3094fee46_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xNC0xLTEtMjA3NzE1_e1dbf5d4-757c-4cc7-9c08-339e0bfa94d1"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i82e229d35290440d93fbde9447d92bd7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMS0xNi0xLTEtMjA3NzE1_0fe1eaeb-f106-4201-88f4-ba48a376b6d8"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi00LTEtMS0yMDc3MTU_83d4ce94-f4ff-4e80-a8f4-1798c0772fe9"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi02LTEtMS0yMDc3MTU_b11383ed-9b1e-4753-9f66-0be85f98ebea"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi04LTEtMS0yMDc3MTU_dba947b0-2ceb-42d8-ba70-e8bfd0733df3"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xMC0xLTEtMjA3NzE1_2bd6b4c0-099d-4344-b34a-8f50fac2bdca"
      unitRef="usd">-798000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xMi0xLTEtMjA3NzE1_85eb1f2b-f8d8-435e-af58-3422c3ad0dbf"
      unitRef="usd">115000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xNC0xLTEtMjA3NzE1_b6c2b8f1-cdab-4208-8cb6-d0dae5f5b585"
      unitRef="usd">683000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMi0xNi0xLTEtMjA3NzE1_6bd1a17c-5f9b-4789-8e32-3b98dac69be7"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy00LTEtMS0yMjkzMDA_d26cf755-3a8d-4f69-8125-0e9895fb3efe"
      unitRef="usd">5000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy02LTEtMS0yMjkzMDA_23572250-32e3-40cf-a9e1-cbee3597d8ae"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy04LTEtMS0yMjkzMDA_0f369d38-b276-43ea-be74-6ba032efab8d"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMC0xLTEtMjI5MzAw_ef3a7518-3270-4082-8b29-c943ec05fb33"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMi0xLTEtMjI5MzAw_c3c6ebeb-8d42-4c43-8d7b-6a26aeec6379"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNC0xLTEtMjI5MzAw_62d2dcd5-aab4-4af5-8f2e-02345b21381e"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNi0xLTEtMjI5MzAw_fd36cb66-f4cd-413a-8030-fdfa8efb4751"
      unitRef="usd">5000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy00LTEtMS0yMDc3MTU_9523ed38-0ffa-4a59-a5f6-aeb5c0cf7dd0"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy02LTEtMS0yMDc3MTU_6e6749a9-86a3-46a9-9d8d-93778401e91a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy04LTEtMS0yMDc3MTU_3b544553-92d3-4d42-a5d8-7612f84cb4e8"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMC0xLTEtMjA3NzE1_c7d34680-acfc-4f74-a342-04175416d42d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xMi0xLTEtMjA3NzE1_ba4080b7-4c80-463d-ac3d-b08d911cd0fd"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNC0xLTEtMjA3NzE1_4b509188-f410-4f85-9d0c-91b374b81ac3"
      unitRef="usd">824000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfMy0xNi0xLTEtMjA3NzE1_e3b2dd7d-35a9-433e-bce2-dced974124f5"
      unitRef="usd">824000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i2f2846d6b8f042aebde67700938b3c37_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC00LTEtMS0yMDc3MTU_a1f2650f-b950-4ada-8970-637163d55a58"
      unitRef="usd">77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iaada6fda157d4396b2f81175d88f995f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC02LTEtMS0yMDc3MTU_3bd2913b-a99d-4fd8-afdf-07e32d5c1851"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i0192ca4caa4f458cb54244080e7fcefc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC04LTEtMS0yMDc3MTU_0402fd9f-7218-4c14-a890-66f2bf9a6d64"
      unitRef="usd">36000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i964fd2fe256f42c993c608ae347d21db_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xMC0xLTEtMjA3NzE1_64495627-aae2-436b-a1e4-dcba38461a8f"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ied9bd4a160fc4539a9d77b03463cc9b6_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xMi0xLTEtMjA3NzE1_4c26c2f3-c28d-45de-bbb4-0f89f35449bb"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4a88863ae99c4f4bb7f8c0c978329e47_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xNC0xLTEtMjA3NzE1_750f5fb8-ee2f-4876-a728-3be17c4b8b09"
      unitRef="usd">-22000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNC0xNi0xLTEtMjA3NzE1_059930e5-3515-4a4f-b6c6-ff3692fa3e76"
      unitRef="usd">91000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="id52bba3d92b045cd9377b763545b3f6b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS00LTEtMS0yMDc3MTU_2091bf15-3e3a-420c-b791-981d33b16081"
      unitRef="usd">5246000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i53fcd851b0d54c2dbe32c186e8d2ecb0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS02LTEtMS0yMDc3MTU_2fc4e4cc-5de9-4752-b210-ac2bd4b72524"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5c329081547a4cdf98e1aa393d8972f9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS04LTEtMS0yMDc3MTU_bfee8db1-1394-4e89-8353-b122f90840c3"
      unitRef="usd">789000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2455a2fae6ad431e922a0ba988eb6a34_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xMC0xLTEtMjA3NzE1_8640a294-154e-48db-b074-0566da69307a"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i05f2a2fe52aa458190c6047336e73de4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xMi0xLTEtMjA3NzE1_f5f703bb-d2f3-4690-8ee5-8fbf1169f97d"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i659a2f673c4a4411ab26d25784b4be92_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xNC0xLTEtMjA3NzE1_fffe2ef3-9a61-4ed8-87c2-be06ed542f2c"
      unitRef="usd">2238000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNS0xNi0xLTEtMjA3NzE1_252aae70-bbee-4993-8847-c34ffb54be18"
      unitRef="usd">11547000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi00LTEtMS0yMDc3MTU_b759d671-4104-4a08-919a-252b10e3ff3e"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi02LTEtMS0yMDc3MTU_b3a6e0ec-4548-4c49-afd8-d7e2a0f15aff"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if298046fc580453c82cae116d877a880_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi04LTEtMS0yMDc3MTU_76e53676-d3af-48ca-885a-9a7ef014a508"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i40a6d2460268490a812b6a04661c6a65_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xMC0xLTEtMjA3NzE1_d8c0875e-9405-4573-9201-542b1bc51aa9"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xMi0xLTEtMjA3NzE1_4e401564-b517-4f22-9351-fec6c51dc488"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xNC0xLTEtMjA3NzE1_2e2e7127-0e2c-4a7b-998a-360f6339fcaf"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfNi0xNi0xLTEtMjA3NzE1_80806805-dd6d-4a89-90e2-e01c433528d0"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC00LTEtMS0yMDc3MTU_680a3a3f-41c2-4736-af6e-36996ee5e1e2"
      unitRef="usd">-14000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC02LTEtMS0yMDc3MTU_7d317d2d-2905-444c-b180-20ea46fceebe"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if298046fc580453c82cae116d877a880_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC04LTEtMS0yMDc3MTU_7ddf1670-9c49-4d9a-a3a6-27391c1549c7"
      unitRef="usd">-22000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i40a6d2460268490a812b6a04661c6a65_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xMC0xLTEtMjA3NzE1_aad96c10-dff8-4d26-b1fe-681ea7dd28c0"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xMi0xLTEtMjA3NzE1_55a73e14-3472-4d62-a17e-ac19d20cd1b5"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xNC0xLTEtMjA3NzE1_382733eb-4094-461b-a3ee-ae2886291799"
      unitRef="usd">6000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOC0xNi0xLTEtMjA3NzE1_2f15b347-b252-44b5-973c-cbe0a84d8f69"
      unitRef="usd">-30000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ic769315b03e548d48d1dd48f1f5ce5a2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS00LTEtMS0yMDc3MTU_c457fde5-3dd9-4a77-807c-83a2f44913bf"
      unitRef="usd">5262000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idc08a22ed7434483b9c22e1d5222d8b0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS02LTEtMS0yMDc3MTU_defe0230-0789-42a0-9f3c-deb6e8ce0d88"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8c8bc248d85e49df8afec2958aab8781_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS04LTEtMS0yMDc3MTU_41096970-2b33-4cef-af84-92dc6196a786"
      unitRef="usd">811000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i294049ce13fc4119883d1b65b4fb4e3f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xMC0xLTEtMjA3NzE1_e36d5639-4985-4726-b6b5-95a9c3fa1796"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9c81e913fa06452b960a94c4319affd4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xMi0xLTEtMjA3NzE1_07f545be-21bf-4b17-a568-90690ac0981b"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4dd72c321919418dbd266cd1519b7af3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xNC0xLTEtMjA3NzE1_4afd7b9e-4568-4cff-8c67-3022649ed579"
      unitRef="usd">2232000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RhYmxlOjZhYWNjMGMxN2JjOTQ0MjRiMmUzNTcxNjM4NTIzNDRkL3RhYmxlcmFuZ2U6NmFhY2MwYzE3YmM5NDQyNGIyZTM1NzE2Mzg1MjM0NGRfOS0xNi0xLTEtMjA3NzE1_e92285df-0452-446b-803e-0872940c0e2e"
      unitRef="usd">11579000000</us-gaap:Goodwill>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i4f49db76bb9048269a4225f0617c7e08_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ4Ng_b14440e5-6c5c-4c67-94b1-9c938b324a58"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i4f49db76bb9048269a4225f0617c7e08_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ5MA_64b9c49f-1cd4-4840-9d06-6c08b3ea7c5f"
      unitRef="number">0.09</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i4f49db76bb9048269a4225f0617c7e08_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ5NA_1e7102b2-8565-448f-b45b-eade07366c8e"
      unitRef="number">0.02</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="id6075831fea84e2eb08c47c4f0c4d29b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDQ5Nw_f266d8c1-812d-42c9-9119-9078a783429b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="id40329b767834642890bfb55575f5122_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUwNg_1a75cf3a-d324-4f56-b55d-899ae79fbe42"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="id40329b767834642890bfb55575f5122_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUxMA_caf17932-895e-4a25-8bc0-4dd36d0391c6"
      unitRef="number">0.10</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate
      contextRef="id40329b767834642890bfb55575f5122_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUxNQ_43d122c4-36a8-42ec-87c9-9aedc6b3b4a3"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if2e632bea1f6478b9fa7efc4a42012da_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUxOQ_e537ae38-acfd-4993-ab1e-7d7daadaeb03"
      unitRef="usd">83000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:NumberOfReportingUnits
      contextRef="i9aa533c5f43d49389b83002df6cdf881_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDUzMQ_e11e61e7-f39a-4f55-8818-f162a3a5e5b5"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="iab9c3331e15a44048291c40dafad29a2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU0Mg_f2478573-198e-4325-9b3e-593ab27afb05"
      unitRef="number">0.02</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i7b85418b2df045ccaf777f6a153cd251_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU0Ng_0540dac8-ff4a-44eb-b80c-fb638be9cecf"
      unitRef="number">0.03</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="iab9c3331e15a44048291c40dafad29a2_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU1MA_ba2c5868-0342-4024-bae4-e6b8fc70ec46"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i7b85418b2df045ccaf777f6a153cd251_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU1Ng_3a373dd1-343c-4fe2-8d17-fb7d5a49897f"
      unitRef="number">0.115</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="iff9524a8dec942a8bde2eb81616907d3_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU2Mw_b19bfe52-a5a6-4b84-969c-f5d937687d97"
      unitRef="number">0.25</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i2ae7f8afd93140b892be236df15ed51f_D20220506-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU2Nw_b9a5cf16-ffcd-4d39-a0b7-4b8e130b3321"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="iad75129d06c348f0be0dddaa52c9ed51_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU3Ng_3e19b5be-8dd2-48d9-996c-a8eafa3cad4c"
      unitRef="number">0.01</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="id40329b767834642890bfb55575f5122_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU4MA_cbeb3668-36bd-4164-b252-3aef00b53669"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="iad75129d06c348f0be0dddaa52c9ed51_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU4Nw_80eeb470-a628-4688-aff2-efdca39a5ff6"
      unitRef="number">0.105</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia0f99abdbe264be492c1ab50a81c5fa7_D20220701-20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDU5NA_93cd5458-c87e-43e8-a8ec-2258b749a6b2"
      unitRef="usd">119000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="iad75129d06c348f0be0dddaa52c9ed51_I20220930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYwOA_89c2cc78-b5c2-4c47-902b-5c4354622854"
      unitRef="usd">480000000</us-gaap:Goodwill>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i370ee4cf54624da09da5e76a026c3802_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYyMg_079bd995-b0f9-4bc6-b2bd-23f4a07697b5"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i41f572ad45a949229f9b0322d3dfb46d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYyNw_7f32192f-1c42-4d1f-b413-268c01f7ca88"
      unitRef="number">0.025</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i9c9e3a1139454651b2a0528c0e2b983c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDYzMw_001f90bd-bb30-48ae-91d0-08e95dde4402"
      unitRef="number">0.0975</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i84e42d2305b3476a936b8caf47cb8b60_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY0MA_ae31a6e8-a82e-46f2-8d18-0a3ec787980b"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i45fcaa6d1e16450c95f03e1749bb60ac_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY0Ng_623ab493-b3ce-4c18-ae72-2211eb007435"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i41f572ad45a949229f9b0322d3dfb46d_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY1NQ_ac3a9f8a-c3c6-460e-88b2-16f95b83afc1"
      unitRef="number">0.05</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY1OQ_b0071e04-c66f-4dd0-94d9-cf34cd115ced"
      unitRef="number">-0.025</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY2Ng_d61445fc-85a4-448e-b35e-15f008624792"
      unitRef="number">0.1025</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="if400b9a66b464bc39f29a0744063105e_D20221001-20221001"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY3NA_dc8ade3b-f815-4c65-92a0-e62e466e3343"
      unitRef="usd">622000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i2a9d4308a7f04fc9b7b9b0fabed44c88_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDY4OA_4d24b04e-fdfe-4b32-8a0b-591c6f28dee5"
      unitRef="usd">1439000000</us-gaap:Goodwill>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i4230998f842f4bbc82a0ea680d4b577b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcxOQ_7b4b3efc-175d-4e02-9296-8f7f9243f916"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="id8d9d9cd168d4fe98734f508386e2be0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcyNQ_c83c7ccf-b568-469b-b0a0-b6671edb523c"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i4230998f842f4bbc82a0ea680d4b577b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcwNA_6d614613-022d-4de2-bc37-fadc86079b33"
      unitRef="number">0.0950</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="id8d9d9cd168d4fe98734f508386e2be0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDcxMQ_2182293b-f71e-4b91-ac0e-2bcec19819ce"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="icfc0cbc0a72349eeb0612d5fd6410c80_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDczMQ_a59f1178-b0cd-44ba-ad41-9291a24e0755"
      unitRef="number">0.25</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i063a380689344325b47343a660c9c908_D20221001-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjE5OTAyMzM1NDczNQ_0730c23a-9151-407b-abdb-18b73440f37d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82MS9mcmFnOjQ4ZmY2YmEyM2Y1MjQwZGQ5Y2U1YTJhYzc1MGY1MzU0L3RleHRyZWdpb246NDhmZjZiYTIzZjUyNDBkZDljZTVhMmFjNzUwZjUzNTRfMjc5NTc_59a41ce8-03df-418c-b71a-7781f9111ad0"
      unitRef="usd">5004000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RleHRyZWdpb246M2Y0ZGE0ODRiYTgwNDJiNGEyMDc2YTE2ZjA0MjQ2YmJfOTY_11368d00-306c-48a1-9e69-b1d406aa329c">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RleHRyZWdpb246M2Y0ZGE0ODRiYTgwNDJiNGEyMDc2YTE2ZjA0MjQ2YmJfOTk_6ed1bb3e-df1c-4da1-8256-743dc7e1dcff">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.740%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:AccruedProductRebateCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS0yLTEtMS0yMjczNzQ_ae050973-f0d6-480d-823a-cdb3439c2350"
      unitRef="usd">914000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS00LTEtMS0yMjczNzY_427420e0-c07b-4cc5-8cc4-503fce454285"
      unitRef="usd">983000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMi0yLTEtMS0yMjczNzQ_23e2bbc7-7faf-48cd-8e32-e998086e702f"
      unitRef="usd">429000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMi00LTEtMS0yMjczNzY_a1f2f7c2-3945-4e72-bae0-0b015bbd50c7"
      unitRef="usd">427000000</bhc:AccruedProductReturnCurrent>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS0yLTEtMS0yMDc3MTU_243314ec-1d63-40ca-a91f-a0260b66c42b"
      unitRef="usd">326000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfMS00LTEtMS0yMDc3MTU_6b2a4bd0-bec6-4460-9af8-d621d86a5fe2"
      unitRef="usd">326000000</bhc:Legalsettlementsandrelatedfees>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC0yLTEtMS0yMTkyNjc_f4b038fb-b99a-4417-bb5b-8cffb2266e39"
      unitRef="usd">260000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC00LTEtMS0yMTkyNjc_466ed9f0-d6ca-4ea9-9ec1-551c53470079"
      unitRef="usd">300000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC0yLTEtMS0yMDc3MTU_e4794daf-ba3a-4a6f-9a8e-28a76b55c2a5"
      unitRef="usd">208000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNC00LTEtMS0yMDc3MTU_d8ccdd31-1263-418b-8103-82a231ff06bb"
      unitRef="usd">208000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNi0yLTEtMS0yMDc3MTU_b8770480-eb92-4244-bf0f-2438d573485a"
      unitRef="usd">46000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNi00LTEtMS0yMDc3MTU_852240f0-8cf6-4e29-ae3f-eade730944b6"
      unitRef="usd">30000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNy0yLTEtMS0yMDc3MTU_6637db2c-c977-4404-a527-d033c6f9bf1f"
      unitRef="usd">733000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfNy00LTEtMS0yMDc3MTU_81b6d494-d026-4d3c-97a0-144bdc68252e"
      unitRef="usd">714000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfOC0yLTEtMS0yMDc3MTU_ae39469f-72c8-49f2-a6f2-ef0501ca92d4"
      unitRef="usd">2916000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82NC9mcmFnOjNmNGRhNDg0YmE4MDQyYjRhMjA3NmExNmYwNDI0NmJiL3RhYmxlOjQ4NGFlODYyOWU5MDQ3MzFiOTlhMzlmYmE4YWFhNGMxL3RhYmxlcmFuZ2U6NDg0YWU4NjI5ZTkwNDczMWI5OWEzOWZiYThhYWE0YzFfOC00LTEtMS0yMDc3MTU_927db464-8f24-44cb-bccb-2a53019a05fa"
      unitRef="usd">2988000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5ODQ_25a02d35-b734-464f-bf81-0768e424d26e">FINANCING ARRANGEMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.00% First Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.00% Second Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.00% Intermediate Holdco Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below), the B+L Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes (as defined and described in the table above), the 9.00% Intermediate Holdco Secured Notes (as defined below) and Senior Unsecured Notes (as defined and described in the table above) contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of March&#160;31, 2023, the amount available for restricted payments under the &#x201c;builder basket&#x201d; in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $9,700&#160;million (although such availability is subject to the Company&#x2019;s compliance with a 2.00:1.00 fixed charge coverage ratio). The 2027 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that, requires the Company to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to ensure compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, the Company closed a series of transactions whereby it exchanged (the &#x201c;Exchange Offer&#x201d;) validly tendered senior unsecured notes with an aggregate outstanding principal balance of $5,594&#160;million as set forth in the table below (collectively, the &#x201c;Existing Unsecured Senior Notes&#x201d;) for $3,125&#160;million in aggregate principal balance of newly issued secured notes, a reduction of outstanding principal of $2,469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The secured notes issued in the Exchange Offer consist of: (i) $1,774&#160;million in aggregate principal amount of new 11.00% First Lien Secured Notes due 2028 (the &#x201c;11.00% First Lien Secured Notes&#x201d;) issued by the Company, (ii) $352&#160;million in aggregate principal amount of new 14.00% Second Lien Secured Notes due 2030 (the &#x201c;14.00% Second Lien Secured Notes&#x201d; and, together with the 11.00% First Lien Secured Notes, the &#x201c;New BHC Secured Notes&#x201d;) issued by the Company and (iii) $999&#160;million in aggregate principal amount of new 9.00% Senior Secured Notes due 2028 (the &#x201c;9.00% Intermediate Holdco Secured Notes&#x201d; and, together with the New BHC Secured Notes, the &#x201c;New Secured Notes&#x201d;) issued by 1375209 B.C. Ltd. (&#x201c;Intermediate Holdco&#x201d;), an existing indirect wholly-owned unrestricted subsidiary of the Company that holds 38.6% of the issued and outstanding common shares of Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an assessment of the Exchange Offer and determined that it met the criteria to be accounted for as a troubled debt restructuring under Accounting Standards Codification 470-60. For each series of the Existing Unsecured Senior Notes exchanged, the undiscounted cash flows associated with the New Secured Notes issued were compared to the carrying value of the Existing Unsecured Senior Notes exchanged for such New Secured Notes and the applicable exchange was accounted for as follows: (i) to the extent the undiscounted cash flows of the New Secured Notes in question were lower than the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the total of these undiscounted cash flows, with a gain recorded for the remaining difference between this value and the carrying value of the applicable Existing Senior Unsecured Notes (as such, no interest expense will be recorded for the applicable New Secured Notes prospectively) and (ii) to the extent the undiscounted cash flows of the New Secured Notes in question exceeded the carrying value of the applicable Existing Unsecured Senior Notes exchanged, the carrying value of the applicable New Secured Notes was established at the carrying value of the applicable Existing Senior Unsecured Notes, and the Company established new effective interest rates based on the carrying value of the applicable Existing Unsecured Senior Notes prior to the Exchange Offer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the principal amount of the New Secured Notes and their carrying value was recorded as a premium and is included in long-term debt on the Company&#x2019;s Condensed Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The premium recorded on the New Secured Notes was $1,835&#160;million, which will be reduced as contractual interest payments are made on the New Secured Notes. During the first quarter of 2023, the Company made contractual interest payments of $128&#160;million related to the New Secured Notes, of which $111&#160;million was recorded as a reduction of the premium. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2018 Restated Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company&#x2019;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#x201c;2018 Restated Credit Agreement&#x201d;). Prior to the 2022 Amended Credit Agreement (as defined below), the 2018 Restated Credit Agreement provided for a revolving credit facility of $1,225 million (the &#x201c;2023 Revolving Credit Facility&#x201d;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#x201c;June 2025 Term Loan B Facility&#x201d;) and November 2025 (the &#x201c;November 2025 Term Loan B Facility&#x201d;), respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the 2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, the Company and certain of its subsidiaries as guarantors entered into a Second Amendment (the &#x201c;Second Amendment&#x201d;) to the Fourth Amended and Restated Credit and Guaranty Agreement (as amended by the Second Amendment, the &#x201c;2022 Amended Credit Agreement&#x201d;). The 2022 Amended Credit Agreement provides for a new term loan facility with an aggregate principal amount of $2,500&#160;million (the &#x201c;2027 Term Loan B Facility&#x201d;) maturing on February 1, 2027 and a new revolving credit facility of $975&#160;million (the &#x201c;2027 Revolving Credit Facility&#x201d;) that will mature on the earlier of February 1, 2027 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#x201c;BHA&#x201d;) in an aggregate principal amount in excess of $1,000&#160;million. Borrowings under the 2027 Revolving Credit Facility can be made in U.S. dollars, Canadian dollars or Euros. After giving effect to the Second Amendment, the 2023 Revolving Credit Facility, June 2025 Term Loan B Facility and November 2025 Term Loan B Facility were refinanced (such refinancing, the &#x201c;Credit Agreement Refinancing&#x201d;), along with certain of the Company&#x2019;s existing senior notes, using net proceeds from the borrowings under the 2027 Term Loan B Facility, the B+L IPO and the B+L Debt Financing (as defined below) and available cash on hand. As of March 31, 2023, the Company had drawn $395&#160;million and had $23&#160;million of issued and outstanding letters of credit on the 2027 Revolving Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Term Loan B Facility bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a forward-looking term rate determined by reference to the financing rate for borrowing U.S. dollars overnight collateralized by U.S. Treasury securities (&#x201c;term SOFR rate&#x201d;) for the interest period relevant to such borrowing&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or (b) a base rate determined by reference to the highest of: (i) the prime rate (as defined in the 2022 Amended Credit Agreement), (ii) the federal funds effective rate plus 1/2 of 1.00% and (iii) the term SOFR rate for a period of one month plus 1.00% (or if such rate shall not be ascertainable, 1.50%) (provided, however that the term SOFR rate with respect to the 2027 Term Loan B Facility shall at no time be less than 0.50% per annum), in each case, plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2027 Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) the term SOFR rate (subject to a floor of 0.00% per annum) or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at the Company&#x2019;s option, either: (a) a Canadian dollar offer rate or (b) a Canadian dollar prime and (iii) euros bear interest at a rate per annum equal to a term benchmark rate determined by reference to the cost of funds for euro deposits (&#x201c;EURIBOR&#x201d;) for the interest period relevant to such borrowing (subject to a floor of 0.00% per annum), in each case, plus an applicable margin. Term SOFR rate loans are subject to a credit spread adjustment ranging from 0.10%-0.25%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margin for borrowings under the 2027 Term Loan B Facility is 5.25% for term SOFR rate loans and 4.25% for U.S. dollar base rate loans. The applicable interest rate margin for borrowings under the 2027 Revolving Credit Facility ranges from 4.75% to 5.25% for term SOFR rate loans, BA rate loans and EURIBOR loans and&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.75% to 4.25% for U.S. dollar base rate loans and Canadian prime rate loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is required to pay commitment fees of 0.25%-0.50% per annum with respect to the unutilized commitments under the 2027 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on term SOFR rate borrowings under the 2027 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the 2022 Amended Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights and net proceeds thresholds), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the 2022 Amended Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the 2022 Amended Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights and net proceeds thresholds). These mandatory prepayments may be used to satisfy future amortization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the 2027 Term Loan B Facility is 5.00% per annum, or $125&#160;million, payable in quarterly installments beginning on September 30, 2022. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of March&#160;31, 2023, the remaining mandatory quarterly amortization payments for the 2027 Term Loan B Facility were $469&#160;million through December 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement permits the incurrence of incremental credit facility borrowings up to the greater of $1,000&#160;million and 40% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the 2022 Amended Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Amended Credit Agreement provides that Bausch + Lomb shall initially be a &#x201c;restricted&#x201d; subsidiary subject to the terms of the 2022 Amended Credit Agreement covenants, but does not require Bausch + Lomb to guarantee the obligations under the 2022 Amended Credit Agreement. The 2022 Amended Credit Agreement permits the Company to designate Bausch + Lomb as an &#x201c;unrestricted&#x201d; subsidiary under the 2022 Amended Credit Agreement and no longer subject to the terms of the covenants thereunder provided that no event of default is continuing or will result from such designation and the total leverage ratio of Remainco (as defined in the 2022 Amended Credit Agreement) will not be greater than 7.60:1.00 on a pro forma basis. The Credit Agreement Refinancing contains provisions that were designed to facilitate the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 29, 2022, the Company designated 1261229 B.C. Ltd., the entity that directly or indirectly holds approximately 89% of the issued and outstanding shares of Bausch + Lomb, as an unrestricted subsidiary of the Company in accordance with the terms of the Company&#x2019;s debt documents. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are unrestricted subsidiaries of the Company and, as a result, are not subject to the covenants under the Bausch Health debt documents, and the earnings and debt of Bausch + Lomb, as defined in the relevant debt documents, are also not included in the calculation of the Company&#x2019;s financial maintenance covenant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Secured Credit Facilities under the B+L Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2022, Bausch + Lomb entered into a credit agreement (the &#x201c;B+L Credit Agreement&#x201d;, and the credit facilities thereunder, the &#x201c;B+L Credit Facilities&#x201d;) providing for a term loan of $2,500&#160;million with a five-year term to maturity (the &#x201c;B+L Term Facility&#x201d;) and a five-year revolving credit facility of $500&#160;million (the &#x201c;B+L Revolving Credit Facility&#x201d; and such financing, the &#x201c;B+L Debt Financing&#x201d;). The B+L Credit Facilities are secured by substantially all of the assets of Bausch + Lomb and its material, wholly-owned Canadian, U.S., Dutch and Irish subsidiaries, subject to certain exceptions. The term loan is denominated in U.S. dollars, and borrowings under the revolving credit facility will be made available in U.S. dollars, euros, pounds sterling and Canadian dollars. As of March&#160;31, 2023, the B+L Revolving Credit Facility had $100&#160;million of outstanding borrowings, $24&#160;million of issued and outstanding letters of credit and remaining availability of $376&#160;million under its Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The B+L Revolving Credit Facility is a source of funding for Bausch + Lomb and its subsidiaries only. Absent the payment of a dividend, which would be determined by the Board of Directors of Bausch + Lomb and paid pro rata to Bausch + Lomb&#x2019;s shareholders, proceeds from the B+L Revolving Credit Facility are not available to fund the operations, investing and financing activities of any other subsidiaries of Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Revolving Credit Facility in: (i) U.S. dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) a term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;)-based rate or (b) a U.S. dollar base rate, (ii) Canadian dollars bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either: (a) a Canadian Dollar Offered Rate (&#x201c;CDOR&#x201d;) or (b) a Canadian dollar prime rate, (iii) euros bear interest at a rate per annum equal to EURIBOR and (iv) pounds sterling bear interest at a rate per annum equal to Sterling Overnight Index Average (&#x201c;SONIA&#x201d;) (provided, however, that the term SOFR-based rate, CDOR, EURIBOR and SONIA shall be no less than 0.00% per annum at any time and the U.S. dollar base rate and the Canadian dollar prime rate shall be no less than 1.00% per annum at any time), in each case, plus an applicable margin. Term SOFR-based loans are subject to a credit spread adjustment of 0.10%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the B+L Revolving Credit Facility are: (i) between 0.75% to 1.75% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.75% to 2.75% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#x2019;s total net leverage ratio and (ii) after: (x) Bausch + Lomb&#x2019;s senior unsecured non-credit-enhanced long term indebtedness for borrowed money receives an investment grade rating from at least two of Standard &amp;amp; Poor&#x2019;s, Moody&#x2019;s and Fitch and (y) the B+L Term Facility has been repaid in full in cash (the &#x201c;IG Trigger&#x201d;), between 0.015% to 0.475% with respect to U.S. dollar base rate or Canadian dollar prime rate borrowings and between 1.015% to 1.475% with respect to SOFR, EURIBOR, SONIA or CDOR borrowings based on Bausch + Lomb&#x2019;s debt rating. In addition, Bausch + Lomb is required to pay commitment fees of 0.25% per annum in respect of the unutilized commitments under the B+L Revolving Credit Facility, payable quarterly in arrears until the IG Trigger and a facility fee between 0.110% to 0.275% of the total revolving commitments, whether used or unused, based on Bausch + Lomb&#x2019;s debt rating and payable quarterly in arrears. Bausch + Lomb is also required to pay letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on SOFR borrowings under the B+L Revolving Credit Facility on a per annum basis, payable quarterly in arrears, as well as customary fronting fees for the issuance of letters of credit and agency fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the B+L Term Facility bear interest at a rate per annum equal to, at Bausch + Lomb&#x2019;s option, either (i) a term SOFR-based rate, plus an applicable margin of 3.25% or (ii) a U.S. dollar base rate, plus an applicable margin of 2.25% (provided, however, that the term SOFR-based rate shall be no less than 0.50% per annum at any time and the U.S. dollar &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;base rate shall not be lower than 1.50% per annum at any time). Term SOFR-based loans are subject to a credit spread adjustment of 0.10%. The stated rate of interest under the Term Facility at March&#160;31, 2023 was 8.46% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the B+L Credit Agreement, Bausch + Lomb is required to make mandatory prepayments of the loans under the B+L Term Facility under certain circumstances, including from: (i) 100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii) 100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the B+L Credit Agreement), (iii) 50% of Excess Cash Flow (as defined in the B+L Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv) 100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for the B+L Term Facility is 1.00% per annum, or $25&#160;million, and the first quarterly installment was paid on September 30, 2022. Bausch + Lomb may direct that prepayments be applied to such amortization payments in order of maturity. As of March&#160;31, 2023, the remaining mandatory quarterly amortization payments for the B+L Term Facility were $100&#160;million through March 2027, with the remaining term loan balance being due in May 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the 2022 Amended Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). In connection with the closing of the B+L IPO, the redemption of the Company&#x2019;s 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d;) (as discussed below) and the related release in respect of the 2018 Restated Credit Agreement, the guarantees and related security provided by Bausch + Lomb and its subsidiaries in respect of the existing senior notes of the Company and BHA were released.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the 2022 Amended Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.125% Senior Secured Notes due 2027 - February 2022 Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). The proceeds from the February 2027 Secured Notes, along with proceeds from the B+L IPO, the 2027 Term Loans and the B+L Debt Financing and cash on hand, were used to redeem the April 2025 Unsecured Notes and the Credit Agreement Refinancing as discussed below. The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;New BHC Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 11.00% First Lien Secured Notes mature on September 30, 2028, and have a stated interest of 11.00% per year that is payable semi-annually in arrears on each March 30 and September 30. The 11.00% First Lien Secured Notes are redeemable, in whole or in part, at any time at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;but not including, the date of redemption plus a &#x201c;make-whole&#x201d; premium as described in the 11.00% First Lien Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 14.00% Second Lien Secured Notes mature on October 15, 2030, and have a stated interest of 14.00% per year that is payable semi-annually in arrears on each April 15 and October 15. The 14.00% Second Lien Secured Notes will be redeemable, in whole or in part, at any time on or after October 15, 2025 at the applicable redemption prices set forth in the 14.00% Second Lien Secured Notes indenture. In addition, some or all of the 14.00% Second Lien Secured Notes may be redeemed prior to October 15, 2025 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of redemption plus a &#x201c;make-whole&#x201d; premium as described in the 14.00% Second Lien Secured Notes indenture. At any time prior to October 15, 2025, up to 40% of the aggregate principal amount of the 14.00% Second Lien Secured Notes may be redeemed with the net proceeds of certain equity offerings at the redemption price set forth in the 14.00% Second Lien Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.00% Intermediate Holdco Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 9.00% Intermediate Holdco Secured Notes mature on January 30, 2028, and have a stated interest of 9.00% per year that is payable semi-annually in arrears on each January 30 and July 30. The 9.00% Intermediate Holdco Secured Notes are redeemable at the option of Intermediate Holdco, in whole or in part, at any time, at the redemption prices set forth in the 9.00% Intermediate Holdco Secured Notes indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 9.00% Intermediate Holdco Secured Notes are general senior secured obligations of Intermediate Holdco and secured by first priority liens (subject to permitted liens and certain other exceptions) on substantially all of the assets of Intermediate Holdco, which as of March 31, 2023 were comprised of 38.6% of the issued and outstanding common shares of Bausch + Lomb Corporation. The 9.00% Intermediate Holdco Secured Notes and Intermediate Holdco&#x2019;s other obligations under the indenture governing such notes are not obligations or responsibilities of, or guaranteed by, the Company, Bausch + Lomb or any of their respective affiliates or subsidiaries (other than the issuer Intermediate Holdco). The sole recourse of the holders of the 9.00% Intermediate Holdco Secured Notes under the 9.00% Intermediate Holdco Secured Notes and the indenture governing such notes is limited to Intermediate Holdco and its assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redemption of April 2025 Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of the B+L IPO, on May 10, 2022, the Company using: (i) the net proceeds from the issuance of the February 2027 Secured Notes, (ii) the net proceeds from the B+L IPO, (iii) the net proceeds from the borrowings under the B+L Debt Financing and (iv) cash on hand caused sufficient funds for the redemption in full of its April 2025 Unsecured Notes at a redemption price of 101.021% of the principal amount then outstanding to be irrevocably deposited with the Bank of New York Mellon, N.A. The April 2025 Unsecured Notes were redeemed on May 16, 2022 and were accounted for as an extinguishment of debt. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The weighted average stated rate of interest for the Company&#x2019;s outstanding debt obligations as of March&#160;31, 2023 and December&#160;31, 2022 was 7.87% and 7.74%, respectively. Due to the accounting treatment for the New Secured Notes, interest expense in the Company&#x2019;s financial statements for 2023 and in future periods will not be representative of the weighted average stated rate of interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may, from time to time, purchase outstanding debt for cash in open market purchases or privately negotiated transactions. Such repurchases or exchanges, if any, will depend on prevailing market conditions, future liquidity requirements, contractual restrictions and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2023, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5OTI_b9d08bdb-9d60-4915-a2f7-04c71c78de9a">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:8pt;padding-left:6.75pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;2022 Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;B+L Credit Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B+L Term Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.50% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.75% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.00% First Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;September 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.00% Second Lien Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;October 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;9.00% Intermediate Holdco Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2263e23bd8e642778b2df9b8853237be_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC00LTEtMS0yMDc3MTU_a0eb1276-60e3-492b-b566-5f2a24a29524"
      unitRef="usd">395000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2263e23bd8e642778b2df9b8853237be_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC02LTEtMS0yMDc3MTU_3edaf28a-32b2-4c0f-8872-1728c8bcc4cd"
      unitRef="usd">395000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i81245af4c6a84955ba0724a4c0e69852_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC04LTEtMS0yMDc3MTU_c9012608-1f4e-4469-ad3b-80b456462afe"
      unitRef="usd">470000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i81245af4c6a84955ba0724a4c0e69852_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOC0xMC0xLTEtMjA3NzE1_c97c0b12-2e17-4d45-97c0-27f7fb977a95"
      unitRef="usd">470000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ieb5c0b0ff6ea4e92a88b245ac951ddde_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS00LTEtMS0yMDc3MTU_563f11c9-3c5a-4b85-931f-22b1277e3e2c"
      unitRef="usd">2406000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ieb5c0b0ff6ea4e92a88b245ac951ddde_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS02LTEtMS0yMDc3MTU_7cee4802-4937-4493-a5fb-41cb956c4301"
      unitRef="usd">2363000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i52924d69272c4ce08a9238494afb5ce1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS04LTEtMS0yMDc3MTU_4b202b34-b9c7-430f-8b86-1fdb03308390"
      unitRef="usd">2437000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i52924d69272c4ce08a9238494afb5ce1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfOS0xMC0xLTEtMjA3NzE1_d4aeb149-11c6-4de3-951a-c48d1097036f"
      unitRef="usd">2392000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i73805f2008b0493784b73a6e474d0511_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtNC0xLTEtMjA3NzE1_b3e1dce3-3826-460b-bc24-1a6aa372a9df"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i73805f2008b0493784b73a6e474d0511_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtNi0xLTEtMjA3NzE1_3f67fac1-0bfa-4374-a543-9a52fe6c391e"
      unitRef="usd">100000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i14e66b94be8048c395bd7d7ffcc1ac3e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtOC0xLTEtMjA3NzE1_9e0997aa-1b63-4a99-b9e7-289b5b1371a3"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i14e66b94be8048c395bd7d7ffcc1ac3e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTEtMTAtMS0xLTIwNzcxNQ_f7f868e7-4e5e-4abc-8f05-537dacc71cb7"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2f96c4977bdf4527aca21c11e00b2edf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItNC0xLTEtMjA3NzE1_39474983-7264-4967-b6e0-550332e9796a"
      unitRef="usd">2481000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2f96c4977bdf4527aca21c11e00b2edf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItNi0xLTEtMjA3NzE1_c11c5ec3-9744-4ec5-bf86-66530880183c"
      unitRef="usd">2436000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i304f673759f44464b17361dc1fe3b487_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItOC0xLTEtMjA3NzE1_5d62d83b-f282-4c3e-9f05-257344687611"
      unitRef="usd">2488000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i304f673759f44464b17361dc1fe3b487_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTItMTAtMS0xLTIwNzcxNQ_db59cef1-6e49-495f-8da5-f3bf3cb28308"
      unitRef="usd">2439000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibacd0f91a9214e0fbe96138d126d5254_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246OGUyZWY0ZTBhNDM5NGFjODk5ZWM2ZWJjNDYxNDU5YjVfNA_6b06fed8-09e4-477c-a994-41618831d036"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibacd0f91a9214e0fbe96138d126d5254_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtNC0xLTEtMjA3NzE1_ce9120ee-d0b5-4246-9041-0b0dd35e202b"
      unitRef="usd">1680000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ibacd0f91a9214e0fbe96138d126d5254_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtNi0xLTEtMjA3NzE1_560c6a63-2faa-4f05-8945-d4a97dc57757"
      unitRef="usd">1673000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4d7b5fbd1e7f4531a59766d450386804_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtOC0xLTEtMjA3NzE1_e914bc91-f5d4-4027-8541-61f6def3a527"
      unitRef="usd">1680000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4d7b5fbd1e7f4531a59766d450386804_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTQtMTAtMS0xLTIwNzcxNQ_f0c4f8d2-289c-4c10-9901-64763f5a16fb"
      unitRef="usd">1672000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d37517b7d6b4cbc982519aae076487f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246N2Y1NTZhZmZkMzc0NGU0YzhmOWNmMDZjZDUzNGVlODJfNA_8e3bf8b6-5c60-40f3-96c7-cc8619b93ec8"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2d37517b7d6b4cbc982519aae076487f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtNC0xLTEtMjA3NzE1_f896068f-4d21-476e-be77-41d602b0100b"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2d37517b7d6b4cbc982519aae076487f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtNi0xLTEtMjA3NzE1_05837872-108a-4984-9535-ca5a5046db14"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9e85debb9de747678b7cdb6f20a35b55_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtOC0xLTEtMjA3NzE1_dd9482e2-cde1-4959-83a1-03514f8da12b"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9e85debb9de747678b7cdb6f20a35b55_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTUtMTAtMS0xLTIwNzcxNQ_d47343f1-f38b-4dfc-be6b-a500597c9cff"
      unitRef="usd">987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib53b662a6d4d41fead56abf94df3152b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246YTZmOWYyZjUxM2VjNGMxMTk2NzJmYTk4OWY4NWE2ZjhfNA_8a188fba-b0c4-4f20-9a5c-56fe1fee2974"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib53b662a6d4d41fead56abf94df3152b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtNC0xLTEtMjA3NzE1_4069cdad-dd62-4dd8-807e-f780639cf6c5"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib53b662a6d4d41fead56abf94df3152b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtNi0xLTEtMjA3NzE1_d6cd8fab-bc78-4080-a4a1-7104ea4a7144"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i59d56d7f093844549b20bc3e68c8d823_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtOC0xLTEtMjA3NzE1_fff51f55-672e-430f-8691-eec8cf777581"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i59d56d7f093844549b20bc3e68c8d823_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTYtMTAtMS0xLTIwNzcxNQ_780cef90-f996-45e9-8938-bb08594b0a35"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5bfca85fb4024a6b94e76897fbe51927_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctMC0xLTEtMjA3NzE1L3RleHRyZWdpb246N2IwZmYyOGNlYzdhNDUyN2E3NjkzYjY2Y2ExNDA4ZWNfNA_32db420e-9b7f-4172-80da-4ea4dd43d38e"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5bfca85fb4024a6b94e76897fbe51927_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctNC0xLTEtMjA3NzE1_aa8f31b4-0fb5-4dc6-bdc5-9732c4a924d2"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5bfca85fb4024a6b94e76897fbe51927_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctNi0xLTEtMjA3NzE1_1bdb2ba3-c9f1-4264-896e-69a441831255"
      unitRef="usd">1584000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i19fce4dedbd8421eb73bafb553597896_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctOC0xLTEtMjA3NzE1_4cd27939-6a47-4e98-9329-892cd0c43448"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i19fce4dedbd8421eb73bafb553597896_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTctMTAtMS0xLTIwNzcxNQ_47a625dd-9c01-4756-90a6-6e1eda6c4e7a"
      unitRef="usd">1583000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246ZTY1ZGU5NjQxY2I4NDUxZWExZWFjNzNhZGJiOWM4ZDNfNA_7f145cd5-f54b-44b4-ac7b-b3bbd45f26d1"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtNC0xLTEtMjA3NzE1_8c2f555e-a22b-4232-a808-865d2a108abb"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtNi0xLTEtMjA3NzE1_934fb64c-5f97-4ab7-a0ec-04104f5eb53a"
      unitRef="usd">2740000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i19dd2ee808a54032b36dcaee1eacb64f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtOC0xLTEtMjA3NzE1_e36fc1b6-268e-4d15-8577-31937e42f42a"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i19dd2ee808a54032b36dcaee1eacb64f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTgtMTAtMS0xLTIwNzcxNQ_e15e976d-23f2-4149-b073-d3b41fd24b42"
      unitRef="usd">2826000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktMC0xLTEtMjA3NzE1L3RleHRyZWdpb246N2Y2YWUzZGZiY2U5NGE1YmFkZDVkZTY0MDBiNGFkOGNfNA_b435feb6-c761-4f22-95bc-b407f0e9bc86"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktNC0xLTEtMjA3NzE1_7595a357-8420-42bf-a423-2ac3d8b317f1"
      unitRef="usd">352000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktNi0xLTEtMjA3NzE1_8972d4e1-de6b-4088-bfce-c13bce9cc912"
      unitRef="usd">711000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i552ec672b451433a9e90f1b3839c487f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktOC0xLTEtMjA3NzE1_5fe96d1a-e725-4d35-98f9-8253641d656a"
      unitRef="usd">352000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i552ec672b451433a9e90f1b3839c487f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMTktMTAtMS0xLTIwNzcxNQ_6e81a7f1-e652-4ef5-ba85-67b5a80907e7"
      unitRef="usd">711000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NzliNThkOGQwYWE2NDgwY2IxZTEzMzVhNWRjNGNjNGFfNA_d1da07f7-c68b-47f1-8cb6-541430308fd9"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtNC0xLTEtMjA3NzE1_46ccf221-a10f-441c-a069-79f5c7e437f7"
      unitRef="usd">999000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtNi0xLTEtMjA3NzE1_07df050b-6221-46cb-a015-4d9a19d7888d"
      unitRef="usd">1397000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if57b9dc8ffac4b9b9b063a8ef1df4a6a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtOC0xLTEtMjA3NzE1_4814d638-2a57-4572-b58d-15fc2ad455dc"
      unitRef="usd">999000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if57b9dc8ffac4b9b9b063a8ef1df4a6a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjAtMTAtMS0xLTIwNzcxNQ_13b2abc1-7a1e-4a36-b6d3-1d827ffdd273"
      unitRef="usd">1423000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4de0d68bab3b4961969accc3d866508c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246YjZhY2UwOWFlNjJiNDFlY2I5ZThhYzlkMTZlNjViMzRfNA_7b9e049c-2939-4663-8647-3ae9eca0216b"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4de0d68bab3b4961969accc3d866508c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtNC0xLTEtMjA3NzE1_4e80c5c3-a050-4b68-b6bd-9e271f18c35a"
      unitRef="usd">959000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4de0d68bab3b4961969accc3d866508c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtNi0xLTEtMjA3NzE1_d34146d6-1c1c-4d76-bc85-ec7724a751cb"
      unitRef="usd">952000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i69eca3a5c1014c4fb4646db720b2ce73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtOC0xLTEtMjA3NzE1_401339f0-9f20-4677-8e9a-f2a8f1b94a1a"
      unitRef="usd">959000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i69eca3a5c1014c4fb4646db720b2ce73_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjMtMTAtMS0xLTIwNzcxNQ_ec72dcd0-83b7-4f81-b1b5-0cd01e86cd53"
      unitRef="usd">951000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2d865df747b04091979d8849df30eb08_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246YzE4MzI4MzY3YjBhNDgwNWE5NTI3NDZmZmFhMWE5NzZfNA_672f9982-6201-4244-b389-9c43d5a01f70"
      unitRef="number">0.0925</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2d865df747b04091979d8849df30eb08_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtNC0xLTEtMjA3NzE1_8fa71876-454e-4c09-b0fc-151e50215726"
      unitRef="usd">741000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2d865df747b04091979d8849df30eb08_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtNi0xLTEtMjA3NzE1_a819f5aa-22ed-41c0-841e-0e5294d34a0d"
      unitRef="usd">737000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3f5d88c4fc174c4ba4624f3bda26b88f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtOC0xLTEtMjA3NzE1_f158ed3a-58e0-4af2-8b0a-c9e0327f2a20"
      unitRef="usd">741000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3f5d88c4fc174c4ba4624f3bda26b88f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjQtMTAtMS0xLTIwNzcxNQ_1142228b-cfa2-4ea3-b83a-5476bf051144"
      unitRef="usd">737000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i95707314425842cd82eb737ebe900f57_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NWViMTYwYmRhMWZkNDdiYWI4NjkxYTQxNzU5MTk5ZjNfNA_62af9bda-a955-4b18-a605-19050f718854"
      unitRef="number">0.0850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i95707314425842cd82eb737ebe900f57_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtNC0xLTEtMjA3NzE1_ee71e44d-4a5f-4887-9f15-7f9f1235f99b"
      unitRef="usd">643000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i95707314425842cd82eb737ebe900f57_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtNi0xLTEtMjA3NzE1_77e37a41-45cc-4ed3-9f36-a2acb25d406d"
      unitRef="usd">644000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i99d21d625b784308ba11c8058938ddbe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtOC0xLTEtMjA3NzE1_211a91bf-6a1f-4a76-8915-54864c07b8a6"
      unitRef="usd">643000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i99d21d625b784308ba11c8058938ddbe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjUtMTAtMS0xLTIwNzcxNQ_eba9a44a-a989-4679-98ad-75f18359c009"
      unitRef="usd">644000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i798ef0f209fb49009a6ca1d36a285f67_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246OThjYTlhY2MyZDZlNGJiN2EwYzI0YmFmN2EyNDdkNThfNA_dd25b366-93a5-4072-95d8-d2a82d2fd024"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i798ef0f209fb49009a6ca1d36a285f67_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtNC0xLTEtMjA3NzE1_41fc640a-541b-45ad-bb9b-f47633f28894"
      unitRef="usd">171000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i798ef0f209fb49009a6ca1d36a285f67_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtNi0xLTEtMjA3NzE1_ed63cf32-2056-41aa-bb1c-92d62edc0743"
      unitRef="usd">170000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a65dde3c3aa45549c7496b96199b6f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtOC0xLTEtMjA3NzE1_04a6cfc6-012b-4085-accf-e40d2d7a252f"
      unitRef="usd">171000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1a65dde3c3aa45549c7496b96199b6f8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjYtMTAtMS0xLTIwNzcxNQ_1ab1826c-d3c4-4971-a0a4-bc19a5b04656"
      unitRef="usd">170000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icd0cd3f81eb14fbb885bef7666346a89_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NDNmYWFhYzY5NThkNDU5MGFmNmQ1M2FhZjUzOWY1ZjBfNA_02096e6b-ddcb-417b-8418-e91bfe20d7aa"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icd0cd3f81eb14fbb885bef7666346a89_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctNC0xLTEtMjA3NzE1_52e69f41-84e4-4fa3-a475-bce6db4704a7"
      unitRef="usd">433000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="icd0cd3f81eb14fbb885bef7666346a89_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctNi0xLTEtMjA3NzE1_9283fc7c-50c7-4e1a-a13f-5c49778f0ffa"
      unitRef="usd">430000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ied3ed0b49365444fad700d85b63bf260_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctOC0xLTEtMjA3NzE1_bd0ee41d-23bd-42e9-bd82-2ab14aa270bb"
      unitRef="usd">433000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ied3ed0b49365444fad700d85b63bf260_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjctMTAtMS0xLTIwNzcxNQ_f960d0a3-ba2b-4ad4-86a9-42e818728b09"
      unitRef="usd">429000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i50270179827249f7adf2f7e4718cc6cb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246MjQwNzkwMzdjYmJlNDM1MWI2NGI2NjFhZjgzMjk4OTdfNA_735685e1-fd01-48ed-a090-1daf9d1511ac"
      unitRef="number">0.0625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i50270179827249f7adf2f7e4718cc6cb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtNC0xLTEtMjA3NzE1_3bf5e973-9f0b-46e2-8492-bbb2630b071d"
      unitRef="usd">821000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i50270179827249f7adf2f7e4718cc6cb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtNi0xLTEtMjA3NzE1_69997a5c-a382-4f76-9a52-72fb3a460f71"
      unitRef="usd">813000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iff54ecadaabf473d8116b32464b6b6a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtOC0xLTEtMjA3NzE1_0ee97204-9cbb-4761-bd23-e6250e28c5a4"
      unitRef="usd">821000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iff54ecadaabf473d8116b32464b6b6a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjgtMTAtMS0xLTIwNzcxNQ_d754ec01-3825-4a2e-a8b9-9c0ae64ed344"
      unitRef="usd">813000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktMC0xLTEtMjA3NzE1_fc1f601a-30b9-4984-afce-f8b3c24d0b65"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktNC0xLTEtMjA3NzE1_fec31d44-0585-4288-a0b0-e549d05f2d32"
      unitRef="usd">452000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id42e9954f9204c6c9fa1cc39133ab7d2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktNi0xLTEtMjA3NzE1_f67507c2-aa3d-4557-b32a-abbafd63e4e5"
      unitRef="usd">448000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2a7af656ef0f457484bd906468e5c84f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktOC0xLTEtMjA3NzE1_a581d02d-694c-42c7-bd80-118997c6d55e"
      unitRef="usd">452000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2a7af656ef0f457484bd906468e5c84f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMjktMTAtMS0xLTIwNzcxNQ_bbd1be48-d915-41ee-9899-65d41a652f95"
      unitRef="usd">448000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id1ae1e47647b4e16abae2c02f07359b3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NDNjYWYxYmMxMzMzNDI3Yjk2YTAzMmYwY2JjMGY1MTlfNA_eb0a1b58-1ca9-41db-92de-d6c6822cb72e"
      unitRef="number">0.0725</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id1ae1e47647b4e16abae2c02f07359b3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtNC0xLTEtMjA3NzE1_31ad8ef7-769c-4728-bb53-6d9c1b976980"
      unitRef="usd">337000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id1ae1e47647b4e16abae2c02f07359b3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtNi0xLTEtMjA3NzE1_52e84f0f-8d58-469b-830a-5d1969528946"
      unitRef="usd">334000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i98cbac4569eb4a4897d65431dc5af7a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtOC0xLTEtMjA3NzE1_003d0bd6-fdad-43cf-9afe-0d16d8bd1516"
      unitRef="usd">337000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i98cbac4569eb4a4897d65431dc5af7a6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzAtMTAtMS0xLTIwNzcxNQ_97646730-7125-4b32-a111-b8b790f0c11d"
      unitRef="usd">334000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i513ab91ef61a48c09cebf7bccfcc7994_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtMC0xLTEtMjA3NzE1L3RleHRyZWdpb246NjZmYTMwZDMyYzM0NGQ2YWEyNDM5NTY4ZjM5YjFlYWJfNA_a38f0550-fb83-4074-ad22-89c2f4f7597e"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i513ab91ef61a48c09cebf7bccfcc7994_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtNC0xLTEtMjA3NzE1_b38a08eb-b07c-47ab-9ef4-876a2ae696b8"
      unitRef="usd">779000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i513ab91ef61a48c09cebf7bccfcc7994_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtNi0xLTEtMjA3NzE1_03760f0e-4016-47f3-8d28-c6632f0af5ea"
      unitRef="usd">772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i80d700d6fa904cbabe449baab21de04e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtOC0xLTEtMjA3NzE1_073f6622-c50f-4095-9d32-db8247f792c5"
      unitRef="usd">779000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i80d700d6fa904cbabe449baab21de04e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzEtMTAtMS0xLTIwNzcxNQ_d2028ee0-23c8-43c7-aac7-fdf7659912bd"
      unitRef="usd">771000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItMC0xLTEtMjA3NzE1_88dcdc71-74ea-4300-ac9d-7f26ac5cf47e"
      unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItNC0xLTEtMjA3NzE1_0ca40d85-4280-495e-8d99-1a919ea02062"
      unitRef="usd">462000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i99abed0d9c0a43279f51f5365f8c9bbd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItNi0xLTEtMjA3NzE1_369a616e-8300-4185-bc86-a50ea78dc5bf"
      unitRef="usd">458000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i573bed6abe6342a9a2cca0beda4b3a3d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItOC0xLTEtMjA3NzE1_0bfdc73d-ff26-4974-9b6e-098153e6fc16"
      unitRef="usd">462000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i573bed6abe6342a9a2cca0beda4b3a3d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzItMTAtMS0xLTIwNzcxNQ_ff761ef5-ce0f-49d0-8284-840982bed5ad"
      unitRef="usd">458000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iaf7970cd462c4d338f9b250f47fc2cc7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtNC0xLTEtMjA3NzE1_9d21b596-871a-44a4-86d3-07521f26e442"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iaf7970cd462c4d338f9b250f47fc2cc7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtNi0xLTEtMjA3NzE1_431af295-afa3-46cc-ab86-4cf1422486eb"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2e2b7f1301cd4d6580b57be2d9bceba4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtOC0xLTEtMjA3NzE1_f959d39a-09e4-4781-aefe-6148d9603d14"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2e2b7f1301cd4d6580b57be2d9bceba4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzMtMTAtMS0xLTIwNzcxNQ_323dc1c1-a290-4677-ac91-72f946c15bf2"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtNC0xLTEtMjA3NzE1_48203210-5e4a-4d91-aec2-e4c54ee1c81e"
      unitRef="usd">19097000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtNi0xLTEtMjA3NzE1_f7c59c01-6f1c-4e1f-bb1a-48d2c669d2c0"
      unitRef="usd">20653000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtOC0xLTEtMjA3NzE1_e13d79bf-4cd9-4b11-a245-4bb3790bf476"
      unitRef="usd">19110000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzQtMTAtMS0xLTIwNzcxNQ_3f03e21f-af71-42fa-9995-90916ac1209f"
      unitRef="usd">20766000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzUtNi0xLTEtMjA3NzE1_99e2f1b4-fdce-4caa-89bf-61292bd8d474"
      unitRef="usd">446000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzUtMTAtMS0xLTIwNzcxNQ_1132080c-5e0e-496b-a9a7-34f313aa2470"
      unitRef="usd">432000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzYtNi0xLTEtMjA3NzE1_85b2c59d-c4d9-46c7-b434-a4cc4632c438"
      unitRef="usd">20207000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOmI4OWQ5MTYzYTgwNTQ2MzY4M2VkYjY3MDkxYzBmZDdjL3RhYmxlcmFuZ2U6Yjg5ZDkxNjNhODA1NDYzNjgzZWRiNjcwOTFjMGZkN2NfMzYtMTAtMS0xLTIwNzcxNQ_e8bda97d-d817-4c99-8152-cd8e12973c5c"
      unitRef="usd">20334000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNDEx_24bdc09e-5663-442a-853f-9a7a2a4036f9"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments
      contextRef="i6d23cbe1712d416fb576aaa815a0484b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQwMA_2ec3f019-b301-454f-a0bd-f63525f4b125"
      unitRef="usd">9700000000</bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="i0f2be8ab73b940ed95457d1d1dafe5af_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQ3Nw_baca9bdf-c77b-4075-96d8-85a14dfa881c"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio
      contextRef="i0f2be8ab73b940ed95457d1d1dafe5af_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcwNw_43284904-2dd1-4e13-b9a7-2fcaadc4bacd"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantComplianceSecuredLeverageRatio>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="if7d45443ba5c4563bf3b25ec62964df1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjg0NA_f5370a51-820c-4885-9089-70012df35887"
      unitRef="usd">5594000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5debb458ebf44991aaa7a159d30b758f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjkzNw_594d7e6c-6c14-4cb0-9164-3a96d6eaa8d5"
      unitRef="usd">3125000000</us-gaap:DebtInstrumentFaceAmount>
    <bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal
      contextRef="i5debb458ebf44991aaa7a159d30b758f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzA0Mg_c85f209b-5c17-4f6a-950c-0280c58d9355"
      unitRef="usd">2469000000</bhc:DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzEwOQ_ef805005-f373-423d-9a7d-1eaea8dce2f7"
      unitRef="usd">1774000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzE0OQ_ebca46a8-742b-461d-a803-9acd67ae951f"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzE5Mg_96f09445-7e44-4491-b6af-46a08dab5e94"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i17d52fbe0aac4ea784789ee582df1295_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzI1MA_d59e5368-4244-45b5-b8ac-cd77c80ff74b"
      unitRef="usd">352000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17d52fbe0aac4ea784789ee582df1295_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzI5MA_f09bf0bf-ec30-4b33-b9b2-e70575bc0a6b"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i17d52fbe0aac4ea784789ee582df1295_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzMzNA_dff46df1-876b-40d5-bc4f-67c5e9967377"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65c38375327d4fa899cba5594e9d68b1_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM4Nw_66d21910-0abe-4c0a-8b20-c36a8f1619ba"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i903eec80383246d8b63564df58e178c8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzQ3Nw_785b683e-eb19-4a02-88cf-39207e8731da"
      unitRef="usd">999000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i903eec80383246d8b63564df58e178c8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzUxNw_7c01a166-d002-4b3e-b0e9-0b30cca70e22"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i903eec80383246d8b63564df58e178c8_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzU1Ng_72c22b67-5533-4b7a-b42c-7850a2651322"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i248fddc88f4a495caa1b4df3c4650cee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzgwMg_6df7afe0-ef5f-42a4-a6ff-fda21bfe47be"
      unitRef="number">0.386</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="i837a88fd5e964623b1aadc43f080279c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjE5OTAyMzMxMzI4MA_1adb2c2e-b099-4176-a49d-8491cb062ab8"
      unitRef="usd">1835000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:InterestPaid
      contextRef="i8a389a27060343e5b22dc6da4936a17a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODY4MzEz_0280af06-2f31-4799-a2dd-de9e5145a971"
      unitRef="usd">128000000</us-gaap:InterestPaid>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i8a389a27060343e5b22dc6da4936a17a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODY4MzI3_274bd015-ec46-404a-af90-dfae3063ecf7"
      unitRef="usd">-111000000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icbfe4cdc452d465ebd08f232cee67b17_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNzQ4MQ_27c0b5c9-fcc7-45aa-8b5e-d1d6238d75ba"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if38bd752f2804e82b66372aac33a299b_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNzgzMg_13460a37-c7d9-4ac6-a0b3-9724e6ae0b62"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i36d1ec0044004c3e9a1bd3cdc1fdd988_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNzgzOQ_7cb53941-8f5b-4d32-bb3e-9f0097a13061"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib2a4f5fc4d13488fa1eb6879e85815a5_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODQzNg_1566d55b-fde9-4766-b50d-0fa590a9b2e8"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODU0MQ_43e3d793-80be-466d-9f08-703ea0b12c5d"
      unitRef="usd">975000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="if6aef544f55e4d479ca0c5fdb0d3ac29_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODY1Ng_ff2962ea-d4ea-424f-8e4b-95185fe418ef">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfODgwOQ_59c17294-4899-4f90-9cf1-b62513d83712"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2263e23bd8e642778b2df9b8853237be_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzNTM0_053c054b-3cad-4bff-8b24-3d97ec689a93"
      unitRef="usd">395000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i69b14ba8ead54d019ac598383a31b62d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzNTQ4_14805d52-e0ae-4ebb-9021-fbf61573e3e1"
      unitRef="usd">23000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iae292b83994f4eaa9429e631a6fdf509_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTAwNDA_720ac605-5aaa-4e79-9aa0-ff98186f052b"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable
      contextRef="i1aa16e6b0d894c1dada5fbfacfcbe3c9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTAwODg_73ae2068-b691-4fb4-ba8d-0236e646527f"
      unitRef="number">0.0150</bhc:DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="icc18552483b945af9947da7d748f3797_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTAyMTE_483d89b6-e799-4642-8d18-f7be4b961ad3"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i941c4bbefa5240ef85c8e4f4ab0ca948_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTA0NjQ_5b81d311-76c8-4d2e-a345-174670b9c0b8"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib4c6dcc61b60403380d1c1c8b2e65827_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTA5MDM_541213b8-124b-4da8-af41-a4402bfc5f44"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i941c4bbefa5240ef85c8e4f4ab0ca948_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEwMzU_67705680-6221-47a6-8527-282b7cc4c97a"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i10b0cd89c2794a4a8c71d587e55cec38_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEwMzg_9fefe3c6-9140-469a-a67a-aff2a08a97cd"
      unitRef="number">0.0025</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1aa16e6b0d894c1dada5fbfacfcbe3c9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTExMzI_f9d4b133-bb38-4072-98ed-a726cdab4f8c"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9c472af859db4ef39a87c178260df1d4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTExNjQ_ac0451ea-7933-44de-9170-43d0e10d2aa3"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3e11f388f2ee40dcbd589e6df1e9378c_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzMDQ_d11f7cf7-5bd2-45eb-8a6f-3bae64cd0309"
      unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6752a30275734197a62fc5a9b8672ce1_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzMTA_7b8043ca-6074-4472-80aa-86efb994e9f2"
      unitRef="number">0.0525</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ief7bb320564f4aceb4edc483cb34a747_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzNzU_f9a7baa3-e9f8-4090-a02c-8635ebec3917"
      unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i577454bd748e4d5a8c05a2a6ddfbd23a_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTEzODE_197d17d2-d2b9-4181-abd2-b7a5563de159"
      unitRef="number">0.0425</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i3948c6f5951248dfa12e05ac7dbbe705_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTE1MTA_3d850af6-7b89-4ab6-885c-e7449e56af61"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i9e21098d0ad2484097856f68e1b275a2_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTE1MTM_6ac98732-f6ad-4749-b5d4-fa9e1761cde3"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTIzMDM_d49b8631-e56c-4403-a9d8-1e1080bc2069"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTI0NjY_b2604d9f-dec4-462f-90d7-932f963db6b6"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTI2MDc_9bbbbb0c-c0e2-4066-b2f8-a98bc172d294"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="ie8ec7b1f781d4b59bb8cdc8c72d7b574_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTI3Njg_9511892c-7eb6-4f38-bab5-8a57249aa7b7"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="ib2a4f5fc4d13488fa1eb6879e85815a5_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTMwMDM_8ce6fe0a-7cc0-444d-8c0b-fedfe4278e26"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="if0cbf9921846406db6bd00b95257c769_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTMwMjA_4127b252-e490-400a-a3d6-b6ddf078ecd7"
      unitRef="usd">125000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="icd9fcf0826bd4e36b2683c1eebfca266_D20230331-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTMyOTk_3fa9276f-033c-4ae2-b75d-341257c13ceb"
      unitRef="usd">469000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM0NDU_3036f51c-e45b-4136-940f-b0e755728472"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage
      contextRef="if6aef544f55e4d479ca0c5fdb0d3ac29_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM0NTI_901843f2-c6a7-437a-9d5d-a7b054706379"
      unitRef="number">0.40</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i56fcb41cb5a94e678206e69414bc0b5d_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM3NTc_a6af77fb-dc44-4a9e-8a69-7a33f1aa8519"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="if2d58899a97e4cab97bd1a214b38f6cb_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM4NTI_042c3175-c072-4b9a-881c-40753f9d47d8"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i74a383df89994d61aacc54ce4b2086ff_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTM5MDc_8681b52f-1003-451b-b54f-b6686af96053"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="i84889b9489a14e36877c0478bea79508_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQ2MTQ_99cfe1e6-0400-4670-a2e7-28455dbc3d4d"
      unitRef="number">7.60</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="i6c18712f4b5d49ac81d008a300ff10e9_D20221129-20221129"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjE5OTAyMzMxMzI5Ng_4cceba36-65e7-4414-94fc-94f9f35319f9"
      unitRef="number">0.89</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib21fed5341d54d0e89405e700d2488cd_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTQ5OTI_70084623-6b52-4631-accf-aacda9d91154"
      unitRef="usd">2500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="i70d7dc79e80f485e9b0e3247e4c85728_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5NzU_af75a741-a66e-4053-941b-9f3dc7ceb2e8">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5OTg_8a2b14f9-d891-4ed8-91e2-d292f716c6fd">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3edcc26eaf534e8eb544ca874238a97e_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTUwOTY_0348629c-b869-4e28-ad6e-f018cfaf5afa"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i73805f2008b0493784b73a6e474d0511_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjE5OTAyMzMxMzQ0OQ_b4eb65be-7923-4f67-9854-9549c801475f"
      unitRef="usd">100000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1dd01cd11a7445c4a00b066d23512c4f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzODE5_9d2c7a72-a345-494c-8554-5b8db01d1925"
      unitRef="usd">24000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i73805f2008b0493784b73a6e474d0511_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfNTQ5NzU1ODYzODMy_30d96ab2-f8f9-4499-bb4c-5d8d03f759a9"
      unitRef="usd">376000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i8621c3667fbf460daa121b9c4ae610ed_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTY4MjI_1bbaaf1c-4aa0-48e9-b79c-de4bfa7e7fe0"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie155f835e73f43c0a0a7a12dcfe3ddb7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTY5MzQ_97b30c28-a014-41aa-a54a-52d1bc7fb57c"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i510257e58ffa4decb28c62ab425bbac7_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcwNjk_576c3689-b3de-4852-b96d-7b51b6421710"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0248ec1e93ba4d7ea8d09b465512a94f_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcxODI_c5d83383-da07-4d77-8608-60ca639d3957"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i1922ecd18a2e46a48b9820d0ee052834_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcxODg_d0f500d0-94eb-45eb-9d68-d911ee3f8229"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9e35bf60d1c341548e91652443b6c303_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcyODI_b31115e4-3a02-49ba-895a-2d70ed4e1663"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id29818a3e24849c9872d1d9f53ab8b00_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTcyODg_06e207f6-1c52-47fe-9107-6fa172264089"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if67b7c28c9224ebf8f9b868d72b01bf9_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc2ODI_82ac0ec0-3f33-4028-8db4-03bf29439d38"
      unitRef="number">0.00015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6520558979e64b11a055e7cb64fefcb3_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc2ODg_5968df55-a49f-4a60-bedc-a7b6516a09d6"
      unitRef="number">0.00475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i07b28056246f43a38618df0e494a97e4_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc3ODI_dbf8c104-a2a1-4f0c-a3be-f624c577e38e"
      unitRef="number">0.01015</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3f67059f3db74cc48b901c7b97bad681_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc3ODg_ef97a816-ca75-466f-9c5b-42aca668c9c5"
      unitRef="number">0.01475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTc5NTA_f93fdde7-2701-4c22-adc5-301d46473d93"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ia22c0fcb53a541a5b34a13bce7623b83_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTgxMjI_e51ba08e-9e22-43c2-a821-2e81cb584054"
      unitRef="number">0.00110</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i10bb7c9cf0764db899519673b3e54aa0_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTgxMjg_2be75a5f-ed47-4622-b8df-1c52fcd78a62"
      unitRef="number">0.00275</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i2a2772683b4144eb8f2ccc0181cce01e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTg4MjY_f57e24c6-c276-4254-aca6-3d5f5667a03f"
      unitRef="number">0.0325</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia7f2841ca1e44cdc95d5d3f351c569c0_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTg4OTE_089eb2e2-6aa4-42c0-bb9f-6334065e5297"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i79f18a15a09b463389c535fe19ade465_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTg5NjY_748a5564-67d4-4473-81bf-c5f1b06c42b5"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ib0cba2f234984f27bed6d219b8e46492_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTkwNDU_2d556417-7c89-4967-89b6-0173e367267e"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate
      contextRef="i2a2772683b4144eb8f2ccc0181cce01e_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTkxMzk_fa3ff459-742d-4a21-8a0e-22e88d40b1c3"
      unitRef="number">0.0010</bhc:DebtInstrumentCreditSpreadAdjustmentOnVariableRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2f96c4977bdf4527aca21c11e00b2edf_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTkyMDU_41e0a6db-ab53-4aad-87c3-578182937a3f"
      unitRef="number">0.0846</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk0NTY_5d389e54-b5b9-462c-b61f-b6ce5fe7e140"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk2NTM_43a18996-7e44-45f9-ba52-d877d58db7c5"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk3ODU_28a8ab59-8e2c-49d5-888d-63c2695a1242"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="i9fefc33381e146a6ae2f749eba083937_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMTk5Mzc_c921b1ed-f53d-4bb3-8bdb-db6ed6c41f6e"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="ib21fed5341d54d0e89405e700d2488cd_I20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjAxOTc_5dcc62be-0715-45a8-9ff0-8aca6b038e3d"
      unitRef="number">0.0100</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="i70d7dc79e80f485e9b0e3247e4c85728_D20220510-20220510"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjAyMTQ_d7624889-e4d6-4c7f-8ae9-3af06a25dde3"
      unitRef="usd">25000000</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization
      contextRef="iba4accda99c8474fb514ff5e90f2c9c5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjA0NTU_add23be9-324e-40ac-9e56-68add53476bf"
      unitRef="usd">100000000</bhc:DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id65c9d3aa0e147cbbacd4d3353c0d376_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjA4NDc_8435b32f-c333-43df-9e9b-e73ee40be2a9"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjI5OTE_aa970314-9ee5-4746-a8d0-e51f301583fc"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjQ4MDM_1c2f9082-e928-4634-a76b-e356b4981a76"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjQ5MDM_7085e4fa-1410-4d96-b42f-dc3207b27f0d"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjQ5MzY_81570c11-df37-440c-9fab-e53b74076a1c"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i031f71ba66044feeb7830f5561dbd4bb_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjUzMzg_81570c11-df37-440c-9fab-e53b74076a1c"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i547ceb5147ad4e2db654418ebe7f7568_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjU3MTc_5e87e565-8617-432e-9728-f212a70e3eb6"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i52c91df8447249489b14e04f36239c8d_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjU4MzQ_7b364223-a94a-4050-a025-b1b1c4c03938"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYwMzI_965f5ba0-7e7e-43f0-9188-cdb68b63ec19"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYxMTM_2ca6b081-cd16-4ad7-93f2-b2b5ae73e414"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYxOTg_1e2985e1-ce49-42c0-bdeb-a131a1be9991"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie985a1f2ae2940ddaae3a79acd52e7d2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjYyOTU_5bfb9c21-c2d6-424f-8418-b606754c80a0"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i016ac45dbd954b42a38d2dbcdf824196_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY0NTg_f691862d-8ed8-4d5c-bfaa-8cc64ea4c18e"
      unitRef="number">0.1100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY1MDE_ec24595f-002b-4cc1-9aca-2d800f6be8d2"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY1ODE_2261758b-aec4-4f08-998e-f11df37ea72e"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY2NjQ_311c68cf-b112-4011-bf62-a83c8c7c6f6b"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY4Mjg_5707cc94-1b52-41df-a434-3b75ed2d4b83"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY5MDA_9f1baf9d-80fd-474e-9a20-27f61ba4deca"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if0760722bf5d4183839a587492c1db15_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjY5OTE_3e896990-a0d2-401c-abcf-c978c08fc47b"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjcxNTQ_d51f8d35-1601-4a53-aad6-daf0f64ae2c3"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i860c8720321c489a82c36ce3d3e91c8a_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjcyMzk_8eee0f6f-5c10-4c26-99c6-2ee5fcd1faf6"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjcyODM_68a7ec08-1afb-4d9b-8091-3db605dd693b"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a5b69b0416d497d8056a590118b802a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc0MTk_4b21be76-1b1c-4af4-aaef-50d362cb2a02"
      unitRef="number">0.1400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc0NTk_bfe4e377-b2a1-45cf-812b-fc4e29f5d952"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc1MDc_290da399-aa0b-42cb-be7e-7928ead98398"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc1OTU_49a52332-2d1f-4b7b-af31-63c4fade2d20"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc2Nzc_9120af08-8873-40f0-a47c-e36770f603bf"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc4NDM_33c2750a-4b0d-40fd-b8f6-d1c547cf6f88"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjc4OTY_8f5dbbde-4382-42e3-8f85-f8150e24c98e"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="id094eccb229a4fd2b63155f5f349149b_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjgxOTc_f07b1f2a-cc3d-4fee-8c5e-3ba8325f2679"
      unitRef="number">0.386</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjgyNzg_15f3d302-d215-4e44-a610-f72ab8c73db3"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjg2Mjg_8f5dbbde-4382-42e3-8f85-f8150e24c98e"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i05ac9da4a9e044b0b3404afa13818036_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMjg2NzU_8f5dbbde-4382-42e3-8f85-f8150e24c98e"
      unitRef="number">0.0900</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i089a9da68a994aa6a72f9953208ab0d3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzAwMDc_39cc3420-108f-4c31-ae71-ec3979c6a8c2"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i970ab9f80f5f40959c2ab1571822b0d8_D20220510-20220510"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzEyNjY_7c736efc-2ccd-4f38-ad83-3fdcfeb48de6"
      unitRef="number">1.01021</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzIzNzY_4a4116af-c341-4af8-8fb9-2a8550fbcaed"
      unitRef="number">0.0787</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzIzODM_143ca549-caae-4149-b509-2e5e74db6a89"
      unitRef="number">0.0774</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RleHRyZWdpb246OTFhMzBjZmFhZWUyNGJhYzkyOGMyZjJkMTEwZTg0MjdfMzM5ODI_4eb830c7-3b44-41ee-b48a-7dd662a32a39">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of debt obligations for the remainder of 2023, the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized premiums, discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMS0xLTEtMS0yMDc3MTU_b2522b48-4934-470f-9c2e-4f36fb3211c3"
      unitRef="usd">113000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMi0xLTEtMS0yMDc3MTU_eefdd04e-e2f2-40b3-a748-2652ae249cd8"
      unitRef="usd">150000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMy0xLTEtMS0yMDc3MTU_a3215e31-f1ac-45ff-8d97-1451102b9bfe"
      unitRef="usd">2789000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNC0xLTEtMS0yMDc3MTU_bd0359f6-9f74-48bd-9fe6-7ae127f9ed58"
      unitRef="usd">891000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNS0xLTEtMS0yMDc3MTU_44487fce-51c0-4ba7-ab75-31011be2bc51"
      unitRef="usd">6962000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNi0xLTEtMS0yMDc3MTU_572ea5b2-cab7-4aba-87ff-b27195860abb"
      unitRef="usd">4990000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfNy0xLTEtMS0yMDc3MTU_facf4a5c-f9f3-48f2-9ea8-91b2120ef84a"
      unitRef="usd">3202000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfOC0xLTEtMS0yMDc3MTU_7fc2a04b-7acd-49fb-baed-22749e5a2748"
      unitRef="usd">19097000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfOS0xLTEtMS0yMDc3MTU_9711e22c-897b-42df-ae56-9fc60cfa9d4a"
      unitRef="usd">-1556000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF82Ny9mcmFnOjkxYTMwY2ZhYWVlMjRiYWM5MjhjMmYyZDExMGU4NDI3L3RhYmxlOjRiZTAzZTVmNjk2MDQxYWE5NDcwZDcyNzYxYzdkNjY4L3RhYmxlcmFuZ2U6NGJlMDNlNWY2OTYwNDFhYTk0NzBkNzI3NjFjN2Q2NjhfMTAtMS0xLTEtMjA3NzE1_f7c59c01-6f1c-4e1f-bb1a-48d2c669d2c0"
      unitRef="usd">20653000000</us-gaap:LongTermDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODM4Ng_ccf4305b-2e64-4d24-af21-e23239bfe389">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch Health&#x2019;s Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2014, shareholders approved Bausch Health&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;) which replaced Bausch Health&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was initially equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares for issuance under the 2014 Plan. The 2014 Plan was amended and restated effective April 30, 2018 and April 28, 2020 to, among other things, increase the number of common shares authorized for issuance under the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective June 21, 2022, Bausch Health further amended and restated the 2014 Plan, as subsequently amended and restated (the &#x201c;Amended and Restated 2014 Plan&#x201d;). Such amendment and restatement increased the number of common shares authorized for issuance under the Amended and Restated 2014 Plan by an additional 11,500,000 common shares, among other things.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 9,527,000 common shares were available for future grants under the Amended and Restated 2014 Plan as of March&#160;31, 2023. The Company uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch Health has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on generating operating cash flow while maintaining focus on improving total shareholder return over the long-term. The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based restricted share units (&#x201c;RSUs&#x201d;) and performance-based RSUs. Performance-based RSUs are comprised of awards that vest: (i) upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;), (iii) upon attainment of Adjusted Operating Cash Flow, as defined in each applicable award agreement, and a Relative Total Shareholder Return modifier performance metric and (iv) fully or partially upon attainment of certain goals that are linked to the B+L Separation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to retain and incentivize certain members of the Company&#x2019;s senior leadership team, on September 5, 2022, the Talent and Compensation Committee of the Board of Directors approved a retention program for certain executive officers and other members of leadership. Under the retention program, certain executive officers and other members of leadership were granted a one-time award of restricted stock units (the &#x201c;Retention RSU Grant&#x201d;) under the Amended and Restated 2014 Plan. The Retention RSU Grants will generally vest in 1/3 installments on each of the first &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzEyOA_7d8122c2-092a-4cd8-b6dd-b57d32d9fc25"&gt;three&lt;/span&gt; anniversaries of the grant date based on continuous employment with Bausch Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bausch + Lomb Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to May 5, 2022, Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb participated in Bausch Health&#x2019;s long-term incentive program. Effective May 5, 2022, Bausch + Lomb established the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan (the &#x201c;B+L Plan&#x201d;). A total of 28,000,000 common shares of Bausch + Lomb were originally authorized under the B+L Plan. Effective April 24, 2023, the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shareholders of Bausch + Lomb approved an amendment and restatement to the B+L Plan to increase the number of shares authorized for issuance thereunder by an additional 10,000,000 common shares, resulting in an aggregate 38,000,000 common shares of Bausch + Lomb authorized for issuance under the Plan (the &#x201c;Plan Amendment&#x201d;). The B+L Plan provides for the grant of various types of awards including RSUs, restricted stock, stock appreciation rights, stock options, performance-based awards and cash awards. Under the Plan, the exercise price of awards, if any, is set on the grant date and may not be less than the fair market value per share on that date. Generally, stock options have a term of ten years and a three-year vesting period, subject to limited exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 9,300,000 Bausch + Lomb common shares were available for future grants as of March&#160;31, 2023. This does not include the additional 10,000,000 common shares authorized for issuance under the Plan Amendment. Bausch + Lomb uses reserved and unissued common shares to satisfy its obligations under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s focus on enhancing its revenue growth while maintaining focus on total shareholder return over the long-term. In addition to stock options and RSUs, during the first quarter of 2023, performance restricted share units (&#x201c;PSUs&#x201d;) were also granted. The PSUs are comprised of awards that vest upon: (i) achievement of certain share price appreciation conditions, including absolute and relative TSR and (ii) attainment of certain performance targets that are based on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s Organic Revenue Growth. If &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s performance is below a specified performance level, no common shares will be paid. Each vested PSU represents the right of a holder to receive a number of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s common shares up to a specified maximum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each TSR PSU granted was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved. The fair value of the Organic Revenue Growth PSUs is estimated based on the trading price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s common shares on the date of grant. Expense recognized for the Organic Revenue Growth PSUs in each reporting period reflects &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Bausch&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; + Lomb&#x2019;s latest estimate of Organic Revenue Growth in determining the number of PSUs that are expected to vest. If the Organic Revenue Growth PSUs do not ultimately vest due to the Organic Revenue Growth targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2023, Bausch + Lomb announced the appointment of Brent Saunders as its Chief Executive Officer, effective March 6, 2023. Pursuant to Mr. Saunders&#x2019; employment agreement, on February 23, 2023, Mr. Saunders was granted the following equity grants: 750,000 PSUs, 1,318,681 stock options and 375,000 RSUs. The RSUs are scheduled to vest 50% on the second anniversary of the grant date and the remaining 50% on the third anniversary of the grant date. The stock options are scheduled to vest in equal one-third installments on each of the first three anniversaries of the grant date. The PSUs vest on the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDI0NA_b622811e-eab0-4467-ba1f-ded7a871e35c"&gt;four&lt;/span&gt;th anniversary from grant date based on Bausch + Lomb&#x2019;s achievement of absolute share price hurdles, or upon achievement of absolute and relative TSR hurdles in relation to the S&amp;amp;P 500 Index during the four-year performance period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of the Company&#x2019;s share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the three months ended March 31, 2023 and 2022 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch Health Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted Operating Cash Flow performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch+ Lomb Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,358,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Organic Revenue Growth performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs amounted to $216 million, which will be amortized over a weighted-average period of 2.31 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the remaining unrecognized compensation expenses related to all outstanding non-vested stock options, time-based RSUs and performance-based RSUs under the B+L Plan amounted to $118&#160;million, which will be amortized over a weighted-average period of 2.49 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i85b588e044c940eca8328840cfc28748_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNDg5_17676023-19d3-4fef-a36c-b8697255a48f"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i85b588e044c940eca8328840cfc28748_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODQ5_2f88d222-ea60-4f01-8c6e-d70cf00c7fd9"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i3c45857d12dd4d23981e438c843ec5cc_D20220621-20220621"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTQwMQ_69a432c6-c3fa-40d3-8e6a-dc1d4de6fa3f"
      unitRef="shares">11500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9a72442b14b74396a03e29bc48cf80d5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTQ1Mw_c07f5c30-cca7-4212-9e9f-670bbad5e3cd"
      unitRef="shares">9527000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ia05b5bf3a3e34503a29b0b66b71f201e_I20220505"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzQ4Ng_45ea6103-70db-4629-80d3-eabb14bc05c9"
      unitRef="shares">28000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ieb50a893b673454784c495a665d8a5a8_D20230424-20230424"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNTQ5NzU1ODM3NTAx_c34ff608-1523-4be9-8c1e-e99df33a1f94"
      unitRef="shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3863db1d928d4e059096c4ab578fc383_I20230424"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNTQ5NzU1ODUyNzg3_4d70c787-cf88-4f59-969e-d88218a2984a"
      unitRef="shares">38000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i8868f6921a25423eaf40a6f726a3c0f9_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMzkwOA_fca1bc3e-7c2e-449b-819a-61a6fefe0db2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8868f6921a25423eaf40a6f726a3c0f9_D20220505-20220505"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODM5NQ_ebff93df-62cf-4dc5-bae2-f63e12688c98">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i095b974a4eda46539b55e501e35cecd5_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNzQ1MQ_d13e77de-8dea-4b06-8223-4a9bc52c4267"
      unitRef="shares">9300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ieb50a893b673454784c495a665d8a5a8_D20230424-20230424"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfNTQ5NzU1ODUyMjgx_a9ab04a3-ff96-4301-9b8e-8f56983933b6"
      unitRef="shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTU4MA_72678dd8-833e-4185-9982-1706fcdfd233"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7a7df102d4344988ae96ebc9a50e6c5f_D20230306-20230306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTU5MA_e442b67c-c406-479c-b003-ca8708587c7a"
      unitRef="shares">1318681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id24036d8d6074ecdacda84c97de2156f_D20230306-20230306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTU5OQ_561c530f-abdd-4f31-88ed-51c79acdc100"
      unitRef="shares">375000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i57dc496593aa4b0eb2e9577518a5942f_D20230306-20230306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTYxNw_ffde8ac3-d5d1-4473-aea7-1799cb965340"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7e8032e2d6aa4162adae2cb4b0bb8097_D20230306-20230306"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMTA5OTUxMTY2MTYyMg_1696517c-3a24-44d9-b39c-5a1035b2dfd8"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod
      contextRef="i00363a31a35441cf88d43fe668cb51b1_D20230306-20230306"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfMjE5OTAyMzI5NDIyOQ_c2684581-be4e-442c-b57f-d1f7666752cf">P4Y</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODQwMg_eefcd3b8-7a90-4875-9b1a-413373e5b85c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components and classification of the Company&#x2019;s share-based compensation expenses related to stock options and RSUs for the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.429%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMi0yLTEtMS0yMDc3MTU_6521c4dd-81d2-4163-9640-a8395df5e982"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMi00LTEtMS0yMDc3MTU_dc593fcc-3edf-4267-9f2d-35efd43dfa3e"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2c3fa275d2440c596a3bed71d4c3b85_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMy0yLTEtMS0yMDc3MTU_62f01a23-7342-4c4d-bd88-646a571937dd"
      unitRef="usd">35000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2ed2192fcc941a696c261e49cf75b05_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfMy00LTEtMS0yMDc3MTU_204a756d-de0a-4051-bee9-7425bf616cd0"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNC0yLTEtMS0yMDc3MTU_ed418b09-42f6-474f-be75-edce7e63aa1b"
      unitRef="usd">41000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNC00LTEtMS0yMDc3MTU_03172189-d97d-4460-a08e-1abf443e0e61"
      unitRef="usd">32000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i406d990fd1d347fe9b57aac1683865e7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNi0yLTEtMS0yMDc3MTU_877328ed-1d3a-41ef-a78e-1a6568d489d7"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68adcae65fa245a48869470ea3438264_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNi00LTEtMS0yMDc3MTU_ffab2dca-94cf-4754-b269-d44f8dbe762e"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i666b40934018485093be0f36415a1be9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNy0yLTEtMS0yMDc3MTU_a09f01de-92e5-4633-a8c5-a0683cc7ed03"
      unitRef="usd">38000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iac84c79811c44f82877f5606d96b198a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfNy00LTEtMS0yMDc3MTU_7c297dc5-7a57-441a-9fde-384122070a50"
      unitRef="usd">29000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfOC0yLTEtMS0yMDc3MTU_7aa230aa-a899-480c-a7dd-2a25d3e419b4"
      unitRef="usd">41000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmMzM2RiNDgwNmI1ODQyNjFiYjM1N2JiYjMxZWU3Zjg3L3RhYmxlcmFuZ2U6YzMzZGI0ODA2YjU4NDI2MWJiMzU3YmJiMzFlZTdmODdfOC00LTEtMS0yMDc3MTU_95a32731-5eb2-4391-a6fb-7465bc68ce6b"
      unitRef="usd">32000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODQwMw_07ca8c6d-536e-469e-a54d-e5adeda6d947">&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based awards granted for the three months ended March 31, 2023 and 2022 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch Health Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted Operating Cash Flow performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch+ Lomb Share-Based Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,358,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TSR performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Organic Revenue Growth performance-based RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMy0xLTEtMS0yMDc3MTU_fd5614d2-e7df-49cd-a2b1-73108303897a"
      unitRef="shares">999000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMy0zLTEtMS0yMDc3MTU_e74ec52a-583f-4b19-93f4-fec2583e39ca"
      unitRef="shares">2545000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNC0xLTEtMS0yMDc3MTU_70214da9-7055-43a0-8e20-cc00a51b0358"
      unitRef="usdPerShare">9.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNC0zLTEtMS0yMDc3MTU_877af579-af03-4a3e-84dc-80af77432551"
      unitRef="usdPerShare">24.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNS0xLTEtMS0yMDc3MTU_9bb70724-a68a-46aa-bd49-9b5d4025a6de"
      unitRef="usdPerShare">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia83a6e86a99d4ca78124241e9287e79d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNS0zLTEtMS0yMDc3MTU_8d62944e-47f6-4824-8062-6458eee4be7d"
      unitRef="usdPerShare">6.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibb261569c3d84cc38298b5c87946b5a9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNy0xLTEtMS0yMDc3MTU_f69929d4-0a8d-4de3-bf2a-51052a44d2d7"
      unitRef="shares">4133000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic545e6c12b6344cf81caeedddfb12a1d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfNy0zLTEtMS0yMDc3MTU_d74965bb-eb05-4732-9103-4a5bd2a7b458"
      unitRef="shares">1662000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibb261569c3d84cc38298b5c87946b5a9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfOC0xLTEtMS0yMDc3MTU_f014c51a-d3a1-4c90-87c9-b58d4280ccd9"
      unitRef="usdPerShare">9.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic545e6c12b6344cf81caeedddfb12a1d_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfOC0zLTEtMS0yMDc3MTU_b72cbd1a-862a-4894-8b35-bd39806a83af"
      unitRef="usdPerShare">24.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib6e00e72db8d42a6b5461ecf16e5d5a6_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTAtMS0xLTEtMjA3NzE1_b0f4fb5f-68c0-4d6f-a3bd-aa6c13f65027"
      unitRef="shares">647000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iad26ab4e7aaa42cead89d21e59618776_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTAtMy0xLTEtMjA3NzE1_92f7734b-0816-41bf-81e1-815ae60df679"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib6e00e72db8d42a6b5461ecf16e5d5a6_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTEtMS0xLTEtMjA3NzE1_29f943ff-861e-4bb0-9678-a9edc3ac0243"
      unitRef="usdPerShare">10.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iad26ab4e7aaa42cead89d21e59618776_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMTEtMy0xLTEtMjA3NzE1_ea6a506d-dfc9-4508-b5b2-7e39d5750978"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjAtMS0xLTEtMjA3NzE1_5f76aa99-db87-4862-bdcd-fbcc94beb64e"
      unitRef="shares">2679000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjAtMy0xLTEtMjA3NzE1_b0bda31e-0295-4990-9bf7-a603df623b7b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjEtMS0xLTEtMjA3NzE1_83bd474a-87b5-4860-8015-99dc8a3759ec"
      unitRef="usdPerShare">18.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjEtMy0xLTEtMjA3NzE1_13016adc-8120-424f-8d7d-16a073bffadf"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic7cbb126b6854bd1a5598668b7ebb364_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjItMS0xLTEtMjA3NzE1_b23ab6fd-c0e8-4c0e-8621-12479dcfa708"
      unitRef="usdPerShare">5.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i020bcc0f28e44b0dbf0c6d0152d53903_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjItMy0xLTEtMjA3NzE1_3c5b6bce-07f5-4aa1-93b4-f9aed64ecdd2"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id19de0acd56e49d687b026d53ef417fa_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjQtMS0xLTEtMjA3NzE1_4e5e6b5a-ca37-4c19-9005-ae8a1901094b"
      unitRef="shares">2358000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4df47c6c0de44dfa8ac7d75e4c88624a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjQtMy0xLTEtMjA3NzE1_748dbeff-45d8-41a4-b3e6-59e48378342e"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id19de0acd56e49d687b026d53ef417fa_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjUtMS0xLTEtMjA3NzE1_30b73ece-233b-4225-b89b-93372d0719e4"
      unitRef="usdPerShare">18.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4df47c6c0de44dfa8ac7d75e4c88624a_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjUtMy0xLTEtMjA3NzE1_ac297adc-2d0f-4c88-937f-69f1115e12bf"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6511364c8e784a6ea61cc24f22c25e3f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjctMS0xLTEtMjMyNzk4_3399e0cc-04c3-4229-b0af-67c4ea4b8949"
      unitRef="shares">1175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibda9a2e4a2b849239f2f10392436563f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjctMy0xLTEtMjMyNzk4_de42a618-4f25-4a69-90c8-a23d1fdca6cc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6511364c8e784a6ea61cc24f22c25e3f_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjgtMS0xLTEtMjMyNzk4_b467d9dd-8ae1-4757-9c27-5707a76a3432"
      unitRef="usdPerShare">27.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibda9a2e4a2b849239f2f10392436563f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMjgtMy0xLTEtMjMyNzk4_a5494ed7-de2c-48a9-b535-c37d632ad9a3"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i76926d6eb76743fb893fda0b5ee0cd1a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzAtMS0xLTEtMjMyNzk4_172ed4b3-01cb-4b55-a6ca-2e4bd3388be2"
      unitRef="shares">142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icdfbb4a76db045fd9ebe9fb23d5d7ecf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzAtMy0xLTEtMjMyNzk4_c12f8dd3-1108-4443-80d7-d23b20c8e8ee"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i76926d6eb76743fb893fda0b5ee0cd1a_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzEtMS0xLTEtMjMyNzk4_0dc76fc0-9b74-4f6f-baa9-e8867e8e1721"
      unitRef="usdPerShare">17.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icdfbb4a76db045fd9ebe9fb23d5d7ecf_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RhYmxlOmU1ZGNjMWQxNzkwYzRhZGJiNmQxZjUwN2ZlM2YzNThiL3RhYmxlcmFuZ2U6ZTVkY2MxZDE3OTBjNGFkYmI2ZDFmNTA3ZmUzZjM1OGJfMzEtMy0xLTEtMjMyNzk4_8ee8308c-f19f-4778-8629-8dad2aa19498"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODA1Mg_73416286-5558-4403-a550-e75721736ba8"
      unitRef="usd">216000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODExNA_9fb91f05-914d-4c12-ba60-d2609b2a3577">P2Y3M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i095b974a4eda46539b55e501e35cecd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODMxMA_1c7c94c3-cef7-440f-a2a2-23cb8ab8f0e2"
      unitRef="usd">118000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i38c3d0bb2bf64e46be06eed20ec48919_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF83Ni9mcmFnOmIyNmE1YTEyYTQwZDRiNjBiNmNjNmI1NTAzNjg2YWFmL3RleHRyZWdpb246YjI2YTVhMTJhNDBkNGI2MGI2Y2M2YjU1MDM2ODZhYWZfODM3Mg_e4c02222-c4ce-490e-95cf-0d2fd7269a2e">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RleHRyZWdpb246OGUyMWQ3ZjBhMDMwNDgwZWE4M2MzYTNlYmZjOWNjMjFfNzY2_65b590a9-1336-447a-b9bc-73df5bb66fb0">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in the Company&#x2019;s ownership interest in Bausch + Lomb, in the second quarter of 2022, the carrying amount of accumulated other comprehensive income was adjusted to reflect the change in the ownership interest in Bausch + Lomb through a corresponding credit of $137&#160;million to equity attributable to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RleHRyZWdpb246OGUyMWQ3ZjBhMDMwNDgwZWE4M2MzYTNlYmZjOWNjMjFfNzY0_89b7204a-ad8d-4ef3-ab63-695be5b32877">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,989)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ffe0c3f62ab46708e444bc96954e538_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMS0yLTEtMS0yMDc3MTU_de765631-289b-4d72-a90b-813a6d026e6c"
      unitRef="usd">-1971000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie78900a84c814e17a0700f44d77a770a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMS00LTEtMS0yMDc3MTU_202e1b29-7297-4ef6-856f-f205ec969f54"
      unitRef="usd">-2038000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08ba76927daa47f698849aaa8387e768_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMy0yLTEtMS0yMDc3MTU_a6023f4b-879c-4e6e-872f-a9bc81e8bf06"
      unitRef="usd">-18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifcf8da1fe72640db95834f27357c5bde_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfMy00LTEtMS0yMDc3MTU_b98a8eb1-55b2-4eb1-9afd-cd83be57bc21"
      unitRef="usd">-18000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7bbac5f0d9d24f8a8f825099f3394fec_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfNC0yLTEtMS0yMDc3MTU_82b2e88f-1bbf-4f12-a12f-16c5bb682be6"
      unitRef="usd">-1989000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e558abb1f7e4945be1efbb15c0857e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RhYmxlOjUzMGE4OWU0YzBlMTQ5ZjJhOTdlYmQ0ZTFhZDk1MjAwL3RhYmxlcmFuZ2U6NTMwYTg5ZTRjMGUxNDlmMmE5N2ViZDRlMWFkOTUyMDBfNC00LTEtMS0yMDc3MTU_ef88f713-2c26-4e50-bbef-45a624dd1edc"
      unitRef="usd">-2056000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i23d3136d31994fbdb7cb150bafef9389_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84Mi9mcmFnOjhlMjFkN2YwYTAzMDQ4MGVhODNjM2EzZWJmYzljYzIxL3RleHRyZWdpb246OGUyMWQ3ZjBhMDMwNDgwZWE4M2MzYTNlYmZjOWNjMjFfNzIz_d739bf3a-da80-48e0-94cf-f93d3c80dd16"
      unitRef="usd">137000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RleHRyZWdpb246NGJiMWRlMzlhYzRlNGQ0YmE2ODA2ZjhjZWQ5YTQxNjlfMjMz_f1ba6a53-9bb5-489d-b106-281162f28654">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RleHRyZWdpb246NGJiMWRlMzlhYzRlNGQ0YmE2ODA2ZjhjZWQ5YTQxNjlfMjM2_f655415b-d6d9-4a9e-929c-a8283ea37419">Research and development costs consist of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMi0yLTEtMS0yMDc3MTU_6b93ff91-67d4-47e3-81ba-b25ffeaee724"
      unitRef="usd">136000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMi00LTEtMS0yMDc3MTU_9f45b810-8714-42fa-a697-ed3339fa86c5"
      unitRef="usd">121000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMy0yLTEtMS0yMDc3MTU_91fe5c6d-540b-4162-980d-6f9d43c5165f"
      unitRef="usd">7000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfMy00LTEtMS0yMDc3MTU_222d4550-854c-4c7b-bbce-28b3da3bc91b"
      unitRef="usd">6000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfNC0yLTEtMS0yMDc3MTU_b3f03d0c-469c-498a-8c18-504fddbad972"
      unitRef="usd">143000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84NS9mcmFnOjRiYjFkZTM5YWM0ZTRkNGJhNjgwNmY4Y2VkOWE0MTY5L3RhYmxlOjY5ODVmNjg0ZGE4ZTQxMzk5M2Y5NzU4YjY0MTU2NThhL3RhYmxlcmFuZ2U6Njk4NWY2ODRkYThlNDEzOTkzZjk3NThiNjQxNTY1OGFfNC00LTEtMS0yMDc3MTU_ad3b3d3e-23f9-415b-8490-2770626d7df6"
      unitRef="usd">127000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RleHRyZWdpb246NmQ5NTgyMjgxNjRkNDM4MzgxNDUyODZkZDQ3NDJlZWVfMjE3_1a81bfe9-e0ec-4abd-bdb8-ca28a3a0cb20">OTHER EXPENSE, NET&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2023, Litigation and other matters primarily relates to an insurance recovery regarding a certain litigation matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration expense for the three months ended March 31, 2023, primarily includes adjustments to reflect the changes in estimates of the future royalty and milestone payments related to a branded product.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RleHRyZWdpb246NmQ5NTgyMjgxNjRkNDM4MzgxNDUyODZkZDQ3NDJlZWVfMjE5_34d31de0-cfcf-4fa5-b3f8-0e632eb33bb7">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.948%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMi0yLTEtMS0yMDc3MTU_2f4b9773-36dd-4904-bf94-aa2039557ace"
      unitRef="usd">8000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMi00LTEtMS0yMDc3MTU_cfb906e2-b04a-4c78-9c31-cf13a31675bd"
      unitRef="usd">1000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMy0yLTEtMS0yMDc3MTU_3105f677-d055-4d9a-bd90-ecc24ea90911"
      unitRef="usd">31000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfMy00LTEtMS0yMDc3MTU_61632955-4c1e-4fad-a512-595f203dabaf"
      unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfNy0yLTEtMS0yMDc3MTU_cd96d496-9c3e-4beb-8177-ff57458ff60c"
      unitRef="usd">-23000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF84OC9mcmFnOjZkOTU4MjI4MTY0ZDQzODM4MTQ1Mjg2ZGQ0NzQyZWVlL3RhYmxlOjQ4MGUzYmIwNDhmZDQ1YTY4YTkwNjkzMmRlMDljZTBkL3RhYmxlcmFuZ2U6NDgwZTNiYjA0OGZkNDVhNjhhOTA2OTMyZGUwOWNlMGRfNy00LTEtMS0yMDc3MTU_d04e7d35-16c8-41e2-bc1d-be3c4b56c041"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfOTA0MA_b23cb45f-68c8-4c7f-8e03-274a00adaff8">INCOME TAXES&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For interim financial statement purposes, U.S. GAAP income tax expense/benefit related to ordinary income is determined by applying an estimated annual effective income tax rate against a company&#x2019;s ordinary income. Income tax expense/benefit related to items not characterized as ordinary income is recognized as a discrete item when incurred. The estimation of the Company&#x2019;s income tax provision requires the use of management forecasts and other estimates, application of statutory income tax rates and an evaluation of valuation allowances. The Company&#x2019;s estimated annual effective income tax rate may be revised, if necessary, in each interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes for the three months ended March 31, 2023 was $73 million and included: (i) $13&#160;million of income tax benefit for the Company&#x2019;s ordinary loss for the three months ended March 31, 2023 and (ii) $86 million of net income tax expense for discrete items, which includes: (a) $41&#160;million of net income tax expense related to final and potential settlements of various tax audits in the first quarter of 2023, (b) $18&#160;million of income tax expense related to changes in uncertain tax positions, (c) $18&#160;million of income tax expense associated with the establishment of a valuation allowance against deferred tax assets of B+L&#x2019;s Canadian parent and (d) $6&#160;million of income tax expense associated with stock compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefit from income taxes for the three months ended March 31, 2022 was $16 million and included: (i) $14&#160;million of income tax expense for the Company&#x2019;s ordinary loss for the three months ended March 31, 2022 and (ii) $30&#160;million of net income tax benefit for discrete items, which includes: (a) $36&#160;million of net income tax benefit recognized for changes in uncertain tax positions and (b) a $6&#160;million tax provision associated with the filing of certain tax returns. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. The valuation allowance against deferred tax assets was approximately $2,000 million as of March&#160;31, 2023 and December&#160;31, 2022. The Company will continue to assess the need for valuation allowances on an ongoing basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March 31, 2023 and December&#160;31, 2022, the Company had $901 million and $881 million, respectively, of unrecognized tax benefits, which included $41 million and $32 million of interest and penalties, respectively. Of the total unrecognized tax benefits as of March&#160;31, 2023, $402 million would reduce the Company&#x2019;s effective tax rate, if recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits at March&#160;31, 2023 could decrease by approximately $5 million in the next 12 months as a result of the resolution of certain tax audits and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be under examination by the Canada Revenue Agency. In the first quarter of 2023, the Company recorded income tax expense related to prior year withholding tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 19, 2021, the Canadian federal government delivered its 2021 budget which contained proposed measures related to limitations on interest deductibility and changes in relation to international taxation. Draft legislative proposals pertaining to interest deductibility were initially released for public comment on February 4, 2022, with revised legislative proposals subsequently released on November 3, 2022. The proposed rules on interest deductibility are expected to be effective no earlier than January 1, 2024. The proposed rules and their application are complex and could have a material adverse impact on our consolidated effective tax rate and financial results in future years if enacted as drafted.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Internal Revenue Service (the &#x201c;IRS&#x201d;) previously completed its examinations of the Company&#x2019;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company&#x2019;s taxable income as a result of these examinations. However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. The Company&#x2019;s annual tax filings for 2015 and 2016 and short period tax return for the period ended September 8, 2017, which was filed as a result of the Company&#x2019;s internal restructuring efforts during 2017 is currently under IRS examination. As part of its examination, the Company received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss resulting from its internal restructuring. The Company previously contested this proposed tax deficiency through the IRS administrative appeals process and if necessary, will continue to contest any proposed tax deficiency through appropriate litigation. Accordingly, no income tax provision had been recorded as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 capital loss&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;deduction were disallowed, the Company estimates, in a worst-case scenario, that it could be liable for additional income taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, as part of an alternative dispute resolution process with the IRS, the Company reached a tentative settlement on the 2017 Capital Loss. This tentative settlement is subject to further review and approvals before it is finalized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In anticipation of the finalization of this settlement agreement the Company has recorded an estimate for the impact of the settlement during the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 8, 2022 the Company&#x2019;s affiliate in the Netherlands received an assessment from the Luxembourg Tax Authorities as successor in interest to its affiliate in Luxembourg for tax years 2018 &#x2013; 2019 for &#x20ac;272&#160;million. The Company is vigorously defending its position and has not recorded any reserves for this assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany and Luxembourg are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits. At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company&#x2019;s Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNzA2_5d582135-bced-4993-96c1-8ade01a915af"
      unitRef="usd">73000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNzI3_84736619-ec6a-4a59-a45f-575d4ad469d0"
      unitRef="usd">-13000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfODA2_a2c65405-1fb1-48c5-8fc6-881d0db4a3b0"
      unitRef="usd">86000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfODc1_54913849-c566-44f5-9ca0-7c642b716b8e"
      unitRef="usd">41000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfOTYx_8283ba33-baac-411e-a956-32aec53a349c"
      unitRef="usd">18000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMTAzMQ_21b189a2-9d32-49ea-9af0-7f392db3979c"
      unitRef="usd">18000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI4MDM1NQ_1db81cb3-7d71-4920-807f-d4d7fc5e693e"
      unitRef="usd">6000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMTExNQ_dc181c69-be22-4194-a2bf-8b0a6df1f1ad"
      unitRef="usd">-16000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjYyMw_335afc71-08af-45b5-9504-93840f754a2e"
      unitRef="usd">14000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjYzNg_0fdd066d-7ac6-4bcf-9022-b47033254090"
      unitRef="usd">-30000000</bhc:EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjY0OQ_48a8cbd3-1741-497b-8cbc-efdaade4d6a4"
      unitRef="usd">-36000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI3MjY2Mg_43fe5f65-672c-44de-ae3f-b39ffc25bcae"
      unitRef="usd">6000000</bhc:EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjEyNw_1376ee25-9cf2-48d0-8395-62c642247740"
      unitRef="usd">2000000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjEyNw_20b1920e-e53e-422a-9447-b86d81fef6ed"
      unitRef="usd">2000000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTY5Ng_a6ad3a48-007f-4d10-8a1c-8230b44c9817"
      unitRef="usd">901000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTcwMw_c7b55b6e-0878-454a-ac62-9aeff4d457be"
      unitRef="usd">881000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTc2Ng_9e12636e-480a-4fbf-9fa1-e6c9a7f2fc8c"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i57d70860978f416995c6e78078eb91fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTc3Mw_d834efba-5de6-44c8-ae3e-0c6d61890d33"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNTg2Ng_49938909-87c8-41a6-bee3-1c784d7018b9"
      unitRef="usd">402000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfNjA3Mg_d53927be-c038-471c-850a-416e5cf27216"
      unitRef="usd">5000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i19848514ed9a48b79bf2c5a2c418cae9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI4MjYwNw_6cba510b-e39f-424c-8174-1f6a9f669fc5"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i0e7f6f3cf8d14cc58d92cb9b35e61a89_D20221108-20221108"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85MS9mcmFnOmEzMTVlOWJkYzA0OTQzNjY4NTk5ZThhNWI4MDM2ODYyL3RleHRyZWdpb246YTMxNWU5YmRjMDQ5NDM2Njg1OTllOGE1YjgwMzY4NjJfMjE5OTAyMzI4MDM4MQ_37cf270b-0635-4acc-96e0-017dbec5551f"
      unitRef="eur">272000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfMTI4OQ_a0aab60b-5b44-4d86-8bc6-9d8ab680e31b">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the three months ended March 31, 2023 and 2022, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 3,426,000 and 3,600,000 common shares for the three months ended March 31, 2023 and 2022, respectively.During the three months ended March 31, 2023 and 2022, time-based RSUs, performance-based RSUs and stock options to purchase approximately 17,636,000 and 9,332,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During the three months ended March 31, 2023 and 2022, an additional 90,000 and 156,000 performance-based RSUs, respectively, were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfMTMwNQ_b4ff2d3e-b39c-4872-81f2-e291b4e7b113">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc. were calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMi01LTEtMS0yMDc3MTU_6ca67acf-d220-4a90-a850-ff16a2e187f4"
      unitRef="usd">-201000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMi03LTEtMS0yMDc3MTU_f673ade8-f303-4505-af57-0231c568cef8"
      unitRef="usd">-69000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy01LTEtMS0yMDc3MTU_7111d1bc-58a2-49d8-a934-5e5b684291a9"
      unitRef="shares">363300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy01LTEtMS0yMDc3MTU_7a77166b-daf2-4880-8f02-3ce576155160"
      unitRef="shares">363300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy03LTEtMS0yMDc3MTU_3b37c142-7b89-4edd-b849-bfa6c7adf67f"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfMy03LTEtMS0yMDc3MTU_f9a9a8d6-52ed-4b00-a907-67ae700cf7c1"
      unitRef="shares">360800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi01LTEtMS0yMTkwMzg_5d2a9f8d-2120-4754-be0f-d5cce55aac30"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi01LTEtMS0yMTkwMzg_759a968e-fbfe-45db-96aa-3f9fac613b69"
      unitRef="usdPerShare">-0.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi03LTEtMS0yMTkwMzg_950d4ee7-017b-47c3-bc7d-013f8fd32d09"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RhYmxlOmNhNWIzYzhmNzI4MjQ1OWVhMDA1ZGVlYmJhMWI5NDJlL3RhYmxlcmFuZ2U6Y2E1YjNjOGY3MjgyNDU5ZWEwMDVkZWViYmExYjk0MmVfNi03LTEtMS0yMTkwMzg_f8c5825f-96a7-4d96-a310-852ed5263f8b"
      unitRef="usdPerShare">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5eb53786821248ca8b1f2d53e1c01d20_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNDg2_622ea9cc-7791-4a33-a365-3694efabd520"
      unitRef="shares">3426000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb496022dc8e4cf08fe49993684b187c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNDkz_fadd9d0c-eb61-4133-9214-18f8cc4188bc"
      unitRef="shares">3600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaebb38b5c93f4c928fa764fbd3fde9ce_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNjM1_b5f2c0a2-92c1-4b83-be9f-0abb463e6ccd"
      unitRef="shares">17636000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i81b6547380c64dd2a50784794125d70e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNjQy_47856a25-9289-416d-adca-b8eb5e3e11d4"
      unitRef="shares">9332000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="i519005c4e8bf4fa49fe850dc4fd0f0ff_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfMTEzOQ_cea0ea52-ff9c-4da0-a441-d8a38171d465"
      unitRef="shares">90000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount
      contextRef="iabca2dedff2549f2a26e0f9e0fc903e9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85NC9mcmFnOjIwZDk0MTZkN2QyNTQ5MzI5YmI1ZjBkMGZjMGI1MjhmL3RleHRyZWdpb246MjBkOTQxNmQ3ZDI1NDkzMjliYjVmMGQwZmMwYjUyOGZfNTQ5NzU1ODE1NTk2_c83099d8-afce-45bd-b7b8-4c77b88c13c2"
      unitRef="shares">156000</bhc:SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNjE0NTc_aceb7d19-d06e-48ed-9d35-998714de5e78">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC and the CSA on February&#160;23, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of March 31, 2023, the Company&#x2019;s Condensed Consolidated Balance Sheets includes accrued current loss contingencies of $326 million related to matters which are both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney&#x2019;s Office for the District of Iowa &#x2013; re OrthoDerm&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a Civil Investigative Demand in May 2021 from the Civil Division of the United States Department of Justice and the United States Attorney&#x2019;s Office for the District of Iowa, requesting documents and other information concerning the sales and marketing of Bryhali&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Jublia&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Siliq&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company is cooperating with this investigation. The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - Opt-Out Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658) (the &#x201c;Securities Class Action Settlement&#x201d;). On January 31, 2021, the District Court issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC (&#x201c;Timber Hill&#x201d;) filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options. On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal en banc. On May 12, 2022, the Third Circuit denied Lochridge&#x2019;s petition for rehearing en banc. The deadline for Lochridge to file a petition for a writ of certiorari with the U.S. Supreme Court was August 10, 2022 and no petition was filed. As such, the deadline for further appeals has passed and the settlement has become final pursuant to the stipulation of settlement. The matter is now concluded with respect to the Company and all claims have been resolved and discharged as to the Company and its current/former officers and directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor Rx Services, LLC (&#x201c;Philidor&#x201d;). On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210&#160;million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and resolved and discharged all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement was subject to appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments were paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. During 2022, the Company&#x2019;s rights to the funds previously paid into the escrow account have been extinguished in accordance with the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016. On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658). On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2022, filed on February 23, 2023. Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b) and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2) and 15 of the Securities Act, common law fraud, negligent misrepresentation and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss were filed in many of these individual actions and the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar opt-out action, closing the case. On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Aly opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut and Delaware actions. On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action. On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discovery in the opt-out actions has concluded. Motions for summary judgment were filed on August 1, 2022. Trial dates have not been set in any of the opt-out actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;factual allegations made in these actions are substantially similar to those outlined herein. These actions were captioned previously in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February&#160;23, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding. On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94,000,000 plus payment of an additional amount to cover notice and settlement administration costs and disbursements. As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action. On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers&#x2019; Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-006589666-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16. The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; Case No. 3:18-CV-00493). In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period) and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company&#x2019;s Consolidated Financial Statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above. On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company has resolved its insurance claims with respect to the Allergan Securities Litigation against the Hartford Fire Insurance Company but its claims against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160;The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160;The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.&#160;On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement. On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. The time to appeal the district court&#x2019;s final approval order expired on March 24, 2022, and the settlement has resolved and discharged all claims against the Company in this action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County that asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming the Company, Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020. The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020. In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;) (discussed in further detail below, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;see Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration. A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#x2019; claims. The deadline to appeal the final approval of the class settlement has now passed, and the settlements have resolved and discharged all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;) and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled In re: Generic Pharmaceuticals Pricing Antitrust Litigation, pending in the United States District Court for the Eastern District of Pennsylvania (MDL 2724, 16- MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been placed in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively the &#x201c;Company&#x201d;) have been named as defendants in a proposed class proceeding entitled Kathryn Eaton v. Teva Canada Limited, et al. in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the In re: Generic Pharmaceuticals Pricing Antitrust Litigation pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These lawsuits cover products of both Bausch + Lomb and the Company&#x2019;s businesses. It is anticipated that Bausch + Lomb and the Company will split the fees and expenses associated with defending these claims, as well as any potential damages or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other liabilities awarded in or otherwise arising from these claims, in the manner set forth in the Master Separation Agreement between Bausch Health and Bausch + Lomb.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822- WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail above), Humana Inc. (&#x201c;Humana&#x201d;), filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;). The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or grant any other company a license to do so. The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that Humana&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed above, were deemed asserted in the State Court Action. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021. On November 29, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend. Humana did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 5, 2022, Health Care Service Corporation filed an action with similar substantive allegations and similar indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others. Defendants&#x2019; answers were filed on June 17, 2022. On November 28, 2022, the Court consolidated this action with the State Court Action for trial and pretrial purposes (the &#x201c;Consolidated State Case&#x201d;). Trial is currently scheduled to start in January 2024 in the Consolidated State Case.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims and intends to vigorously defend these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain intellectual property litigation proceedings in the United States and Canada, including as arising from claims filed against the Company or by the Company (or that the Company anticipates filing within the required time periods) related to certain products sold by or on behalf of the Company, which may be in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers, where such products include Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 200 mg and 550 mg, Arazlo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Nuvessa&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Canada&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A. (&#x201c;Alfasigma&#x201d;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)&#x2019;s Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.&#160;On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 27 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. Trial in this matter was held in March 2022. The court issued a final judgment on August 10, 2022, (the &#x201c;Norwich Legal Decision&#x201d;), finding that the U.S. Patents protecting the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (rifaximin) 550 mg tablets for the reduction in risk of hepatic encephalopathy (&#x201c;HE&#x201d;) recurrence valid and infringed and the U.S. Patents protecting the composition, and use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for treating IBS-D invalid. The Norwich Legal Decision prevents FDA approval of Norwich&#x2019;s 550 mg ANDA until October 2029. The Company appealed the Norwich Legal Decision to the U.S. Court of Appeals for the Federal Circuit on August 16, 2022. Following the Company&#x2019;s appeal, Norwich claimed to have removed the HE indication from its existing ANDA and then filed a motion in the District Court requesting modification of the Norwich Legal Decision to permit the FDA to approve their ANDA before October 2029. The Company opposed this motion and awaits a decision on the motion from the District Court. In January 2023, the U.S. Patent Office issued U.S. Patent No. 11,564,912 (the &#x201c;&#x2019;912 Patent&#x201d;) directed to IBS-D, which was then listed in the FDA&#x2019;s Orange Book for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. On April 28, 2023, the Company received a new Notice of Paragraph IV Certification from Norwich asserting that claims of the &#x2018;912 Patent are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, or &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, under the existing Norwich ANDA. Any suit brought against the existing Norwich ANDA under the &#x2018;912 Patent is not believed to result in a new 30-month stay of approval. The Company remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company received a Notice of Paragraph IV Certification from Taro Pharmaceuticals Inc. (&#x201c;Taro&#x201d;), in which Taro asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotene) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use, sale, offer for sale, or importation of Taro&#x2019;s generic lotion, for which an ANDA has been filed by Taro. On July 21, 2022, the Company filed suit against Taro pursuant to the Hatch-Waxman Act, alleging infringement by Taro of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and triggering a 30-month stay of the approval of the Taro ANDA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg. The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company commenced litigation against Aurobindo Pharma Limited (&#x201c;Auro&#x201d;) alleging patent infringement by Auro&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Auro, in which it asserted that the U.S. patent listed in the FDA&#x2019;s Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of Auro&#x2019;s generic plecanatide tablets, 3 mg. The filing of this suit triggered a 30-month stay of the approval of the Auro ANDA for plecanatide tablets. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; AREDS Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; AREDS 2 are over the counter eye vitamin formulas for those with moderate-to-advanced age-related degeneration (&#x201c;AMD&#x201d;). The PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. Bausch &amp;amp; Lomb Incorporated (&#x201c;B&amp;amp;L Inc.&#x201d;) has filed patent infringement proceedings against 19 named defendants in 16 proceedings, claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Twelve of these proceedings were subsequently settled; two resulted in a default. As of the date of this filing, there are two ongoing actions: (1) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. ZeaVision LLC, C.A. No. 4:22-cv-00914-AGF (E.D. Mo.) and (2) Bausch &amp;amp; Lomb Inc. &amp;amp; PF Consumer Healthcare 1 LLC v. SBH Holdings LLC, C.A. No. 20-cv-01463-GBW-CJB (D. Del.). Bausch + Lomb remains confident in the strength of these patents and B&amp;amp;L Inc. intends to continue to vigorously pursue these matters and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation against Certain Ocuvite and PreserVision &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2021, ZeaVision, LLC (&#x201c;ZeaVision&#x201d;) filed a complaint for patent infringement against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products in the Eastern District of Missouri (Case No. 4:21-cv-00739-RWS). On June 29, 2021, ZeaVision amended its complaint to assert a second patent against certain of the Ocuvite&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products. On November 16, 2021, ZeaVision filed an additional complaint for patent infringement to assert a third patent against certain of the PreserVision&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products (Case No. 4:21-cv-01352-RWS). On March 1, 2022, the cases were consolidated. On March 10, 2022, the court granted Bausch + Lomb&#x2019;s motion to stay all proceedings pending inter partes review. On July 8, 2022, ZeaVision filed a motion to partially lift the stay to allow Case No. 4:21-cv-00739-RWS to proceed, and this motion was denied. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Paragraph IV Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2021, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Slayback Pharma LLC (&#x201c;Slayback&#x201d;), in which Slayback asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Slayback&#x2019;s generic drops, for which an ANDA has been filed by Slayback. B&amp;amp;L Inc., through its affiliate Bausch + Lomb Ireland Limited, exclusively licenses the Lumify Patents from Eye Therapies, LLC (&#x201c;Eye Therapies&#x201d;). On September 10, 2021, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Slayback pursuant to the Hatch-Waxman Act, alleging infringement by Slayback of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Slayback ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 20, 2022, B&amp;amp;L Inc. received a Notice of Paragraph IV Certification from Lupin Ltd. (&#x201c;Lupin&#x201d;), in which Lupin asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (brimonidine tartrate solution) drops (the &#x201c;Lumify Patents&#x201d;), are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Lupin&#x2019;s generic brimonidine tartrate solution, for which its ANDA No. 216716 has been filed by Lupin. On February 2, 2022, B&amp;amp;L Inc., Bausch + Lomb Ireland Limited and Eye Therapies filed suit against Lupin pursuant to the Hatch-Waxman Act, alleging patent infringement by Lupin of one or more claims of the Lumify Patents, thereby triggering a 30-month stay of the approval of the Lupin ANDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;B&amp;amp;L Inc. remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and B&amp;amp;L Inc. intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inter Partes Review Proceedings at the U.S. Patent and Trademark Office&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company&#x2019;s branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#x201c;IPR&#x201d;) at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company&#x2019;s branded pharmaceutical products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board (&#x201c;PTAB&#x201d;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (U.S. Patent No. 7,214,506 (the &#x201c;&#x2018;506 Patent&#x201d;)) and, on June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings. As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion. The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is covered by sixteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2026 through 2035. In 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada. All cases in the U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. Three lawsuits are pending in Canada regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against Apotex Inc. and Pharmascience Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Mylan and MSN have filed IPR petitions for certain U.S. patents listed in the FDA Orange Book for Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide). On March 21, 2022, Mylan filed a petition for IPR of U.S. Patent No. 7,041,786. On October 12, 2022, MSN also filed a petition for IPR of U.S. Patent No. 7,041,786 and the PTAB then issued a decision on December 14, 2022, instituting MSN&#x2019;s IPR and joining it with Mylan&#x2019;s IPR. On June 10, 2022, Mylan filed petitions for IPR of U.S. Patent Nos. 9,610,321, 9,616,097, 9,919,024 and 9,925,231. In the Company&#x2019;s favor, the PTAB issued decisions on Jan. 4, 2022, denying Mylan&#x2019;s petitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company remains confident in the strength of these patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-six (26) of such product liability suits currently remain pending. In three (3) cases pending in the Atlantic County, New Jersey Multi-County Litigation, agreed stipulations of dismissal have been entered by the Court, thus dismissing the Company from those cases. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-five (25) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2021, the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries, has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to court orders entered in November 2021, the case was transferred to the United States District Court for the District of New Jersey (the &#x201c;Bankruptcy Court&#x201d;), and substantially all cases related to Johnson &amp;amp; Johnson&#x2019;s talc liability were stayed for a period of 60 days pursuant to a preliminary injunction. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company&#x2019;s current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. In December 2021, certain talc claimants filed motions to dismiss the bankruptcy case. Shortly thereafter, LTL filed a motion in the Bankruptcy Court to extend the 60-day preliminary injunction. On February 25, 2022, the Bankruptcy Court entered orders denying the motions to dismiss and extending the preliminary injunction staying substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability through at least June 29, 2022, which it later extended indefinitely. The order denying the motions to dismiss and the order extending the preliminary injunction were subject to appeal and the Bankruptcy Court certified their appeals directly to the United States Court of Appeals for the Third Circuit. On May 11, 2022, the Third Circuit granted authorization for the parties to proceed with their direct appeals. Oral argument before the Third Circuit was held on September 19, 2022. On January 30, 2023, a unanimous three-judge Third Circuit Court of Appeals panel issued its decision directing the Bankruptcy Court to dismiss LTL&#x2019;s bankruptcy case, concluding that LTL was not in financial distress and could not file a bankruptcy case in good faith. LTL requested a rehearing and on March 22, 2023, the Third Circuit denied LTL&#x2019;s rehearing request. Thereafter LTL moved for a stay of the mandate of the Third Circuit&#x2019;s dismissal decision while LTL sought review by the Supreme Court. On March 31, 2023, the Third Circuit denied LTL&#x2019;s stay motion. At that juncture, the Bankruptcy Court determined it appropriate to discontinue the proceedings pending there, and on April 4, 2023, entered orders dismissing the bankruptcy case and related adversary proceedings and terminating the preliminary injunction.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, on April 4, 2023, LTL re-filed for chapter 11 in the Bankruptcy Court and again commenced an adversary proceeding seeking a preliminary injunction enjoining substantially all cases subject to the indemnification agreement. The Bankruptcy Court granted a temporary restraining order enjoining litigation against the &#x201c;Protected Parties&#x201d; including the Bausch entities. The Bankruptcy Court held a hearing on April 18, 2023, to consider the preliminary injunction, and on April 20, 2023, the Bankruptcy Court ordered a preliminary injunction solely on a limited basis to enjoin the commencement or continuation of any trial against any Protected Party (including the Bausch entities). The injunction does not enjoin the commencement of a new suit or any discovery or pre-trial activity in pending suits. The talc claimants have sought to have the decision certified for direct appeal to the Third Circuit. Additionally, the Bankruptcy Court will be ordering the parties to continue mediation, and will consider proposals for mediators, a Future Claims Representative, and a fee examiner at a hearing scheduled for May 3, 2023. On April 24, 2023, the talc claimants filed a motion to dismiss the newly filed Chapter 11 case and a hearing is scheduled for May 22, 2023. Meanwhile, LTL has stated that it intends to file a plan of reorganization by May 14, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the bankruptcy case is ultimately dismissed, the Company&#x2019;s position vis a vis J&amp;amp;J would return to the status quo prior to the filing. The litigation against the Company and other defendants will no longer be stayed, and LTL and J&amp;amp;J will continue to have indemnification obligations running to the Company and its affiliates for Shower-to-Shower related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent that any cases proceed during the pendency of the bankruptcy case, or if the case is ultimately dismissed, it is the Company&#x2019;s expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation - New Jersey Declaratory Judgment Lawsu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;it&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2022, the Company and Bausch + Lomb were named in a declaratory judgment action in the Superior Court of New Jersey, Somerset County, Chancery Division, brought by certain individual investors in the Company&#x2019;s common shares and debt securities who are also maintaining individual securities fraud claims against the Company and certain current or former officers and directors as part of the U.S. Securities Litigation. This action seeks a declaratory judgment that alleged transfers of certain Company assets to Bausch + Lomb would constitute a voidable transfer under the New Jersey Voidable Transactions Act and that Bausch + Lomb would be liable for damages, if any, awarded against the Company in the individual opt-out actions. The declaratory judgment action alleges that the future potential separation of Bausch + Lomb from the Company by distribution of Bausch + Lomb stock to the Company&#x2019;s shareholders would leave the Company with inadequate financial resources to satisfy these plaintiffs&#x2019; alleged securities fraud damages in the underlying individual opt-out actions. None of the plaintiffs in this declaratory judgment action have obtained a judgment against the Company in the underlying individual opt-out actions and the Company disputes the claims against it in those underlying actions. The underlying individual opt-out actions assert claims under Sections 10(b) and 20(a) of the Exchange Act, and certain actions assert claims under Section 18 of the Exchange Act. The allegations in those underlying individual opt out actions are made against the Company and several of its former officers and directors only and relate to, among other things, allegedly false and misleading statements made during the 2013-2016 time period by the Company and/or failures to disclose information about the Company&#x2019;s business and prospects including relating to drug pricing and the use of specialty pharmacies. On March 31, 2022, the Company and Bausch + Lomb removed the action to the U.S. District Court for the District of New Jersey. On April 29, 2022, Plaintiffs filed a motion to remand. On November 29, 2022, the District Court granted Plaintiffs&#x2019; remand motion and the case was remanded to the Superior Court. On December 8, 2022, Plaintiffs filed a proposed Order to Show Cause and motion for a preliminary injunction, and sought interim relief including expedited discovery. On December 13, 2022, the Court denied Plaintiffs&#x2019; proposed Order to Show Cause and stayed discovery pending the resolution of the Company and Bausch + Lomb&#x2019;s forthcoming motions to dismiss, while instructing the Company to provide certain notice to Plaintiffs of the intended completion of the distribution referenced above under certain circumstances. On December 22, 2022, Plaintiffs filed an amended complaint which, among other things, added claims seeking injunctive relief. On January 11, 2023, the Company and Bausch + Lomb moved to dismiss the amended complaint. Briefing was complete on February 24, 2023, and the motion to dismiss was heard on March 3, 2023. On April 3, 2023, the court issued a decision granting in part and denying in part the motion to dismiss. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Both the Company and Bausch + Lomb dispute the claims in this declaratory judgment action and intend to vigorously defend this matter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al., Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. Bausch Health US filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted. In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees&#x2019; response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the Bankruptcy Court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. On March 9, 2022, the Ninth Circuit issued an order extending the stay through July 29, 2022. On July 29, 2022, Johnson &amp;amp; Johnson filed a status report in the Gutierrez appeal, outlining the developments since the last status report and the imposition of the stay. Johnson &amp;amp; Johnson noted that following a July 26, 2022, hearing, the Bankruptcy Court left the preliminary injunction in place, and asked the Ninth Circuit to continue to stay this action while the bankruptcy preliminary injunction remained in place. On January 20, 2023, the Ninth Circuit extended the stay until February 17, 2023. On February 17, 2023, Johnson &amp;amp; Johnson requested the court afford it sixty (60) days &#x2013; until April 18, 2023, or seven (7) days following any lifting of the LTL Bankruptcy Court&#x2019;s preliminary injunction &#x2013; whichever comes earliest &#x2013; to provide an additional status report about the bankruptcy proceeding and the Third Circuit dismissal for which LTL has requested a rehearing. On April 7, 2023, Johnson &amp;amp; Johnson Consumer Inc. filed a status report regarding the bankruptcy proceeding advising the Court of the dismissal of the prior bankruptcy proceeding and the filing of the second bankruptcy proceeding, as well as the preliminary &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;injunction and stay order, and requesting the stay of the appeal remain in place until May 10, 2023. The Ninth Circuit has not yet acted on that request.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer, Inc., the Company and Bausch Health US related to Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its alleged causal link to mesothelioma and other cancers. In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial was scheduled to begin on May 30, 2023, until the case was stayed by an interlocutory appeal to the New Mexico Supreme Court by Johnson &amp;amp; Johnson.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 14, 2022, LTL filed an adversary proceeding in the Bankruptcy Court (Case No. 21-30589, Adv. Pro. No. 22-01231) against the State of New Mexico ex rel. Hector H. Balderas, Attorney General, and a motion seeking an injunction barring the New Mexico Attorney General from continuing to prosecute the action while the bankruptcy case is pending. A hearing was held on September 14, 2022, and on October 4, 2022, the Bankruptcy Court entered an order granting the injunction. The New Mexico and Mississippi Attorneys General appealed the order granting the preliminary injunction and sought direct appeal to the Third Circuit. The Bankruptcy Court certified the matter for direct appeal to the Third Circuit Court of Appeals. Following the Third Circuit&#x2019;s decision requiring dismissal of the main bankruptcy proceeding, and its subsequent denials of LTL&#x2019;s requests for a rehearing or a stay pending disposition by the Supreme Court, on April 4, 2023, the Bankruptcy Court entered orders dismissing the bankruptcy case and related adversary proceedings. However, also on April 4, 2023, LTL re-filed for chapter 11 in the Bankruptcy Court and again sought a preliminary injunction, though it does not currently include this lawsuit. The Bankruptcy Court did not grant the broad preliminary injunction requested and, instead, issued a preliminary injunction solely on a limited basis to enjoin the commencement or continuation of any trial against any Protected Party. However, this action remains stayed due to a separate September 13, 2022, stay order from the New Mexico Supreme Court in a pending appeal from a Motion to Compel filed by Johnson &amp;amp; Johnson. Accordingly, at this time this matter remains stayed pending the outcome of that appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, asserting claims for breach of contract and declaratory relief. On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30&#160;million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd. Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 20, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 11, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.&#160;Doctors Allergy claims its damages are not less than $23&#160;million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch &lt;/span&gt;&lt;/div&gt;Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and intends to continue to defend itself vigorously.</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LitigationReserveCurrent
      contextRef="i0498740aa6eb46ce88de603fe0598d20_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTM2Ng_04c4b143-28b6-4c52-966a-aee9713ba6f0"
      unitRef="usd">326000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="if51c4186ebf842d9bc523ee7341ac28b_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI4Nw_a8bbd258-f7cf-4d3e-8c9e-180e728745e6"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="if51c4186ebf842d9bc523ee7341ac28b_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI5Ng_9a33eac2-fb92-46cd-9fa3-80c9b36a17b7"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ifc7b2df681304b2890b3963d6767bdca_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjMwNg_2c88e7f4-624b-4d55-ab1e-cdc4e23b30da"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjMyMQ_6bb97edf-5d9d-4123-8c07-de420207895f"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjMzOA_e31639c2-cb17-464b-93e8-c358ab749aa8"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM1MQ_a15dfcc8-6f75-4aec-94ed-f6d4f3740b68"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM2OA_3ce70c2d-a0fd-4d79-a6dc-a97925a59103"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i4673169a9f5042a890348f2de0d3b0de_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTE0NjM_1e286be5-d4f3-4114-b655-8f5ba4f2f954"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="i458f2edb3ff040f987cabd221cc1abb6_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTE2ODE_3dff5662-7616-4df9-857f-3c67ca9f3601"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ia0de8367b153476aa320c433be6e8642_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMTMyNDQ_e6be60f4-5b10-4236-9e21-4cfc978d855b"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i39bb1640622d4df192d462ee18b711d5_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM4Mw_4e58c495-727d-47e7-ae29-4e51557399c4"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i9f50f038b4734b508b66b728e2f90a2b_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjM5MQ_983c7a51-035c-4c67-993a-02d13cf2956d"
      unitRef="number_business">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="ic47ec016d3f14e9687e6fd9195affb3e_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI0NjA3_90fa0cfa-a213-4ac6-b6c9-b8a7d3ff57af"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i1f2bdc093e6f469e94ae4f92c6ae44c9_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI2NTc4_506a873e-0885-40ac-8a6a-d8e0d5e19778"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="i1f2bdc093e6f469e94ae4f92c6ae44c9_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI2Njk1_5382eabc-efcb-4fff-aeff-c984673a100e"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i1bbfea8bf36146258594bca2c1b2d4fa_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDI2OTMz_8c5227ff-563d-44d0-86cb-aaf3eedee284"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i770a218322c748019334a4cf693ddec3_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQwMA_0d1fb276-0563-464d-b64b-2871bfc19c1f"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5fef41f4b68f4a788694d3e96118dc2d_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ0OA_5c0755ae-a870-45cb-abb8-6f76dd4c040c"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i005975800f4b45b88a890051cc8ed460_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ1OQ_9fdd412f-d308-4541-ab5f-e167fa397aa0"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i09d4ece01b0b4cbe82efb645a38a84ad_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ2OA_7cd6d787-7d12-4729-b9b5-d3607c0b4c8a"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i945b95d4642547dc948d93764b9fa34e_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ3OQ_6279870e-f536-462f-a27e-d5737498e3cb"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i57a59221634247afa741a3029a821408_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjQ5MQ_b4569c96-9482-47db-b8ba-037e3f038b27"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i176472c9a91947a58428394faa66f2cc_D20200326-20200326"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjUwNQ_10b56081-d515-4f3a-b82f-a65945f3b9f4">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i3b70ae48ac824b238ebdfb47f23616a7_D20220721-20220721"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjUyMg_bb6d9fa9-763d-4493-8c5a-93d0e75dafd5">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="if9c399e8c9cd4e7ca1b0299006f338c2_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjUzOA_89b2bd8b-d115-4ba0-b538-f904fef2b37a">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i24d679a98f75427f88c6ebe76a942e45_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU0Ng_fba4c20e-fa29-49a4-827e-39dbbc173367">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="if6350305849648ffb0d2318c6a4aff11_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI1Mg_59abf97f-7485-4276-965a-5fdc748e953c"
      unitRef="defendant">19</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfProceedings
      contextRef="if6350305849648ffb0d2318c6a4aff11_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI1Ng_443072e7-a86e-4b8d-916f-f474d73b3744"
      unitRef="proceeding">16</bhc:GainContingencyNumberOfProceedings>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i4d5d5d30a78743fcbe52b8144e75f596_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI1OQ_6076ad69-b66f-4cce-bf59-e2f0e0ce55ef"
      unitRef="defendant">12</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i52f2f806ddb64cfc8ebb70476e207aae_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI3OQ_ab6b647e-07e4-4bce-b8cf-2f0018e3f8d2"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyNumberOfDefendants
      contextRef="i88b0c4fb144a4119b0353b9e796c5864_D20230504-20230504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjI3MQ_b7c48bb5-4616-4e25-bed6-cea8acfad754"
      unitRef="defendant">2</bhc:GainContingencyNumberOfDefendants>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="i26816d2d301f4b2e814b747046bafd99_D20210910-20210910"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU1NA_eb1f3e81-3f7b-4566-964c-0aec3b0cc0a1">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <bhc:GainContingencyStayOfApprovalPeriod
      contextRef="id1a1acd7be5d4003ac3ff92ab403c379_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU2Mg_8e5c4d6d-f42f-4464-ad65-2299289f5bef">P30M</bhc:GainContingencyStayOfApprovalPeriod>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="i48e4a619c05e48ffb995b93d387f88e3_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU2OQ_aca9b2b3-a903-4bfa-a4a0-3b6636dd0b58"
      unitRef="lawsuit">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i993f123539934cffbde85472ef746930_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU5MA_8998102d-cb34-4fad-a708-288b5ecbf15e"
      unitRef="case">26</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9b05eff1ebcf4f5b980a23bd07d03ae4_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjU4MA_ac1da66b-29f1-40cc-9cfc-592a0ac201d8"
      unitRef="case">3</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ief2eb449f9874ce181c5a5a55b53420a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYwNQ_f1ad1e3d-c281-46ee-ad2d-1df4d8bf5d4f"
      unitRef="case">25</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i879843cb6d494828a7a39d54b19d72ca_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYyMg_4726e20e-392b-42cf-a34b-afe0beaf596b"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i6a43da3b1f6244ca9940203efc29fea7_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYzMA_c552c96e-576f-4368-a735-d535847dca88"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ib68a72c1f5224ee9b35a0e482c1dadbb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjYzOA_7df32555-c5a5-42f7-944d-6c441063bed7"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="ic2b286567c0d4c80b0020c5f649deaeb_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjY0Ng_316de531-b663-49a3-9bfe-7b5d194d45b5">P60D</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriod
      contextRef="i9efca43066164f5f8a7d4d69da63efec_D20211201-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjY1Nw_a0ff2188-7017-4d5e-8ce4-c3a6b408e10d">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriod>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne
      contextRef="i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzUwNTcwOA_b787f3fe-d656-4ba9-9478-6405de01effc">P60D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne>
    <bhc:LossContingencyStayOfApprovalMotionToExtendPeriodTwo
      contextRef="i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzUwNTcyMw_0410cf36-8ab0-4e7f-9ec5-97b3e1e02d5c">P7D</bhc:LossContingencyStayOfApprovalMotionToExtendPeriodTwo>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i0e4af957468b4b74a17f3a7d3f6e1b6d_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfNTQ5NzU2MDUwNDM4_7fbf1604-2afb-43e0-8d48-4950eba13c7a"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="ia80385ad9ebe4c0bb7c80610f3bae724_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF85Ny9mcmFnOmQ3MDI1OGU4ZjkzMjQ4MjhiYjdjNTg4NGY4ZDg2Zjc5L3RleHRyZWdpb246ZDcwMjU4ZThmOTMyNDgyOGJiN2M1ODg0ZjhkODZmNzlfMjE5OTAyMzQ1NjY5MA_b5b84b50-50ed-432c-9a2b-3f5c99fff3ab"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2MzQ_0e484c23-6ab9-4f47-b48e-8dc936f79702">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales in the U.S. of GI products. Sales of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product line represented approximately 80% of the Salix segment&#x2019;s revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Solta Medical segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Solta Medical aesthetic medical devices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:12.53pt"&gt;The Diversified (formerly Diversified Products) segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) dermatology products, (iii) generic pharmaceutical products and (iv) dentistry products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Surgical and Ophthalmic Pharmaceuticals products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation and IPO costs and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Segment and Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The top ten products for the three months ended March 31, 2023 and 2022 represented 48% and 47% of total revenues for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzIxMTM_4d006ffc-7b13-40bd-8149-373fc49cd932"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzIxMTM_756c060e-3107-4ca6-b45b-0aa841a347ea"
      unitRef="number">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2NjQ_39ca2654-602b-4c02-ba9d-366f79744302">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide8c6d648ece4cb38926e0893d4d16cb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzMtMS0xLTEtMjA3NzE1_5fdd7860-2583-4352-838b-c20c8bcae121"
      unitRef="usd">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fa7faccfc9e4b2ca204f3c85a970f69_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzMtMy0xLTEtMjA3NzE1_6074a41b-8340-432a-a6ba-5bcba34b67f3"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i023a58638ddd46eca36de268fb813f97_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzQtMS0xLTEtMjA3NzE1_e5d63f6e-0826-453a-ac79-51d86b476dab"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6be070c32a5a4c1ba81697834d0ed884_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzQtMy0xLTEtMjA3NzE1_d98c6c09-ece8-4b9c-a5fa-cac35bae4534"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d4f39f4056646cc9b55c92a148ec539_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzUtMS0xLTEtMjA3NzE1_23ce5dbb-0903-4181-9595-ff50110f9ddb"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedcb8713c7af444fb8b6d03e82848ff6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzUtMy0xLTEtMjA3NzE1_3eeb807b-a3e5-451a-a948-57dd30931df8"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46df43952df846588596009246e5d41d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzYtMS0xLTEtMjA3NzE1_b56dd571-d9f4-4a29-8f65-1fe136037685"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id24da3a29fc44884abed656c976f1185_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzYtMy0xLTEtMjA3NzE1_4e08b90a-1b97-4394-aebd-93ed707b12d1"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5067f998a0774347a1ba8dddd05e828d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzctMS0xLTEtMjA3NzE1_135c65dd-641f-40c7-99d3-2408f80fc4a1"
      unitRef="usd">931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84476c66acf64d629d1829a442bdd45f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzctMy0xLTEtMjA3NzE1_4a4f8225-78e9-4e18-8cf2-7d267858fd4b"
      unitRef="usd">889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzgtMS0xLTEtMjA3NzE1_41e5e067-186f-494b-a06f-9f11c7200750"
      unitRef="usd">1944000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i844e35405a554f25b15ab800349871ec_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzgtMy0xLTEtMjA3NzE1_51209caf-fc0c-4e2c-b4df-74b56514ebbf"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ide8c6d648ece4cb38926e0893d4d16cb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEwLTEtMS0xLTIwNzcxNQ_4480965b-4ea6-4679-834d-bf7eb7cdd27d"
      unitRef="usd">314000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3fa7faccfc9e4b2ca204f3c85a970f69_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEwLTMtMS0xLTIwNzcxNQ_ae8c624f-a4a6-4ea1-969a-e95c6a74ef0b"
      unitRef="usd">322000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i023a58638ddd46eca36de268fb813f97_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzExLTEtMS0xLTIwNzcxNQ_b808590c-da1e-41a8-9b49-b905813e8447"
      unitRef="usd">77000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6be070c32a5a4c1ba81697834d0ed884_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzExLTMtMS0xLTIwNzcxNQ_b8644fd4-ba7f-43df-8a80-9abdcd765e7c"
      unitRef="usd">91000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6d4f39f4056646cc9b55c92a148ec539_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEyLTEtMS0xLTIwNzcxNQ_f30288ff-fbf0-4f0f-944f-a64a8f9ec2fd"
      unitRef="usd">36000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iedcb8713c7af444fb8b6d03e82848ff6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEyLTMtMS0xLTIwNzcxNQ_be6bcb49-980d-4a2d-a46c-19c3cab60e59"
      unitRef="usd">35000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46df43952df846588596009246e5d41d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEzLTEtMS0xLTIwNzcxNQ_e68ca3ea-eade-4a06-a224-aef32915c95c"
      unitRef="usd">107000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id24da3a29fc44884abed656c976f1185_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzEzLTMtMS0xLTIwNzcxNQ_3a42603d-3cbd-4b4f-a6d0-edc60a39cb8f"
      unitRef="usd">158000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5067f998a0774347a1ba8dddd05e828d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE0LTEtMS0xLTIwNzcxNQ_8259485e-4b52-4b8f-a371-235c35146d5e"
      unitRef="usd">211000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i84476c66acf64d629d1829a442bdd45f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE0LTMtMS0xLTIwNzcxNQ_aab5f083-3fa6-4f79-a0e4-bbe57b20d6ae"
      unitRef="usd">206000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE1LTEtMS0xLTIwNzcxNQ_41cdf442-938a-475c-ba2f-48e1e86857da"
      unitRef="usd">745000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i844e35405a554f25b15ab800349871ec_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE1LTMtMS0xLTIwNzcxNQ_702fe2ea-6d2c-4012-ae7a-2b4b46c655f9"
      unitRef="usd">812000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c0d405070e646faa7642b41b7cf60bc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE2LTEtMS0xLTIwNzcxNQ_17de08c9-e3ef-4982-a719-70e1d0106a81"
      unitRef="usd">-251000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i291a59d0cc7a41f998a11690ab1a3fc2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE2LTMtMS0xLTIwNzcxNQ_9c3a4d59-d4b0-4d45-805a-286f9b908a75"
      unitRef="usd">-194000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE3LTEtMS0xLTIwNzcxNQ_11827f98-b330-4b7f-9211-253ae69a8658"
      unitRef="usd">273000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE3LTMtMS0xLTIwNzcxNQ_fbd9a0ca-be56-4f70-9613-5269af6720d2"
      unitRef="usd">310000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <us-gaap:AssetImpairmentCharges
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE5LTEtMS0xLTIwNzcxNQ_f226030e-fa1c-4819-aff6-8774ed71c867"
      unitRef="usd">13000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzE5LTMtMS0xLTIwNzcxNQ_922823f6-6a29-4e9c-a209-9f3f07b57efb"
      unitRef="usd">8000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIwLTEtMS0xLTIwNzcxNQ_1654bd41-7993-4564-9105-89009d8a6cb2"
      unitRef="usd">10000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIwLTMtMS0xLTIwNzcxNQ_5997e04b-037e-4bf6-8279-b051838f480e"
      unitRef="usd">13000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIxLTEtMS0xLTIwNzcxNQ_41ff1c02-39a5-4a6d-b5ff-d76305c926d0"
      unitRef="usd">-23000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIxLTMtMS0xLTIwNzcxNQ_4c87aaf6-b98c-4548-8dd0-e5f28cfc474a"
      unitRef="usd">-2000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIyLTEtMS0xLTIwNzcxNQ_c30ddd69-63a8-415c-8fa3-009f6ddb6be2"
      unitRef="usd">175000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIyLTMtMS0xLTIwNzcxNQ_134aced4-5393-498d-a5dc-0780097e340b"
      unitRef="usd">285000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIzLTEtMS0xLTIwNzcxNQ_936fff83-3a17-45db-8765-fc7de8c609b5"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzIzLTMtMS0xLTIwNzcxNQ_51bfcf01-4a9f-4f07-8076-d0bcd27b1008"
      unitRef="usd">2000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI0LTEtMS0xLTIwNzcxNQ_11f087de-0b39-4de1-92c5-8b82c1b84eaf"
      unitRef="usd">307000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI0LTMtMS0xLTIwNzcxNQ_511016de-58b5-41b2-a700-3a1222eb9455"
      unitRef="usd">362000000</us-gaap:InterestExpenseDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI2LTEtMS0xLTIwNzcxNQ_eda20f24-1c0d-4262-80b5-d4f02fa22be3"
      unitRef="usd">-10000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI2LTMtMS0xLTIwNzcxNQ_e9ee3d62-bf03-42a1-8016-6d5b04ed0ebf"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI3LTEtMS0xLTIwNzcxNQ_9209143f-b104-40e3-8ada-61809c5aefd6"
      unitRef="usd">-136000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTowMDU4NmJkZjdiODg0OTdmYWUzNGRiY2ZiN2FjNzk2NC90YWJsZXJhbmdlOjAwNTg2YmRmN2I4ODQ5N2ZhZTM0ZGJjZmI3YWM3OTY0XzI3LTMtMS0xLTIwNzcxNQ_ec758731-ce5a-473d-97a1-a6ea05ea41e6"
      unitRef="usd">-82000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2NDU_a8169e50-d962-4b0b-9f0a-910fb9155a6d">&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by segment and product category were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diversified&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if231378ef6374003b9b4b0a7109a7cd7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItMS0xLTEtMjA3NzE1_28216689-532a-4254-bb13-05ba671032d6"
      unitRef="usd">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95a4bade0b5f449babad9d26acb96982_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItMy0xLTEtMjA3NzE1_726ccfc3-ea93-4ba0-9aa0-2700e9260cb0"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ac1d18d3c5e49c2bfc56953bf92f5c6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItNS0xLTEtMjA3NzE1_68b47c9b-d2c8-4948-880c-34ee19c62d74"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12f2d378c39e4f668000688f3e489870_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItNy0xLTEtMjA3NzE1_78ccd702-3019-4ade-aebc-ce2f0452faee"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7dd91b590f846dd9b290718829cfd6a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItOS0xLTEtMjA3NzE1_85d34d96-bd3f-4bce-8992-934f70a5c5bc"
      unitRef="usd">108000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b225b3f8b0746bfb199706e955676a9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzItMTEtMS0xLTIwNzcxNQ_c1636b9b-16ad-4e25-9f7b-e2c7dec9a55e"
      unitRef="usd">823000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id89d66db36c64eceab4715ffe59e84a5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtMS0xLTEtMjA3NzE1_20a6531b-2116-4c83-9683-bc76b9bb2f14"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8743518cdefc482a9aa2ddf769e627d3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtMy0xLTEtMjA3NzE1_64f87eb0-ecce-424d-8186-0774f0a3a0f4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbc1d8878ec541b1826e3e74d410810e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtNS0xLTEtMjA3NzE1_4545c7eb-2344-4928-9056-04cfddedc836"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c847d919d274b11b0a404d202cae423_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtNy0xLTEtMjA3NzE1_b0d8b8cc-66dd-46fd-9031-353dbd94f32a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39116494adc049f9a0fbb011b1049e08_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtOS0xLTEtMjA3NzE1_56bb72f0-1932-46a4-a2bd-5ce66d22afb4"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b5866e33824490488ff419bebdbb6ef_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzMtMTEtMS0xLTIwNzcxNQ_d1141e9d-64bf-4287-b9bc-b618b7fd6e60"
      unitRef="usd">479000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8662c383a6524d2ea7cd1a7de3a66edd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtMS0xLTEtMjA3NzE1_a33c4e18-b529-4630-b209-b8e65bb65726"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia643f63ceee34dc993fdef9436ce2e49_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtMy0xLTEtMjA3NzE1_399916e6-7151-4d70-96a7-b676162b53ac"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a5eb1f6967e48d08f792876eb21bd30_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtNS0xLTEtMjA3NzE1_cea41f09-1ec9-4dbb-8b29-e95a3fcf3ca9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i239109b0a39046aa954f3569a8c23d66_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtNy0xLTEtMjA3NzE1_fe2bd927-9275-45e9-85f6-e72ab025ae5d"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8d23297ea6d4d9baf0ea77a0ff9cf17_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtOS0xLTEtMjA3NzE1_1c9dc658-92b9-448f-981f-061689951ec2"
      unitRef="usd">353000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42629885d170479c82e079fcc16ce6af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzQtMTEtMS0xLTIwNzcxNQ_7e254f0b-c4e6-4ae5-a22a-8076eb46893e"
      unitRef="usd">394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30903274eb934e56a09474d3bcc6a0e1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtMS0xLTEtMjA3NzE1_01cd45ef-4e41-41c8-b7e6-9e4634b3941c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i295b427c6e5842fcb723434d6f3a5a70_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtMy0xLTEtMjA3NzE1_1766eab6-9210-4b58-b75d-1bdde7d198c2"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i324909a15d044fbfa04c98f71ac58540_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtNS0xLTEtMjA3NzE1_78486aff-8ae5-42d6-b5ea-227257bf6d3a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e5c70cdd5da42c8a415fdc4ee3a7406_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtNy0xLTEtMjA3NzE1_5a377035-1479-4038-9767-6d9e1777944e"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05fec92c81a743af8199d506c268b2b6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtOS0xLTEtMjA3NzE1_dd1b83a6-c9d6-4877-a7be-de1dcabfe17f"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a76d1cc780742139bbe99625081f16e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzUtMTEtMS0xLTIwNzcxNQ_4ab15218-a8fb-41ac-a7a8-1ed674374930"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieeb0507fddbe4ccab01b0ef5a88ce5d1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtMS0xLTEtMjA3NzE1_89e0db9b-d981-4d84-af6f-4e11cf53b33d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92ca67bd6ac74e69949d588a28fb81f3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtMy0xLTEtMjA3NzE1_6f849afe-2bdc-45ed-86b7-092a3bceace2"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0507fe44b91427c8643ec0c7610c2bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtNS0xLTEtMjA3NzE1_675e21e7-a916-4307-b9a1-c1ade8274d1e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c93ea65ff5e4ed7b39b1bf2ffc5657f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtNy0xLTEtMjA3NzE1_4e2f0d20-d113-4468-96bb-c75f39b1cade"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6774d58be5dd408890835ff4f0d2deeb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtOS0xLTEtMjA3NzE1_ab3a1d5e-dc7a-4309-92b7-74f78564cb21"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3de643ea5a37490db8249b80a35d9852_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzYtMTEtMS0xLTIwNzcxNQ_757b261c-5d6c-4328-9b9d-bb5aaacf53bc"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa71a7aabee1422c9bc80ff9f264152c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctMS0xLTEtMjA3NzE1_13b9bf49-a248-4f2e-a7ef-007c846f03fe"
      unitRef="usd">496000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if298046fc580453c82cae116d877a880_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctMy0xLTEtMjA3NzE1_00a56ea4-8093-4b4c-b87d-2c6c3fb83ed6"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib454e2af400b4edc87b8f76574db0bbc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctNS0xLTEtMjA3NzE1_6dc4d0ff-6a9e-4716-9159-e09adcc043b8"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia76a36bf32ed4d478b831da31f112eeb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctNy0xLTEtMjA3NzE1_9586a11d-a6fa-4b06-bbdd-2322fed788ac"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifec943da0f9e4157a4edf59d374dfdd3_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctOS0xLTEtMjA3NzE1_faaedeee-79ba-4a3f-8496-6c1e33bcb507"
      unitRef="usd">931000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzctMTEtMS0xLTIwNzcxNQ_a53aa89d-d415-469c-ab3b-756d493325dd"
      unitRef="usd">1944000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8d81a5cdc4704a17830a70621a701a43_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTEtMS0xLTIwNzcxNQ_3862b497-6b58-48da-b9db-349f1dbe993f"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0092c04e97d44cc7b8e987d7db42f7fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTMtMS0xLTIwNzcxNQ_6f24ffc1-37fd-4cf4-a611-b14cc9826928"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3b4496691294c8ab8af9894359f523e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTUtMS0xLTIwNzcxNQ_01b91b84-7ffc-4df8-851f-659bf7565069"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id67a9b004e36401d8688fc07e50d19a4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTctMS0xLTIwNzcxNQ_4348ca5b-a8d6-430f-841f-7f7a3b00308a"
      unitRef="usd">205000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3d7bed392714c149189fa93868f8a48_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTktMS0xLTIwNzcxNQ_00059b4d-f53d-45d8-b5f5-5da379c50290"
      unitRef="usd">107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82cb62cbef5f4deca4f2e8e3e580d3f5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEwLTExLTEtMS0yMDc3MTU_dfbc11d5-8123-45e7-b301-2db5f9052fbc"
      unitRef="usd">834000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e9a2611542a49d9bc16e7aa4527978d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTEtMS0xLTIwNzcxNQ_b7e42e12-4453-4172-bb26-d84370f8cc4a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56013d342ab744dca87c96542224d7e9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTMtMS0xLTIwNzcxNQ_76e2e8ff-59af-4daf-ad00-f871fbca39f6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88fa31de50ca45b6a6a7b566720bcf21_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTUtMS0xLTIwNzcxNQ_d0cb7374-c776-4f0d-8dd1-8e9b88393e0b"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae6f318f371c4cbb8d697ce6f04abbb9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTctMS0xLTIwNzcxNQ_ee39bb93-c22d-4226-965d-ae8df566f0ea"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26e30d1cbd3240e3bfa7140161b77af8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTktMS0xLTIwNzcxNQ_c8bef661-a9ba-46e3-b457-6055011ef614"
      unitRef="usd">386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b3e2d64225341b0baf9cc892bc9fd23_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzExLTExLTEtMS0yMDc3MTU_ee3ef4f2-ed3b-40a0-8973-dd17c4b85ee1"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4924f823451e44f3b29db4603696acb0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTEtMS0xLTIwNzcxNQ_1676b8c3-d905-4f16-867c-2d078b4cb9e1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib78fdb3892eb45d4b6b4521c1d544510_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTMtMS0xLTIwNzcxNQ_006caccb-806a-4b5a-8ff1-5969fe2ebf99"
      unitRef="usd">38000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf234d805c8b4bf18c742891e6f5b611_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTUtMS0xLTIwNzcxNQ_732ee920-d178-4032-aef6-92efcadde788"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13033d3d942041598d62836da3fc1150_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTctMS0xLTIwNzcxNQ_f3229097-88d2-4182-a7e7-c321f282abb8"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1a6ba62744a40428a6ebad3dd21ae27_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTktMS0xLTIwNzcxNQ_d234e77d-6dce-40f1-a319-929d485ab0f9"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6956da0da306428e9c7adf2d607c14ed_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEyLTExLTEtMS0yMDc3MTU_25341c45-0b81-4d17-b03d-929c471d45eb"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i954aadc6d7e24b478f75085b14eb996d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTEtMS0xLTIwNzcxNQ_857447a6-ebd8-4d57-99af-80100cb066d4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice48058f29044c469949c88a452cb9bd_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTMtMS0xLTIwNzcxNQ_5cee5de9-21d3-4a33-8780-d31915464078"
      unitRef="usd">133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if15d3638d8904493b1d72ff76791bcb8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTUtMS0xLTIwNzcxNQ_ef41d21f-195d-4026-9a39-2e257706d038"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25ae1eb1ecc54f668ec2295f497fe096_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTctMS0xLTIwNzcxNQ_baf66bfd-0aec-4dce-ab15-fe0a49c7cac6"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e328edc701b4e18a474924165dee258_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTktMS0xLTIwNzcxNQ_cd973470-950d-4e92-bcf0-2a8ce4f4e3db"
      unitRef="usd">54000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i015bfad0089f4e8fb03abd4e78cccd35_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzEzLTExLTEtMS0yMDc3MTU_8ed7eb3b-a809-496e-ae89-4a96ef8fcded"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if576ecdebb9d4e7ea72213c7c3d64c5f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTEtMS0xLTIwNzcxNQ_9affd5e8-f0eb-4480-845a-143217f41e35"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8814d42191f44bb4856713e244453471_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTMtMS0xLTIwNzcxNQ_3972caad-fb7c-44cf-ab34-e7fa504e55f6"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba18df505885492da7aa2619531de2b2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTUtMS0xLTIwNzcxNQ_36275903-abd0-4049-b40a-2c944a626d89"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id92b667bc7804456b38e70fa08da5099_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTctMS0xLTIwNzcxNQ_349faadd-ec53-46ab-b120-1063aea64ab1"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabb0e6403a294c32ae63824bc6e1c102_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTktMS0xLTIwNzcxNQ_e92720ae-8215-4789-b9fa-21468f2b5901"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8101afe6ef64e7d899f1670a46f8de9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE0LTExLTEtMS0yMDc3MTU_d261821c-8771-424d-9c95-7be8dfd2daa3"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice4470b739f04d39a1886b3405bfed9f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTEtMS0xLTIwNzcxNQ_1f2474b9-2c0e-4614-8801-f25b3bf1ab5f"
      unitRef="usd">464000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i284ff13718b143468083c69139f95230_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTMtMS0xLTIwNzcxNQ_c5f4941a-fbe3-4568-974b-e39eaa9db6fb"
      unitRef="usd">244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4d85c2876042450a967e14abaddd63cc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTUtMS0xLTIwNzcxNQ_e054db11-d36d-459a-8f98-6570f8a8bfcf"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdbe909a002041d9bac599bf26407059_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTctMS0xLTIwNzcxNQ_26770aab-89ab-47f5-bf61-61d9cd38e216"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic36a4000ae884c6883a2abeb82097b07_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTktMS0xLTIwNzcxNQ_485340e2-827e-4dc4-8313-1e0160dd96cb"
      unitRef="usd">889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpmM2I3YzI0MDQ5NmM0MTFlOGEyYTRjMWZkYmY1MzNkMi90YWJsZXJhbmdlOmYzYjdjMjQwNDk2YzQxMWU4YTJhNGMxZmRiZjUzM2QyXzE1LTExLTEtMS0yMDc3MTU_ec877c88-beaa-4619-87f9-884ccf5a169a"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyMjE_0ea611f2-84df-46c1-8a7c-e07c1617ac25"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyMjE_df160381-0216-47f1-a8fa-42857846bd1e"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib4db0b41aa7f45ffbc8ed78d848702cd_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyNTY_78f9f7e5-d04c-4c48-a0a6-502184e64e40"
      unitRef="number">0.48</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idccd693104244d1e850fcf6797ba4971_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQyNjM_b83e9ff6-c390-4f3a-9368-74d0e3600506"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2MjA_a6aa2ffe-8896-433e-ae2e-fc1a9e6a5f93">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer and were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;South Korea&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34eb56c13bb140ba8a8a420a15ef17ba_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzItNS0xLTEtMjA3NzE1_a3c86521-4f63-4252-98c2-3a947f9ec74a"
      unitRef="usd">1111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2544c5919fe1473d9274d0f8c6f34aba_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzItNy0xLTEtMjA3NzE1_fb3f7ede-9e78-486b-b5d6-5103b436a9a9"
      unitRef="usd">1115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd68bfa811af4e1f80cef02be120e2ef_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzMtNS0xLTEtMjA3NzE1_67aec372-0eb7-434c-8ff8-56294cc7a69b"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54f840f01d0d48f58279fe4612f1e496_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzMtNy0xLTEtMjA3NzE1_dacbaeb8-3d60-40fb-9706-e970cad23ddf"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ab38f7e31c74f2c8d237669db709e1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzQtNS0xLTEtMjA3NzE1_65f54016-098d-45b8-a4fa-4c894b9c69b7"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5a6fa5e6dc44421b695211384e133e5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzQtNy0xLTEtMjA3NzE1_c06bf27d-0962-4f4f-a792-96161e2ae8a4"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e193566415d44f1b34e042c627e3a6a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzUtNS0xLTEtMjA3NzE1_dbc215b1-f086-4f30-9871-3584fc4c8ca8"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f5c293c01084dc9ada28fd87e45e84f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzUtNy0xLTEtMjA3NzE1_2abcced5-1c56-4966-b9a7-bcb75992360a"
      unitRef="usd">76000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie56aa6955c9e4050b0a86980dfe8ef9c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzYtNS0xLTEtMjA3NzE1_9f9d9952-df51-4221-a25c-ee5469fd48d9"
      unitRef="usd">69000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35c155e8345e4852a74a094f971e33b4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzYtNy0xLTEtMjA3NzE1_c4204b9f-78a1-49f4-8e1d-e208c10fc2b2"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe94207c53504992b03639c875317423_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzctNS0xLTEtMjA3NzE1_ab948853-a871-48b9-9a0f-96db1209227b"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b71032da9c24495bd516ea636fbb96a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzctNy0xLTEtMjA3NzE1_1beab48e-5841-487a-ae2c-5451771cc210"
      unitRef="usd">57000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f0b8edeace144f9838fb73ef992a4bf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzgtNS0xLTEtMjA3NzE1_7984b54b-b470-4999-ac4b-61b225d0978f"
      unitRef="usd">50000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia525c6b1240948b7ac3d8f4ff68a197a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzgtNy0xLTEtMjA3NzE1_03f7aa45-d72e-43ec-b377-a6c51641540d"
      unitRef="usd">51000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i228b85d7ce4e492abb7d118eda50756f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzktNS0xLTEtMjA3NzE1_687a5079-9a65-41af-b883-010788947f5c"
      unitRef="usd">43000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4208ff78234d48a6b95a64d673fb7301_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzktNy0xLTEtMjA3NzE1_8e0b45de-0432-4319-8bf5-6bdcb74838a8"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i490f355f2ecc4859b9a79fb726c9eab2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEwLTUtMS0xLTIwNzcxNQ_d6ca0437-78cd-4ff4-9103-877d1a766735"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4991ff736cbb4e52a8b67af6a4dd540d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEwLTctMS0xLTIwNzcxNQ_0fa5a535-d87d-4653-86d4-41073401a6b8"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia62501d6a5964b1fb2ce175fd8d9ab7a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzExLTUtMS0xLTIwNzcxNQ_5b58f539-4678-45ab-a17a-f8ed29339ba6"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdf32169d53448eaa447c6c6a95ff0ee_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzExLTctMS0xLTIwNzcxNQ_d6e22f5d-a816-4212-a00b-191a8acf1764"
      unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd0ec5f9323645c896a31a7b9d2c0ffc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEyLTUtMS0xLTIwNzcxNQ_fb008817-4817-4cb0-9e6a-e70d918ee878"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7febcf7dfef54f08a344f4e803874e80_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEyLTctMS0xLTIwNzcxNQ_fc6016e9-0c86-4386-ae59-75deb9e9b455"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i269a979c418a4bc98d8b0cfceca3b1df_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEzLTUtMS0xLTIwNzcxNQ_bebdb628-a4d3-4fad-92f8-92a8598b236e"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd3eef7c95b3471bad3220dc8f4e560d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzEzLTctMS0xLTIwNzcxNQ_0d0f1dbe-37ad-497a-880b-00bc7ac3dd8f"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i470bfc29961247a9b005e84b7140ad3c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE0LTUtMS0xLTIwNzcxNQ_d2a068f5-3e77-4aa8-a5e9-ba02910aa4d2"
      unitRef="usd">22000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c45e66c585145df8939a8f99dceb756_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE0LTctMS0xLTIwNzcxNQ_16d7685f-353c-49e9-ab0e-c6a1ca5d7427"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i020c8cc6877448239e19574641b420c0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE1LTUtMS0xLTIwNzcxNQ_1e14d5f1-e8a4-4c10-b0be-f39d46c74265"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibeb78d4f9fa147ca952eee7a47399459_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE1LTctMS0xLTIwNzcxNQ_b38ac8f5-eace-4021-a993-2c7cd2bcfa5f"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE2LTUtMS0xLTIwNzcxNQ_6d6fb590-54ec-43c6-acab-217d45bccbc2"
      unitRef="usd">1944000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c18c3fe13f54519b1d0a3b582f30a03_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpjYjc0ZmE4OWEyZTc0Mjc3YmQ1ODJjNWExM2JiOWFjMC90YWJsZXJhbmdlOmNiNzRmYTg5YTJlNzQyNzdiZDU4MmM1YTEzYmI5YWMwXzE2LTctMS0xLTIwNzcxNQ_4475023a-b5c2-414f-9f1c-a5f5a3c8697f"
      unitRef="usd">1918000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90ZXh0cmVnaW9uOjg5MDhhZGM2NzU1NTRkNDQ5Y2UyZmRjNjU0N2I0MGI2XzQ2NDY_8a4b33c6-8668-4511-a2de-2d9e2355eb19">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation (including McKesson Specialty)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i53c0c9f9a29c4194a26ee2fc5d2a2278_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzItMS0xLTEtMjA3NzE1_5dab22fd-a772-4b01-b7a5-64525ec2e5c3"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2e7e267a0214438590a982060fcfc8e9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzItMy0xLTEtMjA3NzE1_f985d5cd-1a76-4ffd-95d4-1ac5c2952ba5"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifdbf70eb870c4f4c96edf59101416ef8_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzMtMS0xLTEtMjA3NzE1_673ea522-bc87-439a-a949-49f538ea8b3a"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i940b858ec7d04ba6b3901bcdc58f422f_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzMtMy0xLTEtMjA3NzE1_fb40a6ea-6c93-486c-a220-eaad726a6ecd"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia377fd0a03cc4bc29b88b780401b204b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzQtMS0xLTEtMjA3NzE1_fa3af1ec-7e3d-45fb-a3b5-d2fab87cf7f8"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia318e977ae6f4e10a9742bbf5ef4c757_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQwM2ZkODE2MWNhNjRkNWFiMjg2NThmY2Q3NDhhOGU0L3NlYzo0MDNmZDgxNjFjYTY0ZDVhYjI4NjU4ZmNkNzQ4YThlNF8xMDAvZnJhZzo4OTA4YWRjNjc1NTU0ZDQ0OWNlMmZkYzY1NDdiNDBiNi90YWJsZTpiMzRiNDE2ZDNjYTE0MjYwYmZhM2VjNjY4MjZjM2VlNC90YWJsZXJhbmdlOmIzNGI0MTZkM2NhMTQyNjBiZmEzZWM2NjgyNmMzZWU0XzQtMy0xLTEtMjA3NzE1_fb08546a-e9ce-429e-89ba-a8985b825cc0"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;4"!\9>(3)5_T69KZPU0LE):Y-O!H"#G1?6?/FXGHC4 3SH&D.T \M(!_G:
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M<^?N( YJ32S!#B.?=.AMT(;[V;8+WT,S:^/*CXG5Z5Q6DXY\( W42#_4SA)
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MQL[0(3DLZ;K4#V)[#:V?,\.7B5+9+]DVN5'@D&RMM*A:,"JH&&_^]+D]ASW
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M=(8 BR='<<F-9%M]FO7,I&21OMQ0XE.N#.#W%6-R?Z->D!V(3O\!4$L#!!0
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M>GAQG3K&G>,/^\UFA5V=D7\BDK[W\QGS?I$@N<AB>4FHUI+-MYK.$RP 0;C
M#:ZEP#>+KS'D&O!PU=9Y_M4R6[]:%S4VC?"$GM*S[/^JGJJ, =UB5T?N@28Z
MMD\+Y0R4>5:N:K7XQQ>H'U;34VOE=RIZW%+'D8)<VT9,82UON<Z>ZF*U:/;N
M;(M361^8)M!V,C]AL@X2'^(UXXHDL$)([^H: RRSIBR;:+&Q?<U<:.R2[##&
M1A:D,<#]E1#Z=6(^4+3&_7\!4$L#!!0    ( ":%I%91>1-L30<  .XT   8
M    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULM5MK;YM(%/TK(V^UFVC7-<.;
M-K&4& .6TB0;I[O:C]2>Q*@\7!C'[;_? 5/;#,/82+?Y$(-][[F7N6=>![C:
M9OG78D4(1=^3."VN!RM*UQ]&HV*Q(DE8O,_6)&6_O&1Y$E)VFK^.BG5.PF7E
ME,0C55',41)&Z6!\57WWF(^OL@V-HY0\YJC8)$F8_[@E<;:]'N#!SR^>HM<5
M+;\8C:_6X2N9$_IY_9BSL]$>91DE)"VB+$4Y>;D>W. /@:J7#I7%/Q'9%D?'
MJ+R4+UGVM3R9+:\'2ID1B<F"EA A^W@C$Q+')1++XUL-.MC'+!V/CW^B>]7%
MLXOY$A9DDL7_1DNZNA[8 [0D+^$FID_9-B#U!1DEWB*+B^H_VM:VR@ M-@7-
MDMJ999!$Z>XS_%XWQ)$#UCH<U-I!Y1P,W.&@U0X:'T'O<-!K!YUS4*T.!Z-V
M,'B'KHLV:P>3<]"Z(EBU@\5',#L<[-K!KJJ[*T=52S>DX?@JS[8H+ZT96GE0
M$:+R9B6,TI*[<YJS7R/F1\>3AWMW>C^?NH@=S1_N9N[-,SN9/[./3]/[YSEZ
M\- \N'F:!@]W[O1I_@>:_OUY]OP?NG"GWFPR>[Y$0_1Y[J*+=Y?H'8I2]"F*
M8T;+XFI$68)EF-&B3N9VEXS:D<QS1L-8X#:1N]V&&]:G44#"F*[0)$O681J1
MXO??L*E\G*6+]VB^"G.RRN(ER=G7MHJMC\@E+]$BHH)PKCP<"Y"P7E=ABBYR
M*G>_62ZCLMN&,7H,H^5PEJ))N([$5^Z=P%HL-LDF#BE92J['/Q_D@:Y(7C4A
M:Z]RA'HCZ"XK1)<9R%'OLW2(%EE*\XS1(7U%LY02UF!<@B/&USUIU3UIU0I;
M[RHX>8W2M 2]#>,P71!TP7A75 6Y1"%E;<&*KN&_D*JH6,1#*7XY7WPHUN&"
M7 ]8.Q0D?R.#\8Y.(G9"@KD[,*,"*R>>M[%F.+I2_EV-WHYI!AG6@P3S(<$"
M(+ &T;0]T;2>1#N'7#M,\ZB$0TUO%F\BL,&*V31RVT98T;#%\:!MI9MJT\83
MA+,=$S>M?%%2CLJE'K2MK$.X1C/K^V;6*Q^MHYG9&,W6707KQJQMJZ/+<B(Y
M'K79M/-M$]$?HO;6(3LS))@+"3:%!/,@P7Q(L  (K$%$8T]$0]K?ZZE]-Y.@
MJ"@V;$[<I(R N^^&Y3)YR::UA.T=BK!:?:_9P% <3T BBDK#]J4H))AKM.8;
M[(AF&\B@'B28#PD6 ($UV&?NV6?^&O:)&&>VZLK-"9.3%J[9&ND-;HJ:MD&&
M!C=A>-*K[EMM2+  "*Q1;6M?;4M:[7E'247%M-J+0KZ:ITU<:3Y]9Z/3\3S(
M>#XD6  $UJB[O:^[+:W[-%G'V0]"V$:?KLK53;F\I.%WUN5SLMN%T:S1X<-M
MF"^%G=QN]S[5X(AQAHTKS;@O,\X(Z$$&]"'! B"P!C6</34<*37N"447,=MN
ME\M?-B804<V==O.:W*@\$=DX7,VEJ?2M.228=T;V/F3 H!U0$V]HL'*0U11I
M*7="RJ(AI,1B(>6VAFI.HMSZ:W*.D2M/JF]10=$\4#3_G.8(H$(V.7 DK6+Y
M2)\N)1K5IS#?RPBJD!92]+Z;!E TMT9K=!D3:Z*- VA@#Q3-!T4+H-":=#N(
MHEBNBG)T.XMBJD#QT3$_]+0UR:&*>;%*@(45S=)X.K3!=,PO#T01'47CJ.6+
MS+!C\8*5P,PR.@;X@S*(^TJ#$@U:W/B:J _9CFWK_'PNSZ5WYQ4&%N[Z00-[
MH&@^*%H A=:DTT$!Q5)=Z[32+*:0WNISJME:.>BB]12_.11 L>[K8)X0;3!L
M.'SW%41TL&WRW5=@IBJ\Q! (S!RC0W'&!Z4/&[]2<\:@BAXHF@N*-@5%\T#1
M?%"T  JMR<B#^H=_D?QW2GR6Q^W-54@T%[<%1&P)9R+(L!XHF@^*%D"A-6EX
MD"6Q7)<$5:%Q6R9L34^0RIY;HS6F,9VG4CNI(6_D@:;E@Z(%4&A-AAP$3"Q7
M,/LHU[BM!K;W%Z=M7'E*O>>TTQ$]T(@^*%H A=8DP$&FQ'*=$E+"Q@*U#_,W
M-\XQ<N5)]Z;(&2$]T) ^*%H A=9\0NL@@*IR ?3VSSOT1HJ2"T77DW*W:EO%
MXZ<'@<F0TQ1<>2I]*W]&1 \TH@^*%@CR[Y"SU8.4J<JES+/N3*AM49#MYQR^
MH$(K?KR7Y].[I* :Y%E7X(/&#$0Q[8ZJ'CU&*5<,^]RD4-ORGLG?:E3;0IMI
M\86%?#AP"HKF@:+Y9[1&(+ 9=D@;ZD&:5.72Y/GW'31AI47RH&8JEL(_5CB1
M)]+[T=>.P*)G7T%U25 T'Q0M@$)K<NF@2ZIR75)^4T','X&2J+>&BK;1T.;+
M[(J@%%TQ>#8(S"Q^/2^*Z&BVQ0_; C/LV [?<=MFCL[?5!@=O9=1O@G$FNXU
M2@L4DQ?FI;RW&-7SW<LUNQ.:K:M7-;YDE&9)=;@B(=MZEP;L]Y<LHS]/RK<_
M]J\XC?\'4$L#!!0    ( ":%I%:.NGC9- @  $,E   8    >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&ULO5IK;^.V$OTKA&]1[ +QVJ+D1]+$0#:/=H'F@?7V
M]C,CT;;N2J)+TO&FO_X.)5N4I2&=H$&_)+(\I,X,9^;,C'6^%?*[6G&NR8\\
M*]1%;Z7U^FPP4/&*YTQ]$FM>P#<+(7.FX:-<#M1:<I:4B_)L0(?#\2!G:=&;
MG9?W'N7L7&QTEA;\41*UR7,F7S[S3&PO>D%O?^-KNEQI<V,P.U^S)9]S_<?Z
M4<*G0;U+DN:\4*DHB.2+B]YE<'85C<V"4N*_*=^JQC4QJCP)\=U\^))<](8&
M$<]XK,T6#/X]\RN>968GP/'7;M->_4RSL'F]W_VV5!Z4>6**7XGLSS31JXO>
MM$<2OF";3'\5V]_X3J&1V2\6F2K_DNU.=M@C\49ID>\6 X(\+:K_[,?.$(T%
ML ^^@.X6T/:"R+$@W"T(2T4K9*5:UTRSV;D46R*--.QF+DK;E*M!F[0PQSC7
M$KY-89V>73W<7]_<SV^N"5S-'W[_<GWY#3[,O\&_NYO[;W/R<$NN+N>_D=O?
M'_Z<DS[Y8WY-/OSTD?Q$TH+<I5D&IZ'.!QK F"T'\>[!GZL'4\>#0W(G"KU2
MY*9(>'*X?@!*U)K0O2:?J7?#.R8_D3 X(71(0P3/U>N74P^<L#9L6.X7N@S+
MU(K<0I0H<BM%3A[67#*=%DMR:3PWU2E'K5;M&N&[FJ ^4VL6\XL>1*WB\IGW
M9C__)Q@/?\%4?J?-#@P0U0:(?+O/[B$'94*A2E8KQ^5*DVB>9WTZ/#T?/#?!
M(T+C<2US@&E48QIY#^4R^1^$%&0AK8@6D(9B4<1IQDFQ VONFNO8G-Y:BN<4
MG),\O1!1'Q^KC^\,4VWTGN?W3IL=V&I<VVKL/;]K#IO&*:NR;9$0E@NIT[^K
M&V(!X:]9L4R?P'Q,*:[1DZZ>,6H<8ABT#QJ1&5'\H"<U^(D7_&43JP&_E:GF
M?;%8&.0)?])PNCQ/-[DZ(4FJ8K$Q/F$D4Z4VK(@YB87"=9IT\ 9!2R5$),(U
MFM8:3?T:&1.3-%^S5)8.C"&;=A\;MI!U1:8XL-,:V*D?6/S7)E6IL71?\HQI
M"!@(*Q,K --<*@@B61X%AOD4\9 69D0$QQP,+>T-_:@S2,WFF!6!6JB,?;@$
M9]&2)=QD!IX^L]*WC4\4SZ"+D(Z<O7O6@=V'+1TP&8=+! WR#H[$Z()+R0W
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M;W)K<VAE971S+W-H965T,3$N>&ULI5==<Q,W%/TK&I?IP#3$L9U )DTRXX0
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M>1; ^=RYN%FP@_[_@,M_ 5!+ P04    "  FA:164T:0A+T%  "I#P  &0
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M]A#(^#JS>RCT@J\03W11Z(S_G"L)BZ,!^#[5V*9_H 7J.^6O_@M02P,$%
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MYL?1>'(!WZ+9]#S8_?C@C8S[P!]-0SA;.(#M3(85Y W>1888GXU#AAB-:JR
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M]V0,,7+#5*(D\32V33)A($$;'M4MQ!S]K1N7)ZRRFEW95>NDVT)4W6ULPMP
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M.3G]$(%MRU$[(=.$$I ;XH(2AA57<+3>@/=7QM#3Q!^P_R>,?@-02P,$%
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M+2)9=V?=/$9;X>X%K+TD;P?DAOP&^@-E= :@;E@J/6:=B/L-1K+,*M'KC1$
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M3CAMJ3^4V1:'!*U3EMF&WJYE"*C&!O#[70;LKC[@!/<@C@F\5_\+4$L#!!0
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M &DSA+CU+9<O&!V5UG+WQ&\M\#^B'?T)PK[B-'@C81EU3$@1H@=KNV#!B!+
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M1-(HV1O$_NRD]_]BAL>'G)N6B8$J_Q/+#,^#97;]?.FD\WNS0J%5I5_5T2P
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M*PY^5!1CQM. F1*[RCFE\\ 0<.,I]"60H0Z>9@@4:L$D01 ;<L+E$@W!:,"
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MJ6?6Q?*VFZ(YY2@'*%BM/*#<Y]=954>G?<OT0W%;CHXM)'?[C3C*S&)?600
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M@^A'8\OO^%S'X<>\D-Z=Q!/TU-PF6I$>VQ#A2F[>/N>BT[#+^I=[<](C]WZ
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MYW:P-J\6JJYZ^FR@S>P^JD?6W?5Z\"<EYSEYJ, 9D;KO8GI7R7J8K@]:+.T
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M1E#B1K2*UF9WA_MX+CU?890+7]AUMI=)!$7KR-1[,"NHI>YZ\;P_AR/ \"U
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M&/Y[H)H2OQD8N7!E]40:+-)==X[_BIBR OA]*C'8M0.[0/<_:_@O4$L#!!0
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MZ7L=#V)<LX*;N=S>X;Z>2\L72:[=%[:E[_6E!U&AC<SV8,H@2T7Y9[M]'XX
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M<=YANL6<U)CQ,Y@)W"AI<P-3F6'V-#XD?GN2\8[D)#X)>,-T"Y+V&<11G)S
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M;UF;)HC3[6'8 RT?6\0DTB.I7/;K=TC9<MPZ;CH,2"2*/'=^WZ%Y<J_T7Z9
MM/!0E=*<=@IK%\>]GLD+K+@Y4@N4M#)3NN*6/O6\9Q8:^=0K566/]?M)K^)"
M=H8G?NY:#T]4;4LA\5J#J:N*Z\=S+-7]:2?HK"9NQ+RP;J(W/%GP.8[1?EU<
M:_KJM5:FHD)IA)*@<7;:.0N.SU,G[P5^$WAOGHS!93)1ZB_W<3$][?1=0%AB
M;IT%3J\['&%9.D,4QM]+FYW6I5-\.EY9?^]SIUPFW.!(E;^+J2U..UD'ICCC
M=6EOU/U'7.83.WNY*HU_PGTCF_8[D-?&JFJI3!%40C9O_K"LPQ.%[#D%ME1@
M/N[&D8_R+;=\>*+5/6@G3=;<P*?JM2DX(=VFC*VF54%Z=CA^]^'RW9=;N/CR
M_NKF\NSVXNH+'-SR28FF>]*SY,')]?*EM?/&&GO&6@B72MK"P#LYQ>FF?H\B
M:\-CJ_#.V4Z#EUP?01@< NNS<(>]L$TW]/;"Y]+%.2'*P@TNE+9"SN&/LXFQ
MFL#QY[9T&VO1=FN.,,=FP7,\[1 C#.H[[ Q?OPJ2_IL=L49MK-$NZ\,Q$7!:
MEPAJ!F89M\8[E#4:X'(*"ZUFPFX+^P>&GS=FX!XU C<P4R41UAS#;:$1-_85
M:%?RPF_+@9"$RK(D@IFNWR3W8%3?QO0QC'DI'F /HD'BGDD$%]*BEMR1DI?
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M/TKIX-7-_:KYL&KA[S039:GR?EC0E12U$Z#UF5)V]>$<M)?<X;]02P,$%
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M84K/-RI[@/83*<W3Q#XI]1^"X!=02P,$%     @ )H6D5NYW/PYK P  S1$
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M!A?TTA\QE@65ZYP*:J&"P5T<\74"9I%/_>IX0Z15YH;><KM&6L [PBX AF<
MF0@K^$Q/'XXT='!9:ISAX1:\Q]D4/(IEZ.]">@8@.C>],Y'RGHI5P=/2/9-P
MEQ?Z*A3+BT1+F@ 2^6!.$\KVXN+O>1R&0,S? V'^/ZH2YQ0L-854$RZ3+5G2
M\4 L^@QT,/GU%^B8OZGJTQ-8I5I662U+ASXI<@8+N@JB*(A68K6&:4E46>=0
M3@:5"M=^ CUHCHS]<3:*H*&#RZ *2[MD:6M93G>,I4]O2UD0^V!;+A 5RQS*
M/B: 75ACJ0A"MJ-FZ90L'2W+!_(CG6/Y9%HRZ@=<2=!I_/8YM&Q<8ZB*0LA5
M4W1+BNY)CYM&_CO/VFT6:(B&-8ZJ( ^I*0Y+BD,MQ9L@6<:[MS+*):HBJ47J
MN@Q[ JLD[95)>Q\O6EZ?U>H)K%(M:,IV:O8G6P56=9K6I[(B"*&6J0R/VC[L
M3[@*K*IR>76>JB"KA2>2/%$OTE7 U+2K44M5E--63-G8H;83=A"O JA2)+=1
M2460UU9)V4_A>PV5[UC+\]6.[+H ^T*KYBD[,K0_7K&@UA9TKEA/:-6*27<
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M*!K+3WKS"QYOL\/21<QYO,D^KBGQ*4L#Q/<O<<S?+M(?*,_;)_\!4$L#!!0
M   ( ":%I%;X@1?R00,  "L)   9    >&PO=V]R:W-H965T<R]S:&5E=#0S
M+GAM;*V646_:,!#'O\HIFZ9-6AM(@-(.(@%E6Z6UJ^BZ/4Q[<),+L>;8S#;0
M?ON=$\@HA&P/>X'8N?O[=V?[+H.UTC]-AFCA,1?2#+W,VL6%[YLXPYR94[5
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MSK)YDB6KXN=*[I,L2Y;%PP5GDKKF!O+]AR3)7I[DOX!2_43.Z']02P,$%
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MLB!(A61Q 58>Q#3)G^1;D8@C@--Y ^ 6 /=[0/<-0+L M-]KH5, .N\%= M
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ME#; G&^$T,\+.YE5@WCP/U!+ P04    "  FA:16Y"CA3D(#   Z"0  &0
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MJE<%Z1YIO(8",X)LG76H$55U4U<3(Y?NLGN4AJY.-\SI<8/*&M!^)J5YGM@
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M Z+LGN5$\8UM0 NN=#NSP[7^X: P 7I]R;G:3TQ/JW]AT3]02P,$%     @
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ME*PHSP+D[VO&Q/-.]HJT?"4^_A]02P,$%     @ )H6D5K_@_$L+#P  4=D
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M?=^FCU8.4$VBFD*U$-4B2M.;J4DF..;/9+AO)O%(,ST3JR*Y6<VKG]^TGU]
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MNF3W;"B['^COO9F9*#!:@@KPJ&H,2TTU60)\YA[@,U2 1U5C6&JJO1+@,Z<
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MI6[$_3M>G]"@Y(5BE5?_T7U]K-=#89$KD=3!N@=)G*Y?V4,MQ%: YC0'X#H
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MIF7PG4BK9+DJ_U(O_/M[$7SWSW]Y>5'5F]2 +^;M\'(W?/3$\*/@YSRK[LI
M9HMT8:]_4>_*X_Y$^_UY'3F!/R?%>3 *7P31930:V)X;]^IO\T_G033;KAX-
MK"Z.C?X0A)=/KBV_;MN5>W61SA]7'QI=NU?_<9.=!Y?;U<,KQY$8/29KM.6-
MGMR<#U7P)BNK8E.?NZK@OWZJ%PC>5.FZ_.^!K7N]HXV':<TI^?OR/IFG/YS5
MY]PR+3ZE9]?_\D_AY/+?AXXR"1,D3)(P1<(T!+/",GX,R]A%O_ZU6&;SY7VR
M"I)UOJG34I?-LDJRQ3+[.!26'6VRI37E]M-U.+N<32^W_[V\^&1FP3FR;Q9(
MF/38"S6T;!A>#BVKH8VTCF3\>"1CYY%\M3M^BR+YG 6;^JQ>!/-=[;C=U8Z'
MH>,9'^Q==#F)1X/'TSF^[_$D87('BT_9"S6T['0R&3R>T$9:QW/R>#PGSN/Y
M.MG4%\#!OP8_Y>L/0X?.N;KO>9N$"1(F29@B81J"6>F8/J9CBA;Y*1D6$B9(
MF"1ABH1I"&:%Y>HQ+%?N(I\6\SHD]2UND-\&Y5U2#Q'<I:O%4%)VJ)EQ?KP\
MOYKU2H%S/-\$D#!)PA0)TQ#,2L#L,0$S9P+":!)&T2QX?7YS'OQ4+<Z#?P1'
M"XP3Z7O.(&&"A$D2IDB8AF!68L++3E!<HB6FQ4%Y06D"I4F4IE":IFAV: RK
M%7*EQLWR3DQX0N42Z)@2I2F4IBF:G82H2T+D3,)O:;&N2TN2!:_W]O(A$)LT
M^'%3GT:BRR@>C(03ZAT)DB90FD1I"J5IBF9'IQ.8(6LP0U1AHC2!TB1*4RA-
M4S0[-)W(#/U,YF!02(MX@]($2I,H3:$T'1XJU7$\B7L&SHY!9T%#MP9]LNR\
MS3^EZP]I\73I(97D#4H3*$VB-(72-$6SX]-)UW#"EA[4PJ(T@=(D2E,H35,T
M.S2=BPV=]NZTTH,:6)0F4)I$:0JEZ99F?OH3MH7GR=+36=;0K5F?+#TJ_5!L
MDN*A*3W3P7"0HO$&I0F4)E&:0FF:HMGQZ11M.&-+#^IG49I :1*E*92F*9K]
MT%4G:2.GSSNI]+@1OD%!::*E60\@')Z0VX>X4.V*TC1%LV/0:=?HB';U?(RG
MQ5F_]O'EX$,0-^ZAO0\XZE];6GS"?JC!94>##_UH:BOMP]FYT\CM3K_L69X6
M:NW@:#+\+(][ [P/*FI&/?9##2X[BX8/ZG-8S:BSFI%3@%V_RK+-[A]H42W_
M-]D^$%XD51I\EY1!$MSO/CD9>I;WM9OL?09'!6=+LS]VN8S[YVY47*(T3='L
M7'3B,G*+R_^H;PVJM%@]V-&X3QZ:R\!R, ^HQT1I(CJT>V'4EWMM*%!)B=(T
M1;-#T6G,R*TQWZ7-^RQU]0[^_@7Q.'S&<3R9#=<!5%.B-(G2%$K3%,V.1Z<I
M(_?#H:>IAN ?]??UQ4-==51]%3&<%51@HC2!TB1*4RA-4S0[3IW C-BG22-4
M9J(T@=(D2E,H35,T.S2=[HS<NO-O2;%,/JS2DR]B4<F)TD1+"T/[*O;P,A;5
MERA-4S0[#IV^C-R/F)Y<DEXG91J\:S)3+U;EQ8O@_2_JW6!B4,.)T@1*DRA-
MH31-T>R7&3O#.6(?0QVAMA.E"90F49I":9JBV:'I?.C([4-]:Y,;YQT:U)B.
MAIYKO0Q[E0D=4Z$T3='L,'0V=?2%3Z+V*U-3A[:5:3 BZ).I*$V@-(G2%$K3
M%,V.DO%J/?QN/?MR/?MV/?MZ/?M^/?N"_7,(WE$G>$=NP>M=C%"[B])$2^O?
M*,51_TX)'5:A-$W1[#QT;G?D=KM6'EX$R]M=,+*\"I)RGA95LLRV?W]"5-!G
M5E&::&G]J(0'24$U+TK3%,U.2J=Y1Y#F?;QRJ;_^>9DMUYOU8%Q0V8O2!$J3
M*$VA-$W1[%!ULG?$RMX1*GM1FD!I$J4IE*8IFAV:3O:.6-GKQGF'!I6]HQ-E
M+SJJ0FF:HMEQZ&3OB):]@R%!_2Y*$RA-HC2%TC1%L_N/=7YWS/K=,>IW49I
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MGE?[;YH!/N?%']O-N_X_4$L#!!0    ( ":%I%9B!%24WP8  #,\   9
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M"D'SXG )> Y,!<CK"TK%4T/M"]4[C>,_4$L#!!0    ( ":%I%9HB$7'?P(
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M4$U^#&;:*#S,/]NR5K%VVUEM@5_H)<V@[V$%:U!K\-+W[SIQ\*G-\G\B>Y6
M;I. [B'V] LS;$&KPD7[TN4#B]" :CTN%5OLV&PC6J>GYXF_WK73$M)I0EZ)
M[#4B>P=%#K+G%=/,JCQ5P*F!G&1X+IE8@#!VJ%D.RMEH$UVQ]W8419T]T2TA
M[9KC1G-\4'-ULF!;GP),F[+XKUR%T9ZREI ]9?Y.ERE!+5SSU9B6E3!593:K
M37\?N+:VMS[$OE^UZ3\TU:6!=;=@0A,.<Z0,SCYBIE35B*N)D4O7RV;28&=T
MPP+O+E V /?G4IKMQ'Z@N0W3WU!+ P04    "  FA:16GJX=?#H&   Y)
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M'U=($A1F@OZ^X%R]#HR#NG,U^1M02P,$%     @ )H6D5K;YHUJJ"   (G$
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M,RW&OM(#,K;^JNP\.78>G>D\A$>>JZV$NSS%M*[W=2!5--%;-+=1J^%G?.Y
M.+R"*(BZ#>.)V^6_DKP#T<C(P^NF<-KELT)TH!M8^:@EFF[U;+K6KW?&+R:,
MZI6=4P(+P0LNJ5TJ@SX\(2,*4W@D2J& N:[8$%/9,.C;UD[,OG(C"[+"B:<W
M#HEBC][TQQ_"0?!S$T"79HDCLQK<7@6W9]V[YR8^EQ)B/?UHOL%\15'"GW/=
M!AX49O*O)I ]ER!=FB6.S&H@^Q7(?NLL72KR"GP-I"@$WQ-V!1FW\U1QP!>%
M>7H%!0K*4^ Y-G%M]Q\$D)+7IMTE;A5>RM"168WAH&(X<,50'7@3PW;_X5F$
MK;I+$3HRJR$<5@B'K2&^[X'Z#:JV8$X%>FM<ZCWT!>*[+TW06ATO7= NS1)'
M9C62HXKDR/7..'()TJ59XLBL!O*Z GG=.B43DNFCLP3)=_KPV<2M57\IMZ/9
MP)J9X_Y^V@W&_OZ4AJ/^:C3"X/VH&;3SX"O%A8098R@VKW:)[ABY@OD\_I<S
M3+OSI:2<NB6NW.I43P[PH>OE6CJZHNG2+7'E5J<9O=.,_N>:;3>X&)Y+MZ1T
M.]T#3!ZT/T7BGR2+^@VYL4FWA!7?Y>J8-U9WJ\1^9M-9_[WY\:O (Q$;JE-#
MAFLM#3I#?882QT3[6%"\L*GG,U<ZD;676R0I"M- UZ\Y5V\%TT'UN6/Z-U!+
M P04    "  FA:16=_CZNJ("  #O!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970X-RYX;6RM55UOVC 4_2M7F31M4D=" EW70:1"VZT/4 3=QZN;7(A%8F>V
M^9BT'[]K)V10 =I#7Q)_G>-SKGVO>QNIECI#-+ M<J'[7F9,>>W[.LFP8+HE
M2Q0T,Y>J8(:Z:N'K4B%+':C(_3 (+OV"<>'%/3<V47%/KDS.!4X4Z%51,/5[
M@+G<]+VVMQN8\D5F[( ?]TJVP!F:;^5$4<]O6%)>H-!<"E X[WLW[>MAUZYW
M"[YSW.B]-E@GSU(N;><A[7N!%80Y)L8R,/JM<8AY;HE(QJ^:TVNVM,#]]H[]
MWGDG+\],XU#F/WAJLKYWY4&*<[;*S51NOF+MQPE,9*[=%S;UVL"#9*6-+&HP
M*2BXJ/YL6\=A#T \QP%A#0A? CHG %$-B)S12IFS=<L,BWM*;D#9U<1F&RXV
M#DUNN+"G.#.*9CGA3#R[^S*Z&S_!P_C^<3JZ>7IX',,'&#.EF(TOO+M%PWBN
MW_=\0]M9D)_4U(.*.CQ!'<%("I-IN!,IIH=XGV0V6L.=UD%XEG#$5 NB]@6$
M01@=T3/\?WAX1D[4A"YR?)U3H6,YW\(?^,GG;,L$#!2S1F&B9+I*C*:I*:Y1
MK!#F2A8PI&@HNK9TPB:#H3M;5!<PPP6EA8$!BB2C5%H2L.:PF 0MS-WY*=?+
M8^=P5J>M ]>Z9 GV/4ITC6J-7OSV3?LR^'PLB*]$=A#23A/2CF./3H6T#H7"
M4BK#Q0*XJ"H5V3_FO/.:SE^)[,!YMW'>/7N9#@]:T4%#B<H.42T]YKRB^^3H
M;*E>QT'KJN>O]PV=7U/I]/=J!UW'A2NI&A*Y$J9*S6:TJ=HWKEB]&!]0-:^*
M[S^:ZBF@Q%MPH2''.5$&K8^D2U7EM>H86;H*]2P-Y81K9O0BH;(+:'XNI=EU
M[ ;-&Q?_!5!+ P04    "  FA:16=[,J.LL&  "P+0  &0   'AL+W=O<FMS
M:&5E=',O<VAE970X."YX;6RU6FMOVS84_2N$5PPMEM;F0WYDB8$\VBU W01)
MNWUF;-H6*HD>22?9L!\_2E9$2Z08JV.^)+)\>7PN>:E[[A5/'KGX+M>,*?"4
M)ID\[:V5VASW^W*^9BF5'_B&9?J;)1<I5?JC6/7E1C"Z* :E21\-!L-^2N.L
M-STI[MV(Z0G?JB3.V(T <INF5/Q]SA+^>-J#O><;M_%JK?(;_>G)AJ[8'5/?
M-C="?^I7*(LX99F,>08$6Y[VSN#Q113E PJ+/V+V*/>N0>[*/>??\P]7B]/>
M(&?$$C97.035_Q[8!4N2'$GS^*L$[56_F0_<OWY&_U0XKYVYIY)=\.3/>*'6
MI[UQ#RS8DFX3=<L??V>E0P7!.4]D\1<\EK:#'IAOI>)I.5@S2.-L]Y\^E1.Q
M-T#CN >@<@!J#B M W Y !>.[I@5;EU21:<G@C\"D5MKM/RBF)MBM/8FSO)E
MO%-"?QOK<6IZ]_&WV<<O7\'5ET_7M[.SKU?77\![<,=6>JD4N&4/+-LR"6BV
M #>"+V,%WEXR1>-$OM-VW^XNP=LW[\ ;$&=@%B>)7AEYTE>:6 [?GY<DSG<D
M4 L)#&8\4VL)/F8+MJB/[VN'*J_0LU?GR LXH^(#P/ (H '"#CX7AP]''CJX
MFF1<X.&V22ZG4[ -%RK.5GJZ=CM0SY=KNG9PQ V7[^QCN:%S=MK36U<R\<!Z
MTY]_@L/!KRY? X'5/">5Y\2'/GT.()>3NY'#8F3^M'F8P@DA)_V'??(N(SBN
MC&JDHHI4Y"5UO6&"ELLPYRESD=LA1/N_.XH:W&P;-([<U(85M:&7VEF:!\@_
M16  OM0$%<U6\7W" )62*>=$#BT>[]$(-\@ZC# <N-F.*K8C/]N<$HC3#8U%
M'N!.=B/[AV&3G,.F98W'%;7Q"X$GE=C.U5;H=3[*YY&M1#&M1T"R#=U=%\^U
MJYMK,.?2S7[L8#]HL'?98#?]245_X@]1M68"L">=K24[ AE3+G(3Q\(WI]9E
MX^8&!R9G#+SLKO1LZF>%\NR?$F'_=X<-9@Z3-F9[V0P>QJR<.B<UZ-@*@U&3
MG<MJV$80&8+(2U!K#ZTL,LUOOM8[FQ41R//5=E)%!X2?RVC4PM-D+.A-"]//
M7$IPSW268N4J T6?W _R$JJQ :SE=EB-V^;3Y!?H3S!W-(F?G*2\X[KFT%!H
M=2]-PH)16 $!O1FPL_>!T.K>FYP(_4G1)R*@G=?(Q H]A]&0M(2>27[0G_V*
M9TU6+ %-G-R\XSLO0B"TNK<FG\)QX!#T)NC.W@="JWMOTC'TYV-O"-HI%A$K
MG;B,6D(0F42,_(GXCB>*@AE;Q'-W"/K'=UV$4&AU;TUR1S!L""*O6.CL?2"T
MNO=&.2"_<O"%(+(E@%4 N&Q:TB\R,@'Y9<)E_,"$C)=QLVPO>04M9$.AU7TU
M4@.1P.$75(*$0JM[;R0(\A?-WO!S5,N3YA/0883(I"4 C39 ?FUP3K=RO@:_
M@,\\O7=R\X[OO B!T.K>&LF!1H%#,*@$"856]]Y($/123>\)0;L(GV#8#$';
M:#QN"T&C#= +M7K53BJ7Q\G/B]%Y(0*AU;N91G;@0>!^9E 9$@JM[KV1(=C?
M8_"%(;:[!HZFIM.JK:N)C4+ ?H5P2%\3.U0 :38V'49CV*(5\%X3W*\5K'T"
M_@6MY;L?JW/$O(9RP$8YX,#* 0=5#J'0ZMX;Y8!_7#E@6Q38Y;O+J*U\QT8Y
M8+]R.&BWV(T##*W=[#!";;O%I'KL[RZX=LN+'0<_9N>X>8UTCTVZQX$[#CAH
MQR$46MU[HRKPCW<<\"$=!Z=1RZXA)O43?\?AD%U#[,;^J,G.83.!+>1,9B;^
MS.S,,"^U2/R87:,F%%I]!HP$("CLGB%>2='9^T!H=>^-PB!^A>%]VVR_?K!:
M)"Z;E@<YV7L#[G]#<=".(78*:69!ETW+VV9B<C,Y]%6XV3$O]'3\B)TCYC5>
M+1 C L@P\'X)VDX(A5;WWF@,XM<8WOUBOY.W>SH.H]:>#C&)G_CK_(-VC%W*
M0^L=KLLH:BFSB,G,I&.]K_?,BVTH/V;GN'F-^C\R(B *7/]'0>O_4&AU[XW*
MB'Z\_H_LRMYN0SF,6MM0D4G]T?^O_B.[L$?0HN<P&@Q;Z)G<'/ES\P47.EBH
M<O,*6NV'0JM[:A)^%+C:CX)6^Z'0ZM[OG:T+<+AN![%_JN\]BJPX=%C!2;."
MZ>^=?4V96!5'@B68\VVF=@=&J[O5L>.SXK!MX_XY/+[8'1XV,+NSS#,J5G$F
M0<*6&G+P8:2)B=WQX-T'Q3?%"=M[KA1/B\LUHPLF<@/]_9)S]?PA_X'JD/;T
M/U!+ P04    "  FA:16P+-1]L4)   $8   &0   'AL+W=O<FMS:&5E=',O
M<VAE970X.2YX;6RU7%UOV\@5_2N$NBAVT38BA]^I+2"VLUL#ZR2(L^U#T0=&
M&EO$4J*7I.T4Z(\O2=&ZG ]>>9@[+[8EWSF^<^>8.C.'O&?/9?5[O>6\<;[M
MBGU]OM@VS</;Y;)>;_DNJ]^4#WS?_N:NK'99T[ZL[I?U0\6S33]H5RR9ZT;+
M79;O%ZNS_KU/U>JL?&R*?,\_54[]N-MEU7\O>%$^GR^\Q<L;G_/[;=.]L5R=
M/63W_)8WOSU\JMI7RR/*)M_Q?9V7>Z?B=^>+=][;2\]-NQ%]R#]S_ER/?G:Z
MN7PMR]^[%]>;\X7;I<0+OFXZC*S]]L0O>5%T4&TB?PRHB^,?[0:.?WY!_[F?
M?3N;KUG-+\OB7_FFV9XODH6SX7?98]%\+I__P8<9A1W>NBSJ_JOS/,2Z"V?]
M6#?E;AC<9K#+]X?OV;>A$J,!+8Y^ !L&,'E ,#' 'P;X_40/F?73NLJ:;'56
ME<].U46W:-T/?6WZT>UL\GVWCK=-U?XV;\<UJ]OWO]R\__#%N?[P\\?/-^^^
M7'_\X/S-N<KK[/Z^XO=97^ORSOG,G_C^D3L_7O$FRXOZIS;JM]LKY\<??G)^
M</*]<Y,711M;GRV;-JT.?+D>4K@XI, F4O"=FW+?;&OG_7[#-^+X93N=XYS8
MRYPN& IXDU5O'-_[J\-<YFORN7S]<(:DXQ]+[/=X_@3>=#'__6L;ZEPW?%?_
M1U>W VZ@Q^W^P]_6#]F:GR_:?^&:5T]\L?KSG[S(_;MNTD1@0@F"8PD"#'TU
M3%A+CL/(J!_9776>5EX:!&?+IW'RNB O.08)287'I$(TJ4_;K+T.K/ECDZ^S
M0IL;"F"Z $1@PERCXUPC2QR,*$M !":4(#Z6()[-P</(<$2OI+MR"!34Q/B!
MGH'),:4$3>F*/^5K?4;H0-.R$X$)<TR/<TPM,2^E+ $1F% "SX4/67<V]X:A
M8V(%<2J13Q<43ES_O-%GOX>F]?'+I38C=)1IY:G0Q#DRF".SQ+\!F*H,1&AB
M&4"#>.CG.\Y 7R&7G\J?P+J@.)I@(.@"#Q<&%U76B3ZG_>I\;+:\<G[A>U[E
M:WVB*)CQBA"AB5,']>&%MHA)*DNHT,0R@##QT ]]G)B1PCG&(IF8NB!_@I@@
M%CQ<+1S(6&')H0#&JT"$)DX7A(B7V"(CJ5*A0A/+ %K%0W4 3L94PS.9BYJ8
M6$]%!N*!X>+A-BOR;[J,\'&FI:="$V<)6H1YEAC(2.4*%9I8!I K#-4!* .'
MH8((3.7+H2XHFMBG,) /#)<//0>=_SFOV#/C2,;+8>/8@H$^88$M5I)J%2HT
ML0R@51A^5(*R,GP-*S5!DZP$[<!P[?#"2F0?C2,8+X.- PP&HH3%MMA(*E:H
MT,0R@%AA^+$)RL9$(9HK<Q$+$5,"X<!PX?#"Q(D=-3[:N/PV#C-\T".^:^L\
MFU2P4*&)90#!XN.')Q@+AZ$8"]$0,240#SXN'EY8:+:KQD&-5\7&.8<_\EJL
MF2VT;HL-W>*#;O'G&R[#4)2<6(B8$F@(']<0QTODR9TU#F2\$C;.-WS0*+XM
MY\4GE2Y4:&(90+KX\]T77[56%$)B(6)*("-\7$9<[QM>[?MER0IM7J1'&U1H
MXFQ!H?BV?!B?5+Q0H8D^-(B78+X3$Z@F"PMBV8G6!4WL9 (0$P$N)@0NOFZ?
MC2.:+@L5FCA_4"Z!+9<F(%4O5&AB&4"]!/-=FD U8$*%G)J8"9<P&-V[@6L)
MF9O(;AM',EX,&X<> 0B6P)9!$Y *&"HTL0P@8(+Y!DV@>B_R)S<:(J8$8B+
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M_O"B*1_ZINU?RZ8I=_V/6YYM>-4%M+^_*\OFY47W!XZ-_U?_!U!+ P04
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M'9'; T%7V:;"9RKD[<]>+@F>$98&R/?GE(KW@_0"Q;[4X;]02P,$%     @
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MJ375VY^G+6HZD2PQ7=XCD^KZS7"AVGK@.D#MSQB3VXD^(/^C$/P#4$L#!!0
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M$+&<44RDF &S8ZX=+Q)WCJ_;^E8Z\2(B ;WV6HV.)#-@MHP7Z/XX#Z/V#3)
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MMJL"   K-@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I-:N-
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  FA:167C5O!>\    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  F
MA:16F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( ":%I%;QZRWE^ 4  ,X?   8
M  " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  F
MA:16TXW78&L&   )&P  &               @($\#@  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ )H6D5H*@0R1C @  YP4  !@
M         ("!W10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( ":%I%:E[5I9, 8  !P=   8              " @787  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  FA:16#KATH),#   F"P
M&               @('<'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ )H6D5E%Y$VQ-!P  [C0  !@              ("!I2$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ":%I%:.NGC9- @
M $,E   8              " @2@I  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  FA:16,/OQ!K #  ! "   &               @(&2
M,0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ )H6D5O@<
M?8K9"0  =QD  !@              ("!>#4  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( ":%I%8J<ZMW+PL  &,>   9
M  " @8<_  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M)H6D5HHW",V;!0  $PP  !D              ("![4H  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  FA:164T:0A+T%  "I#P  &0
M            @(&_4   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( ":%I%;O$$A!(@X  %\N   9              " @;-6  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ )H6D5OH NKUG @
M/@4  !D              ("!#&4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  FA:16[WZNC"$:   <;   &0              @(&J
M9P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ":%I%8^
M[]#!T0(  !\&   9              " @0*"  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ )H6D5H=FM#;6(   )X,  !D
M     ("!"H4  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M"  FA:167E3%>N8,  #:*   &0              @($7I@  >&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ":%I%:1&2.5U0,  *P(   9
M              " @32S  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M A0#%     @ )H6D5H.S$,6Q @  1P8  !D              ("!0+<  'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  FA:16D=X5Y?\"
M  #?!@  &0              @($HN@  >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+ 0(4 Q0    ( ":%I%:EL&0H8PL  '<@   9              "
M@5Z]  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ )H6D
M5I>@U[ZW @  4P8  !D              ("!^,@  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  FA:16,3C39ZHF  #+AP  &0
M        @('FRP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( ":%I%;)1Z&,K0@  # 6   9              " @<?R  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ )H6D5A&W)H]<"P  U1\
M !D              ("!J_L  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  FA:16-'>FVO($   K#   &0              @($^!P$
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ":%I%9,7BEN
M5@8  #L5   9              " @6<, 0!X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ )H6D5II IC6" @  7@4  !D
M ("!]!(! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  F
MA:16;!3BRY(%  #=$   &0              @(&M%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ":%I%;0:[MXX@(   X&   9
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M970S-2YX;6Q02P$"% ,4    "  FA:16!]SB7'L"  !O!0  &0
M    @($?+@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M ":%I%:(_?%5T (  %(&   9              " @=$P 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ )H6D5GS#(PK<!0  \ X  !D
M             ("!V#,! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    "  FA:16J?3-X>$"   <"   &0              @('K.0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( ":%I%;N=S\.:P,
M ,T1   9              " @0,] 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ )H6D5N*;I:P.!   ?1@  !D              ("!
MI4 ! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  FA:16
MX J=BWX%  !['P  &0              @('J1 $ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( ":%I%;X@1?R00,  "L)   9
M      " @9]* 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ )H6D5M<L%!=D!   %1H  !D              ("!%TX! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  FA:16TU6C_UX#  !O#
M&0              @(&R4@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( ":%I%8_<$Z:T <  "Y'   9              " @4=6 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ )H6D5BD9%#HD
M!   K!,  !D              ("!3EX! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    "  FA:16LRLB6S4#  "3"0  &0
M@(&I8@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ":%
MI%:Y_R:&60,  )0+   9              " @15F 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ )H6D5N0HX4Y" P  .@D  !D
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M=#4T+GAM;%!+ 0(4 Q0    ( ":%I%9JND3XH00  #P2   9
M  " @39Z 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M)H6D5K[]H,^U @  S@8  !D              ("!#G\! 'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    "  FA:16XS*NWY8"  #:!@  &0
M            @('Z@0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4
M Q0    ( ":%I%8SSOJ2, 4  !X?   9              " @<>$ 0!X;"]W
M;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ )H6D5K_@_$L+#P
M4=D  !D              ("!+HH! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6Q02P$"% ,4    "  FA:16'D@#Q <#  !3"@  &0              @(%P
MF0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ":%I%:(
MR8EBK@8  )@N   9              " @:Z< 0!X;"]W;W)K<VAE971S+W-H
M965T-C$N>&UL4$L! A0#%     @ )H6D5F$/=FY" P  J@D  !D
M     ("!DZ,! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ":%I%9B!%24WP8  #,\   9              "
M@6+8 0!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ )H6D
M5L\1^9T& P  G L  !D              ("!>-\! 'AL+W=O<FMS:&5E=',O
M<VAE970V."YX;6Q02P$"% ,4    "  FA:16#PJ'ICT"   M!0  &0
M        @(&UX@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0
M   ( ":%I%;:QW^W7@,  .H+   9              " @2GE 0!X;"]W;W)K
M<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ )H6D5A\YO1A9#0  '\4
M !D              ("!ON@! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q0
M2P$"% ,4    "  FA:16VILJ58X#   '$0  &0              @(%.]@$
M>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( ":%I%;[H<\X
M*04  & =   9              " @1/Z 0!X;"]W;W)K<VAE971S+W-H965T
M-S,N>&UL4$L! A0#%     @ )H6D5B9*KV"E P  =10  !D
M ("!<_\! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    "  F
MA:16:(A%QW\"  "M!0  &0              @(%/ P( >&PO=V]R:W-H965T
M<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( ":%I%8C ?WKM0(  "4'   9
M          " @04& @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#
M%     @ )H6D5L<+?Z._ @  &0<  !D              ("!\0@" 'AL+W=O
M<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    "  FA:16GJX=?#H&   Y
M)   &0              @('G"P( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM
M;%!+ 0(4 Q0    ( ":%I%8AG,?@. ,  'P)   9              " @5@2
M @!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ )H6D5GF2
MI35H P  &PT  !D              ("!QQ4" 'AL+W=O<FMS:&5E=',O<VAE
M970X,"YX;6Q02P$"% ,4    "  FA:16$U86O"L"  !+!   &0
M    @(%F&0( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (
M ":%I%8.SWWH5@D  (9R   9              " @<@; @!X;"]W;W)K<VAE
M971S+W-H965T.#(N>&UL4$L! A0#%     @ )H6D5CF#?":W P  Q1(  !D
M             ("!524" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"
M% ,4    "  FA:16MOFC6JH(   B<0  &0              @(%#*0( >&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    ( ":%I%9[H%OON00
M /@@   9              " @20R @!X;"]W;W)K<VAE971S+W-H965T.#4N
M>&UL4$L! A0#%     @ )H6D5GWU#ZBC P  ^A   !D              ("!
M%#<" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"% ,4    "  FA:16
M=_CZNJ("  #O!@  &0              @('N.@( >&PO=V]R:W-H965T<R]S
M:&5E=#@W+GAM;%!+ 0(4 Q0    ( ":%I%9WLRHZRP8  + M   9
M      " @<<] @!X;"]W;W)K<VAE971S+W-H965T.#@N>&UL4$L! A0#%
M  @ )H6D5L"S4?;%"0  !&   !D              ("!R40" 'AL+W=O<FMS
M:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    "  FA:16FX9JE]@"  "+"
M&0              @('%3@( >&PO=V]R:W-H965T<R]S:&5E=#DP+GAM;%!+
M 0(4 Q0    ( ":%I%9#)'59KP4  *,J   9              " @=11 @!X
M;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%     @ )H6D5AHO$7DD
M P  - P  !D              ("!NE<" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,BYX;6Q02P$"% ,4    "  FA:16?HY^&5$#  "L%   #0
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:+GAM;%!+!08     9 !D ',;  #+:P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>542</ContextCount>
  <ElementCount>362</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>190</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>20</UnitCount>
  <MyReports>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITION</Role>
      <ShortName>REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - LICENSING AGREEMENTS AND ACQUISITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITION</Role>
      <ShortName>LICENSING AGREEMENTS AND ACQUISITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - OTHER EXPENSE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENET</Role>
      <ShortName>OTHER EXPENSE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - REVENUE RECOGNITION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONTables</Role>
      <ShortName>REVENUE RECOGNITION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/REVENUERECOGNITION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - OTHER EXPENSE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETTables</Role>
      <ShortName>OTHER EXPENSE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSENET</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - REVENUE RECOGNITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails</Role>
      <ShortName>REVENUE RECOGNITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails</Role>
      <ShortName>REVENUE RECOGNITION - Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - LICENSING AGREEMENTS AND ACQUISITION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails</Role>
      <ShortName>LICENSING AGREEMENTS AND ACQUISITION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - INVENTORIES - Components of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails</Role>
      <ShortName>INVENTORIES - Components of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Exchange Offer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Legal Proceeds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Antitrust (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Intellectual Property (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Product Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - General Civil Actions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenue by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentBasisSpreadOnVariableRate1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage -  bhc-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="bhc-20230331.htm">bhc-20230331.htm</File>
    <File>bhc-20230331.xsd</File>
    <File>bhc-20230331_cal.xml</File>
    <File>bhc-20230331_def.xml</File>
    <File>bhc-20230331_lab.xml</File>
    <File>bhc-20230331_pre.xml</File>
    <File>exhibit101formofpsuagreeme.htm</File>
    <File>exhibit311q12023.htm</File>
    <File>exhibit312q12023.htm</File>
    <File>exhibit321q12023.htm</File>
    <File>exhibit322q12023.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1144">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 44,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1144,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 542,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 736,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 14
   },
   "keyCustom": 68,
   "keyStandard": 294,
   "memberCustom": 114,
   "memberStandard": 74,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.bauschhealth.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - REVENUE RECOGNITION",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITION",
     "shortName": "REVENUE RECOGNITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LicensingAgreementsAndAcquisitionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - LICENSING AGREEMENTS AND ACQUISITION",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITION",
     "shortName": "LICENSING AGREEMENTS AND ACQUISITION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LicensingAgreementsAndAcquisitionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - FINANCING ARRANGEMENTS",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - SHARE-BASED COMPENSATION",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - RESEARCH AND DEVELOPMENT",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - OTHER EXPENSE, NET",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENET",
     "shortName": "OTHER EXPENSE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - LEGAL PROCEEDINGS",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - SEGMENT INFORMATION",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - REVENUE RECOGNITION (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables",
     "shortName": "REVENUE RECOGNITION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - OTHER EXPENSE, NET (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETTables",
     "shortName": "OTHER EXPENSE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - SEGMENT INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i7e0c7a0e030f4effa3695934ea837e9f_I20220601",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - REVENUE RECOGNITION - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
     "shortName": "REVENUE RECOGNITION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i318586ad088847fe9e02f2dbe2f1d9be_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i57d70860978f416995c6e78078eb91fe_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails",
     "shortName": "REVENUE RECOGNITION - Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i57d70860978f416995c6e78078eb91fe_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails",
     "shortName": "REVENUE RECOGNITION - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i57d70860978f416995c6e78078eb91fe_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - LICENSING AGREEMENTS AND ACQUISITION - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails",
     "shortName": "LICENSING AGREEMENTS AND ACQUISITION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i69d5bfc5ac6d4673a9361f510f04204f_D20230117-20230117",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i274f7bd9f55d4414ae43d99e682cd28a_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i06ac642717c94b2bb1846110be0fc60d_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i6a9fc2637fe14e8da7c94ff2d6063b4f_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i6a9fc2637fe14e8da7c94ff2d6063b4f_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "idf6e5891da834960a8eb4d5a50ad53f2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "idf6e5891da834960a8eb4d5a50ad53f2_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ibccb47312bd346279aaf43b1d2624d18_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ibccb47312bd346279aaf43b1d2624d18_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i1660d479841841a083afc611c4742172_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i1660d479841841a083afc611c4742172_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i1660d479841841a083afc611c4742172_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i1660d479841841a083afc611c4742172_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ifaeb1d30cde14bc6af235fa0f4f5aa89_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i82576bfa08994cd9af972d7222b8c478_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i82576bfa08994cd9af972d7222b8c478_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "rate",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i57d70860978f416995c6e78078eb91fe_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Acquisition-related Contingent Consideration Obligations, Reconciliation of Contingent Consideration Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i57d70860978f416995c6e78078eb91fe_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i3e658e3f4fe444859560086bf4a59a49_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS - Assets and Liabilities Measured on a Non-Recurring Basis and Fair Value of Long-term Debt, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i3e658e3f4fe444859560086bf4a59a49_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - INVENTORIES - Components of Inventories (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails",
     "shortName": "INVENTORIES - Components of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Major Components of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "if9bd15273b3c45cb9e5d9e10c7eb4cc8_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i57d70860978f416995c6e78078eb91fe_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Changes in Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i4eece1c12f094009b4bd03024e7e8ce9_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:AccruedProductRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:AccruedProductRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ibacd0f91a9214e0fbe96138d126d5254_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i6d23cbe1712d416fb576aaa815a0484b_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i6d23cbe1712d416fb576aaa815a0484b_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i63bf7af9472e4ef792681b0e8c4f7da0_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - FINANCING ARRANGEMENTS - Exchange Offer (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
     "shortName": "FINANCING ARRANGEMENTS - Exchange Offer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i248fddc88f4a495caa1b4df3c4650cee_I20220930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i6c18712f4b5d49ac81d008a300ff10e9_D20221129-20221129",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id65c9d3aa0e147cbbacd4d3353c0d376_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Aggregate Maturities of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Award Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i1c8eb89ffd8d41a6be016809e07511dc_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of Components of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i3ffe0c3f62ab46708e444bc96954e538_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i23d3136d31994fbdb7cb150bafef9389_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i23d3136d31994fbdb7cb150bafef9389_D20220401-20220630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Summary of Research and Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails",
     "shortName": "OTHER EXPENSE, NET - Summary of Other Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - INCOME TAXES - Narrative (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Schedule of Calculation of Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - DESCRIPTION OF BUSINESS",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i5eb53786821248ca8b1f2d53e1c01d20_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - EARNINGS (LOSS) PER SHARE - Narrative (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i5eb53786821248ca8b1f2d53e1c01d20_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - LEGAL PROCEEDINGS - Legal Proceeds (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsDetails",
     "shortName": "LEGAL PROCEEDINGS - Legal Proceeds (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i0498740aa6eb46ce88de603fe0598d20_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserveCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
     "shortName": "LEGAL PROCEEDINGS - Securities and RICO Class Actions and Related Matters (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i3603067927b34ed0861be7b4c4ab01a3_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i5fef41f4b68f4a788694d3e96118dc2d_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - LEGAL PROCEEDINGS - Antitrust (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
     "shortName": "LEGAL PROCEEDINGS - Antitrust (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i5fef41f4b68f4a788694d3e96118dc2d_D20190801-20200730",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "case",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i176472c9a91947a58428394faa66f2cc_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:GainContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
     "shortName": "LEGAL PROCEEDINGS - Intellectual Property (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i176472c9a91947a58428394faa66f2cc_D20200326-20200326",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:GainContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ic2b286567c0d4c80b0020c5f649deaeb_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - LEGAL PROCEEDINGS - Product Liability (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
     "shortName": "LEGAL PROCEEDINGS - Product Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "ic2b286567c0d4c80b0020c5f649deaeb_D20211101-20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
     "shortName": "LEGAL PROCEEDINGS - General Civil Actions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i956db6dc693f4d028f267a06461cc5f6_D20230217-20230217",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:LossContingencyStayOfApprovalMotionToExtendPeriodOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskPercentage1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i3422200e3eca4c57b3a53d10fa4721aa_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id97aa636f91b4ce89c060d073ef8778d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i2b225b3f8b0746bfb199706e955676a9_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "id13ace1eb1d44d9fb45fbb921ee17108_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
     "shortName": "SEGMENT INFORMATION - Revenue by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i34eb56c13bb140ba8a8a420a15ef17ba_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i53c0c9f9a29c4194a26ee2fc5d2a2278_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "bhc-20230331.htm",
      "contextRef": "i53c0c9f9a29c4194a26ee2fc5d2a2278_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 190,
   "tag": {
    "bhc_A1261229BCLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1261229 B.C. Ltd.",
        "label": "1261229 B.C. Ltd. [Member]",
        "terseLabel": "1261229 B.C. Ltd."
       }
      }
     },
     "localname": "A1261229BCLtdMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A1375209BCLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1375209 B.C. Ltd.",
        "label": "1375209 B.C. Ltd. [Member]",
        "terseLabel": "Intermediate Holdco"
       }
      }
     },
     "localname": "A1375209BCLtdMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A2022OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Omnibus Incentive Plan",
        "label": "2022 Omnibus Incentive Plan [Member]",
        "terseLabel": "2022 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "A2022OmnibusIncentivePlanMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcuFocusIncAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AcuFocus, Inc. Acquisition",
        "label": "AcuFocus, Inc. Acquisition [Member]",
        "terseLabel": "AcuFocus, Inc. Acquisition"
       }
      }
     },
     "localname": "AcuFocusIncAcquisitionMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Operating Cash Flow Performance-Based Restricted Stock Units",
        "label": "Adjusted Operating Cash Flow Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Adjusted Operating Cash Flow performance-based RSUs"
       }
      }
     },
     "localname": "AdjustedOperatingCashFlowPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivable and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AurobindoPharmaLimitedLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aurobindo Pharma Limited Litigation",
        "label": "Aurobindo Pharma Limited Litigation [Member]",
        "terseLabel": "Aurobindo Pharma Limited Litigation"
       }
      }
     },
     "localname": "AurobindoPharmaLimitedLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate",
        "label": "Base Rate Factor, Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "Base Rate Factor, SOFR"
       }
      }
     },
     "localname": "BaseRateFactorSecuredOvernightFinancingRateSOFROvernightIndexSwapRateMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessAcquisitionMaximumTermForRemainingPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Maximum Term For Remaining Payment",
        "label": "Business Acquisition, Maximum Term For Remaining Payment",
        "terseLabel": "Purchase price, repayment term"
       }
      }
     },
     "localname": "BusinessAcquisitionMaximumTermForRemainingPayment",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CaliforniaProposition65RelatedMatterLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Proposition 65 Related Matter Litigation",
        "label": "California Proposition 65 Related Matter Litigation [Member]",
        "terseLabel": "California Proposition 65 Related Matter Litigation"
       }
      }
     },
     "localname": "CaliforniaProposition65RelatedMatterLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CertainExecutiveOfficersAndOtherMembersOfLeadershipMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Executive Officers And Other Members Of Leadership",
        "label": "Certain Executive Officers And Other Members Of Leadership [Member]",
        "terseLabel": "Certain Executive Officers and Other Members of Leadership"
       }
      }
     },
     "localname": "CertainExecutiveOfficersAndOtherMembersOfLeadershipMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "label": "Debt Instrument, Basis Spread On Variable Rate, If Rate Not Ascertainable",
        "terseLabel": "Variable rate, if rate not ascertainable (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRateIfRateNotAscertainable",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Covenant, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantComplianceSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Compliance, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCreditSpreadAdjustmentOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "label": "Debt Instrument, Credit Spread Adjustment on Variable Rate",
        "terseLabel": "Credit spread adjustment (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentCreditSpreadAdjustmentOnVariableRate",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Remaining Quarterly Amortization",
        "terseLabel": "Remaining quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentRemainingQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal",
        "label": "Debt Instrument, Repurchased Face Amount, Decrease Outstanding Principal",
        "terseLabel": "Reduction of outstanding principal"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmountDecreaseOutstandingPrincipal",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DefaultJudgementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Default Judgement",
        "label": "Default Judgement [Member]",
        "terseLabel": "Default Judgement"
       }
      }
     },
     "localname": "DefaultJudgementMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DermatologyReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermatology Reporting Unit",
        "label": "Dermatology Reporting Unit [Member]",
        "terseLabel": "Dermatology Reporting Unit"
       }
      }
     },
     "localname": "DermatologyReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DermatologySegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermatology Segment",
        "label": "Dermatology Segment [Member]",
        "terseLabel": "Dermatology"
       }
      }
     },
     "localname": "DermatologySegmentMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiversifiedSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Segment [Member]",
        "label": "Diversified Segment [Member]",
        "terseLabel": "Diversified"
       }
      }
     },
     "localname": "DiversifiedSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Discrete Items, Amount",
        "terseLabel": "Income tax expense (benefit) for discrete items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDiscreteItemsAmount",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Expense Filing Tax Returns, Amount",
        "terseLabel": "Income tax expense associated with filing certain tax returns"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpenseFilingTaxReturnsAmount",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Time-based RSUs, Performance-based RSUs and Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EuropeInterbankOfferedRateEURIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Europe Interbank Offered Rate (EURIBOR)",
        "label": "Europe Interbank Offered Rate (EURIBOR) [Member]",
        "terseLabel": "EURIBOR"
       }
      }
     },
     "localname": "EuropeInterbankOfferedRateEURIBORMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ExchangeOfferMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Offer",
        "label": "Exchange Offer [Member]",
        "terseLabel": "Exchange Offer"
       }
      }
     },
     "localname": "ExchangeOfferMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "label": "Fair Value Adjustments, Changes In Estimates Of Other Future Payments [Member]",
        "terseLabel": "Fair value adjustments due to changes in estimates of other future payments"
       }
      }
     },
     "localname": "FairValueAdjustmentsChangesInEstimatesOfOtherFuturePaymentsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag",
        "label": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag",
        "terseLabel": "Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List Not Disclosed Flag"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleListNotDisclosedFlag",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Finite Lived and Indefinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_GainContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Defendants",
        "label": "Gain Contingency, Number Of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberOfDefendants",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyNumberOfProceedings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Number Of Proceedings",
        "label": "Gain Contingency, Number Of Proceedings",
        "terseLabel": "Number of proceedings"
       }
      }
     },
     "localname": "GainContingencyNumberOfProceedings",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_GainContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Contingency, Stay Of Approval, Period",
        "label": "Gain Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "GainContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedLabel": "Adjustments to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Interest settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LicensingAgreementsAndAcquisitionDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing Agreements And Acquisition Disclosure",
        "label": "Licensing Agreements And Acquisition Disclosure [Text Block]",
        "terseLabel": "LICENSING AGREEMENTS AND ACQUISITION"
       }
      }
     },
     "localname": "LicensingAgreementsAndAcquisitionDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Threshold for incremental borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings, Percentage",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsPercentage",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of suits filed but not yet served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors filing action"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period",
        "terseLabel": "Stay of approval, motion to extend, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriod",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriodOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period One",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period One",
        "terseLabel": "Stay of approval, motion to extend, period one"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriodOne",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalMotionToExtendPeriodTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Motion To Extend, Period Two",
        "label": "Loss Contingency, Stay Of Approval, Motion To Extend, Period Two",
        "terseLabel": "Stay of approval, motion to extend, period two"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalMotionToExtendPeriodTwo",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of approval, period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LumifyParagraphIVProceedingsLupinANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Lupin ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsLupinANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LumifyParagraphIVProceedingsSlaybackANDALitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation",
        "label": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation [Member]",
        "terseLabel": "Lumify Paragraph I V Proceedings Slayback ANDA Litigation"
       }
      }
     },
     "localname": "LumifyParagraphIVProceedingsSlaybackANDALitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation (including McKesson Specialty)"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted Average Risk-Adjusted Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NeurologyAndOtherReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurology And Other Reporting Unit",
        "label": "Neurology And Other Reporting Unit [Member]",
        "terseLabel": "Neurology and Other Reporting Unit"
       }
      }
     },
     "localname": "NeurologyAndOtherReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NorwichPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Norwich Pharmaceuticals Inc. Litigation",
        "label": "Norwich Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Norwich Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "NorwichPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OmnibusIncentivePlan2014RetentionRSUGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014, Retention RSU Grant",
        "label": "Omnibus Incentive Plan 2014, Retention RSU Grant [Member]",
        "terseLabel": "2014 Plan, Retention RSU Grant"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014RetentionRSUGrantMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organic Revenue Growth Performance-Based Restricted Stock Units",
        "label": "Organic Revenue Growth Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Organic Revenue Growth performance-based RSUs"
       }
      }
     },
     "localname": "OrganicRevenueGrowthPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PaymentsToAcquireBusinessesAndForOtherInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Businesses And For Other Investments",
        "label": "Payments To Acquire Businesses And For Other Investments",
        "negatedTerseLabel": "Acquisitions and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesAndForOtherInvestments",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PendingLitigationAgreedStipulationsOfDismissalSubmittedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted",
        "label": "Pending Litigation, Agreed Stipulations Of Dismissal Submitted [Member]",
        "terseLabel": "Pending Litigation, Agreed Stipulations of Dismissal Submitted"
       }
      }
     },
     "localname": "PendingLitigationAgreedStipulationsOfDismissalSubmittedMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units",
        "label": "Performance-Based Restricted Stock Units [Member]",
        "verboseLabel": "Performance-Based RSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PerformanceRestrictedShareUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Restricted Share Units",
        "label": "Performance Restricted Share Units [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceRestrictedShareUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PreserVisionAREDSPatentLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PreserVision\u00ae AREDS Patent Litigation",
        "label": "PreserVision\u00ae AREDS Patent Litigation [Member]",
        "terseLabel": "PreserVision\u00ae AREDS Patent Litigation"
       }
      }
     },
     "localname": "PreserVisionAREDSPatentLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions Litigation",
        "label": "RICO Class Actions Litigation [Member]",
        "terseLabel": "RICO Class Actions Litigation"
       }
      }
     },
     "localname": "RICOClassActionsLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Increase (Decrease) In Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, change in discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsIncreaseDecreaseInDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure",
        "label": "Restructuring And Related Activities And Initial Public Offering Costs Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAndInitialPublicOfferingCostsDisclosureTextBlock",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedTerseLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due February 2027",
        "label": "Revolving Credit Facility Due February 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due February 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due May 2027",
        "label": "Revolving Credit Facility Due May 2027 [Member]",
        "terseLabel": "Revolving Credit Facility Due May 2027"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDORAndEURIBORRatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR and EURIBOR Rates",
        "label": "SOFR, CDOR and EURIBOR Rates [Member]",
        "terseLabel": "SOFR, CDOR and EURIBOR Rates"
       }
      }
     },
     "localname": "SOFRCDORAndEURIBORRatesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SOFRCDOREURIBORAndSONIARatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SOFR, CDOR, EURIBOR and SONIA Rates",
        "label": "SOFR, CDOR, EURIBOR and SONIA Rates [Member]",
        "terseLabel": "SOFR, CDOR, EURIBOR and SONIA Rates"
       }
      }
     },
     "localname": "SOFRCDOREURIBORAndSONIARatesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SalixReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Reporting Unit",
        "label": "Salix Reporting Unit [Member]",
        "terseLabel": "Salix Reporting Unit"
       }
      }
     },
     "localname": "SalixReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the carrying value of amortizable and nonamortizable intangibles assets, in total and by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Finite Lived and Indefinite Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "label": "Securities Excluded From Computation Of Earnings Per Share, Performance Conditions Not Met, Amount",
        "terseLabel": "Excluded from computation of earnings per share, performance conditions not met (in shares)"
       }
      }
     },
     "localname": "SecuritiesExcludedFromComputationOfEarningsPerSharePerformanceConditionsNotMetAmount",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "verboseLabel": "5.00% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "verboseLabel": "5.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "verboseLabel": "5.25% Senior Notes Due February 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "verboseLabel": "5.25% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "verboseLabel": "6.25% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "verboseLabel": "7.00% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "verboseLabel": "7.25% Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "verboseLabel": "8.50% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "verboseLabel": "9.00% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "verboseLabel": "9.250% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured1100NotesFirstLienDueSeptember2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 11.00% Notes, First Lien, Due September 2028",
        "label": "Senior Secured 11.00% Notes, First Lien, Due September 2028 [Member]",
        "terseLabel": "11.00% First Lien Senior Notes, Due September 2028"
       }
      }
     },
     "localname": "SeniorSecured1100NotesFirstLienDueSeptember2028Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured1400NotesSecondLienDueOctober2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 14.00% Notes, Second Lien, Due October 2030",
        "label": "Senior Secured 14.00% Notes, Second Lien, Due October 2030 [Member]",
        "terseLabel": "14.00% Second Lien Senior Notes, Due October 2030"
       }
      }
     },
     "localname": "SeniorSecured1400NotesSecondLienDueOctober2030Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.500% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.750% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "6.125% Senior Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028",
        "label": "Senior Secured 9.00% Notes, Intermediate Holdco, Due January 2028 [Member]",
        "terseLabel": "9.00% Intermediate Holdco Senior Notes, Due January 2028"
       }
      }
     },
     "localname": "SeniorSecured900NotesIntermediateHoldcoDueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facility",
        "label": "Senior Secured Credit Facility [Member]",
        "terseLabel": "Senior Secured Credit Facility"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilityMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Performance Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Performance Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation, Alleging Caused Ovarian Cancer, Mesothelioma or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower To Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SoltaMedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solta Medical Segment",
        "label": "Solta Medical Segment [Member]",
        "terseLabel": "Solta Medical"
       }
      }
     },
     "localname": "SoltaMedicalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR performance-based RSUs"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaroPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taro Pharmaceuticals Inc. Litigation",
        "label": "Taro Pharmaceuticals Inc. Litigation [Member]",
        "terseLabel": "Taro Pharmaceuticals Inc. Litigation"
       }
      }
     },
     "localname": "TaroPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxYear2018AndTaxYear2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2018 And Tax Year 2019",
        "label": "Tax Year 2018 And Tax Year 2019 [Member]",
        "terseLabel": "Tax Years 2018 and 2019"
       }
      }
     },
     "localname": "TaxYear2018AndTaxYear2019Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermFacilityDueMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Facility Due May 2027",
        "label": "Term Facility Due May 2027 [Member]",
        "terseLabel": "Term Facility Due May 2027"
       }
      }
     },
     "localname": "TermFacilityDueMay2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due February 2027",
        "label": "Term Loan B Facility Due February 2027 [Member]",
        "terseLabel": "Term Loan B Facility Due February 2027"
       }
      }
     },
     "localname": "TermLoanBFacilityDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TradeNamesNoLongerUsedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Names No Longer Used",
        "label": "Trade Names No Longer Used [Member]",
        "terseLabel": "Trade Names No Longer Used"
       }
      }
     },
     "localname": "TradeNamesNoLongerUsedMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TroubledDebtRestructuringDebtorTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Troubled Debt Restructuring, Debtor, Type",
        "label": "Troubled Debt Restructuring, Debtor, Type [Axis]",
        "terseLabel": "Troubled Debt Restructuring, Debtor, Type [Axis]"
       }
      }
     },
     "localname": "TroubledDebtRestructuringDebtorTypeAxis",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_TroubledDebtRestructuringDebtorTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Troubled Debt Restructuring, Debtor, Type [Domain]",
        "label": "Troubled Debt Restructuring, Debtor, Type [Domain]",
        "terseLabel": "Troubled Debt Restructuring, Debtor, Type [Domain]"
       }
      }
     },
     "localname": "TroubledDebtRestructuringDebtorTypeDomain",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_USDollarBaseRateAndCanadianDollarPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate",
        "label": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate [Member]",
        "terseLabel": "U.S. Dollar Base Rate and Canadian Dollar Prime Rate"
       }
      }
     },
     "localname": "USDollarBaseRateAndCanadianDollarPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_VisionCareSurgicalAndOphthalmicReportingUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision Care, Surgical And Ophthalmic Reporting Units",
        "label": "Vision Care, Surgical And Ophthalmic Reporting Units [Member]",
        "terseLabel": "Vision Care, Surgical and Ophthalmic Reporting Units"
       }
      }
     },
     "localname": "VisionCareSurgicalAndOphthalmicReportingUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_XifaxanBrandedProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xifaxan Branded Products",
        "label": "Xifaxan Branded Products [Member]",
        "terseLabel": "Xifaxan Branded Products"
       }
      }
     },
     "localname": "XifaxanBrandedProductsMember",
     "nsuri": "http://www.bauschhealth.com/20230331",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Smaller Reporting Company"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r248",
      "r291",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r313",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r373",
      "r375",
      "r376",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r248",
      "r291",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r313",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r373",
      "r375",
      "r376",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r246",
      "r247",
      "r381",
      "r409",
      "r592",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r319",
      "r609",
      "r689",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r438",
      "r550",
      "r569",
      "r588",
      "r589",
      "r606",
      "r619",
      "r629",
      "r686",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r438",
      "r550",
      "r569",
      "r588",
      "r589",
      "r606",
      "r619",
      "r629",
      "r686",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r319",
      "r609",
      "r689",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r315",
      "r551",
      "r607",
      "r627",
      "r681",
      "r682",
      "r689",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r315",
      "r551",
      "r607",
      "r627",
      "r681",
      "r682",
      "r689",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r431",
      "r438",
      "r465",
      "r466",
      "r467",
      "r549",
      "r550",
      "r569",
      "r588",
      "r589",
      "r606",
      "r619",
      "r629",
      "r676",
      "r686",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r431",
      "r438",
      "r465",
      "r466",
      "r467",
      "r549",
      "r550",
      "r569",
      "r588",
      "r589",
      "r606",
      "r619",
      "r629",
      "r676",
      "r686",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r246",
      "r247",
      "r381",
      "r409",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r316",
      "r317",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r608",
      "r628",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r316",
      "r317",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r608",
      "r628",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r662",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "BRITISH COLUMBIA"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "QUEBEC"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "NEW JERSEY",
        "verboseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r181",
      "r192"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r30",
      "r35",
      "r146",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension adjustment, net of tax"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r216",
      "r562",
      "r574",
      "r575"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r229",
      "r230",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income Loss [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r146",
      "r544",
      "r570",
      "r571",
      "r643",
      "r644",
      "r645",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r29",
      "r35",
      "r146",
      "r230",
      "r231",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r655",
      "r656",
      "r657",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r117",
      "r118",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r217",
      "r321",
      "r324",
      "r325",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries of amounts previously written off"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs charged against the allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r46",
      "r59",
      "r174",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "negatedTerseLabel": "Amortization of debt premium"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r400",
      "r542",
      "r604",
      "r605",
      "r649"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Dilutive effect of potential common shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-dilutive shares not included in the computation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r59",
      "r92"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments",
        "terseLabel": "Asset impairments",
        "verboseLabel": "Asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r179",
      "r191",
      "r214",
      "r243",
      "r299",
      "r305",
      "r311",
      "r322",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r374",
      "r376",
      "r377",
      "r502",
      "r506",
      "r528",
      "r626",
      "r684",
      "r685",
      "r732"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r208",
      "r219",
      "r243",
      "r322",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r374",
      "r376",
      "r377",
      "r502",
      "r506",
      "r528",
      "r626",
      "r684",
      "r685",
      "r732"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r154",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r497",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r497",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r131",
      "r132",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Up-front payment"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r500",
      "r648"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r130",
      "r133",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r130",
      "r134"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion included in Accrued and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r130",
      "r134"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r61",
      "r210",
      "r590"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r55",
      "r61",
      "r62"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, beginning of period",
        "totalLabel": "Cash, cash equivalents, restricted cash and other settlement deposits, end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r55",
      "r173"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r185",
      "r199"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 18)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r655",
      "r656",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common shares, no par value, unlimited shares authorized, 363,607,062 and 361,898,846 issued and outstanding at March 31, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r36",
      "r226",
      "r228",
      "r235",
      "r558",
      "r566"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r139",
      "r140",
      "r150",
      "r226",
      "r228",
      "r234",
      "r557",
      "r565"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive loss (income) attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r138",
      "r150",
      "r226",
      "r228",
      "r233",
      "r556",
      "r564"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r48",
      "r232",
      "r555",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r67",
      "r68",
      "r171",
      "r172",
      "r319",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r67",
      "r68",
      "r171",
      "r172",
      "r319",
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r67",
      "r68",
      "r171",
      "r172",
      "r319",
      "r578",
      "r742"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r67",
      "r68",
      "r171",
      "r172",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r67",
      "r68",
      "r171",
      "r172",
      "r319",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": {
     "auth_ref": [
      "r147",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.",
        "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]",
        "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]"
       }
      }
     },
     "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r75",
      "r304",
      "r305",
      "r306",
      "r307",
      "r313",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r43",
      "r551"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Cross-currency swaps"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r65",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r242",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r394",
      "r401",
      "r402",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r180",
      "r182",
      "r190",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r543",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r182",
      "r190",
      "r405"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total debt obligations",
        "verboseLabel": "Principal amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r175",
      "r177",
      "r378",
      "r543",
      "r602",
      "r603"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount",
        "verboseLabel": "Aggregate principal amount issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r392",
      "r527",
      "r602",
      "r603"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r543",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "verboseLabel": "Repurchased debt, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r103",
      "r104",
      "r105",
      "r106",
      "r174",
      "r175",
      "r177",
      "r189",
      "r248",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r384",
      "r390",
      "r391",
      "r392",
      "r393",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r403",
      "r543",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r176",
      "r390",
      "r406",
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized premiums, discounts and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r174",
      "r177",
      "r687"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Debt instrument, premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Unrecognized tax benefit, amount possible to decrease in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r59",
      "r93"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r220",
      "r221",
      "r527",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives.",
        "label": "Derivative, Fair Value, Net",
        "terseLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r155",
      "r156",
      "r161",
      "r163",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r153",
      "r155",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r153",
      "r155",
      "r161",
      "r163",
      "r165",
      "r167",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain": {
     "auth_ref": [
      "r160",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain",
        "terseLabel": "Gain related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r160",
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r160",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r220",
      "r221",
      "r527",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r428",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r442",
      "r470",
      "r471",
      "r473",
      "r477",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r236",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r268",
      "r270",
      "r272",
      "r273",
      "r274",
      "r278",
      "r515",
      "r516",
      "r559",
      "r567",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic loss per share attributable to Bausch Health Companies Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r236",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r270",
      "r272",
      "r273",
      "r274",
      "r278",
      "r515",
      "r516",
      "r559",
      "r567",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted loss per share attributable to Bausch Health Companies Inc. (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and other"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r717",
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "verboseLabel": "Income tax expense associated with stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average service period over which compensation cost is expected to be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "terseLabel": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r102",
      "r204",
      "r229",
      "r230",
      "r231",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267",
      "r280",
      "r323",
      "r410",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r514",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r544",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Extinguishment of Debt [Line Items]",
        "terseLabel": "Extinguishment of Debt [Line Items]"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r517",
      "r518",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r392",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r518",
      "r546",
      "r547",
      "r548",
      "r602",
      "r603",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r517",
      "r518",
      "r520",
      "r521",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r392",
      "r432",
      "r437",
      "r518",
      "r546",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r392",
      "r432",
      "r437",
      "r518",
      "r547",
      "r602",
      "r603",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r392",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r518",
      "r548",
      "r602",
      "r603",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "verboseLabel": "Reconciliation of contingent payment obligations measured on a recurring basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r168",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r168",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Acquisition of AcuFocus Inc."
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments/Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsReconciliationofContingentConsiderationObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r392",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r546",
      "r547",
      "r548",
      "r602",
      "r603",
      "r614",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r517",
      "r518",
      "r520",
      "r521",
      "r523",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Nonrecurring adjustment"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisandFairValueofLongtermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r212",
      "r347"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r344",
      "r346",
      "r347",
      "r349",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r87",
      "r553"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r83",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r87",
      "r552"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Finite-lived intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r60",
      "r727",
      "r728"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r594",
      "r614",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r678"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r211",
      "r331",
      "r554",
      "r600",
      "r626",
      "r664",
      "r671"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r334",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r333",
      "r340",
      "r600"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r59",
      "r332",
      "r337",
      "r343",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r153",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "B+L IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r649",
      "r675"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r39",
      "r178",
      "r186",
      "r201",
      "r299",
      "r304",
      "r310",
      "r313",
      "r560",
      "r599"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r350",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r244",
      "r482",
      "r485",
      "r487",
      "r490",
      "r492",
      "r494",
      "r495",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "terseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r245",
      "r266",
      "r267",
      "r297",
      "r480",
      "r491",
      "r493",
      "r568"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "(Provision for) benefit from income taxes",
        "terseLabel": "Income tax expense (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Income tax expense, establishment of stock valuation allowance on B+L's Canadian parent"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax expense (benefit) on ordinary income (loss)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Income tax expense (benefit) related to changes in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "terseLabel": "Income tax expense from final and potential settlement of various tax audits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Indefinite-lived intangible assets:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r84",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Total intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r46",
      "r398",
      "r408",
      "r604",
      "r605"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r650"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Contractual interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r638"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total Inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r218",
      "r591",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r639"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESComponentsofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r45",
      "r292"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r243",
      "r322",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r374",
      "r376",
      "r377",
      "r503",
      "r506",
      "r507",
      "r528",
      "r598",
      "r684",
      "r732",
      "r733"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r184",
      "r196",
      "r626",
      "r653",
      "r663",
      "r726"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r209",
      "r243",
      "r322",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r374",
      "r376",
      "r377",
      "r503",
      "r506",
      "r507",
      "r528",
      "r626",
      "r684",
      "r732",
      "r733"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Facility fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r15"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (as a percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r23",
      "r678"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Current accrued loss contingencies"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSLegalProceedsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount to be received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, agreed to pay",
        "verboseLabel": "Settlement, escrow fund included in restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r182",
      "r193",
      "r391",
      "r407",
      "r602",
      "r603"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total long-term debt and other",
        "verboseLabel": "Amount drawn under credit facility"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Less: Current portion of long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r98",
      "r248",
      "r688"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r98",
      "r248",
      "r396"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r98",
      "r248",
      "r396"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r98",
      "r248",
      "r396"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r98",
      "r248",
      "r396"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r98",
      "r248",
      "r396"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSAggregateMaturitiesofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r96",
      "r97",
      "r360",
      "r361",
      "r362",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r96",
      "r97",
      "r360",
      "r361",
      "r362",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r678",
      "r679",
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSGeneralCivilActionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r96",
      "r97",
      "r360",
      "r361",
      "r362",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of suits filed",
        "verboseLabel": "Number of putative antitrust class actions filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of lawsuits pending"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LuxembourgInlandRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Luxembourg.",
        "label": "Luxembourg Inland Revenue [Member]",
        "terseLabel": "Luxembourg Inland Revenue"
       }
      }
     },
     "localname": "LuxembourgInlandRevenueMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAcquisitionrelatedContingentConsiderationObligationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r27",
      "r183",
      "r195",
      "r243",
      "r322",
      "r365",
      "r368",
      "r369",
      "r370",
      "r376",
      "r377",
      "r528"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership percentage by parent",
        "verboseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r281",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r55",
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r40",
      "r60",
      "r187",
      "r200",
      "r207",
      "r224",
      "r227",
      "r231",
      "r243",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r266",
      "r267",
      "r271",
      "r299",
      "r304",
      "r310",
      "r313",
      "r322",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r374",
      "r376",
      "r377",
      "r516",
      "r528",
      "r599",
      "r684"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Bausch Health Companies Inc.",
        "totalLabel": "Net loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r143",
      "r149",
      "r224",
      "r227",
      "r266",
      "r267",
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss (income) attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r108",
      "r141",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "B+L vested shares"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r136",
      "r410",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "terseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r299",
      "r304",
      "r310",
      "r313",
      "r599"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segment"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESSummaryofAccruedandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r31",
      "r33",
      "r138",
      "r145"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Pension and postretirement benefit plan adjustments, net of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r222",
      "r223",
      "r508",
      "r511",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedTerseLabel": "Loss recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r37",
      "r102",
      "r225",
      "r228",
      "r232",
      "r534",
      "r539",
      "r540",
      "r555",
      "r563",
      "r643",
      "r644"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTotalLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETSummaryofOtherExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense, net",
        "verboseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedTerseLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "negatedTerseLabel": "Receipts in interest settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Payments of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r49",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Payments for intangible and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSAntitrustDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSProductLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r642"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r646",
      "r647"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails_1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r207",
      "r224",
      "r227",
      "r239",
      "r243",
      "r258",
      "r266",
      "r267",
      "r299",
      "r304",
      "r310",
      "r313",
      "r322",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r372",
      "r374",
      "r376",
      "r377",
      "r501",
      "r504",
      "r505",
      "r516",
      "r528",
      "r560",
      "r599",
      "r623",
      "r624",
      "r645",
      "r684"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "netLabel": "Net (loss) income",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r94",
      "r198",
      "r561",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r237",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for expected credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r197",
      "r202",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r342",
      "r343",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [
      "r342",
      "r343",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Fair value of reporting value, greater than its carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTSummaryofResearchandDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r637",
      "r651"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r352",
      "r355",
      "r357",
      "r359"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Costs incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r59",
      "r356",
      "r357",
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation, and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r352",
      "r353",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r107",
      "r194",
      "r573",
      "r575",
      "r626"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r204",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267",
      "r323",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r514",
      "r570",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r290",
      "r291",
      "r303",
      "r308",
      "r309",
      "r315",
      "r316",
      "r319",
      "r427",
      "r428",
      "r551"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Price appreciation credits"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r430",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerSegmentBenchmarkMember": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified business segment for satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Segment Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer, Segment Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerSegmentBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE RECOGNITION"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Percentage of shares held"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r35",
      "r729",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LICENSINGAGREEMENTSANDACQUISITIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r114",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExtinguishmentOfDebtTable": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to debt extinguished, including the amount of gain (loss) on the debt extinguished, the income tax effect on the gain (loss), and the amount of gain (loss), net of the related income tax.",
        "label": "Schedule of Extinguishment of Debt [Table]",
        "terseLabel": "Schedule of Extinguishment of Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfExtinguishmentOfDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r83",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r600",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories, net"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of customers that accounted for 10% or more of total revenue"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r42",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenue attributed to a geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r38",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuebyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r110",
      "r111",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of share-based awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r439",
      "r441",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Notes"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR Rate"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r355",
      "r359",
      "r600",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r299",
      "r302",
      "r307",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Separation and IPO-related costs included in selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSANDFINANCIALINSTRUMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures [Abstract]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting Period One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Vesting Period Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting Period Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Incentive stock plan, term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r63",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r206",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r313",
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r351",
      "r355",
      "r359",
      "r600",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLChangesinCarryingAmountofGoodwillDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONDisaggregationofRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r102",
      "r204",
      "r229",
      "r230",
      "r231",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r267",
      "r280",
      "r323",
      "r410",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r514",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r544",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails",
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r280",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Stock Options and RSUs"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures [Abstract]",
        "terseLabel": "Other Than Stock Options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeituresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofShareBasedCompensationAwardActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r102",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Adjustment to reflect change in ownership interest in Bausch + Lomb"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r4",
      "r5",
      "r107",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r79",
      "r626",
      "r653",
      "r663",
      "r726"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r136",
      "r137",
      "r148",
      "r204",
      "r205",
      "r230",
      "r255",
      "r256",
      "r257",
      "r259",
      "r265",
      "r323",
      "r410",
      "r474",
      "r475",
      "r476",
      "r488",
      "r489",
      "r514",
      "r534",
      "r535",
      "r540",
      "r544",
      "r571",
      "r572",
      "r653",
      "r663",
      "r726"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total equity",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSSummaryofComponentsofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r541",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r541",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r541",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSIntellectualPropertyDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2014Member": {
     "auth_ref": [
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2014.",
        "label": "Tax Year 2014 [Member]",
        "terseLabel": "Tax Year 2014"
       }
      }
     },
     "localname": "TaxYear2014Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "B&amp;L Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLMajorComponentsofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r352",
      "r353",
      "r357",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSSecuritiesandRICOClassActionsandRelatedMattersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits related to interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would reduce the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSExchangeOfferDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r69",
      "r70",
      "r71",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r249",
      "r254"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Reserve ending balance",
        "periodStartLabel": "Reserve beginning balance",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Current period provisions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONNarrativeDetails",
      "http://www.bauschhealth.com/role/REVENUERECOGNITIONVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r269",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Diluted weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r268",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares outstanding (in shares)",
        "verboseLabel": "Basic weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.bauschhealth.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/EARNINGSLOSSPERSHAREScheduleofCalculationofLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 20
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4M",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591554-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5634876-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "https://asc.fasb.org/subtopic&trid=2197926",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r631": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r632": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r633": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0000885590-23-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-23-000018-xbrl.zip
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MQ/8#$",5A&!I1U()"FQ2P98T3(IKT2>3T8C_]H<.P\H0_EFO/^$MQI?"V'T
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M=OTFRX<-GUW.3+NW7= 3ZW-%2$VR&-<<%W'-<B[#W@ZJ(_;SM+]\\6(J=;1
M^02F3<S5T&7%!UID+I +:!:@4<\8<>13] /H"C*87&UY*\=#"KWX56RK$3Q6
M] )!A"$&R.9T?\T-!.TZ<[4E=CHPTD"]98E8^W@U<L0^09$=!B=U8TWL.G*U
MY:%4G94<JDOH#6A^5KBO.L,22FV(=7-MZIIRM67V&X-@7,U95.V+M=EYU%P
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MIPP2]!^LIOB6R"0"K\^1<3,,Y^'D<$Z[PJ-*A\."AXO7O A:%>OT7R[,I")
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MR3M#=K94&0Q5WMNJ_ )9_GZK\@N'?H'LCKE8*(1]-P]@8S/5D%&=$7E;HAM
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MN]8WOFW)>LUDO9(H:YG[%AO64@((%<B88F+?>"%85V&-V_AO  F68F.#["B
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M8;]5V[*AM*VI+,^WY;Z\/$]HEX@+X(\8'$L)<S!!M/+6!4J)]\0Z-P^E%)^
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M=Z$M=FQS4!)D&&IVH053=BA\ZE;=;(?JU!3!B^.K-:+'P-?@I!K )L0HSQ#
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M(=!3*^@W>0\>IWKC+25R.W9[G=+G&)VL[/V#XX+>;7;& NY<H]*D]*+S:<_
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MWL=69\RHS'76Y&.^6/5P!*G^QM]: WB:_S%EHIDR'1W'RGI?1P>=Y\O G>X
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M3ZF.G!E.2<E-VAC.>Y#K*>?XQ]->/(Z=?NO+1<'!7S(7GI+*LI#A.T;-WL\
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M78!W.>0T#_ ^I*>T .^# ^^4$]3YI$Q.[>F\$8CS:)#+X:928)IOHQ*L;'.
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ML!Q;)KF/V*HDB1(:3$VOHW(?=F?"FYB$-T"VDVZGKK%9YS/J#RMM%D2;"]$
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MT2Q9005W7.B[4^J:<6Q=)1R[];EU)MG[<7"0CNRW0K;G(MOO9Y695CI1QX-
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M];I[XD"]>Z?=X99RL;:NM;A<^1<K^%8K%Q;H]84YL1RK7_)R@BY6[6R5P2?
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MG!W[J1T,9^X'%CLJ9^B5M([C&B<E7&(FYN(2$OY:'6A-+++E5<G.ZPDM+V2
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MLFQ Y'+0G4GB+$0:N/;AV0LP?1K.?9J<>[_^^89S;\NYRSYYQB+\OXDH<DE
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M8UWE&!0&%ZLIY9MA6M^S86\%@5,;=DS%,P)LUWYKGXQ.#D#U>=WKOQL/LV:
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M2DU]H-K>N(K+)>(T@\M./<#\\Z-0;.]=EH*M??&9<Q]EBAR99!5(4DIRUHU
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MI,_O^HRUFN3$I5GJ 9<J?*>#^'S\PV\@+$\[]OQYNUM6LCSTV_P'<P>MA5K
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M461=C(A;09 +"2.=?6-,2,-(DXK8H-%ZS.U!FZ0WVL\=A$?5J&.R7,#8(:5
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MEZ8*_H^BU06@U-O//(8@K6,(C#>9,<HBPWE"+(*Z;F6B,;>G%"OR5^90ZI%
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MD>N.XJUF_R9]RLN*-:C7?35O1"V];4H,M-HQB^+I\KC'MH>PQ4CD-GK#"/W
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M_@=P0T[B/6^U*]X=' (6<@5J[CK3&YRVU2] ]8-?-VY.L2A.]J7U>+V 7OF
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M@1W0TC@U3(')A;.XAAM=CYWU6C,.FA9VNF!FO?F909DG(^Z:3&6-W^@3E0<
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M9BE.FO<ZK RNS5WW>-]N=3K+D8"]#&"W]\<4EX.,QA*E$1%.YJ-U*;(*,^1
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M!;IWK5[QT\V(<]]WQT\PQ5(&++U%21B#>' 16:PHZ':$R6@B,PH,5\F*HZX
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MO]:CA9L7EILYMC)0+C&5FAML-:%.6N!O2;RT4A1N7D!NG@PU!NVQ5B(BP[$
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MI_6F;P&(=.WWX3B'$^^_KV[8C6UX+EP[.B-8IM;U+HULT'JU8<-M'-YML(W
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M$_D[SV.G^?9[-G+VTQ\#Q6*KTBL*QPTY;F_K"XF*8.HHTD+F?L,Z(<>%0Z"
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M]D/3XY>-]1*.WTD4SL##ECD>EX0A6/#<;#Y2!'&/ LL,OK?,1>",Y?1X\3R
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MT][Q_7S0J=>^-EJABRW=7)W]K-77,ARPO&U%?=U#?;5G'3#*(G7.*Z223>"
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M,TPR;IE\<'_.@MN5Q:V@AO(@#574<Q^QMH8RB+VX38#H2!Z'Z"DX?C0<S[!
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M_")V#O^;6AM[TF&98M (FPC!L%(>66/@;T02K1D)F,FUU^*5F,TF^-=5*_&
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MC$.)*\E8HEH;T#Y$E;/R@M3B\R\3F=.\60R2^<0HHEA(Q(FU@$SBD:$0GL4
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M7GDDL%>(1V*1)2PAX<'[5SKAE&Q&YH,]_H+,E45F#"P&[+AA4G .VCDHC /
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M4!Y2;Z+%%,M<2BD?'$27(^T7C]3BFC\$F=/T%I/&2B)C3@8#9!*=YUYHB:S
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M[>20*D-GJ&B)(!19#_>8YT(+%2"#") J,:-)Y$Q[S5GTPON:BE12@D8_W'=
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M S?T6:"-C,+>-]A#'%;#96%BI\(#H^!BI;R79G:<.C3D&;89QY+2-4'4W?)
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MQ'_G.?:%:SRX;L]0RAXU^""I<T&9=OCU'8T:;DAB&CUN$M/H-R,Q?2O.Z/"
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MA*%G1Z$;VH1GB1T'46;[+(1E2C(_=%Q,/TTZ\DYU:F2%G,O3YX:P5V 9"%?
M1DB>)X6R2L$NJD+"1?]";HW%TG(=6??%%?=?7.'VQ15U<<6UQ1*+U*JQ2XC
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M5YBG.2XGO@2.1O8",/M&+Q]M?X(_F^;PD>2ZJ9A(S,1*8RKG>J8*E''U6W3
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MGFGS9N&@[MYQ83W;<)LSN$;V&<B?W'@J/?Y(@DHMC%$W-1!Z',A(_CC>9<,
MV93[6-5K/BT.9!,K&X8N"&FE!.N$(:8,-V%'#C*1$3<C:1AGA$9Q'":$^R()
M73?FS..J+;H3*RY9QXG\57GO/CZ^U_C8.=H^#9@3!0$5-HTCQR8!)OS25';>
M"CDGS"$.>_922L=R?/P\?E%[K;3:#,O(B4W$Q7&") IBQP&)(4$:Q\BG[00N
M8['@)'1Z<?E%XN(>O3]-,A *U\ML[CLQB MQ05R"S!9N&&743R)*G54%(Q@
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M5I&37R<GXQD<LU5 IO[;CX-0);>'X>P4#F5 .OO;K>GLT%@QI8UAB5 F&/S
M/9C2(;<;5C0FQ:5A^.]GE[2@?YO,9ET+NC+6'A?&1F\Q7]9B%@>Y$X#1!-.
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MF(^X6#=(=$PT.LY-,EIQ'XDF7ECXGW""<8IM+]%?4Z)?OSO\_>]$;""1P:%
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M',(MX(NP+F<G%[,R,)AL.YR>-B2=YNEQ_&9RT937' U3A$.R*]ZSR6 6XS^
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M!]6ZG'7T7DLF>UE5K7U4E[==U)YX7+Q<!6.4'?'H[&Q4QP7NV<QF]];CY32
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M2/,$=F;6!B[#KA_KK\38,5YF9Z!78G7!K'*<MBVPFM+^=:.K6D#K_ESO*K[
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M5$+_:#2*T^.+ EW.1[:J+?&1N@X[]<X?K[:U""%DKMJ6%UYN^K!RT:+5P"J
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MW8@)%DX.N@H0'D_&V=BKG.!_#&?_O "LG;L6'$?2>C 0O7<@X=G[@Z.#OWG
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MCD%KWD.@713E50@4#)C8'AL$)K9&W!F/K$@6>>N9<#:"</,LRM>&0%]<E.\
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MRV#MD^=<:VY=#%)(;Y1,A&C1XY]=%.55_,,CULY@BX@S"H%JYLA&%Y!A,2C
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M 3),6\25\,A9FA#7D40MM5#![CU4_-H^X"O)PRWR@MQ7 ;_QG,9>P&]"P->
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MCB7ML.+2)4>,45A&(X14TII>S^V@GCO8T!F 2"8=6+Q$VH!XI *9I!R*-!?
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MO7J;,=" .F LVJQI#<PF W7(JCP]ATW+/:?=X=VNT^EWS';']?J#UH#UO<'
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M:N0G2!;]LOC] QBH[TV?_)1["V'PA?T1Q89BXDD9'B6R>@2=OBQ0KIP1=[.
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MP1X"N X_XG8,8F JK8>6..\&*"GTB&CBA[#VVB/(?="+D/D8@  &<Y$4)>0
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M=:Q-UMNF5\/[P'Y8ON!6L[S@>^[2[%0,T9&#>_,(Z#T;%G0IWX4(\>$?Q^N
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MC#E'A2[)&WU\09V!W"^GPD6$C_X0L5AW7#JGUB !P"/)YS?*^63'+&0ND]W
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M'Y;+ZH4P@0/EJ5I0WE-(Q,31;STFQYVH/RFZ76Y'0M*(M L5FB>I)/JJ>%E
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MO4I)W52T*9,"0+,"&JB)P9'" I!=Q H\88:WYSGTBI46_1'#*')GV-<D1D\
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MG@'KY>(M^F%AA#>D\$@6- Z4GBZRPL'=<B"@UV9MT&X;\*Y -7+'C\R^_DB
M#2D&&>I8,%2^B 7CS<A9:_".9,(='' = .W /@%)D,@X'O)KJZL>#J@8&^9/
M#0,)75]S"]28'ZF;H8]%$%7Q24#(-U&0(73PH;U\Q9+$K^ 4?M24<^;OQN=H
M;-,:KZ(@9<87B=@)']+T%4E3\!9Z!7Z&WR+_F'/X, >H)?$1;<7;K7Q'A%Q
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MFE"F41.@3!Z/!%TWY+P ;!W&;"Q97P!Z<R!,HASQ1 I;/18J.@ _ESP^0@@
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M2 91<H\^7!D!?H0@5HH\Q-!;YGU$J]L[@F>2/J9/L;<KGA3:1S_W9<"(T$'
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M&B $T LHHPFP%"DPNR5B'W-"/8ZX,0^(I2+RI8EJH[.<9&989H2'Z!#4!:2
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MJB^KRP=TJ382CJ^=G1T<GW5G7CX\6/7:R?'Q2D_.6^SYP?G9[*N;M];%UO/
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M5YIW@SF1(BT38!_L']29W<:1DULYQ9<@IS/3J6P*>W)CT7V#2!.N34%LN96
ML?!)S#=$6L3CPE1A4Z6"&;6H7:6!#/2 ,UUC1>W$6=!5B!CS.JG*H0I&72Q
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M19:'@RG_%,:!C/.WO6/R;SS?3NF-;\,<EN#/WWL/]_XY'8HX]+VO:BZ2)^+
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M (42>;,L >4.\0[)>EEMBWF_5@9):J,RA]\%+#5?&:3)&) 1U'I#N.J%J&Z
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M6SU?=T'(7P;HW.*:=VJ1X2>Q'T:<[!#&?C*6WA[J66_P,O[HHV]MDB9W(=K
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M;*2E#^/D8EGNYQ3QEX[7=KK="W=(FWU(>]W.26\]YNQK,):>2&9(O/PH:?&
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MD[3IJ-KX.1Q'!Q9DJ%[-AJ;U 2"HH9,YC$#V<Y,+U*&?)DEJIHS (:6 ! 4
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MV#+[=CHDYDHHTXCT2';HM.] K4B*S&:X$>!#3.87GT4RP1A4$3,3AA.4\8A
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M$=])EGZXN %KJ?@O4!;NC+1!"<CZ3UUC4:O_38HH'STC*1P?G&V2%+@"]01
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M< F5)S=Z<DY&TPS$K:B@! ^8U?)DP-$0$6W.Z9[#_ZT$VMY6GN[1P;D^70D
M"]4)#R@C5'7"5WGOXH>7HW$?VIJ]/8*(AM[<6_$N?(3& )GD%ZLW2D+O3@;U
MM"PSFMV5FZZ;YA6OKJF*^.OG="CB4'46QL.]UEUSKY)]D_!+:/+>&IZC-!!4
M)$"3E/=)^AW9_"_80N0Z33+]S!?"#N]V% ZXLU(U,#:,DCX.=0?5>%R,06RD
MDX3\ 1KA.J7%6\1YJE+I53*CU.X#UP)G_>AEM=VD]N%E0P+Q0^&0;6II.Y,>
MJHQW-*V\]%CKYLQ,W6 'G\(V9H 2@<12GM X)*SA,0'W7\=\OS*S1OA^6FR2
MN'J]F*/['"BQ4;6ZTSR6/$)(5T&KQ,U4A=,S*5)_U+%[;&,KM[A +S,-.:AT
M=K/="-94;=,GM<*?0O8BVX7ZUDP'[+ZH.G\#:Q)^F6:M=Z3:U*B^1@HML=T+
MIXX-H@+'TK6E?K)GO%J!J!MH.XQ=-\:J 44M*<PACV'08[Y\$% :K^WJF1++
MV'8&+(ZI"Q=/6.2N/]R6WI1XE9[O>PJA2!P?$7N4"&M<8?P-\EF3%TB'^R15
MM0QE0O-60+KKU^]5!;+U%9_B/^3O:[ZITJ%B2##7102EI-9+CZ5*V[>*KRTZ
M0I_[?A\G ZNV-Z9Q/YR=(@%#:U:/))?HLN9"-C6[42EQK>,62NQB\X%FTPTB
MU5.>F"<'(FQTQQHW. =5C(7-P/0,J;*&@#'E+L%7D<V"?J?2_IBM,@8)9ULZ
M;\1&(!%ELE'5;&,T<J4]U=4HC(4K77ATZ4+/E2ZT ?D2BV5VTB%4U2O)4EM\
M%KD1X?('ENB9;H4=2S0WFUZ@6T#KKF2J432.INRI#BA]68]H(Z%W=-]^NU&-
M4294YDJU)YZYD893*5[/^^AXOP#]Z[G2:$F0^-G\*>NO"1?_B*D^CV;P9?N_
MRQ^AG^PK++ *M%7T^(_;WZ\N*^'CREQ<DR!K>M"P9"FS%C;XU%^#L*^%'CA&
MWBE#$)19 W9XG&'./"8IANQLS&6$39*Y7S$:.?""%#^64:?-9D*JQ!$NIN)R
M@&G1)O7-2B%*=-RJ[0-[.CVMI>R:^Q=$*F*NYX1^J?1'SKR;V#\PR*MN,NB+
MJC"L]K+?Q_:@9&HAZ-]C .Z2K2.>'Z>>O_STOL1]]-0^/'JT=]0=]-SHT9;1
MHWLI @\K*-YX)R>'WAC,7S1&+8.[/G)-ITJHH1MX_++$*HT",\+?;UI\//BO
M&1-FR3B:T0G&1%Y4+[Y.<S!VZ5&J#M)R[&^3V)^J"AH4$<XHGDPDCG"T\I4J
M+7K?AZQ; 5H6H(CI,)SY&>Y]#PAZ+ZBS9"L":\2=C[+$WBQ>18\B[V%K73//
MQBUM]0K>. G"00AD0B_@5..[) PXL>2R& +B>-W##F<M(AY'WC^+0,T=4:IA
M;>ND\XU#-;'1S5]>G0F.)'9 ]SWT/4[@8!/XYVAJ!,YOUT;< $UK<83@_^T:
M]/^!A-,.1#['*G=<Y84\*!CK4.15R6,N>SERGQ559":HLVP*J!J4X3:G3JQ.
M24KWI!I^+7S+$*758"G2G=Y*RQ?0.J64"\$%I4"01CDQ+Y8BQ4FS7&/QGR(N
M,%\/F.9Y/:*.H0E^65G_H!)&N:BG^0U8*#TU23'WF_H",2<N8I9*Y*774LE1
M^]JI7=>ZZ#P.=:0=KQ\" <%"1%J&-JTR&,T'RMDNEL6DLZC;&E0T/UF.?D$\
MKU<75<PQNB-(J!\/.8*XF(>2DD%ZH'.?4DE"8],Y%-LD-35$. '8M)V!#,ZG
M5D@X%#A1/9+0A!YR*8_5Q2G'FC*JK;%57:Y1%CPN&MBCR,+2[+*+$^UIPYUR
M#%U9<C8K!#M,RWQX7[5M,B5O';O 2'5N=I6JZ\<[:J(:4JF5ZKO+[$JU^TK2
M^KG-LZ>X:I4JR]3H\NJK8ZM]5X1!;)$E,;>TII; K4C*<ZW4;/2F03_S4Y6!
MAC5YK3N!:JL-H4CI+G;N@+'Y$SW]P<M& BD0"% EPI!NUZ%%\(\Q9>A7RL!C
M/3 1.W7;G2!1BNA.?49TZ,:1:IB7CO=B-A6F5^%D9*K31%>=1!*K-1IMA8<C
MLK7K#P],S3:3FTT/U$7F:(NT'^96@HM=,HF5OOU)(F,L&4?TL6-&UB";(.01
MI0",6#_)LY,JR1\\"JN<9JO5CB(S)4TA#WU6P1\>]JSG+;K91NM'PQKKCN4P
MH2'$M:;LINVYSZX?W1E'N[_*@[7SSUL'Z5@(X\Y^D\[>G/!XDL3<K!;G.6B+
MF>=6A7&859HE906&2+05'::Z*:9(*0J\EREF5G98Q_FJ(0ZIW&?M,; +4"L)
MHPIU5&4D?FA:4TLIS2\M)F4$/(#;IPZSUB_<@C!3!X/'#\>"\Q+*HOQZLZTT
MP:)]22..U-AKA0@R()7(G>EZS]2D%>HV213P9;*N=W^($YVA,J-MEI5[2"0,
M.@HG)G::28?J=XTH998!ET69+&VSKM@X6,LQZ];0+)74"_CA4&J]*%4Y^AG)
MW#1K(4I8DZ3[J/5_/TE3FDWLSG"CE B[IXPI\9#M++_:\8SL@[(_8[W5!-@U
M*;(/ESZTT6?.3>O4_,/[N'[H-&YMH"IP]DV'.U-?Y YV[7I;C08'130(HXA[
MM%@DR-SY'R+"G+X8I/^!+>J;71&30<=RFJ52J,2<1'<?L]]M%<. 6:&;'N#P
M\$1U+%,CPU6OF$Y;BYB9@YO?E,H$:BDA: J!75]FRKX:VZT5G3ELW20VE$D:
MT<8]QU0BHXT6BY4H<MICM5J10F1.%FTD$IA8.X4W*WH&3^+P18$N5FJ_@ $#
M.51%</S[!/@*U0B&\3\+5?>F'>PLV+!!G!2!\F26YH=*XT)F9+(.-#KZD0A5
M\"(08Z$:?OY,7E$?%D'.%&0I.#*3?"M6*%=G@K GA;'05=P\NN+FR%7<O&8F
M@=-^V ,-I'<'J X2@JIFD1ZKY-AP4IG<+*W76.,>*R:K:[.U.0=>ZZ33:0M5
M*Y^WK3/ ?8'\LT!/0QAG14HJ(?;Y3($UF F)]:Z^5/R0\A-E_@T%49*\D@!(
M>%.*!RTSPK*>'+L72)5NSB-I;#6F7!3U8H@&^^87AW1KUT<1.N,8T<*>BUX&
M/RI3^LIAWCR_FQX=3#EXJIM;<G)").\P58#*\&1*F&":7!!J9?4,1X<,:^=
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MBM=E);S>\K[L;CI&56^DG$X[9'=F[0,N /]9\_X=G9+0"?X6VC.%BQM%I36
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MFJLJ]]FD(KL7,L45;"OTG1B'9>UN],$-X_YXUUT,9VYTA;@!$YX;KB-J99-
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MZ8@&LLT:K6A"*VJ8 *V8,S(':F+U]/V#%*V#%?U<R;*J>J.B)*JA U]\Y33
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M]SM^9_^/O8.CDTZJCF^_Y-F*CQ]97Z4:Y#L&L5P.89$TH<&6"=#Y*OF',@%
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M%C0J+:&"%-&^W!S#K9;6JQ*'#D'<1Z2L::F7GY<?WDW3O_[Q_P%02P,$%
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MYW_E.KO@!(+4BH-*7D%(.D-.O'@C TLN_K^?_AI2YLQ9#S)*^C7.+017+(C
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ME Z1!P.11])!3];'<15 FJR+=R9A;.W4]@;YX!5D6%JNZY%OJD<'M#U)D9D
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M'_P(%&)X@0]PPWZSH5L20 +WG<E[/0EQ<C19?CM(4FA26P-<"5M'8Y)<M.6
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MT'32Q3J*,2R])0XE!&$*N9$ZY,)TT'DP"W,=SE-3D'58&,F"R%-HQ4=GA+)
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MB'O8@YC+Z R9+&NCA<(S!\6PQED8(=0,ZB@RV<O6XY+&5()[LK/&TH$^4AZ
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M/K(>Q*^\?Q ">L,B8@3A3$W2D1E"-@J\<8)AX!A<^WOWAS2)HA>':TRBZ$/
MP(G%P1:;'6V(@=$"5>8$)9@$-B,K$2N<NY)3GF!B\3K.Q*:2'S*QN N.1YA8
MW$O\MV:EKB&[(1.+'3..YY0A*S(GRF0&%"!',-*'8 6SPMTU9VH7..R16-R$
MPCXB&SJQ&'FPQF@.++!:B$SVQ3,R+5ZGC"DYVC*NQ/J[GEC<2[IW)1;W$<U#
M22S>GZ:CXXQY,GT^FRYF1Y-<W89GX2A,$WXX1-JGMI5RW /:3B0CKRO**VG*
M06EEF559:J<0943&N3$I6D3K"VZ8IMP#Y?:SUUZ?YU-ISPS'(H$QB]5=C1 %
M+R"]D\Z2;))J?1*UHPG,Y[#>EDM9L[@\R":1.X@"B@P,%$H/W@D$$X(33I?Z
MT\%.[&]#]=#33?OHW>VG_$TX&^#8MUU$HI(+-J4"SAFL_:\D1*,1N$&R9E*(
MM),%!@\XPW03S=P.[[N287IYLWM=?_OL,*[4"C1G'>BZ!*6SA!!+!!E"\5QQ
MYGWKAN.W87GX9Q2]-&,V $,#G&S>A.LTRNB";*!+C]M1;>?:HPU['51B ]&/
MJQQ,.!%\5&!9I&W>V=I=.F>P3LJ4N"/<K6=OCZT4]UQ_C*T3?20^@"ZLFM*3
M83P)O9;?V="3(F43 V-90-!UZKSB]%7,F@3 H@JNSE]L?1UV'Z;Q7?56_,T&
M%/X0185S_!(F^>77+_3R8-UC5XA/LD*6)QOOV9%34D(&B@\XO12@ B'U2M:#
M?E4T0Z;)]VNL)MW1/1J%&8B005/V;LA(TU+6J:UUE \J(-.)$$H.@$&2 *SW
MQ;=NJ_FX\X,W<6&;,35V?G 7;#_R@WNSV"<#=!T*QLX/5L99ZY0$QAT'A29#
M5-X!C]*HPH/QKG6L_+#R@P?3CCZ2'R<_. =60I ,K*D==XS6X(2.]123=D5I
M;(SAJ>4']V+I_OS@/B(>J2ZI0[6>1IX-$[1T*RVH0B^"4YZ<LNCJ#/C$;&GM
MOC[5HNS6ODIC=H?+/[ZA-K +L!]%V:V8[5QENPXMHQ9E>Q&L]%:#,,60S58,
M8LH>I(I2LF0HE&S=)N51%&4/HRY]V!BW*+OXA)X5"P9M !42;<;61/ A1IN<
M4Z&TONQ\&$79O2CK7I3=1][C%4?5P5U)%@G(=2('WP7P3AK@FO9:$PBJ&[ZB
MX8?STH"=AJG-]^;U=\'UE(NC>O'6M2!F':&/61R%$JTQE@'ZVN7=^  AA@ E
M2I>=+PE+Z_O!AU <-8@N])'UEHJCHK(ZT0X'O'8;5#X21 K^@6 &9T)VZ6IS
MYR=6'-6+PS6*H_H0,'!QE"YHLTZT-EHK^3XV0T A048D*82 4OTHCMK8F=A4
M\M>50#<KJ.F"XQ$61_42_VV5->O(;LCB*,5CX"%K0)U,U4T+H9!N,L>--BA4
M#'<=B.X"ASV*HYI0V$=D0Q=')6:X])@@119I7P@U!BT",&:M94 N[960;]>+
MHWI)]Z[BJ#ZB>2C%42]+P;2<E6MNPF(V?369AFF:A*-+?[NM2JEU<>Y$V503
M(5^IH?(R.TV1 _*:!:]RQ")%%#8+C"$+L6$-U;J0![R#>WU>%R"P&.2"7F$E
MR.@Z92 D+H'$P6P.]-/FQU+=D#7)J7P^^_QECH=U,ZI/(QW$^I!KAX=X?FJ-
M938GJY&.PF(Q*9/3U--I_AB^'K! "B(R X%!G%9T2JGJ=#6D( (=:]X7O?TJ
MMGGQW4P3;\SAW![9 YPBW[6B"X&^_'I2GEE_<3:E]=$OS2GZP1=X\M^3)>[E
M_SX^6?_B='5>!J>5M2#YJCBY,(A991"JZ&"C,U:USL$8=D5/3JU'5H*1LE/O
MOCY\]NUD_>>S3\^R>I]]NRVYZB3(#^1/HJGM<9PE=[/8T[Y)P<0L3.(FR>VW
M^U]W=6,5)(Z@\#NJ$KM2BKCFA;LM-K)Z RJ<*J!BLA!UX.!X$'6RB*?0;>O:
MO\W3Q%U5NS:)5WWH'S6!I@NP'XE7K9CMG$FS#BWC3L- %T6,"CQS=2ZV$N#0
M:]"!(;-:*LU:5ZX\BL2K8=2E#QOC)E[57AG*20>R9%F1.7!)!?!:%R62\24\
MT6D8?2CKGGC51]YC3\,PCADM:R2?2NV!& 4$BN=IR<J'8AE*/MSDSMVI=GO
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MZV#:T4?R VC%Z7'MU6/:LQZ]661,M,S -:V:RP(^APBB=ET1-EFC2NO3F+L
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M.^'>^/YU@3S0H<@:<+=S,#*H&O13N68<CI_=<2/T7- P<K@@BNJ<8]$0??*
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M <-*M^&!\CU SUK*Y^=A<?CJ:/;GHDX:FQU/ERO0-D>#B2R:<AQ!!6TAI&3
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MJO:J.<?@16S-EW87Q;[NV ?K]7:/U3#YCM%L=P/1NA&P Z:Q&C$WX-E3!^9
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M8D0A52ZJ]+@:>O!1AZ7P)@+=H/ &6<"+XV9ED!>WE6MH)2>;>4[ 6#&@E"]
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MF<8=8/L23&)+>8]:-[?13'_-<9[I1R?GR\42IXFD\WX^F<;)-SP[U82/<9F
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M)JHYX![S)@8SH@(:TUM]FL_.R<=>14@K7K;SN#R?DR->?S";7^59N!=%\UR
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MPT?O<;14+QG/V@GHWE-Q-Q07][.W3/*B,>5%IV>-28'1?[&W*#&T4]EHQW/
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M>9.(@C&CC6]]RNS/>'I=:.W'=OKH8^<V<S)=\[$QFXV)J0Z98XDV76O!IV*
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MZ,TTSKZ2D5.@7^7P]M+W7>W=E9_,&L$@EXM<;: H3'':Q26/+-&&'EKW\3T
MY^_XH;7.1KBROP?:Y5O4!=Q(8<&#P/;CWS=38S?S&*"#W>T[ER"9+)$[#,"8
M1E#"&/"L&,C9QY)4446W'G^[!P-YQ)'>CWWT$?T(=E$'G-,'?J$C^-?\/9_-
MOE6,E\GFRR/395%D,!H*6EZ;*3($R17$:%0,0@LN6]^L=("U>T^GH2+ONBQ-
MM3!&XC^?T:\^_Y:G>8YG!/0H?26)DZN%E<[H$NNZTS3D2"Z:12B)I5K'H,%G
M%2'SP"SYZ\+;YE/^^@ \).,93S/W[C=[*0C87$9Y%&F1M?%KU+* ;L_>87'
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M&,\,[FQKK=0QQN7_34R7OGP74",52VT$M*>A4.T4=_LFOYG4=V824H02HK3
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MHL^)-L;J73H*7LG-U"!TT2())^@G';::;9Y]"*:Q$[G?M1,_=$.Y'_.%@*Z
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M;7/57;0XY3:'Q!W!$X)7IG1RN))EH$4NOM2DB G;V\WFAQZRC300<T,NW U
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MQ3!#)Z6'$+67^IYS="C9SLBBC@*^ 7K]%[*__/P%)K.JN&>?8/81ZVQY< 6
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MP*VGUC;$W0<G3%Y^N##)NF3)FW4FU+X-[5G )%E08)Q,3IO5H7(' /?RPSD
MUU-K&X [.&/RUW<7(=.G'2"P%$*E5/7UC$5@V1DAM!8F-(R\_WH6D4!/K6T
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MKWQM\GL)$SB"(N8F[Z^@D.%$0DR0CT7(_"!&_3VC3G<\-TILA0.Y2>OV(RT
M!7J8N%;B=,+\RZ"WH\ Q !V9] Z<J2JI02TVR%9@ [:1?"RGJO-0C>)EU='M
M"[I=G0>CVP_+XGU'QZR\7-R:FYKFEE!1%>*JDIK  42<,$ABG\% )E3(1! /
M6R6[>M;NW&CFL]F%%67*Z1+\)JEQ*JQS!+S.'FBZLCS1? Y>-Y-< ,G8UE%?
M-.P=O([KWC7S]2L[LU[_M./I]:RU:=R]CJNP\?DZ\>=^=H/QP] OW5^OQ&OY
M52ZSQRJQ0GM&SD*DD@#'$(6>#Q$A 21A0F!,D4@"@D@4.$6-=7<WM\G;2EL=
MI^_(V_M&X@S:=@;"<!B./-LO@<_9%K!#92 +X$QGDZ[[=HH_7^TMW^H;S-69
M>N W^H\LOUG2HOB@OYZ:^A=1XO$XU$P3,^-8*J,8$AQX,$@(\6,F/(J=ZI'T
MD&%N]//N>0*5@R0>)KY2ZP$J18#1Q-&PN&3$[-AJY'$8F<+.YU'I,P0]PLQZ
M@SA8^)F[!!.'I?6&Z#!<K7]30YS>M&6#S7;+6,Q2?*H/)NB=7' ?49)0#I/0
MU_LF/TX@\QB#W,<LPD+1**"7%!CJZMQE8DY3;JB6T&26JH2N#W.R55T=9[A#
MG<X1Z7.L,Q3*4Q_LM')7!SE7H(%_*_M89SLV>(URNM/9\0N>[]@ TGW"8]7"
MI7=WI@;I:BV+MUJ=-]]UARNZO%D79?:@[2=M>YJLQ17)UM3ZZNE7F=WE]/'>
M'!%<YY(^3^;FH0AQ/_9A(GP*D2(>)'Y ( EXHDA 8D6<?&_'$W5NUN3NS51>
MZPIH4[_>%,W,-%?>;532C]Q9^[9,,.ZNUX<O.9H37C$V:@)#%Z#5$VP4K7;>
M5=KWVGIM35;V!';U!97"$]U%CC4R@]]7#B[H"]UIC@7XZ7O/T7KL78>=2RDJ
M<3[3I?' ;$L??%2_T?P/69KNMGFZ%E%(5&(*PV$2)1"A)(9$< *5"J-01"P,
M M?B[&X2S&WQ:!6HB::@-?L\;"0'Q49TY\+MCF-CMQ*,BOC(!+\/MI&^XO%6
M?H/\5H.=1'Z#UGGOA]YPQ=\=^Y^Z(GP_>(Z4B>_94,]SADUFDX_J9B=\Z[9V
M<;XQ@5N?[VDN&2WT?J"):M\&J/ XD$@F4-O>'"+L1]!XC4#I1QSS.%2*.Q4H
MNDR<N7%D)2FL1 6-K-JPRLU5W4671A<.FN7QQ&1#,;9U7(W"JTM&P?VL8A#P
MACJ_N$R8:<\T!@'NX)QCF%9[)F65=W2I2;RL3=V-OS37[+W=SL:)XBP@!(;"
MY%)AB$#& P&1D(K&-$'"<\O&:M/KW CS_9M?K]^#3[<?;]Z\>?WNPZ^?';.O
M6B%M1W^#XS<RRU7R@D;@RCK<$UEOY<?8Q#NA-%2&5:L^ITVMZ@+#04Y5IY=[
M%&;+N![$XGJYE/G=T]LL?U@OZ?OW-X=)^0E.(DH8]+!QP/.QMET"%L! A3&G
MF(:$6NUQ73J=&P,U<H-&<-!(?@6T[+UR]%NCWTU+8V$Z]G61'9Q]"L'9XNI0
M&&X$?*<J%#<4SFY5Y!P!ZZHJ9]O4=%7F')7;JSKG^F[/K#1"5 ')=/F)IN+=
MZH8^IB5=:@OW(5M]+HVQ0QF-$R\Q_M2A*2_.A.9TS"$/]-9=,WJH;4NGS#1G
MNYP;HV\E!H]:9)BN3&Y_([1C0IKS8-M9EL-".#*![Z!GI 4:O49>$]AK) :5
MR .FI[&&9Z@4-><[G#9-C34 !ZEJ[-]T-R--*>'W&5V]:O/^OU[+#]G7BL=,
M3>YFN:68Z)VJXC!F1.E]+-%&)*$^Y#C $JN(A8F5UZ9]EW,CG*J>MA$;O-J4
MO0!:<M"*#NQ+F#L ?]Y^'![.D<G'#LD>QJ,EI/:FX_#03F0X#@6QD]WHAE:'
MU6C9T&0VHYMBNQ:CXYL79!LSB1EH<;\7>+SPF<<BACV(DL"'2)HD"9(0F"11
MH@120>RI-HFSG:%XLB^K2;"?L'EDPJY$[9%(["B2=C;@9>A,F3ZL$?(@3\'
MB<.ZL!@R9]C1?J9/%]:E[M%,89TON!MSUP\R3^M/Y97>HLK5398_9OGNN8G"
MB 5<QE!@02&*(VW(29]"D7".$DYEJ*PN).RZFYL1=R QV!'9WM"PP/F\W38L
M>F-O&+?"@D/D>MAJ%A#:VVG#0CF1C78K'W5S534!307@H8HNXHWWG/'],;_5
M?Z[*ZW5^N#\/8[_9H]AANUDT,IG=9J_0KLWF\)8[0[_/3):M]BKHZ;,LRV7E
MKW!]E\OJ'\6'M>G#U'4V-]MYL8@85W$4^6;;K?^#8Q\R;=A!Z<58A5XBL'U5
MY1[]SXW#MS(#NA'Z"JPJL>MZ]+7@]F349U3.$_S(6(]]\YQ5&?\VXE^!'>"O
M=X"O=0 ?33'Z*8"W7Q9&'H")UHDQ!L)I7;@ QHZ%HD^KDZT<%ZB\NY1<TDR_
MLX /LJPW$Z;K!0Y5F& >0A$G""+JA9!$(H1A&$8!PB+DIAI*5M*EW>Y_KW6G
M=6'3QWCS1 L'EF:NM,%.E==TF8%7=%WP>_ 729?EO;G>>*0KXSNC53EM.5F@
MF_B"44]$,/:9T.NRU%NI.$0P0=@+8B^4GEN(6G]T)UAU)T?7[L2E-V8CKYX&
MKO9LQ8CV$[A^AMLG.FS]AZ-(#'3&LM_VI.<J1]5Z?I9R_*%^#+J3KNK=ZG%=
M?M'--(DP>$CB*$$1I-13$'&%(%.$P@33)/!P0GS/*5KH=%=SF_V[.;PJ48&1
MM6<.D@Z$[2;],+B-S !](7.>^.?1&(@%.CJ:E!+.*_R<'RS>Z.FJHVT[D2[7
M9?IU)WCGS7>^7 LI3+2/61#7]1;AHWI#\Y6V!8M/,J_\TM^G*_FNE _%PA<Q
M%UA@&!+-*L@W-S5QPJ$G-:_$B".* B>'GH$$FQL1&;U@JQ@HC*P%6&6EWO37
MJAE7%G-PQK?JF3.!ZA7]5]DH:K*%U*\[N@L-->!V3/<2PSCV2?*.2CLQC:!5
MJ@Z&O-D?OE8QDX$$5*J!OQOE0*7=@&0Z-.!#.3,-)=:T+D\#@WG@&#5T^R^R
M"%P_9.M5J5< )!2//9C$<6**@ND5@'(, XI)D@0L\GD\X0I02S4W^G_=$H=4
M2O+24,-C5II+$KHTE&\<%YM%X<>T_:=C1JAAAG,2?G<?I/\>Y&[NNXQFL^'U
M?:#G0>J-3/^=&'T?QH'I_%GC_;C\1-F;5T]FRW#]/2T6'D<8,QY 'JA8\S17
MD,5(_ZAH@F6@ B6X"T^?[7%N''RJ\)-)-E1O<8W4CF<"YW&W(]1!T1R9+"\%
MTID$K<$9B.#.]S<I>5FK_YR8[%]T=PCXF-_15<J;3$J_YMFW\EXSFLKR!ZJU
MJO(;W,JBS%.N]Z^5M__OJ[0L&A^96"(:HXC! !G? )DDD(6!@*&'51(%7 EI
M%0ATN2ASHZE&FTWFM%H?L^]O%6I2>-Q^_MWAQOK"\3KO-3#=*(Q,;R<&8$>7
M)GO'5ILZZ A4^O3P*;MP;.P="Z8;HXE\#"X<JV'\#(9!M</EX,(.)O,^& :(
M74>$@5J\-$MLD_-*6_4?E<D-:,(C3++:9SE ?86%Q,J#4B@)$=4K&Q4201SI
MW\8(DQ [F=BN LQM*=M-!+HT23Y+$]Y3I;Y^V"C4-X.KY9C8F=]C(CWR<K4+
M\E9X\U.55[6*J*K29$^3/=4-O\%SHEIV_T*93MW .9V_U+&=GO2W9H7\YUHO
MXF\T^Y:;#2T+"$-Q$D$_2A1$H>]#[$L)5<R"@,1>R-QRCY[H9W9DMA$35'+V
M/S,X!:PE55T.U]B,U <I=\KIQF$H9CG1R[0$TJWJ 4^<>;Q/?%:6E^E_-0>8
MS^N-U">=Z>IN]['K936$4GS)VFS+)J_=1_5KEHG/V5(L?$1IQ%D,HT0*B *I
M((L0@5&(F8AP0")E5>AU+ 'G1D"[PM?A IM*/[12TR6(:83QY#&CB/D)5-C#
M$)G@/.:3&)I@7=]G412'U"YH]T5'=-)8W[F/Z?ECGY>>>6-?##X;H(/R6F"C
M(MA[=J.D\9EMU01&3].,T10855]X?%U"%5]VG"<Z4*HOXXY-14!WAU?6,<_Z
M?]O1W_LSW1U]_4-J3BNJ-)AY]D27Y=.VPHG^'6^^BCN-2P$*C0P0VK[7C1J/
ML$>9IYD8+%9RO&'LC*X<H=L)XS'' VT_@G/$?OIM M]*<VNT?+M>B>)-Y;MB
M+KF_T4=3E:DY?R:"8HF)@IB91)T>5Y 0BB"1<> G)" <)RX;0HL^YV:;-2*#
M2F:WW: -PG8[PX%Q&WEEU=+6<(&-K%71-O#QJ\Q7Z=V]<3\7\CLP&M1_&2[M
M3P_(!MI0VO0XZ>;2 8+G&TV75_O1SQ?Z_5.U_#5Q%H@SC'R!8."K$"*A^8:2
M.(0"20_C6*A$.#D;/FM_;K2BQ0.U?#U#5I[C9T<D%Z R,FFX .),!B?4'FCB
M/V]]TDE^0K7G$_K48_TF[YM_KM/RR?B^92MMN3>?H(?BF#,2P(#KB8O\R--V
M XM@P&3@LU!Y8>1D+1SM96X3N182;*3L.9V/(VHWJ2_&:>2I[0Z1\P3OA&"@
M:7Z\CTDG>Z>:SZ=\]\.]G5'U)C85U0[EO2R*+_=T];?[;+E\^OAM)84YH$Y%
M2O.G.IC8_#(O[M/'MN1K;4P4']7-O:F+4WR0]=76@K(P\"(_AK'>9D!$E0>I
M"#W(/2\F-%(1#YS(8S1)YT9 >XI> :,J*+7(H%865-J"K;I739PWV&B\*:U\
MU1CLU1USH_85,('C]0VSNP?M2!^+'2_.XA,8F5MG,?I]W'[''9GAW(5'DG-J
M-^-QX3[BGCQRAX,Y/C26ED2,HH"&T ^DA$@&#&*]\$ /(2YIY/D$6UU9GNUI
M;LO'B2O]7D;L:7A[.T#,SICMB=<03A"C6+6G^WEI1XANZ_;\"SV/Q6F:_Y4N
MUW(G0T/Q(5OE)OS+W-PT![>8$R:%CV'BQQY$2B)(3*($#_E*L@0+S'RGHW&[
M?N=&'[L2 BK^L2[*AZXD0A=A;GE8/CR28Q^8:XE!)?(5V -TA&-Q-W"&.AJW
M['7:XW$W* Z.R!U?=_?-^OWS:VTQT=SXPIMS=U.SCZZHMIM6]1\^Y>F#W+E,
MP@R%>K-,(4&Q@B@*),1,$!A*%00AI40%S-;ORK7SN1'3[S]__AG4D@*C0WW/
M5)6K;-1H_UHI4OW9WF7#>6BZJ6MLP$?FKSY8]PBF<@;=W@=F3/ G\F\9](-W
M\CSI"UZ'5XESDY-YC/15=M<;I'<;/7>]9D62PH01-!.#)23"W!BO$D<0T0A#
M%DH?1B2@/!%1J-QR>QWT,+?5H!%06U>E<US2 7J6F]E+,!E[$]O 44</#6YD
MGE1]J#WK0?O3[E5/J7>P1SWYX#")0$VU>>/4N+/D>=0782(4U/\-],P.%*3F
M2E:0.$D0#B5"3MO2\UW.;:H?9+F\ JW0#D:> ^1V=# LD"/SPSD,1^ ,>WQ&
MRAUZI,,7S2%Z&H!SN40[WNS'.YM3^=HUNOGN0Y\P/U0,2DQ"334"0Q($QMW#
M1$LG89!(IYCHH[W,C5U:(4$CI1N;' ?2CD NAF=DSGB.S @<T0G!0+1PO(])
MF:!3S>>3O_OA?O/=&"SO5D695_O66RGDPZ/9O.IM"9>?I/Y@]&[V3BYD1#U&
M(@^B4,][%% &,0X85)X,B9=(*CPGGPW+?N?&"5M!P:.1%/Q("T!-=(<1V#'7
MHRWV=J0Q J(CTTBU)=F*? 5VT*VDO@);N8>C%D>@!B(;VUXGI1]'*)X3DNOK
M?4T24USA"_U^*XU:Z3*MCM=J=X%WJ]=2R5QOO?0#=8B-.:G?A-5\,S%;"Z4)
MRU-Q"!DE%"*&?8@32J 4C$HD$N+%3ENERT6:&[$UY4)*^KV-BKL">JFA;)D6
M]]7F(%.@J)(N?6V5J0+D*FV _N'5_WK_K\7V /*QN\+(6"-M:V!-.7XCT^@V
M\J891.-?7VW=]K6[:CR]3)+Z5L/JV28&=J,DV&@Y?"K<X9 ?S B\6*")+<:A
M #PT+P=KV8WHB[Q<;-S"JB0J,E"(XY!#R:(8H@A%D"1<6YLDX!)YG!&[0^N#
MEN=&NUO73)<<-(> ==/>13",S%[6"%A3S4EMNQA#O[3#%OJG+5,<MC?)A#^I
M1CMO3S_0\^[(Y+&NLI*:0 )M M23.\_-_#<FP*NG[2.?Z%-52O ;S47UG[]J
M:R%=W=V:F,]B9_/B)3R@A"0PBKT$(BYB2(0O8<0C&@0)B95OY:@PJI1SHX5*
M5O"U%A;DE;17[2ZS:S,TX<!:7HV]]'"-?;UFA&_2D^YJ"'94-"FU=Y]KU 25
MBE?U_X!&57#;#/88.]]1!V.H"[]19)SVTG!,F \N'D?MS-V3[5864K]P?[T2
MK^57N<P>38_-D>5_K.DR+9^T_;C.J^T:CO7V.XP)Y KKU4$R#U*J?\2!3)@O
M0T(\Z^KB3CW/C?$;^4R6FEI >U\I-\2[:7M4'$>FXE9NH 4'.Y*WMQ17H 7Y
M>FR0[;W11@-[(E>T(4%W\D3K!5R'&YI;>Y/YH/52<]<!K5\#_780G_2G\4%_
M+-66%#&4L$!(*'C@0X0C'[*$*<AQ)#B-1!1P[&+X[S8^-_8VL@$C7*]4LGNP
MV9G5?<$8F8*M<7 V78\I/)#%N=?TI(;B,:6>VW='GW$WR[[DV9HM:P>U*M?^
MFI=5=CKSBRS?I"_&B%)%"(6,5<&1V#B5Z>VZQSGU"/("CJQR\SCT.;?)W(I=
MNTSN"7X%:M&OW/-&NPS">1MM!&A'IH:71]7>*!L!W8G,,6N4AS'"'('J,+]L
M6YK,\')4;=?D<GVUG['U%RGNJC:+]&Y5?59- +:(/1HPY$&L]]80"<XA21B"
MF 41#Z,X0$BY&%ZG.IH;;S=R@AU!>P:WGX36SC@; K"1V;@75LY&VSD@!C+@
M3G8SJ3%W3MGGAMW9YWMD^%_G&4M7(OMT3_,'^CY]2$WV\[1,[ZH.&B=4/Y0L
M9))!*0F"B.,$4ADHR$)!N!^'"@>>=<Y^JR[G1A4;J4$M-FCD!EO!'7)ZVZ%^
MWJ@;'LN16<0"QAZQGY9X.F0]'QS7J?*87_"9NB44=T*H*T6X74/3)?UV4FPO
MC;?;FSVOW#?%H%[+//U*C1?7UJ&R>+>JJT^_6WW):94TW/AY526CMK71" K#
M2)FX+[U1ARA4@4GA3:#PE<\3C$*BW"[8+Y=I;G2_6UU-9;G4"Z[)^5][P^FO
MJ,QIE0MM5:7JWV:TJNI,ZO^I%#<O?WQLJN\6=;3UZ2=O:'$/WBZS;[U+X_7_
M(BQOYJ<=Y['OX7>&>*O/CG=Y 5J-C/]CHQ/8*C519;V+L1Z\V%Y_B5ZH_M[%
M$)XNR7=YTSTS4:4KO;J\U_V*YP4C/LCRFA450RT")A'C00(-@! 1GQC#/8!>
M0 +I)2A*9.B4B,JJV[FQ>2TU7!JQ#VLM_<DQ'Y4=\G:4.CR>([-F V4E\6%5
MI"8C:"OWD*FIG( :*C.57:?3)J9R N(@+Y7;VWTC! \Y\38M_JC.U).0*OW_
M"8RBP(,H%AZDB4>@9+&7<!HBRJS\=VPZFQL/'34S>ET =T)L1SU# 3<RX?3"
MK$>$WWDP!@OKZ^AJXEB^\TH?!O!9O.-^#OE9KM(LKQ+P)$'T>BU_HT\:.=*<
MW,B8QSP2$8QB$4/DA0(2WZ2#CSRI=ZS$]U2P^"ISEMF<0'9WYO+M[W8YWA1(
M?@ZB_PEJJ>LD14 +#;34P(AM?TYV!N7SYXW#(3?VYFX'K"M0 7BU!UJ/4\8S
MZ-F?+@Z'XD2GBGN?G@&S]35WA-3IA-$.I8Z3Q3,-3':B:*?([DFBY1N7N=PU
M%Y1AC ** @8I,M1*A80DI(&IM(489DR(V.GN=[_YN5E@.^YFO>YYGX%G9VGU
MAV1DEG1 H[?[W2CWM\\:?Q$7O.Z[VA-/]9NRIJCGMW2Y?)^NY+M2/A250424
MSR ATA3$0Q+J-Q7T%?=QQ./(9T[G.@<]S&WBM@*"OQL1026CX]P]1-%N^EZ$
MS<@SV T6YTE\4O6!YO%A^Y-.Y9/J/9_-IQ_L>8O7WOQ\5.;:I[KUV9[9)H2%
MQL4"4Y[HN<TX9#3A4.G%F5 1)[';W.[J;&[3?"/K_HV8S9&B.]"6MUX#P3?V
MCJ<_<NZ74Q:0#'7KU-75M-=)%DH?W!/9O.-&(4*FBS>KTL3@"*$_H*+JXV/^
M*<^^IB:2#$F"?$03$T!#(.*1@(22 *HHICA4*@AB*_HXU]'<J*.6%33"7M6W
MZQI2T ILQQQG\>UFC2%1&YDQ^@-F31BV:!PABT+RG^^RK[_H)FJ>T/_8TL/9
MAB>A!EOU6EJP?O["ZD15HM?BO0G>\YO3*1Y&@OLR@C*,3-@T]2"5D80>QCPA
M4>AAZ>3ST]'7W(BAD@WX/:L.'<'2SFX8"*&126"WNE MJ*D360$V9H&ATY@,
M753H2$\O4TCHM,HGBP=UO-*/(;[0[_\I:1YX/FJ^Y8!Z ?<# A,L*$1$^=I:
MB /(HHAASI22D5/,[4$/<V,#D[[.2 B,B&Z<<(B>'1-<A,G(\W\/CA%F_$G=
M!YKGA^U/.KM/JO=\3I]^L-],KG*Q; (5 Q3Z4>(S&/F)MOEQ&$.*0@J)D$BO
M_#P)8^(RB_=:G]L,KK,?.0=^'D?.;@;WQF/DV6L/A?/$/:KR0)-VO^U))^Q1
MM9Y/UN,/]9NH-]G*Y$N2J]+X?J>B<0<WK3>72%C&1 E*8,P8APA1!FE($!18
MFDI,/@_<?#3/]CBW";T5&.Q)?$FUX?.PV\W\0<$<F0TNQ+%/H78[;(8KN'ZF
MOZD+I]NI?Z0 NN6+_2CG@RS-:6-UJB"D>/7T>V'</9M0E%UO]$6@(BQ0P*'P
M"-:&@Q]!["L&8Z$BDGB((Z4-AZRD2SONL>_:B80V HPW>8SC,C?'YH^-["8'
MXX_KHO(8_PEDK0: ;E1P8R2'4;&CIG&P'IFC#,S5[<2G79A_;V'>"+\39S,<
M8;DC-A!S.70\*86Y _*<RWJT<*E3>>VNOO ((@$)?4@81Q"Q!$,24P55@"/%
MDQBSR,EQZ7D'<[.2WC9AB*: M%SQIR/QB'U]R!M$[6CG$IQ&)I<=7_%*MC'\
MP_>5'MPGO&G^A?S ]Y4[[?O][+E+0YG?/#PNLR<I/\O\:\IEE7WVU4&"VF4U
M3/I?'Y6I-W"W2O]+BD]:IDP_5Y1%%8VY2&)&0QJ&D$F3/1Q+#^*$Q9#'*HZC
M),%2N7E/C"'EW+BESC7-]G--;Q,"7[6Y.453,OHQU0:94:PM]]'$PKIZ9XSR
M!=C1V(N/Z\A<>#1]^*!#>D%,\PB0#Q[E/*2,+Q3W/ +,IR.AQ^BLW\)R*[_*
MU5J^U<C<-*;1W]+R_F9=E-F#S#_+NRK+N3:B[A]H_D=SET-])*+0$WHK'#!S
M#$<A0::"3*BBB&/ER\ JC^5%4LQM86B4 .8K ZT:X)O6 [2*7(%&%;#1Q6T5
MZ#=<=BP_^B",S.+]\!_A'N\B( ?BYGXR3,J]%\'TG%LO:^Q"'Z*=NM&FT]]7
M&2LTLQMZKMT2]FM^W9IJ]B9CI:;\M'B?4I::/.&?95DNZQPW"^P'48),8:XP
MTAMV+!34.W<?^EY$E(Q4P#7!KN2=R8WSI8<GTN 26_$ J7G@0.[Q.*&QYHI?
M=D3MZ=PT_"#;T?(+C]GTKE4[>M;LO:MIXWAU4'QQHRVHU+T"&X4-YY\?^_[N
M6:,-R]#>7<,+^C+.8:,!?M*W;+P>W18>4Y-N6Q=R):H"$^JI.CKF9A]:O$X+
MOLR,L.\WD5M1PJ6/E:=7$&VQHR3DD'EQ#,, 8Y)03@*%;,L].O<^-R/]\YL;
MT.[#KH ?0(]<[=1F-?O[K5Z@50QL->L15-=OV+I7A]$'8^PCEVG&P:FL96\\
M+RA]Z=[G9.4Q>\.Q6T*S?R,]$J/HYK_?RL<L-[=IOZ_2LMG_1BJ*41)(&%(?
M0^1S"2D.8IB$0EO5D0CBR,JAOZN3V1&=D1-L! 5&4H?\':>@[&:EH0 :FWR.
M8-,GR<DID!S2FPP UE2)35P^*+?L)6= Z,I;<NK5Z3*6G!%^+U?)N6<OO1R\
M7I6I2)=K<^_XV5BAE3?!F^]UBLWZ<.1!&ZS-J?(;FJ^T(*8T974$7=\)T1@1
M+U021G$00H1\!6FH0D@C*11B/I6QT^'NL.+-CF=W4N/NZ@>V"H)6P_9H<J.C
M>:G5TN0)J@O97GI!.,A7X'HS./78CKU$O,"P7G!)."3Z@]\.#B+<"UT+#@GL
MZ?O 07OIMXB\6_'L0;?T??\L0_]BXX++C;^E$+[TD0B@4$1"%!("L=1+!.8A
M"TC,0T\ZN9)9]CLWVJ_%!B7]#F3M' !^9'(E55K^!'*YK)+6EQFHW<X*DQ5]
MK3^]O*3Z7^:MQZQ(JUSW;BQO.TQV]#T"^"/S\ANE)&\RG%8C8(+R;DTP_O,3
M8?.'K19/K:O&<.SK"-Y M&K;ZZ1\Z0C%<R)T?;UO=%%1%M<KT3CS;'/;1(0@
M3!(/)J&B$/$PA$1S&60J1 1+)O2?W8**CG<T-PYKY7.-%CH!HQWE# '.R!Q3
MB5@=0;9"CI(9Z!P2@T4"G>AFX@"@;F4/XW[./.]^//@^*XJ=!>%S29^TY?5H
M8ECH\K>L8ISLS?=2KAHGJX7DD<)Z,PR].-"V3D(89$B$,$P"@GT4^23P;<\-
MG7N?&UL8B<W&AC8R7X&'2FICY<A*[BOP6$EN?X+F/B3GSQ]'!7IDYC&R[QLM
M%>H?]1YT@WJM OB2@3<-ZI]&1]W^0'-4]"<ZZ1QE%)Q.1'NCV'%4ZM[F9&>H
MO=7=/5SMWXC[4O):*IGG)GBK,5P_:"5I<=^L5J_JC> B8%X4^I)!'$D,D8@I
MQ-3C,&$LQLA7/E/6I4#MNIS;HM%*K?>_[7[9UMYTP/G\HC \>B.O!!O@=K:Y
MC<RM50I^;,3^:7! [?E^>&"GJN5^+\&J 52+_IBMFGR@Z>')CLKRJG9A;=Z
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M<]"@ "H83-:K!@A0(6$R'VRQ !488!^-JXW/Q=->G:VKG7CGCZJIGG(%MM
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MP$T_=%,>V9U=0[9*MK7;]W(=-(&DS[6M+@6TO@,?^8TR%D,>$@XKX/3'BJ,
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MS3.0BU>2[4HYW-S=VK34Z;8XGO!\X0@"!58KA#"-(0U<!P;4T=570H$\SZ(
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MU_:\0WPJY]7727T  \OE@T:_NX_AL?@82H[!K02:9U P#1Y7VX9W'-1\JV%
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M$5;'!,'*BN;8I3[W*$61D8;<8>ZIG16:U$);TSWT*HJ!(AD4-)O++-LE.']
M# CLP =$13G8DEX ##3Q1U'N$-9E"[?Y$3$@[",=$;;P]W,V=,2MY6RP'7&T
MLZ$CJ\VSH>L0/?52?%3C5#4*'5=2PF,!A:_/ E_X,"9^#"5&G+& 82:BBUHI
M[N::FNP_; H(-+%=*T"V@&SJ;.T%NL'=K1U1N[R9XB$>0_52;,ST:ULI'K)\
MMI/BD5?LQ$:>K75Q?/7!/)-<%,&AI0:[T>5G7TFV?ONJ/I#JVXYQQ,+8BV$8
M4]U^W>4P1I&$"#E1$$HG)!XQ$2!6LTY/E.RH!)I,2R%B!WF[.!D,R,$%BS6&
MQB*E$R9MPD4-V! LZE\[H6(WURCBI1/[M:#I]G(W3>7+*L^50-,AHR)E;Y_(
MBS*/\X?5YNEY73:,][R 4>9&,$*NMEV1"ZE+E/KH42)"*AR!K$(WS\XX-5%3
M40CR@D0['>4\O&::2J^@#2Q6OA0EMG;$SD"-8$GO#!04]Z>V&(/3D_)R?KY1
M51AC]M\K,N8O=JU,Q_6-3;(6193D^^)3']_^)/^YRJZ6),_G/Y-\X?J,BSB*
M82!C!%'L1!"C*((!)LBGH1.Z,K1KQ6,U_]3DSHY\N"PBC0]JKX&_--V69I/M
MJI@)J &Q'EA<-6#^T@WF#M7L.H'56UD[N]E'KF_7"9K#0G?=ANE8\6Z]8O]X
M7BUU/>;K?VZ2]=N"TD@$4H;0C[$'$0TQQ )'T'%<J629Q^-(VI3;/)S"2ER-
M4%KS4<_17G2J*#15,?'?_I_8<Z/_!?0ZL<12K3H"N)F8N@S&@251D[C_#DKR
M3L2Q]%C9[B0B?16T.YQ@W#IV)QD\*%]W^DG[*\)'\O,_!,D\QXWG*=_]"U<7
M)-@-/,*9,J8D]W6/7%\I.SZ%Q(V$ZZ&8$FY\)7AFKJDI-KJ7GJ8PUU<D<9&-
MH8DUOXPZA^WYN[X>$1M8*-1@E5CI6/WF;W"'J[QSZ)E?W?6(XDA7=6?0[.=F
MSA"6EINX<R.,=O-FR$KSILWTE6ZJUM]UE^STJ?++<C<.E)J%H"=0 %$0.Y!X
M/(">%[N1=)6.Y5I9C'NC3TUL5L1UO"W;!\Y,6^H,Q\ RT1@):VWH*,<]*4+[
M8X^J QUEZ[WZ<_PA>\WG7N0B^ZZ3E>IDV7NQWF1I7O<X"SCBVL/CDE#7SG(<
M&#,10!:ZS',P<GT4FVH^9^::VA:NB+-I'-^.Y7E-IT>$!M[5%:5%DF)-*ZB(
M[:#FG(/.7,WI$<+1*CE> J65LF,(3HNR<VZ$$9O=&[&RW]+>[!7[>(#;'VG9
MW:LZL9$C N'[ 218YQQ(1B&-I -#%Q'DHXA'OF=ZZ_]N[*E)R2UY'>[TW\/6
M+B O!&-@@6B!@]6]_ F.+[A]?S_B:'?L)UAIWJ2?>L1>L;F64C =/+AM/Z_;
M0M\+36>R3 J9?OWS5:2Y^*S^G3[I)TIQ4#8:6H@@P"PD%!+N"(@\%D+J20]*
MYD@A_"!DR+B]Z\743&W;EWSH)$D@2KH!R?,52XJ$OZ+.L"P8 :SJ=ZD?S6Q5
MJLM7\;S2->K:#"R%MKR :H&TQT2S _;YF8&*(U"R5#Y7,C6SZK35SRJ9ZW>C
MKM9(&N HJV:E*/:&<HLJ>?D<HRF;O<'15$?[&[2;=^Z3R)+OI"2@SL/*_U"B
M6H>:?-E5 W0E$8)Z,/8##A%'%,81PQ"'KN<)=3ZZ=EW S*:=VGFWH[J17ZC[
MZ>FC[8,F_;<+"OT9+H69([!_@ <^M'K#UMJ#: =53ZY%PTE']3G: ?'>&6GY
MMIVXXB)97*?K9/UVHR-J22$R/Y$UN=ID^G9](3R?!C1PH.N&,40,NY!0'D%.
M:, <'=(A7!,!=6ZBJ8FDDE;0(!9H:D%%KID$.HMNN\SI$[.A5>..<!D+%5,L
MCHB17+#?GU;?_X<:HI0@ZH>=X#@[\"BBPI2]6C@8/V]OVVO1THB%_;K1[CM=
M/%F*E!/=,2@6D?!%Z$'A8ET)3:LO#@V@$[*0A]1COF]4*MUHMJD)AI)"7<.(
M;VDT-^;.@WO>I.X5LH'E0J%E[$7 5_CIY@V#X&=N[/:*XTC&[(5X6IFIQOBT
MF*'GQQC-S#1FIVE&FK_4,5Z6Z!ZQ1;A=/7;1\3&_R?.-CM9]S$B::_&N/F;&
MF0@<A*%6O72Z(X.4"P0%%2Z/><S<F%FUC+:8?&IBN"04Y*LE+SJX%@&UN67K
M5BOTS>S#H3 =6$YKLO695A"^%2KZ%R7.)?6Z2W>#_AY#;SN@UE=0KLW4XX;K
M=@#E()"WRQC=1-GGTTD&C<IU\Y=5MD[^59[.W->QO3A2 DTRB(+ AS%5%B;C
M'@J(=%S)@KI:NYE(LR?":!/N5VH?6+0UBSLV*2W"@V]>7DF26;0.O6!YS"3>
M0)"/(_<^MZ8[S<"IM>A/]'6'KR<!V(& 4<5@=X#>"\,+1NI@1B^5/;#^%YEK
M*SW;Y.M=S[.OJ[3(M](Y04NE8*[K0"SJ$X?&'H7$B7V(N!] C#T/$D8]2I@3
MAB@P-JSMYY^:CE>S +8\[/4$U!6W"S[ CA$+2[+#^AC8YL.B/K2U;@]XAW#$
M+LA;6/7#KL!8=OX0*V%G_7?'L<T?T&'4\3P$W5G>\QE<,(S].?-1*?!<<%*U
MO_A#I")+V%VVXANVW3Z^I-P-20Q]20A$3L!@'.NX219C!P<BE-RHTIKIA%,[
M22J:"PVZH!I49%L<&$9 GS\A^H9OX"/A)'*@)KG#"6 $I;G([QO2D61\']!:
MB70;G%IDN-$PHPEM&Z::4MKJO6X>D;M,*&.=5V%&>=VAJ+JB*PV/NKD0(T+I
M_A0&CHPADI$'8Q0SZ$0HB!&3!$LCS=]^ZJF)ZHKR.O UW[6H ZRD7L?""EOW
MA\5:F+D]AD%X8&E>@WO=!+>4/17AVT(OO7<'L0>L)P>'Q<2C.C;L 7GOT.@P
M0M?Z52P3)!>?1/G?F_3V5>BRG^G3%7E-UF0YI_E:AR$L8AH'Q$%*=/FQ!Q%"
M!.+ 48(M%IP'4KK"+&#(?NJI2;*KHB]=KB]-5C7)E>PJ]MTR(319*MM Y/_3
MMG"5\7*8";-A0!Y8F-5$@P\UV;]IK+>4@XIT\%=-?*^%JVP1ZZUFE?'$(Y>K
ML@7DL%*5]0C]WU0UG+^56-5%&Q[5XHD%CWP>$4QA%.L^1Y[@D,:>@-QC3JQ[
M'[G8*.[I0CJF)N?4)QKV=Q?5M@"77TCU!.NOO)4J\U38^QNI65F[I6!EG-LI
M RQ'N*)JHV(R]U0&4-E<5ID,UU$TDB0K"IY^V2DG?RIAK%L&W:;WNG=0IN3Q
M1Y(G^;=T177.MZ['=I.^;M;[V36/XN?ZHP+H'PLO9)1ZR(6^+RA$41A#&G@!
M%(($(O"(I+%1?[@AB9R:4'U@SX)ORJ"<;(]D_1M6AZ2M]8]YPD75$V%%EY6K
M.0<O%21 AP[H04I8 -6X@$VN?\Z3IS21"=.M<#8-J)0BI;#*P0?=)VH)?,O
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M^P7>U/[O>59[+X!.5=,W?[LB_+?I5::H*J]OV=O##_*:+R3%(7,H@MBE!*)
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M40JR)JD6MX*G\32X0^T%I:%O4"N ]JCL<G]Z&BF+V]->$!O-]MD+^DS2H@9
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MC$(FF-&]M&6:J@23V"GSL'NZJ0FDFEKP@EQ@Z'6316= MA-!_J ;6/*<1FV
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MT8MTO:OS.&<L"@.L$*2AU JM9!'$011"2CF1,@HSJ:SDY['!IR8PW]%MP1_
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MIAP2GB8P#9AB0<(XBXAMS86.>:8F-DI2P8Y64!-K7WVA"],S)[D_I 86$2=
M\EALQ1*+"THT=(T^6JT&"Q;;11ML'N_9YB1?ZO&NUU+DFZ:HR^]+TSKQFNJ/
MP$08K!X?\](U\5'*+W)M?&ST7LYE' ?*E&4)%0XAPAF"1,0$,HTVQTF".;.J
MS7(Q)9.3)#LR@9(2_$0+0,%31:YC-?S^JV.GF8R"^< RR?!@E)6*BUTYJ!FH
M& $-)R:G:+<PFAFPY\9C6X]+ ?75[*,W'>.V +D4KH/&(!</V*_RYE^_S%&
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M:LI-<3#<J^#:*<2[Q99_%(>VXUZ45\OVY=7: %Y6NNX4DKTJUWE ] T*UY7
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MI%48^! Q7+0*5FE-?;<BW\H5V?%2Z_"@X09\&W=%7%JVC+(RHW5V&7"%'+O
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MD[5?/UR#IOW0#(01#,@,-'R9@ND[SL">M:HY3LT<^,.P!VK^''.:^JRBW9W
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MQ7&;:IZ%F6",Q3"4+(1(I2DD*0^@/E0SJ4C$M9GCY*!RIV%JIZVF[7'5.*!
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MUA%E!%D8*)@PF=(@B1$/G.KI]*)B:HJDWA")FU#O![Z=Y!X<TH'%<T4_+!D
M>PZJ;*E9*8]YV?6[Q<P,&#Z 9L2?T+T(1T^2M1\-HXK/BV!Z+2,O&VR@>D"%
M4RV*O\G\_L&T!=<:*+W7)KM<\[R07]8YEW.:,AP&"84AHMR8V*&I_6D$*8X5
MBQ,>I&ZQ!>/1/C6AV] *:46L5L K:DT;5R[+3*UM(<!3D]3EN]"0Q\_"TE\Y
MS<4>VMMI4:*HZ%^CJ$$!U#" !@=0 C%BP2+_JS=6-2./E$^KU)'_)7&N@S0
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M>+Y-2K+<Z%7_: (>ET+MI'3^$C('Q:H$K-&F?L V/J3W )KQXS##XIDLMTH
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MMR\^SV[+?I5J:@%^7I(YW]3P8SP53 8QC @.U"Y=V>XY"1D4F")),HI$:&3
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MTF$QWV:Y8C-2EH4LV-;_K$KW VFUTV4MA3>A_WWMZR$_)%N+?:2?Q\<ZFTR
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M@CA4^[<HT9?>.(8813G,F$28A)3EW*J,[WX78UM=+I>+LH2LD1.42E!+R_\
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M^6 <R[^._GDS_.I&R,SL8'[HIM/OP_'5W]SH)@UP<Z5,8E#F54X@0@S@@M-
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M);5!MIEHIPE(EI$KP2T8RP5$D42,%D.'ZE5MZU'6KV7J!%P=J*0!H)VC9I"
M,N;J+6[JH\FB/_N*F?M]//SS9KBXL8[A:ECTUIC-!Y)0$EEV8)W5N*:206D*
M BYR8IG.^'/MS, .Y/9[W: 32.Y+>3WBM#1T.;@N17O_M=#567[< _Z>SP=?
M.Q@M'HF>Y^36\;W?'!8;0F1<.!M*RUY2;D0[ MXK"=1YSH7GZ!X_,IW/]MSI
M@K9^[R=416H3ZFO S"YX/;[^XH;3LD0//[OI59H-,J4\Y)C+4"^!K&0.MB2$
MN++&&Z4BK5ZR]3PE_=9A=F(<*XB\9[NWF!UX$^8W4UP>*_I12L?CX;Q4Y-SX
MT3"<922K_+J(<&",CH*E#(HP-.I$8HPM; 8,O63R)GFFU!I&;>,7]WNUH;K%
MZE;P#9BCQ1G#V9=%&[12\%[*+%;2*PV(K*':4I% 6QY!)$[!6TTA*<>2\Y[(
M4#NL>)VB?F\I=&*>*JI@<T#9):#&Z6JQR7:6-!LH(05UTH.6WF$TI S8Z"1$
MERAG67*,OSM.EJV%'?-+86<G,3=P4^41[,N]U &GAD>F4O'@+ A:KHPYJ< 2
MEZDG1C%6NY'S,V3T?2>]:D9U5S$W@)0RZG2VZ#^TY.'N;I;VE@69-+AL$?$:
M]UKO-$.YA.A--EZ'VL.R7J*E[^OD53%31> ->#BW=*],9&G8.2!*,D$5@>22
M!*%R!,M%!&7PY^!E8+F#Z7R/R6CDRELMN.PFYEU=ERI8>3>9IN'5>-EV.GR_
MG+KQ#+=HU,A[-QP7L_DF9?Q..<5DBF8CE01>.BH*J0-XE@S$J+RAN&N'ZA79
M&Y#7]Q7SJMCJ2BU-6*?;#?GV"'TXOL&->K5C3\8KUNXZQ*;9T3?T&U&#P[&;
M?E\(]X5;RYIQ:85,X,N<7\%4&=>L!&J &UMZQT95NPM9A^ST?3^]LK5L0^U-
M.'8K%E<[QYLT3GE8AB\2SHD7D'79/#"H :M8.4-+O,R.")G7;NKR BG]QHV=
M(&\W<;>39O@XG2#QRWC&IL04FGN7 BMY$@V6^>)L.$<TR5R'VOOQ_=O7@HC]
M12"RI5 ;L"6G:7YO6=?J[)&%=(O^-)Z6BZ86C:6AP@%7469K5$B^=B2P,9'K
MU>>07P1=W>JH'=/T Y\#W)$YBX1!&76/FW*PI9.DAJ"X=<PXXE1MZ_0# >MA
MZ%<I;=Y>M@T8J=N&D!_3=''G_8V;#<. 4,JDE0JH1WP+91,8;QSH+()5F9&@
M:P/D64+6 \JO4DJZNZR;F.O]F(VWP]$-&JM!MC$2*C,HBN2+2##8#3F 3)PQ
M%;FWL?;N]0(IZ\'F5\F7UY!W$\#Y>QI>?4;*#_"A[BJ=WI3+9&?Y2:^-Y;KP
MV3@?4L#M-080CE- AG&C931)$9CVI/85K8T(7 ]DOTJ"O3O=M R]U5)ZVNW%
MVJQ(+@*T)I9CA0B>45X*9Q--N.XRJ=V9>D,2UX/?KY*P[U(_%0'81S^>P[,/
M'\^/_H+?.?[;T<G912=M>9Z^9'_=>7["8/U>=4MO?3$XYDDSZKM""&>BTI80
MH"Z70@B$F0M1 I$I61F55;QV\YX-2:R8KDJ<$&E( I^I!D$#!ZN(!VIQ95&:
ME*Y^4W'#=-4^^M15Q\4KN:Q-)-[ R= ZO=N?[6&[;$)Y+SU% U6X*=A(T&>U
ME(%CU@ 7R84454BL]KY:B?1&+C7N :5]Z+IQB+]\YHMZ6/QMM(1"_#\WRS*5
MNX$&0A+*G&+E*C,%(0VZRE;G,AF(*9Z32*EV15 WG/1KIGL!Y08+8T\(:7B=
ME#DRXQ171W@?1\CR4V9?4=' \2B)H!&X#:@:@DKRIHS^P#^5T\X(63OIV!4O
M_6X6+:^5O:*DB3*NM<;>,.,YHZ6G/W48SRJIP7IC('AAA$O*.UJ[OJ#:2*+.
M\J@MXWAK[35PYO,,.[>L;#60PE#OE+(4M"\SFXAF9;"SA4A8B)&RY*H/<*C,
M0B/U]7MP[OO4?=O07XM=IJPVEF3 O2:4\60&O+<!HM,B9^^(I7N$>C5H[V-N
M;Y_0KJ[;=BH[7N%ZD)(2%JF'Z!-&%DE(L YY(X11$J44(78P/N E<AJY8= O
M$C?2R2\W6N=A6O_B+P?G1W\Y.WE[='YQ]-=/QY?_^^W1N^/#X\LNSB]>?MG^
MSC'69+C^><8KX\J<$-Y$:8"EB&@C/(,STH,/P;K,&-&R=O9I+<(J#R1(E)0>
M"1*X9PI-=XK@4RF%P%!1$"8XU;6WY98&$M3'PD_&$VPB[P925G?4+R52S/-D
MC'^=+5JP9\DQ)L3H3<;HT2+3A,SP!"'Z;)C(@=/.!E0]1U C6-I"TR^!9F>Q
M-X"A1SRL6FQ+[B0U*!EF;+G>@D$_1O[H+UBC!:$F25K[5M.SA#2"F=T5_;CV
M;6>I-P"=93IJU3M=.>]]- RL7M2/!P;&BP3,I4@,6F@=:I^ /GQ_OT"IH,['
M1^K;RK8!7#R8-[9BP&&@J?!-D(U'21"OP4O)0<58LBP\(0_U [8?B>@7(=OK
M\^5A;EL(MP%T',2X&&WG1A_=,!Z/#]V7(49U*V:TI#)%8<L0.A1-Z:_B=7(0
M0AE,+(W2OG;%SJL$]7OB50TU]83> (+.T]R5P[;; O+;Z1VR5$@* E&5V2],
M1G"444@^4:.M(4G5WH&>IZ3?K'LUS%00<P-@.0CAYOIF5)*3+YUYK1C+)D=)
M. %C<[FP$F,9<Y= F:P),9+1ZD-)UR:NWVQW/3/4B3(:0-GSJ?<5+\%YK5-2
M(!?W>W,68#EWX ASF65OLJR=Q7F-GGZWM/JN<C79-X"C9ZX?1*$Y1I@2=^/2
M:R5D"9X%#L$KQX/*TK#:)12-CW2JDKO93L -0 3-Y#2YTOQI^>_C\=/<Z#FN
MA7>3Z1]N&@?!>F4"8T U6FE!64![78:':T:TCMI)7KLGY(8D-I+DV1(13UM_
M=*:>!M#WTG1ZI8SG0GM@')>C0*L-+LL$G#FCLDO)R]JW&E\@I?<9RMVI_V=S
MW;?0Q=:0^I*FPTG$Q3.=5]KY'HMIJ[J=K+TET6IP3J#?Z*4'9ZD#%;C1/J($
M7.V^IG4H[W>'W2=L>]!T6RA?+M.WBW;G'Y<O6"S?V^8):5' @4'10OV#8' Q
M)T\A++(SN(+!R*# <6*,$4%9R;J ]&9D]IOTV#M^.]1A [O\"RS^S8UNT@L<
M\AB=+KUJ&8^ZS!OT@ )%GXGKR%4I(*Z>N-V<RG[3* V M)8&&\#H_?6*V>7D
MA?SV@E/_F-/SA**>#>=I-;)N*9KS%"97X\53%E(:.!.LE-*""8Z4,).#T39!
M-((Q0:V1KO:]G:YYZK=4<9_X;PH=;:V6\S1:SGJZ=-_*&-DB?S00*/47# /E
MT4CN.7@7RST3D<%G[B$&RQ'!VL7J1_L[D-MO4^:>,-ZI3MLI"G\^%+B5>>GR
M>W'C9\,X=-/OJ] "MT W#FG HB6"8WR@I>9E@EG&]:H"1!I*Y;)4+M?N>[$]
MM?VV8=XGAO>DT08L\(,F&3)AY*I3!,MTJ1RSI9=B") 54THKHICON8MN9XV6
M]XFM+26^@[FKDR18ZVXF489[H2QD7V[UB!C :</+M0[B;?'D=1\=1_KMT;Q/
M=%774@,VZJ6,<O#!BN049.8$B, 4.!\\,$424SPXYCNX'KA]=K^S-LTMI/<W
M4<:.B<^C<9U> 952OB%EE7S$U91+Z4F('IS$/Y+(CN<H2 KUC\+WEMSOKC'T
M+YC=WT3554'>2RO$@XN_O#LY^WLW+1#O'K['UH?/,U3_BN"AFWU^-YK\<3_H
MT3*5*,<M-@FM$#C2@0F: /7)B)B<S*3#_H9/Z*G0X+X\$UW9KT.4W)OOGV9E
MM/S=K,&#,!]^'<Z'#T9=6JX\Y4*"9A1]W8P.K^<^071>:BH8Q3]K1[H;4]E(
MS<>N"'JF9WZ7ZFK 17P05*D0>9D$!CQ)=&YI-N!=*K<O<;=0V3H;:R^U5KIK
M=JWGER/9383>1(OJ'S+Q)8T^#L-1^F&XQ.5D4V'*X*7++('-'->H)@),SB@4
MHH*V2CE.;&7H=<%'OT4?>P9Q[T!HP'J^3?CF,'2K!HH'U\4E_J]E2C[&3(/E
M#E@@Z/)JR< )*H$FKJBF&-NYVG=N7R&G7_O:/U8FW2BN 0P^I/TLOQN.'0IW
M?'4[Y?SM<!8F-RCX@:9*:4<Y&%["0$)%:>F20 7*B9"*X:*O;637I*U?P]D<
M.CM1:0M0G<U0J-=?W'!:I'WXV4VOTFQ@;<A22@\V>HV[$+%06EP!451ZDI+6
MLOI-K6<IZ;?HK3T8[JZN7EU6_SD,WMS,AN,TFQU.KCVNHZ++Y>38J\+19#Q#
M04Y7*IXZ_'0A?V05?SP>XT*\6425+_PG14!%(X,8;-(N$S FIK)G*# $PTV3
M@M9"21[YHQOQ3S(_^Z.VW[*Y9F#>*#QZM--%(@>CT>2/<B!?>H479:39V?@@
M+#<<5%<:?BV97MR&CL=?D>/)%/4P,#)*JQ7RED,$$;T$1U2YET>,IDYH:^D:
M^-_JY?U6P34%Y^Z5US,ZWZY>>3>1N9PWH' ?#6:V61K'C00FHP#!#4%FA !/
MD5=*N%6/YW<\"\?UWM9OA5I3^.M /3T#[KT;CHL,[RKR3E!25POM7J3Y?+38
M$-Y/2RJ/*21>BP":6N0J212?R*459X[>":&UUVN ;OTW]EM6UA3P.E)3$YWY
M/[KO"RD7DXZ/'=TS-$/'PAB&'C<HIAF(0%@99A>!1T:M59'Z5/LRT2OD]%N+
MU@P@:RNNG8+=%ZJ/B4X^9QK!F;P:-NZ)BB!3)BZ)Y#ROWIIR^V+QSLK5F@-@
M!74UD#5Z>6;1K=7_-)XF-QK^5XH#XY/UQ!H(99JYD-J!I92!\DEG$E5FNO:%
MX4WHZ[G>K3F$=J;;7G?NI2L\Q6 +A94*)T??2M'4<ATN&N4,%$LF)N.!&FY+
M4PH.7AH+0:H4=9:6"[56B/+J:WJN5&L&;[4UTLZ6O*A;7H592ZFN@JU!SBJZ
M<JXKG4!^%&<88)7E(CTCTG@B6&W?\$5BUL/A_YP3GCI::R(\>5J->B>TU<7,
M.XDI[FQBN*Z4YN6*#R-@4Q 0@XHI)>N8[+YWT4O4K0?1_SFG/QWIM0&'\BEG
M3U.D Q*8SUIQR*YTFDN,HK-A,D1F?!39$F.[Q^I3NEIKAU0'$S^%WHX*:M10
M/DS"4RJ"]F[1[+D,C'0<+&&V7$!/Q"829:C=<>M5@EIK8+0GH&VKDD81]G&:
MOKAAO,W+KYR,@_&R7^OB@'(VT-)0'J4 :CVN)(/.AQ66 P\B.F*HU:)V]>5V
ME+;6E&A/F*RNQ$;!>FOD/[KOJU-*_&1Z@^\;.C\<+5R; 4D\Y8BR#"JA2T.(
M I^4!:]#-M%Z2VGW=G(=2EMK3K3GG;J:$AMP&->OK!Y$2V/TZ'$K66Z;D'+1
M35L"GJ00B&/6ZNI]*=:FKE_[N>?Z](Z4UL!TV!<X*Z[+[ 5!<L6I,2I!]D:#
MP*4-/DN#:YQKG[Q6T=4NL=R<RD:Z4N_I$EDM=?5<('%[R'DY.0C_O!E.TVU)
M72JERN\FTX63LF1V>?2I'4\T> ]9T-*.V5)P3!M01*7 #8O:K%,GL?&+F[QB
M5@T%DWVII)W4]Q,^4;AHW>??/X[<>(ZLE@OK7\I7!LEZE6E9L$)&$.CI@#&X
MDHF6,F!DIU3U$^KUJ6ORVEAM8':LM"9"FB>\':,>QU?#X@<OHS3)5,;_=^A:
ME,$8QE/TM:.&%%7D).-Z4[4GI_V4J":]PKW!;R<5-6P+/[CI/]*B*<=%"C?3
MI:/+4N:&"G2E7< _5"A<&H%QE]$I$AVHJ-U+8"W"^HV5^X;@SJIJP_A-)R&E
M.%LT^7.+R/^#FQ=VOI_E9UF,D67NRB0#&P.R2 1890,XE[P,5-OZS?TW)K+?
MRP7[1F:G*NPY4+GM171?A7DV/BP5P;?%1Q=_N"^S@26D-/PM\\G0\UC.(:"6
M &$&;3^ZQL+R-:*3]=[6[]6!/88D'0B_W;S@,P(<<**\XB&!#=2AX!+^Q&D&
M;QS+3LJ<>TS ]'N18,]&KB.EM9L7O+L__HP@-=%.IX3>+2^-5(G08&RT0)F(
M)$A.$JL]YF%S*OL-4/:=%ZREK@;LXT-_XK;/\UD^F8RO,/"Y?IL\QO@B1"$2
MAQQS<2"" 8M!/B1<SHJ:J)FM?9SW<ZJ:S!16P\4K3E\%)34 N_/T915B/>+#
M4L--%!R(#P*$7,RZS1I<$D1KFXW0M:W=2[0TF?/K"F)5%-)&D+OB8^,!#5D*
M'6E.0"(790G%<N<F ?->8(S$HE1=95XZF;BQ[WQ@9]9O'PIM";K(T0OM*FX+
M-+X_(^M!XB'3H"-(9RE&9@LO.&7(AJ$8O)4L=I2XWH[@)C.*'8-X#ZIM"<FX
MF91-Y-9G673'&HB0=2D@ B$RBI$KCSL*KDV2'7/>:TYD[5K&5\AI,GO8M2G=
M52UM8.R!5_S@'O?BY/RY1>1SBK@E&*!2EB'FI58X"P&&2*>(XE++VLWU-B2Q
MR5SC/H*:VNIK(,)97YJ#K)TA1&HT[ 1C-\,\6*8,&)62HX;Z5+U>=GWJFDP\
M=H7)CI360.+Q*.<4YF?YZ%M8=$8[1S-\-B[,EO^5@HZO;K3TLE&.PX!&NOSB
M8!Q__.#!-P=,2HVTAC(B(J,<E 5K<$6ZX )-7G%?O2ED!VSTZX9VEKKL6^$-
MF."=F%T.(7U:/+^:K/)0K$M1#QA&F\E8#DXP7EIFY3+[S #AFFK<NX00M<_*
M]\MAOZYR9RNE89@TL''L9C%L#DHDQ3"H6##K*-C(<4=6@EO/M5&Q=E%G]YM!
M9QYXFQ#?2(D[3H9""4SKC'3<C>5$,@L2?3J.P2^(T@7,.$D EZXFAAK!9>UC
MB.YQVYF7WBAN-U%B(V/[5CP]XN0 HY+I]#ON)\M)Z"(D24IN)EIG<$$B=RYD
M749)*^8]5U%VX6G\E+!^FPMVBL*Z2FG .?YQV2QKO.8#CR$R1K42<N*FS#J2
M9<D@)S'P%(,))-2^&_DL(?UV">P,2;L+O8D!4[N991=C8MDKD!*-L="AS(A&
M+YA23B7E0EG[Z^VMW34$;'1SW42+U<*8#D:%OCVZ.#P__GAY?'9Z]N[-IXOC
MTZ.+;::"/O^<:@- UR"STJS/L^F5&Z\FVY03RLEH&&^','U\P,/=U!LWNH/H
M/3"-\$HY$4 904%D8<$PW!(5Y][[[$FPM0_YJA"^<]J_%..GL[RZPXYD#!S+
ME#J,G&@0N$8M5V!E<,!9(/@_CGY![7.GIU3T6R^W?TP]R>SOII=J#EL'%NSB
M^/WI\;OCPX/3RX/#P[-/IY?'I^\_GIT<'QX?;6/)7G]>-8NV =F5+-NJ[\EB
M+O9H&!X>&CF>4C(T HL"=S-K IBLT9=WQ,=,K)2L=BNYEZG9N07X\&H\S,-0
M+NL^><DE"O,-?OL?@VR44#EC9"Q*YT%G,[B,"\M1@2L@EJQ.;;NT'F4]#T*L
M@Y(GC;[K*Z5EHW1^]+>CTT]'YT>'9[C,B]NRA25ZYB'5S,_/"*QD<\[3US2^
M2:7(H11^%1B5VL7#F]E\<IVF=]!*2A,J%&Y&1%N, 9,";R@!%;A)/"N)D*L>
M>*]%VNZ)AE=?<P_]*#3UEFI<4[[<++,:G X2M,V.Z,QU"K7/"M:EK5^+U 6&
MGF8F.M!2RP8*_8RC4PRCWA^\/S\Z^G!T>GEQ</KVX/"OGXXOMK57/W]F-?.U
M(?F5K-DSL_A*][C2E6%Q47XV7'QT"TC<)7E,ED&6I>&AD@A(9PWBTQ'CK+!!
MUE[1FU&XRV7EDV%(XUDI"KJ:IE6D4CKIW;VDS( =3688=MRO'L8#Y9)[($)(
M$$8Y, F7: [9Q<PTDX]]KF>O+F_S[GYM6(?(>7B)N7.EM&S2SH\N+L\_'5[B
MMT_?'Y]>'KT_/RBFX.+HX\'R)S01QQ_/#L\N+K<)##=[?D5/;6NVJCEQ",N;
M4-HL(+)*5G1Q$^6Y;HBV3#CA)95ORG5D*Q!*3( B&#IPK0WOYOQD'>)V,78_
M?TF95XD_N=''&X]!S5G&M7$[$/NY11<%-Y0'#MF7N=@\X:*+0@&CRC)#E$\J
MKV$)JQ/6MZO7!=(>6LA^-=FR^7QW<'S^MX.33^A-'5Q\.K]SJMX=HX$Y/#XX
M.3XMAFCQ\1;6<Z/'5S.>VS-5R7:^<\/IXH#\'CKW(";:1)YCQA#%"=QY=0 ;
MLX8RYC$KXI0(M:]<OD;/SF/0GGGV S?#.<$R(6 8IR!"Q!@J1HS6G(PJ"&,L
MCWM@MA%+5PT73^:555-"R\;J^/1ON&3/SK=+\3_\KZN9FA=)JF1);N<^?+]7
M['V\D BU0DK@*D<0&C<BHWGI5DZ(H8@E(6O??7V%G-W[[C]Y]#V"@Z-)!NZ@
M3()$!#,+5B0/614$DX2<UIX9]AH]?4^[J8.)ITWS*VF@;1MR>8 1U9L3= TN
MCA9NP?NSL[=_/SXYV<JFO/RTBC9F39(KV9SWDTG\8S@:+9SB'[N0/H,X(4PV
MUEH0.93S(86(H\H!8\Q;QR)*J_8IXD8$[FJ7UGK9_3H14F?G<>\V4LE2/,[
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M-@A#?/ 9 WFO;:G%YR@<*QF0P!GG69399YU9S0H,--ST<1/<O6P\]ZWDIKR
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M,=ZZY>V.V8]I&@I6KM*;E1P&5G"T"<E#9BR!B%Z R4("%[B[",:T#[6O_F]
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MG;' ,8G,0&"]F=R2_TNIR-(:2T)TK/EX]?9:]')SUPYKCW&1S>?XUKS-TZR
M;WYX\=<5<W#]@ZLEF87^T!K#!G_%J[]?6>99_J_+*[-MKHWB97!:60N2;T=A
MT#$9L\H@5-'!1F>L:DWG,JU&';_53;\RC@R(GZ6,^"598O%A>?-N0+;[&)8?
M;I\E-F_">KVUZG&JA4>+,TM1\&%&.T;MKPLJZE(T"&%Y;6T3$)FAP%^X3(FC
M\YY-QLS=-65Y$H9[%AWP'%.]Y4O@4"M B\4J$QEO7MK[=Z L'X.WZ2C+QSBW
M@PC_B=<3Y[G'9 (4SS6EV-Q#R"F C-I(S9.+IO7[^ %/G5UW(.T!BV$OF6-\
MU"72;AY5HN>%:0=9R3J)R)!IG!"@(R_%AN"9:<V+>5(OF:/\//@E<X31.P /
MK:I\^WYV\U@F&6K2'G)F!I1'!ZY6 S.DWY'9,YZ:\W0]%*,WR.SCW_M5K@<:
MNP.\[*R+8RKYDGGE;*D3CY.JPZ.L \MIE1EMA,BB,7#Z+6_MXXAKYJ^NL/=(
M81W:*#3G$KQ!7FLR(P0F$O@8$G<A:5/,9-@[J>K545X?4[TZQ@4=P.DZT;^?
MX-\0)F:1,9%9 M=D)2X+^!QBS8$R_3]9HTKK7'*70+T ZE"_W\\/FSFA!T0U
MY55((?G(,(/T%&0H9SUXBQ)2Y2\J02G>G(#P^.0L)\ I?<CQ.Q\B.E@.3X[(
M+38&P56";$NNG$L*7&$(RE@CI,C9^=:7('^'<<:CX#%TG/$87_UD[R8/KOZ[
M&0K;0, YWU::&?88KRW(K7;11-#656ZN8L!%6EJ<IV!UH7]96M^BG<9KBV8Y
M:(D&<F"58=&18;)W=>YYXDHF=*%UU_W?X;5E#-ZF>VT9X]P.0HTG1U&B+JD6
M-8+P@JP9K08O*9?@DC)@X2,JU[J;YV<?$#L*&D,'Q([Q4Z=XN\Z&G>8Z2XO@
M&66J*G@%T01*85/PT:.0*;4.;D]N0.PH;P\?$#O&]#/3]3Y+:7V)^=YXR(>C
M2;-B47GM:77Y[7.#A\"= *YRED9[HPW[06 YXG/]P64?SZZF-7,'V\^((:.A
M<&.33!"%VLXRC>!4G0"8,W.28@W*&!MO1S_!!-A]\#:Q<SJ W<YG!9&-XTBK
M)Z"OM\ L@R^TIXLL2G:,B30A?<C/^_AW2+35S%]=8>^1%PA^153FP!4=0)E0
M2"NN0*LH))=26O$OZIKQ7A_S^#?&!1W :?>[$WI:6((AR"A"[<ZT=9)?J:0M
M1@FK,-E_/?[MX?=1CW]CG- !HIXH,HL84E8*P5&& TI;TH)7(KML,:=HT>G6
MQ50]<MOT<2 V\%&72+N)6J6,#DWE7:P]+CE18&EU I]HSY?>\Y#_U@6?H_P\
MM.!SC-$[ ,^C-8B<R:PL!YDS93LZ: BZ\FS:).KK-M>V=;/<Z11\CO+OD(+/
M$<;N "]MGZB=S@5]'1KI#!G3>0TN> ,UW;86?;*F]3"6X]>TG,#<UT,.T?D0
MT<%R&#"PILC$@Y>E]I=N*4(Y+?#,:?_(R5@=70GMB;_^3@.'1D%F_,"A,?[[
MNU2\K+XKS+@E -FLRMO/N+YB" G+_-0?>AXV'U^>K_[LI#RFM39=UM),ZK*C
MM#EKZV+6$6P]GA2=2>"YIKC)!^ZX3"'XR883=EUX@TI(%1'IM-:*(LABP+O*
MNR^"+K'HPM*_"F_&%]Z,P=MTA3=CG-M5//3(9;.LHP&5B9 IJ*Q1)B5105@(
M1DO+<Y!!3]>3L^>34-<QT!X0&?,D-,9?76'OD7MI:4IQ6@7(OK[H<QXA8M%@
MF&;2H9*Y>>'7B3X)C?+ZF">A,2[H $Z[7R-8]B$%4H:YE.J()$HZBH\0;*A$
MB8%^7NO>UE-]$AKE]U%/0F.<T &BGKB&MB5*&W@&Q-HOIRG!I-B# ^-,,NVX
MMZGUZ^(!3T(G4"-QR('8P$==(NUZ+3*K;&#.0U';>349:2UZ#8F9&L\*+</?
M^DEHE)^'/@F-,7H'X'GLE2(7YDA8#FD[YXBK"(XSVFY59,9')I-L?5%_.D]"
MH_P[X$EHC+$[P$OCKL5<1! 4=*(WM *=H^/<40+.,#GD2GFC)IMD_:\VYS:'
MZ'R(Z& Y/,J-^F9UL7,NR2UY:GUQ$"4KXU&#+HX43L9 D*2_2-E+9C0:W7JS
M/5CHT[],V1-P0_C))_/^R<*]*GLFN58I8 &[30P])8;>T3%J B8CC"B1MPY&
M]Y?V]).C.0$^VM_],)/OOZ+/HM#,B6!!.*8JM9*'Z+@&2C%"2DI[(8XR:F*0
MM*<?N,R]@X_R]\]2*O L_<_E8K.HGUW7X2"5BWUY0<8A8>IC\B)?ORZ_C>>+
M#U?OS$<F&F\BXBR/^NV->XR7^IQY$9(C..8S*!&WQ3(&+%96S*!"-*W?^8[R
M4K][1]IN0?]<KN(&UU]J"O5J^?GR@GY[M4ST7VV=<Y5:"1&CD]I!$LI0:J5S
M;?.CO8(KM%Y%'N5DA.V-=.@DW#\4?4\FKG.XNH-@_E;_7[Y>JUT/MY=K_)_+
M.OS@BB]2%]1"1N Q%E#6QCJJ+D!DQ3KZ7Y1^,@*<I\7J!)"SX.8I$#=R8D^X
M?$RA&R9FG6W(A4/,/I#)G(48?&T7HY5O46)IWG \0*Q.<-D*"D]!K9%?.H7:
MYG8%7]_0:QV$$%?#ZQ*H7 J$6 )XP2(++'@G)KNDWB%7)V!K!88!8#O(,QV@
M[8XJV[.@EDU<#2,PM"S)/A!MK3XLB4QF;89LK?7)2,]DZZZ!IV3IY.:KAZ.U
MB;LZA=W-8R:3SAJE@=:CJ34UO"X@^HLP6F7#8L;6=U9/2S/OAM;&VP,@M(?I
M.P113<8J1^R[<'$S05@%64KE2H[&URE[V=:LS(".2:E(O\E"ZW/RQU+U!ZI]
M_/\#6!WHC)GIT.YK\Y^X^/"QWKQ^P77X@(\H5RQE_854,EX+4"XR\,ER*"H+
MIWS61@PA1AO]X7D/Q\9@FM[T'6Q;=W*BVU_^^X*46Z>/7U_C%SS?[O$A*N,P
M9E*H4@((%2%D3G^AJ"$JE,SYUDWPPR3KY)VFAW!L E?V!-"[><Y#_:[7>:#-
M/&)VX"6CC(J1AAZ]@"@2ZJ($HRW_&*GH4P)VDI,V1,B0M+2)NWK"XG;];K86
MDS?[?LK9Z4RRJZ! 2=KR([,2;!%:1^8HJ)ALO.I#<3K!67L0/ 6W STR([@V
MZXNS=[6=XRJ9XK2Z,!@H%(F!4HI1@*I9G:RBA169L_N1V^,PHI]Z!T+T3]_@
M\]T'.^'LF//\W-\!/:#F!NPF:Z:LAA"*J$QS"'55 2\YE<IC0GAOA9LYMY@#
MG'7?W7M8;F:'_[98+CY=?KJA ,PYNF#JEJD+J<PH@_49R0S9**M<8'%08<$/
M7/[=1V=V^CXN6[6PW]R.#W_=$5P&(Y*0B8Y);NNLH011TOGIE!%"H^#>#4K&
M?N3XNQ^=)[-OYOB][==3U'GX(?GZMB:0J\Q#2;6-P5*@+Q,#BI4T>)YH.2@?
M??-BS"GT& 1+_5.'+]W I(.E\LOEAD3?;)ZO/L7%55?:$R6"-T;Z>O^&[TP+
M+<GP$H1GI'+@M-MPRZ ('[Q,KJ!K/J+D<+$[2?AFP][].2A'!L+?N7[Y>_^M
MRH__BWX+G??7Y60JHANYZQBETSKP8A7%:$S6KLM@+ 3E-#@*WHK ;!EO3BMR
M2J733BGAC,^0:2LB^]C:D$HQ0T+O!1:ADFA-X_,W*IT>@[[)2Z?'N+J#0.R)
M3>67K[=5(Y;'R!)+8(-TH 2G<SY&"8R[@"+'Y)N3'?]0J$[ . MF5E,ZL%]$
MWJT1<-XXRS1PRSW%FY+RKB)JQ21%G,G$@+%UX/]#H>9%9&,0#(/8GA[I8&0A
M5O%?KM9_+#[A-7GR;ZLE?KV^=O(BFF"]!Z/K7$>MD/()(T$&P6(207GK?Q#^
M#OM2EZ#9UZVKR6P\,V*^]?CF_[K<7&S?2)]O>=TVKY8O-A>+3Q3/;]Z6[7R\
MEY<7= S\'KYN_]BULM8A\F@Y*%L,*.\M>.,+Y!R++"%D'?0 0!TLR+Q57]/A
M[;@>ZN",G.0:QR3$$H4&P6N3 Y<<O,L!(K<Q1E5$D)-UAQS[IOETZOX/B0UG
MA\G>2^4+KN.JO\7R/)RGR_/M+]^MSL_I>/LSK/-9\MD*KQREG;5W%TTML9<(
MJ)!Y2QN(*,T'[4VMU$^38NV)W.F64@,0]70$W;F._\_%Q<<'RM^[Q]R\NT=^
M<GVKO_U99U:A#3H@"(=DA&H.3QD+D&<"(BH=U60<#"T5^6E63PNP#J@\/2YR
M]EX^GW&]6-4!(^N+61?1$Y:XX6.[&9Y"P6]8+^F/;<YX-DE[RK*B- E48;S.
MSDV Z*RW,3EM>UE8HY7[:2*^CA;;M @[X?/K"</\?KE.'\,&-V?%("61!8&A
M8:!,?8T.,D/QV6A5LG;-!Z=-I<M/T[/3_\+:#S\_WSIZCQ<7YU=]"&=*QI*"
M-5#J& 95.?&<$QF814J!72@B3M;+UER;GZ9^O_^UM"^&^B'OG"9$9LSZHBT%
MQI$V%>6B!,^4!VM1.N=2*C@9!=;1DZM3J"7M:"FU0\Z!R=6+99ZKPO0Y&8!^
M\XS5-RG*)D&I0-J&5, )VCA*PL*D,L7HUNMD?VD'+0;S]UP,1\) !U'8'IJ^
M(=O?*"NRXSK5*5=!5BZU IX+"S85EX7W5@[K29L6\-\$'H1Y^R_,3XN$7I[E
M1[X&W+O)N)T6_+:\6J;5)WQ1ZV4W"_K/7R\V%Y5!^ZKD$//+\_#AS(:491((
M3I.#**!DX!WGD+U65BLIL-Q+2G:_Y1]5^I_FINRP1YT3@<]/TZNPY<8/CW+C
MKY;AS?U$CO[DK7=6Y?5J^8$4^O0KQHMC,[!/)_@\70A'<L0Q6@X\!NF+U.!5
M9<R,-D)4#*%$5G+BO(ATDFSM!T_ LCYXDV($S0P%#T5D"-K:RO*GT7I:!V*R
M7HR?>*[Z&+Q--U=]C',[2$N&$#F;4*P2F2R9*O]MSKDR_>7ZC"10:UNBPJGP
MVCTQ^W$!LP<C^QCO]03('63/.=O"$[,@),K*4!(H!V("4DI&9EKOF(_Q5'YR
MC.RCH+ '(_L8OW0*M<W=57I#E9&C5X4;D%G7SHQ0*^$KM[CP(;'@=3H.*?M#
MT3J!7"M(#"' .] _/<%N-W6@)<FM206DC1:4M@$<0TLQC2\,><R86G?U->0)
M[7I@8=.#MY4/>T+F(+)!Z;U7CE1*(:=Z!ZJ@-K !8XYB;<%DF6Y>ST]#$#H*
M(0<1A(YQ5T]8O$-'*:XW?*.+4<H'T")4:M62:Q&I 2[195/J.-#)FO4?BM,)
MSMJ#8 !!Z#X>Z0E<38:"&N3<H97@):\7W-&#CX)!<EQ2#.*4=I,Q)?]KLGSC
M _WHB.BB ZO>&'\;.GMKC#-,"C$&"2CJX%F,#BK',""C5#+KZ*UKG6D_(4HG
MN^SQX?%@BO#AGNKYV>K5F_]X\>:/M^]>O7C_?/7I\VI9S[-5>;7\0K]8K<G<
M^[\L#?_9S1Y_]E2GT?O,S6>^?KLOO[TNCQ4QSFO"7Z7N9+P08'0!;BH1L,_<
MN-:TE3O$.70#N_W1[\*?OP7"Z2*<;\YT04G)OP5MM0&EZJMNB!HT5\YYIV7F
MK>N3'Q5DWLVK%0KN;T6'V[R#4/!6B?]<K?_[U?+W]2KAAK1 AE&C ATR:8$4
MU49A,T@IHW(R"M.\&^MQ2>:];9D<.OM;O2?LO%PL%YN/F/^Q6N7-F>=&>DKL
M@8Y=#BJX>A3'#$7*;%3FZ%/K^^+')9DWL)\<._M;O2?L_&.](N1G"@+1%@F%
MRTC2!TK,@V;@K%<F657R?4:C=IC92C!O]\OD6!EOY?TQLKH(YU,'R7\\>_./
M5[^\?O'L_?L7VVJB?[Q]^^M_OGK]^K?P7ZOU]Z'F15A^J.5N5[G+(>'SX5]M
M&%@W-D&CD+MN1G\NSL\I WSPV8?8UA:-EL6#=<Q7TC?*!#4B",Y5"A0QT1]H
MO.Q'"7A(^>_[1'OSY3F^+76COL#7BR^8MU_-6+[]FWM"_/+URGWG87-]K:,*
M9<E:*,C,5B*RFBTGH<%P,EY)UIL2?X#<AN+,&\I/AZZ[E;=S>*Z#(_GEDZIM
M[NIV-2['"LV9U722, $JTJ%$64Z=36DBEBRM:YY9CA!O'I#.!IW[=[D3^;%O
MB'Y3[$WX=,/75P0J)] !ESE0P%,"Q"PD,!-%2C%9VSP5&2GBS/>Z4T%E."0/
M]MO,73Z4N^?+=/'+.BSS#5EC+#8XQ RT@LE4=:*8\U* =CEZ'UCQ10TXLA_Y
MT=W"Y7 WKMK9M(.=ZH]UR%A-<2._1TJZ3'9U;K2O[#,&7+$<DO0E*68%LZU;
M&._+,'/ETA' T\3Z':"G-D36$/8RG+^K8\)OU' J1I>T@^BBJFWN!CP3!G1(
M(D59>5E:UQP](<K,C^9'Q%(+7\Q]1H7UQ1+7[_"JDW?S<?'Y1HOBLF2&%1#6
MU8H8^E6H@^TU.B5+DO3W']V+[/["S+0RQSJQVEAX9IR\O;QXO4BXW%2JF/1Q
MN3I??;CA0P_.2 P^D&4H\J/PKPY,I/-7T5%<4$JA![45[_C$S*PI1T)**QMW
M<$KM3FH?9A#:!F&BCN $9;;*<OJ5] Y49L[D"I74_CEZE(CS1$B]7!Q,Z<_^
MX?KH*L\%#:/SO+[#4MR(14/TR0/2 J5%JI3D@X:HMX-L?Y<(D\)F'$0/]F$'
M,-WF+I_"^K]O HB@9++:%TIU700EE ?G<@:7!2UOX2C[;5VI=%^&K@%VN-,?
MRQ[W]<#<I#,C3H^[)9G*QJ)2 >2*@E13%#@ER%R:!T0M>=9Y0'2WW]?GR27G
M/G6/Y*T.=K0=H?4;O+A]KDN>2QV3@2H#::41 BMT+I1HBC>*V=2<%V*09/,]
M)QT#'\.OZO=U5M\0O"J-<8G):$*$Y*L6W@M:P2R#D!*U<$6$YH'>CV3J]JY_
M;QP,A]IXI_0-LF<I77ZZW,Y5?O9IM;Y8_+^M(\\"1IV3J[=!6RI'QRA@*1%\
M3ME9YE(L1WR@?$+*;M\-C@#$%HX[E+;Y"(?PF='<ZZ0<)&$*J$1A3$23(?+B
MG>?)VG+$_8\DZO:!X0B@&^N09K6:DUVNO/BKCN-8+#_<5G#=%FF54)36"7(,
MOMYY&@@B6:"86;N<$@K>^EUT7UGGNQV<(0X\BD,[.+3'ZGDF [=*10<,G0!%
M*M&FKP4P::7%DH3W[=L;QLG8]75-(^0<"-=1;NP"I@^.B*<-&52V6M*QY)2V
M=!CQ!)$L".ATR398*V+KLNHQ\LUWWS/+/CJ1XSH$Y39K>[C4(M=%%9_!B>AK
M&XN$F+6';!B+@F(H-<&[WQ#)YMXGIT+&#R#8P$U=1)P_-M^9D[&P6 088;:C
M$@HXIR,D%Z-%YF7.[0_K'\LU=U?K3, [V$4GVI36@!5\S$\_1I/94?BUQ[7[
MQ(+!*%& ASJ(/&8&!*L(12-GVLF I?4[Z5&:R6X^]NVQZN:S5X]/W#N6E63
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MNOQ'4-K3_AU Z;IB^X%&MT-7+ D=+)3$#2B?)(1L(Z!3*123&&O^1K!;HLX
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M@1L.C+N<7/0^^N$7P[N^- PGIW8/W,RV_6'EV^8H^<TKB2K">$T6DKJ (B'
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MG:,7N$*2+O.KU0(_=?'"&<:TU%I1C%Z8*J]*<H!RZP#$J215UISI6-_1J<=
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MW\G-KZS(SDN+7HHI$36&YF"8LL"%L]P327(:XI[N$)J;M(I]$/74'<W1E-A
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MA93R;E?;+E9FH94I/ZUXBF,BI %G8,O9MCW](\:W^__*HWWA)#((D:&)\8:
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M';45-G#!:G>T_ LG4@XY,0=570/0?*8N;ETD=I'^6/]F<44LBY1+=&U9Z8[
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M<YB:GP//_C)O$CG;8@E-?&$D@>.6@B"E1QL>LZ"-,2@7EH2I76?Y'"V-H.<
M/;\(G3V$W@!XWJW^3#=^MIJCOW;MIG$[J69;"$/0#; .0X LT3R+["E8X2*D
M0)7+5NF<:A>*["2H-1CMH_/94 IH $THFTW=P'I_68PFK)<:LE;%\<^XOR0W
M$#-&$Q+_9ZK7>?]$P+BY@&&.K/TEW!(\MON&RDA4<!9X+DU$663H^'$"5,O
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MXRKZF",:5(S<:$;G'S<,1FX6(P 2> G]2=A5([I(X=\^S[[]>_FX#2C*5_<
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M.ECTIU2B^FN:IKF[?CWY-KD^"^ND8KTJU1T?/EBA:E>&1JE5C<XK*9( Q6Q
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M!:#]5/>:E!0F& ^*9@E"X!]&N@ 4XP]MC!#F86N+?YT"\%Z*W5D WD?*#1:
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M<[)">0BF1&#1!+#.6PBZU,)QXD/UP'0/,IN(8"IBI5]U],&*:P";=\GGM].
M/)7N.%>*9*;6?94$+6_V8@#'-4$6; P63W*M:[\^>H*,)B*EX;!UJ.!']I[.
M;HI<_G<MD,N,$:&;?IZ@\2];8;GXL3/N_;6SZ_5'XC:9W5:JO)XMEI?YU]DL
M8D@1KPB1R7AM -T4Y%]F U:BCR+1QS+.>F%8E\!["-J:"-OJH[$)5?:'LMU
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M^[.SMS'%-I3,:HRQ-@RCY#ESY&,PO<UIA!0)JE%E)UF5M"LL7$ETW7T8##O
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M,1D[WC>?MWT>$+L3B[OM*JB2INVPNO9I!CV T%@3OKI3<7.K6&H(D NZ"/9
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M>H**Y8)\,/U*86.%,MU;Q7TY&*=>X_?TWZ[&[]G$:OQ>F0HVL S(D2WA!,W
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MOBHKS7BAD^._&JL4[P$Z.I4F8["S6^W"SUZG,80!%NT"6Y55E(!SL$.O4UK
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MQA[E,*R.2%L=]*4*8C*T&0?M-L2E5"MEE0WIN=H[9@3$M:(<1E;<>)1Y?NG
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M&M>O:2B&NB\*=6JD(G[;P!WKTQ]M,,OTRQO!XQK#.:M=@R@)T4J;T*H3J[6
MR=$^4M+/RWQ3F,P8?YLU0A9TGR"[3Y#M48*,XR$DXL;^#:!\HUL/?WAS<S:I
M>+&]U'JW_++MWSA6^,']W^S8[IN_\5DV-8J<LS4XO.D$RKRV<C0/5+%P2 LY
M<EQ!EQ\:1_,3*:&QSI"D%$4)9)PYI3@FZ B>P,A$9IV!BJR ^UYFZSHZH]O9
M/U]&JFG H!0\+K(YXYTFR4@[C14W;+38%(,3&[9M!%@ 92+T8(2:9".=2+0Q
M".,B-OZ*O&2!N''-C4\"]Q+[A'N02F%=V&6BUYRO2Q3K57@';4H''Y_58Y4
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M%HC/(C"CJI?[ CS;6L=H.P"B":Q,Y)_\\?_3ZKE.=BGT7X/8CH#]D,-T&1G
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MI/,X#^9ENH'_+)M5_H__#U!+ P04    "  FA:16KQP+$)$(  !4)P  %
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MZLU#OOX5U\:O4S9^UY5=W==H]KNX]W\!4$L#!!0    ( ":%I%98_>8!,08
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M+")ZXUQ[<5]06K]1(1Z>XIE:K_+MN_ZUEX]K;_^+I_G-(O_U9/]?4$L#!!0
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M,S$N:'1M4$L! A0#%     @ )H6D5O""R19D(0  N&\! !
M ( !A;X# &)H8RTR,#(S,#,S,2YX<V102P$"% ,4    "  FA:16U1=FUWLC
M   :50$ %               @ $7X , 8FAC+3(P,C,P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    "  FA:16NB\G%+;$   4IP@ %               @ '$ P0
M8FAC+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    "  FA:16*7KL\T5O 0 :
MI X %               @ &LR 0 8FAC+3(P,C,P,S,Q7VQA8BYX;6Q02P$"
M% ,4    "  FA:16!^OYCY[[   5+0L %               @ $C. 8 8FAC
M+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    "  FA:16E,UJ9$Q9  !N: (
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M &5X:&EB:70S,C%Q,3(P,C,N:'1M4$L! A0#%     @ )H6D5MD^ 9=*!@
MS!D  !0              ( !>J4' &5X:&EB:70S,C)Q,3(P,C,N:'1M4$L%
3!@     +  L V (  /:K!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
